
<html lang="en"     class="pb-page"  data-request-id="be688ecf-c4a1-4bc8-a142-05cd95e368f6"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;article:article:10.1021/acs.jmedchem.9b00511;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2019.62.issue-23"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Precision Cancer Nanotherapy: Evolving Role of Multifunctional Nanoparticles for Cancer Active Targeting" /></meta><meta name="dc.Creator" content="Anas  Ahmad" /></meta><meta name="dc.Creator" content="Farheen  Khan" /></meta><meta name="dc.Creator" content="Rakesh Kumar  Mishra" /></meta><meta name="dc.Creator" content="Rehan  Khan" /></meta><meta name="dc.Description" content="Nanoparticles with multifunctionality are being designed and formulated to overcome various limitations of drugs as well as conventional drug delivery systems. Engineered nanoparticles to specifica..." /></meta><meta name="Description" content="Nanoparticles with multifunctionality are being designed and formulated to overcome various limitations of drugs as well as conventional drug delivery systems. Engineered nanoparticles to specifica..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 24, 2019" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b00511" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00511" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b00511" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00511" /></link>
        
    
    

<title>Precision Cancer Nanotherapy: Evolving Role of Multifunctional Nanoparticles for Cancer Active Targeting | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b00511" /></meta><meta property="og:title" content="Precision Cancer Nanotherapy: Evolving Role of Multifunctional Nanoparticles for Cancer Active Targeting" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00511/20191205/images/large/jm9b00511_0004.jpeg" /></meta><meta property="og:description" content="Nanoparticles with multifunctionality are being designed and formulated to overcome various limitations of drugs as well as conventional drug delivery systems. Engineered nanoparticles to specifically target cancer cells have the ability to reduce collateral damage on normal tissue due to pan-toxic effects of drugs. Pragmatic approaches are in consideration to make advancement in cancer therapy as the new developed methods exhibited an improved targeted anticancer therapeutic delivery with better treatment outcomes. An effective cancer therapy requires both the passive and active targeting, along with a consistent knowledge of various physiologic barriers to successfully achieve targeted delivery. The nanoparticles can be linked with tumor targeting moieties like specific ligands, monoclonal antibodies, and carbohydrates for active targeting of cancer cells with great affinity and precision. This review presents some recent research on targeted delivery for cancer therapy and also discusses examples of types of engineered nanoparticles exploited for active cancer targeting." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b00511"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00511">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b00511&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b00511&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b00511&amp;href=/doi/10.1021/acs.jmedchem.9b00511" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 23</span><span class="cit-fg-pageRange">, 10475-10496</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/23" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.9b00683" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Precision Cancer Nanotherapy: Evolving Role of Multifunctional Nanoparticles for Cancer Active Targeting</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Anas Ahmad</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anas Ahmad</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Nano Science and Technology, Habitat Centre, Phase 10, Sector 64, Mohali 160062, Punjab, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anas++Ahmad">Anas Ahmad</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Farheen Khan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Farheen Khan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Nano Science and Technology, Habitat Centre, Phase 10, Sector 64, Mohali 160062, Punjab, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Farheen++Khan">Farheen Khan</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rakesh Kumar Mishra</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rakesh Kumar Mishra</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Nano Science and Technology, Habitat Centre, Phase 10, Sector 64, Mohali 160062, Punjab, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rakesh+Kumar++Mishra">Rakesh Kumar Mishra</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Rehan Khan</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rehan Khan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Nano Science and Technology, Habitat Centre, Phase 10, Sector 64, Mohali 160062, Punjab, India</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: 0172−2210075. Cell: +91 8699646338. E-mail: <a href="/cdn-cgi/l/email-protection#3240575a535c595a535c725b5c41461c53511c5b5c"><span class="__cf_email__" data-cfemail="6416010c050a0f0c050a240d0a17104a05074a0d0a">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rehan++Khan">Rehan Khan</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2406-1129" title="Orcid link">http://orcid.org/0000-0002-2406-1129</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00511&amp;href=/doi/10.1021%2Facs.jmedchem.9b00511" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 23</span><span class="cit-pageRange">, 10475–10496</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 24, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>23 March 2019</li><li><span class="item_label"><b>Published</b> online</span>24 July 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 12 December 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b00511" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00511</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D10475%26pageCount%3D22%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DAnas%2BAhmad%252C%2BFarheen%2BKhan%252C%2BRakesh%2BKumar%2BMishra%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D23%26contentID%3Dacs.jmedchem.9b00511%26title%3DPrecision%2BCancer%2BNanotherapy%253A%2BEvolving%2BRole%2Bof%2BMultifunctional%2BNanoparticles%2Bfor%2BCancer%2BActive%2BTargeting%26numPages%3D22%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D10496%26publicationDate%3DDecember%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b00511"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2636</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">32</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b00511" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Precision Cancer Nanotherapy: Evolving Role of Multifunctional Nanoparticles for Cancer Active Targeting&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Anas&quot;,&quot;last_name&quot;:&quot;Ahmad&quot;},{&quot;first_name&quot;:&quot;Farheen&quot;,&quot;last_name&quot;:&quot;Khan&quot;},{&quot;first_name&quot;:&quot;Rakesh&quot;,&quot;last_name&quot;:&quot;Kumar Mishra&quot;},{&quot;first_name&quot;:&quot;Rehan&quot;,&quot;last_name&quot;:&quot;Khan&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;24&quot;,&quot;issue&quot;:&quot;23&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;10475-10496&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b00511&quot;},&quot;abstract&quot;:&quot;Nanoparticles with multifunctionality are being designed and formulated to overcome various limitations of drugs as well as conventional drug delivery systems. Engineered nanoparticles to specifically target cancer cells have the ability to reduce collateral damage on normal tissue due to pan-toxic effects of drugs. Pragmatic approaches are in consideration to make advancement in cancer therapy as the new developed methods exhibited an improved targeted anticancer therapeutic delivery with better treatment outcomes. An effective cancer therapy requires both the passive and active targeting, along with a consistent knowledge of various physiologic barriers to successfully achieve targeted delivery. The nanoparticles can be linked with tumor targeting moieties like specific ligands, monoclonal antibodies, and carbohydrates for active targeting of cancer cells with great affinity and precision. This review presents some recent research on targeted delivery for cancer therapy and also discusses examples of types &quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00511&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00511" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00511&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00511" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00511&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00511" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00511&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00511&amp;href=/doi/10.1021/acs.jmedchem.9b00511" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b00511" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b00511" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b00511%26sid%3Dliteratum%253Aachs%26pmid%3D31339714%26genre%3Darticle%26aulast%3DAhmad%26date%3D2019%26atitle%3DPrecision%2BCancer%2BNanotherapy%253A%2BEvolving%2BRole%2Bof%2BMultifunctional%2BNanoparticles%2Bfor%2BCancer%2BActive%2BTargeting%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D23%26spage%3D10475%26epage%3D10496%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292544" title="Targeting">Targeting</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=290920" title="Nanoparticles">Nanoparticles</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/23" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/jmcmar.2019.62.issue-23/20191212/jmcmar.2019.62.issue-23.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00511/20191205/images/medium/jm9b00511_0004.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00511/20191205/images/large/jm9b00511_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00511&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Nanoparticles with multifunctionality are being designed and formulated to overcome various limitations of drugs as well as conventional drug delivery systems. Engineered nanoparticles to specifically target cancer cells have the ability to reduce collateral damage on normal tissue due to pan-toxic effects of drugs. Pragmatic approaches are in consideration to make advancement in cancer therapy as the new developed methods exhibited an improved targeted anticancer therapeutic delivery with better treatment outcomes. An effective cancer therapy requires both the passive and active targeting, along with a consistent knowledge of various physiologic barriers to successfully achieve targeted delivery. The nanoparticles can be linked with tumor targeting moieties like specific ligands, monoclonal antibodies, and carbohydrates for active targeting of cancer cells with great affinity and precision. This review presents some recent research on targeted delivery for cancer therapy and also discusses examples of types of engineered nanoparticles exploited for active cancer targeting.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06313" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06313" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Cancer remains one of the most serious diseases and leading causes of deaths worldwide that kills millions of people every year. According to the National Cancer Institute data, it is estimated that from 2012 to 2030, worldwide cancer cases are expected to be increased by 50%, i.e., from 14 million to 21 million, and worldwide cancer deaths are expected to be increased by 60%, i.e., from 8 million to 13 million.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Cancer is a disease of uncontrolled cell proliferation that arises due to accretion of multiple genetic and somatic mutations in genes (proto-oncogenes and tumor suppressor genes) which regulate cell proliferation and apoptosis. Because of intratumor heterogeneity, tumor cells exhibit genetic diversity and drug resistance, which requires a very complex process of treatment paradigms. Hence, several approaches are being practiced for the treatment of cancer and each currently available treatment options has some significant limitations and side effects.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a></div><div class="NLM_p">Currently available cancer treatments present a combination of surgical resection of a tumor along with radiation therapy and/or chemotherapy. The major limitation of surgery is mainly due to the lack of a clear-cut boundary between tumor tissue and adjacent normal tissue. The other limitations of the presently available therapy include lack of specificity due to off-target effects on normal cells which leads to enhanced systemic toxicity. Chemotherapeutic agents disrupt normal cell functioning by inhibiting DNA replication or by inducing apoptosis, thereby provoking most deleterious and cytotoxic effects to rapidly proliferating normal cells.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a></div><div class="NLM_p">Outstanding progress has been made in the fundamental understanding of cancer biology, leading to better diagnostic and treatment methods. Among diverse advancements, nanotechnology presents a versatile platform for cancer imaging and therapy. Cancer nanomedicine is a targeted approach which offers the significant edge of overcoming both systemic and tumor barriers by providing specific and targeted delivery of therapeutic agents selectively to cancer cells while minimizing the exposure to healthy cells.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a></div><div class="NLM_p">A specific and effective drug/siRNA delivery to the tumor site without damaging normal tissues is the eventual goal of all cancer treatment strategies. Targeting is a promising approach for selective and efficient therapeutic delivery to tumor cells with reduced detrimental side effects.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Paul Ehrlich coined the term “‘magic bullet”’ for modern medicine in the early 20th century; since then, the development of targeted drug delivery systems has gained massive interdisciplinary attention, ranging from chemistry over biology to medicine.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Besides providing enhanced half-lives of drugs in the circulation with superior pharmacokinetic properties, tissue oriented selectivity and capability of a drug nanocarrier to overcome biological barriers has brought a revolution in the field of oncology. Nanoformulations with a targeted approach to a specific cell surface receptor allow a higher dose to be delivered to the target cell.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Various types of nanoparticles (NPs) that have been explored for applications in cancer therapy are dendrimers, carbon nanotubes, polymeric nanoparticles, micelles, liposomes, and nanoparticles of protein, lipid, viral, ceramic, and metallic constitution.<a onclick="showRef(event, 'ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11">(9−11)</a> Nanoparticle mediated drug/siRNA delivery can either be an active or passive process.</div><div class="NLM_p">Passive delivery exemplifies to the nanocarrier mediated delivery of therapeutics within the tumor through their permeable vasculature primarily by passive diffusion, whereas active targeting refers to the delivery to a targeted site based on molecular recognition.<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12,13)</a> In passive targeting (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), nanoparticles take the benefit of the leaky tumor vasculature and preferentially accumulate within the perivascular tumor environment due to enhanced permeability and retention (EPR) effect.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> As apoptosis mechanism is deregulated in cancerous cells, they uncontrollably divide and proliferate by gaining energy or nutrition abnormally from the surrounding blood vessels and thus forming wide and leaky blood vessels around the cells induced by neoangiogenesis. Leaky blood vessels are formed due to abnormalities of basement membrane and reduced number of pericytes which line swiftly proliferating endothelial cells. Therefore, the molecules are able to permeate through the vessel wall in an increased manner into the interstitium which is surrounding the tumor cells.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> To reach the drug molecule to the tumor of a particular organ, nanoparticles can be targeted to that area of capillary endothelium around tumor cells and permeate the tumor cells by passive diffusion or convection.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Extensive circulating nanoparticles enable their efficient delivery to the tumor site by the EPR effects and thus internalization of the nanocarrier within tumor cells, which results in improved therapeutic effect.<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17,18)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00511/20191205/images/medium/jm9b00511_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00511/20191205/images/large/jm9b00511_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Active and passive targeting in tumor and adjacent normal tissues.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00511/20191205/images/large/jm9b00511_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00511&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The use of physiological properties of the tumor tissue alone may not be adequate for efficient targeting, consequently, the concept of active targeting (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) was evolved where the drug or nanocarrier is modified with a specific ligand (binding moiety) that can selectively interact with some unique cell surface receptors which are overexpressed or present only on the specific target cells, leading to its internalization into the desired cells. This method is generally known as active targeting or ligand-based targeting.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> It is indeed the functionalization of nanoparticles with biological targeting moieties to bind to specific biomarkers on the surface of cancerous cells, enabling drug delivery for tumor specific applications.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> The ligands used for targeting can be enlisted as proteins (antibody and its fragments), nucleic acids (aptamers), or other ligands (peptides, vitamins, and carbohydrates), which generally bind to the receptor uniquely overexpressed by tumor cells or vasculature. The targeting ligands participate in a vital role to increase cellular uptake of nanoparticles through the process of endocytosis, pinocytosis, or macropinocytosis.<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21,22)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00511/20191205/images/medium/jm9b00511_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00511/20191205/images/large/jm9b00511_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Active targeting of cancer cell by various targeting moieties.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00511/20191205/images/large/jm9b00511_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00511&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2.  Ligand Mediated Receptor Targeting</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00078" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00078" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Conventional chemotherapy exhibited less desired response rates in cancer patients due to the emergence of multidrug resistance, nonspecific drug delivery, off-target effects of drug, severe side effects, fast clearance rate, and low drug concentration in cancer cells.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> In the ligand receptor targeting, the surface of the delivery system functionalized with ligands which recognizes and binds to the receptors mainly expressed onto the surface of target cells and then internalized into the cells with high specificity and efficiency. Therefore, targeting specific receptors which are overexpressed onto the surface of cancer cells help in the appropriate selection of patients for personalized treatment.<a onclick="showRef(event, 'ref24 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26">(24−26)</a> Nanoparticles are exploited for targeted drug delivery, specifically to cancer cells by the attachment of a specific ligand which shows recognition to its receptors on the target cells. A number of different ligands have already been reported for active targeting, which includes but is not limited to receptors for nucleoside, glycoproteins, peptides, proteins, transferrin, and folate residues. A recent example of ligand mediated receptor targeting is the formulation of hydrogel particles with surface conjugated tumor cell targeting ligand for specific targeting and controlled release of antineoplastic agent. Polymethacrylic acid hydrogel cubes were formulated with direct conjugation of the hepsin-targeting surface peptide with surface disulfide group. The surface functionalization was reported not to hamper the structural integrity, stability, or hydrophobicity of the system. The peptide attachment significantly enhanced the cellular uptake of hydrogel cubes and imparted selectivity of the system toward hepsin-positive MCF-7 and SK-OV-3 cells compared to hepsin negative cells.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> A number of other ligand receptor based targeting approaches have been studied (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) which are described below.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Summary of Ligand-Based Targeting in Experimental Stages</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">no.</th><th class="colsep0 rowsep0" align="center">ligands</th><th class="colsep0 rowsep0" align="center">receptors</th><th class="colsep0 rowsep0" align="center">formulations</th><th class="colsep0 rowsep0" align="center">cancer types</th><th class="colsep0 rowsep0" align="center">ref</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">AMP</td><td class="colsep0 rowsep0" align="left">adenosine A<sub>1</sub> receptors</td><td class="colsep0 rowsep0" align="left">AMP conjugated polymeric nanoparticles</td><td class="colsep0 rowsep0">colon cancer</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">adenosine</td><td class="colsep0 rowsep0" align="left">adenosine receptors</td><td class="colsep0 rowsep0" align="left">adenosine conjugated solid lipid nanoparticles</td><td class="colsep0 rowsep0">human cancer</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">transferrin</td><td class="colsep0 rowsep0" align="left">Tfr receptors</td><td class="colsep0 rowsep0" align="left">transferrin modified PEG–PE based polymer micelles</td><td class="colsep0 rowsep0">ovarian carcinoma</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">transferrin</td><td class="colsep0 rowsep0" align="left">Tfr receptors</td><td class="colsep0 rowsep0" align="left">transferrin eight arm polyethylene glycol-dihydroartemisinine nanoparticles</td><td class="colsep0 rowsep0">Lewis lung carcinoma</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">transferrin</td><td class="colsep0 rowsep0" align="left">Tfr receptors</td><td class="colsep0 rowsep0" align="left">TF-PEG-CUR nanoparticles</td><td class="colsep0 rowsep0">breast cancer</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">EGFR</td><td class="colsep0 rowsep0" align="left">EGFR receptors</td><td class="colsep0 rowsep0" align="left">GE11 peptide conjugated exosomes for microRNA delivery</td><td class="colsep0 rowsep0">breast cancer</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="left">folate</td><td class="colsep0 rowsep0" align="left">folate receptors</td><td class="colsep0 rowsep0" align="left">folate targeted mitomycin containing PEGylated liposomes</td><td class="colsep0 rowsep0">human cancer</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">integrins</td><td class="colsep0 rowsep0" align="left">α<sub>V</sub> integrins</td><td class="colsep0 rowsep0" align="left">active dual targeted paclitaxel containing liposomes</td><td class="colsep0 rowsep0">lung carcinoma</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">9</td><td class="colsep0 rowsep0" align="left">somatostatin</td><td class="colsep0 rowsep0" align="left">SSTR2</td><td class="colsep0 rowsep0" align="left">somatostatin receptor 2 analogue decorated diacerin loaded liposomes</td><td class="colsep0 rowsep0">breast cancer</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">chlorotoxin</td><td class="colsep0 rowsep0" align="left">CTX receptors</td><td class="colsep0 rowsep0" align="left">anti-GFP siRNA nanovector</td><td class="colsep0 rowsep0">brain cancer</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="left">cytokeratin</td><td class="colsep0 rowsep0" align="left">CK-19 receptors</td><td class="colsep0 rowsep0" align="left">PLGA based immuno-nanoparticle</td><td class="colsep0 rowsep0">estrogen receptor-negative breast cancer</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">glucose</td><td class="colsep0 rowsep0" align="left">GLUT1</td><td class="colsep0 rowsep0" align="left">glucose modified PEG-polytrimethylene carbonate nanoparticles</td><td class="colsep0 rowsep0">intracranial glioma cancer</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">13</td><td class="colsep0 rowsep0" align="left">glucose</td><td class="colsep0 rowsep0" align="left">glucose receptors</td><td class="colsep0 rowsep0" align="left">glucose functionalized silica nanoparticles</td><td class="colsep0 rowsep0">breast cancer</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="left">cellulose</td><td class="colsep0 rowsep0" align="left">cellulose receptors</td><td class="colsep0 rowsep0" align="left">curcumin loaded cellulose nanoparticles</td><td class="colsep0 rowsep0">prostate cancer</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">HER-2 antibody</td><td class="colsep0 rowsep0" align="left">mAb receptors</td><td class="colsep0 rowsep0" align="left">PLGA-montmorillonite nanoparticles</td><td class="colsep0 rowsep0">breast cancer</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">anti-VCAM-1 mAb</td><td class="colsep0 rowsep0" align="left">mAb receptors</td><td class="colsep0 rowsep0" align="left">VCAM-1 conjugated immunoliposomes</td><td class="colsep0 rowsep0">angiogenic tumor blood vessels</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a></td></tr></tbody></table></div></div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5">2.1.  Adenosine Receptors</h3><div class="NLM_p">Adenosine is a purine nucleoside composed of adenine and ribose sugar, and it plays a role in regulation of cellular function by activation of different adenosine receptors. Importantly, according to reports, the adenosine A1 receptor has been found to be overexpressed in cancer cells. Therefore, adenosine receptors have emerged as a novel means to be targeted in the course of cancer therapeutics by means of functionalization with adenosine as a ligand. Both adenosine and the agonist of have adenosine receptor have been reported to be regressed various tumor types such as breast cancer, colon cancer, prostrate carcinoma, lymphoma, and melanoma, etc., in preclinical models specifically exerting the effects on tumor cells only.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> In a study, adenosine 5′-monophosphate (AMP) as a ligand was conjugated to polymeric fluorescent nanoparticles to specifically target tumors with an overexpressed adenosine A1 receptor. AMP-conjugated nanoparticles were effectively bound and internalized into colon cancer and breast cancer cells due to specific binding of AMP to adenosine A<sub>1</sub> receptors present on cancer cells. It also reported that these nanoparticles selectively accumulate in colon and breast tumor tissue after injection via tail vein in a xenograft tumor mouse model and internalized into tumor tissues, thus validating the successful translation of AMP-functionalized polymeric nanoparticles into in vivo study.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div><div class="NLM_p last">Additionally, docetaxel-contained solid lipid nanoparticles (SLN) have undergone surface modification with adenosine receptor ligand (AND) by using the method of carbodiimide coupling. Compared to free drug and unconjugated nanoformulation, docetaxel-loaded AND-conjugated SLN exhibited significantly higher efficacy as shown by cell-based assays.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> In another study, the surface modification of superparamagnetic iron oxide nanoparticles (SPION) was carried out by coating with uracil triphosphate (UTP) and adenosine triphosphate (ATP) in order to exploit the advantages for clinical use in nuclear medicine imaging. The biodistribution study was performed using a rodent cancer model. After intravenous injection, modified SPION showed that enhanced uptake in tumor tissue and increased in intratumoral accumulation in a time dependent manner, thus the developed modified SPION have potential to be used in the clinic for nuclear imaging.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6">2.2.  Transferrin Receptors</h3><div class="NLM_p">Transferrin, a serum glycoprotein of 80 kDa, helps in iron transportation into rapidly growing cells via transferrin receptors (TFR). Cancer cells are rapidly proliferating cells, hence their iron demand is much greater than normal cells. This increases the TFR expression on the surface of cancer cells, and these overexpressed TFR could be exploited for active targeting of cancer cells.<a onclick="showRef(event, 'ref31 ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref31 ref32 ref33">(31−33)</a> In a recent report, transferrin-targeted polymeric micelles were designed for the reversal of multi-drug resistance (MDR) in ovarian carcinoma cells by the codelivery of tariquidar (TRQ), a potent third-generation P-glycoprotein (P-gp) inhibitor and paclitaxel (PTX). It was a transferrin-modified polyethylene glycol–phosphatidyl ethanolamine (PEG–PE) oriented micellar drug delivery system, which encapsulated TRQ and PTX into the micellar structure containing vitamin E as the enhancer for encapsulation. These micelles were internalized in ovarian cancer cell lines via clathrin- and caveolin-dependent endocytosis and exhibited significantly enhanced cytotoxicity in SKOV-3TR cell lines and cancer spheroid culture.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Liu and co-workers developed transferrin-eight-arm-polyethylene glycol-dihydroartemisinine nanoparticles for the delivery of dihydroartemisinin (DHA) to Lewis lung carcinoma (LLC) cells overexpressing the transferrin receptors. These nanoparticles possessed high solubility, higher drug loading, and long circulating half-lives and showed enhanced efficacy by inducing in vitro cytotoxicity as well as in vivo tumor growth inhibition in tumor bearing mice.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> In another study, transferrin-decorated nanoparticles for the codelivery of curcumin<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> and doxorubicin (DOX) was developed for the treatment of breast cancer. First, a pH sensitive pro-drug Tf-PEG-CUR was formulated and self-assembled into Tf-PEG-CUR nanoparticles, followed by the doxorubicin incorporation into these nanoparticles to obtain Tf-PEG-CUR/DOX nanoparticles. In vitro and in vivo studies showed significantly higher efficiency in terms of cytotoxicity, efficient tumor targeted drug delivery, and strong antitumor effects as compared to other systems.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></div><div class="NLM_p last">Deshpande et al. described a study where they developed a nanocarrier for the targeted delivery of anticancer therapeutics to overcome the serious adverse effects associated with these drugs. They formulated the liposomes loaded with doxorubicin and surface modified with arginine rich cell penetrating peptide and transferrin for the improved targeting of ovarian carcinoma cells to enhance the cytotoxic effects of doxorubicin. The flow cytometry and confocal microscopy based analysis established the significantly enhanced cellular uptake of doxorubicin. Also, enhanced cytotoxicity in vitro and significantly effective control of tumor growth in vivo in an ovarian xenograft animal model was reported. Improved drug accretion in tumors and a prominent advantage of dual targeting by arginine and transferrin led to the specificity of the drug in targeting ovarian cancer.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7">2.3.  Epidermal Growth Factor Receptor (EGFR)</h3><div class="NLM_p">EGFR is one of the prototypic members of the class I family of receptor tyrosine kinase (RTK). EGFR have been reported to be overexpressed on cancer cells of various tumor types, and it serves as a target antigen because of its easy accessibility on cell surface receptors, which provides a basis for selective targeting of cancer cells on which it is overexpressed. The overexpression of EGFR is reported in many solid tumors, and in a few cases it is also correlated with poor prognosis.<a onclick="showRef(event, 'ref6 ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref6 ref39 ref40">(6,39,40)</a> Mamot et al. formulated immunoliposomes for targeting tumor cells which overexpressed EGFR for efficient intracellular drug delivery by covalently linking of monoclonal antibody fragments (MAF) to liposomes containing different drugs like doxorubicin, vinorelbine, and methotrexate or reporter molecules, etc. MAFs obtained from C225 and C10 anti-EGFR scFv binds specifically to EGFR. In vitro studies confirmed that only EGFR-targeted immunoliposomes are efficiently bound and internalized by EGFR-overexpressed cells like glioma cells (U-87) and carcinoma cells (A-431 and MDA-MB 438) and showed significantly higher in vitro cell cytotoxicity than nontargeted liposomal drugs.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a></div><div class="NLM_p">Ohno et al. employed the delivery of microRNA (miRNA) to EGFR expressing breast cancer cells through small endosomally derived vesicles called exosomes or microvesicles secreted by a variety of cell types or tissues. Donor cells were engineered to express the growth factor receptors to achieve the targeting. After intravenous injection, exosomes were able to deliver the miRNA in an efficient manner to EGFR overexpressed breast xenograft tumors, which suggests that cancer cells or tissue overexpressed EGFR can be therapeutically and selectively targeted by exosomes.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a></div><div class="NLM_p last">A novel approach for targeting EGFR has been recently studied by Simone et al., where they have synthesized nanobody-targeted polypeptide nanoparticles incorporated with an unnatural amino acid <i>p</i>-acetylphenylalanine for the attachment of doxorubicin. Peptide-based drug delivery carriers are least toxic, can be readily synthesized, and lead to improved pharmacokinetics of drug. However, the limitation of this paradigm is the nonspecificity in targeting as the residues that are employed for drug binding are also distributed efficiently on surface receptor proteins. To overcome this limitation, the site specific attachment of an external molecule to a peptide-based delivery system was undertaken so that no cross reactivity with targeting domains comes into the picture. This nanosystem significantly enhanced cytotoxicity in a number of cell lines.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8">2.4.  Folate Receptors</h3><div class="NLM_p">Cell surface receptors for folic acid, i.e., folate receptors (FR), are identified based on their potential physiological role in cellular folate uptake and belong to a class of high affinity folate binding proteins. Folate receptors are overexpressed in different tumors, including epithelial cancers of ovary, breasts, colon, lung, kidney, prostate, endometrium, testicular, head, neck, and brain as well as in several pathological states and are relatively absent from normal tissues. Certain studies also reported that overexpressed folate receptors are associated with poor clinical outcomes in patients with breast cancer.<a onclick="showRef(event, 'ref43 ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref43 ref44 ref45">(43−45)</a> Also, the recurrence rate increases with increase in folate receptor expression. Folate is a small targeting ligand molecule which is nontoxic and nonimmunogenic which can be conveniently conjugated and inserted into exposed layers of targeting carriers. It retains high binding affinity to receptors as a lipophilic conjugate and is stable while storing and in circulation. The binding of a folate ligand to its receptors facilitates the receptor mediated endocytosis, carrying the folate conjugated carriers into endosomal vesicles.<a onclick="showRef(event, 'ref25 ref43 ref46'); return false;" href="javascript:void(0);" class="ref ref25 ref43 ref46">(25,43,46)</a></div><div class="NLM_p">Patil et al. described the targeting of PEGylated liposomes against folate receptors of cancer cells by grafting a folate ligand to develop folate receptor-targeted liposomes loaded with mitomycin-C for its enhanced cellular internalization and elevated cytotoxicity. This study was aimed at reducing the fast clearance and dose-limiting toxicity of mitomycin-C as well as enhancing its potential antitumor activity. The folate conjugated PEGylated liposomes showed enhanced uptake and intracytoplasmic delivery and were 5 times more cytotoxic as compared to folate nonconjugated liposomes as shown by cell-based studies. Furthermore, in vivo studies showed no difference in pharmacokinetics and biodistribution and enhanced tumor cell level of the targeted liposomes.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Folate-decorated chitosan nanoparticles loaded with a dual drug (5-fluorouracil and leucovorin) were prepared by ionic gelation method, and then nanoparticles were microencapsulated by the enteric polymer Eudragit. This study was aimed at enhancing the drug encapsulation efficiency and improving the pH-dependent release profile.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Assaraf et al. synthesized a hybrid material in which a radioactive probe was attached to folic acid in order to target the diseased tissue. A folic acid conjugate of Vintafolide (Vinca alkaloid) was used as a folate receptor (FR) targeting agent that selectively binds and is taken up by the FR-positive tumor cells and facilitates the noninvasive whole-body monitoring of folate receptor expression status in the patients with folate receptor positive tumors.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div><div id="sec2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i9" class="anchor-spacer"></div><h4 class="article-section__title" id="_i9">2.5.  Integrins</h4><div class="NLM_p">Integrins are heterodimeric cell surface adhesion receptors which are composed of α and β subunits. It has been reported that integrins were found to be overexpressed onto cancer cells and regulate various functions like cancer cell survival, proliferation, migration, and invasion. Several types of integrins play a part in tumor development, but some integrins, e.g., α<sub>v</sub>β<sub>6</sub>, α<sub>v</sub>β<sub>3</sub>, and a<sub>5</sub>β<sub>1</sub>, which are commonly overexpressed onto some tumor types while underexpressed at normal epithelial cells.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Basically, there are two types of integrins, i.e., α<sub>v</sub>β<sub>3</sub> and α<sub>v</sub>β<sub>5</sub>, which are mainly overexpressed onto angiogenic endothelial cells and are responsible for new blood vessel formation or tumor-associated angiogenesis.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Therefore, integrins signify potential pharmacological targets that could be exploited for antiangiogenic therapy using inhibitors of angiogenesis.</div><div class="NLM_p">Self-assembled hydrogel nanoparticles were developed which can imbibe a peptide sequence that specifically binds to α<sub>v</sub>β<sub>3</sub> integrin. The nanoparticles can release the peptide in a sustained manner, and they may be used to monitor or destroy angiogenic vessels.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> In another study, peptide was developed with dual-targeting ability which contains Arg-Gly-Asp (RGD) as a specific ligand for alpha-V integrins and heptapeptide (Ala-Thr-Trp-Leu-Pro-Pro-Arg) for specifically binding to neuropilin-1 (NRP-1), a VEGF coreceptor. Both RGD and heptapeptide were connected to each other and then conjugated onto the surface of liposomes containing paclitaxel. Lung carcinoma cells (A549) and human umbilical vein endothelial cells (HUVEC) were used as cell-based models, as both the cell types express alpha-V integrins and NRP-1. The paclitaxel-loaded dual-targeted liposome exhibited greater binding affinity, enhanced cellular uptake, and significant suppression of HUVEC and A549 cells as compared to general paclitaxel injection. The growth of tumor significantly reduced when tumor bearing mice were treated with paclitaxel-loaded dual-targeted liposomes.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a></div><div class="NLM_p">Novel drug delivery system was customized to encapsulate cilengitide for the treatment of glioblastoma. Cilengitide, a peptide, has high affinity to bind to α<sub>v</sub>β<sub>3</sub> and α<sub>v</sub>β<sub>5</sub> integrins which have been reported to be overexpressed onto glioblastoma cells. Because of limitations associated with cilengitide like low penetration through the blood–brain barrier, higher hepatic and renal accumulation, rapid clearance from tumors as well as from blood created a challenge for its clinical application. To overcome aforementioned limitations of cilengitide, nanoparticles were developed using gelatin and poloxamer-188 embedded heparin copolymer for delivery of cilengitide. Cilengitide-loaded nanoparticles (CGT-NPs) were reported to induce significant cytotoxicity and apoptosis in C6 mouse glioblastoma cells. For effective treatment of glioblastoma, combination therapy of ultrasound-targeted microbubble destruction (UTMD) along with cilengitide-loaded nanoparticles was used. After treatment with combined therapy, the rat models of glioblastoma have shown 3-fold enhanced accumulation of cilengitide within tumors with reduced renal clearance and prolongation of cilengitide retention in tumors as compared to free cilengitide in presence or absence of UTMD. Overall, the combined therapeutic strategy of cilengitide-loaded nanoparticles and UTMD has strong clinical translation potential as it enhanced median survival up to about 80 days as compared to control (less than 20 days) and cilengitide only (∼30 days).<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a></div><div class="NLM_p">The recent report by Ma et al. describes how α<sub>v</sub>β<sub>3</sub> integrin receptors can be targeted by some linear peptides other than RGD using pharmacophore-based virtual screening and high-throughput molecular docking. The affinity of these peptides for α<sub>v</sub>β<sub>3</sub> receptors was established by competitive binding and cellular uptake while high binding affinity, specificity, and stability was verified by the intermolecular interaction measurements and dynamic simulations.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Another report by Chen et al. describes the formulation and characterization of a multifunctional dendrimer-entrapped gold nanoparticle, covalently modified with RGD peptide for targeted computed tomography and magnetic resonance dual model imaging of tumors overexpressing α<sub>v</sub>β<sub>3</sub> integrin receptors.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> Similarly, the study by Shan et al. discusses that α<sub>v</sub>β<sub>3</sub> integrin receptors overexpressed on tumors play a vital part in the promotion of angiogenesis and metastasis in tumor cells. They formulated RGD-modified solid lipid NPs and demonstrated enhanced tumor retention of these NPs as well as greater uptake by the mononuclear phagocyte system. They aimed at α<sub>v</sub>β<sub>3</sub> integrin receptor inhibition and increasing the RGD concentration on NPs. It was observed that the NPs led to the inhibition of MDA-MB cell adhesion and invasion and showed maximum tumor accumulation and enhanced tumor retention in the breast tumor models.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a></div><div class="NLM_p last">Previously, Graf et al. formulated and characterized cisplatin loaded PLGA–PEG NPs for targeting α<sub>v</sub>β<sub>3</sub> integrin receptors using RGDfk pentapeptide for improving the therapeutic index of cisplatin. The targeted NPs demonstrated enhanced efficacy compared to cisplatin alone in prostate and breast cancer models. Also, in human breast cancer xenograft models, the nanocarriers showed enhanced efficacy and better tolerability.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> The study by Montet et al. discusses the formulation of RGD NPs targeting α<sub>v</sub>β<sub>3</sub> integrins on a BT-20 tumor model system to image overexpressed α<sub>v</sub>β<sub>3</sub> integrins fluorescence and magnetic imaging.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> Likewise, Haubner et al. demonstrated that uptake of <sup>18</sup>F-labeled glycosylated α<sub>v</sub>β<sub>3</sub> antagonist (<sup>18</sup>F-Ggalacto-RGD) correlates with the α<sub>v</sub>β<sub>3</sub> expression on tumor cells. They established that this approach is a vital tool to visualize α<sub>v</sub>β<sub>3</sub> expression, especially on tumor vasculature, and a noninvasive quantitative evaluation can be achieved for the α<sub>v</sub>β<sub>3</sub> expression pattern using a A431 human squamous cell carcinoma model.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a></div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i10" class="anchor-spacer"></div><h4 class="article-section__title" id="_i10">2.6.  Chlorotoxin</h4><div class="NLM_p">Chlorotoxin (CTX) is a small peptide containing 36 amino acids obtained from <i>Leiurus quinquestriatus</i> scorpion venom.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> Basically, CTX was used to study chloride ion channels. Interestingly, later it was found that CTX has specific binding affinity to cancer cells of glioma, breast cancer, prostate cancer, and neuroectodermal tumors (neuroblastoma, melanoma, ganglioneuroma, pheochromocytoma, small cell lung carcinoma, etc.). Therefore, CTX can be exploited for active targeting which may function as a tumor targeting ligand. It also has the ability to permeate across the blood–brain barrier and therefore has potential to be used for gliomas.<a onclick="showRef(event, 'ref60 ref61'); return false;" href="javascript:void(0);" class="ref ref60 ref61">(60,61)</a></div><div class="NLM_p">Different types of synthetic and recombinant CTX conjugated with <sup>125</sup>I, <sup>131</sup>I, biotin, and several fluorescent probes were synthesized to study their selective binding to glioma cells. It was found that iodine conjugated CTXs exhibited selective binding to glioma cells and also showed persistent accumulation within tumors. Furthermore, biotin- and fluorescent-labeled CTX also exhibited very high selectivity toward glioma cells based on cellular and in situ studies as well as in human tumor tissue sections.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> Later, another study was conducted to develop CTX conjugated with Cy5.5, which is a near-infrared (NIR) responsive fluorescent molecule for the purpose of intraoperative detection and surgical resection of tumors. Cy5.5 conjugated CTX (Cy5.5-CTX), called tumor paint, was found to bind cancer cells via matrix metalloproteinase-2 (MMP-2), and the binding of Cy5.5-CTX was higher as compared to unconjugated CTX with no toxicity. Therefore, Cy5.5-CTX has strong potential to be used to delineate tumors with normal adjacent tissue.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> On the basis of the above-mentioned findings, unconjugated or conjugated-CTX can be exploited for active targeting of certain cancer cells.</div><div class="NLM_p">Mok et al. designed a glioma targeting pH-sensitive siRNA nanovector by using CTX. The nanovector constitutes iron oxide magnetic nanoparticles containing polyethyleneimine (PEI),<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> CTX, and siRNA. Citraconic anhydride is used to block primary NH<sub>2</sub> group of PEI, which is detachable at acidic pH, and CTX was used as a ligand to selectively bind to tumor cells and siRNA was used as a therapeutic molecule. The studies suggest that the presence of CTX on the surface of nanoparticles facilitates cellular internalization of the nanovectors and induces significant cytotoxic and gene silencing effects on C6 glioma cells at acidic pH but not at physiological pH.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a></div><div class="NLM_p">Also, a nonviral vector system was developed for gene delivery purposes. PEI has been shown to be promising for gene delivery efficiency due to the presence of cationic charge that mediates electrostatic interaction between negatively charged siRNA/DNA and positively charged PEI, but PEI was reported to be toxic and nonselective. Therefore, PEI was PEGylated with the aim to reduce the toxicity of PEI, but PEGylation reduces the transfection efficiency due to covering of surface cationic charge of PEI. Subsequently, PEG–PEI was linked to Alexa Fluor 647 (AF) and then to enhance the transfection efficiency, CTX was conjugated to PEG–PEI. The developed nanovector (DNA-PEI-PEG-AF-CTX) has shown high selectivity and high transfection efficiency in C6 glioma and DAOY medulloblastoma cells.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a></div><div class="NLM_p">Iron oxide NPs was conjugated to CTX and methotrexate with the help of PEG linker (heterobifunctional PEG silane) for the purpose of tumor specific delivery of anticancer drugs. On the basis of the in vitro magnetic resonance imaging<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> and cell viability studies, methotrexate–CTX-conjugated NPs exhibited preferential accumulation and enhanced cytotoxicity in 9L rat glioma and D283 human medulloblastoma cells as compared to rat cardiomyocytes normal cells. Moreover, methotrexate–CTX-conjugated NPs also exhibited persistent intratumoral accumulation in xenograft tumor-bearing mice as demonstrated by MRI.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a></div><div class="NLM_p">Zhang and co-workers investigated the therapeutic potential of the same nanosized delivery system (CTX-PEG-IONPs) to suppress invasiveness of glioma cells and to discover the mechanism of action of CTX-PEG-IONPs. The study demonstrated that CTX-PEG-IONPs exhibited specific binding to C6 glioma cells and also significantly higher inhibition rate of invasion as compared to free CTX. CTX-PEG-IONPs exhibited cellular endocytosis due to binding of CTX to MMP-2. It has been reported that MMP-2 gets deactivated by CTX-PEG-IONPs and then internalized the membrane lipid rafts that expressed MMP-2. The developed nanoparticles have potential to be used for treatment of MMP-2 overexpressed cancer types and for diagnosis purposes.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a></div><div class="NLM_p">In another study, Zhang and co-workers developed two different types of nanoparticles (NPs) containing iron oxide (IO) core coated with PEG to enhance biocompatibility. Subsequently, RGD and CTX were separately conjugated to PEG-grafted iron oxide NPs to form RGD-PEG-IO NPs and CTX-PEG-IO NPs for specific binding to cancer cells which overexpress αvβ3 integrin or MMP-2 receptors, respectively. Both types of NPs reported to have high dispersibility and long-term stability in culture media. On the basis of the magnetic resonance imaging, tumors surrounded by blood vessels initially exhibited high accumulation for RGD-PEG-IONPs but later showed quick clearance, while CTX-PEG-IONPs exhibited persistent intratumoral accumulation.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a></div><div class="NLM_p">Several types of nanosized micelles and liposomes have been developed for the delivery of hydrophobic anticancer drug, i.e., paclitaxel, but they have limitations. To deal with limitations associated with paclitaxel and for tumor diagnostic imaging, oleic acid (OA) coated super paramagnetic iron oxide nanoparticles (SPION) were developed. Chitosan was modified using PEG and hexanoic anhydride to get amphiphilic hexanoyl–chitosan–PEG triblock copolymer. Later, hydrophobic interaction between six-carbon chains of copolymer and OA onto SPIONs was used to coat copolymers over OA-SPIONs and paclitaxel drug was encapsulated within hydrophobic regions. Then CTX was conjugated to copolymer-OA-SPION for active targeting of cancer cells. The nanosystem exhibited more than 30% drug loading, sustained drug release, and specific binding to glioblastoma cells.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a></div><div class="NLM_p last">Several chemotherapeutic drugs have short circulation half-life and pan-toxic effects due to their nonspecificity. To address these issues, gemcitabine and CTX-conjugated iron oxide NPs (IONPs) were developed for glioblastoma therapy. IONPs were conjugated to hyaluronic acid (HA), a biodegradable cross-linking agent used to link gemcitabine and CTX onto HA-IONPs. The developed nanoparticles were reported to be stable, effectively internalized within SF-763 and U-118 MG glioblastoma cells. Additionally, CTX-HA-IONPs did not exhibit cytotoxicity while gemcitabine-conjugated CTX-HA-IONPs induced similar cytotoxic potential to that of free gemcitabine. Thus the potency of gemcitabine did not reduce after conjugation onto CTX-HA-IONPs. In vivo studies demonstrated that gemcitabine-conjugated CTX-HA-IONPs exhibited enhanced circulation time, renal clearance, and ability to cross the blood–brain barrier.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a></div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i11" class="anchor-spacer"></div><h4 class="article-section__title" id="_i11">2.7.  Somatostatin Receptors</h4><div class="NLM_p">Somatostatin receptors are a class of G-protein coupled receptors overexpressed in a number of tumor cells including but not limited to breast cancer, neuroendocrine tumors, etc., and have been exploited clinically both for the diagnosis and imaging of tumors during treatment. The physiological effects of somatostatin receptors normally occur after ligand binding and receptor activation and are mediated through intracellular signaling mechanism including the adenylyl cyclase inhibition.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> Octreotide (OCT) containing quantum dots (Qdots) nanoparticles were developed for targeting of somatostatin receptors with the aim of enhancing the drug delivery efficacy of octreotide, a somatostatin analogue. The Q-dots were linked with aminated-PEG and then further conjugated to octreotide at lower pH to yield Qdots-OCT. Highly specific cellular interactions were demonstrated by cellular uptake, and a massive accumulation of these Q-dots was shown in in vivo studies, proving high delivery efficacy.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a></div><div class="NLM_p">Similarly, Sreenivasan and co-workers developed a quantum dot (QD)-based fluorescent somatostatin (SRIF) probe for the specific targeting of somatostatin receptors and presented the receptor mediated endocytosis of biotinylated-SRIF by this probe. They employed in situ two-step bioconjugation strategies to allow quantum dots to be targeted to somatostatin receptors and enabling the visualization of receptor-mediated endocytosis. This may be helpful in the fluorescent tagging of SRIF to demonstrate the molecular trafficking in cells and targeted delivery in live animals.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a></div><div class="NLM_p last">Somatostatin receptor targeted liposomes with diacerin for inhibition of IL-6 were formulated for targeted breast cancer therapy. For targeting the SST-2 somatostatin receptor, a synthetic somatostatin analogue was decorated onto diacerin-loaded nanoliposomes (DAL). The liposomes were reported to be biocompatible, which exhibited significantly enhanced antitumor activity against breast cancer cells. SST-2-DAL have been shown to suppress xenograft tumors by inhibiting angiogenesis and cellular proliferation, thus the developed formulation provides improved therapeutic efficacy for breast cancer.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a></div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i12" class="anchor-spacer"></div><h4 class="article-section__title" id="_i12">2.8.  Cytokeratin</h4><div class="NLM_p last">Cytokeratins are different types of polypeptides which form a significant component of intermediate filaments. Cytokeratins are mostly used as biomarkers for malignancy as they release from cancer cells.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> They are reported to be overexpressed mainly on breast cancer cells and are employed clinically to identify the origin of various human tumors.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> Mainly, two types of cytokeratins are found within the cells which form heterodimers, i.e., acidic type I (cytokeratin 9–23) and basic type II (cytokeratin 1–8). Kocbek et al. developed polylactic-<i>co</i>-glycolic acid (PLGA)-based immuno-nanoparticles where monoclonal antibody (mAb) against the specific cytokeratin was covalently or noncovalently attached for targeting the invasive epithelial breast cancer cells. Only mAb attached nanoparticles demonstrated the recognition properties bound to the target cells, localized solely to MCF-10A neoT cells, thereby exhibiting the specific targeting of cancer cells.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a></div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">3.  Carbohydrate Targeting</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60626" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60626" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Many specific carbohydrate-based ligand receptor mechanisms have been introduced in inflammation, cell surface communication, and immune response.<a onclick="showRef(event, 'ref78 ref79'); return false;" href="javascript:void(0);" class="ref ref78 ref79">(78,79)</a> Likewise, lectins are the proteins of nonimmunological origin that bind to glycoproteins expressed on the cell surface to the extracellular side of the plasma membrane. Lectin interactions with certain carbohydrates are quite specific, and lectin moieties are used for the delivery of drugs specifically to desired cells and tissues. These lectin–carbohydrate interactions can be exploited either by incorporating lectin onto nanoparticles targeted for cell surface carbohydrates or carbohydrates can be attached to nanoparticles to target lectins.<a onclick="showRef(event, 'ref80 ref81'); return false;" href="javascript:void(0);" class="ref ref80 ref81">(80,81)</a> The study by Wirth et al. describes the application of wheat germ agglutinin as a targeting carrier protein to deliver doxorubicin drug into colon carcinoma cells. The conjugated drug showed significantly enhanced antiproliferative effect on MOLT-4 cells in a site-specific drug delivery in colon cancer chemotherapy.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a></div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14">3.1.  Glucose</h3><div class="NLM_p last">Exploitation of cellular glucose metabolism can be a vital approach in the identification of cancer cells which could help in the prognosis of cancer. Glucose coated magnetic nanoparticles (MNPs) show differential uptake in metabolically active normal cells and cancer cells. This establishes that glucose coating over the nanoparticles is vital in recognizing high metabolically active cells, and glucose transporter channel 1 is involved in the permeation of glucose coated nanoparticles into the cells.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> It has also been reported that glucose-coated gold nanoparticles cross the human primary brain endothelium three times faster than nonbrain endothelium and in turn get accumulated in the nuclei of astrocytes in significant numbers, thus proving to be an efficient and specific carrier for the delivery of therapeutic molecules across the blood–brain barrier.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> Because of the overexpression of glucose transporter (GLUT) over glioma cells, glucose modified polyethylene glycol-polytrimethylene carbonate nanoparticles (NPs) were formulated as a dual targeted delivery system which exhibited GLUT-mediated transcytosis and improved the drug accumulation in glioma cells. A significant level of cellular internalization was exhibited by NPs through caveolin- and clathrin-mediated endocytosis and showed greater cytotoxicity, high specificity, and efficiency in vivo with no acute toxic effects on blood, liver, kidney, heart, lung, and spleen of mice.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> In another study, therapy resistance of breast cancer stem cells was overcome by exploiting the high glycolytic activity of the aggressive hormone-independent tumor. Glucose functionalized silica nanoparticles (Glu-Si-NPs) loaded with a potent γ-secretase inhibitor were formulated and showed efficient internalization as exhibited by in vitro and in vivo model. Breast cancer stem cell population of the tumor was significantly reduced after the treatment with γ-secretase- loaded Glu-Si-NPs treatment.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15">3.2.  Mannan</h3><div class="NLM_p last">Mannan is a natural biodegradable hemicellulose polysaccharide of plant origin and a linear polymer of mannose. Mannose receptors are expressed over the surface of antigen presenting cells (APC) which can be targeted for the chemotherapeutic or vaccine delivery using mannan formulations.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> Budzynska et al. formulated a mannan–methotrexate conjugate to enhance the therapeutic efficacy, modify the toxicity profile, and increase selective targeting of methotrexate. The conjugated methotrexate exhibited significantly better antitumor activity than unconjugated methotrexate as shown by the P388 mouse leukemia model.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> Supramolecular amphiphilic mannan was developed to form nanogels which contained negative charge, exhibited long-term stability, and was also stable in salt or urea solutions at the 3–8 pH range. The mannan-based nanogel was reported to be cytocompatible as synthesized nanogel exhibited no cytotoxicity based on in vitro assays using 3T3 mouse embryonic fibroblast cells and mouse bone marrow derived macrophages (BMDM). Nanogel has the potential to be used for drug or vaccine delivery.<a onclick="showRef(event, 'ref89 ref90'); return false;" href="javascript:void(0);" class="ref ref89 ref90">(89,90)</a> Vasso et al. carried out a clinical study in breast cancer patients where they targeted mucin 1 (MUC1), a high molecular weight glycoprotein overexpressed on adenocarcinoma cells. Oxidized mannan–mucin injections were administered to subjects having stage II breast cancer to immunize against MUC1 and prevent cancer recurrence and metastasis. Patients who received immunotherapy showed no recurrence, with significantly measurable level of antibodies to MUC1 and MUC1-specific T cell responses.<a onclick="showRef(event, 'ref91 ref92'); return false;" href="javascript:void(0);" class="ref ref91 ref92">(91,92)</a></div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16">3.3.  Cellulose</h3><div class="NLM_p">Cellulose is a highly abundant natural resource which is a biocompatible, nontoxic, nonimmunogenic, and low-cost material. The Food and Drug Administration (FDA) has approved cellulose as a Generally Regarded as Safe (GRAS) polymer to be used in number of food, ophthalmic, cosmetic, drug additive, and adhesive products. These properties make it a material of choice to be employed in a number of diagnostic and therapeutic applications.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> Cellulose-based nanosystems are employed for a variety of applications and offer its potential use in detection and targeted drug delivery. Its shape provides the ability to be used for cellular uptake, its size can increase circulation time, and its surface has abundant modifiable hydroxyl groups for conjugating moieties.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a></div><div class="NLM_p">Colacino et al. developed cellulose nanocrystals conjugated with folic acid with the aim to enhance the cell death induced by irreversible electroporation in folic acid receptor (FR) positive cancer cells (KB oral squamous carcinoma cells and MDA-MB-468 breast cancer cells). Irreversible electroporation is a noninvasive ablative technique which is used to enhance permeation of cellular membrane by exposing them to nonthermal, electrical pulses.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> FR conjugated cellulose nanocrystals exhibited enhanced irreversible electroporation-induced cytotoxicity in KB and MDA-MB-468 FR-positive cancer cells while not inducing significant cytotoxicity in A549 FR-negative lung cancer cells. Cellulose nanocrystals without conjugated folic acid did not show enhanced irreversible electroporation-induced cytotoxicity in FR-positive cancer cells.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a></div><div class="NLM_p last">5-Fluoro uracil (5FU) folic acid conjugated, carboxymethyl cellulose (CMC) coated magnetic nanoparticles (5FU-FA-CMC-MNPs) were synthesized and exhibited superparamagnetic characteristics and lower aggregation due to CMC. FITC-loaded FA-CMC-MNPs showed efficient cellular uptake mechanistically by FA receptor mediated endocytosis. 5FU-FA-CMC-MNPs have been reported to induce significant cytotoxicity in MCF-7 human breast cancer cells. CMC-NPs without drug was found to exhibit higher cytocompatibility for MCF-7, G1 glial cells and L929 mouse fibroblast cells as compared to bare MNPs. A cell-based magnetic hyperthermia study suggests that 5FU-loaded FA-CMC-MNPs in combination with hyperthermia induced much greater cytotoxicity in cancer cells as compared to the treatment by hyperthermia and drug-free FA-CMC-MNPs.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> Yallapu et al. developed and assessed efficacy of magnetic nanoparticles, poly(lactic-<i>co</i>-glycolic acid) (PLGA), β-cyclodextrin, cellulose, and dendrimer based curcumin nanoformulations (NFs). Cellulose-based curcumin nanoformulation showed maximum cellular internalization and superior anticancer efficacy as compared to other types of nanoformulations.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">4.  Antibodies Targeting</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04520" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04520" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Antibodies are composed of glycoproteins that form the specific defense mechanism in vertebrate animals. Using antibody labeled nanoparticles is one of the most popular mode of active targeting for cancer therapy. The therapeutic efficacy of targeting antibodies can be improved by conjugating them with chemotherapeutic drugs. The antibody–drug conjugate can target malignant cells and can release large amounts of drug within the cytoplasm, thereby minimizing the drug associated side effects.</div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18">4.1.  Rituximab</h3><div class="NLM_p">In 1997, monoclonal antibodies (mAbs) entered in the field of oncohematology and the U.S. FDA approved the first antibody, rituximab (a humanized anti-CD20 mAbs) for the treatment of chronic lymphocytic leukemia.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> Immunoconjugates are composed of an antibody bonded to an effector moiety, i.e., a cytotoxic drug by either covalent cross-links or by genetic fusion and used for targeting the tumor.</div><div class="NLM_p">Voltan et al. designed and synthesized poly(lactide-glycolide) nanoparticles conjugated with rituximab, loaded with Nutlin-3 (N3-Rit-PLG NP) to selectively target CD20 positive JVM-2 B-leukemic cancer cells. Nutlin-3 has shown promising therapeutic potential against several p53-wild type cancer cells by inhibiting the interaction between p53 and MDM2. Both Nutlin-3 loaded PLG NPs (without rituximab) and N3-Rit-PLG NPs showed similar capacity to activate p53 signaling pathway in p53-wild type JVM-2 cells. Intratumoral administration of N3-Rit-PLG NPs exhibited highest therapeutic efficacy and enhanced median survival in JVM2 xenograft tumor bearing mice as compared to Nutlin-3 loaded PLG NPs (without rituximab) and rituximab conjugated PLG NPs (without Nutlin-3).<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a></div><div class="NLM_p last">Rituximab conjugated mesoporous silica nanoparticles (MSNPs) with pH-responsive capability were synthesized to encapsulate doxorubicin (DOX-Rit-MSNPs) for the effective treatment of B cell lymphoma with selective targeting efficiency and minimal side effects. The DOX-Rit-MSNPs exhibited low drug release at physiological pH 7.4 and pH-responsive release in mild acidic conditions (pH 5.0). Cellular studies demonstrated that DOX-Rit-MSNPs selectively bind to CD20 and are then internalized mainly in CD20-positive cells as compared to CD20-negative cells. Thus DOX-Rit-MSNPs induced higher cytotoxic effects in CD20-positive Raji lymphoma B-cells. Xenograft tumor mice model were developed using CD20-positive Raji lymphoma cells to assess the efficacy of DOX-Rit-MSNPs. It was found that doxorubicin efficiently and preferentially accumulated in tumors in a pH-responsive manner and consequently inducex apoptosis and thus tumor regression. Furthermore, in vivo study also confirmed that Rit-MSNPs (drug free) nanocarrier did not induce any histopathological alterations in vital organs and thus exhibited good biocompatibility.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19">4.2.  Trastuzumab</h3><div class="NLM_p">Trastuzumab antibodies (Herceptin) against human epidermal growth factor receptor were surface decorated over poly (<span class="smallcaps smallerCapital">d</span>,<span class="smallcaps smallerCapital">l</span>-lactide-<i>co</i>-glycolide)-montmorillonite nanoparticles (PLGA/MMT NPs) loaded with the anticancer drug paclitaxel. Such a system was expected to be multifunctional with reduced side effects of paclitaxel, providing synergistic benefits of therapy and targeted delivery. Significant cellular uptake was shown by the antibody decorated NPs in Caco-2 colon adenocarcinoma cells and SK-BR-3 breast cancer cells. In vitro cytotoxicity studies also revealed substantial therapeutic benefits in SK-BR-3 cells.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a></div><div class="NLM_p">Ito et al. synthesized immunoliposomes which contain magnetite nanoparticles (MNPs) conjugated with HER2 antibody (Trastuzumab) for the treatment of HER2-overexpressing cancer cells. HER2 antibody acted as a therapeutic molecule and as a targeting ligand, while MNPs were used for the purpose of magnetic hyperthermia. HER2-conjugated immunoliposomes were found to induce significant cytotoxic effects in SKBr3 breast cancer cells. Most of the MNPs (60%) were internalized by SKBr3 cells and then exposed to an alternating magnetic field, which exerted highly significant cytotoxicity.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a></div><div class="NLM_p last">Chitosan-based nanoparticles conjugated with Herceptin and loaded with gemcitabine chemotherapeutic drug (GEM-HER-Chit-NPs) were developed as a targeted drug delivery nanocarrier for the treatment of pancreatic cancer. GEM-HER-Chit-NPs exhibited superior cytotoxic effects with enhanced cell arrest and apoptosis as compared to GEM-Chit NPs (without HER2) and free gemcitabine drug in Mia Paca2 and PANC1 pancreatic cancer cells.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20">4.3.  Gemtuzumab</h3><div class="NLM_p">Gemtuzumab–ozogamicin (GEM-OZO) is an immuneconjugate composed of calicheamicin hydrazine derivative and anti-CD33 murine antibody, which is the first antibody targeted therapeutic agent approved by FDA. It showed potent activity and was selectively cytotoxic to HL-60 leukemia cells. In the mice bearing HL-60 xenograft tumors, long-term tumor free survivors resulted and the conjugate also showed selective inhibition of leukemia colony formation by marrow cells. In phase II clinical trials, Gem-ozo exhibited significant activity in acute myeloid leukemia patients.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a></div><div class="NLM_p last">Later, lipid-based nanoparticles (LNPs) were developed, and a further single chain variable fragment against CD33 (anti-CD33 scFv) was conjugated as a targeting ligand onto LNPs. CD33 was found to be overexpressed onto the surface of acute myeloid leukemia (AML) cells. Anti-CD33-LNPs were synthesized for the targeted delivery of antisense oligonucleotide (GTI-2040) in AML cells. GTI-2040 is an oligonucleotide complementary to R2 subunit of human ribonucleotide reductase (RNR). Cytarabine (cytosine arabinoside or Ara-C) is commonly used chemotherapeutic drug to treat acute myeloid leukemia patients, but patients elicit chemoresistance to Ara-C due to overexpression of RNR, which is an enzyme that forms deoxyribonucleotide triphosphate (dNTP) from NTP. Combination treatment of GTI-2040 and Ara-C in phase I clinical trials exhibited reduced RNR expression and also showed GTI-2040 treatment was safe, but it needed improved efficacy to develop as a therapeutic agent. Previously, deoxycholic acid (DOCA) and polyethyleneimine (PEI) conjugate has shown significant potential to successfully deliver oligonucleotide. Therefore, DOCA-PEI conjugate was added to LNPs to enhance silencing efficiency of GTI-2040 oligonucleotide. CD33-positive Kasumi-1 (AML) cells showed significant cellular internalization of GTI-2040-anti-CD33-LNPs. Both GTI-2040-LNPs and GTI-2040-anti-CD33-LNPs exhibited superior downregulation of the R2 subunit of RNR in Kasumi-1 cells. Additionally, combination treatment of GTI-2040-anti-CD33-LNPs and Ara-C has shown significant tumor regression and increased the overall survival time of the Kasumi-1 xenograft model. The study suggests that combination of GTI-2040-anti-CD33-LNPs and Ara-C has promising therapeutic potential for AML and anti-CD33-LNPs are efficient nanodelivery systems for oligonucleotide.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21">4.4.  BR96</h3><div class="NLM_p last">BR96 is a human–mouse chimeric monoclonal antibody, and it highly selectively binds to tumor antigen which is closely associated to Lewis Y and highly overexpressed on human cancer cells. Therefore, immuno-conjugates composed of BR96 and doxorubicin (DOX) were developed for highly efficient active targeting of cancer cells. BR96-DOX showed higher specificity, which showed selective binding and uptake by cancer cells and therefore able to deliver doxorubicin to cancer cells. The immuno-conjugate exhibited promising results as it completely regressed and treated human colon, breast, and lung xenograft tumors in mice and also treated almost 70% of mice with metastasized human lung cancer.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> Overall, BR96-DOX is an effective immuno-conjugate against cancer. In fact, it is also found that immuno-conjugate is only effective against BR96-positive human ectopic and orthotopic tumors; therefore, it acts truly as an active targeting agent.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> On the basis of the promising preclinical results, BR96-DOX entered into phase I clinical trials to assess its efficacy in patients with Lewis Y-positive tumors. This trial was conducted to evaluate immunogenicity, maximally tolerated dose, toxicity, and pharmacokinetics of immuno-conjugate. It was observed that BR96-DOX did not elicit side effects as produced by free doxorubicin and the dose of 700 mg/m<sup>2</sup> once in 3 weeks was well tolerated by patients. A large amount of doxorubicin can be selectively delivered to LewisY-positive tumors.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a></div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22">4.5.  Vascular Cell Adhesion Molecule-1 (VCAM-1) Antibody</h3><div class="NLM_p">Vascular cell adhesion molecule-1 (VCAM-1) is an immunoglobulin (Ig)-like protein which contains transmembrane-Ig-like- and cytoplasmic-domain. VCAM-1 plays a key role in intercellular connection and immune surveillance and expressed on the stimulated endothelial cells in cases of inflammatory conditions and cancer. VCAM-1 is reported to be highly expressed in several cancer types including stomach cancer, melanoma, lung cancer, breast cancer, renal cell carcinoma, leukemia, and lymphoma.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> Liposomes were synthesized and modified using polyethylene glycol, and later the PEG-modified liposomes were conjugated to VCAM-1 antibody. The developed immunoliposomes (VCAM-1-PEG-liposomes) comprised of VCAM-1 and PEG to specifically target VCAM-1 overexpressed tumor endothelial cells and enhanced circulation time, respectively. In vitro studies in stagnant and circulation simulated flow conditions showed specific binding of immunoliposomes to stimulated endothelial cells. Moreover, it exhibited higher tumor accumulation in mice having xenograft tumors of human colo-677, thereby providing an approach to target tumor vasculature by changing tumor endothelial function for targeted cancer therapy approach.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a></div><div class="NLM_p last">VCAM-1 first attracted attention more than two decades ago as an endothelial adhesion receptor with a key function for leukocyte recruitment in terms of cellular immune response. The early finding of VCAM-1 binding to melanoma cells, and thus a suggested mechanistic contribution to metastatic spread, was the first and for a long time the only link of VCAM-1 to cancer sciences. In the past few years, hallmarked by a growing insight into the molecular understanding of tumorigenicity and metastasis, an impressive variety of VCAM-1 functionalities in cancer have been elucidated. By illustrating the intriguing role of VCAM-1 in cancer disease, VCAM-1 is suggested as a new and up to now underestimated target in cancer treatment and in clinical diagnosis of malignancies.</div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">5.  Immunocell Targeted Delivery in Cancer</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74088" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74088" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The genetic mutational changes in the cells that bring forth the cancer lead to the activation of the immune system and generate responses that distinguish and terminate cancer cells. However, this elimination of cancer cells is just a little measure in the cancer immunity rhythm, which controls a fragile equilibrium between the nonself recognition and autoimmunity prevention.<a onclick="showRef(event, 'ref63 ref111'); return false;" href="javascript:void(0);" class="ref ref63 ref111">(63,111)</a> This identification, recognition, and elimination of cancer cells by immune cells motivated the development of a new class of cancer immunotherapy that elaborates the already existing anticancer immune responses. Certain immunosuppressive factors exist in the tumor microenvironment which limits the activity of immune-based cancer therapies, but these therapies can be rendered more effective in concomitance with other approaches that target other points in the cancer immune cycle (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).<a onclick="showRef(event, 'ref112 ref113'); return false;" href="javascript:void(0);" class="ref ref112 ref113">(112,113)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00511/20191205/images/medium/jm9b00511_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00511/20191205/images/large/jm9b00511_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Schematic illustration for cancer stem cell active targeting and cancer immune cell active targeting.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00511/20191205/images/large/jm9b00511_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00511&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The recent upsurge in the clinical data indicates that cancer immunotherapy soon will become an integral part of the clinical cancer management settings. Some of the immune checkpoint obstructing therapies recently exhibited efficacy against a variety of tumor types, however, a number of limitations are associated along with these which restrict the clinical utility of these and include serious off-target side effects, very confined patient response, and high cost.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> Certain biomaterial carriers may enable the scientists to surpass the delivery issues, expand the immunomodulatory potential, incorporate the synergism among different molecules, and most significantly can harbor and control the immune cells in vivo. For example, biomaterial-based dendritic cell modulation, nanomaterial-based cancer vaccines also called nanovaccines, biomaterial-based scaffolds for cancer vaccines, and biomaterial-based targeted manipulation of immune cells, biomaterials enabling checkpoint blockade therapy, and biomaterials for tumor associated macrophages regulation are some of the approaches that have been undertaken recently.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a></div><div class="NLM_p">In this context, the promising potential of dendritic cells in cancer immunity was exploited by Chao Li et al., where they studied the limitations associated with the enhancement of dendritic cells immunotherapeutic effects in cancer targeted immunotherapy. They formulated a dendritic cell and tumor cell fused vaccine in combination of cytokine induced killing cells for its increased efficacy against gastric cancer cells. Mature dendritic cells and inactive gastric cancer MGC803 cells were fused by PEG mediation immunotherapeutic and prophylactic potency was studied in animal models. NIR quantum dots were employed to assess the migration process and homing potential, and it was found that vaccine could trigger the tumor specific cytotoxic T-lymphocytes against gastric cancer cells. The formulation could also target the tumor tissue, increase the prophylactic potential, and significantly inhibit the tumor growth in vivo.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> Another study by Yao Yang et al. employed human cytokine-induced killer<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> cells loaded with gold nanorods for targeted imaging and potentiated immunotherapy and photothermal therapy of gastric cancer. Human CIK cells were treated with these nanorods and assessed for their cytotoxic ability and targeting of gastric cancer cells in vitro and in vivo. These were shown to inhibit cancer cellular growth and induced apoptosis under NIR laser treatment. In vivo experiments also proved that gold nanorod labeled CIK cells actively targeted gastric cancer vessels, potentiated the immunotherapeutic efficacy, and inhibited gastric cancer cells.<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> Another cancer immunotherapy study describes the unparalleled tumor targeting and cytotoxic properties of cytokine-induced killer cells, where these cells were labeled with CD3 antibody conjugated with chlorine molecules assisted gold nanoclusters. This CIK-based drug delivery system possessed significantly high tumor targeting ability and quite splendid therapeutic efficacy in a tumor bearing animal model. Also, the synergistic effects between the gold nanoclusters and cytokine-induced killer cells could be exploited to be employed in cancer theranostics for targeted imaging and combinatorial treatment.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a></div><div class="NLM_p">It has been reported time and again that most of the tumors exhibit immune evasion and become resistant to conventional chemotherapeutics. To surpass these limitations, ipilimumab, a human monoclonal antibody against cytotoxic T-lymphocytes-associated antigen 4 (CTLA-4), was found to enhance the median survival time and steadfastness of the disease progression in the patients of metastatic melanoma. Ipilimumab, concomitant with Aldesleukin, has been approved for advanced melanoma and is an established antitumor immunotherapeutic agent. Ipilimumab and paclitaxel albumin stabilized nanoparticle formulation, along with Bevacizumab targeting CTLA4 and VEGF-A receptors, were also tested in stage IV clinical trials for unresectable melanoma.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> Recently, Toll-like-receptor-7 antagonist, imiquimod, and indocyanin green were coencapsulated PLGA nanoparticles for photothermal and checkpoint blockade immunotherapy for primary tumors elimination, metastasis inhibition, and tumor relapse prevention. Imiquimod NPs exhibited vaccine-like function, and using anticytotoxic T-lymphocyte antigen-4 (CTLA4), the immunological response was potentiated by attacking the remnant tumor cells. It also imparts impregnable immunological memory which protects against further tumor relapses.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> Engineered antitumor immunotherapies by employing nanoparticulate materials thus become a prognosticating arena for further investigations and research. In vivo studies employing various nanoparticles, especially those less than 300 nm having both positive and negative surface charges, have been surface modified for selective targeting approaches for effective delivery of immunotherapeutics and actively stimulating the immune system targets.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a></div><div class="NLM_p last">Sometimes due to tumor complexity or tumor heterogeneity or due to varied patients’ response, the success rate of immunotherapy comes down drastically. Hence, early diagnosis of sensitive or resistant tumors becomes difficult as is the case with programmed death ligand 1 (αPDL1) antibody for immune checkpoint blockade. Therefore, now the straightforward noninvasive approach by employing computed tomography along with gold NPs conjugated to αPDL1 predicts the tumor response as early as within 48 h of treatment. Also, these NPs inhibit the tumor growth and may be quite beneficial in the differentiation of patients among responders and nonresponders.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> Similarly, Cano-Mejia et al. presented photothermal immunotherapy by employing Prussian blue NPs with anti-CTLA-4 checkpoint inhibition in neuroblastoma immunotherapy. The survival rate in mice treated with immune targeted NPs becomes significantly higher as compared to only CTLA-4 or only Prussian blue NPs treated mice.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> The present immunotherapy approaches have only selected clinical advantages as the cancer antigens are inefficiently extradited to the immune cellular targets and solid tumors dodge the antitumor immunity by configuring an immunosuppressive tumor microenvironment; that is, where to surpass such limitations, cancer immune cell targeted NPs are employed. Nanotechnology-based materials provide numerous approaches and properties for immunotherapeutic targeting, viz checkpoint inhibitors, targeted antigen presenting cells, targeted delivery of antibodies, gene and cytokine delivery, etc.<a onclick="showRef(event, 'ref125 ref126 ref127'); return false;" href="javascript:void(0);" class="ref ref125 ref126 ref127">(125−127)</a></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24">6.  Stem Cells Targeted Delivery in Cancer</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64100" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64100" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Stem cell based therapies have seen a prevalent upsurge in the treatment of a number of disorders including cancer.<a onclick="showRef(event, 'ref128 ref129'); return false;" href="javascript:void(0);" class="ref ref128 ref129">(128,129)</a> A number of challenges in stem cell based therapies like drug resistance, troublesome specific targeting, and self-renewal has led to lack of success in cancer treatment. Cancer stem cells have been exploited both in terms of primary cancer seeds and therapeutic targets in chemo- and radiotherapy resistance management.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> The characteristics of cancer stem cells like self-renewal, tumor initiation, and supporting cellular processes like epithelial to mesenchymal transition have seen a great deal of interest among cancer scientists as these properties provide an arena for new therapeutic targets in drug development.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a></div><div class="NLM_p">The potential for precise delivery of anticancer compounds specifically to cancer stem cells presents an urgent need in cancer therapeutics, with nanotechnology dependent drug delivery platforms as one of the most significant instruments to be applied in preclinical and clinical systems.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> However, the recognition of possible cancer stem cell based targets comes with significant challenges like deficiency of specific cancer stem cell markers, plasticity of cancer stem cells, etc. Mesenchymal stromal cells, also called mesenchymal stem cells, are able to migrate to the location of injured tissue and take part in tissue repair and regeneration. Likewise, in cancer, these are regularly attracted to the tumor site and become a vital part of the tumor microenvironment. It has been reported that such tumor associated MSCs trigger cancer initiation, participate in cancer progression, and also take part in metastasis (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a></div><div class="NLM_p">Some of the recent approaches in stem cell targeted delivery systems have come up for the effective theranostics of cancer. One such study by Yanlei Liu et al. describes the tumor photothermal therapy with gold nanorods for the plasmonic gold improved accumulation and intratumoral distribution. They fabricated the gold nanorods with silica as well as G-protein coupled receptors and loaded the prepared nanoparticles into human induced pluripotent stem cells. The system exhibited significant optical properties and tumor targeting, and stem cell mediated gold delivery possessed enhanced retention times and uniform distribution in tumor bearing mice. It possessed a rich migration potential to the tumor site and aided in significantly ameliorated the photothermal therapeutic ability in the tumor xenograft in mice.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a></div><div class="NLM_p">Certain exosomes-based stem cell therapies have been undertaken for targeting cancer stem cells and take advantage of the nontoxicity, nonimmunogenicity, strong delivery capacity, and target specificity of exosomes. Exosomes are described as natural nanosystems derived from cells and are found in the body fluids and take part in many disease processes. Therefore, this imparts to exosomes a strong character for drug delivery platform in cancer stem cell mediated therapies.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a></div><div class="NLM_p last">Some other nanomaterials as drug delivery platforms for targeting cancer stem cells include carbon-based-like graphene oxide conjugated with hyaluronic acid in specific targeting of skin cancer, chitosan coated carbon nanotubes specifically for breast cancer treatment, nanodiamonds carrying anticancer agent eupirubicin to surpass chemoresistance in liver cancer, etc.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> Also, DNA self-assembled nanostructures, particularly DNA origami, has been extensively employed as drug delivery platforms for targeting cancer stem cells. Many properties of DNA origami like obvious biocompatibility, ease of modification, and high functionalization capability render it one of the most suitable structures for cancer stem cell targeted drug delivery systems.<a onclick="showRef(event, 'ref136 ref137'); return false;" href="javascript:void(0);" class="ref ref136 ref137">(136,137)</a> In addition to these gold nanoparticles, gold nanorods, polymeric nanoparticles, liposomes, etc., have been exploited for drug delivery applications in cancer stem cell targeting.<a onclick="showRef(event, 'ref138 ref139 ref140'); return false;" href="javascript:void(0);" class="ref ref138 ref139 ref140">(138−140)</a></div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">7.  Protein Corona over Nanoparticles</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32858" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32858" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec7_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26">7.1.  Implications on Nanocarrier Mediated Tumor-Targeting</h3><div class="NLM_p">Depending upon the physicochemical properties of the nanoparticles like size, shape, surface composition, interfacial charge, surface functionality, and other properties of the surrounding biological fluid like blood, various kinds of proteins get adsorbed on these nanocarriers. The proteins may either adhere weakly to the nanoparticle surface which get removed by mild washing and therefore form what is called the “soft protein corona”. However, a number of proteins are attached tightly to the nanoparticle surface and may not be removed by gentle wash and hence form the “hard protein corona”.<a onclick="showRef(event, 'ref151 ref152'); return false;" href="javascript:void(0);" class="ref ref151 ref152">(151,152)</a></div><div class="NLM_p">The efficient biological applications, overall safety and toxicity profiles, and final biological fate of nanoparticles sometimes depend largely on the nature and types of proteins forming the corona. Some of the proteins which take part in the corona formation include but are not limited to serum albumin, prothrombin, transferrin, α-fetoproteins, immunoglobulin G, fibrinogen, clusterin, apolipoproteins, etc. Many times, positive or negative electrical charge presented over nanoparticle surfaces and manifested in terms of particle zeta potential attracts protein of an opposite charge and results in complete reversal of the zeta potential values. Because of the protein corona formation, it is actually the “corona proteins” which form the direct contact with the living surface of cells or tissue rather than the original naked surface of the nanoparticles. To date, several studies have been performed regarding the protein corona formation, separation, isolation, and characterization of the nature and types of proteins, their electrical charge and relative abundance, targeting abilities, toxicological profiles, and ultimate biological fate. The identification and characterization of corona forming proteins start with the washing and separation of proteins by centrifugation or by a combination of ultracentrifugation, size exclusion chromatography, ultrafiltration, etc. The proteins are then separated by uni- or bidimensional SDS-PAGE electrophoresis, their in situ digestion, and mass spectroscopic identification.<a onclick="showRef(event, 'ref153 ref154'); return false;" href="javascript:void(0);" class="ref ref153 ref154">(153,154)</a></div><div class="NLM_p">One such example is the transferrin conjugated nanoparticles formulated to specifically target overexpressed transferrin receptors on cancer cells, where the protein corona formation was found to be interfering with the transferrin conjugation and targeting ability of NPs vanished.<a onclick="showRef(event, 'ref155 ref156'); return false;" href="javascript:void(0);" class="ref ref155 ref156">(155,156)</a> Similarly, engineered silica nanoparticles coated with a small antibody mimetic ligand (affibody) for targeting cancer cells showed a dramatic inhibition of specific particle–cell association only due to protein coronas.<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a> Likewise, Safavi-Sohi et al. describe that surface functionalization of nanoparticles with active molecules for specific organ, cell, or organelle targeting is shielded and hampered by the protein corona layer, and this shielding effect then leads to mistargeting and scavenging of NPs by liver kidney and spleen.<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a></div><div class="NLM_p last">The other instance is the alteration in the biodistribution of nanoparticulate material where the protein corona formation alters the blood residence time or systemic circulation behavior of nanocarriers. It happens as the protein adsorption and desorption over the NP surface is in continuous equilibrium ,and proteins which are most abundant in serum are attached during the initial phase of NP administration, while during subsequent stages, the loosely attached proteins of the “soft corona” get replaced by other “hard corona” proteins with higher affinity. The inherent or naïve charge of the nanoparticle can manifest into toxicological reactions as positively charged surfaces are reported to interact and perturb the continuity and integrity of plasma membranes. However, this toxicity gets reduced by making the negatively charged proteins get adsorbed onto the positive NP surfaces.<a onclick="showRef(event, 'ref155 ref159'); return false;" href="javascript:void(0);" class="ref ref155 ref159">(155,159)</a></div></div><div id="sec7_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27">7.2.  Strategies</h3><div class="NLM_p">Different strategies have been employed to control and inhibit protein corona-induced shielding effects, mistargeting, and masking of the active targeting on NPs’ surfaces, such that targeting capabilities of NPs can be enhanced even in the presence of complex biological media like blood. One recent example is the designing of biotin–cysteine conjugated NPs where biotin is the targeting moiety while cysteine is employed as the zwitterionic ligand to inhibit the corona-induced mistargeting. This zwitterionic coating has emerged as a vital strategy to yield corona-free NPs with better targeting abilities. Another such technique is the coating of NPs with some specific proteins to formulate a selected protein corona before their administration into the complex biological fluid media and then enriching such a preferred corona with specific plasma proteins selected for straight tissue targeting.<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a></div><div class="NLM_p">The report by Tonigold et al. demonstrate that the protein corona typically masks the NP surface functionalized with targeting molecules, antibodies, or ligands, once the NPs are exposed to complex biological media, and this masking inevitably hinders the targeting capabilities of the nanoparticulate system. However, the preadsorption of antibodies is the solution to this problem and the preadsorbed antibodies remain functional and are not entirely replaced or masked by the protein corona. The authors resolved that preadsorption is possibly a competent, effective, and speedy approach for sequestration of targeting ligands onto the NPs’ surface.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a></div><div class="NLM_p last">Sometimes the preadsorption of antibodies can alter the spatial orientation of the targeting molecule and subsequently affects the accessibility of the proteins to the active binding site and may render the molecule inactive, thereby hampering the targeting efficacy of nanoparticles. In particular, a chemical functionality on the active targeting ligand reacts with another functional group on or in close proximity to the antigen binding site on the antibody, thereby inactivating the active site of the antibodies on surface of nanoparticulate material, leading to its unavailability for other interactions. Any further customization which can inhibit the inactivation of antigen binding site of the antibody will lead to the retention of targeting abilities of NPs. Another approach is the recruitment of proteins, forming a corona over the NP surface such that these target the same receptor as that targeted by the active molecule. The chemical conjugation approach offers some advantage over the preadsorption approach as in preadsorption due to the lower binding energy as compared to chemical conjugation; the antibodies may get detached from the NPs surface due to the dynamic nature of the blood circulation.<a onclick="showRef(event, 'ref161 ref162'); return false;" href="javascript:void(0);" class="ref ref161 ref162">(161,162)</a></div></div></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i28">8.  Cell Sex and Cellular Uptake of Nanoparticles</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56661" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56661" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In the recent past, a number of reports have emerged regarding the significant dependence of cellular functions on the cell sex types. It has now been established that quite a considerable number of cell functions exhibit great variations in relation to the secretion of biomolecules and signaling pathways that vary between sexes. For instance, subsequent to the nanoparticle administration, the protein corona forming around the cells may entirely consist of some sex-specific protein repertoires, which can entirely alter the extent of nanoparticle uptake inside the cancerous cells. Sex-subjected variations in cellular functionalities potentially maneuver both the cause and treatment of diseases. Likewise, sex specific versatility in proteins and hormone secretion can influence the biological identity and cellular fate of NPs in context of safety, efficacy, toxicity, subcellular trafficking, etc.<a onclick="showRef(event, 'ref163 ref164 ref165 ref166 ref167'); return false;" href="javascript:void(0);" class="ref ref163 ref164 ref165 ref166 ref167">(163−167)</a></div><div class="NLM_p">Some of the prominent studies on cell sex include one by Hayashi et al., which employed the zebrafish model in which the blood plasma exhibits sexual demarcation in terms of the distinct presence or absence of egg yolk precursor vitellogenin, thus forming the sex-specific protein coronas around the NPs. They observed contrasting differences in the biological identities of silica NPs in terms of the protein corona formation and cellular uptake and preferred accumulation of “sexually different” NPs in certain particular types of cells.<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a> Another recent report by Sarpooshan et al. studied the role of cell sex in cellular uptake of NPs and demonstrated that male and female human amniotic stem cells exhibit a differential approach with comparatively more uptake being shown by the female cells. They replicated the experiments in different cells viz primary fibroblasts obtained from the salivary glands of similar aged adult male and female donors and again observed that uptake was enhanced in male cells. They also established that amniotic cells of different sex types responded differently to the cellular reprogramming by Yamanaka factors.<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a> Similarly, it was shown by Chen et al. that gold NPs when administered to mice of different sex exhibited different cellular responses in terms of toxicological effects like inflammation, immune response, etc. The toxicological response of different organs in various doses was also significantly diverse among the male and female animals, where male mice exhibited more severe liver damage whereas female mice showed severe kidney damage.<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a></div><div class="NLM_p last">Thus, it has now been established that cell sex exerts quite a significant impact on the cellular outcomes of NP treatment in terms of several phenomena including differential and sex-specific protein corona formation, cellular uptake of NPs, diversity in the release of paracrine, and endocrine factors. These factors can entirely alter the biological individuality of NPs along with their physicochemical properties. This significant information about the cell sex has been an important missing link from most of the reports in the arena of NP studies. The consideration of different cell sex in the context of the physicochemical properties of NPs and various cellular–biomolecular interactions, cellular secretions, endocrine, and paracrine functions needs to be given due significance as far as nanoparticles’ studies are concerned.<a onclick="showRef(event, 'ref166 ref167'); return false;" href="javascript:void(0);" class="ref ref166 ref167">(166,167)</a></div></div><div id="sec9" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i29">9.  Toxicity and Safety Challenges</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85525" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85525" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">During the employment of nanoparticles in preclinical stages, their biocompatibility, safety, and nontoxicity may become one of the main overlooked aspects. In this context, the investigation and evaluation of various toxicological prospects of NPs become significant before their applicability in the clinical settings. The major concern of today’s researchers is to design and formulate nanoparticles which are not only efficacious but also completely biocompatible, safe, hemocompatible, and nontoxic in their entirety. These efforts target the better biological characterization of NPs to gain a deep interpretation of their biological functions as well as their inherent toxicological attributes. The advances that have been achieved in our understanding and integration of nanomedicine has not been proportionately extended to its clinical employability because the same characteristics of NPs which render them considerably fitted for industry also make them toxic and nonsafe in biological and medicinal contexts. Serious efforts have been put in to design and validate various assays to evaluate the toxicological potential of NPs so as to satiate the existing breach between their in vitro and in vivo outcomes.<a onclick="showRef(event, 'ref168 ref169 ref170'); return false;" href="javascript:void(0);" class="ref ref168 ref169 ref170">(168−170)</a></div><div class="NLM_p">Liang Yan et al. state that despite the appreciable achievements, the new nanomedicine-based formulations still possess an incomplete realization of safety parameters and toxicological characteristics. They reviewed the vital nanomedicinal materials along with clinical applicability and toxicological studies and summarized the principles in the development of safe medicinal nanoformulations. The authors described how the measurement of physicochemical properties of nanomaterials, quantification of the in vivo trafficking viz the absorption, distribution, metabolism, and excretion (ADME) and disclosure of the interaction mechanisms of the nanomaterials with the biological milieu and development of structure–activity-based models for nanomedicinal substances have led to the step-by-step formulation of strategies for assessment of safety of nanomaterials. Out of several designs, coating of nanoparticles with biocompatible polymers, loading of nanoparticles onto another structure or into a matrix system, grafting of biocompatible functional moieties, and doping of nanomaterials with other nontoxic and biocompatible material serve as the vital strategies for safe, biocompatible, and nontoxic nanoparticle designs.<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a></div><div class="NLM_p">Recently, Laura Hodson et al. reviewed the regulatory aspects regarding the safety and toxicity of engineered nanomaterials in light of the toxicity and safety data sheets (SDS) released by Occupational Safety and Health Administration (OSHA). The purpose of these data sheets is to convey the information regarding the safety hazards of nanomaterials on the exposure or administration of these to biological systems. These data sheets undertake many of the physicochemical properties of nanoparticles like particle size in terms of hydrodynamic diameter, surface area, and particle charge in terms of zeta potential as well as the various permissible limits of their release into the environment or exposure of the living organisms to these engineered nanomaterials.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a></div><div class="NLM_p">Another more practical approach was followed by Joossens et al., who performed in vitro high throughput imaging for toxicity aspects of nanomaterials so as to reduce the testing on animals. They included several vital parameters in their testing like high contrast imaging, cell-based assays like viable cell counts, cell membrane permeability, apoptotic cell death, mitochondrial membrane potential, etc. They suggest that testing such a large set of nanomaterials in different concentrations provides a huge database that can be employed in the exploitation of in silico hazard testing evaluation, an anticipatory tool and can be conjugated with other toxicological aspects to establish safety and toxicity standards.<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a></div><div class="NLM_p">Another regulatory aspect by Karmanizadeh et al. analyzes the toxicological hazards of nanomaterials for their potential use in consumer products viz. pharmaceutical products, nanomedicine, and cosmeceutical formulations and discusses many of their physicochemical properties like size, shape, and structure, material composition, agglomeration, solubility, charge, etc. It also accounts for many potential exposure routes and toxicological outcomes of biological systems to nanomaterials toxicity, including exposure through the pulmonary route, ingestive administration into the gastrointestinal tract, their toxicological effects on the hepatobilliary and cardiovascular systems, and their final excretion and elimination through the renal systems.<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a></div><div class="NLM_p last">A similar aspect was studied by Blázquez et al., where they evaluated the predictive toxicology for the approval of nanomaterial employability in biocidal active substances prescribed under the biocidal product regulation. Many nanoparticlulate insecticides, acaricides, and substances for other arthropods, silicon dioxide, etc., were evaluated in the context of Biocides Product Regulation (BPR). The quantitative structure–activity relationship approach (Nano-QSAR) was employed for genesis of ecotoxicological data needed for the recommendation of novel active products in the nanometric scale. They suggest that these recommendations can set the frameworks for novel approaches in the regulatory approval of nanomaterial-based products that require special considerations.<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a></div></div><div id="sec10" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i30">10.  Nanomedicine-Based Anticancer Therapeutics in Clinical Stages</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88147" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88147" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Because of some of the very grievous challenges associated with the development of nanomedicine-based drug delivery systems, only a few of the approaches are able to make it up to the clinical systems. Although in preclinical stages, a broad scene of combinations are being tried among biomaterials to develop nanoscale cancer targeting paradigms due to the associated toxicities and side effects, most of the nanotherapies cannot survive up to the clinical settings. Some of the prominent model nanosystems which either have marked their presence up to the clinical stages or have been approved by any of the drug regulatory bodies include proteins-based nanocarriers like albumin nanoparticles loaded with paclitaxel, some lipid-based nanosystems like liposomes containing number of payloads like drugs and siRNAs, some nucleic acid conjugation based systems, and some polymeric micellar nanocarriers.</div><div class="NLM_p">As the development stages proceed from preclinical to clinical systems, an attritional bottleneck starts coming into existence accompanied by a number of safety and regulatory issues in testing the safety and efficacy of the targeted nanocarriers being developed. Some of the prominent nanomedicine-based systems which are in various developmental stages of clinical trials or have passed the clinical phase are described in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Summary of Nanomedicines-Based Anticancer Therapeutics in Clinical Stages</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">no.</th><th class="colsep0 rowsep0" align="center">nanosystems</th><th class="colsep0 rowsep0" align="center">drug/payload</th><th class="colsep0 rowsep0" align="center">cancer types</th><th class="colsep0 rowsep0" align="center">stages of development</th><th class="colsep0 rowsep0" align="center">ref</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">PEGylated liposomes</td><td class="colsep0 rowsep0" align="left">doxorubicin</td><td class="colsep0 rowsep0" align="left">ovarian carcinoma</td><td class="colsep0 rowsep0" align="left">FDA approved (nontargeted therapy)</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">albumin nanospheres</td><td class="colsep0 rowsep0" align="left">paclitaxel</td><td class="colsep0 rowsep0" align="left">breast cancer, pancreatic ductal adenocarcinoma</td><td class="colsep0 rowsep0" align="left">FDA approved (targeted therapy)</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">polymeric micelles</td><td class="colsep0 rowsep0" align="left">cisplatin</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">ongoing phase III clinical trials</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">PEG bioconjugates</td><td class="colsep0 rowsep0" align="left">asparginase</td><td class="colsep0 rowsep0" align="left">acute lymphoblastic leukemia</td><td class="colsep0 rowsep0" align="left">FDA approved (nontargeted)</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">polyplex</td><td class="colsep0 rowsep0" align="left">nucleic acid based nanomedicine</td><td class="colsep0 rowsep0" align="left">bladder cancer, ovarian cancer</td><td class="colsep0 rowsep0" align="left">phase II (targeted)</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">PLGA nanoparticles</td><td class="colsep0 rowsep0" align="left">nucleic acid based nanomedicine</td><td class="colsep0 rowsep0" align="left">pancreatic ductal adenocarcinoma</td><td class="colsep0 rowsep0" align="left">phase II (nontargeted)</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="left">polyconjugates</td><td class="colsep0 rowsep0" align="left">nucleic acid based nanomedicine</td><td class="colsep0 rowsep0" align="left">ovarian cancer</td><td class="colsep0 rowsep0" align="left">phase II (nontargeted)</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">revusiran</td><td class="colsep0 rowsep0" align="left">siRNA based medicine</td><td class="colsep0 rowsep0" align="left">liver cancer</td><td class="colsep0 rowsep0" align="left">phase III clinical trial terminated</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">9</td><td class="colsep0 rowsep0" align="left">liposomes</td><td class="colsep0 rowsep0" align="left">cytarabine + daunorubicin</td><td class="colsep0 rowsep0" align="left">acute myeloid leukemia</td><td class="colsep0 rowsep0" align="left">FDA approved (nontargeted)</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">liposomes</td><td class="colsep0 rowsep0" align="left">vincristine</td><td class="colsep0 rowsep0" align="left">acute myeloid leukemia</td><td class="colsep0 rowsep0" align="left">approved</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="left">polyglutamate based polymeric nanosystem</td><td class="colsep0 rowsep0" align="left">paclitaxel</td><td class="colsep0 rowsep0" align="left">head and neck cancer</td><td class="colsep0 rowsep0" align="left">phase III clinical trials</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">cyclodextran conjugated nanosystem</td><td class="colsep0 rowsep0" align="left">camptothecin</td><td class="colsep0 rowsep0" align="left">rectal cancer, advanced solid tumor malignancies</td><td class="colsep0 rowsep0" align="left">phase II clinical trials</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">13</td><td class="colsep0 rowsep0" align="left">dendrimer conjugated nanosystems</td><td class="colsep0 rowsep0" align="left">docetaxel</td><td class="colsep0 rowsep0" align="left">advanced cancer</td><td class="colsep0 rowsep0" align="left">phase I clinical trials</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="left">liposomes</td><td class="colsep0 rowsep0" align="left">irinotecan</td><td class="colsep0 rowsep0" align="left">pancreatic cancer</td><td class="colsep0 rowsep0" align="left">approved</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">nanomicellar formulation</td><td class="colsep0 rowsep0" align="left">paclitaxel</td><td class="colsep0 rowsep0" align="left">metastatic breast cancer</td><td class="colsep0 rowsep0" align="left">approved</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">liposomes</td><td class="colsep0 rowsep0" align="left">oxaliplatin</td><td class="colsep0 rowsep0" align="left">colorectal cancer, glioma</td><td class="colsep0 rowsep0" align="left">phase II clinical trials</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">17</td><td class="colsep0 rowsep0" align="left">lipid based nanosystem</td><td class="colsep0 rowsep0" align="left">lurtotecan</td><td class="colsep0 rowsep0" align="left">small cell lung cancer</td><td class="colsep0 rowsep0" align="left">phase II clinical trials completed</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">18</td><td class="colsep0 rowsep0" align="left">polymeric nanosystem</td><td class="colsep0 rowsep0" align="left">RRM2 siRNA</td><td class="colsep0 rowsep0" align="left">solid tumors</td><td class="colsep0 rowsep0" align="left">phase II clinical trials terminated</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">19</td><td class="colsep0 rowsep0" align="left">polymer protein conjugate</td><td class="colsep0 rowsep0" align="left">styrene maleic anhydride</td><td class="colsep0 rowsep0" align="left">renal cancer</td><td class="colsep0 rowsep0" align="left">approved</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">20</td><td class="colsep0 rowsep0" align="left">liposome (non-PEGylated)</td><td class="colsep0 rowsep0" align="left">mifamurtide</td><td class="colsep0 rowsep0" align="left">osteosarcoma</td><td class="colsep0 rowsep0" align="left">approved</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a></td></tr></tbody></table></div></div></div><div id="sec11" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i32">11.  Challenges with Active Targeting Approaches</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35351" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35351" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Despite the enormous quantity of research being carried out on the active targeting nanocarriers, only a small percentage of it has translated itself into the clinical practice. Although every aspect has been tried and tested to minimize and limit the barriers associated with the delivery of active targeting NPs, there still remains a significant number of physiological and technological barriers which need proactive consideration to make the active targeting more efficient, cost-effective, and patient compliant. These challenges can be categorized based upon technical feasibilities of the formulation and characterization of nanocarriers, the physiological parameters between in vitro and in vivo correlations, and regulatory considerations for the approval of nanomedicine-based targeted approaches for clinical applications.<a onclick="showRef(event, 'ref173 ref174 ref175'); return false;" href="javascript:void(0);" class="ref ref173 ref174 ref175">(173−175)</a></div><div class="NLM_p">A recent report by Benchimol et al. describes that transport across tumor endothelium is a major challenge in nanomedicine-based drug delivery and poses significant challenges in the penetration and diffusion of nanoparticles and accumulation of these inside tumors. It takes into account several of the difficult to measure parameters like tumor flux, permeability, nonlinear diffusion rates, viscous tumor interstitium, blood vessel marginal efficiency, and nonpredictable intratumoral blood flow rates, etc.<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a> Similarly Rosenblum et al. describe a number of other limitations associated with the targeted delivery of cancer nanotherapeutics and discuss numerous reasons responsible for the limited translation of preclinical research into clinical success. According to them, many physiological barriers like tumor penetrability of NPs, distinct morphological and phonotypical profiles of tumors, relative hypoxia, and endosomal escape pose a significant challenge in the design of active targeting nanocarriers. Some other hurdles like strict regulatory considerations by administrative bodies, viz, FDA and EMA, for their dictation of minimal standards for preclinical laboratory assessments become significant.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a></div><div class="NLM_p">Raucher et al. reviewed the challenges associated with targeting of various receptors overexpressed in tumor cells and explained that heterogeneity of tumor cells in the expression of receptors becomes a challenge in active targeting. Other hurdles like endosomal escape, hard parenchyma of the blood–brain barrier, aggressiveness, and recurrence of tumors also pose significant challenges in the nanoparticle mediated active targeting.<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a> Likewise, Congcong Zu et al. reviewed some major challenges in the active targeting nanoparticle mediated anticancer therapeutics. They categorized these challenges like tissue penetration by nanoparticles, nanoparticle aggregation, unpredictable pharmacokinetic properties, intentional recognition of nanoparticles by the reticulo-endothelial system (RES), and hence the fast systemic clearance, accumulation of nanoparticles in different organs, nanoparticle heterogeneity, etc., and to overcome such challenges, they suggested a strategy which undertakes formulation of RNA-based nanoparticles. However, even these RNA-based nanocarriers suffer from a limitation of endosomal escape which, as the authors suggest, need significant improvement.<a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a></div><div class="NLM_p">Maniam et al. recently reviewed some of the key limitations with active targeting drug delivery platforms for cancer therapy. They state that in liquid formulation coalescence, creaming, and Ostwald ripening while in powdered formulations, aggregation and clustering are main hindrances as far as their scale-up is concerned. Also, the need for these biological nanocarriers to cross multiple biological barriers poses significant hindrances in the active targeted drug delivery.<a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a></div><div class="NLM_p">Lisa Belfiore et al. discussed about the hurdles associated with the active targeted ligand functionalized liposomes. They described that therapeutic resistance develops to targeted anticancer therapeutics because of the tumor heterogeneity which can be overcome by targeting multiple tumor cell subtypes within a heterogeneous tumor cell population. Also, the lacunae in the established protocols for the scale-up production and clinical translation of these technologies pose significant hindrances and prove a vital limitation in their clinical success.<a onclick="showRef(event, 'ref179 ref180'); return false;" href="javascript:void(0);" class="ref ref179 ref180">(179,180)</a></div><div class="NLM_p last">Apart from these, several other hindrances, limitations, and challenges arise due to the adsorption of proteins over nanoparticles from the biological milieu and thus, formation of protein corona over nanoparticles. The protein corona formation affects several of the physicochemical and biological properties of active targeting NPs and holds vital control on the overall pharmacodynamics and pharmacokinetics (absorption, distribution, metabolic biotransformation, and excretory elimination) of nanoparticles. This aspect has been detailed in the earlier sections.</div></div><div id="sec12" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i33">12.  Future Perspectives and Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01666" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01666" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Although cancer is one of the deadliest diseases, the therapeutic interventions are surgery, chemotherapy, and radiotherapy as the major available options. The research arena for the nanotechnology-based targeted delivery of cancer therapeutics has enormously expanded in  recent years with the sole aim of minimizing the toxic effects and enhancing the efficacy of anticancer chemotherapeutics and better imaging of tumors. Both newer drugs as well as new approaches for directing the drugs to the tumor site are being constantly tried and tested both at preclinical and clinical levels. Both passive and active nanocarrier mediated targeting strategies have been put into practice as far as the cancer chemotherapy is concerned, and many of these have been established at the clinical levels and are being used for improving the patients’ quality of life and overall survival.</div><div class="NLM_p">This review describes, in brief, a number of active targeting methods which have been undertaken for the nanotechnology-based targeted cancer therapy. A number of biomolecules, receptors, antibodies, and some other special features and unique pathophysiological characteristics that are especially and particularly present in cancer cells are described here which have been exploited for selectively targeting cancer cells. It has been briefed how certain specific features in cancer cells can be aimed for selectively inhibiting cancer cells while sparing the normal healthy cells unharmed. A number of interesting nanoformulations and nanocarriers like polymeric and metallic nanoparticles, nanotubes, nanosized micelles, nanoliposomes, nanovectors, nanogels, and nanocrystals have been described that have undergone research for the passive and active targeting of antineoplastic diseases. Only a few of the nanocarrier systems have been able to reach clinical trial phases or have been approved by the regulatory bodies, which imparts to us an insight into the actual script in the development of active-targeting nanomedicines for cancer therapies.</div><div class="NLM_p last">However, there is a great deal more that can be achieved as far as the early and effective diagnosis, detection, and treatment of cancer is concerned. Hope for early diagnosis, detection, and treatment of cancer has been the impetus to develop aforementioned effective targeting strategies. But, a good deal of superior strategies is still needed so that cancer detection and targeting techniques can further be improved. The contribution of cancer nanomedicine- and nanocarrier-based targeted cancer therapies will continuously grow, and many more goals will undoubtedly be pursued and hopefully achieved in years to come.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b00511" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57667" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57667" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rehan Khan</span> - <span class="hlFld-Affiliation affiliation">Institute
of Nano Science and Technology, Habitat Centre, Phase 10, Sector 64, Mohali 160062, Punjab, India</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2406-1129" title="Orcid link">http://orcid.org/0000-0002-2406-1129</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#f0829598919e9b98919eb0999e8384de9193de999e"><span class="__cf_email__" data-cfemail="c9bbaca1a8a7a2a1a8a789a0a7babde7a8aae7a0a7">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anas Ahmad</span> - <span class="hlFld-Affiliation affiliation">Institute
of Nano Science and Technology, Habitat Centre, Phase 10, Sector 64, Mohali 160062, Punjab, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Farheen Khan</span> - <span class="hlFld-Affiliation affiliation">Institute
of Nano Science and Technology, Habitat Centre, Phase 10, Sector 64, Mohali 160062, Punjab, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rakesh Kumar Mishra</span> - <span class="hlFld-Affiliation affiliation">Institute
of Nano Science and Technology, Habitat Centre, Phase 10, Sector 64, Mohali 160062, Punjab, India</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70774" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70774" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Anas Ahmad</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00511&amp;id=BIO-d7e1796-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Anas Ahmad</b> is a doctoral fellow in the Department of Nano-Therapeutics, Institute of Nano Science and Technology (INST), Mohali, Punjab, India. He pursued a Bachelor’s degree in Pharmaceutical Sciences (B.Pharm.) from Jamia Hamdard University, New Delhi, and M.S. (Pharm.) with specialization in Pharmacology and Toxicology from the National Institute of Pharmaceutical Education and Research (NIPER) Mohali, India. He has six years of experience in the arena of nanosytems mediated delivery of pharmacological agents to be employed in the treatment of cancer and other inflammatory diseases. He has contributed to a number of reputed research and review publications on nanoparticle medicated delivery of anticancer and anti-inflammatory drugs.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Farheen Khan</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00511&amp;id=BIO-d7e1801-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Farheen Khan</b> worked as a Department of Science and technology (DST) project fellow in the department of Nano-Therapeutics, Institute of Nano Science and Technology (INST), Mohali, Punjab, India. She pursued a Bachelor’s degree in Pharmaceutical Sciences (B.Pharm.) from Banasthali Vidyapith, Rajasthan, India, and a Masters in Pharmaceutical Sciences (M.Pharm.) with specialization in Pharmaceutics from Babasaheb Bhimrao Ambedkar University, Lucknow, India. Currently, she is working as a Pharmacovigilance Scientist in Docplexus Contract Research Organization (CRO), Pune, India.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Rakesh Kumar Mishra</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00511&amp;id=BIO-d7e1806-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Rakesh Kumar Mishra</b> is a doctoral fellow in the Department of Nano-Therapeutics, Institute of Nano Science and Technology (INST), Mohali, Punjab, India. He pursued Bachelor’s degree in Pharmaceutical Sciences (B.Pharm.) from Uttar Pradesh Technical University, Lucknow, India, and a Masters in Pharmacy (M.Pharm.) in pharmacology from Babasaheb Bhimrao Ambedkar University, Lucknow, India. He has five years of work experience in the field of Pharmacology and Toxicology and has some reputed publications to his credit. He also worked as a CSIR-project fellow in CSIR-Central Institute of Medicinal and Aromatic Plants (CIMAP), Lucknow, India, where he worked on colon targeted delivery of anticancer and anti-inflammatory pharmaceutical agent. Currently, he is working in the area of nanoparticle mediated delivery of anticancer agents in preclinical models.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Rehan Khan</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00511&amp;id=BIO-d7e1811-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Rehan Khan</b> is Scientist-C at the Institute of Nano Science and Technology (INST), Mohali, India. Dr. Khan received his Ph.D. on Chemoprevention of Colon Cancer from the Hamdard University, New Delhi. During his postdoc at the University of Manitoba, he worked on exploring novel drug targets for selective killing of cancer. Dr. Khan has authored several publications in various journals. His publications reflect his research interests in targeted cancer therapy using a nanocarrier for efficient anticancer drug delivery.</p></figure></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i38">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80383" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80383" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work is supported by Department of Science and Technology SERB, grant nos. YSS/2015/001851 and DST-Nanomission with grant no. SR/NM/NB-1044/2016(G). A.A. and R.K.M. are thankful to INST for providing fellowship.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">DNA</td><td class="NLM_def"><p class="first last">deoxyribonucleic acid</p></td></tr><tr><td class="NLM_term">RNA</td><td class="NLM_def"><p class="first last">ribonucleic acid</p></td></tr><tr><td class="NLM_term">NPs</td><td class="NLM_def"><p class="first last">nanoparticles</p></td></tr><tr><td class="NLM_term">siRNA</td><td class="NLM_def"><p class="first last">small interfering ribonucleic acid</p></td></tr><tr><td class="NLM_term">EPR</td><td class="NLM_def"><p class="first last">enhanced permeability and retention</p></td></tr><tr><td class="NLM_term">AMP</td><td class="NLM_def"><p class="first last">adenosine 5′-monophosphate, adenosine 5′-phosphate</p></td></tr><tr><td class="NLM_term">SLN</td><td class="NLM_def"><p class="first last">solid lipid nanoparticles</p></td></tr><tr><td class="NLM_term">AND</td><td class="NLM_def"><p class="first last">adenosine receptor ligand</p></td></tr><tr><td class="NLM_term">SPION</td><td class="NLM_def"><p class="first last">superparamagnetic iron oxide nanoparticle</p></td></tr><tr><td class="NLM_term">UTP</td><td class="NLM_def"><p class="first last">uracil triphosphate</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">TFR</td><td class="NLM_def"><p class="first last">transferrin receptors</p></td></tr><tr><td class="NLM_term">MDR</td><td class="NLM_def"><p class="first last">multi-drug resistance</p></td></tr><tr><td class="NLM_term">TRQ</td><td class="NLM_def"><p class="first last">tariquidar</p></td></tr><tr><td class="NLM_term">P-gp</td><td class="NLM_def"><p class="first last">P-glycoprotein</p></td></tr><tr><td class="NLM_term">PTX</td><td class="NLM_def"><p class="first last">paclitaxel</p></td></tr><tr><td class="NLM_term">PEG–PE</td><td class="NLM_def"><p class="first last">polyethylene glycol–phosphatidyl ethanolamine</p></td></tr><tr><td class="NLM_term">DHA</td><td class="NLM_def"><p class="first last">dihydroartemisinin</p></td></tr><tr><td class="NLM_term">LLC</td><td class="NLM_def"><p class="first last">Lewis lung carcinoma</p></td></tr><tr><td class="NLM_term">DOX</td><td class="NLM_def"><p class="first last">doxorubicin</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">RTK</td><td class="NLM_def"><p class="first last">receptor tyrosine kinase</p></td></tr><tr><td class="NLM_term">MAF</td><td class="NLM_def"><p class="first last">monoclonal antibody fragments</p></td></tr><tr><td class="NLM_term">miRNA</td><td class="NLM_def"><p class="first last">microRNA</p></td></tr><tr><td class="NLM_term">FR</td><td class="NLM_def"><p class="first last">folate receptors</p></td></tr><tr><td class="NLM_term">NRP-1</td><td class="NLM_def"><p class="first last">neuropilin-1</p></td></tr><tr><td class="NLM_term">VEGF</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor</p></td></tr><tr><td class="NLM_term">HUVEC</td><td class="NLM_def"><p class="first last">human umbilical vein endothelial cells</p></td></tr><tr><td class="NLM_term">CGT-NPs</td><td class="NLM_def"><p class="first last">cilengitide-loaded nanoparticles</p></td></tr><tr><td class="NLM_term">UTMD</td><td class="NLM_def"><p class="first last">ultrasound-targeted microbubble destruction</p></td></tr><tr><td class="NLM_term">CTX</td><td class="NLM_def"><p class="first last">chlorotoxin</p></td></tr><tr><td class="NLM_term">NIR</td><td class="NLM_def"><p class="first last">near-infrared</p></td></tr><tr><td class="NLM_term">PEI</td><td class="NLM_def"><p class="first last">polyethylenimine</p></td></tr><tr><td class="NLM_term">IO</td><td class="NLM_def"><p class="first last">iron oxide</p></td></tr><tr><td class="NLM_term">MMP-2</td><td class="NLM_def"><p class="first last">matrix metalloproteinase-2</p></td></tr><tr><td class="NLM_term">OA</td><td class="NLM_def"><p class="first last">oleic acid</p></td></tr><tr><td class="NLM_term">OCT</td><td class="NLM_def"><p class="first last">octreotide</p></td></tr><tr><td class="NLM_term">Qdots</td><td class="NLM_def"><p class="first last">quantum dots</p></td></tr><tr><td class="NLM_term">DAL</td><td class="NLM_def"><p class="first last">diacerin-loaded nanoliposomes</p></td></tr><tr><td class="NLM_term">PLGA</td><td class="NLM_def"><p class="first last">polylactic-<i>co</i>-glycolic acid</p></td></tr><tr><td class="NLM_term">GLUT</td><td class="NLM_def"><p class="first last">glucose transporter</p></td></tr><tr><td class="NLM_term">Glu-Si-NPs</td><td class="NLM_def"><p class="first last">glucose functionalized silica nanoparticles</p></td></tr><tr><td class="NLM_term">APC</td><td class="NLM_def"><p class="first last">antigen presenting cells</p></td></tr><tr><td class="NLM_term">BMDM</td><td class="NLM_def"><p class="first last">bone marrow-derived macrophages</p></td></tr><tr><td class="NLM_term">MUC1</td><td class="NLM_def"><p class="first last">mucin 1</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and Drug Administration</p></td></tr><tr><td class="NLM_term">GRAS</td><td class="NLM_def"><p class="first last">Generally Regarded as Safe</p></td></tr><tr><td class="NLM_term">5FU</td><td class="NLM_def"><p class="first last">5-fluorouracil</p></td></tr><tr><td class="NLM_term">CMC</td><td class="NLM_def"><p class="first last">carboxymethyl cellulose</p></td></tr><tr><td class="NLM_term">NFs</td><td class="NLM_def"><p class="first last">nanoformulations</p></td></tr><tr><td class="NLM_term">mAbs</td><td class="NLM_def"><p class="first last">monoclonal antibodies</p></td></tr><tr><td class="NLM_term">MSNPs</td><td class="NLM_def"><p class="first last">mesoporous silica nanoparticles</p></td></tr><tr><td class="NLM_term">PLGA/MMT NPs</td><td class="NLM_def"><p class="first last">poly(<span class="smallcaps smallerCapital">d</span>,<span class="smallcaps smallerCapital">l</span>-lactide-<i>co</i>-glycolide)-montmorillonite nanoparticles</p></td></tr><tr><td class="NLM_term">LNPs</td><td class="NLM_def"><p class="first last">lipid-based nanoparticles</p></td></tr><tr><td class="NLM_term">AML</td><td class="NLM_def"><p class="first last">acute myeloid leukemia</p></td></tr><tr><td class="NLM_term">RNR</td><td class="NLM_def"><p class="first last">ribonucleotide reductase</p></td></tr><tr><td class="NLM_term">dNTP</td><td class="NLM_def"><p class="first last">deoxyribonucleotide triphosphate</p></td></tr><tr><td class="NLM_term">DOCA</td><td class="NLM_def"><p class="first last">deoxycholic acid</p></td></tr><tr><td class="NLM_term">VCAM-1</td><td class="NLM_def"><p class="first last">vascular cell adhesion molecule-1</p></td></tr><tr><td class="NLM_term">CIK</td><td class="NLM_def"><p class="first last">cytokine-induced killer</p></td></tr><tr><td class="NLM_term">MSCs</td><td class="NLM_def"><p class="first last">mesenchymal stromal cells</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i40">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31084" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31084" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 180 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jemal, A.</span></span> <span> </span><span class="NLM_article-title">Cancer Statistics, 2016</span>. <i>Ca-Cancer J. Clin.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.3322/caac.21332</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.3322%2Fcaac.21332" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=26742998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A280%3ADC%252BC28rot1Kjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2016&pages=7-30&author=R.+L.+Siegelauthor=K.+D.+Millerauthor=A.+Jemal&title=Cancer+Statistics%2C+2016&doi=10.3322%2Fcaac.21332"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer statistics, 2016</span></div><div class="casAuthors">Siegel Rebecca L; Miller Kimberly D; Jemal Ahmedin</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival.  Incidence data were collected by the National Cancer Institute (Surveillance, Epidemiology, and End Results [SEER] Program), the Centers for Disease Control and Prevention (National Program of Cancer Registries), and the North American Association of Central Cancer Registries.  Mortality data were collected by the National Center for Health Statistics.  In 2016, 1,685,210 new cancer cases and 595,690 cancer deaths are projected to occur in the United States.  Overall cancer incidence trends (13 oldest SEER registries) are stable in women, but declining by 3.1% per year in men (from 2009-2012), much of which is because of recent rapid declines in prostate cancer diagnoses.  The cancer death rate has dropped by 23% since 1991, translating to more than 1.7 million deaths averted through 2012.  Despite this progress, death rates are increasing for cancers of the liver, pancreas, and uterine corpus, and cancer is now the leading cause of death in 21 states, primarily due to exceptionally large reductions in death from heart disease.  Among children and adolescents (aged birth-19 years), brain cancer has surpassed leukemia as the leading cause of cancer death because of the dramatic therapeutic advances against leukemia.  Accelerating progress against cancer requires both increased national investment in cancer research and the application of existing cancer control knowledge across all segments of the population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSKAn5ROFAaRS86Js-BCLiifW6udTcc2eZ1cU41k6hjwLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rot1Kjug%253D%253D&md5=2d4030a531945c5ebaaab181bfd80457</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3322%2Fcaac.21332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.21332%26sid%3Dliteratum%253Aachs%26aulast%3DSiegel%26aufirst%3DR.%2BL.%26aulast%3DMiller%26aufirst%3DK.%2BD.%26aulast%3DJemal%26aufirst%3DA.%26atitle%3DCancer%2520Statistics%252C%25202016%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2016%26volume%3D66%26spage%3D7%26epage%3D30%26doi%3D10.3322%2Fcaac.21332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holohan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Schaeybroeck, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longley, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, P. G.</span></span> <span> </span><span class="NLM_article-title">Cancer Drug Resistance: An Evolving Paradigm</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">714</span>– <span class="NLM_lpage">726</span>, <span class="refDoi"> DOI: 10.1038/nrc3599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1038%2Fnrc3599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=24060863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVyqurnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=714-726&author=C.+Holohanauthor=S.+Van+Schaeybroeckauthor=D.+B.+Longleyauthor=P.+G.+Johnston&title=Cancer+Drug+Resistance%3A+An+Evolving+Paradigm&doi=10.1038%2Fnrc3599"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer drug resistance: an evolving paradigm</span></div><div class="casAuthors">Holohan, Caitriona; Van Schaeybroeck, Sandra; Longley, Daniel B.; Johnston, Patrick G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">714-726</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Resistance to chemotherapy and molecularly targeted therapies is a major problem facing current cancer research.  The mechanisms of resistance to 'classical' cytotoxic chemotherapeutics and to therapies that are designed to be selective for specific mol. targets share many features, such as alterations in the drug target, activation of prosurvival pathways and ineffective induction of cell death.  With the increasing arsenal of anticancer agents, improving preclin. models and the advent of powerful high-throughput screening techniques, there are now unprecedented opportunities to understand and overcome drug resistance through the clin. assessment of rational therapeutic drug combinations and the use of predictive biomarkers to enable patient stratification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrykBEUSgvv7Vg90H21EOLACvtfcHk0lhdE7VMbqgLVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVyqurnE&md5=b497a823bbd968904ce1591b918d0679</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc3599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3599%26sid%3Dliteratum%253Aachs%26aulast%3DHolohan%26aufirst%3DC.%26aulast%3DVan%2BSchaeybroeck%26aufirst%3DS.%26aulast%3DLongley%26aufirst%3DD.%2BB.%26aulast%3DJohnston%26aufirst%3DP.%2BG.%26atitle%3DCancer%2520Drug%2520Resistance%253A%2520An%2520Evolving%2520Paradigm%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2013%26volume%3D13%26spage%3D714%26epage%3D726%26doi%3D10.1038%2Fnrc3599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Byrne, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betancourt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brannon-Peppas, L.</span></span> <span> </span><span class="NLM_article-title">Active Targeting Schemes for Nanoparticle Systems in Cancer Therapeutics</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1615</span>– <span class="NLM_lpage">1626</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2008.08.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.addr.2008.08.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=18840489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVSjsL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2008&pages=1615-1626&author=J.+D.+Byrneauthor=T.+Betancourtauthor=L.+Brannon-Peppas&title=Active+Targeting+Schemes+for+Nanoparticle+Systems+in+Cancer+Therapeutics&doi=10.1016%2Fj.addr.2008.08.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Active targeting schemes for nanoparticle systems in cancer therapeutics</span></div><div class="casAuthors">Byrne, James D.; Betancourt, Tania; Brannon-Peppas, Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1615-1626</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The objective of this review is to outline current major cancer targets for nanoparticle systems and give insight into the direction of the field.  The major targeting strategies that have been used for the delivery of therapeutic or imaging agents to cancer have been broken into three sections.  These sections are angiogenesis-assocd. targeting, targeting to uncontrolled cell proliferation markers, and tumor cell targeting.  The targeting schemes explored for many of the reported nanoparticle systems suggest the great potential of targeted delivery to revolutionize cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7soOyI6FoYLVg90H21EOLACvtfcHk0lg3_LxBFT1ouw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVSjsL%252FP&md5=aeeb388245fec939e63fda98fb154d99</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2008.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2008.08.005%26sid%3Dliteratum%253Aachs%26aulast%3DByrne%26aufirst%3DJ.%2BD.%26aulast%3DBetancourt%26aufirst%3DT.%26aulast%3DBrannon-Peppas%26aufirst%3DL.%26atitle%3DActive%2520Targeting%2520Schemes%2520for%2520Nanoparticle%2520Systems%2520in%2520Cancer%2520Therapeutics%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2008%26volume%3D60%26spage%3D1615%26epage%3D1626%26doi%3D10.1016%2Fj.addr.2008.08.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, R.</span></span> <span> </span><span class="NLM_article-title">Selective Targeting of Cancer Cells Using Personalized Nanomedicine</span>. <i>Toxicol Forensic Med. Open J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">e12</span>– <span class="NLM_lpage">e13</span>, <span class="refDoi"> DOI: 10.17140/TFMOJ-1-e005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.17140%2FTFMOJ-1-e005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2016&pages=e12-e13&author=A.+Guptaauthor=A.+Ahmadauthor=A.+Darauthor=A.+Bhattauthor=R.+Khan&title=Selective+Targeting+of+Cancer+Cells+Using+Personalized+Nanomedicine&doi=10.17140%2FTFMOJ-1-e005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.17140%2FTFMOJ-1-e005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.17140%252FTFMOJ-1-e005%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DAhmad%26aufirst%3DA.%26aulast%3DDar%26aufirst%3DA.%26aulast%3DBhatt%26aufirst%3DA.%26aulast%3DKhan%26aufirst%3DR.%26atitle%3DSelective%2520Targeting%2520of%2520Cancer%2520Cells%2520Using%2520Personalized%2520Nanomedicine%26jtitle%3DToxicol%2520Forensic%2520Med.%2520Open%2520J.%26date%3D2016%26volume%3D1%26spage%3De12%26epage%3De13%26doi%3D10.17140%2FTFMOJ-1-e005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prabhu, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patravale, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, M. D.</span></span> <span> </span><span class="NLM_article-title">Polymeric Nanoparticles for Targeted Treatment in Oncology: Current Insights</span>. <i>Int. J. Nanomed.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1001</span>– <span class="NLM_lpage">1018</span>, <span class="refDoi"> DOI: 10.2147/IJN.S56932</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.2147%2FIJN.S56932" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=25678788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktl2qt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1001-1018&author=R.+H.+Prabhuauthor=V.+B.+Patravaleauthor=M.+D.+Joshi&title=Polymeric+Nanoparticles+for+Targeted+Treatment+in+Oncology%3A+Current+Insights&doi=10.2147%2FIJN.S56932"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Polymeric nanoparticles for targeted treatment in oncology: current insights</span></div><div class="casAuthors">Prabhu, Rashmi H.; Patravale, Vandana B.; Joshi, Medha D.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Nanomedicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1001-1018</span>CODEN:
                <span class="NLM_cas:coden">IJNNHQ</span>;
        ISSN:<span class="NLM_cas:issn">1178-2013</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Chemotherapy, a major strategy for cancer treatment, lacks the specificity to localize the cancer therapeutics in the tumor site, thereby affecting normal healthy tissues and advocating toxic adverse effects.  Nanotechnol. intervention has greatly revolutionized the therapy of cancer by surmounting the current limitations in conventional chemotherapy, which include undesirable biodistribution, cancer cell drug resistance, and severe systemic side effects.  Nanoparticles (NPs) achieve preferential accumulation in the tumor site by virtue of their passive and ligand-based targeting mechanisms.  Polymer-based nanomedicine, an arena that entails the use of polymeric NPs, polymer micelles, dendrimers, polymersomes, polyplexes, polymer-lipid hybrid systems, and polymer-drug/protein conjugates for improvement in efficacy of cancer therapeutics, has been widely explored.  The broad scope for chem. modifying the polymer into desired construct makes it a versatile delivery system.  Several polymer-based therapeutic NPs have been approved for clin. use.  This review provides an insight into the advances in polymer-based targeted nanocarriers with focus on therapeutic aspects in the field of oncol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTKOWCqQFfKrVg90H21EOLACvtfcHk0liEgo0CVnXjrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktl2qt7s%253D&md5=23a5f2583db59d156fe6cf9954c00ac3</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.2147%2FIJN.S56932&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIJN.S56932%26sid%3Dliteratum%253Aachs%26aulast%3DPrabhu%26aufirst%3DR.%2BH.%26aulast%3DPatravale%26aufirst%3DV.%2BB.%26aulast%3DJoshi%26aufirst%3DM.%2BD.%26atitle%3DPolymeric%2520Nanoparticles%2520for%2520Targeted%2520Treatment%2520in%2520Oncology%253A%2520Current%2520Insights%26jtitle%3DInt.%2520J.%2520Nanomed.%26date%3D2015%26volume%3D10%26spage%3D1001%26epage%3D1018%26doi%3D10.2147%2FIJN.S56932" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haeri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osouli, M.</span></span> <span> </span><span class="NLM_article-title">EGFR Targeted Nanocarriers for Cancer Diagnosis and Therapy</span>. <i>Trends Pept. Protein Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">55</span>, <span class="refDoi"> DOI: 10.22037/tpps.v1i2.13611</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.22037%2Ftpps.v1i2.13611" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2017&pages=41-55&author=A.+Haeriauthor=M.+Osouli&title=EGFR+Targeted+Nanocarriers+for+Cancer+Diagnosis+and+Therapy&doi=10.22037%2Ftpps.v1i2.13611"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.22037%2Ftpps.v1i2.13611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.22037%252Ftpps.v1i2.13611%26sid%3Dliteratum%253Aachs%26aulast%3DHaeri%26aufirst%3DA.%26aulast%3DOsouli%26aufirst%3DM.%26atitle%3DEGFR%2520Targeted%2520Nanocarriers%2520for%2520Cancer%2520Diagnosis%2520and%2520Therapy%26jtitle%3DTrends%2520Pept.%2520Protein%2520Sci.%26date%3D2017%26volume%3D1%26spage%3D41%26epage%3D55%26doi%3D10.22037%2Ftpps.v1i2.13611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Strebhardt, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullrich, A.</span></span> <span> </span><span class="NLM_article-title">Paul Ehrlich’s Magic Bullet Concept: 100 Years of Progress</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">473</span>– <span class="NLM_lpage">480</span>, <span class="refDoi"> DOI: 10.1038/nrc2394</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1038%2Fnrc2394" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=18469827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmt1Oksbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=473-480&author=K.+Strebhardtauthor=A.+Ullrich&title=Paul+Ehrlich%E2%80%99s+Magic+Bullet+Concept%3A+100+Years+of+Progress&doi=10.1038%2Fnrc2394"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Paul Ehrlich's magic bullet concept: 100 years of progress</span></div><div class="casAuthors">Strebhardt, Klaus; Ullrich, Axel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">473-480</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">One hundred years ago, Paul Ehrlich received the Nobel Prize for Physiol. or Medicine.  His idea of creating 'magic bullets' for use in the fight against human diseases has inspired generations of scientists to devise powerful mol. cancer therapeutics.  Exceptional advances in mol. biol. and genetic research have expedited cancer drug development tremendously.  The declared paradigm is the development of 'personalized and tailored drugs' that precisely target the specific mol. defects of a cancer patient.  It is therefore appropriate to revisit the intellectual foundations of the development of such agents, as many have shown great clin. success.  One hundred years ago, Paul Ehrlich, the founder of chemotherapy, received the Nobel Prize for Physiol. or Medicine.  His postulate of creating 'magic bullets' for use in the fight against human diseases inspired generations of scientists to devise powerful mol. cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA71zae_BVCbVg90H21EOLACvtfcHk0lgfykrnDZYXGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmt1Oksbw%253D&md5=e56fb7160426e409a7cb48ecf56a4483</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrc2394&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2394%26sid%3Dliteratum%253Aachs%26aulast%3DStrebhardt%26aufirst%3DK.%26aulast%3DUllrich%26aufirst%3DA.%26atitle%3DPaul%2520Ehrlich%25E2%2580%2599s%2520Magic%2520Bullet%2520Concept%253A%2520100%2520Years%2520of%2520Progress%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2008%26volume%3D8%26spage%3D473%26epage%3D480%26doi%3D10.1038%2Fnrc2394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ambade, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savariar, E. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thayumanavan, S.</span></span> <span> </span><span class="NLM_article-title">Dendrimeric Micelles for Controlled Drug Release and Targeted Delivery</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">264</span>– <span class="NLM_lpage">272</span>, <span class="refDoi"> DOI: 10.1021/mp050020d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp050020d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkslSltL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=264-272&author=A.+V.+Ambadeauthor=E.+N.+Savariarauthor=S.+Thayumanavan&title=Dendrimeric+Micelles+for+Controlled+Drug+Release+and+Targeted+Delivery&doi=10.1021%2Fmp050020d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Dendrimeric micelles for controlled drug release and targeted delivery</span></div><div class="casAuthors">Ambade, Ashootosh V.; Savariar, Elamprakash N.; Thayumanavan, S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">264-272</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This review highlights the developments in dendrimer-based micelles for drug delivery.  Dendrimers, the perfectly branched monodisperse macromols., have certain structural advantages that make them attractive candidates as drug carriers for controlled release or targeted delivery.  As polymeric micelle-based approaches precede the work in dendrimers, these are also discussed briefly.  The review concludes with a perspective on possible applications of biaryl-based dendrimeric micelles that exhibit environment-dependent conformations, in drug delivery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6H0x54VbddLVg90H21EOLACvtfcHk0lgXCX4vRcVQYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkslSltL4%253D&md5=05e7a1fdee6ec635bef9d85f7608bc6c</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fmp050020d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp050020d%26sid%3Dliteratum%253Aachs%26aulast%3DAmbade%26aufirst%3DA.%2BV.%26aulast%3DSavariar%26aufirst%3DE.%2BN.%26aulast%3DThayumanavan%26aufirst%3DS.%26atitle%3DDendrimeric%2520Micelles%2520for%2520Controlled%2520Drug%2520Release%2520and%2520Targeted%2520Delivery%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2005%26volume%3D2%26spage%3D264%26epage%3D272%26doi%3D10.1021%2Fmp050020d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">K M, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ansari, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayamurugan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, R.</span></span> <span> </span><span class="NLM_article-title">Nanocarrier Composed of Magnetite Core Coated with Three Polymeric Shells Mediates LCS-1 Delivery for Synthetic Lethal Therapy of BLM-Defective Colorectal Cancer Cells</span>. <i>Biomacromolecules</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">803</span>– <span class="NLM_lpage">815</span>, <span class="refDoi"> DOI: 10.1021/acs.biomac.7b01607</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biomac.7b01607" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivVais7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=803-815&author=A.+Guptaauthor=A.+Ahmadauthor=H.+Singhauthor=S.+Kaurauthor=N.+K+Mauthor=M.+M.+Ansariauthor=G.+Jayamuruganauthor=R.+Khan&title=Nanocarrier+Composed+of+Magnetite+Core+Coated+with+Three+Polymeric+Shells+Mediates+LCS-1+Delivery+for+Synthetic+Lethal+Therapy+of+BLM-Defective+Colorectal+Cancer+Cells&doi=10.1021%2Facs.biomac.7b01607"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Nanocarrier composed of magnetite core coated with three polymeric shells mediates LCS-1 delivery for synthetic lethal therapy of BLM-defective colorectal cancer cells</span></div><div class="casAuthors">Gupta, Anuradha; Ahmad, Anas; Singh, Hardeep; Kaur, Sharanjeet; Neethu, K. M.; Ansari, Md. Meraj; Jayamurugan, Govindasamy; Khan, Rehan</div><div class="citationInfo"><span class="NLM_cas:title">Biomacromolecules</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">803-815</span>CODEN:
                <span class="NLM_cas:coden">BOMAF6</span>;
        ISSN:<span class="NLM_cas:issn">1525-7797</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Synthetic lethality is a mol.-targeted therapy for selective killing of cancer cells.  We exploited a lethal interaction between superoxide dismutase 1 inhibition and Bloom syndrome gene product (BLM) defect for the treatment of colorectal cancer (CRC) cells (HCT 116) with a customized lung cancer screen-1-loaded nanocarrier (LCS-1-NC).  The drug LCS-1 has poor aq. soly.  To overcome its limitations, a customized NC, composed of a magnetite core coated with three polymeric shells, namely, aminocellulose (AC), branched poly(amidoamine), and paraben-PEG, was developed for encapsulating LCS-1.  Encapsulation efficiency and drug loading were found to be 74% and 8.2%, resp.  LCS-1-NC exhibited sustained release, with ∼85% of drug release in 24 h.  Blank NC (0.5 mg/mL) exhibited cytocompatibility toward normal cells, mainly due to the AC layer.  LCS-1-NC demonstrated high killing selectivity (104 times) toward BLM-deficient HCT 116 cells over BLM-proficient HCT 116 cells.  Due to enhanced efficacy of the drug using NC, the sensitivity difference for BLM-deficient cells increased to 1.7 times in comparison to that with free LCS-1.  LCS-1-NC induced persistent DNA damage and apoptosis, which demonstrates that LCS-1-NC effectively and preferentially killed BLM-deficient CRC cells.  This is the first report on the development of a potential drug carrier to improve the therapeutic efficacy of LCS-1 for specific killing of CRC cells having BLM defects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjpxH-q-AazbVg90H21EOLACvtfcHk0lguMqKD-43Twg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivVais7g%253D&md5=3dd493e08c0a3212138ed4ba465909fb</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Facs.biomac.7b01607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biomac.7b01607%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DAhmad%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DH.%26aulast%3DKaur%26aufirst%3DS.%26aulast%3DK%2BM%26aufirst%3DN.%26aulast%3DAnsari%26aufirst%3DM.%2BM.%26aulast%3DJayamurugan%26aufirst%3DG.%26aulast%3DKhan%26aufirst%3DR.%26atitle%3DNanocarrier%2520Composed%2520of%2520Magnetite%2520Core%2520Coated%2520with%2520Three%2520Polymeric%2520Shells%2520Mediates%2520LCS-1%2520Delivery%2520for%2520Synthetic%2520Lethal%2520Therapy%2520of%2520BLM-Defective%2520Colorectal%2520Cancer%2520Cells%26jtitle%3DBiomacromolecules%26date%3D2018%26volume%3D19%26spage%3D803%26epage%3D815%26doi%3D10.1021%2Facs.biomac.7b01607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dar, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, R.</span></span> <span> </span><span class="NLM_article-title">Synthetic Lethality: From Research to Precision Cancer Nanomedicine</span>. <i>Curr. Cancer Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">337</span>– <span class="NLM_lpage">346</span>, <span class="refDoi"> DOI: 10.2174/1568009617666170630141931</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.2174%2F1568009617666170630141931" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=28669337" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnvFejtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=337-346&author=A.+Guptaauthor=A.+Ahmadauthor=A.+I.+Darauthor=R.+Khan&title=Synthetic+Lethality%3A+From+Research+to+Precision+Cancer+Nanomedicine&doi=10.2174%2F1568009617666170630141931"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic Lethality: From Research to Precision Cancer Nanomedicine</span></div><div class="casAuthors">Gupta, Anuradha; Ahmad, Anas; Dar, Aqib Iqbal; Khan, Rehan</div><div class="citationInfo"><span class="NLM_cas:title">Current Cancer Drug Targets</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">337-346</span>CODEN:
                <span class="NLM_cas:coden">CCDTB9</span>;
        ISSN:<span class="NLM_cas:issn">1568-0096</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Cancer is an evolutionary disease with multiple genetic alterations, accumulated due to chromosomal instability and/or aneuploidy and it sometimes acquires drug-resistant phenotype also.  Whole genome sequencing and mutational anal. helped in understanding the differences among persons for predisposition of a disease and its treatment non-responsiveness.  Thus, mol. targeted therapies came into existence.  Among them, the concept of synthetic lethality have enthralled great attention as it is a pragmatic approach towards exploiting cancer cell specific mutations to specifically kill cancer cells without affecting normal cells and thus enhancing anti-cancer drug therapeutic index.  Thus, this approach helped in discovering new therapeutic mols. for development of precision medicine.  Nanotechnol. helped in delivering these mols. to the target site in an effective concn. thus reducing off target effects of drugs, dose and dosage frequency drugs.  Researchers have tried to deliver siRNA targeting synthetic lethal partner for target cancer cell killing by incorporating it in nanoparticles and it has shown efficacy by preventing tumor progression.  This review summarizes the brief introduction of synthetic lethality, and synthetic lethal gene interactions, with a major focus on its therapeutic anticancer potential with the application of nanotechnol. for development of personalized medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNT60k7B0777Vg90H21EOLACvtfcHk0lhHQFQOaOFKNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnvFejtbc%253D&md5=a2385841eda520b634f1f6ab2eaa885a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2174%2F1568009617666170630141931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568009617666170630141931%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DAhmad%26aufirst%3DA.%26aulast%3DDar%26aufirst%3DA.%2BI.%26aulast%3DKhan%26aufirst%3DR.%26atitle%3DSynthetic%2520Lethality%253A%2520From%2520Research%2520to%2520Precision%2520Cancer%2520Nanomedicine%26jtitle%3DCurr.%2520Cancer%2520Drug%2520Targets%26date%3D2018%26volume%3D18%26spage%3D337%26epage%3D346%26doi%3D10.2174%2F1568009617666170630141931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayamurugan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, R.</span></span> <span> </span><span class="NLM_article-title">Applying Synthetic Lethality to Nanomedicine: LCS-1 Loaded Magnetite and Polymeric Nanoparticles for the Treatment of BLM and CHEK2-Deficient Colorectal Cancer Cells</span>. <i>Cancer Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">28</span>, <span class="refDoi"> DOI: 10.1186/s12964-018-0238-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1186%2Fs12964-018-0238-x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2018&pages=27-28&author=A.+Ahmadauthor=A.+Guptaauthor=G.+Jayamuruganauthor=R.+Khan&title=Applying+Synthetic+Lethality+to+Nanomedicine%3A+LCS-1+Loaded+Magnetite+and+Polymeric+Nanoparticles+for+the+Treatment+of+BLM+and+CHEK2-Deficient+Colorectal+Cancer+Cells&doi=10.1186%2Fs12964-018-0238-x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1186%2Fs12964-018-0238-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12964-018-0238-x%26sid%3Dliteratum%253Aachs%26aulast%3DAhmad%26aufirst%3DA.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DJayamurugan%26aufirst%3DG.%26aulast%3DKhan%26aufirst%3DR.%26atitle%3DApplying%2520Synthetic%2520Lethality%2520to%2520Nanomedicine%253A%2520LCS-1%2520Loaded%2520Magnetite%2520and%2520Polymeric%2520Nanoparticles%2520for%2520the%2520Treatment%2520of%2520BLM%2520and%2520CHEK2-Deficient%2520Colorectal%2520Cancer%2520Cells%26jtitle%3DCancer%2520Med.%26date%3D2018%26volume%3D7%26spage%3D27%26epage%3D28%26doi%3D10.1186%2Fs12964-018-0238-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blanco, M.</span>; <span class="NLM_string-name">Teijón, C.</span>; <span class="NLM_string-name">Olmo, R.</span>; <span class="NLM_string-name">Teijón, J.</span></span> <span> </span><span class="NLM_article-title">Targeted Nanoparticles for Cancer Therapy</span>. In  <i>Recent Advances in Novel Drug Carrier Systems</i>; <span class="NLM_publisher-name">InTech</span>: <span class="NLM_publisher-loc">Janeza Trdine 9, 51000 Rijeka, Croatia</span>, <span class="NLM_year">2012</span>; <span class="refDoi"> DOI: 10.5772/51382</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.5772%2F51382" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=M.+Blanco&author=C.+Teij%C3%B3n&author=R.+Olmo&author=J.+Teij%C3%B3n&title=Recent+Advances+in+Novel+Drug+Carrier+Systems"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.5772%2F51382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.5772%252F51382%26sid%3Dliteratum%253Aachs%26aulast%3DBlanco%26aufirst%3DM.%26atitle%3DTargeted%2520Nanoparticles%2520for%2520Cancer%2520Therapy%26btitle%3DRecent%2520Advances%2520in%2520Novel%2520Drug%2520Carrier%2520Systems%26pub%3DInTech%26date%3D2012%26doi%3D10.5772%2F51382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haley, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frenkel, E.</span></span> <span> </span><span class="NLM_article-title">In Nanoparticles for Drug Delivery in Cancer Treatment</span>. <i>Urol. Oncol.: Semin. Orig. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">64</span>, <span class="refDoi"> DOI: 10.1016/j.urolonc.2007.03.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.urolonc.2007.03.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=18190833" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlsVWqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=57-64&author=B.+Haleyauthor=E.+Frenkel&title=In+Nanoparticles+for+Drug+Delivery+in+Cancer+Treatment&doi=10.1016%2Fj.urolonc.2007.03.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Nanoparticles for drug delivery in cancer treatment</span></div><div class="casAuthors">Haley, Barbara; Frenkel, Eugene</div><div class="citationInfo"><span class="NLM_cas:title">Urologic Oncology: Seminars and Original Investigations</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-64</span>CODEN:
                <span class="NLM_cas:coden">UOSOAA</span>;
        ISSN:<span class="NLM_cas:issn">1078-1439</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Nanoparticles (size in nanometer range) provide a new mode of cancer drug delivery functioning as a carrier for entry through fenestrations in tumor vasculature allowing direct cell access.  These particles allow exquisite modification for binding to cancer cell membranes, the microenvironment, or to cytoplasmic or nuclear receptor sites.  This results in delivery of high drug concns. to the targeted cancer cell, with reduced toxicity of normal tissue.  Several such engineered drugs are in clin. practice, including liposomal doxorubicin and albumin conjugate paclitaxel.  The carrier mediated paclitaxel has already shown significant efficacy in taxane resistant cancers, an approach highly relevant in prostate cancer, where taxanes are the treatment of choice.  Other modifications including transferrin receptor and folate receptor targeted drug delivery mols. are in study.  This new technol. provides many exciting therapeutic approaches for targeted high concn. drug delivery to cancer cells with reduced injury of normal cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJHhEKhqrLzrVg90H21EOLACvtfcHk0lgnvjPbYtAj9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlsVWqtQ%253D%253D&md5=2e9523ea06f91249f9b0cee8440837b6</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.urolonc.2007.03.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.urolonc.2007.03.015%26sid%3Dliteratum%253Aachs%26aulast%3DHaley%26aufirst%3DB.%26aulast%3DFrenkel%26aufirst%3DE.%26atitle%3DIn%2520Nanoparticles%2520for%2520Drug%2520Delivery%2520in%2520Cancer%2520Treatment%26jtitle%3DUrol.%2520Oncol.%253A%2520Semin.%2520Orig.%2520Invest.%26date%3D2008%26volume%3D26%26spage%3D57%26epage%3D64%26doi%3D10.1016%2Fj.urolonc.2007.03.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Torchilin, V.</span></span> <span> </span><span class="NLM_article-title">Tumor Delivery of Macromolecular Drugs Based on the EPR Effect</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">131</span>– <span class="NLM_lpage">135</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2010.03.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.addr.2010.03.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=20304019" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktF2jur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2011&pages=131-135&author=V.+Torchilin&title=Tumor+Delivery+of+Macromolecular+Drugs+Based+on+the+EPR+Effect&doi=10.1016%2Fj.addr.2010.03.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor delivery of macromolecular drugs based on the EPR effect</span></div><div class="casAuthors">Torchilin, Vladimir</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">131-135</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Enhanced permeability and retention (EPR) effect is the physiol.-based principal mechanism of tumor accumulation of large mols. and small particles.  This specific issue of Advanced Drug Delivery Reviews is summing up multiple data on the EPR effect-based drug design and clin. outcome.  In this commentary, the role of the EPR effect in the intratumoral delivery of protein and peptide drugs, macromol. drugs and drug-loaded long-circulating pharmaceutical nanocarriers is briefly discussed together with some addnl. opportunities for drug delivery arising from the initial EPR effect-mediated accumulation of drug-contg. macromol. systems in tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosnNJqwkqLNLVg90H21EOLACvtfcHk0liDCYOg-whp-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktF2jur4%253D&md5=25ea755afea49f20c4301756bf15c6a1</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2010.03.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2010.03.011%26sid%3Dliteratum%253Aachs%26aulast%3DTorchilin%26aufirst%3DV.%26atitle%3DTumor%2520Delivery%2520of%2520Macromolecular%2520Drugs%2520Based%2520on%2520the%2520EPR%2520Effect%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2011%26volume%3D63%26spage%3D131%26epage%3D135%26doi%3D10.1016%2Fj.addr.2010.03.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sutradhar, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amin, M. L.</span></span> <span> </span><span class="NLM_article-title">Nanotechnology in Cancer Drug Delivery and Selective Targeting</span>. <i>ISRN Nanotechnol</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>2014</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1155/2014/939378</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1155%2F2014%2F939378" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2014&publication_year=2014&pages=1-12&author=K.+B.+Sutradharauthor=M.+L.+Amin&title=Nanotechnology+in+Cancer+Drug+Delivery+and+Selective+Targeting&doi=10.1155%2F2014%2F939378"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1155%2F2014%2F939378&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2014%252F939378%26sid%3Dliteratum%253Aachs%26aulast%3DSutradhar%26aufirst%3DK.%2BB.%26aulast%3DAmin%26aufirst%3DM.%2BL.%26atitle%3DNanotechnology%2520in%2520Cancer%2520Drug%2520Delivery%2520and%2520Selective%2520Targeting%26jtitle%3DISRN%2520Nanotechnol%26date%3D2014%26volume%3D2014%26spage%3D1%26epage%3D12%26doi%3D10.1155%2F2014%2F939378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, H.</span></span> <span> </span><span class="NLM_article-title">The Enhanced Permeability and Retention (EPR) Effect in Tumor Vasculature: The Key Role of Tumor-Selective Macromolecular Drug Targeting</span>. <i>Adv. Enzyme Regul.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">189</span>– <span class="NLM_lpage">207</span>, <span class="refDoi"> DOI: 10.1016/S0065-2571(00)00013-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2FS0065-2571%2800%2900013-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=11384745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmtlekt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2001&pages=189-207&author=H.+Maeda&title=The+Enhanced+Permeability+and+Retention+%28EPR%29+Effect+in+Tumor+Vasculature%3A+The+Key+Role+of+Tumor-Selective+Macromolecular+Drug+Targeting&doi=10.1016%2FS0065-2571%2800%2900013-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting</span></div><div class="casAuthors">Maeda, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Enzyme Regulation</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">189-207</span>CODEN:
                <span class="NLM_cas:coden">AEZRA2</span>;
        ISSN:<span class="NLM_cas:issn">0065-2571</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review, with 59 refs., describes the vascular permeability effect in tumor tissues, macromol. drug delivery, and pathophysiol. of tumor vessels.  Tumor vasculature can be an excellent target for delivery of macromol. anticancer drugs, the most beneficial class of drugs in view of tumor-selective targeting based on the enhanced permeability and retention effect in solid tumor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtl5whieMPvbVg90H21EOLACvtfcHk0lg5_I-bnLAFyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmtlekt7k%253D&md5=9be9d39fe75e3765a7907669fd354536</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2FS0065-2571%2800%2900013-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0065-2571%252800%252900013-3%26sid%3Dliteratum%253Aachs%26aulast%3DMaeda%26aufirst%3DH.%26atitle%3DThe%2520Enhanced%2520Permeability%2520and%2520Retention%2520%2528EPR%2529%2520Effect%2520in%2520Tumor%2520Vasculature%253A%2520The%2520Key%2520Role%2520of%2520Tumor-Selective%2520Macromolecular%2520Drug%2520Targeting%26jtitle%3DAdv.%2520Enzyme%2520Regul.%26date%3D2001%26volume%3D41%26spage%3D189%26epage%3D207%26doi%3D10.1016%2FS0065-2571%2800%2900013-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drummond, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benz, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirpgtin, D. B.</span></span> <span> </span><span class="NLM_article-title">Liposome Targeting to Tumors Using Vitamin and Growth Factor Receptors</span>. <i>Vitam. Horm.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">332</span>, <span class="refDoi"> DOI: 10.1016/S0083-6729(00)60022-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2FS0083-6729%2800%2960022-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=11037627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A280%3ADC%252BD3cvovVagtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2000&pages=285-332&author=D.+C.+Drummondauthor=K.+Hongauthor=J.+W.+Parkauthor=C.+C.+Benzauthor=D.+B.+Kirpgtin&title=Liposome+Targeting+to+Tumors+Using+Vitamin+and+Growth+Factor+Receptors&doi=10.1016%2FS0083-6729%2800%2960022-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Liposome targeting to tumors using vitamin and growth factor receptors</span></div><div class="casAuthors">Drummond D C; Hong K; Park J W; Benz C C; Kirpotin D B</div><div class="citationInfo"><span class="NLM_cas:title">Vitamins and hormones</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">285-332</span>
        ISSN:<span class="NLM_cas:issn">0083-6729</span>.
    </div><div class="casAbstract">Liposome-encapsulated anticancer drugs reveal their potential for increased therapeutic efficacy and decreased nonspecific toxicities due to their ability to enhance the delivery of chemotherapeutic agents to solid tumors.  Advances in liposome technology have resulted in the development of ligand-targeted liposomes capable of selectively increasing the efficacy of carried agents against receptor-bearing tumor cells.  Receptors for vitamins and growth factors have become attractive targets for ligand-directed liposomal therapies due to their high expression levels on various forms of cancer and their ability to internalize after binding to the liposomes conjugated to receptors' natural ligands (vitamins) or synthetic agonists (receptor-specific antibodies and synthetic peptides).  This chapter summarizes various strategies and advances in targeting liposomes to vitamin and growth factor receptors in vitro and in vivo with special emphasis on two extensively studied liposome-targeting systems utilizing folate receptor and HER2/neu growth factor receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQKMqKy8820ZJQHPYJuLg8TfW6udTcc2eZ7ExCRIIAJz7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3cvovVagtg%253D%253D&md5=e0f876c862b4df692898e0d9bab05fb5</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS0083-6729%2800%2960022-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0083-6729%252800%252960022-5%26sid%3Dliteratum%253Aachs%26aulast%3DDrummond%26aufirst%3DD.%2BC.%26aulast%3DHong%26aufirst%3DK.%26aulast%3DPark%26aufirst%3DJ.%2BW.%26aulast%3DBenz%26aufirst%3DC.%2BC.%26aulast%3DKirpgtin%26aufirst%3DD.%2BB.%26atitle%3DLiposome%2520Targeting%2520to%2520Tumors%2520Using%2520Vitamin%2520and%2520Growth%2520Factor%2520Receptors%26jtitle%3DVitam.%2520Horm.%26date%3D2000%26volume%3D60%26spage%3D285%26epage%3D332%26doi%3D10.1016%2FS0083-6729%2800%2960022-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iinuma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maruyama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okinaga, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekine, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishida, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogiwara, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johkura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yonemura, Y.</span></span> <span> </span><span class="NLM_article-title">Intracellular Targeting Therapy of Cisplatin-Encapsulated Transferrin-Polyethylene Glycol Liposome on Peritoneal Dissemination of Gastric Cancer</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">130</span>– <span class="NLM_lpage">137</span>, <span class="refDoi"> DOI: 10.1002/ijc.10242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1002%2Fijc.10242" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=11948504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD38XivVCgsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=130-137&author=H.+Iinumaauthor=K.+Maruyamaauthor=K.+Okinagaauthor=K.+Sasakiauthor=T.+Sekineauthor=O.+Ishidaauthor=N.+Ogiwaraauthor=K.+Johkuraauthor=Y.+Yonemura&title=Intracellular+Targeting+Therapy+of+Cisplatin-Encapsulated+Transferrin-Polyethylene+Glycol+Liposome+on+Peritoneal+Dissemination+of+Gastric+Cancer&doi=10.1002%2Fijc.10242"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Intracellular targeting therapy of cisplatin-encapsulated transferrin-polyethylene glycol liposome on peritoneal dissemination of gastric cancer</span></div><div class="casAuthors">Iinuma, Hisae; Maruyama, Kazuo; Okinaga, Kota; Sasaki, Katsunori; Sekine, Toshiyuki; Ishida, Osamu; Ogiwara, Naoko; Johkura, Kohei; Yonemura, Yutaka</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">130-137</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Peritoneal dissemination in gastric cancer is a common fatal clin. condition with few effective therapies available.  The authors studied the therapeutic effect of a tumor-targeting drug delivery system that uses cisplatin-encapsulated and Tf-conjugated PEG liposomes (Tf-PEG liposomes) in nude mice with peritoneal dissemination of human gastric cancer cells.  Small unilamellar Tf-PEG, PEG or DSPC/CH liposomes (bare liposomes) encapsulating cisplatin were prepd. by reverse-phase evapn. followed by extrusion.  Electron microscopic studies revealed that Tf-PEG liposomes were internalized into tumor cells by receptor-mediated endocytosis.  To examine the biodistribution of each liposome and cisplatin level, nude mice were inoculated i.p. with 107 MKN45P human gastric tumor cells.  On the fourth day after tumor inoculation, 3H-CHE-labeled and cisplatin-encapsulated Tf-PEG, PEG or bare liposome were inoculated i.p.  The Tf-PEG liposome-administered group maintained high liposome and cisplatin levels in ascites and showed a prolonged residence time in the peripheral circulation.  Uptake of Tf-PEG liposomes into the liver and spleen was significantly lower than that of bare liposomes.  Uptake of Tf-PEG liposomes in disseminated tumor cells of ascites and the greater omentum was significantly higher than that of PEG or bare liposomes and a significant increase in cisplatin levels was obsd. in these tumor cells.  Mice receiving Tf-PEG liposomes 1 and 4 days after the day of tumor inoculation showed significantly higher survival rates compared with those receiving PEG liposomes without Tf, bare liposomes or free cisplatin soln.  These results suggest that cisplatin-encapsulated Tf-PEG liposomes may be useful as a new intracellular targeting carrier for treatment of gastric cancer with peritoneal dissemination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquaA71UaqPMbVg90H21EOLACvtfcHk0lgTu32zGYgfqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XivVCgsL4%253D&md5=1b6fb36bc94650ed008ebde0fc9a17d7</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1002%2Fijc.10242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.10242%26sid%3Dliteratum%253Aachs%26aulast%3DIinuma%26aufirst%3DH.%26aulast%3DMaruyama%26aufirst%3DK.%26aulast%3DOkinaga%26aufirst%3DK.%26aulast%3DSasaki%26aufirst%3DK.%26aulast%3DSekine%26aufirst%3DT.%26aulast%3DIshida%26aufirst%3DO.%26aulast%3DOgiwara%26aufirst%3DN.%26aulast%3DJohkura%26aufirst%3DK.%26aulast%3DYonemura%26aufirst%3DY.%26atitle%3DIntracellular%2520Targeting%2520Therapy%2520of%2520Cisplatin-Encapsulated%2520Transferrin-Polyethylene%2520Glycol%2520Liposome%2520on%2520Peritoneal%2520Dissemination%2520of%2520Gastric%2520Cancer%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2002%26volume%3D99%26spage%3D130%26epage%3D137%26doi%3D10.1002%2Fijc.10242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamaly, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farokhzad, O. C.</span></span> <span> </span><span class="NLM_article-title">Cancer Nanotechnology: The Impact of Passive and Active Targeting in the Era of Modern Cancer Biology</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">2</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2013.11.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.addr.2013.11.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=24270007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisV2hug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2014&pages=2-25&author=N.+Bertrandauthor=J.+Wuauthor=X.+Xuauthor=N.+Kamalyauthor=O.+C.+Farokhzad&title=Cancer+Nanotechnology%3A+The+Impact+of+Passive+and+Active+Targeting+in+the+Era+of+Modern+Cancer+Biology&doi=10.1016%2Fj.addr.2013.11.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology</span></div><div class="casAuthors">Bertrand, Nicolas; Wu, Jun; Xu, Xiaoyang; Kamaly, Nazila; Farokhzad, Omid C.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2-25</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Cancer nanotherapeutics are progressing at a steady rate; research and development in the field has experienced an exponential growth since early 2000's.  The path to the commercialization of oncol. drugs is long and carries significant risk; however, there is considerable excitement that nanoparticle technologies may contribute to the success of cancer drug development.  The pace at which pharmaceutical companies have formed partnerships to use proprietary nanoparticle technologies has considerably accelerated.  It is now recognized that by enhancing the efficacy and/or tolerability of new drug candidates, nanotechnol. can meaningfully contribute to create differentiated products and improve clin. outcome.  This review describes the lessons learned since the commercialization of the first-generation nanomedicines including DOXIL and Abraxane.  It explores our current understanding of targeted and non-targeted nanoparticles that are under various stages of development, including BIND-014 and MM-398.  It highlights the opportunities and challenges faced by nanomedicines in contemporary oncol., where personalized medicine is increasingly the mainstay of cancer therapy.  We revisit the fundamental concepts of enhanced permeability and retention effect (EPR) and explore the mechanisms proposed to enhance preferential "retention" in the tumor, whether using active targeting of nanoparticles, binding of drugs to their tumoral targets or the presence of tumor assocd. macrophages.  The overall objective of this review is to enhance our understanding in the design and development of therapeutic nanoparticles for treatment of cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrO44x5Hz86PrVg90H21EOLACvtfcHk0ljCM1Pag2J5IA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisV2hug%253D%253D&md5=0980da1a1b75cde64cc1cf82184e01b7</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2013.11.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2013.11.009%26sid%3Dliteratum%253Aachs%26aulast%3DBertrand%26aufirst%3DN.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DKamaly%26aufirst%3DN.%26aulast%3DFarokhzad%26aufirst%3DO.%2BC.%26atitle%3DCancer%2520Nanotechnology%253A%2520The%2520Impact%2520of%2520Passive%2520and%2520Active%2520Targeting%2520in%2520the%2520Era%2520of%2520Modern%2520Cancer%2520Biology%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2014%26volume%3D66%26spage%3D2%26epage%3D25%26doi%3D10.1016%2Fj.addr.2013.11.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span> <span> </span><span class="NLM_article-title">AMP-Guided Tumour-Specific Nanoparticle Delivery via Adenosine A1 Receptor</span>. <i>Biomaterials</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">37</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1016/j.biomaterials.2016.01.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.biomaterials.2016.01.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=26773664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC28Xks1Wkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2016&pages=37-50&author=T.+Daiauthor=N.+Liauthor=F.+Hanauthor=H.+Zhangauthor=Y.+Zhangauthor=Q.+Liu&title=AMP-Guided+Tumour-Specific+Nanoparticle+Delivery+via+Adenosine+A1+Receptor&doi=10.1016%2Fj.biomaterials.2016.01.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">AMP-guided tumour-specific nanoparticle delivery via adenosine A1 receptor</span></div><div class="casAuthors">Dai, Tongcheng; Li, Na; Han, Fajun; Zhang, Hua; Zhang, Yuanxing; Liu, Qin</div><div class="citationInfo"><span class="NLM_cas:title">Biomaterials</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">37-50</span>CODEN:
                <span class="NLM_cas:coden">BIMADU</span>;
        ISSN:<span class="NLM_cas:issn">0142-9612</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Active targeting-ligands have been increasingly used to functionalize nanoparticles for tumor-specific clin. applications.  Here we utilize nucleotide AMP as a novel ligand to functionalize polymer-based fluorescent nanoparticles (NPs) for tumor-targeted imaging.  We demonstrate that AMP-conjugated NPs (NPs-AMP) efficiently bind to and are following internalized into colon cancer cell CW-2 and breast cancer cell MDA-MB-468 in vitro.  RNA interference and inhibitor assays reveal that the targeting effects mainly rely on the specific binding of AMP to adenosine A1 receptor (A1R), which is greatly up-regulated in cancer cells than in matched normal cells.  More importantly, NPs-AMP specifically accumulate in the tumor site of colon and breast tumor xenografts and are further internalized into the tumor cells in vivo via tail vein injection, confirming that the high in vitro specificity of AMP can be successfully translated into the in vivo efficacy.  Furthermore, NPs-AMP exhibit an active tumor-targeting behavior in various colon and breast cancer cells, which is pos. related to the up-regulation level of A1R in cancer cells, suggesting that AMP potentially suits for more extensive A1R-overexpressing cancer models.  This work establishes AMP to be a novel tumor-targeting ligand and provides a promising strategy for future diagnostic or therapeutic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjfCiknuemWrVg90H21EOLACvtfcHk0lhVHkjIlJQNQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xks1Wkuw%253D%253D&md5=47b3e0c6d28d2266fca5297209a1fb56</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.biomaterials.2016.01.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biomaterials.2016.01.011%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DHan%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DAMP-Guided%2520Tumour-Specific%2520Nanoparticle%2520Delivery%2520via%2520Adenosine%2520A1%2520Receptor%26jtitle%3DBiomaterials%26date%3D2016%26volume%3D83%26spage%3D37%26epage%3D50%26doi%3D10.1016%2Fj.biomaterials.2016.01.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Danhier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feron, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Préat, V.</span></span> <span> </span><span class="NLM_article-title">To Exploit the Tumor Microenvironment: Passive and Active Tumor Targeting of Nanocarriers for Anti-Cancer Drug Delivery</span>. <i>J. Controlled Release</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">135</span>– <span class="NLM_lpage">146</span>, <span class="refDoi"> DOI: 10.1016/j.jconrel.2010.08.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.jconrel.2010.08.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=20797419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVCmsrzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2010&pages=135-146&author=F.+Danhierauthor=O.+Feronauthor=V.+Pr%C3%A9at&title=To+Exploit+the+Tumor+Microenvironment%3A+Passive+and+Active+Tumor+Targeting+of+Nanocarriers+for+Anti-Cancer+Drug+Delivery&doi=10.1016%2Fj.jconrel.2010.08.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery</span></div><div class="casAuthors">Danhier, Fabienne; Feron, Olivier; Preat, Veronique</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">135-146</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Because of the particular characteristics of the tumor microenvironment and tumor angiogenesis, it is possible to design drug delivery systems that specifically target anti-cancer drugs to tumors.  Most of the conventional chemotherapeutic agents have poor pharmacokinetics profiles and are distributed non-specifically in the body leading to systemic toxicity assocd. with serious side effects.  Therefore, the development of drug delivery systems able to target the tumor site is becoming a real challenge that is currently addressed.  Nanomedicine can reach tumor passively through the leaky vasculature surrounding the tumors by the enhanced permeability and retention effect whereas ligands grafted at the surface of nanocarriers allow active targeting by binding to the receptors overexpressed by cancer cells or angiogenic endothelial cells.  This review is divided into 2 parts: the first one describes the tumor microenvironment and the second one focuses on the exploitation and the understanding of these characteristics to design new drug delivery systems targeting the tumor.  Delivery of conventional chemotherapeutic anti-cancer drugs is mainly discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgLX-Ce0wBO7Vg90H21EOLACvtfcHk0lhGAz0hc-7J8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVCmsrzF&md5=04d79d93a1828d379bfde830da737608</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2010.08.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2010.08.027%26sid%3Dliteratum%253Aachs%26aulast%3DDanhier%26aufirst%3DF.%26aulast%3DFeron%26aufirst%3DO.%26aulast%3DPr%25C3%25A9at%26aufirst%3DV.%26atitle%3DTo%2520Exploit%2520the%2520Tumor%2520Microenvironment%253A%2520Passive%2520and%2520Active%2520Tumor%2520Targeting%2520of%2520Nanocarriers%2520for%2520Anti-Cancer%2520Drug%2520Delivery%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2010%26volume%3D148%26spage%3D135%26epage%3D146%26doi%3D10.1016%2Fj.jconrel.2010.08.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kirpotin, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drummond, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shalaby, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, U. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benz, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. W.</span></span> <span> </span><span class="NLM_article-title">Antibody Targeting of Long-Circulating Lipidic Nanoparticles Does Not Increase Tumor Localization But Does Increase Internalization in Animal Models</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">6732</span>– <span class="NLM_lpage">6740</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-05-4199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1158%2F0008-5472.CAN-05-4199" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=16818648" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD28XmsVamu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=6732-6740&author=D.+B.+Kirpotinauthor=D.+C.+Drummondauthor=Y.+Shaoauthor=M.+R.+Shalabyauthor=K.+Hongauthor=U.+B.+Nielsenauthor=J.+D.+Marksauthor=C.+C.+Benzauthor=J.+W.+Park&title=Antibody+Targeting+of+Long-Circulating+Lipidic+Nanoparticles+Does+Not+Increase+Tumor+Localization+But+Does+Increase+Internalization+in+Animal+Models&doi=10.1158%2F0008-5472.CAN-05-4199"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody Targeting of Long-Circulating Lipidic Nanoparticles Does Not Increase Tumor Localization but Does Increase Internalization in Animal Models</span></div><div class="casAuthors">Kirpotin, Dmitri B.; Drummond, Daryl C.; Shao, Yi; Shalaby, M. Refaat; Hong, Keelung; Nielsen, Ulrik B.; Marks, James D.; Benz, Christopher C.; Park, John W.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6732-6740</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">We describe evidence for a novel mechanism of monoclonal antibody (MAb)-directed nanoparticle (immunoliposome) targeting to solid tumors in vivo.  Long-circulating immunoliposomes targeted to HER2 (ErbB2, Neu) were prepd. by the conjugation of anti-HER2 MAb fragments (Fab' or single chain Fv) to liposome-grafted polyethylene glycol chains.  MAb fragment conjugation did not affect the biodistribution or long-circulating properties of i.v.-administered liposomes.  However, antibody-directed targeting also did not increase the tumor localization of immunoliposomes, as both targeted and nontargeted liposomes achieved similarly high levels (7-8% injected dose/g tumor tissue) of tumor tissue accumulation in HER2-overexpressing breast cancer xenografts (BT-474).  Studies using colloidal gold-labeled liposomes showed the accumulation of anti-HER2 immunoliposomes within cancer cells, whereas matched nontargeted liposomes were located predominantly in extracellular stroma or within macrophages.  A similar pattern of stromal accumulation without cancer cell internalization was obsd. for anti-HER2 immunoliposomes in non-HER2-overexpressing breast cancer xenografts (MCF-7).  Flow cytometry of disaggregated tumors posttreatment with either liposomes or immunoliposomes showed up to 6-fold greater intracellular uptake in cancer cells due to targeting.  Thus, in contrast to nontargeted liposomes, anti-HER2 immunoliposomes achieved intracellular drug delivery via MAb-mediated endocytosis, and this, rather than increased uptake in tumor tissue, was correlated with superior antitumor activity.  Immunoliposomes capable of selective internalization in cancer cells in vivo may provide new opportunities for drug delivery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQlkzKL-iioLVg90H21EOLACvtfcHk0ljadHdXQPJgBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmsVamu7Y%253D&md5=20bd18c2355cc8a328aa8cc51153bc44</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-05-4199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-05-4199%26sid%3Dliteratum%253Aachs%26aulast%3DKirpotin%26aufirst%3DD.%2BB.%26aulast%3DDrummond%26aufirst%3DD.%2BC.%26aulast%3DShao%26aufirst%3DY.%26aulast%3DShalaby%26aufirst%3DM.%2BR.%26aulast%3DHong%26aufirst%3DK.%26aulast%3DNielsen%26aufirst%3DU.%2BB.%26aulast%3DMarks%26aufirst%3DJ.%2BD.%26aulast%3DBenz%26aufirst%3DC.%2BC.%26aulast%3DPark%26aufirst%3DJ.%2BW.%26atitle%3DAntibody%2520Targeting%2520of%2520Long-Circulating%2520Lipidic%2520Nanoparticles%2520Does%2520Not%2520Increase%2520Tumor%2520Localization%2520But%2520Does%2520Increase%2520Internalization%2520in%2520Animal%2520Models%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D6732%26epage%3D6740%26doi%3D10.1158%2F0008-5472.CAN-05-4199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cochran, J. R.</span></span> <span> </span><span class="NLM_article-title">Targeting Ligand–Receptor Interactions for Development of Cancer Therapeutics</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">62</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2017.03.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.cbpa.2017.03.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=28371692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlvVGjs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2017&pages=62-69&author=J.+W.+Kimauthor=J.+R.+Cochran&title=Targeting+Ligand%E2%80%93Receptor+Interactions+for+Development+of+Cancer+Therapeutics&doi=10.1016%2Fj.cbpa.2017.03.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting ligand-receptor interactions for development of cancer therapeutics</span></div><div class="casAuthors">Kim, Jun Woo; Cochran, Jennifer R.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">62-69</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The biol. importance and druggable properties of receptors and their cognate ligands have designated them as esp. useful clin. targets.  This significance continues to expand as new mol. insights underlying disease pathophysiol. are uncovered.  While both ligands and receptors have been exploited as drug targets, their differing biochem. properties require nuanced considerations for drug development, including where in the body they are located and how they are regulated on a cellular and mol. level.  In this review we will discuss ligands and receptors as therapeutics targets, including their biodistribution and biol. function.  We provide examples of monoclonal antibodies (mAbs) used to modulate the activity of these targets, and discuss approaches for using engineered versions of ligands and receptors themselves for therapeutic intervention in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5_8FhF3LTGrVg90H21EOLACvtfcHk0lichT32RaZbzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlvVGjs7Y%253D&md5=a9aa41f641165205f47ca9227ea16206</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2017.03.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2017.03.010%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DJ.%2BW.%26aulast%3DCochran%26aufirst%3DJ.%2BR.%26atitle%3DTargeting%2520Ligand%25E2%2580%2593Receptor%2520Interactions%2520for%2520Development%2520of%2520Cancer%2520Therapeutics%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2017%26volume%3D38%26spage%3D62%26epage%3D69%26doi%3D10.1016%2Fj.cbpa.2017.03.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Q. C.</span></span> <span> </span><span class="NLM_article-title">Ligand-Based Targeted Therapy: A Novel Strategy for Hepatocellular Carcinoma</span>. <i>Int. J. Nanomed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">5645</span>– <span class="NLM_lpage">5669</span>, <span class="refDoi"> DOI: 10.2147/IJN.S115727</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.2147%2FIJN.S115727" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=27920520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXot1eisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=5645-5669&author=M.+Liauthor=W.+Zhangauthor=B.+Wangauthor=Y.+Gaoauthor=Z.+Songauthor=Q.+C.+Zheng&title=Ligand-Based+Targeted+Therapy%3A+A+Novel+Strategy+for+Hepatocellular+Carcinoma&doi=10.2147%2FIJN.S115727"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma</span></div><div class="casAuthors">Li, Min; Zhang, Weiyue; Wang, Birong; Gao, Yang; Song, Zifang; Zheng, Qi Chang</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Nanomedicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">5645-5669</span>CODEN:
                <span class="NLM_cas:coden">IJNNHQ</span>;
        ISSN:<span class="NLM_cas:issn">1178-2013</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Hepatocellular carcinoma (HCC) is the most common primary liver cancer with high morbidity and mortality worldwide.  Chemotherapy is recommended to patients with intermediate or advanced stage cancer.  However, the conventional chemotherapy yields low desired response rates due to multidrug resistance, fast clearance rate, nonspecific delivery, severe side effects, low drug concn. in cancer cells, and so on.  Nanoparticle-mediated targeted drug delivery system can surmount the aforementioned obstacles through enhanced permeability and retention effect and active targeting as a novel approach of therapeutics for HCC in recent years.  The active targeting is triggered by ligands on the delivery system, which recognize with and internalize into hepatoma cells with high specificity and efficiency.  This review focuses on the latest targeted delivery systems for HCC and summarizes the ligands that can enhance the capacity of active targeting, to provide some insight into future research in nanomedicine for HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoS3qkbh1aM97Vg90H21EOLACvtfcHk0liwYqb-9rhvIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXot1eisQ%253D%253D&md5=44586aff848cab79a4df79c0c52ebdfc</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.2147%2FIJN.S115727&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIJN.S115727%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DZheng%26aufirst%3DQ.%2BC.%26atitle%3DLigand-Based%2520Targeted%2520Therapy%253A%2520A%2520Novel%2520Strategy%2520for%2520Hepatocellular%2520Carcinoma%26jtitle%3DInt.%2520J.%2520Nanomed.%26date%3D2016%26volume%3D11%26spage%3D5645%26epage%3D5669%26doi%3D10.2147%2FIJN.S115727" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Assaraf, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leamon, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, J. A.</span></span> <span> </span><span class="NLM_article-title">The Folate Receptor as a Rational Therapeutic Target for Personalized Cancer Treatment</span>. <i>Drug Resist. Updates</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">89</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1016/j.drup.2014.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.drup.2014.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=25457975" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A280%3ADC%252BC2MzjtFyisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2014&pages=89-95&author=Y.+G.+Assarafauthor=C.+P.+Leamonauthor=J.+A.+Reddy&title=The+Folate+Receptor+as+a+Rational+Therapeutic+Target+for+Personalized+Cancer+Treatment&doi=10.1016%2Fj.drup.2014.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The folate receptor as a rational therapeutic target for personalized cancer treatment</span></div><div class="casAuthors">Assaraf Yehuda G; Leamon Christopher P; Reddy Joseph A</div><div class="citationInfo"><span class="NLM_cas:title">Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4-6</span>),
    <span class="NLM_cas:pages">89-95</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Conventional cancer treatment modalities have several limitations including lack of sufficient efficacy, serious untoward toxicity, as well as innate and acquired drug resistance.  In contrast, targeted imaging agents can identify patients with receptors overexpressed on the surface of cancer cells, thus allowing appropriate selection of patients for personalized treatment with a desirable targeted therapeutic.  The folate receptor (FR) has been identified as a new molecularly targeted entity, which is highly overexpressed on the surface of a spectrum of solid tumor cells, including ovarian, kidney, lung, brain, endometrial, colorectal, pancreatic, gastric, prostate, testicular, bladder, head and neck, breast, and non-small cell lung cancer.  Folic acid conjugation is a novel approach for targeting FR-expressing tissues for personalized treatment.  With the development of FRα-targeted therapies comes a concomitant prerequisite for reliable methods for the quantification of FRα tissue expression.  Therefore, attaching a radioactive probe to folic acid to target diseased tissue has become a novel and powerful imaging technique.  Currently available diagnostic tools frequently require invasive surgical biopsy.  In contrast, the noninvasive single-photon emission computed tomography-based companion imaging agent, (99m)Tc-etarfolatide ((99m)Tc-EC20), is in development for use as a companion diagnostic with the FRα-targeted folate conjugate, vintafolide (EC145), to identify patients whose tumors express FRα.  Vintafolide is a folic acid conjugate of Vinca alkaloid (desacetylvinblastine hydrazide) that targets FRα-expressing tumors, thereby disrupting microtubule polymerization. (99m)Tc-etarfolatide is taken up by FR-positive tumors and allows for noninvasive, whole-body monitoring of FRα expression status throughout treatment.  The combination of vintafolide plus etarfolatide has been evaluated in three Phase 2 studies for the treatment of various solid tumors, including ovarian, endometrial, peritoneal, and platinum-resistant ovarian cancer, as well as lung cancer.  Patients with FR-positive tumors, as identified by etarfolatide uptake, have had better clinical outcomes than patients with FR-negative tumors, indicating the potential of etarfolatide as a companion biomarker for predicting vintafolide response.  Targeted therapies combined with a reliable companion diagnostic test represent a novel approach toward efficient personalized medicine for malignant and nonmalignant disorders.  Furthermore, the recent availability of the crystal structures of FRα and FRβ in complex with folates and antifolates forms a realistic basis for the rational design and implementation of novel FR-targeted drugs for the treatment of cancer and inflammatory disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRJfpf2NhY2spPq5LRczm8ffW6udTcc2eZibr0LLTLaFrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MzjtFyisw%253D%253D&md5=95dd062e28385ab37836a4545dbd197f</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.drup.2014.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drup.2014.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DAssaraf%26aufirst%3DY.%2BG.%26aulast%3DLeamon%26aufirst%3DC.%2BP.%26aulast%3DReddy%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520Folate%2520Receptor%2520as%2520a%2520Rational%2520Therapeutic%2520Target%2520for%2520Personalized%2520Cancer%2520Treatment%26jtitle%3DDrug%2520Resist.%2520Updates%26date%3D2014%26volume%3D17%26spage%3D89%26epage%3D95%26doi%3D10.1016%2Fj.drup.2014.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanna, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nurra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pala, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marceddu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pathania, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neamati, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sechi, M.</span></span> <span> </span><span class="NLM_article-title">Targeted Nanoparticles for The Delivery of Novel Bioactive Molecules to Pancreatic Cancer Cells</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">5209</span>– <span class="NLM_lpage">5220</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01571</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01571" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC28XntFCjs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=5209-5220&author=V.+Sannaauthor=S.+Nurraauthor=N.+Palaauthor=S.+Marcedduauthor=D.+Pathaniaauthor=N.+Neamatiauthor=M.+Sechi&title=Targeted+Nanoparticles+for+The+Delivery+of+Novel+Bioactive+Molecules+to+Pancreatic+Cancer+Cells&doi=10.1021%2Facs.jmedchem.5b01571"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted Nanoparticles for the Delivery of Novel Bioactive Molecules to Pancreatic Cancer Cells</span></div><div class="casAuthors">Sanna, Vanna; Nurra, Salvatore; Pala, Nicolino; Marceddu, Salvatore; Pathania, Divya; Neamati, Nouri; Sechi, Mario</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5209-5220</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with poor prognosis and limited therapeutic options.  Therefore, there is an urgent need to identify new, safe, and targeted therapeutics for effective treatment of late as well as early stage disease.  Plectin-1 (Plec-1) was recently identified as specific biomarker for detecting PDAC at an early stage.  We envisioned that multivalent attachment of nanocarriers incorporating certain drugs to Plec-1-derived peptide would increase specific binding affinity and impart high specificity for PDAC cells.  Previously, we discovered a novel class of compds. (e.g., quinazolinediones, QDs) that exert their cytotoxic effects by modulating ROS-mediated cell signaling.  Herein, we prepd. novel QD242-encapsulated polymeric nanoparticles (NPs) functionalized with a peptide to selectively bind to Plec-1.  Similarly, we prepd. QD-based NPs densely decorated with an isatoic anhydride deriv.  Furthermore, we evaluated their impact on ligand binding and antiproliferative activity against PDAC cells.  The targeted NPs were more potent than the nontargeted constructs in PDAC cells warranting further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoU4vXa1piLRLVg90H21EOLACvtfcHk0lgZgY8-FNwkiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntFCjs7s%253D&md5=68751c7a9d5f15e158df8aa0b5324373</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01571%26sid%3Dliteratum%253Aachs%26aulast%3DSanna%26aufirst%3DV.%26aulast%3DNurra%26aufirst%3DS.%26aulast%3DPala%26aufirst%3DN.%26aulast%3DMarceddu%26aufirst%3DS.%26aulast%3DPathania%26aufirst%3DD.%26aulast%3DNeamati%26aufirst%3DN.%26aulast%3DSechi%26aufirst%3DM.%26atitle%3DTargeted%2520Nanoparticles%2520for%2520The%2520Delivery%2520of%2520Novel%2520Bioactive%2520Molecules%2520to%2520Pancreatic%2520Cancer%2520Cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D5209%26epage%3D5220%26doi%3D10.1021%2Facs.jmedchem.5b01571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xue, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozlovskaya, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherwani, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratnayaka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habib, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manuvakhova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klampfer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yusuf, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kharlampieva, E.</span></span> <span> </span><span class="NLM_article-title">Peptide-Functionalized Hydrogel Cubes for Active Tumor Cell Targeting</span>. <i>Biomacromolecules</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">4084</span>– <span class="NLM_lpage">4097</span>, <span class="refDoi"> DOI: 10.1021/acs.biomac.8b01088</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biomac.8b01088" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1WksbfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=4084-4097&author=B.+Xueauthor=V.+Kozlovskayaauthor=M.+A.+Sherwaniauthor=S.+Ratnayakaauthor=S.+Habibauthor=T.+Andersonauthor=M.+Manuvakhovaauthor=L.+Klampferauthor=N.+Yusufauthor=E.+Kharlampieva&title=Peptide-Functionalized+Hydrogel+Cubes+for+Active+Tumor+Cell+Targeting&doi=10.1021%2Facs.biomac.8b01088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide-Functionalized Hydrogel Cubes for Active Tumor Cell Targeting</span></div><div class="casAuthors">Xue, Bing; Kozlovskaya, Veronika; Sherwani, Mohammad Asif; Ratnayaka, Sithira; Habib, Shahriar; Anderson, Theron; Manuvakhova, Marina; Klampfer, Lidija; Yusuf, Nabiha; Kharlampieva, Eugenia</div><div class="citationInfo"><span class="NLM_cas:title">Biomacromolecules</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4084-4097</span>CODEN:
                <span class="NLM_cas:coden">BOMAF6</span>;
        ISSN:<span class="NLM_cas:issn">1525-7797</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Conjugation of bioactive targeting mols. to nano- or micrometer-sized drug carriers is a pivotal strategy to improve their therapeutic efficiency.  Herein, we developed pH- and redox-sensitive hydrogel particles with a surface-conjugated cancer cell targeting ligand for specific tumor-targeting and controlled release of the anticancer drug doxorubicin.  The poly(methacrylic acid) (PMAA) hydrogel cubes of 700 nm and 2 μm with a hepsin-targeting (IPLVVPL) surface peptide are produced through multilayer polymer assembly on sacrificial cubical mesoporous cores.  Direct peptide conjugation to the disulfide-stabilized hydrogels through a thiol-amine reaction does not compromise the structural integrity, hydrophilicity, stability in serum, or pH/redox sensitivity but does affect internalization by cancer cells.  The cell uptake kinetics and the ultimate extent of internalization are controlled by the cell type and hydrogel size.  The peptide modification significantly promotes the uptake of the 700 nm hydrogels by hepsin-pos. MCF-7 cells due to ligand-receptor recognition but has a negligible effect on the uptake of 2 μm PMAA hydrogels.  The selectivity of 700 nm IPLVVPL-PMAA hydrogel cubes to hepsin-overexpressing tumor cells is further confirmed by a 3-10-fold higher particle internalization by hepsin-pos. MCF-7 and SK-OV-3 compared to that of hepsin-neg. PC-3 cells.  This work provides a facile method to fabricate enhanced tumor-targeting carriers of submicrometer size and improves the general understanding of particle design parameters for targeted drug delivery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobs2I6YCcPv7Vg90H21EOLACvtfcHk0lh8yn3JliJPqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1WksbfI&md5=f327450acbe2018737eb3ed76dafab16</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facs.biomac.8b01088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biomac.8b01088%26sid%3Dliteratum%253Aachs%26aulast%3DXue%26aufirst%3DB.%26aulast%3DKozlovskaya%26aufirst%3DV.%26aulast%3DSherwani%26aufirst%3DM.%2BA.%26aulast%3DRatnayaka%26aufirst%3DS.%26aulast%3DHabib%26aufirst%3DS.%26aulast%3DAnderson%26aufirst%3DT.%26aulast%3DManuvakhova%26aufirst%3DM.%26aulast%3DKlampfer%26aufirst%3DL.%26aulast%3DYusuf%26aufirst%3DN.%26aulast%3DKharlampieva%26aufirst%3DE.%26atitle%3DPeptide-Functionalized%2520Hydrogel%2520Cubes%2520for%2520Active%2520Tumor%2520Cell%2520Targeting%26jtitle%3DBiomacromolecules%26date%3D2018%26volume%3D19%26spage%3D4084%26epage%3D4097%26doi%3D10.1021%2Facs.biomac.8b01088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fishman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bar-Yehuda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohn, I.</span></span> <span> </span><span class="NLM_article-title">A3 Adenosine Receptor as a Target for Cancer Therapy</span>. <i>Anti-Cancer Drugs</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">437</span>– <span class="NLM_lpage">443</span>, <span class="refDoi"> DOI: 10.1097/00001813-200206000-00001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1097%2F00001813-200206000-00001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=12045454" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD38Xks12hsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2002&pages=437-443&author=P.+Fishmanauthor=S.+Bar-Yehudaauthor=L.+Madiauthor=I.+Cohn&title=A3+Adenosine+Receptor+as+a+Target+for+Cancer+Therapy&doi=10.1097%2F00001813-200206000-00001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">A3 adenosine receptor as a target for cancer therapy</span></div><div class="casAuthors">Fishman, Pnina; Bar-Yehuda, Sara; Madi, Lea; Cohn, Ilan</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Drugs</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">437-443</span>CODEN:
                <span class="NLM_cas:coden">ANTDEV</span>;
        ISSN:<span class="NLM_cas:issn">0959-4973</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Targeting the A3 adenosine receptor (A3AR) by adenosine or a synthetic agonist to this receptor (IB-MECA and CI-IB-MECA) results in a differential effect on tumor and on normal cells.  Both the adenosine and the agonists inhibit the growth of various tumor cell types such as melanoma, colon or prostate carcinoma and lymphoma.  This effect is specific and is exerted on tumor cells only.  Moreover, exposure of peripheral blood mononuclear cells to adenosine or the agonists leads to the induction of granulocyte colony stimulating factor (G-CSF) prodn.  When given orally to mice, the agonists suppress the growth of melanoma, colon and prostate carcinoma in these animals, while inducing a myeloprotective effect via the induction of G-CSF prodn.  The de-regulation of the Wnt signaling pathway was involved in the anticancer effect.  Receptor activation induces inhibition of adenylyl cyclase with a subsequent decrease in the level of protein kinase A and protein kinase B/Akt leading to activation of glycogen synthase kinase-3β, a key element in the Wnt pathway.  The oral bioavailability of the synthetic A3AR agonists, and their induced systemic anticancer and myeloprotective effect, renders them potentially useful in three different modes of treatment: as a stand-alone anticancer treatment, in combination with chemotherapy to enhance its therapeutic index and myelprotection.  It is evident that use of the A3AR agonist for increasing the therapeutic index of chemotherapy may also invariably give rise to myeloprotection and vice versa.  The A3AR agonists are thus a promising new class of agents for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMRGo7OpTcU7Vg90H21EOLACvtfcHk0ljBdGtAm18Hng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xks12hsL8%253D&md5=d034dcf99d0f2ca90e63ae8a08df82ea</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1097%2F00001813-200206000-00001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00001813-200206000-00001%26sid%3Dliteratum%253Aachs%26aulast%3DFishman%26aufirst%3DP.%26aulast%3DBar-Yehuda%26aufirst%3DS.%26aulast%3DMadi%26aufirst%3DL.%26aulast%3DCohn%26aufirst%3DI.%26atitle%3DA3%2520Adenosine%2520Receptor%2520as%2520a%2520Target%2520for%2520Cancer%2520Therapy%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2002%26volume%3D13%26spage%3D437%26epage%3D443%26doi%3D10.1097%2F00001813-200206000-00001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swami, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeengar, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naidu, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sistla, R.</span></span> <span> </span><span class="NLM_article-title">Adenosine Conjugated Lipidic Nanoparticles for Enhanced Tumor Targeting</span>. <i>Int. J. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>486</i></span>,  <span class="NLM_fpage">287</span>– <span class="NLM_lpage">296</span>, <span class="refDoi"> DOI: 10.1016/j.ijpharm.2015.03.065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.ijpharm.2015.03.065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=25839415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2MXls1ejt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=486&publication_year=2015&pages=287-296&author=R.+Swamiauthor=I.+Singhauthor=M.+K.+Jeengarauthor=V.+Naiduauthor=W.+Khanauthor=R.+Sistla&title=Adenosine+Conjugated+Lipidic+Nanoparticles+for+Enhanced+Tumor+Targeting&doi=10.1016%2Fj.ijpharm.2015.03.065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine conjugated lipidic nanoparticles for enhanced tumor targeting</span></div><div class="casAuthors">Swami, Rajan; Singh, Indu; Jeengar, Manish Kumar; Naidu, V. G. M.; Khan, Wahid; Sistla, Ramakrishna</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">486</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">287-296</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Delivering chemotherapeutics by nanoparticles into tumor is impeded majorly by two factors: nonspecific targeting and inefficient penetration.  Targeted delivery of anti-cancer agents solely to tumor cells introduces a smart strategy because it enhances the therapeutic index compared with untargeted drugs.  The present study was performed to investigate the efficiency of adenosine (ADN) to target solid lipid nanoparticles (SLN) to over expressing adenosine receptor cell lines such as human breast cancer and prostate cancer (MCF-7 and DU-145 cells), resp.  SLN were prepd. by emulsification and solvent evapn. process using docetaxel (DTX) as drug and were characterized by various techniques like dynamic light scattering, differential scanning calorimeter and transmission electron microscopy.  DTX loaded SLNs were surface modified with ADN, an adenosine receptors ligand using carbodiimide coupling.  Conjugation was confirmed using IR spectroscopy and quantified using phenol-sulfuric acid method.  Conjugated SLN were shown to have sustained drug release as compared to unconjugated nanoparticles and drug suspension.  Compared with free DTX and unconjugated SLN, ADN conjugated SLN showed significantly higher cytotoxicity of loaded DTX, as evidenced by in vitro cell expts.  The IC50 was 0.41 μg/mL for native DTX, 0.30 μg/mL for unconjugated SLN formulation, and 0.09 μg/mL for ADN conjugated SLN formulation in MCF-7 cell lines.  Whereas, in DU-145, there was 2 fold change in IC50 of ADN-SLN as compared to DTX.  IC50 was found to be 0.44 μg/mL for free DTX, 0.39 μg/mL for unconjugated SLN and 0.22 μg/mL for ADN-SLN.  Annexin assay and cell cycle anal. assay further substantiated the cell cytotoxicity.  Fluorescent cell uptake and competitive ligand-receptor binding assay corroborated the receptor mediated endocytosis pathway indicated role of adenosine receptors in internalization of conjugated particles.  Pharmacokinetic studies of lipidic formulations depicted significant improvement in pharmacokinetic parameters than marketed formulation.  ADN conjugated SLN proved to be an efficient drug delivery vehicle.  Hence, ADN can be used as a potential ligand to target breast and prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZmJphk2UznbVg90H21EOLACvtfcHk0lhKQHnwuspk7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXls1ejt7k%253D&md5=870d5af504d546fc65b27133c74dde41</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpharm.2015.03.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpharm.2015.03.065%26sid%3Dliteratum%253Aachs%26aulast%3DSwami%26aufirst%3DR.%26aulast%3DSingh%26aufirst%3DI.%26aulast%3DJeengar%26aufirst%3DM.%2BK.%26aulast%3DNaidu%26aufirst%3DV.%26aulast%3DKhan%26aufirst%3DW.%26aulast%3DSistla%26aufirst%3DR.%26atitle%3DAdenosine%2520Conjugated%2520Lipidic%2520Nanoparticles%2520for%2520Enhanced%2520Tumor%2520Targeting%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D2015%26volume%3D486%26spage%3D287%26epage%3D296%26doi%3D10.1016%2Fj.ijpharm.2015.03.065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, H.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, P.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Iron Oxide Nanoparticles Coated with Nonpolymeric Azidopropyl-Uracil Triphosphate (UTP) and Adenosine Triphosphate (ATP) for Multimodality Imaging</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">1218</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2016&pages=1218&author=H.-S.+Jeongauthor=D.+H.+Kimauthor=I.+S.+Kimauthor=H.+Hwangauthor=P.-S.+Ohauthor=E.-M.+Kimauthor=J.-H.+Choiauthor=J.+Kwonauthor=H.+S.+Kimauthor=M.+Kim&title=Synthesis+of+Iron+Oxide+Nanoparticles+Coated+with+Nonpolymeric+Azidopropyl-Uracil+Triphosphate+%28UTP%29+and+Adenosine+Triphosphate+%28ATP%29+for+Multimodality+Imaging"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJeong%26aufirst%3DH.-S.%26aulast%3DKim%26aufirst%3DD.%2BH.%26aulast%3DKim%26aufirst%3DI.%2BS.%26aulast%3DHwang%26aufirst%3DH.%26aulast%3DOh%26aufirst%3DP.-S.%26aulast%3DKim%26aufirst%3DE.-M.%26aulast%3DChoi%26aufirst%3DJ.-H.%26aulast%3DKwon%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DH.%2BS.%26aulast%3DKim%26aufirst%3DM.%26atitle%3DSynthesis%2520of%2520Iron%2520Oxide%2520Nanoparticles%2520Coated%2520with%2520Nonpolymeric%2520Azidopropyl-Uracil%2520Triphosphate%2520%2528UTP%2529%2520and%2520Adenosine%2520Triphosphate%2520%2528ATP%2529%2520for%2520Multimodality%2520Imaging%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2016%26volume%3D57%26spage%3D1218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Durand, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storz, P.</span></span> <span> </span><span class="NLM_article-title">Targeting Reactive Oxygen Species in Development and Progression of Pancreatic Cancer</span>. <i>Expert Rev. Anticancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.1080/14737140.2017.1261017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1080%2F14737140.2017.1261017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=27841037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFCgtbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=19-31&author=N.+Durandauthor=P.+Storz&title=Targeting+Reactive+Oxygen+Species+in+Development+and+Progression+of+Pancreatic+Cancer&doi=10.1080%2F14737140.2017.1261017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting reactive oxygen species in development and progression of pancreatic cancer</span></div><div class="casAuthors">Durand, Nisha; Storz, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-31</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Pancreatic ductal adenocarcinoma (PDA) is characterized by expression of oncogenic KRas which drives all aspects of tumorigenesis.  Oncogenic KRas induces the formation of reactive oxygen species (ROS) which have been implicated in initiation and progression of PDA.  To facilitate tumor promoting levels and to avoid oncogene-induced senescence or cytotoxicity, ROS homeostasis in PDA cells is balanced by addnl. up-regulation of antioxidant systems.  We examine the sources of ROS in PDA, the mechanisms by which ROS homeostasis is maintained, and the biol. consequences of ROS in PDA.  Addnl., we discuss the potential mechanisms for targeting ROS homoeostasis as a point of therapeutic intervention.  An extensive review of the relevant literature as it relates to the topic was conducted using PubMed. Even though oncogenic mutations in the KRAS gene have been detected in over 95% of human pancreatic adenocarcinoma, targeting its gene product, KRas, has been difficult.  The dependency of PDA cells on balancing ROS homeostasis could be an angle for new prevention or treatment strategies.  These include use of antioxidants to prevent formation or progression of precancerous lesions, or methods to increase ROS in tumor cells to toxic levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGcAyB4qAqGbVg90H21EOLACvtfcHk0liWWzuBCmVwbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFCgtbfO&md5=dd51ffe392d672754074fc7afa8ec44e</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1080%2F14737140.2017.1261017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14737140.2017.1261017%26sid%3Dliteratum%253Aachs%26aulast%3DDurand%26aufirst%3DN.%26aulast%3DStorz%26aufirst%3DP.%26atitle%3DTargeting%2520Reactive%2520Oxygen%2520Species%2520in%2520Development%2520and%2520Progression%2520of%2520Pancreatic%2520Cancer%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2017%26volume%3D17%26spage%3D19%26epage%3D31%26doi%3D10.1080%2F14737140.2017.1261017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nogueira-Librelotto, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Codevilla, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farooqi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolim, C. M.</span></span> <span> </span><span class="NLM_article-title">Transferrin-Conjugated Nanocarriers as Active-Targeted Drug Delivery Platforms for Cancer Therapy</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">454</span>– <span class="NLM_lpage">466</span>, <span class="refDoi"> DOI: 10.2174/1381612822666161026162347</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.2174%2F1381612822666161026162347" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=27784246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjslSjsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=454-466&author=D.+R.+Nogueira-Librelottoauthor=C.+F.+Codevillaauthor=A.+Farooqiauthor=C.+M.+Rolim&title=Transferrin-Conjugated+Nanocarriers+as+Active-Targeted+Drug+Delivery+Platforms+for+Cancer+Therapy&doi=10.2174%2F1381612822666161026162347"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Transferrin-Conjugated Nanocarriers as Active-Targeted Drug Delivery Platforms for Cancer Therapy</span></div><div class="casAuthors">Nogueira-Librelotto, Daniele R.; Codevilla, Cristiane F.; Farooqi, Ammad; Rolim, Clarice M. B.</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">454-466</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  A lot of effort has been devoted to achieving active targeting for cancer therapy in order to reach the right cells.  Hence, increasingly it is being realized that active-targeted nanocarriers notably reduce off-target effects, mainly because of targeted localization in tumors and active cellular uptake.  In this context, by taking advantage of the overexpression of transferrin receptors on the surface of tumor cells, transferrin-conjugated nanodevices have been designed, in hope that the biomarker grafting would help to maximize the therapeutic benefit and to minimize the side effects.  Notably, active targeting nanoparticles have shown improved therapeutic performances in different tumor models as compared to their passive targeting counterparts.  In this review, current development of nano-based devices conjugated with transferrin for active tumor-targeting drug delivery are highlighted and discussed.  The main objective of this review is to provide a summary of the vast types of nanomaterials that have been used to deliver different chemotherapeutics into tumor cells, and to ultimately evaluate the progression on the strategies for cancer therapy in view of the future research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoU-f_yBvZ307Vg90H21EOLACvtfcHk0ljDxXtMUdbRZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjslSjsLo%253D&md5=21dc2ce1c79777c40883a9c0b8c9f0ec</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.2174%2F1381612822666161026162347&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612822666161026162347%26sid%3Dliteratum%253Aachs%26aulast%3DNogueira-Librelotto%26aufirst%3DD.%2BR.%26aulast%3DCodevilla%26aufirst%3DC.%2BF.%26aulast%3DFarooqi%26aufirst%3DA.%26aulast%3DRolim%26aufirst%3DC.%2BM.%26atitle%3DTransferrin-Conjugated%2520Nanocarriers%2520as%2520Active-Targeted%2520Drug%2520Delivery%2520Platforms%2520for%2520Cancer%2520Therapy%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2017%26volume%3D23%26spage%3D454%26epage%3D466%26doi%3D10.2174%2F1381612822666161026162347" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levin, A. A.</span></span> <span> </span><span class="NLM_article-title">Targeting Therapeutic Oligonucleotides</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>376</i></span>,  <span class="NLM_fpage">86</span>– <span class="NLM_lpage">88</span>, <span class="refDoi"> DOI: 10.1056/NEJMcibr1613559</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1056%2FNEJMcibr1613559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=28052219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A280%3ADC%252BC1c7it1amsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=2017&pages=86-88&author=A.+A.+Levin&title=Targeting+Therapeutic+Oligonucleotides&doi=10.1056%2FNEJMcibr1613559"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Therapeutic Oligonucleotides</span></div><div class="casAuthors">Levin Arthur A</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">376</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">86-88</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT7RKT9ESs8MENoizSOkG_FfW6udTcc2eZyffnBKaNLLrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7it1amsA%253D%253D&md5=b812c708430de18b6902ce1380829e4e</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1056%2FNEJMcibr1613559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMcibr1613559%26sid%3Dliteratum%253Aachs%26aulast%3DLevin%26aufirst%3DA.%2BA.%26atitle%3DTargeting%2520Therapeutic%2520Oligonucleotides%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D376%26spage%3D86%26epage%3D88%26doi%3D10.1056%2FNEJMcibr1613559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarisozen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torchilin, V. P.</span></span> <span> </span><span class="NLM_article-title">The Reversal of Multidrug Resistance in Ovarian Carcinoma Cells by Co-Application of Tariquidar and Paclitaxel in Transferrin-Targeted Polymeric Micelles</span>. <i>J. Drug Targeting</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">234</span>, <span class="refDoi"> DOI: 10.1080/1061186X.2016.1236113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1080%2F1061186X.2016.1236113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=27616277" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1Wnu7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=225-234&author=W.+Zouauthor=C.+Sarisozenauthor=V.+P.+Torchilin&title=The+Reversal+of+Multidrug+Resistance+in+Ovarian+Carcinoma+Cells+by+Co-Application+of+Tariquidar+and+Paclitaxel+in+Transferrin-Targeted+Polymeric+Micelles&doi=10.1080%2F1061186X.2016.1236113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The reversal of multidrug resistance in ovarian carcinoma cells by co-application of tariquidar and paclitaxel in transferrin-targeted polymeric micelles</span></div><div class="casAuthors">Zou, Wanting; Sarisozen, Can; Torchilin, Vladimir P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Drug Targeting</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">225-234</span>CODEN:
                <span class="NLM_cas:coden">JDTAEH</span>;
        ISSN:<span class="NLM_cas:issn">1026-7158</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">In this study, a transferrin (Tf)-modified polyethylene glycol-phosphatidyl ethanolamine (PEG-PE)-based micellar delivery system contg. paclitaxel (PTX) and tariquidar (TRQ), a potent third generation P-gp inhibitor, was prepd.  The nanoformulation was evaluated by targeting efficiency, cellular assocn., cellular internalization pathway and cytotoxicity for reversal of PTX resistance on two multidrug resistant (MDR) ovarian carcinoma cell lines, SKOV-3TR and A2780-Adr.  PTX and TRQ are both hydrophobic compds.  They were successfully encapsulated into the micellar structure contg. vitamin E as the encapsulation enhancer.  The Tf-targeted micelles were internalized mainly via clathrin-dependent endocytosis by both cell lines.  For SKOV-3TR, addnl. mechanisms including caveolin-dependent endocytosis and macropinocytosis were found to play a significant role.  The PTX cytotoxicity against the SKOV-3TR and A2780-Adr MDR cells was increased significantly in the presence of micellar encapsulation.  However, unlike the A2780-Adr cell line, the Tf-targeting effect was significant on SKOV-3TR cells when co-administrated with TRQ.  Penetration of the Tf-targeted micelles in a cancer cell spheroid culture was also investigated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKCUPXXfrcKrVg90H21EOLACvtfcHk0lgzJIYAea3BiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1Wnu7%252FM&md5=60ca58f49d51a3c624963d1161029dac</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1080%2F1061186X.2016.1236113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F1061186X.2016.1236113%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DW.%26aulast%3DSarisozen%26aufirst%3DC.%26aulast%3DTorchilin%26aufirst%3DV.%2BP.%26atitle%3DThe%2520Reversal%2520of%2520Multidrug%2520Resistance%2520in%2520Ovarian%2520Carcinoma%2520Cells%2520by%2520Co-Application%2520of%2520Tariquidar%2520and%2520Paclitaxel%2520in%2520Transferrin-Targeted%2520Polymeric%2520Micelles%26jtitle%3DJ.%2520Drug%2520Targeting%26date%3D2017%26volume%3D25%26spage%3D225%26epage%3D234%26doi%3D10.1080%2F1061186X.2016.1236113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, J.</span></span> <span> </span><span class="NLM_article-title">Self-Assembled Targeted Nanoparticles Based on Transferrin-Modified Eight-Arm-Polyethylene Glycol–Dihydroartemisinin Conjugate</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">29461</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1038/srep29461</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1038%2Fsrep29461" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=28442746" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslGmu77L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=1-12&issue=29461&author=K.+Liuauthor=L.+Daiauthor=C.+Liauthor=J.+Liuauthor=L.+Wangauthor=J.+Lei&title=Self-Assembled+Targeted+Nanoparticles+Based+on+Transferrin-Modified+Eight-Arm-Polyethylene+Glycol%E2%80%93Dihydroartemisinin+Conjugate&doi=10.1038%2Fsrep29461"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Evolution of the intrinsic electronic phase separation in La0.6Er0.1Sr0.3MnO3 perovskite</span></div><div class="casAuthors">Chen, Lili; Fan, Jiyu; Tong, Wei; Hu, Dazhi; Ji, Yanda; Liu, Jindong; Zhang, Lei; Pi, Li; Zhang, Yuheng; Yang, Hao</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-9</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Magnetic and electronic transport properties of perovskite manganite La0.6Er0.1Sr0.3MnO3 have been thoroughly examd. through the measurements of magnetization, ESR(EPR), and resistivity.  It was found that the substitution of Er3+ for La3+ ions introduced the chem. disorder and addnl. strain in this sample.  An extra resonance signal occurred in EPR spectra at high temps. well above TC gives a strong evidence of electronic phase sepn.(EPS).  The anal. of resistivity enable us to identify the polaronic transport mechanism in the paramagnetic region.  At low temp., a new ferromagnetic interaction generates in the microdomains of Er3+-disorder causing the second increase of magnetization.  However, the new ferromagnetic interaction does not improve but decreases electronic transport due to the enhancement of interface resistance among neighboring domains.  In view of a really wide temp. region for the EPS existence, this sample provides an ideal platform to uncover the evolution law of different magnetic structures in perovskite manganites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEVtObrKK5DLVg90H21EOLACvtfcHk0liDIGY4j8e1Sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslGmu77L&md5=3ea2f182469394f5b72ed446be3960ad</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fsrep29461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep29461%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DDai%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLei%26aufirst%3DJ.%26atitle%3DSelf-Assembled%2520Targeted%2520Nanoparticles%2520Based%2520on%2520Transferrin-Modified%2520Eight-Arm-Polyethylene%2520Glycol%25E2%2580%2593Dihydroartemisinin%2520Conjugate%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26issue%3D29461%26spage%3D1%26epage%3D12%26doi%3D10.1038%2Fsrep29461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohan
Yallapu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray Dobberpuhl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michele Maher, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaggi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chand Chauhan, S.</span></span> <span> </span><span class="NLM_article-title">Design of Curcumin Loaded Cellulose Nanoparticles for Prostate Cancer</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">120</span>– <span class="NLM_lpage">128</span>, <span class="refDoi"> DOI: 10.2174/138920012798356952</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.2174%2F138920012798356952" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=21892919" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=120-128&author=M.+Mohan%0AYallapuauthor=M.+Ray+Dobberpuhlauthor=D.+Michele+Maherauthor=M.+Jaggiauthor=S.+Chand+Chauhan&title=Design+of+Curcumin+Loaded+Cellulose+Nanoparticles+for+Prostate+Cancer&doi=10.2174%2F138920012798356952"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.2174%2F138920012798356952&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920012798356952%26sid%3Dliteratum%253Aachs%26aulast%3DMohan%2BYallapu%26aufirst%3DM.%26aulast%3DRay%2BDobberpuhl%26aufirst%3DM.%26aulast%3DMichele%2BMaher%26aufirst%3DD.%26aulast%3DJaggi%26aufirst%3DM.%26aulast%3DChand%2BChauhan%26aufirst%3DS.%26atitle%3DDesign%2520of%2520Curcumin%2520Loaded%2520Cellulose%2520Nanoparticles%2520for%2520Prostate%2520Cancer%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2012%26volume%3D13%26spage%3D120%26epage%3D128%26doi%3D10.2174%2F138920012798356952" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span> <span> </span><span class="NLM_article-title">Co-Delivery of Doxorubicin and pH-Sensitive Curcumin Prodrug by Transferrin-Targeted Nanoparticles for Breast Cancer Treatment</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1253</span>– <span class="NLM_lpage">1260</span>, <span class="refDoi"> DOI: 10.3892/or.2017.5345</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.3892%2For.2017.5345" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=28075466" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFyis7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2017&pages=1253-1260&author=T.+Cuiauthor=S.+Zhangauthor=H.+Sun&title=Co-Delivery+of+Doxorubicin+and+pH-Sensitive+Curcumin+Prodrug+by+Transferrin-Targeted+Nanoparticles+for+Breast+Cancer+Treatment&doi=10.3892%2For.2017.5345"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Co-delivery of doxorubicin and pH-sensitive curcumin prodrug by transferrin-targeted nanoparticles for breast cancer treatment</span></div><div class="casAuthors">Cui, Tongxing; Zhang, Sihao; Sun, Hong</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1253-1260</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1791-2431</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">The natural product curcumin and the chemotherapeutic agent doxorubicin have been used in the treatment of many cancers, including breast cancer.  However, fast clearance and unspecific distribution in the body after i.v. injection are still challenges to be overcome by an ideal nanosized drug delivery system in cancer treatment.  In this study we design transferrin (Tf) decorated nanoparticles (NPs) to co-deliver CUR and DOX for breast cancer treatment.  A pH-sensitive prodrug, transferrin-poly(ethylene glycol)-curcumin (Tf-PEG-CUR), was synthesized and used for the self-assembling of NPs (Tf-PEG-CUR NPs).  DOX is incorporated into the Tf-PEG-CUR NPs to obtain Tf-PEG-CUR/DOX NPs.  In vitro cytotoxicity studies and in vivo antitumor activity were carried out using MCF-7 cells and mice bearing MCF-7 cells, resp.  Tf-PEG-CUR/DOX NPs has a particle size of 89 nm and a zeta potential of -15.6 mV.  This system displayed remarkably higher efficiency than other systems both in vitro and in vivo.  DOX and CUR were successfully loaded into nanocarriers.  The in vitro cell viability assays revealed the combination of Tf-PEG-CUR and DOX NPs exhibited higher cytotoxicity in vitro in MCF-7 cells compared with Tf-PEG-CUR NPs alone.  Using the breast cancer xenograft mouse model, we demonstrate that this co-encapsulation approach resulted in an efficient tumor-targeted drug delivery, decreased cytotoxic effects and exhibited stronger antitumor effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCI__DprrsWbVg90H21EOLACvtfcHk0lijTkT9Un7NOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFyis7s%253D&md5=90d2f1f9453e0511987b192fd60ab173</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.3892%2For.2017.5345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2017.5345%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DH.%26atitle%3DCo-Delivery%2520of%2520Doxorubicin%2520and%2520pH-Sensitive%2520Curcumin%2520Prodrug%2520by%2520Transferrin-Targeted%2520Nanoparticles%2520for%2520Breast%2520Cancer%2520Treatment%26jtitle%3DOncol.%2520Rep.%26date%3D2017%26volume%3D37%26spage%3D1253%26epage%3D1260%26doi%3D10.3892%2For.2017.5345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deshpande, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhaveri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattni, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biswas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torchilin, V.</span></span> <span> </span><span class="NLM_article-title">Transferrin and Octaarginine Modified Dual-Functional Liposomes with Improved Cancer Cell Targeting and Enhanced Intracellular Delivery for the Treatment of Ovarian Cancer</span>. <i>Drug Delivery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">517</span>– <span class="NLM_lpage">532</span>, <span class="refDoi"> DOI: 10.1080/10717544.2018.1435747</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1080%2F10717544.2018.1435747" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=29433357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXis1Oksrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=517-532&author=P.+Deshpandeauthor=A.+Jhaveriauthor=B.+Pattniauthor=S.+Biswasauthor=V.+Torchilin&title=Transferrin+and+Octaarginine+Modified+Dual-Functional+Liposomes+with+Improved+Cancer+Cell+Targeting+and+Enhanced+Intracellular+Delivery+for+the+Treatment+of+Ovarian+Cancer&doi=10.1080%2F10717544.2018.1435747"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Transferrin and octaarginine modified dual-functional liposomes with improved cancer cell targeting and enhanced intracellular delivery for the treatment of ovarian cancer</span></div><div class="casAuthors">Deshpande, Pranali; Jhaveri, Aditi; Pattni, Bhushan; Biswas, Swati; Torchilin, Vladimir</div><div class="citationInfo"><span class="NLM_cas:title">Drug Delivery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">517-532</span>CODEN:
                <span class="NLM_cas:coden">DDELEB</span>;
        ISSN:<span class="NLM_cas:issn">1071-7544</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Off-target effects of drugs severely limit cancer therapy.  Targeted nanocarriers are promising to enhance the delivery of therapeutics to tumors.  Among many approaches for active tumor-targeting, arginine-rich cell penetrating peptides (AR-CPP) and ligands specific to target over-expressed receptors on cancer-cell surfaces, are popular.  Earlier, we showed that the attachment of an AR-CPP octaarginine (R8) to the surface of DOXIL (Doxorubicin encapsulated PEGylated liposomes) improved cytoplasmic and nuclear DOX delivery that enhanced the cytotoxic effect in vitro and improved therapeutic efficacy in vivo.  Here, we report on DOX-loaded liposomes, surface-modified with, R8 and transferrin (Tf) (Dual DOX-L), to improve targeting of A2780 ovarian carcinoma cells via the over-expressed transferrin receptors (TfRs) with R8-mediated intracellular DOX delivery.  Flow cytometry anal. with fluorescently labeled DualL (without DOX) showed two-fold higher cancer-cell assocn. than other treatments after 4 h treatment.  Blocking entry pathways of R8 (macropinocytosis) and Tf (receptor-mediated endocytosis, RME) resulted in a decreased cancer-cell assocn. of DualL.  Confocal microscopy confirmed involvement of both entry pathways and cytoplasmic liposome accumulation with nuclear DOX delivery for Dual DOX-L.  Dual DOX-L exhibited enhanced cytotoxicity in vitro and was most effective in controlling tumor growth in vivo in an A2780 ovarian xenograft model compared to other treatments.  A pilot biodistribution study showed improved DOX accumulation in tumors after Dual DOX-L treatment.  All results collectively presented a clear advantage of the R8 and Tf combination to elevate the therapeutic potential of DOX-L by exploiting TfR over-expression imparting specificity followed by endosomal escape and intracellular delivery via R8.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5wsXPrjATArVg90H21EOLACvtfcHk0ljdbBebAU_WSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXis1Oksrw%253D&md5=1e986de2158d956e56e31195dbb87a41</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1080%2F10717544.2018.1435747&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10717544.2018.1435747%26sid%3Dliteratum%253Aachs%26aulast%3DDeshpande%26aufirst%3DP.%26aulast%3DJhaveri%26aufirst%3DA.%26aulast%3DPattni%26aufirst%3DB.%26aulast%3DBiswas%26aufirst%3DS.%26aulast%3DTorchilin%26aufirst%3DV.%26atitle%3DTransferrin%2520and%2520Octaarginine%2520Modified%2520Dual-Functional%2520Liposomes%2520with%2520Improved%2520Cancer%2520Cell%2520Targeting%2520and%2520Enhanced%2520Intracellular%2520Delivery%2520for%2520the%2520Treatment%2520of%2520Ovarian%2520Cancer%26jtitle%3DDrug%2520Delivery%26date%3D2018%26volume%3D25%26spage%3D517%26epage%3D532%26doi%3D10.1080%2F10717544.2018.1435747" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haeri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalba, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ten Hagen, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dadashzadeh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koning, G. A.</span></span> <span> </span><span class="NLM_article-title">EGFR Targeted Thermosensitive Liposomes: ANovel Multifunctional Platform for Simultaneous Tumor Targeted and Stimulus Responsive Drug Delivery</span>. <i>Colloids Surf., B</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">657</span>– <span class="NLM_lpage">669</span>, <span class="refDoi"> DOI: 10.1016/j.colsurfb.2016.06.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.colsurfb.2016.06.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=27434152" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFyntb3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2016&pages=657-669&author=A.+Haeriauthor=S.+Zalbaauthor=T.+L.+Ten+Hagenauthor=S.+Dadashzadehauthor=G.+A.+Koning&title=EGFR+Targeted+Thermosensitive+Liposomes%3A+ANovel+Multifunctional+Platform+for+Simultaneous+Tumor+Targeted+and+Stimulus+Responsive+Drug+Delivery&doi=10.1016%2Fj.colsurfb.2016.06.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR targeted thermosensitive liposomes: A novel multifunctional platform for simultaneous tumor targeted and stimulus responsive drug delivery</span></div><div class="casAuthors">Haeri, Azadeh; Zalba, Sara; ten Hagen, Timo L. M.; Dadashzadeh, Simin; Koning, Gerben A.</div><div class="citationInfo"><span class="NLM_cas:title">Colloids and Surfaces, B: Biointerfaces</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">657-669</span>CODEN:
                <span class="NLM_cas:coden">CSBBEQ</span>;
        ISSN:<span class="NLM_cas:issn">0927-7765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) is a promising target for anti-cancer therapy.  The aim of this study was to design thermosensitive liposomes (TSL), functionalized with anti-EGFR ligands for targeted delivery and localized triggered release of chemotherapy.  For targeting, EGFR specific peptide (GE11) and Fab' fragments of cetuximab were used and the effect of ligand d. on in vitro tumor targeting was investigated.  Ligand conjugation did not significantly change the physicochem. characteristics of liposomes.  Fab'-decorated TSL (Fab'-TSL) can specifically and more efficiently bind to the EGFR overexpressed cancer cells as compared to GE11 modified TSL.  Calcein labeled Fab'-TSL showed adequate stability at 37 °C in serum (<4% calcein released after 1 h) and a temp. dependent release at above 40 °C.  FACS anal. and live cell imaging showed efficient and EGFR mediated cellular assocn. as well as dramatic intracellular cargo release upon hyperthermia.  Fab'-conjugation and hyperthermia induced enhanced tumor cell cytotoxicity of doxorubicin loaded TSL.  The relative cytotoxicity of Fab'-TSL was also correlated to EGFR d. on the tumor cells.  These results suggest that Fab'-TSL showed great potential for combinational targeted and triggered release drug delivery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0ZPfYPxO7NLVg90H21EOLACvtfcHk0lig5e-qqObAQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFyntb3E&md5=6a182679690f77684459b2e9ad914707</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.colsurfb.2016.06.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.colsurfb.2016.06.012%26sid%3Dliteratum%253Aachs%26aulast%3DHaeri%26aufirst%3DA.%26aulast%3DZalba%26aufirst%3DS.%26aulast%3DTen%2BHagen%26aufirst%3DT.%2BL.%26aulast%3DDadashzadeh%26aufirst%3DS.%26aulast%3DKoning%26aufirst%3DG.%2BA.%26atitle%3DEGFR%2520Targeted%2520Thermosensitive%2520Liposomes%253A%2520ANovel%2520Multifunctional%2520Platform%2520for%2520Simultaneous%2520Tumor%2520Targeted%2520and%2520Stimulus%2520Responsive%2520Drug%2520Delivery%26jtitle%3DColloids%2520Surf.%252C%2520B%26date%3D2016%26volume%3D146%26spage%3D657%26epage%3D669%26doi%3D10.1016%2Fj.colsurfb.2016.06.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mamot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drummond, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greiser, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirpotin, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. W.</span></span> <span> </span><span class="NLM_article-title">Epidermal Growth Factor Receptor (EGFR)-Targeted Immunoliposomes Mediate Specific and Efficient Drug Delivery to EGFR-and EGFRvIII-Overexpressing Tumor Cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">3154</span>– <span class="NLM_lpage">3161</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=12810643" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD3sXks1eiur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=3154-3161&author=C.+Mamotauthor=D.+C.+Drummondauthor=U.+Greiserauthor=K.+Hongauthor=D.+B.+Kirpotinauthor=J.+D.+Marksauthor=J.+W.+Park&title=Epidermal+Growth+Factor+Receptor+%28EGFR%29-Targeted+Immunoliposomes+Mediate+Specific+and+Efficient+Drug+Delivery+to+EGFR-and+EGFRvIII-Overexpressing+Tumor+Cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells</span></div><div class="casAuthors">Mamot, Christoph; Drummond, Daryl C.; Greiser, Udo; Hong, Keelung; Kirpotin, Dmitri B.; Marks, James D.; Park, John W.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3154-3161</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">We hypothesized that immunoliposomes (ILs) that target epidermal growth factor receptor (EGFR) and/or its truncated variant EGFRvIII can be constructed to provide efficient intracellular drug delivery in tumor cells overexpressing these receptors.  Monoclonal antibody fragments included Fab' fragments derived from C225, which binds both EGFR and EGFRvIII, or novel anti-EGFR scFv C10, which binds EGFR only.  Monoclonal antibody fragments were covalently linked to liposomes contg. various reporters or drugs.  ILs were evaluated for specific binding, internalization, and cytotoxicity in EGFR/EGFRvIII-overexpressing cell lines in vitro.  Flow cytometry and fluorescence microscopy showed that EGFR-targeted ILs, but not nontargeted liposomes or irrelevant ILs, were efficiently bound and internalized by EGFR-overexpressing cells, including glioma cells (U-87), carcinoma cells (A-431 and MDA-MB-468), and EGFRvIII stable transfectants (NR-6M).  Furthermore, EGFR-targeted ILs did not bind to non-EGFR-overexpressing cells (MCF-7 and parental NR-6).  ILs showed 3 orders of magnitude greater accumulation in NR-6-EGFRvIII stable transfectants vs. parental NR-6 cells.  Quant. internalization studies indicated binding of EGFR-targeted ILs to target cells within 5 min, followed by intracellular accumulation beginning at 15 min; total uptake reached ∼13,000 ILs/cell.  ILs were used to deliver cytotoxic drugs doxorubicin, vinorelbine, or methotrexate to EGFR/EGFRvIII-overexpressing target cells in vitro.  In each case, the IL agent was significantly more cytotoxic than the corresponding nontargeted liposomal drug in target cells, whereas it was equiv. in cells lacking EGFR/EGFRvIII overexpression.  We conclude that EGFR-targeted ILs provide efficient and targeted delivery of anticancer drugs in cells overexpressing EGFR or EGFRvIII.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWh4lD4DzGIbVg90H21EOLACvtfcHk0ljUD3_GimKf3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXks1eiur4%253D&md5=1c5ac0e83ffa20720d9c1c0347706bad</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMamot%26aufirst%3DC.%26aulast%3DDrummond%26aufirst%3DD.%2BC.%26aulast%3DGreiser%26aufirst%3DU.%26aulast%3DHong%26aufirst%3DK.%26aulast%3DKirpotin%26aufirst%3DD.%2BB.%26aulast%3DMarks%26aufirst%3DJ.%2BD.%26aulast%3DPark%26aufirst%3DJ.%2BW.%26atitle%3DEpidermal%2520Growth%2520Factor%2520Receptor%2520%2528EGFR%2529-Targeted%2520Immunoliposomes%2520Mediate%2520Specific%2520and%2520Efficient%2520Drug%2520Delivery%2520to%2520EGFR-and%2520EGFRvIII-Overexpressing%2520Tumor%2520Cells%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D3154%26epage%3D3161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, S.-i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takanashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuyama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizutani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohgi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochiya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotoh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuroda, M.</span></span> <span> </span><span class="NLM_article-title">Systemically Injected Exosomes Targeted to EGFR Deliver Antitumor Microrna to Breast Cancer Cells</span>. <i>Mol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">191</span>, <span class="refDoi"> DOI: 10.1038/mt.2012.180</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1038%2Fmt.2012.180" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=23032975" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVegsb7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=185-191&author=S.-i.+Ohnoauthor=M.+Takanashiauthor=K.+Sudoauthor=S.+Uedaauthor=A.+Ishikawaauthor=N.+Matsuyamaauthor=K.+Fujitaauthor=T.+Mizutaniauthor=T.+Ohgiauthor=T.+Ochiyaauthor=N.+Gotohauthor=M.+Kuroda&title=Systemically+Injected+Exosomes+Targeted+to+EGFR+Deliver+Antitumor+Microrna+to+Breast+Cancer+Cells&doi=10.1038%2Fmt.2012.180"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells</span></div><div class="casAuthors">Ohno, Shin-ichiro; Takanashi, Masakatsu; Sudo, Katsuko; Ueda, Shinobu; Ishikawa, Akio; Matsuyama, Nagahisa; Fujita, Koji; Mizutani, Takayuki; Ohgi, Tadaaki; Ochiya, Takahiro; Gotoh, Noriko; Kuroda, Masahiko</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">185-191</span>CODEN:
                <span class="NLM_cas:coden">MTOHCK</span>;
        ISSN:<span class="NLM_cas:issn">1525-0016</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Despite the therapeutic potential of nucleic acid drugs, their clin. application has been limited in part by a lack of appropriate delivery systems.  Exosomes or microvesicles are small endosomally derived vesicles that are secreted by a variety of cell types and tissues.  Here, we show that exosomes can efficiently deliver microRNA (miRNA) to epidermal growth factor receptor (EGFR)-expressing breast cancer cells.  Targeting was achieved by engineering the donor cells to express the transmembrane domain of platelet-derived growth factor receptor fused to the GE11 peptide.  I.v. injected exosomes delivered let-7a miRNA to EGFR-expressing xenograft breast cancer tissue in RAG2-/- mice.  Our results suggest that exosomes can be used therapeutically to target EGFR-expressing cancerous tissues with nucleic acid drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRVVvNb0XOhLVg90H21EOLACvtfcHk0lj-o-JxCxNfMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVegsb7P&md5=4b0a2eac9cf0e73f090b1bb5a9b6928d</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2Fmt.2012.180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmt.2012.180%26sid%3Dliteratum%253Aachs%26aulast%3DOhno%26aufirst%3DS.-i.%26aulast%3DTakanashi%26aufirst%3DM.%26aulast%3DSudo%26aufirst%3DK.%26aulast%3DUeda%26aufirst%3DS.%26aulast%3DIshikawa%26aufirst%3DA.%26aulast%3DMatsuyama%26aufirst%3DN.%26aulast%3DFujita%26aufirst%3DK.%26aulast%3DMizutani%26aufirst%3DT.%26aulast%3DOhgi%26aufirst%3DT.%26aulast%3DOchiya%26aufirst%3DT.%26aulast%3DGotoh%26aufirst%3DN.%26aulast%3DKuroda%26aufirst%3DM.%26atitle%3DSystemically%2520Injected%2520Exosomes%2520Targeted%2520to%2520EGFR%2520Deliver%2520Antitumor%2520Microrna%2520to%2520Breast%2520Cancer%2520Cells%26jtitle%3DMol.%2520Ther.%26date%3D2013%26volume%3D21%26spage%3D185%26epage%3D191%26doi%3D10.1038%2Fmt.2012.180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Costa, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mozhdehi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dzuricky, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaacs, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brustad, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chilkoti, A.</span></span> <span> </span><span class="NLM_article-title">Active Targeting of Cancer Cells by Nanobody Decorated Polypeptide Micelle with Bio-Orthogonally Conjugated Drug</span>. <i>Nano Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">247</span>– <span class="NLM_lpage">254</span>, <span class="refDoi"> DOI: 10.1021/acs.nanolett.8b03837</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.nanolett.8b03837" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFWhtr%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=247-254&author=S.+A.+Costaauthor=D.+Mozhdehiauthor=M.+J.+Dzurickyauthor=F.+J.+Isaacsauthor=E.+M.+Brustadauthor=A.+Chilkoti&title=Active+Targeting+of+Cancer+Cells+by+Nanobody+Decorated+Polypeptide+Micelle+with+Bio-Orthogonally+Conjugated+Drug&doi=10.1021%2Facs.nanolett.8b03837"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Active Targeting of Cancer Cells by Nanobody Decorated Polypeptide Micelle with Bio-orthogonally Conjugated Drug</span></div><div class="casAuthors">Costa, Simone A.; Mozhdehi, Davoud; Dzuricky, Michael J.; Isaacs, Farren J.; Brustad, Eric M.; Chilkoti, Ashutosh</div><div class="citationInfo"><span class="NLM_cas:title">Nano Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">247-254</span>CODEN:
                <span class="NLM_cas:coden">NALEFD</span>;
        ISSN:<span class="NLM_cas:issn">1530-6984</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Polypeptides are promising carriers for chemotherapeutics: they have minimal toxicity, can be recombinantly synthesized with precise control over mol. wt., and enhance drug pharmacokinetics as self-assembled nanoparticles.  Polypeptide-based systems also provide the ability to achieve active targeting with genetically encoded targeting ligands.  While passive targeting promotes accumulation of nanocarriers in solid tumors, active targeting provides an addnl. layer of tunable control and widens the therapeutic window.  However, fusion of most targeting proteins to polypeptide carriers exposes the limitations of this approach: the residues that are used for drug attachment are also promiscuously distributed on protein surfaces.  We present here a universal methodol. to solve this problem by the site-specific attachment of extrinsic moieties to polypeptide drug delivery systems without cross-reactivity to fused targeting domains.  We incorporate an unnatural amino acid, p-acetylphenylalanine, to provide a biorthogonal ketone for attachment of doxorubicin in the presence of reactive amino acids in a nanobody-targeted, elastin-like polypeptide nanoparticle.  These nanoparticles exhibit significantly greater cytotoxicity than nontargeted controls in multiple cancer cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN4KqSVn3PObVg90H21EOLACvtfcHk0li8fMqEjMCjBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFWhtr%252FI&md5=5e0340cfc5fc4902770ab3e7ed66dd15</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Facs.nanolett.8b03837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.nanolett.8b03837%26sid%3Dliteratum%253Aachs%26aulast%3DCosta%26aufirst%3DS.%2BA.%26aulast%3DMozhdehi%26aufirst%3DD.%26aulast%3DDzuricky%26aufirst%3DM.%2BJ.%26aulast%3DIsaacs%26aufirst%3DF.%2BJ.%26aulast%3DBrustad%26aufirst%3DE.%2BM.%26aulast%3DChilkoti%26aufirst%3DA.%26atitle%3DActive%2520Targeting%2520of%2520Cancer%2520Cells%2520by%2520Nanobody%2520Decorated%2520Polypeptide%2520Micelle%2520with%2520Bio-Orthogonally%2520Conjugated%2520Drug%26jtitle%3DNano%2520Lett.%26date%3D2019%26volume%3D19%26spage%3D247%26epage%3D254%26doi%3D10.1021%2Facs.nanolett.8b03837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patil, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amitay, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohana, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shmeeda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabizon, A.</span></span> <span> </span><span class="NLM_article-title">Targeting of Pegylated Liposomal Mitomycin-C Prodrug to the Folate Receptor of Cancer Cells: Intracellular Activation and Enhanced Cytotoxicity</span>. <i>J. Controlled Release</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>225</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1016/j.jconrel.2016.01.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.jconrel.2016.01.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=26809007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1Gjt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=225&publication_year=2016&pages=87-95&author=Y.+Patilauthor=Y.+Amitayauthor=P.+Ohanaauthor=H.+Shmeedaauthor=A.+Gabizon&title=Targeting+of+Pegylated+Liposomal+Mitomycin-C+Prodrug+to+the+Folate+Receptor+of+Cancer+Cells%3A+Intracellular+Activation+and+Enhanced+Cytotoxicity&doi=10.1016%2Fj.jconrel.2016.01.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting of pegylated liposomal mitomycin-C prodrug to the folate receptor of cancer cells: Intracellular activation and enhanced cytotoxicity</span></div><div class="casAuthors">Patil, Yogita; Amitay, Yasmine; Ohana, Patricia; Shmeeda, Hilary; Gabizon, Alberto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">225</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">87-95</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Mitomycin C (MMC) is a powerful anti-bacterial, anti-fungal and anti-tumor antibiotic, often active against multidrug resistant cells.  Despite a broad spectrum of antitumor activity, MMC clin. use is relatively limited due to its fast clearance and dose-limiting toxicity.  To exploit the potential antitumor activity of MMC and reduce its toxicity we have previously developed a formulation of pegylated liposomes with a lipophilic prodrug of MMC (PL-MLP), activated by endogenous reducing agents which are abundant in the tumor cell environment in the form of different thiols.  PL-MLP has minimal in vitro cytotoxicity unless reducing agents are added to the cell culture to activate the prodrug.  In the present study, we hypothesized that targeting PL-MLP via folate receptors will facilitate intracellular activation of prodrug and enhance cytotoxic activity without added reducing agents.  We grafted a lipophilic folate conjugate (folate-PEG(5000)-DSPE) to formulate folate targeted liposomes (FT-PL-MLP) and examd. in vitro cell uptake and cytotoxic activity in cancer cell lines with high folate receptors (HiFR). 3H-cholesterol-hexadecyl ether (3H-Chol)-radiolabeled liposomes were prepd. to study liposome-cell binding in parallel to cellular uptake of prodrug MLP. 3H-Chol and MLP cell uptake levels were 4-fold and 9-fold greater in KB HiFR cells when FT-PL-MLP is compared to non-targeted PL-MLP liposomes.  The cytotoxic activity of FT-PL-MLP liposomes was significantly increased up to ∼ 5-fold compared with PL-MLP liposomes in all tested HiFR expressing cell lines.  The enhanced uptake and intracytoplasmic liposome delivery was confirmed by confocal fluorescence studies with Rhodamine-labeled liposomes.  In vivo, no significant differences in pharmacokinetics and biodistribution were obsd. when PL-MLP was compared to FT-PL-MLP by the i.v. route.  However, when liposomes were directly injected into the peritoneal cavity of mice with malignant ascites of J6456 HiFR lymphoma cells, the tumor cell levels of MLP were significantly greater with the folate-targeted liposomes.  Thus, folate targeting enhances liposome uptake by tumor cells enabling intracellular activation of prodrug in the absence of exogenous reducing agents, and leading to increased cytotoxicity.  These results may be particularly relevant to the application of folate-targeted PL-MLP in intracavitary or intravesical treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGre2whzZITQELVg90H21EOLACvtfcHk0lhTMxR0PYfnQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1Gjt7k%253D&md5=b7879ef5119375335a1c1f2c3d6dd3b6</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2016.01.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2016.01.039%26sid%3Dliteratum%253Aachs%26aulast%3DPatil%26aufirst%3DY.%26aulast%3DAmitay%26aufirst%3DY.%26aulast%3DOhana%26aufirst%3DP.%26aulast%3DShmeeda%26aufirst%3DH.%26aulast%3DGabizon%26aufirst%3DA.%26atitle%3DTargeting%2520of%2520Pegylated%2520Liposomal%2520Mitomycin-C%2520Prodrug%2520to%2520the%2520Folate%2520Receptor%2520of%2520Cancer%2520Cells%253A%2520Intracellular%2520Activation%2520and%2520Enhanced%2520Cytotoxicity%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2016%26volume%3D225%26spage%3D87%26epage%3D95%26doi%3D10.1016%2Fj.jconrel.2016.01.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tacha, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremer, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Da, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skinner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicks, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, P.</span></span> <span> </span><span class="NLM_article-title">Medicine, L. Folate Receptor-A Associated with Triple-Negative Breast Cancer and Poor Prognosis</span>. <i>Arch. Pathol. Lab. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">890</span>– <span class="NLM_lpage">895</span>, <span class="refDoi"> DOI: 10.5858/arpa.2013-0309-OA</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.5858%2Farpa.2013-0309-OA" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=24028341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A280%3ADC%252BC3sbnsV2itg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2014&pages=890-895&author=Z.+Zhangauthor=J.+Wangauthor=D.+E.+Tachaauthor=P.+Liauthor=R.+E.+Bremerauthor=H.+Chenauthor=B.+Weiauthor=X.+Xiaoauthor=J.+Daauthor=K.+Skinnerauthor=D.+G.+Hicksauthor=H.+Buauthor=P.+Tang&title=Medicine%2C+L.+Folate+Receptor-A+Associated+with+Triple-Negative+Breast+Cancer+and+Poor+Prognosis&doi=10.5858%2Farpa.2013-0309-OA"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Folate receptor α associated with triple-negative breast cancer and poor prognosis</span></div><div class="casAuthors">Zhang Zhang; Wang Jianmin; Tacha David E; Li Pamela; Bremer Ryan E; Chen Huijiao; Wei Bing; Xiao Xiuli; Da Jiping; Skinner Kristin; Hicks David G; Bu Hong; Tang Ping</div><div class="citationInfo"><span class="NLM_cas:title">Archives of pathology & laboratory medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">890-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">CONTEXT:  Folate receptor α (FRA) has been shown to be selectively expressed in several types of human cancer, including breast cancer.  Currently, several FRA target therapies are under intensive study.  OBJECTIVE:  To investigate the expression pattern of FRA in a large cohort of patients with breast cancer and analyze its relationship with different clinicopathologic features, with expression of several key biomarkers, and with clinical outcome.  DESIGN:  Four hundred forty-seven cases of infiltrating ductal carcinoma diagnosed between 1997 and 2008 at the University of Rochester Medical Center were identified and reviewed, and 25 blocks of tissue microassays were constructed.  The association between expression of FRA and clinicopathologic features; expression of estrogen receptor (ER), progesterone receptor (PR), HER2/neu, and Ki-67; and clinical outcome of these tumors were evaluated.  RESULTS:  The expression of FRA was significantly associated with tumors with high histologic grade, higher nodal stages, ER/PR negativity, and high proliferative activity (Ki-67 ≥ 15%), and was independent of HER2/neu overexpression.  In all, 74% of ER/PR-negative and 80% of triple-negative breast cancers expressed FRA.  The expression of FRA was significantly associated with a worse disease-free survival.  CONCLUSIONS:  Our data demonstrate that a significant subgroup of ER/PR-negative and triple-negative breast cancers express FRA, and its expression is associated with worse clinical outcome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQcfU0t4X4JDNts4TFFB11gfW6udTcc2eZgVw6IHBxcLrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sbnsV2itg%253D%253D&md5=314882f46da416cf2f23fcc3a75330fe</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.5858%2Farpa.2013-0309-OA&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5858%252Farpa.2013-0309-OA%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DTacha%26aufirst%3DD.%2BE.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DBremer%26aufirst%3DR.%2BE.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DXiao%26aufirst%3DX.%26aulast%3DDa%26aufirst%3DJ.%26aulast%3DSkinner%26aufirst%3DK.%26aulast%3DHicks%26aufirst%3DD.%2BG.%26aulast%3DBu%26aufirst%3DH.%26aulast%3DTang%26aufirst%3DP.%26atitle%3DMedicine%252C%2520L.%2520Folate%2520Receptor-A%2520Associated%2520with%2520Triple-Negative%2520Breast%2520Cancer%2520and%2520Poor%2520Prognosis%26jtitle%3DArch.%2520Pathol.%2520Lab.%2520Med.%26date%3D2014%26volume%3D138%26spage%3D890%26epage%3D895%26doi%3D10.5858%2Farpa.2013-0309-OA" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xia, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, P. S.</span></span> <span> </span><span class="NLM_article-title">Folate-Targeted Therapies for Cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">6811</span>– <span class="NLM_lpage">6824</span>, <span class="refDoi"> DOI: 10.1021/jm100509v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100509v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVCit7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=6811-6824&author=W.+Xiaauthor=P.+S.+Low&title=Folate-Targeted+Therapies+for+Cancer&doi=10.1021%2Fjm100509v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Folate-Targeted Therapies for Cancer</span></div><div class="casAuthors">Xia, Wei; Low, Philip S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6811-6824</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This article discusses the use of folic acid as a ligand to target therapeutic cargos of many sizes, shapes, mechanisms of action to tumor cells both in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpihPD6hMJ_77Vg90H21EOLACvtfcHk0liPM5g0EnD2-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVCit7w%253D&md5=8d302235e47b742beed54f482c637c49</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjm100509v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100509v%26sid%3Dliteratum%253Aachs%26aulast%3DXia%26aufirst%3DW.%26aulast%3DLow%26aufirst%3DP.%2BS.%26atitle%3DFolate-Targeted%2520Therapies%2520for%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D6811%26epage%3D6824%26doi%3D10.1021%2Fjm100509v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weil, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, R. L.</span></span> <span> </span><span class="NLM_article-title">Farletuzumab (AMonoclonal Antibody Against Folate Receptor Alpha) in Relapsed Platinum-Sensitive Ovarian Cancer</span>. <i>Gynecol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">452</span>– <span class="NLM_lpage">458</span>, <span class="refDoi"> DOI: 10.1016/j.ygyno.2013.03.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.ygyno.2013.03.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=23474348" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC3sXls1Sns78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2013&pages=452-458&author=D.+K.+Armstrongauthor=A.+J.+Whiteauthor=S.+C.+Weilauthor=M.+Phillipsauthor=R.+L.+Coleman&title=Farletuzumab+%28AMonoclonal+Antibody+Against+Folate+Receptor+Alpha%29+in+Relapsed+Platinum-Sensitive+Ovarian+Cancer&doi=10.1016%2Fj.ygyno.2013.03.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer</span></div><div class="casAuthors">Armstrong, Deborah K.; White, Allen J.; Weil, Susan C.; Phillips, Martin; Coleman, Robert L.</div><div class="citationInfo"><span class="NLM_cas:title">Gynecologic Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">452-458</span>CODEN:
                <span class="NLM_cas:coden">GYNOA3</span>;
        ISSN:<span class="NLM_cas:issn">0090-8258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Objective: Farletuzumab is a humanized monoclonal antibody to folate receptor-α, which is over-expressed in most epithelial ovarian cancers but largely absent on normal tissue.  We evaluated clin. activity of farletuzumab, alone and combined with chemotherapy, in women with first-relapse, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancers.  Methods: Fifty-four eligible subjects received open-label farletuzumab weekly, single agent or combined with carboplatin (AUC5-6) and taxane (paclitaxel 175 mg/m2 or docetaxel 75 mg/m2), every 21 days for 6 cycles, followed by farletuzumab maintenance until progression.  Twenty-eight subjects with asymptomatic CA125 relapse received single-agent farletuzumab and could receive platinum/taxane chemotherapy plus farletuzumab after single-agent progression.  Twenty-six subjects with symptomatic relapse entered the combination arm directly; 21 subjects entered after single agent.  Primary endpoints included normalized CA125 and Overall Response Rate (ORR).  Duration of each subject's second progression-free interval (PFI2) was compared with her own first response interval (PFI1).  Results: Farletuzumab was well-tolerated as single agent, without additive toxicity when administered with chemotherapy.  Of 47 subjects who received farletuzumab with chemotherapy, 38 (80.9%) normalized CA125.  In 9/42 (21%) evaluable subjects, PFI2 was ≥ PFI1, better than the historical rate (3%).  There was a high response rate among subjects with PFI1 < 12 mo (75%), comparable to that in subjects with PFI1 ≥ 12 mo (84%).  Complete or partial ORR was 75% with combination therapy.  Conclusions: Based on this study, farletuzumab with carboplatin and taxane may enhance the response rate and duration of response in platinum-sensitive ovarian cancer patients with first relapse after remission of 6-18 mo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9MihV5zqvabVg90H21EOLACvtfcHk0liPM5g0EnD2-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXls1Sns78%253D&md5=d9190e9c360045d3a15f580f3be2789c</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.ygyno.2013.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ygyno.2013.03.002%26sid%3Dliteratum%253Aachs%26aulast%3DArmstrong%26aufirst%3DD.%2BK.%26aulast%3DWhite%26aufirst%3DA.%2BJ.%26aulast%3DWeil%26aufirst%3DS.%2BC.%26aulast%3DPhillips%26aufirst%3DM.%26aulast%3DColeman%26aufirst%3DR.%2BL.%26atitle%3DFarletuzumab%2520%2528AMonoclonal%2520Antibody%2520Against%2520Folate%2520Receptor%2520Alpha%2529%2520in%2520Relapsed%2520Platinum-Sensitive%2520Ovarian%2520Cancer%26jtitle%3DGynecol.%2520Oncol.%26date%3D2013%26volume%3D129%26spage%3D452%26epage%3D458%26doi%3D10.1016%2Fj.ygyno.2013.03.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span> <span> </span><span class="NLM_article-title">Microencapsulation of Coupled Folate and Chitosan Nanoparticles for Targeted Delivery of Combination Drugs to Colon</span>. <i>J. Microencapsulation</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">40</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.3109/02652048.2014.944947</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.3109%2F02652048.2014.944947" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=25198909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFSmsb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2015&pages=40-45&author=P.+Liauthor=Z.+Yangauthor=Y.+Wangauthor=Z.+Pengauthor=S.+Liauthor=L.+Kongauthor=Q.+Wang&title=Microencapsulation+of+Coupled+Folate+and+Chitosan+Nanoparticles+for+Targeted+Delivery+of+Combination+Drugs+to+Colon&doi=10.3109%2F02652048.2014.944947"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Microencapsulation of coupled folate and chitosan nanoparticles for targeted delivery of combination drugs to colon</span></div><div class="casAuthors">Li, Puwang; Yang, Ziming; Wang, Yichao; Peng, Zheng; Li, Sidong; Kong, Lingxue; Wang, Qinghuang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Microencapsulation</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">40-45</span>CODEN:
                <span class="NLM_cas:coden">JOMIEF</span>;
        ISSN:<span class="NLM_cas:issn">0265-2048</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Folate-chitosan nanoparticles, co-loaded with 5-fluourouacil (5-FU) and leucovorin (LV) and prepd. by ionic gelation technol. were phys. microencapsulated by enteric polymer using a solvent evapn. method.  Av. particle size of the microencapsulated particles was in the range of 15 to 35 μm.  High drug encapsulation efficiency was obtained for both 5-FU and LV in the microencapsulated particles.  Both drugs were in amorphous state in the microencapsulated particles.  By enteric coating, excellent pH-dependent release profile was achieved and no drug release was obsd. in simulated gastric and intestinal fluids.  However, when the pH value reached the sol. threshold of Eudragit S-100, a const. and slow drug release was obsd.  The results indicated that these microencapsulated particles are a promising vehicle for selectively targeting drugs to colon in the chemotherapy of colon cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGre9RWRJOdz4rVg90H21EOLACvtfcHk0lhK-ZExV__Bpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFSmsb7O&md5=0ba026c8118deb382e3057af80b9f423</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.3109%2F02652048.2014.944947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F02652048.2014.944947%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DPeng%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DKong%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DQ.%26atitle%3DMicroencapsulation%2520of%2520Coupled%2520Folate%2520and%2520Chitosan%2520Nanoparticles%2520for%2520Targeted%2520Delivery%2520of%2520Combination%2520Drugs%2520to%2520Colon%26jtitle%3DJ.%2520Microencapsulation%26date%3D2015%26volume%3D32%26spage%3D40%26epage%3D45%26doi%3D10.3109%2F02652048.2014.944947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Desgrosellier, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheresh, D. A.</span></span> <span> </span><span class="NLM_article-title">Integrins in Cancer: Biological Implications and Therapeutic Opportunities</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.1038/nrc2748</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1038%2Fnrc2748" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=20029421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsF2hsLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=9-22&author=J.+S.+Desgrosellierauthor=D.+A.+Cheresh&title=Integrins+in+Cancer%3A+Biological+Implications+and+Therapeutic+Opportunities&doi=10.1038%2Fnrc2748"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Integrins in cancer: biological implications and therapeutic opportunities</span></div><div class="casAuthors">Desgrosellier, Jay S.; Cheresh, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-22</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The integrin family of cell adhesion receptors regulates a diverse array of cellular functions crucial to the initiation, progression and metastasis of solid tumors.  The importance of integrins in several cell types that affect tumor progression has made them an appealing target for cancer therapy.  Integrin antagonists, including the αvβ3 and αvβ5 inhibitor cilengitide, have shown encouraging activity in Phase II clin. trials and cilengitide is currently being tested in a Phase III trial in patients with glioblastoma.  These exciting clin. developments emphasize the need to identify how integrin antagonists influence the tumor and its microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL2sajdsDI07Vg90H21EOLACvtfcHk0ljurxVsciNaFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsF2hsLzI&md5=43d0b526ca38021e780aba991a58451b</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fnrc2748&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2748%26sid%3Dliteratum%253Aachs%26aulast%3DDesgrosellier%26aufirst%3DJ.%2BS.%26aulast%3DCheresh%26aufirst%3DD.%2BA.%26atitle%3DIntegrins%2520in%2520Cancer%253A%2520Biological%2520Implications%2520and%2520Therapeutic%2520Opportunities%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D9%26epage%3D22%26doi%3D10.1038%2Fnrc2748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brannon-Peppas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchette, J. O.</span></span> <span> </span><span class="NLM_article-title">Nanoparticle and Targeted Systems for Cancer Therapy</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">206</span>– <span class="NLM_lpage">212</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2012.09.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.addr.2012.09.033" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2012&pages=206-212&author=L.+Brannon-Peppasauthor=J.+O.+Blanchette&title=Nanoparticle+and+Targeted+Systems+for+Cancer+Therapy&doi=10.1016%2Fj.addr.2012.09.033"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2012.09.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2012.09.033%26sid%3Dliteratum%253Aachs%26aulast%3DBrannon-Peppas%26aufirst%3DL.%26aulast%3DBlanchette%26aufirst%3DJ.%2BO.%26atitle%3DNanoparticle%2520and%2520Targeted%2520Systems%2520for%2520Cancer%2520Therapy%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2012%26volume%3D64%26spage%3D206%26epage%3D212%26doi%3D10.1016%2Fj.addr.2012.09.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, J.-O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, R.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, I.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, S. Y.</span></span> <span> </span><span class="NLM_article-title">Self-Assembled Nanoparticles Based on Glycol Chitosan Bearing 5β-Cholanic Acid for RGD Peptide Delivery</span>. <i>J. Controlled Release</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">579</span>– <span class="NLM_lpage">588</span>, <span class="refDoi"> DOI: 10.1016/j.jconrel.2003.12.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.jconrel.2003.12.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=15023468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitVKgt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2004&pages=579-588&author=J.+H.+Parkauthor=S.+Kwonauthor=J.-O.+Namauthor=R.-W.+Parkauthor=H.+Chungauthor=S.+B.+Seoauthor=I.-S.+Kimauthor=I.+C.+Kwonauthor=S.+Y.+Jeong&title=Self-Assembled+Nanoparticles+Based+on+Glycol+Chitosan+Bearing+5%CE%B2-Cholanic+Acid+for+RGD+Peptide+Delivery&doi=10.1016%2Fj.jconrel.2003.12.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Self-assembled nanoparticles based on glycol chitosan bearing 5β-cholanic acid for RGD peptide delivery</span></div><div class="casAuthors">Park, Jae Hyung; Kwon, Seunglee; Nam, Ju-Ock; Park, Rang-Woon; Chung, Hesson; Seo, Sang Bong; Kim, In-San; Kwon, Ick Chan; Jeong, Seo Young</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">579-588</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The synthetic peptide bearing Arg-Gly-Asp (RGD) sequence is considered to specifically bind to αvβ3 integrin expressed on endothelial cells in the angiogenic blood vessels, which provides a potential to inhibit the tumor growth.  As a carrier for the RGD peptide, hydrophobically modified glycol chitosan (HGC) capable of forming nano-sized self-aggregates was prepd. by the chem. conjugation of 5β-cholanic acid to the main backbone of glycol chitosan.  The RGD peptide labeled with fluorescein isothiocyanate (FITC-GRGDS) was loaded into self-aggregates in three different conditions: simple mixing, sonication, and solvent evapn. methods.  Of different methods applied, solvent evapn. method showed the most promising results for peptide loading, as judged by the yield (>70%) and loading efficiency (>75%).  It was found that the presence of FITC-labeled peptides makes the self-aggregates to be compact, possibly due to the role of both hydrophobic FITC and peptides contg. carboxylic acids that allow hydrogen bonding and electrostatic interaction with the primary amino groups in the main backbone of glycol chitosan.  FITC-labeled peptides were released from self-aggregates in a physiol. soln. (pH 7.4) for up to 1 day.  From the cell adhesion and migration assays, it was demonstrated that FITC labeling of peptides does not significantly deteriorate biol. activity of the parent peptide drug (GRGDS).  Overall, the self-aggregates loaded with FITC-GRGDS might be useful for monitoring or destroying the angiogenic vessels surrounding the tumor tissue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpglbBn1FC4b7Vg90H21EOLACvtfcHk0ljurxVsciNaFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitVKgt70%253D&md5=3a46df347d9d27b98c177fa446177530</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2003.12.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2003.12.020%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.%2BH.%26aulast%3DKwon%26aufirst%3DS.%26aulast%3DNam%26aufirst%3DJ.-O.%26aulast%3DPark%26aufirst%3DR.-W.%26aulast%3DChung%26aufirst%3DH.%26aulast%3DSeo%26aufirst%3DS.%2BB.%26aulast%3DKim%26aufirst%3DI.-S.%26aulast%3DKwon%26aufirst%3DI.%2BC.%26aulast%3DJeong%26aufirst%3DS.%2BY.%26atitle%3DSelf-Assembled%2520Nanoparticles%2520Based%2520on%2520Glycol%2520Chitosan%2520Bearing%25205%25CE%25B2-Cholanic%2520Acid%2520for%2520RGD%2520Peptide%2520Delivery%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2004%26volume%3D95%26spage%3D579%26epage%3D588%26doi%3D10.1016%2Fj.jconrel.2003.12.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span> <span> </span><span class="NLM_article-title">Enhanced Antitumor Effect of Novel Dual-Targeted Paclitaxel Liposomes</span>. <i>Nanotechnology</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">415103</span>, <span class="refDoi"> DOI: 10.1088/0957-4484/21/41/415103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1088%2F0957-4484%2F21%2F41%2F415103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=20852356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVygt7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2010&pages=415103&author=S.+Mengauthor=B.+Suauthor=W.+Liauthor=Y.+Dingauthor=L.+Tangauthor=W.+Zhouauthor=Y.+Songauthor=H.+Liauthor=C.+Zhou&title=Enhanced+Antitumor+Effect+of+Novel+Dual-Targeted+Paclitaxel+Liposomes&doi=10.1088%2F0957-4484%2F21%2F41%2F415103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced antitumor effect of novel dual-targeted paclitaxel liposomes</span></div><div class="casAuthors">Meng, Shuyan; Su, Bo; Li, Wei; Ding, Yongmei; Tang, Liang; Zhou, Wei; Song, Yin; Li, Heyan; Zhou, Caicun</div><div class="citationInfo"><span class="NLM_cas:title">Nanotechnology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">415103/1-415103/7</span>CODEN:
                <span class="NLM_cas:coden">NNOTER</span>;
        ISSN:<span class="NLM_cas:issn">1361-6528</span>.
    
            (<span class="NLM_cas:orgname">Institute of Physics Publishing</span>)
        </div><div class="casAbstract">A novel dual-targeted peptide contg. an alpha V integrins specific ligand and a neuropilin-1 specific motif was developed which showed an increased specific targeting affinity to tumors.  Active dual-targeted liposomes were then produced with this peptide and exhibited greater binding activity than single-targeted liposomes in vitro.  Paclitaxel entrapped in this formulation greatly increased the uptake of paclitaxel in the targeting cells and significantly suppressed the growth of HUVEC and A549 cells compared with general paclitaxel injections (Taxol) and single-targeted paclitaxel liposomes.  The treatment of tumor xenograft models with dual-targeted paclitaxel liposomes also resulted in better tumor growth inhibition than any other treatment groups.  Therefore, the dual-targeted paclitaxel liposomes prepd. in the present study might be a more promising drug for cancer treatment.  Therefore, Furthermore, the dual-targeting approach may produce synergistic effects that can be applied in the development of new drug delivery systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDH1k9TGynn7Vg90H21EOLACvtfcHk0liwTVFZD3ZU0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVygt7fM&md5=a9d721a7bb45e63605bf7646c094bbcc</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1088%2F0957-4484%2F21%2F41%2F415103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1088%252F0957-4484%252F21%252F41%252F415103%26sid%3Dliteratum%253Aachs%26aulast%3DMeng%26aufirst%3DS.%26aulast%3DSu%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DDing%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DC.%26atitle%3DEnhanced%2520Antitumor%2520Effect%2520of%2520Novel%2520Dual-Targeted%2520Paclitaxel%2520Liposomes%26jtitle%3DNanotechnology%26date%3D2010%26volume%3D21%26spage%3D415103%26doi%3D10.1088%2F0957-4484%2F21%2F41%2F415103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, X.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, K.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, F.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.-T.</span></span> <span> </span><span class="NLM_article-title">Glioma-Targeted Therapy Using Cilengitide Nanoparticles Combined with UTMD Enhanced Delivery</span>. <i>J. Controlled Release</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>224</i></span>,  <span class="NLM_fpage">112</span>– <span class="NLM_lpage">125</span>, <span class="refDoi"> DOI: 10.1016/j.jconrel.2016.01.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.jconrel.2016.01.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=26792571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC28XovFCntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=224&publication_year=2016&pages=112-125&author=Y.-Z.+Zhaoauthor=Q.+Linauthor=H.+L.+Wongauthor=X.-T.+Shenauthor=W.+Yangauthor=H.-L.+Xuauthor=K.-L.+Maoauthor=F.-R.+Tianauthor=J.-J.+Yangauthor=J.+Xuauthor=J.+Xiaoauthor=C.-T.+Lu&title=Glioma-Targeted+Therapy+Using+Cilengitide+Nanoparticles+Combined+with+UTMD+Enhanced+Delivery&doi=10.1016%2Fj.jconrel.2016.01.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Glioma-targeted therapy using Cilengitide nanoparticles combined with UTMD enhanced delivery</span></div><div class="casAuthors">Zhao, Ying-Zheng; Lin, Qian; Wong, Ho Lun; Shen, Xiao-Tong; Yang, Wei; Xu, He-Lin; Mao, Kai-Li; Tian, Fu-Rong; Yang, Jing-Jing; Xu, Jie; Xiao, Jian; Lu, Cui-Tao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">224</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112-125</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Malignant gliomas esp. glioblastoma (GBM) are poorly responsive to the current treatments.  Cilengitide (CGT) is a cyclic pentapeptide that demonstrated efficacy for GBM treatment by targeting the integrins avβ3 and avβ5 over-expressed on GBM cells.  However, clin. translation of this therapy has been limited by issues including fast blood clearance, high kidney and liver uptake, poor blood-brain barrier (BBB) penetration, low tumor specificity and rapid washout from tumors.  In this study, these issues were tackled in an integrated manner using a multi-stage strategy combining ultrasound-targeted microbubble destruction (UTMD) with CGT nanotherapy.  CGT nanoparticles (CGT-NP) prepd. using gelatin and Poloxamer 188-grafted heparin copolymer demonstrated significant apoptotic and cytotoxic effects in C6 GBM cells.  Biodistribution study in a rat GBM model demonstrated buildup of high CGT level in tumors subjected to CGT-NP + UTMD combined therapy.  The tumor CGT level in these animals was increased over 3-fold, tumor retention of CGT prolonged and renal clearance significantly reduced when compared with free CGT with or without UTMD.  CGT-NP + UTMD treatment was further shown to extend the median survival period from less than 20 days in the control and about 30 days in free CGT group to about 80 days.  This was achieved with low CGT dosing level (2 mg/kg twice weekly).  In situ monitoring of GFAP, Ki67, caspase-3, Beclin-1, and LC-3 in the tumor samples together with TUNEL assay, transmission electron microscope imaging and Western blot assay all demonstrated high apoptotic and autophagy activities induced by the combined therapy.  In conclusion, this study has provided extensive preclin. data supporting the use of this combined therapy to overcome the limitations of std. CGT treatment of gliomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoe14j1RuKTibVg90H21EOLACvtfcHk0lhBX_qY_w2oWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XovFCntw%253D%253D&md5=f4b92cef3e3eafca4491a5ad77502a1e</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2016.01.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2016.01.015%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DY.-Z.%26aulast%3DLin%26aufirst%3DQ.%26aulast%3DWong%26aufirst%3DH.%2BL.%26aulast%3DShen%26aufirst%3DX.-T.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DXu%26aufirst%3DH.-L.%26aulast%3DMao%26aufirst%3DK.-L.%26aulast%3DTian%26aufirst%3DF.-R.%26aulast%3DYang%26aufirst%3DJ.-J.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DXiao%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DC.-T.%26atitle%3DGlioma-Targeted%2520Therapy%2520Using%2520Cilengitide%2520Nanoparticles%2520Combined%2520with%2520UTMD%2520Enhanced%2520Delivery%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2016%26volume%3D224%26spage%3D112%26epage%3D125%26doi%3D10.1016%2Fj.jconrel.2016.01.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ai, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Y.</span></span> <span> </span><span class="NLM_article-title">Novel Linear Peptides with High Affinity to Avβ3 Integrin for Precise Tumor Identification</span>. <i>Theranostics</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1511</span>– <span class="NLM_lpage">1523</span>, <span class="refDoi"> DOI: 10.7150/thno.18401</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.7150%2Fthno.18401" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=28529634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtV2rt77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=1511-1523&author=Y.+Maauthor=G.+Aiauthor=C.+Zhangauthor=M.+Zhaoauthor=X.+Dongauthor=Z.+Hanauthor=Z.+Wangauthor=M.+Zhangauthor=Y.+Liuauthor=W.+Gaoauthor=S.+Liauthor=Y.+Gu&title=Novel+Linear+Peptides+with+High+Affinity+to+Av%CE%B23+Integrin+for+Precise+Tumor+Identification&doi=10.7150%2Fthno.18401"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Novel linear peptides with high affinity to αvβ3 integrin for precise tumor identification</span></div><div class="casAuthors">Ma, Yi; Ai, Guanhua; Zhang, Congying; Zhao, Menglu; Dong, Xue; Han, Zhihao; Wang, Zhaohui; Zhang, Min; Liu, Yuxi; Gao, Weidong; Li, Siwen; Gu, Yueqing</div><div class="citationInfo"><span class="NLM_cas:title">Theranostics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1511-1523</span>CODEN:
                <span class="NLM_cas:coden">THERDS</span>;
        ISSN:<span class="NLM_cas:issn">1838-7640</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">Development of alternative linear peptides for targeting αvβ3 integrin has attracted much attention, as the traditional peptide ligand, cyclic RGD, is limited by inferior water-soly. and complex synthesis.  Using pharmacophore-based virtual screening and high-throughput mol. docking, we identified two novel linear small peptides RWr and RWrNM with high affinity and specificity to αvβ3 integrin.  The competitive binding with cyclic RGD (c(RGDyK)) and cellular uptake related to the integrin expression levels verified their affinity to αvβ3 integrin.  The intermol. interaction measurement and dynamics simulation demonstrated the high binding affinity and stability, esp. for RWrNM.  In vivo peptide-guided tumor imaging and targeted therapy further confirmed their specificity.  Results indicated that the newly identified small linear peptide RWrNM, with high affinity and specificity to αvβ3 integrin, better water-soly., and simplified synthetic process, could overcome limitations of the current cyclic RGD peptides, paving the way for diverse use in diagnosis and therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpqcHMImewU7Vg90H21EOLACvtfcHk0lg34gBw1aDpgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtV2rt77I&md5=247b1d9e2663c1aacfb0b1f157231d4a</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.7150%2Fthno.18401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fthno.18401%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DY.%26aulast%3DAi%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DDong%26aufirst%3DX.%26aulast%3DHan%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DGu%26aufirst%3DY.%26atitle%3DNovel%2520Linear%2520Peptides%2520with%2520High%2520Affinity%2520to%2520Av%25CE%25B23%2520Integrin%2520for%2520Precise%2520Tumor%2520Identification%26jtitle%3DTheranostics%26date%3D2017%26volume%3D7%26spage%3D1511%26epage%3D1523%26doi%3D10.7150%2Fthno.18401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.</span></span> <span> </span><span class="NLM_article-title">Multifunctional Dendrimer-Entrapped Gold Nanoparticles Modified with RGD Peptide for Targeted Computed Tomography/Magnetic Resonance Dual-Modal Imaging of Tumors</span>. <i>Anal. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">3949</span>– <span class="NLM_lpage">3956</span>, <span class="refDoi"> DOI: 10.1021/acs.analchem.5b00135</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.analchem.5b00135" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksVOktr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2015&pages=3949-3956&author=Q.+Chenauthor=H.+Wangauthor=H.+Liuauthor=S.+Wenauthor=C.+Pengauthor=M.+Shenauthor=G.+Zhangauthor=X.+Shi&title=Multifunctional+Dendrimer-Entrapped+Gold+Nanoparticles+Modified+with+RGD+Peptide+for+Targeted+Computed+Tomography%2FMagnetic+Resonance+Dual-Modal+Imaging+of+Tumors&doi=10.1021%2Facs.analchem.5b00135"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Multifunctional Dendrimer-Entrapped Gold Nanoparticles Modified with RGD Peptide for Targeted Computed Tomography/Magnetic Resonance Dual-Modal Imaging of Tumors</span></div><div class="casAuthors">Chen, Qian; Wang, Han; Liu, Hui; Wen, Shihui; Peng, Chen; Shen, Mingwu; Zhang, Guixiang; Shi, Xiangyang</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Chemistry (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3949-3956</span>CODEN:
                <span class="NLM_cas:coden">ANCHAM</span>;
        ISSN:<span class="NLM_cas:issn">0003-2700</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report the use of multifunctional dendrimer-entrapped gold nanoparticles (Au DENPs) loaded with gadolinium (Gd) chelator/Gd(III) complexes and surface-modified with thiolated cyclo(Arg-Gly-Asp-Phe-Lys(mpa)) (RGD) peptide for targeted dual-mode computed tomog. (CT)/magnetic resonance (MR) imaging of small tumors.  In this study, amine-terminated generation 5 poly(amidoamine) dendrimers were used as a nanoplatform to be covalently modified with Gd chelator, RGD via a polyethylene glycol (PEG) spacer, and PEG monomethyl ether.  Then the multifunctional dendrimers were used as templates to entrap gold nanoparticles, followed by chelating Gd(III) ions and acetylation of the remaining dendrimer terminal amines.  The thus-formed multifunctional Au DENPs (in short, Gd-Au DENPs-RGD) were characterized via different techniques.  We show that the multifunctional Au DENPs with a Au core size of 3.8 nm are water-dispersible, stable under different pH (5-8) and temp. conditions (4-50 °C), and noncytotoxic at a Au concn. up to 100 μM.  With the displayed X-ray attenuation property and the r1 relaxivity (2.643 mM-1s-1), the developed Gd-Au DENPs-RGD are able to be used as a dual-mode nanoprobe for targeted CT/MR imaging of an αvβ3 integrin-overexpressing xenografted small tumor model in vivo via RGD-mediated active targeting pathway.  The developed multifunctional Gd-Au DENPs-RGD may be used as a promising dual-mode nanoprobe for targeted CT/MR imaging of different types of αvβ3 integrin-overexpressing cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovu9WBepJIuLVg90H21EOLACvtfcHk0lj09kKrPJfEgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksVOktr0%253D&md5=44ea751128488a605a6a1c45481cb021</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Facs.analchem.5b00135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.analchem.5b00135%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DWen%26aufirst%3DS.%26aulast%3DPeng%26aufirst%3DC.%26aulast%3DShen%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DShi%26aufirst%3DX.%26atitle%3DMultifunctional%2520Dendrimer-Entrapped%2520Gold%2520Nanoparticles%2520Modified%2520with%2520RGD%2520Peptide%2520for%2520Targeted%2520Computed%2520Tomography%252FMagnetic%2520Resonance%2520Dual-Modal%2520Imaging%2520of%2520Tumors%26jtitle%3DAnal.%2520Chem.%26date%3D2015%26volume%3D87%26spage%3D3949%26epage%3D3956%26doi%3D10.1021%2Facs.analchem.5b00135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauth, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X. Y.</span></span> <span> </span><span class="NLM_article-title">RGD-Conjugated Solid Lipid Nanoparticles Inhibit Adhesion and Invasion of Avβ3 Integrin-Overexpressing Breast Cancer Cells</span>. <i>Drug Delivery Transl. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1007/s13346-014-0210-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1007%2Fs13346-014-0210-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=25787336" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFSqurjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=15-26&author=D.+Shanauthor=J.+Liauthor=P.+Caiauthor=P.+Prasadauthor=F.+Liuauthor=A.+M.+Rauthauthor=X.+Y.+Wu&title=RGD-Conjugated+Solid+Lipid+Nanoparticles+Inhibit+Adhesion+and+Invasion+of+Av%CE%B23+Integrin-Overexpressing+Breast+Cancer+Cells&doi=10.1007%2Fs13346-014-0210-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">RGD-conjugated solid lipid nanoparticles inhibit adhesion and invasion of αvβ3 integrin-overexpressing breast cancer cells</span></div><div class="casAuthors">Shan, Dan; Li, Jason; Cai, Ping; Prasad, Preethy; Liu, Franky; Rauth, Andrew Michael; Wu, Xiao Yu</div><div class="citationInfo"><span class="NLM_cas:title">Drug Delivery and Translational Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-26</span>CODEN:
                <span class="NLM_cas:coden">DDTRCY</span>;
        ISSN:<span class="NLM_cas:issn">2190-3948</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">αvβ3 Integrin receptors expressed on cancer cell surfaces play a crucial role in promoting tumor angiogenesis and cancer cell metastasis.  Thus, cyclic arginyl-glycyl-aspartic acid (cRGD) peptides have been explored as a αvβ3 integrin receptor-specific targeting moiety for the targeted delivery of nanoparticle-loaded therapeutics.  However, our previous study showed that cyclic RGD could act as a double-edged sword that, on one hand, extended the retention of cRGD-modified solid lipid nanoparticles (RGD-SLNs) at αvβ3 integrin receptor overexpressing breast carcinoma, and yet on the other hand, decreased the amt. of tumor accumulation of RGD-SLNs attributable to the greater uptake by the mononuclear phagocyte system (MPS).  Therefore, we aimed to optimize the RGD-decorated nanoparticle systems for (1) inhibiting αvβ3 integrin receptor overexpressing tumor cell metastasis and (2) increasing nanoparticle accumulation to tumor site.  SLNs with cRGD content ranging from 0 to 10 % mol of total polyethyleneglycol (PEG) chains were synthesized.  The binding of RGD-SLNs with αvβ3 integrin receptors increased with increasing cRGD concn. on the nanoparticles.  RGD-SLNs were demonstrated to inhibit MDA-MB-231 cell adhesion to fibronectin and invasion through Matrigel.  In vivo whole-body fluorescence imaging revealed that 1 % cRGD on the SLNs' surface had max. tumor accumulation with extended tumor retention among all formulations tested in an orthotopic MDA-MB-231/EGFP breast tumor model.  This work has laid a foundation for further development of anticancer drug-loaded optimized cRGD nanoparticle formulations for the treatment of breast cancer metastasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsVjZUfCe6XLVg90H21EOLACvtfcHk0lh-G758gXwQsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFSqurjP&md5=00ac02d020650fefd627f270f403c9ef</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1007%2Fs13346-014-0210-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13346-014-0210-2%26sid%3Dliteratum%253Aachs%26aulast%3DShan%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DCai%26aufirst%3DP.%26aulast%3DPrasad%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DRauth%26aufirst%3DA.%2BM.%26aulast%3DWu%26aufirst%3DX.%2BY.%26atitle%3DRGD-Conjugated%2520Solid%2520Lipid%2520Nanoparticles%2520Inhibit%2520Adhesion%2520and%2520Invasion%2520of%2520Av%25CE%25B23%2520Integrin-Overexpressing%2520Breast%2520Cancer%2520Cells%26jtitle%3DDrug%2520Delivery%2520Transl.%2520Res.%26date%3D2015%26volume%3D5%26spage%3D15%26epage%3D26%26doi%3D10.1007%2Fs13346-014-0210-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Graf, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielenberg, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolishetti, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muus, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banyard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farokhzad, O. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span> <span> </span><span class="NLM_article-title">Avβ3 Integrin-Targeted PLGA-PEG Nanoparticles for Enhanced Anti-Tumor Efficacy of aPt (IV) Prodrug</span>. <i>ACS Nano</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">4530</span>– <span class="NLM_lpage">4539</span>, <span class="refDoi"> DOI: 10.1021/nn301148e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/nn301148e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC38XmvFGhu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2012&pages=4530-4539&author=N.+Grafauthor=D.+R.+Bielenbergauthor=N.+Kolishettiauthor=C.+Muusauthor=J.+Banyardauthor=O.+C.+Farokhzadauthor=S.+J.+Lippard&title=Av%CE%B23+Integrin-Targeted+PLGA-PEG+Nanoparticles+for+Enhanced+Anti-Tumor+Efficacy+of+aPt+%28IV%29+Prodrug&doi=10.1021%2Fnn301148e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">αVβ3 Integrin-Targeted PLGA-PEG Nanoparticles for Enhanced Anti-tumor Efficacy of a Pt(IV) Prodrug</span></div><div class="casAuthors">Graf, Nora; Bielenberg, Diane R.; Kolishetti, Nagesh; Muus, Christoph; Banyard, Jacqueline; Farokhzad, Omid C.; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Nano</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">4530-4539</span>CODEN:
                <span class="NLM_cas:coden">ANCAC3</span>;
        ISSN:<span class="NLM_cas:issn">1936-0851</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Targeted delivery of therapeutics to tumor neovasculature is potentially a powerful approach for selective cancer treatment.  Integrins are heterodimeric transmembrane proteins involved in cell adhesion and cell signaling, and their expression is commonly upregulated in cancers and inflammatory diseases.  The αvβ3 integrin is differentially upregulated on angiogenic endothelial cells as well as on many cancer cells.  Here we demonstrate the differential targeting of cisplatin prodrug-encapsulated poly(D,L-lactic-co-glycolic acid)-block-polyethylene glycol (PLGA-PEG) nanoparticles (NPs) to the αvβ3 integrin on cancer cells using the cyclic pentapeptide c(RGDfK).  Cisplatin is one of the most widely used anticancer drugs, and approaches that can improve its therapeutic index are of broad importance.  The RGD-targeted Pt(IV)-encapsulated NPs displayed enhanced cytotoxicity as compared to cisplatin administered in its conventional dosage form in model prostate and breast cancer epithelial cells in vitro.  Cytotoxicities were also elevated in comparison to those of previously reported systems, a small mol. Pt(IV)-RGD conjugate and a Pt(IV) nanoscale coordination polymer carrying RGD moieties.  This result encouraged us also to evaluate the anticancer effect of the new construct in an animal model.  The RGD-targeted PLGA-PEG NPs were more efficacious and better tolerated by comparison to cisplatin in an orthotopic human breast cancer xenograft model in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMAV6ynbyup7Vg90H21EOLACvtfcHk0lh-G758gXwQsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmvFGhu70%253D&md5=7650624390ad2befa90ce40577b2edcd</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fnn301148e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fnn301148e%26sid%3Dliteratum%253Aachs%26aulast%3DGraf%26aufirst%3DN.%26aulast%3DBielenberg%26aufirst%3DD.%2BR.%26aulast%3DKolishetti%26aufirst%3DN.%26aulast%3DMuus%26aufirst%3DC.%26aulast%3DBanyard%26aufirst%3DJ.%26aulast%3DFarokhzad%26aufirst%3DO.%2BC.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DAv%25CE%25B23%2520Integrin-Targeted%2520PLGA-PEG%2520Nanoparticles%2520for%2520Enhanced%2520Anti-Tumor%2520Efficacy%2520of%2520aPt%2520%2528IV%2529%2520Prodrug%26jtitle%3DACS%2520Nano%26date%3D2012%26volume%3D6%26spage%3D4530%26epage%3D4539%26doi%3D10.1021%2Fnn301148e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montet, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montet-Abou, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissleder, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josephson, L.</span></span> <span> </span><span class="NLM_article-title">Nanoparticle Imaging of Integrins on Tumor Cells</span>. <i>Neoplasia</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">214</span>– <span class="NLM_lpage">222</span>, <span class="refDoi"> DOI: 10.1593/neo.05769</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1593%2Fneo.05769" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=16611415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD28XovVKlurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2006&pages=214-222&author=X.+Montetauthor=K.+Montet-Abouauthor=F.+Reynoldsauthor=R.+Weisslederauthor=L.+Josephson&title=Nanoparticle+Imaging+of+Integrins+on+Tumor+Cells&doi=10.1593%2Fneo.05769"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Nanoparticle imaging of integrins on tumor cells</span></div><div class="casAuthors">Montet, Xavier; Montet-Abou, Karin; Reynolds, Fred; Weissleder, Ralph; Josephson, Lee</div><div class="citationInfo"><span class="NLM_cas:title">Neoplasia (Ann Arbor, MI, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">214-222</span>CODEN:
                <span class="NLM_cas:coden">NEOPFL</span>;
        ISSN:<span class="NLM_cas:issn">1522-8002</span>.
    
            (<span class="NLM_cas:orgname">Neoplasia Press Inc.</span>)
        </div><div class="casAbstract">Nanoparticles 10 to 100 nm in size can deliver large payloads to mol. targets, but undergo slow diffusion and/or slow transport through delivery barriers.  To examine the feasibility of nanoparticles targeting a marker expressed in tumor cells, we used the binding of cyclic arginine-glycine-aspartic acid (RGD) nanoparticle targeting integrins on BT-20 tumor as a model system.  The goals of this study were: (1) to use nanoparticles to image αvβ3 integrins expressed in BT-20 tumor cells by fluorescence-based imaging and magnetic resonance imaging, and, (2) to identify factors assocd. with the ability of nanoparticles to target tumor cell integrins.  Three factors were identified: (1) tumor cell integrin expression (the αvβ3 integrin was expressed in BT-20 cells, but not in 9L cells); (2) nanoparticle pharmacokinetics (the cyclic RGD peptide cross-linked iron oxide had a blood half-life of 180 min and was able to escape from the vasculature over its long circulation time); and (3) tumor vascularization the tumor had a dense capillary bed, with distances of <100 μm between capillaries.  These results suggest that nanoparticles could be targeted to the cell surface markers expressed in tumor cells, at least in the case wherein the nanoparticles and the tumor model have characteristics similar to those of the BT-20 tumor employed here.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryyuzlfn7Pn7Vg90H21EOLACvtfcHk0lhkbdk38uSCnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XovVKlurY%253D&md5=83f23d8309416bf17b6565213400e9f7</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1593%2Fneo.05769&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1593%252Fneo.05769%26sid%3Dliteratum%253Aachs%26aulast%3DMontet%26aufirst%3DX.%26aulast%3DMontet-Abou%26aufirst%3DK.%26aulast%3DReynolds%26aufirst%3DF.%26aulast%3DWeissleder%26aufirst%3DR.%26aulast%3DJosephson%26aufirst%3DL.%26atitle%3DNanoparticle%2520Imaging%2520of%2520Integrins%2520on%2520Tumor%2520Cells%26jtitle%3DNeoplasia%26date%3D2006%26volume%3D8%26spage%3D214%26epage%3D222%26doi%3D10.1593%2Fneo.05769" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haubner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beer, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vabuliene, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reim, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarbia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, K.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goebel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wester, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwaiger, M.</span></span> <span> </span><span class="NLM_article-title">Noninvasive Visualization of the Activated Avβ3 Integrin in Cancer Patients by Positron Emission Tomography and [18F] Galacto-RGD</span>. <i>PLoS Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">244</span>– <span class="NLM_lpage">252</span>, <span class="refDoi"> DOI: 10.1371/journal.pmed.0020070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1371%2Fjournal.pmed.0020070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFyhsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=244-252&author=R.+Haubnerauthor=W.+A.+Weberauthor=A.+J.+Beerauthor=E.+Vabulieneauthor=D.+Reimauthor=M.+Sarbiaauthor=K.-F.+Beckerauthor=M.+Goebelauthor=R.+Heinauthor=H.-J.+Westerauthor=H.+Kesslerauthor=M.+Schwaiger&title=Noninvasive+Visualization+of+the+Activated+Av%CE%B23+Integrin+in+Cancer+Patients+by+Positron+Emission+Tomography+and+%5B18F%5D+Galacto-RGD&doi=10.1371%2Fjournal.pmed.0020070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Noninvasive visualization of the activated αvβ3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD</span></div><div class="casAuthors">Haubner, Roland; Weber, Wolfgang A.; Beer, Ambros J.; Vabuliene, Eugenija; Reim, Daniel; Sarbia, Mario; Becker, Karl-Friedrich; Goebel, Michael; Hein, Ruediger; Wester, Hans-Juergen; Kessler, Horst; Schwaiger, Markus</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">244-252</span>CODEN:
                <span class="NLM_cas:coden">PMLEAC</span>;
        ISSN:<span class="NLM_cas:issn">1549-1277</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background The integrin αvβ3 plays an important role in angiogenesis and tumor cell metastasis, and is currently being evaluated as a target for new therapeutic approaches.  Several techniques are being studied to enable noninvasive detn. of αvβ3 expression.  We developed [18F]Galacto-RGD, a 18F-labeled glycosylated αvβ3 antagonist, allowing monitoring of αvβ3 expression with positron emission tomog. (PET).  Methods and Findings Here we show by quant. anal. of images resulting from a small-animal PET scanner that uptake of [18F]Galacto-RGD in the tumor correlates with αvβ3 expression subsequently detd. by Western blot analyses.  Moreover, using the A431 human squamous cell carcinoma model we demonstrate that this approach is sensitive enough to visualize αvβ3 expression resulting exclusively from the tumor vasculature.  Most important, this study shows, that [18F]Galacto-RGD with PET enables noninvasive quant. assessment of the αvβ3 expression pattern on tumor and endothelial cells in patients with malignant tumors.  Conclusions Mol. imaging with [18F]Galacto-RGD and PET can provide important information for planning and monitoring anti-angiogenic therapies targeting the αvβ3 integrins and can reveal the involvement and role of this integrin in metastatic and angiogenic processes in various diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUO_C1ztS9H7Vg90H21EOLACvtfcHk0lhkbdk38uSCnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFyhsLg%253D&md5=edef779afc8302d55bff67877e21ea17</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pmed.0020070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pmed.0020070%26sid%3Dliteratum%253Aachs%26aulast%3DHaubner%26aufirst%3DR.%26aulast%3DWeber%26aufirst%3DW.%2BA.%26aulast%3DBeer%26aufirst%3DA.%2BJ.%26aulast%3DVabuliene%26aufirst%3DE.%26aulast%3DReim%26aufirst%3DD.%26aulast%3DSarbia%26aufirst%3DM.%26aulast%3DBecker%26aufirst%3DK.-F.%26aulast%3DGoebel%26aufirst%3DM.%26aulast%3DHein%26aufirst%3DR.%26aulast%3DWester%26aufirst%3DH.-J.%26aulast%3DKessler%26aufirst%3DH.%26aulast%3DSchwaiger%26aufirst%3DM.%26atitle%3DNoninvasive%2520Visualization%2520of%2520the%2520Activated%2520Av%25CE%25B23%2520Integrin%2520in%2520Cancer%2520Patients%2520by%2520Positron%2520Emission%2520Tomography%2520and%2520%255B18F%255D%2520Galacto-RGD%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26spage%3D244%26epage%3D252%26doi%3D10.1371%2Fjournal.pmed.0020070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soroceanu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillespie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khazaeli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sontheimer, H.</span></span> <span> </span><span class="NLM_article-title">Use of Chlorotoxin for Targeting of Primary Brain Tumors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4871</span>– <span class="NLM_lpage">4879</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=9809993" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADyaK1cXnt1yis7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1998&pages=4871-4879&author=L.+Soroceanuauthor=Y.+Gillespieauthor=M.+Khazaeliauthor=H.+Sontheimer&title=Use+of+Chlorotoxin+for+Targeting+of+Primary+Brain+Tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Use of chlorotoxin for targeting of primary brain tumors</span></div><div class="casAuthors">Soroceanu, Liliana; Gillespie, Yancey; Khazaeli, M. B.; Sontheimer, Harald</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4871-4879</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">AACR Subscription Office</span>)
        </div><div class="casAbstract">Gliomas are primary brain tumors that arise from differentiated glial cells through a poorly understood malignant transformation.  Although glioma cells retain some genetic and antigenic features common to glial cells, they show a remarkable degree of antigenic heterogeneity and variable mutations in their genome.  Glioma cells have recently been shown to express a glioma-specific chloride ion channel (GCC) that is sensitive to chlorotoxin (CTX), a small peptide purified from Leiurus quinquestriatus scorpion venom.  Using native and recombinant 125I-labeled CTX, we show that toxin binding to glioma cells is specific and involves high affinity [dissocn. const. (Kd) = 4.2 nM] and low affinity (Kd = 660 nM) binding sites.  In radioreceptor assays, 125I-labeled CTX binds to a protein with Mr = 72,000, presumably GCC or a receptor that modulates GCC activity.  In vivo targeting and biodistribution expts. were obtained using 125I- and 131I-labeled CTX injected into severe combined immunodeficient mice bearing xenografted gliomas.  CTX selectively accumulated in the brain of tumor-bearing mice with calcd. brain: muscle ratios of 36.4% of injected dose/g (ID/g), as compared to 12.4% ID/g in control animals.  In the tumor-bearing severe combined immunodeficient mice, the vast majority of the brain-assocd. radioactivity was localized within the tumor (tumor:muscle ratio, 39.13% ID/g; contralateral brain:muscle ratio, 6.68% ID/g).  Moreover, 131I-labeled CTX distribution, visualized through in vivo imaging by gamma ray camera scans, demonstrates specific and persistent intratumoral localization of the radioactive ligand.  Immunohistochem. studies using biotinylated and fluorescently tagged CTX show highly selective staining of glioma cells in vitro, in situ, and in sections of patient biopsies.  Comparison tissues including normal human brain, kidney, and colon were consistently neg. for CTX immunostaining.  These data suggest that CTX and CTX-conjugated mols. may serve as glioma-specific markers with diagnostic and therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5ZrYqlVfEVrVg90H21EOLACvtfcHk0lgIiQYOqrMyGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnt1yis7s%253D&md5=e7eba505cd6d39156fe9161a2543407d</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSoroceanu%26aufirst%3DL.%26aulast%3DGillespie%26aufirst%3DY.%26aulast%3DKhazaeli%26aufirst%3DM.%26aulast%3DSontheimer%26aufirst%3DH.%26atitle%3DUse%2520of%2520Chlorotoxin%2520for%2520Targeting%2520of%2520Primary%2520Brain%2520Tumors%26jtitle%3DCancer%2520Res.%26date%3D1998%26volume%3D58%26spage%3D4871%26epage%3D4879" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jon, S.</span></span> <span> </span><span class="NLM_article-title">Targeting Strategies for Multifunctional Nanoparticles in Cancer Imaging and Therapy</span>. <i>Theranostics</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.7150/thno.3463</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.7150%2Fthno.3463" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=22272217" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A280%3ADC%252BC387nt1Wnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=3-44&author=M.+K.+Yuauthor=J.+Parkauthor=S.+Jon&title=Targeting+Strategies+for+Multifunctional+Nanoparticles+in+Cancer+Imaging+and+Therapy&doi=10.7150%2Fthno.3463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy</span></div><div class="casAuthors">Yu Mi Kyung; Park Jinho; Jon Sangyong</div><div class="citationInfo"><span class="NLM_cas:title">Theranostics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-44</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Nanomaterials offer new opportunities for cancer diagnosis and treatment.  Multifunctional nanoparticles harboring various functions including targeting, imaging, therapy, and etc have been intensively studied aiming to overcome limitations associated with conventional cancer diagnosis and therapy.  Of various nanoparticles, magnetic iron oxide nanoparticles with superparamagnetic property have shown potential as multifunctional nanoparticles for clinical translation because they have been used asmagnetic resonance imaging (MRI) constrast agents in clinic and their features could be easily tailored by including targeting moieties, fluorescence dyes, or therapeutic agents.  This review summarizes targeting strategies for construction of multifunctional nanoparticles including magnetic nanoparticles-based theranostic systems, and the various surface engineering strategies of nanoparticles for in vivo applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTtHCiTxwHPpTToTC3aBaesfW6udTcc2eYqgO1K4Jzkq7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC387nt1Wnsg%253D%253D&md5=d842af826431047f6cfd6be7b8d3054b</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.7150%2Fthno.3463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fthno.3463%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DM.%2BK.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DJon%26aufirst%3DS.%26atitle%3DTargeting%2520Strategies%2520for%2520Multifunctional%2520Nanoparticles%2520in%2520Cancer%2520Imaging%2520and%2520Therapy%26jtitle%3DTheranostics%26date%3D2012%26volume%3D2%26spage%3D3%26epage%3D44%26doi%3D10.7150%2Fthno.3463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sontheimer, H.</span></span> <span> </span><span class="NLM_article-title">Chlorotoxin, A Scorpion-Derived Peptide, Specifically Binds to Gliomas and Tumors of Neuroectodermal Origin</span>. <i>Glia</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">162</span>– <span class="NLM_lpage">173</span>, <span class="refDoi"> DOI: 10.1002/glia.10083</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1002%2Fglia.10083" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=12112367" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A280%3ADC%252BD38zms1KjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2002&pages=162-173&author=S.+A.+Lyonsauthor=J.+O%E2%80%99Nealauthor=H.+Sontheimer&title=Chlorotoxin%2C+A+Scorpion-Derived+Peptide%2C+Specifically+Binds+to+Gliomas+and+Tumors+of+Neuroectodermal+Origin&doi=10.1002%2Fglia.10083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Chlorotoxin, a scorpion-derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin</span></div><div class="casAuthors">Lyons Susan A; O'Neal Jeffrey; Sontheimer Harald</div><div class="citationInfo"><span class="NLM_cas:title">Glia</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">162-73</span>
        ISSN:<span class="NLM_cas:issn">0894-1491</span>.
    </div><div class="casAbstract">Highly migratory neuroectodermal cells share a common embryonic origin with cells of the central nervous system (CNS).  They include enteric, parasympathetic, sympathoadrenal, and sensory neurons of the peripheral nervous system, Schwann cells, melanocytes, endocrine cells, and cells forming connective tissue of the face and neck.  Because of their common embryologic origin, these cells and the tumors that derive from them can share genetic and antigenic phenotypes with gliomas, tumors derived from CNS glia.  We recently discovered that chlorotoxin (ClTx), a 4-kD peptide purified from Leiurus quinquestriatus scorpion, is a highly specific marker for glioma cells in biopsy tissues (Soroceanu et al.  Cancer Res 58:4871-4879, 1998) that can target tumors in animal models.  We report on the specificity of ClTx as a marker for tumors of neuroectodermal origin that include peripheral neuroectodermal tumors (PNET) and gliomas.  Specifically, we histochemically stained frozen and paraffin tissue sections of human biopsy tissues from 262 patients with a synthetically manufactured and biologically active ClTx bearing an N-terminal biotin.  The vast majority (74 of 79) of primary human brain tumors investigated showed abundant binding of ClTx with greater than 90% ClTx-positive cells in each section.  By comparison, 32 biopsies of uninvolved brain used for comparison were largely ClTx-negative, with only a few isolated reactive astrocytes showing some ClTx binding.  However, as with gliomas, the vast majority of PNETs examined showed specific ClTx binding (31 of 34).  These include medulloblastomas (4 of 4), neuroblastomas (6 of 7), ganglioneuromas (4 of 4), melanomas (7 of 7), adrenal pheochromocytomas (5 of 6), primitive PNET (1), small cell lung carcinoma (2 of 3), and Ewing's sarcoma (2 of 2).  Under identical staining conditions, normal tissues from brain, skin, kidney, and lung were consistently negative for ClTx.  These results suggest that chlorotoxin is a reliable and specific histopathological marker for tumors of neuroectodermal origin and that chlorotoxin derivatives with cytolytic activity may have therapeutic potential for these cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQTkuSPR0MIXvEeosoOnpOLfW6udTcc2eYqgO1K4Jzkq7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38zms1KjtQ%253D%253D&md5=479e66a95551cf8f3cddffeaceba6c48</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1002%2Fglia.10083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fglia.10083%26sid%3Dliteratum%253Aachs%26aulast%3DLyons%26aufirst%3DS.%2BA.%26aulast%3DO%25E2%2580%2599Neal%26aufirst%3DJ.%26aulast%3DSontheimer%26aufirst%3DH.%26atitle%3DChlorotoxin%252C%2520A%2520Scorpion-Derived%2520Peptide%252C%2520Specifically%2520Binds%2520to%2520Gliomas%2520and%2520Tumors%2520of%2520Neuroectodermal%2520Origin%26jtitle%3DGlia%26date%3D2002%26volume%3D39%26spage%3D162%26epage%3D173%26doi%3D10.1002%2Fglia.10083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Veiseh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabikian, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahrami, S.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veiseh, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackman, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravanpay, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroud, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusuma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, S.</span></span> <span> </span><span class="NLM_article-title">Tumor Paint: A Chlorotoxin: Cy5.5 Bioconjugate for Intraoperative Visualization of Cancer Foci</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">6882</span>– <span class="NLM_lpage">6888</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-3948</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1158%2F0008-5472.CAN-06-3948" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=17638899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslOisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=6882-6888&author=M.+Veisehauthor=P.+Gabikianauthor=S.-B.+Bahramiauthor=O.+Veisehauthor=M.+Zhangauthor=R.+C.+Hackmanauthor=A.+C.+Ravanpayauthor=M.+R.+Stroudauthor=Y.+Kusumaauthor=S.+Hansen&title=Tumor+Paint%3A+A+Chlorotoxin%3A+Cy5.5+Bioconjugate+for+Intraoperative+Visualization+of+Cancer+Foci&doi=10.1158%2F0008-5472.CAN-06-3948"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor Paint: A Chlorotoxin:Cy5.5 Bioconjugate for Intraoperative Visualization of Cancer Foci</span></div><div class="casAuthors">Veiseh, Mandana; Gabikian, Patrik; Bahrami, S-Bahram; Veiseh, Omid; Zhang, Miqin; Hackman, Robert C.; Ravanpay, Ali C.; Stroud, Mark R.; Kusuma, Yumiko; Hansen, Stacey J.; Kwok, Deborah; Munoz, Nina M.; Sze, Raymond W.; Grady, William M.; Greenberg, Norman M.; Ellenbogen, Richard G.; Olson, James M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6882-6888</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Toward the goal of developing an optical imaging contrast agent that will enable surgeons to intraoperatively distinguish cancer foci from adjacent normal tissue, we developed a chlorotoxin:Cy5.5 (CTX:Cy5.5) bioconjugate that emits near-IR fluorescent signal.  The probe delineates malignant glioma, medulloblastoma, prostate cancer, intestinal cancer, and sarcoma from adjacent non-neoplastic tissue in mouse models.  Metastatic cancer foci as small as a few hundred cells were detected in lymph channels.  Specific binding to cancer cells is facilitated by matrix metalloproteinase-2 (MMP-2) as evidenced by redn. of CTX:Cy5.5 binding in vitro and in vivo by a pharmacol. blocker of MMP-2 and induction of CTX:Cy5.5 binding in MCF-7 cells following transfection with a plasmid encoding MMP-2.  Mouse studies revealed that CTX:Cy5.5 has favorable biodistribution and toxicity profiles.  These studies show that CTX:Cy5.5 has the potential to fundamentally improve intraoperative detection and resection of malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo04sI0a6cQdLVg90H21EOLACvtfcHk0lgMoJ8B_EwlsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslOisb8%253D&md5=9f9bbe1bf8df8b3ef12fa79df5e671e0</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-3948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-3948%26sid%3Dliteratum%253Aachs%26aulast%3DVeiseh%26aufirst%3DM.%26aulast%3DGabikian%26aufirst%3DP.%26aulast%3DBahrami%26aufirst%3DS.-B.%26aulast%3DVeiseh%26aufirst%3DO.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DHackman%26aufirst%3DR.%2BC.%26aulast%3DRavanpay%26aufirst%3DA.%2BC.%26aulast%3DStroud%26aufirst%3DM.%2BR.%26aulast%3DKusuma%26aufirst%3DY.%26aulast%3DHansen%26aufirst%3DS.%26atitle%3DTumor%2520Paint%253A%2520A%2520Chlorotoxin%253A%2520Cy5.5%2520Bioconjugate%2520for%2520Intraoperative%2520Visualization%2520of%2520Cancer%2520Foci%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D6882%26epage%3D6888%26doi%3D10.1158%2F0008-5472.CAN-06-3948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">Necroptotic Cancer Cells-Mimicry Nanovaccine Boosts Anti-Tumor Immunity with Tailored Immune-Stimulatory Modality</span>. <i>Biomaterials</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>164</i></span>,  <span class="NLM_fpage">80</span>– <span class="NLM_lpage">97</span>, <span class="refDoi"> DOI: 10.1016/j.biomaterials.2018.02.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.biomaterials.2018.02.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=29499438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjsVGnsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2018&pages=80-97&author=T.+Kangauthor=Y.+Huangauthor=Q.+Zhuauthor=H.+Chengauthor=Y.+Peiauthor=J.+Fengauthor=M.+Xuauthor=G.+Jiangauthor=Q.+Songauthor=T.+Jiangauthor=H.+Chenauthor=X.+Gaoauthor=J.+Chen&title=Necroptotic+Cancer+Cells-Mimicry+Nanovaccine+Boosts+Anti-Tumor+Immunity+with+Tailored+Immune-Stimulatory+Modality&doi=10.1016%2Fj.biomaterials.2018.02.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Necroptotic cancer cells-mimicry nanovaccine boosts anti-tumor immunity with tailored immune-stimulatory modality</span></div><div class="casAuthors">Kang, Ting; Huang, Yukun; Zhu, Qianqian; Cheng, Hao; Pei, Yuanyuan; Feng, Jingxian; Xu, Minjun; Jiang, Gan; Song, Qingxiang; Jiang, Tianze; Chen, Hongzhuan; Gao, Xiaoling; Chen, Jun</div><div class="citationInfo"><span class="NLM_cas:title">Biomaterials</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">80-97</span>CODEN:
                <span class="NLM_cas:coden">BIMADU</span>;
        ISSN:<span class="NLM_cas:issn">0142-9612</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Recent breakthroughs in cancer immunotherapy offer new paradigm-shifting therapeutic options for combating cancer.  Personalized therapeutic anti-cancer vaccines training T cells to directly fight against tumor cells endogenously offer tremendous benefits in working synergistically with immune checkpoint inhibitors.  Biomimetic nanotechnol. offers a versatile platform to boost anticancer immunity by efficiently co-delivering optimized immunogenic antigen materials and adjuvants to antigen presenting cells (APC).  Necroptotic tumor cells can release danger assocd. mol. patterns (DAMPs) like heat shock proteins, being more immunogenic than naive tumor cells.  Here, nano-size "artificial necroptotic cancer cell" (αHSP70p-CM-CaP) composing of phospholipid bilayer and a phosphate calcium core was designed as a flexible vaccine platform for co-delivering cancer membrane proteins (CM), DAMPs signal-augmenting element α-helix HSP70 functional peptide (αHSP70p) and CpG to both natural killer (NK) cells and APC.  Mech., immunogenic B16OVA tumor cells membrane-assocd. antigens and αHSP70p were reconstituted in artificial outer phospholipid bilayer membrane via one-step hydration and CpG encapsulated in the phosphate calcium core.  The resulted αHSP70p-CM-CaP exhibited 30 nm in diam. with the immunogenic membrane proteins reserved in the particles to produce synergistic effect on bone marrow derived dendritic cells maturation and antigen-presentation.  Following αHSP70p-CM-CaP vaccination, efficient lymph node trafficking and multi-epitope-T cells response was obsd. in mice.  Vitally, αHSP70p-CM-CaP was also able to induce expansion of IFN-γ-expressing CD8+ T cells and NKG2D+ NK cells subsets.  Most promisingly, αHSP70p-CM-CaP vaccination led to the killing of target cells and tumor regression in vivo when combined with anti-PD-1 antibody treatment on mice B16OVA melanoma models.  Altogether, we demonstrated proof-of-concept evidence for the feasibility, capability and safety of a nanovaccine platform towards efficient personalized anticancer application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpArZnnpxP1xLVg90H21EOLACvtfcHk0ljodEOuiZiBfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjsVGnsbc%253D&md5=bca7d0b132925bbef99ef63fa7f52010</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.biomaterials.2018.02.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biomaterials.2018.02.033%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DQ.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DPei%26aufirst%3DY.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DJiang%26aufirst%3DG.%26aulast%3DSong%26aufirst%3DQ.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DNecroptotic%2520Cancer%2520Cells-Mimicry%2520Nanovaccine%2520Boosts%2520Anti-Tumor%2520Immunity%2520with%2520Tailored%2520Immune-Stimulatory%2520Modality%26jtitle%3DBiomaterials%26date%3D2018%26volume%3D164%26spage%3D80%26epage%3D97%26doi%3D10.1016%2Fj.biomaterials.2018.02.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mok, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veiseh, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kievit, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span> <span> </span><span class="NLM_article-title">pH-Sensitive siRNA Nanovector for Targeted Gene Silencing and Cytotoxic Effect in Cancer Cells</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1930</span>– <span class="NLM_lpage">1939</span>, <span class="refDoi"> DOI: 10.1021/mp100221h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp100221h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFGrtbbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=1930-1939&author=H.+Mokauthor=O.+Veisehauthor=C.+Fangauthor=F.+M.+Kievitauthor=F.+Y.+Wangauthor=J.+O.+Parkauthor=M.+Zhang&title=pH-Sensitive+siRNA+Nanovector+for+Targeted+Gene+Silencing+and+Cytotoxic+Effect+in+Cancer+Cells&doi=10.1021%2Fmp100221h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">pH-Sensitive siRNA Nanovector for Targeted Gene Silencing and Cytotoxic Effect in Cancer Cells</span></div><div class="casAuthors">Mok, Hyejung; Veiseh, Omid; Fang, Chen; Kievit, Forrest M.; Wang, Freddy Y.; Park, James O.; Zhang, Miqin</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1930-1939</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A small interfering RNA (siRNA) nanovector with dual targeting specificity and dual therapeutic effect is developed for targeted cancer imaging and therapy.  The nanovector is composed of an iron oxide magnetic nanoparticle core coated with three different functional mols.: polyethyleneimine (PEI), siRNA, and chlorotoxin (CTX).  The primary amine group of PEI is blocked with citraconic anhydride that is removable at acidic conditions, not only to increase its biocompatibility at physiol. conditions but also to elicit a pH-sensitive cytotoxic effect in the acidic tumor microenvironment.  The PEI is covalently immobilized on the nanovector via a disulfide linkage that is cleavable after cellular internalization of the nanovector.  CTX as a tumor-specific targeting ligand and siRNA as a therapeutic payload are conjugated on the nanovector via a flexible and hydrophilic PEG linker for targeted gene silencing in cancer cells.  With a size of ∼60 nm, the nanovector exhibits long-term stability and good magnetic property for magnetic resonance imaging.  The multifunctional nanovector exhibits both significant cytotoxic and gene silencing effects at acidic pH conditions for C6 glioma cells, but not at physiol. pH conditions.  Our results suggest that this nanovector system could be safely used as a potential therapeutic agent for targeted treatment of glioma as well as other cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpit6qK7PZ_HbVg90H21EOLACvtfcHk0ljodEOuiZiBfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFGrtbbI&md5=b89b0fbf2a9dc796621ee7ab76b90104</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1021%2Fmp100221h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp100221h%26sid%3Dliteratum%253Aachs%26aulast%3DMok%26aufirst%3DH.%26aulast%3DVeiseh%26aufirst%3DO.%26aulast%3DFang%26aufirst%3DC.%26aulast%3DKievit%26aufirst%3DF.%2BM.%26aulast%3DWang%26aufirst%3DF.%2BY.%26aulast%3DPark%26aufirst%3DJ.%2BO.%26aulast%3DZhang%26aufirst%3DM.%26atitle%3DpH-Sensitive%2520siRNA%2520Nanovector%2520for%2520Targeted%2520Gene%2520Silencing%2520and%2520Cytotoxic%2520Effect%2520in%2520Cancer%2520Cells%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2010%26volume%3D7%26spage%3D1930%26epage%3D1939%26doi%3D10.1021%2Fmp100221h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Veiseh, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kievit, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunn, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratner, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span> <span> </span><span class="NLM_article-title">Ligand-Mediated Nanovector for Targeted Gene Delivery and Transfection in Cancer Cells</span>. <i>Biomaterials</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">649</span>– <span class="NLM_lpage">657</span>, <span class="refDoi"> DOI: 10.1016/j.biomaterials.2008.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.biomaterials.2008.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=18990439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A280%3ADC%252BD1cjnt1Chsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=649-657&author=O.+Veisehauthor=F.+M.+Kievitauthor=J.+W.+Gunnauthor=B.+D.+Ratnerauthor=M.+Zhang&title=Ligand-Mediated+Nanovector+for+Targeted+Gene+Delivery+and+Transfection+in+Cancer+Cells&doi=10.1016%2Fj.biomaterials.2008.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">A ligand-mediated nanovector for targeted gene delivery and transfection in cancer cells</span></div><div class="casAuthors">Veiseh Omid; Kievit Forrest M; Gunn Jonathan W; Ratner Buddy D; Zhang Miqin</div><div class="citationInfo"><span class="NLM_cas:title">Biomaterials</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">649-57</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">As conventional cancer therapies struggle with toxicity issues and irregular remedial efficacy, the preparation of novel gene therapy vectors could offer clinicians the tools for addressing the genetic errors of diseased tissue.  The transfer of gene therapy to the clinic has proven difficult due to safety, target specificity, and transfection efficiency concerns.  Polyethylenimine (PEI) nanoparticles have been identified as promising gene carriers that induce gene transfection with high efficiency.  However, the inherent toxicity of the material and non-selective delivery are the major concerns in applying these particles clinically.  Here, a non-viral nanovector has been developed by PEGylation of DNA-complexing PEI in nanoparticles functionalized with an Alexa Fluor 647 near infrared fluorophore, and the chlorotoxin (CTX) peptide which binds specifically to many forms of cancer.  With this nanovector, the potential toxicity to healthy cells is minimized by both the reduction of the toxicity of PEI with the biocompatible copolymer and the targeted delivery of the nanovector to cancer cells, as evaluated by viability studies.  The nanovector demonstrated high levels of targeting specificity and gene transfection efficiency with both C6 glioma and DAOY medulloblastoma tumor cells.  Significantly, with the CTX as the targeting ligand, the nanovector may serve as a widely applicable gene delivery system for a broad array of cancer types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSRn5vRovxvJ-b6AVA-44PTfW6udTcc2eZmhgvvQoT6Yrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cjnt1Chsg%253D%253D&md5=70fac702d68745ab4bffee9cc35fea6a</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.biomaterials.2008.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biomaterials.2008.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DVeiseh%26aufirst%3DO.%26aulast%3DKievit%26aufirst%3DF.%2BM.%26aulast%3DGunn%26aufirst%3DJ.%2BW.%26aulast%3DRatner%26aufirst%3DB.%2BD.%26aulast%3DZhang%26aufirst%3DM.%26atitle%3DLigand-Mediated%2520Nanovector%2520for%2520Targeted%2520Gene%2520Delivery%2520and%2520Transfection%2520in%2520Cancer%2520Cells%26jtitle%3DBiomaterials%26date%3D2009%26volume%3D30%26spage%3D649%26epage%3D657%26doi%3D10.1016%2Fj.biomaterials.2008.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bharti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dey, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dey, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parida, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pal, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukherjee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pradhan, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emdad, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandal, M.</span></span> <span> </span><span class="NLM_article-title">Somatostatin Receptor Targeted Liposomes with Diacerein Inhibit IL-6 for Breast Cancer Therapy</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>388</i></span>,  <span class="NLM_fpage">292</span>– <span class="NLM_lpage">302</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2016.12.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.canlet.2016.12.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=28025102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFKru77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=388&publication_year=2017&pages=292-302&author=R.+Bhartiauthor=G.+Deyauthor=I.+Banerjeeauthor=K.+K.+Deyauthor=S.+Paridaauthor=P.+B.+Kumarauthor=C.+K.+Dasauthor=I.+Palauthor=M.+Mukherjeeauthor=M.+Misraauthor=A.+J.+Pradhanauthor=L.+Emdadauthor=S.+K.+Dasauthor=P.+B.+Fisherauthor=M.+Mandal&title=Somatostatin+Receptor+Targeted+Liposomes+with+Diacerein+Inhibit+IL-6+for+Breast+Cancer+Therapy&doi=10.1016%2Fj.canlet.2016.12.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Somatostatin receptor targeted liposomes with Diacerein inhibit IL-6 for breast cancer therapy</span></div><div class="casAuthors">Bharti, Rashmi; Dey, Goutam; Banerjee, Indranil; Dey, Kaushik Kumar; Parida, Sheetal; Kumar, B. N. Prashanth; Das, Chandan Kanta; Pal, Ipsita; Mukherjee, Manabendra; Misra, Mridula; Pradhan, Anjan K.; Emdad, Luni; Das, Swadesh K.; Fisher, Paul B.; Mandal, Mahitosh</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">388</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">292-302</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Selective targeting to the tumor niche remains a major challenge in successful cancer therapy.  Somatostatin receptor 2 (SSTR2) is overexpressed in breast cancer cells thus making this receptor an attractive target for selective guidance of ligand-conjugated drug liposomes to the tumor site.  In this study, a synthetic somatostatin analog (SST) was used as SSTR2 targeting agent and Diacerein was employed as therapeutic mol.  Diacerein loaded liposomes (DNL) were prepd. and they were further decorated with the synthetic and stable analog of somatostatin (SST-DNL).  Fabricated liposomes were nano-size in range and biocompatible.  SST-DNL displayed significantly better anti-tumor efficacy as compared to free Diacerein (DN) and DNL in breast cancer models.  Enhanced apoptosis in breast cancer cells was detected in SST-DNL treated groups as monitored by cell cycle anal. and changes in expression level of apoptotic/anti-apoptotic proteins Bcl-2, Bax, cleaved Caspase 3 and PARP.  SST-DNL more effectively inhibited the oncogenic IL-6/IL-6R/STAT3/MAPK/Akt signalling pathways as compared to DN or DNL in cancer cells.  In addn., SST-DNL effectively suppressed angiogenesis and cancer cell invasion.  In vivo tumor growth in a MDA-MB-231 mouse xenograft model was significantly suppressed following SST-DNL treatment.  In xenograft model, immunohistochem. of Ki-67 and CD-31 indicated that SST-DNL improved the anti-proliferative and anti-angiogenic impacts of Diacerein.  In vivo pharmacokinetic studies in rats showed enhanced circulation time in the DNL or SST-DNL treated groups as compared to free DN.  Considering all of these findings, we conclude that SST-DNL provides a novel strategy with better efficacy for breast cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxN_W9iylZ6rVg90H21EOLACvtfcHk0lifxUcfNb3KxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFKru77J&md5=ca6703ff79681e6ce8d56a43258c6129</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2016.12.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2016.12.021%26sid%3Dliteratum%253Aachs%26aulast%3DBharti%26aufirst%3DR.%26aulast%3DDey%26aufirst%3DG.%26aulast%3DBanerjee%26aufirst%3DI.%26aulast%3DDey%26aufirst%3DK.%2BK.%26aulast%3DParida%26aufirst%3DS.%26aulast%3DKumar%26aufirst%3DP.%2BB.%26aulast%3DDas%26aufirst%3DC.%2BK.%26aulast%3DPal%26aufirst%3DI.%26aulast%3DMukherjee%26aufirst%3DM.%26aulast%3DMisra%26aufirst%3DM.%26aulast%3DPradhan%26aufirst%3DA.%2BJ.%26aulast%3DEmdad%26aufirst%3DL.%26aulast%3DDas%26aufirst%3DS.%2BK.%26aulast%3DFisher%26aufirst%3DP.%2BB.%26aulast%3DMandal%26aufirst%3DM.%26atitle%3DSomatostatin%2520Receptor%2520Targeted%2520Liposomes%2520with%2520Diacerein%2520Inhibit%2520IL-6%2520for%2520Breast%2520Cancer%2520Therapy%26jtitle%3DCancer%2520Lett.%26date%3D2017%26volume%3D388%26spage%3D292%26epage%3D302%26doi%3D10.1016%2Fj.canlet.2016.12.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veiseh, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellenbogen, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span> <span> </span><span class="NLM_article-title">Tumor-Targeted Drug Delivery and MRI Contrast Enhancement by Chlorotoxin-Conjugated Iron Oxide Nanoparticles</span>. <i>Nanomedicine</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">495</span>– <span class="NLM_lpage">505</span>, <span class="refDoi"> DOI: 10.2217/17435889.3.4.495</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.2217%2F17435889.3.4.495" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=18694312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVWnsL7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=495-505&author=C.+Sunauthor=C.+Fangauthor=Z.+Stephenauthor=O.+Veisehauthor=S.+Hansenauthor=D.+Leeauthor=R.+G.+Ellenbogenauthor=J.+Olsonauthor=M.+Zhang&title=Tumor-Targeted+Drug+Delivery+and+MRI+Contrast+Enhancement+by+Chlorotoxin-Conjugated+Iron+Oxide+Nanoparticles&doi=10.2217%2F17435889.3.4.495"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor-targeted drug delivery and MRI contrast enhancement by chlorotoxin-conjugated iron oxide nanoparticles</span></div><div class="casAuthors">Sun, Conroy; Fang, Chen; Stephen, Zachary; Veiseh, Omid; Hansen, Stacey; Lee, Donghoon; Ellenbogen, Richard G.; Olson, Jim; Zhang, Miqin</div><div class="citationInfo"><span class="NLM_cas:title">Nanomedicine (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">495-505</span>CODEN:
                <span class="NLM_cas:coden">NLUKAC</span>;
        ISSN:<span class="NLM_cas:issn">1743-5889</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">This study examines the capabilities of an actively targeting superparamagnetic nanoparticle to specifically deliver therapeutic and MRI contrast agents to cancer cells.  Iron oxide nanoparticles were synthesized and conjugated to both a chemotherapeutic agent, methotrexate, and a targeting ligand, chlorotoxin, through a poly(ethylene glycol) linker.  Cytotoxicity of this nanoparticle conjugate was evaluated by Alamar Blue cell viability assays, while tumor-cell specificity was examd. in vitro and in vivo by MRI.  Characterization of these multifunctional nanoparticles confirms the successful attachment of both drug and targeting ligands.  The targeting nanoparticle demonstrated preferential accumulation and increased cytotoxicity in tumor cells.  Furthermore, prolonged retention of these nanoparticles was obsd. within tumors in vivo.  The improved specificity, extended particle retention and increased cytotoxicity toward tumor cells demonstrated by this multifunctional nanoparticle system suggest that it possesses potential for applications in cancer diagnosis and treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH3qeR-YOfPrVg90H21EOLACvtfcHk0liSkJTyEfMxbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVWnsL7K&md5=1778124206b94c18414389dcb6b23879</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.2217%2F17435889.3.4.495&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252F17435889.3.4.495%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DC.%26aulast%3DFang%26aufirst%3DC.%26aulast%3DStephen%26aufirst%3DZ.%26aulast%3DVeiseh%26aufirst%3DO.%26aulast%3DHansen%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DD.%26aulast%3DEllenbogen%26aufirst%3DR.%2BG.%26aulast%3DOlson%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DM.%26atitle%3DTumor-Targeted%2520Drug%2520Delivery%2520and%2520MRI%2520Contrast%2520Enhancement%2520by%2520Chlorotoxin-Conjugated%2520Iron%2520Oxide%2520Nanoparticles%26jtitle%3DNanomedicine%26date%3D2008%26volume%3D3%26spage%3D495%26epage%3D505%26doi%3D10.2217%2F17435889.3.4.495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Veiseh, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunn, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kievit, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Tumor-Cell Invasion with Chlorotoxin-Bound Superparamagnetic Nanoparticles</span>. <i>Small</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">256</span>– <span class="NLM_lpage">264</span>, <span class="refDoi"> DOI: 10.1002/smll.200800646</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1002%2Fsmll.200800646" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=19089837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvVWlsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=256-264&author=O.+Veisehauthor=J.+W.+Gunnauthor=F.+M.+Kievitauthor=C.+Sunauthor=C.+Fangauthor=J.+S.+Leeauthor=M.+Zhang&title=Inhibition+of+Tumor-Cell+Invasion+with+Chlorotoxin-Bound+Superparamagnetic+Nanoparticles&doi=10.1002%2Fsmll.200800646"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of tumor-cell invasion with chlorotoxin-bound superparamagnetic nanoparticles</span></div><div class="casAuthors">Veiseh, Omid; Gunn, Jonathan W.; Kievit, Forrest M.; Sun, Conroy; Fang, Chen; Lee, Jerry S. H.; Zhang, Miqin</div><div class="citationInfo"><span class="NLM_cas:title">Small</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">256-264</span>CODEN:
                <span class="NLM_cas:coden">SMALBC</span>;
        ISSN:<span class="NLM_cas:issn">1613-6810</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Nanoparticles have been investigated as drug delivery vehicles, contrast agents, and multifunctional devices for patient care.  Current nanoparticle-based therapeutic strategies for cancer treatment are mainly based on delivery of chemotherapeutic agents to induce apoptosis or DNA/siRNA to regulate oncogene expression.  Here, a nanoparticle system that demonstrates an alternative approach to the treatment of cancers through the inhibition of cell invasion, while serving as a magnetic resonance and optical imaging contrast agent, is presented.  The nanoparticle comprises an iron oxide nanoparticle core conjugated with an amine-functionalized poly (ethylene glycol) silane and a small peptide, chlorotoxin (CTX), which enables the tumor cell-specific binding of the nanoparticle.  It is shown that the nanoparticle exhibits substantially enhanced cellular uptake and an invasion inhibition rate of ∼98% compared to unbound CTX (∼45%).  Significantly, the investigation from flow cytometry anal., transmission electron microscopy, and fluorescent imaging reveals that the CTX-enabled nanoparticles deactivated the membrane-bound matrix metalloproteinase 2 (MMP-2) and induced increased internalization of lipid rafts that contain surface-expressed MMP-2 and vol.-regulating ion channels through receptor-mediated endocytosis, leading to enhanced prohibitory effects.  Since upregulation and activity of MMP-2 have been obsd. in tumors of neuroectodermal origin, and in cancers of the breast, colon, skin, lung, prostate, ovaries, and a host of others, this nanoparticle system can be potentially used for non-invasive diagnosis and treatment of a variety of cancer types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowRagWbq7a9LVg90H21EOLACvtfcHk0lh49mqnFDKqgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvVWlsLo%253D&md5=d4886bab53a03e00ffb5688edfb175ee</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1002%2Fsmll.200800646&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fsmll.200800646%26sid%3Dliteratum%253Aachs%26aulast%3DVeiseh%26aufirst%3DO.%26aulast%3DGunn%26aufirst%3DJ.%2BW.%26aulast%3DKievit%26aufirst%3DF.%2BM.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DFang%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DZhang%26aufirst%3DM.%26atitle%3DInhibition%2520of%2520Tumor-Cell%2520Invasion%2520with%2520Chlorotoxin-Bound%2520Superparamagnetic%2520Nanoparticles%26jtitle%3DSmall%26date%3D2009%26volume%3D5%26spage%3D256%26epage%3D264%26doi%3D10.1002%2Fsmll.200800646" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veiseh, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kievit, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattarai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellenbogen, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span> <span> </span><span class="NLM_article-title">Functionalization of Iron Oxide Magnetic Nanoparticles with Targeting Ligands: Their Physicochemical Properties and In-Vivo Behavior</span>. <i>Nanomedicine</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1357</span>– <span class="NLM_lpage">1369</span>, <span class="refDoi"> DOI: 10.2217/nnm.10.55</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.2217%2Fnnm.10.55" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=21128719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFWjs7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=1357-1369&author=C.+Fangauthor=O.+Veisehauthor=F.+Kievitauthor=N.+Bhattaraiauthor=F.+Wangauthor=Z.+Stephenauthor=C.+Liauthor=D.+Leeauthor=R.+G.+Ellenbogenauthor=M.+Zhang&title=Functionalization+of+Iron+Oxide+Magnetic+Nanoparticles+with+Targeting+Ligands%3A+Their+Physicochemical+Properties+and+In-Vivo+Behavior&doi=10.2217%2Fnnm.10.55"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Functionalization of iron oxide magnetic nanoparticles with targeting ligands: their physicochemical properties and in vivo behavior</span></div><div class="casAuthors">Fang, Chen; Veiseh, Omid; Kievit, Forrest; Bhattarai, Narayan; Wang, Freddy; Stephen, Zach; Li, Chun; Lee, Donghoon; Ellenbogen, Richard G.; Zhang, Miqin</div><div class="citationInfo"><span class="NLM_cas:title">Nanomedicine (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1357-1369</span>CODEN:
                <span class="NLM_cas:coden">NLUKAC</span>;
        ISSN:<span class="NLM_cas:issn">1743-5889</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">Aim: To develop and evaluate two tumor-specific nanoprobes by functionalization of a polyethylene glycol-immobilized nanoparticle with arginine-glycine-aspartic acid (RGD) or chlorotoxin ligand that targets αvβ3 integrin and matrix metalloproteinase-2 receptors, resp.  Materials & methods: The nanoprobes were made of iron oxide cores, biocompatible polymer coating, and surface-conjugated RGD or chlorotoxin peptide.  The tumor-targeting specificity of the nanoprobes was evaluated both in vitro and in vivo.  Results & discussion: Both nanoprobes were highly dispersive and exhibited excellent long-term stability in cell culture media.  The RGD-conjugated nanoprobe displayed a strong initial accumulation near neovasculatures in tumors followed by quick clearance.  Conversely, the chlorotoxin-enabled nanoprobe exhibited sustained accumulation throughout the tumor.  Conclusion: These findings revealed the influence of the targeting ligands on the intratumoral distribution of the ligand-enabled nanoprobes.  With flexible surface chem., our nanoparticle platform can be used in a modular fashion to conjugate biomols. for intended applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAev-QcazH7rVg90H21EOLACvtfcHk0lh49mqnFDKqgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFWjs7vO&md5=d307d69e73d4894dfaae16ed52a56c06</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.2217%2Fnnm.10.55&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fnnm.10.55%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DC.%26aulast%3DVeiseh%26aufirst%3DO.%26aulast%3DKievit%26aufirst%3DF.%26aulast%3DBhattarai%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DStephen%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DD.%26aulast%3DEllenbogen%26aufirst%3DR.%2BG.%26aulast%3DZhang%26aufirst%3DM.%26atitle%3DFunctionalization%2520of%2520Iron%2520Oxide%2520Magnetic%2520Nanoparticles%2520with%2520Targeting%2520Ligands%253A%2520Their%2520Physicochemical%2520Properties%2520and%2520In-Vivo%2520Behavior%26jtitle%3DNanomedicine%26date%3D2010%26volume%3D5%26spage%3D1357%26epage%3D1369%26doi%3D10.2217%2Fnnm.10.55" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, M.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephen, Z. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span> <span> </span><span class="NLM_article-title">Hexanoyl-Chitosan-PEG Copolymer Coated Iron Oxide Nanoparticles for Hydrophobic Drug Delivery</span>. <i>ACS Macro Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">403</span>– <span class="NLM_lpage">407</span>, <span class="refDoi"> DOI: 10.1021/acsmacrolett.5b00091</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmacrolett.5b00091" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltFSlsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=403-407&author=M.-H.+Hsiaoauthor=Q.+Muauthor=Z.+R.+Stephenauthor=C.+Fangauthor=M.+Zhang&title=Hexanoyl-Chitosan-PEG+Copolymer+Coated+Iron+Oxide+Nanoparticles+for+Hydrophobic+Drug+Delivery&doi=10.1021%2Facsmacrolett.5b00091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Hexanoyl-chitosan-PEG copolymer coated iron oxide nanoparticles for hydrophobic drug delivery</span></div><div class="casAuthors">Hsiao, Meng-Hsuan; Mu, Qingxin; Stephen, Zachary R.; Fang, Chen; Zhang, Miqin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Macro Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">403-407</span>CODEN:
                <span class="NLM_cas:coden">AMLCCD</span>;
        ISSN:<span class="NLM_cas:issn">2161-1653</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nanoparticle (NP) formulations may be used to improve in vivo efficacy of hydrophobic drugs by circumventing soly. issues and providing targeted delivery.  In this study, we developed a hexanoyl-chitosan-PEG (CP6C) copolymer coated, paclitaxel (PTX)-loaded, and chlorotoxin (CTX) conjugated iron oxide NP (CTX-PTX-NP) for targeted delivery of PTX to human glioblastoma (GBM) cells.  We modified chitosan with polyethylene glycol (PEG) and hexanoyl groups to obtain the amphiphilic CP6C.  The resultant copolymer was then coated onto oleic acid-stabilized iron oxide NPs (OA-IONP) via hydrophobic interactions.  PTX, a model hydrophobic drug, was loaded into the hydrophobic region of IONPs.  CTX-PTX-NP showed high drug loading efficiency (>30%), slow drug release in PBS and the CTX-conjugated NP was shown to successfully target GBM cells.  Importantly, the NPs showed great therapeutic efficacy when evaluated in GBM cell line U-118 MG.  Our results indicate that this nanoparticle platform could be used for loading and targeted delivery of hydrophobic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx9qKeUyVy57Vg90H21EOLACvtfcHk0liOXzDSgvjPSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltFSlsrw%253D&md5=11356590e2fbb0ffb3d487abededbb55</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1021%2Facsmacrolett.5b00091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmacrolett.5b00091%26sid%3Dliteratum%253Aachs%26aulast%3DHsiao%26aufirst%3DM.-H.%26aulast%3DMu%26aufirst%3DQ.%26aulast%3DStephen%26aufirst%3DZ.%2BR.%26aulast%3DFang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DM.%26atitle%3DHexanoyl-Chitosan-PEG%2520Copolymer%2520Coated%2520Iron%2520Oxide%2520Nanoparticles%2520for%2520Hydrophobic%2520Drug%2520Delivery%26jtitle%3DACS%2520Macro%2520Lett.%26date%3D2015%26volume%3D4%26spage%3D403%26epage%3D407%26doi%3D10.1021%2Facsmacrolett.5b00091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patton, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Press, O. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span> <span> </span><span class="NLM_article-title">Gemcitabine and Chlorotoxin Conjugated Iron Oxide Nanoparticles for Glioblastoma Therapy</span>. <i>J. Mater. Chem. B</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.1039/C5TB02123E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1039%2FC5TB02123E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=26835125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvV2jsr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2016&pages=32-36&author=Q.+Muauthor=G.+Linauthor=V.+K.+Pattonauthor=K.+Wangauthor=O.+W.+Pressauthor=M.+Zhang&title=Gemcitabine+and+Chlorotoxin+Conjugated+Iron+Oxide+Nanoparticles+for+Glioblastoma+Therapy&doi=10.1039%2FC5TB02123E"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Gemcitabine and chlorotoxin conjugated iron oxide nanoparticles for glioblastoma therapy</span></div><div class="casAuthors">Mu, Qingxin; Lin, Guanyou; Patton, Victoria K.; Wang, Kui; Press, Oliver W.; Zhang, Miqin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Materials Chemistry B: Materials for Biology and Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-36</span>CODEN:
                <span class="NLM_cas:coden">JMCBDV</span>;
        ISSN:<span class="NLM_cas:issn">2050-7518</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Many small-mol. anti-cancer drugs have short blood half-lives and toxicity issues due to non-specificity.  Nanotechnol. has shown great promise in addressing these issues.  Here, we report the development of anti-cancer drug gemcitabine-conjugated iron oxide nanoparticles for glioblastoma therapy.  A glioblastoma targeting peptide, chlorotoxin, was attached after drug conjugation.  The nanoparticles have a small size (∼32 nm) and uniform size distribution (PDI ≈ 0.1), and are stable in biol. medium.  The nanoparticles effectively enter cancer cells without losing potency compared to the free drug.  Significantly, the nanoparticles showed a prolonged blood half-life and the ability to cross the blood-brain barrier in wild type mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7XXHozRQDdLVg90H21EOLACvtfcHk0liHzjDfSkACOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvV2jsr%252FN&md5=211b9c1916eb46d9607cb72c4ad97600</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1039%2FC5TB02123E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5TB02123E%26sid%3Dliteratum%253Aachs%26aulast%3DMu%26aufirst%3DQ.%26aulast%3DLin%26aufirst%3DG.%26aulast%3DPatton%26aufirst%3DV.%2BK.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DPress%26aufirst%3DO.%2BW.%26aulast%3DZhang%26aufirst%3DM.%26atitle%3DGemcitabine%2520and%2520Chlorotoxin%2520Conjugated%2520Iron%2520Oxide%2520Nanoparticles%2520for%2520Glioblastoma%2520Therapy%26jtitle%3DJ.%2520Mater.%2520Chem.%2520B%26date%3D2016%26volume%3D4%26spage%3D32%26epage%3D36%26doi%3D10.1039%2FC5TB02123E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Breeman, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwekkeboom, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valkema, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakker, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kooij, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visser, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krenning, E. P.</span></span> <span> </span><span class="NLM_article-title">Somatostatin Receptor-Mediated Imaging and Therapy: Basic Science, Current Knowledge, Limitations and Future Perspectives</span>. <i>Eur. J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1421</span>– <span class="NLM_lpage">1429</span>, <span class="refDoi"> DOI: 10.1007/s002590100502</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1007%2Fs002590100502" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=11585303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmt1GntLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2001&pages=1421-1429&author=W.+A.+Breemanauthor=M.+de+Jongauthor=D.+J.+Kwekkeboomauthor=R.+Valkemaauthor=W.+H.+Bakkerauthor=P.+P.+Kooijauthor=T.+J.+Visserauthor=E.+P.+Krenning&title=Somatostatin+Receptor-Mediated+Imaging+and+Therapy%3A+Basic+Science%2C+Current+Knowledge%2C+Limitations+and+Future+Perspectives&doi=10.1007%2Fs002590100502"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives</span></div><div class="casAuthors">Breeman, Wout A. P.; de Jong, Marion; Kwekkeboom, Dik J.; Valkema, Roelf; Bakker, Willem H.; Kooij, Peter P. M.; Visser, Theo J.; Krenning, Eric P.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1421-1429</span>CODEN:
                <span class="NLM_cas:coden">EJNMD9</span>;
        ISSN:<span class="NLM_cas:issn">0340-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">A review.  In vivo somatostatin receptor-mediated scintigraphy has proven to be a valuable method for the visualization of neuroendocrine tumors and their metastases.  A new application is the use of radiolabeled analogs for somatostatin receptor-mediated therapy.  This paper presents a review on the basic science, historical background and current knowledge of somatostatin receptor subtypes and their expression in neuroendocrine tumors.  New somatostatin analogs, new chelators, "new" radionuclides and combinations thereof are also discussed.  Due attention is given to limitations and future perspectives of somatostatin receptor-mediated imaging and therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrE-Y8-1DzeMrVg90H21EOLACvtfcHk0lhjs-pbHRBcrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmt1GntLo%253D&md5=d56f38d0e22c4acc65d7e5aca49ee86d</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1007%2Fs002590100502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs002590100502%26sid%3Dliteratum%253Aachs%26aulast%3DBreeman%26aufirst%3DW.%2BA.%26aulast%3Dde%2BJong%26aufirst%3DM.%26aulast%3DKwekkeboom%26aufirst%3DD.%2BJ.%26aulast%3DValkema%26aufirst%3DR.%26aulast%3DBakker%26aufirst%3DW.%2BH.%26aulast%3DKooij%26aufirst%3DP.%2BP.%26aulast%3DVisser%26aufirst%3DT.%2BJ.%26aulast%3DKrenning%26aufirst%3DE.%2BP.%26atitle%3DSomatostatin%2520Receptor-Mediated%2520Imaging%2520and%2520Therapy%253A%2520Basic%2520Science%252C%2520Current%2520Knowledge%252C%2520Limitations%2520and%2520Future%2520Perspectives%26jtitle%3DEur.%2520J.%2520Nucl.%2520Med.%26date%3D2001%26volume%3D28%26spage%3D1421%26epage%3D1429%26doi%3D10.1007%2Fs002590100502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abdellatif, A. A.</span></span> <span> </span><span class="NLM_article-title">Targeting of Somatostatin Receptors Using Quantum Dots Nanoparticles Decorated with Octreotide</span>. <i>J. Nanomed. Nanotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>S6</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">1</span>, <span class="refDoi"> DOI: 10.4172/2157-7439.S6-005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.4172%2F2157-7439.S6-005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=S6&publication_year=2015&pages=1-1&author=A.+A.+Abdellatif&title=Targeting+of+Somatostatin+Receptors+Using+Quantum+Dots+Nanoparticles+Decorated+with+Octreotide&doi=10.4172%2F2157-7439.S6-005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.4172%2F2157-7439.S6-005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4172%252F2157-7439.S6-005%26sid%3Dliteratum%253Aachs%26aulast%3DAbdellatif%26aufirst%3DA.%2BA.%26atitle%3DTargeting%2520of%2520Somatostatin%2520Receptors%2520Using%2520Quantum%2520Dots%2520Nanoparticles%2520Decorated%2520with%2520Octreotide%26jtitle%3DJ.%2520Nanomed.%2520Nanotechnol.%26date%3D2015%26volume%3DS6%26spage%3D1%26epage%3D1%26doi%3D10.4172%2F2157-7439.S6-005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sreenivasan, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodchild, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvyagin, A. V.</span></span> <span> </span><span class="NLM_article-title">Targeting Somatostatin Receptors Using In-Situ Bioconjugated Fluorescent Nanoparticles</span>. <i>Nanomedicine</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1551</span>– <span class="NLM_lpage">1560</span>, <span class="refDoi"> DOI: 10.2217/nnm.12.42</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.2217%2Fnnm.12.42" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=22812712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1GlsLnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=1551-1560&author=V.+K.+Sreenivasanauthor=E.+J.+Kimauthor=A.+K.+Goodchildauthor=M.+Connorauthor=A.+V.+Zvyagin&title=Targeting+Somatostatin+Receptors+Using+In-Situ+Bioconjugated+Fluorescent+Nanoparticles&doi=10.2217%2Fnnm.12.42"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting somatostatin receptors using in situ-bioconjugated fluorescent nanoparticles</span></div><div class="casAuthors">Sreenivasan, Varun K. A.; Kim, Eun J.; Goodchild, Ann K.; Connor, Mark; Zvyagin, Andrei V.</div><div class="citationInfo"><span class="NLM_cas:title">Nanomedicine (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1551-1560</span>CODEN:
                <span class="NLM_cas:coden">NLUKAC</span>;
        ISSN:<span class="NLM_cas:issn">1743-5889</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">Aim: The author's group report, for the first time, on the development of a quantum dot (QD)-based fluorescent somatostatin (somatotropin release-inhibiting factor [SRIF]) probe that enables specific targeting of somatostatin receptors.  Receptor-mediated endocytosis of SRIF was imaged using this probe.  Materials & methods: Biotinylated SRIF-analog (SRIF-B) and streptavidin (Sav)-coated QDs were used for the probe synthesis.  A dye-labeled streptavidin complex was used to evaluate the effect of Sav binding on the activity of SRIF-B.  Results: A preconjugated probe of the form SRIF-B:Sav-QD, was inactive and unable to undergo receptor-mediated endocytosis.  An alternative in situ bioconjugation strategy, where SRIF-B and Sav-QD were added in two consecutive steps, enabled visualization of the receptor-mediated endocytosis.  The process of Sav binding appeared to be responsible for the inactivity in the first case.  Conclusion: The in situ two-step bioconjugation strategy allowed QDs to be targeted to somatostatin receptors.  This strategy should enable flexible fluorescent tagging of SRIF for the investigation of mol. trafficking in cells and targeted delivery in live animals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCYCNT1wgkrrVg90H21EOLACvtfcHk0limBLTkJenpfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1GlsLnN&md5=644ce9dae87354bc7eda222014bed874</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.2217%2Fnnm.12.42&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fnnm.12.42%26sid%3Dliteratum%253Aachs%26aulast%3DSreenivasan%26aufirst%3DV.%2BK.%26aulast%3DKim%26aufirst%3DE.%2BJ.%26aulast%3DGoodchild%26aufirst%3DA.%2BK.%26aulast%3DConnor%26aufirst%3DM.%26aulast%3DZvyagin%26aufirst%3DA.%2BV.%26atitle%3DTargeting%2520Somatostatin%2520Receptors%2520Using%2520In-Situ%2520Bioconjugated%2520Fluorescent%2520Nanoparticles%26jtitle%3DNanomedicine%26date%3D2012%26volume%3D7%26spage%3D1551%26epage%3D1560%26doi%3D10.2217%2Fnnm.12.42" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barak, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goike, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panaretakis, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einarsson, R.</span></span> <span> </span><span class="NLM_article-title">Clinical Utility of Cytokeratins as Tumor Markers</span>. <i>Clin. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">529</span>– <span class="NLM_lpage">540</span>, <span class="refDoi"> DOI: 10.1016/j.clinbiochem.2004.05.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.clinbiochem.2004.05.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=15234234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD2cXltl2gtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2004&pages=529-540&author=V.+Barakauthor=H.+Goikeauthor=K.+W.+Panaretakisauthor=R.+Einarsson&title=Clinical+Utility+of+Cytokeratins+as+Tumor+Markers&doi=10.1016%2Fj.clinbiochem.2004.05.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical utility of cytokeratins as tumor markers</span></div><div class="casAuthors">Barak, Vivian; Goike, Helena; Panaretakis, Katja W.; Einarsson, Roland</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Biochemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">529-540</span>CODEN:
                <span class="NLM_cas:coden">CLBIAS</span>;
        ISSN:<span class="NLM_cas:issn">0009-9120</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Cytokeratins, belonging to the intermediate filament (IF) protein family, are particularly useful tools in oncol. diagnostics.  At present, more than 20 different cytokeratins have been identified, of which cytokeratins 8, 18, and 19 are the most abundant in simple epithelial cells.  Upon release from proliferating or apoptotic cells, cytokeratins provide useful markers for epithelial malignancies, distinctly reflecting ongoing cell activity.  It appears that motifs in certain cytokeratins make them likely substrates for caspase degrdn., and their subsequent release occurs during the intermediate events in apoptosis.  The clin. value of detg. sol. cytokeratin protein fragments in body fluids lies in the early detection of recurrence and the fast assessment of the efficacy of therapy response in epithelial cell carcinomas.  The three most applied cytokeratin markers used in the clinic are tissue polypeptide antigen (TPA), tissue polypeptide specific antigen (TPS), and CYFRA 21-1.  TPA is a broad spectrum test that measures cytokeratins 8, 18, and 19.  TPS and CYFRA 21-1 assays are more specific and measure cytokeratin 18 and cytokeratin 19, resp.  By following patients with repeated testing during management, the oncologist may obtain crit. information regarding the growth activity in symptomatic patients.  Although their main use is to monitor treatment and evaluate response to therapy, early prognostic information particularly on tumor progression and metastasis formation is also provided for several types of cancers.  Cytokeratin tumor markers can accurately predict disease status before conventional methods and offer a simple, noninvasive, cheap, and reliable tool for more efficient management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsEQvH8gCQZrVg90H21EOLACvtfcHk0limBLTkJenpfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXltl2gtLc%253D&md5=f123b3dd99548a29ead48f23e07ebac7</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.clinbiochem.2004.05.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clinbiochem.2004.05.009%26sid%3Dliteratum%253Aachs%26aulast%3DBarak%26aufirst%3DV.%26aulast%3DGoike%26aufirst%3DH.%26aulast%3DPanaretakis%26aufirst%3DK.%2BW.%26aulast%3DEinarsson%26aufirst%3DR.%26atitle%3DClinical%2520Utility%2520of%2520Cytokeratins%2520as%2520Tumor%2520Markers%26jtitle%3DClin.%2520Biochem.%26date%3D2004%26volume%3D37%26spage%3D529%26epage%3D540%26doi%3D10.1016%2Fj.clinbiochem.2004.05.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herrmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bär, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreplak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strelkov, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aebi, U.</span></span> <span> </span><span class="NLM_article-title">Intermediate Filaments: From Cell Architecture to Nanomechanics</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">562</span>– <span class="NLM_lpage">573</span>, <span class="refDoi"> DOI: 10.1038/nrm2197</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1038%2Fnrm2197" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=17551517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmvVaktLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=562-573&author=H.+Herrmannauthor=H.+B%C3%A4rauthor=L.+Kreplakauthor=S.+V.+Strelkovauthor=U.+Aebi&title=Intermediate+Filaments%3A+From+Cell+Architecture+to+Nanomechanics&doi=10.1038%2Fnrm2197"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Intermediate filaments: from cell architecture to nanomechanics</span></div><div class="casAuthors">Herrmann, Harald; Baer, Harald; Kreplak, Laurent; Strelkov, Sergei V.; Aebi, Ueli</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">562-573</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Intermediate filaments (IFs) constitute a major structural element of animal cells.  IFs build 2 distinct systems, one in the nucleus and one in the cytoplasm.  In both cases, their major function is assumed to be that of a mech. stress absorber and an integrating device for the entire cytoskeleton.  In line with this, recent disease mutations in human IF proteins indicate that the nanomech. properties of cell-type-specific IFs are central to the pathogenesis of diseases as diverse as muscular dystrophy and premature aging.  However, the anal. of these various diseases suggests that IFs also have an important role in cell-type-specific physiol. functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQxp0AlM747rVg90H21EOLACvtfcHk0lgDM30T6iQH0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmvVaktLg%253D&md5=22a72f84bf1a8403ca4c90af97bfc4eb</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1038%2Fnrm2197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2197%26sid%3Dliteratum%253Aachs%26aulast%3DHerrmann%26aufirst%3DH.%26aulast%3DB%25C3%25A4r%26aufirst%3DH.%26aulast%3DKreplak%26aufirst%3DL.%26aulast%3DStrelkov%26aufirst%3DS.%2BV.%26aulast%3DAebi%26aufirst%3DU.%26atitle%3DIntermediate%2520Filaments%253A%2520From%2520Cell%2520Architecture%2520to%2520Nanomechanics%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2007%26volume%3D8%26spage%3D562%26epage%3D573%26doi%3D10.1038%2Fnrm2197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kocbek, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermajer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cegnar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kristl, J.</span></span> <span> </span><span class="NLM_article-title">Targeting Cancer Cells Using PLGA Nanoparticles Surface Modified with Monoclonal Antibody</span>. <i>J. Controlled Release</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">18</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1016/j.jconrel.2007.03.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.jconrel.2007.03.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=17509712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmt1Gls7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2007&pages=18-26&author=P.+Kocbekauthor=N.+Obermajerauthor=M.+Cegnarauthor=J.+Kosauthor=J.+Kristl&title=Targeting+Cancer+Cells+Using+PLGA+Nanoparticles+Surface+Modified+with+Monoclonal+Antibody&doi=10.1016%2Fj.jconrel.2007.03.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody</span></div><div class="casAuthors">Kocbek, Petra; Obermajer, Natasa; Cegnar, Mateja; Kos, Janko; Kristl, Julijana</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">18-26</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Targeting drugs to their sites of action is still a major challenge in pharmaceutical research.  In this study, polylactic-co-glycolic acid (PLGA) immuno-nanoparticles were prepd. for targeting invasive epithelial breast tumor cells.  Monoclonal antibody (mAb) was used as a homing ligand and was attached to the nanoparticle surface either covalently or non-covalently.  The presence of mAb on the nanoparticle surface, its stability and recognition properties were tested.  Protein assay, surface plasmon resonance, flow cytometry and fluorescence-immunostaining confirmed the presence of mAb on nanoparticles in both cases.  However, a binding assay using cell lysate revealed that the recognition properties were preserved only for nanoparticles with adsorbed mAb.  These nanoparticles were more likely to be bound to the targeted cells than non-coated nanoparticles.  Both types of nanoparticles entered the target MCF-10A neoT cells in mono-culture.  In co-culture of MCF-10A neoT and Caco-2 cells immuno-nanoparticles were localized solely to MCF-10A neoT cells, whereas non-coated nanoparticles were distributed randomly.  Immuno-nanoparticles entered only MCF-10A neoT cells, while non-coated nanoparticles were taken up by both cell types, indicating specific targeting of the immuno-nanoparticles.  In conclusion, we demonstrate a method by which mAbs can be bound to nanoparticles without detriment to their targeting ability.  Furthermore, the results show the effectiveness of the new carrier system for targeted delivery of small or large active substances into cells or tissues of interest.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8ctO-ZaMI3rVg90H21EOLACvtfcHk0lgDM30T6iQH0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmt1Gls7g%253D&md5=dcf085731137e0433b4a8e9da491a507</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2007.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2007.03.012%26sid%3Dliteratum%253Aachs%26aulast%3DKocbek%26aufirst%3DP.%26aulast%3DObermajer%26aufirst%3DN.%26aulast%3DCegnar%26aufirst%3DM.%26aulast%3DKos%26aufirst%3DJ.%26aulast%3DKristl%26aufirst%3DJ.%26atitle%3DTargeting%2520Cancer%2520Cells%2520Using%2520PLGA%2520Nanoparticles%2520Surface%2520Modified%2520with%2520Monoclonal%2520Antibody%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2007%26volume%3D120%26spage%3D18%26epage%3D26%26doi%3D10.1016%2Fj.jconrel.2007.03.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, G.</span></span> <span> </span><span class="NLM_article-title">Targeting Cells for Drug and Gene Delivery: Emerging Applicationsof Mannans and Mannan Binding Lectins</span>. <i>J. Sci. Ind. Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">465</span>– <span class="NLM_lpage">483</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1OksLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2009&pages=465-483&author=A.+Guptaauthor=R.+K.+Guptaauthor=G.+Gupta&title=Targeting+Cells+for+Drug+and+Gene+Delivery%3A+Emerging+Applicationsof+Mannans+and+Mannan+Binding+Lectins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cells for drug and gene delivery: emerging applications of mannans and mannan binding lectins</span></div><div class="casAuthors">Gupta, Anita; Gupta, Rajesh K.; Gupta, G. S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Scientific & Industrial Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">465-483</span>CODEN:
                <span class="NLM_cas:coden">JSIRAC</span>;
        ISSN:<span class="NLM_cas:issn">0022-4456</span>.
    
            (<span class="NLM_cas:orgname">National Institute of Science Communication and Information Resources</span>)
        </div><div class="casAbstract">This review outlines exclusive applications of mannose, mannan conjugates, and their specific interacting proteins (macrophage mannose receptors, dendritic cell receptors) in gene delivery and drug targeting, and their scope in development of targeted delivery systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIRfKfxrgc5rVg90H21EOLACvtfcHk0lgDM30T6iQH0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1OksLc%253D&md5=ce63e9349732075ea7d966d6ee74c000</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DGupta%26aufirst%3DR.%2BK.%26aulast%3DGupta%26aufirst%3DG.%26atitle%3DTargeting%2520Cells%2520for%2520Drug%2520and%2520Gene%2520Delivery%253A%2520Emerging%2520Applicationsof%2520Mannans%2520and%2520Mannan%2520Binding%2520Lectins%26jtitle%3DJ.%2520Sci.%2520Ind.%2520Res.%26date%3D2009%26volume%3D68%26spage%3D465%26epage%3D483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span> <span> </span><span class="NLM_article-title">Targeted Polysaccharide Nanoparticle for Adamplatin Prodrug Delivery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">9725</span>– <span class="NLM_lpage">9736</span>, <span class="refDoi"> DOI: 10.1021/jm4014168</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4014168" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVShsL7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=9725-9736&author=Y.+Yangauthor=Y.+M.+Zhangauthor=Y.+Chenauthor=J.+T.+Chenauthor=Y.+Liu&title=Targeted+Polysaccharide+Nanoparticle+for+Adamplatin+Prodrug+Delivery&doi=10.1021%2Fjm4014168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted Polysaccharide Nanoparticle for Adamplatin Prodrug Delivery</span></div><div class="casAuthors">Yang, Yang; Zhang, Ying-Ming; Chen, Yong; Chen, Jia-Tong; Liu, Yu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9725-9736</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of conjugated hyaluronic acid particles (HAP), composed of a hydrophobic anticancer drug core and hydrophilic cyclodextrin/hyaluronic acid shell, were prepd. through self-assembling and characterized by 1H NMR titrn., electron microscopy, zeta potential, and dynamic light-scattering expts.  The nanometer-sized HAP thus prepd. was biocompatible and biodegradable and was well-recognized by the hyaluronic acid receptors overexpressed on the surface of cancer cells, which enabled us to exploit HAP as an efficient targeted delivery system for anticancer drugs.  Indeed, HAP exhibited anticancer activities comparable to the com. anticancer drug cisplatin but with lower side effects both in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplSUSSw7s3k7Vg90H21EOLACvtfcHk0liTahDtVg82cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVShsL7O&md5=dc1c697d34fbd6f8c0e32e68ed7a447c</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1021%2Fjm4014168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4014168%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%2BM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DJ.%2BT.%26aulast%3DLiu%26aufirst%3DY.%26atitle%3DTargeted%2520Polysaccharide%2520Nanoparticle%2520for%2520Adamplatin%2520Prodrug%2520Delivery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D9725%26epage%3D9736%26doi%3D10.1021%2Fjm4014168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kojima, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bovin, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabius, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabius, H.-J.</span></span> <span> </span><span class="NLM_article-title">Endogenous Lectins as Targets for Drug Delivery</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">244</span>, <span class="refDoi"> DOI: 10.1016/S0169-409X(00)00071-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2FS0169-409X%2800%2900071-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10967228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmtVClu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=225-244&author=N.+Yamazakiauthor=S.+Kojimaauthor=N.+V.+Bovinauthor=S.+Andreauthor=S.+Gabiusauthor=H.-J.+Gabius&title=Endogenous+Lectins+as+Targets+for+Drug+Delivery&doi=10.1016%2FS0169-409X%2800%2900071-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Endogenous lectins as targets for drug delivery</span></div><div class="casAuthors">Yamazaki, N.; Kojima, S.; Bovin, N. V.; Andre, S.; Gabius, S.; Gabius, H.-J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">225-244</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">A review with 110 refs.  To minimize side effects of drugs it would be ideal to target them exclusively to those cell types which require treatment.  As a means to this end prototypical cellular recognition systems pique our interest to devise biomimetic strategies.  Since oligosaccharides of glycoconjugates outmatch other information-carrying biomols. (proteins, nucleic acids) in theor. storage capacity by far, work on the sugar code can spark off development of effective targeting devices.  Conjugation of custom-made glycan epitopes to proteins or biocompatible non-immunogenic polymeric scaffolds produces neoglycoconjugates with purpose-adaptable properties.  In the interplay with endogenous receptors such as lectins, suitable oligosaccharides such as histo-blood group trisaccharides as parts of neoglycoconjugates have already proven their practical applications in histopathol.  Elucidation of the structure of cell lectins with currently five main families aids to tailor ligand characteristics rationally.  They include the types of functional groups and their topol. presentation to optimize the bimol. binding as well as the optimal spatial clustering and spacer characteristics to exploit cooperativity.  Indeed, the potent trivalent cluster glycosides designed for the C-type asialoglycoprotein receptors furnish an instructive example how to turn the theor. guideline on ligand modification into nM-affinity.  By placing emphasis on tissue lectins as targets of neoglycoconjugate-mediated drug delivery, the long-term perspective is opened to likewise test members of these families themselves for routing of therapeutic payloads, aiming at cell addressins.  This review illustrates the conceivable potential which work on the sugar code with custom-made neoglycoconjugates and tissue lectins can have in store for drug delivery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4gcIIbPwwf7Vg90H21EOLACvtfcHk0liTahDtVg82cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmtVClu7o%253D&md5=7d6c735f008c58f354b0d9fc9284cba4</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2800%2900071-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252800%252900071-5%26sid%3Dliteratum%253Aachs%26aulast%3DYamazaki%26aufirst%3DN.%26aulast%3DKojima%26aufirst%3DS.%26aulast%3DBovin%26aufirst%3DN.%2BV.%26aulast%3DAndre%26aufirst%3DS.%26aulast%3DGabius%26aufirst%3DS.%26aulast%3DGabius%26aufirst%3DH.-J.%26atitle%3DEndogenous%2520Lectins%2520as%2520Targets%2520for%2520Drug%2520Delivery%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2000%26volume%3D43%26spage%3D225%26epage%3D244%26doi%3D10.1016%2FS0169-409X%2800%2900071-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Minko, T.</span></span> <span> </span><span class="NLM_article-title">Drug Targeting to the Colon with Lectins and Neoglycoconjugates</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">491</span>– <span class="NLM_lpage">509</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2003.10.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.addr.2003.10.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=14969755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD2cXht1KnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2004&pages=491-509&author=T.+Minko&title=Drug+Targeting+to+the+Colon+with+Lectins+and+Neoglycoconjugates&doi=10.1016%2Fj.addr.2003.10.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Drug targeting to the colon with lectins and neoglycoconjugates</span></div><div class="casAuthors">Minko, Tamara</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">491-509</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review and discussion.  Targeting of drugs to specific sites of action provides several advantages over non-targeted drugs.  These include the prevention of side effects of drugs on healthy tissues and enhancement of drug uptake by targeted cells.  This review will cover traditional approaches of colon drug targeting as well as the use of lectins and neoglycoconjugates for the targeted delivery.  Direct and reverse targeting strategies, potential mol. targets and targeting moieties for colon drug delivery, targeted drug delivery systems (DDS) for colon delivery, anticancer DDS targeted to colon cancer are examd.  Directions of future development are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWXcDEhZJQjLVg90H21EOLACvtfcHk0liTahDtVg82cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXht1KnsLc%253D&md5=ffad4ef76afc8e2d31d4ef8b2013bead</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2003.10.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2003.10.017%26sid%3Dliteratum%253Aachs%26aulast%3DMinko%26aufirst%3DT.%26atitle%3DDrug%2520Targeting%2520to%2520the%2520Colon%2520with%2520Lectins%2520and%2520Neoglycoconjugates%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2004%26volume%3D56%26spage%3D491%26epage%3D509%26doi%3D10.1016%2Fj.addr.2003.10.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ertl, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabor, F.</span></span> <span> </span><span class="NLM_article-title">Lectin-Mediated Drug Targeting: Preparation, Binding Characteristics, and Antiproliferative Activity of Wheat Germ Agglutinin Conjugated Doxorubicin on Caco-2 Cells</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1031</span>– <span class="NLM_lpage">1037</span>, <span class="refDoi"> DOI: 10.1023/A:1011926026653</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1023%2FA%3A1011926026653" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=9688056" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADyaK1cXkvVWgtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1998&pages=1031-1037&author=M.+Wirthauthor=A.+Fuchsauthor=M.+Wolfauthor=B.+Ertlauthor=F.+Gabor&title=Lectin-Mediated+Drug+Targeting%3A+Preparation%2C+Binding+Characteristics%2C+and+Antiproliferative+Activity+of+Wheat+Germ+Agglutinin+Conjugated+Doxorubicin+on+Caco-2+Cells&doi=10.1023%2FA%3A1011926026653"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Lectin-mediated drug targeting: preparation, binding characteristics, and antiproliferative activity of wheat germ agglutinin conjugated doxorubicin on Caco-2 cells</span></div><div class="casAuthors">Wirth, Michael; Fuchs, Andrea; Wolf, Michaela; Ertl, Bernhard; Gabor, Franz</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1031-1037</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Plenum Publishing Corp.</span>)
        </div><div class="casAbstract">To investigate the usefulness of wheat germ agglutinin as a targeting carrier protein for an acid-labile chemotherapeutic prodrug directed against colon carcinoma cells in vitro.  Cis-aconityl-linked doxorubicin-wheat germ agglutinin was prepd. by a two step procedure and the conjugate-binding capacity of target- and non-target cells was assayed by flow cytometry.  The antiproliferative activity of the prodrug on Caco-2 and MOLT-4 cells was detd. by the XTT- and BrdU-test and compared with that of the parent drug and the lectin alone.  At pH 4.0, about 50% of the conjugated doxorubicin were released within 24 h from the water sol. prodrug exhibiting a conjugation no. of 24 (mol doxorubicin/mol WGA).  The prodrug-binding capacity of colon carcinoma cells exceeded that of human colonocytes and lymphoblastic MOLT-4 cells 4.5-fold.  Addnl., the antiproliferative effect of the conjugate on Caco-2 cells was 39% as opposed to 5% in case of MOLT-4 cells.  As the unmodified carrier protein inhibited or stimulated Caco-2 cell growth in a concn.-dependent manner, the cytostatic activity of the conjugate was detd. at WGA concns. without an effect on cell-proliferation.  Considering 50% release of conjugated drug at the most, the prodrug yielded 160% of the cytostatic activity of free doxorubicin.  WGA-prodrug targeting offers new perspectives for site specific, cytoinvading drug delivery in colon cancer chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2Y8vaYwhUurVg90H21EOLACvtfcHk0ljl-2kwDEqMFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXkvVWgtbk%253D&md5=a5f5fc4cdbf10a5c911164f7b6424f24</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1023%2FA%3A1011926026653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1011926026653%26sid%3Dliteratum%253Aachs%26aulast%3DWirth%26aufirst%3DM.%26aulast%3DFuchs%26aufirst%3DA.%26aulast%3DWolf%26aufirst%3DM.%26aulast%3DErtl%26aufirst%3DB.%26aulast%3DGabor%26aufirst%3DF.%26atitle%3DLectin-Mediated%2520Drug%2520Targeting%253A%2520Preparation%252C%2520Binding%2520Characteristics%252C%2520and%2520Antiproliferative%2520Activity%2520of%2520Wheat%2520Germ%2520Agglutinin%2520Conjugated%2520Doxorubicin%2520on%2520Caco-2%2520Cells%26jtitle%3DPharm.%2520Res.%26date%3D1998%26volume%3D15%26spage%3D1031%26epage%3D1037%26doi%3D10.1023%2FA%3A1011926026653" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Venturelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nappini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bulfoni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gianfranceschi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dal Zilio, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coceano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Ben, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turetta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scoles, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaccari, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cesselli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cojoc, D.</span></span> <span> </span><span class="NLM_article-title">Glucose is a Key Driver for GLUT1-Mediated Nanoparticles Internalization in Breast Cancer Cells</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">21629</span>, <span class="refDoi"> DOI: 10.1038/srep21629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1038%2Fsrep21629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=26899926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC28XivFKhtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=21629&author=L.+Venturelliauthor=S.+Nappiniauthor=M.+Bulfoniauthor=G.+Gianfranceschiauthor=S.+Dal+Zilioauthor=G.+Coceanoauthor=F.+Del+Benauthor=M.+Turettaauthor=G.+Scolesauthor=L.+Vaccariauthor=D.+Cesselliauthor=D.+Cojoc&title=Glucose+is+a+Key+Driver+for+GLUT1-Mediated+Nanoparticles+Internalization+in+Breast+Cancer+Cells&doi=10.1038%2Fsrep21629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Glucose is a key driver for GLUT1-mediated nanoparticles internalization in breast cancer cells</span></div><div class="casAuthors">Venturelli, Leonardo; Nappini, Silvia; Bulfoni, Michela; Gianfranceschi, Giuseppe; Dal Zilio, Simone; Coceano, Giovanna; Del Ben, Fabio; Turetta, Matteo; Scoles, Giacinto; Vaccari, Lisa; Cesselli, Daniela; Cojoc, Dan</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">21629</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The mesenchymal state in cancer is usually assocd. with poor prognosis due to the metastatic predisposition and the hyper-activated metab.  Exploiting cell glucose metab. we propose a new method to detect mesenchymal-like cancer cells.  We demonstrate that the uptake of glucose-coated magnetic nanoparticles (MNPs) by mesenchymal-like cells remains const. when the glucose in the medium is increased from low (5.5 mM) to high (25 mM) concn., while the MNPs uptake by epithelial-like cells is significantly reduced.  These findings reveal that the glucose-shell of MNPs plays a major role in recognition of cells with high-metabolic activity.  By selectively blocking the glucose transporter 1 channels we showed its involvement in the internalization process of glucose-coated MNPs.  Our results suggest that glucose-coated MNPs can be used for metabolic-based assays aimed at detecting cancer cells and that can be used to selectively target cancer cells taking advantage, for instance, of the magnetic-thermotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTx-GhEtVkM7Vg90H21EOLACvtfcHk0ljl-2kwDEqMFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XivFKhtb8%253D&md5=395719c191fc8b17dabc028e35e5f30d</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1038%2Fsrep21629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep21629%26sid%3Dliteratum%253Aachs%26aulast%3DVenturelli%26aufirst%3DL.%26aulast%3DNappini%26aufirst%3DS.%26aulast%3DBulfoni%26aufirst%3DM.%26aulast%3DGianfranceschi%26aufirst%3DG.%26aulast%3DDal%2BZilio%26aufirst%3DS.%26aulast%3DCoceano%26aufirst%3DG.%26aulast%3DDel%2BBen%26aufirst%3DF.%26aulast%3DTuretta%26aufirst%3DM.%26aulast%3DScoles%26aufirst%3DG.%26aulast%3DVaccari%26aufirst%3DL.%26aulast%3DCesselli%26aufirst%3DD.%26aulast%3DCojoc%26aufirst%3DD.%26atitle%3DGlucose%2520is%2520a%2520Key%2520Driver%2520for%2520GLUT1-Mediated%2520Nanoparticles%2520Internalization%2520in%2520Breast%2520Cancer%2520Cells%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D21629%26doi%3D10.1038%2Fsrep21629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gromnicova, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sreekanthreddy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lund, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roitt, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Male, D. K.</span></span> <span> </span><span class="NLM_article-title">Glucose-Coated Gold Nanoparticles Transfer Across Human Brain Endothelium and Enter Astrocytes in Vitro</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">e81043</span> 1–10 <span class="refDoi"> DOI: 10.1371/journal.pone.0081043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1371%2Fjournal.pone.0081043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=24339894" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltl2rsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&author=R.+Gromnicovaauthor=H.+A.+Daviesauthor=P.+Sreekanthreddyauthor=I.+A.+Romeroauthor=T.+Lundauthor=I.+M.+Roittauthor=J.+B.+Phillipsauthor=D.+K.+Male&title=Glucose-Coated+Gold+Nanoparticles+Transfer+Across+Human+Brain+Endothelium+and+Enter+Astrocytes+in+Vitro&doi=10.1371%2Fjournal.pone.0081043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Glucose-coated gold nanoparticles transfer across human brain endothelium and enter astrocytes in vitro</span></div><div class="casAuthors">Gromnicova, Radka; Davies, Heather A.; Sreekanthreddy, Peddagangannagari; Romero, Ignacio A.; Lund, Torben; Roitt, Ivan M.; Phillips, James B.; Male, David K.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e81043/1-e81043/10, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The blood-brain barrier prevents the entry of many therapeutic agents into the brain.  Various nanocarriers have been developed to help agents to cross this barrier, but they all have limitations, with regard to tissue-selectivity and their ability to cross the endothelium.  This study investigated the potential for 4 nm coated gold nanoparticles to act as selective carriers across human brain endothelium and subsequently to enter astrocytes.  The transfer rate of glucose-coated gold nanoparticles across primary human brain endothelium was at least three times faster than across non-brain endothelia.  Movement of these nanoparticles occurred across the apical and basal plasma membranes via the cytosol with relatively little vesicular or paracellular migration; antibiotics that interfere with vesicular transport did not block migration.  The transfer rate was also dependent on the surface coating of the nanoparticle and incubation temp.  Using a novel 3-dimensional co-culture system, which includes primary human astrocytes and a brain endothelial cell line hCMEC/D3, we demonstrated that the glucose-coated nanoparticles traverse the endothelium, move through the extracellular matrix and localize in astrocytes.  The movement of the nanoparticles through the matrix was >10 μm/h and they appeared in the nuclei of the astrocytes in considerable nos.  These nanoparticles have the correct properties for efficient and selective carriers of therapeutic agents across the blood-brain barrier.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfS2FgUtqjpLVg90H21EOLACvtfcHk0ljpy30QsdOZeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltl2rsrw%253D&md5=3448a63d0dbf90ccbf49227264e2f384</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0081043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0081043%26sid%3Dliteratum%253Aachs%26aulast%3DGromnicova%26aufirst%3DR.%26aulast%3DDavies%26aufirst%3DH.%2BA.%26aulast%3DSreekanthreddy%26aufirst%3DP.%26aulast%3DRomero%26aufirst%3DI.%2BA.%26aulast%3DLund%26aufirst%3DT.%26aulast%3DRoitt%26aufirst%3DI.%2BM.%26aulast%3DPhillips%26aufirst%3DJ.%2BB.%26aulast%3DMale%26aufirst%3DD.%2BK.%26atitle%3DGlucose-Coated%2520Gold%2520Nanoparticles%2520Transfer%2520Across%2520Human%2520Brain%2520Endothelium%2520and%2520Enter%2520Astrocytes%2520in%2520Vitro%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26doi%3D10.1371%2Fjournal.pone.0081043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sha, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, X.</span></span> <span> </span><span class="NLM_article-title">Nanoparticles of 2-Deoxy-D-Glucose Functionalized Poly (Ethylene Glycol)-Co-Poly (Trimethylene Carbonate) for Dual-Targeted Drug Delivery in Glioma Treatment</span>. <i>Biomaterials</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">518</span>– <span class="NLM_lpage">529</span>, <span class="refDoi"> DOI: 10.1016/j.biomaterials.2013.09.094</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.biomaterials.2013.09.094" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=24125772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Sku7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2014&pages=518-529&author=X.+Jiangauthor=H.+Xinauthor=Q.+Renauthor=J.+Guauthor=L.+Zhuauthor=F.+Duauthor=C.+Fengauthor=Y.+Xieauthor=X.+Shaauthor=X.+Fang&title=Nanoparticles+of+2-Deoxy-D-Glucose+Functionalized+Poly+%28Ethylene+Glycol%29-Co-Poly+%28Trimethylene+Carbonate%29+for+Dual-Targeted+Drug+Delivery+in+Glioma+Treatment&doi=10.1016%2Fj.biomaterials.2013.09.094"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Nanoparticles of 2-deoxy-d-glucose functionalized poly(ethylene glycol)-co-poly(trimethylene carbonate) for dual-targeted drug delivery in glioma treatment</span></div><div class="casAuthors">Jiang, Xinyi; Xin, Hongliang; Ren, Qiuyue; Gu, Jijin; Zhu, Lingjun; Du, Fengyi; Feng, Chunlai; Xie, Yike; Sha, Xianyi; Fang, Xiaoling</div><div class="citationInfo"><span class="NLM_cas:title">Biomaterials</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">518-529</span>CODEN:
                <span class="NLM_cas:coden">BIMADU</span>;
        ISSN:<span class="NLM_cas:issn">0142-9612</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Based on the facilitative glucose transporter (GLUT) over-expression on both blood-brain barrier (BBB) and glioma cells, 2-deoxy-d-glucose modified poly(ethylene glycol)-co-poly(trimethylene carbonate) nanoparticles (dGlu-NP) were developed as a potential dual-targeted drug delivery system for enhancing the BBB penetration via GLUT-mediated transcytosis and improving the drug accumulation in the glioma via GLUT-mediated endocytosis.  In vitro physicochem. characterization of the dual-targeted nanoparticulate system presented satisfactory size of 71 nm with uniform distribution, high encapsulation efficiency and adequate loading capacity of paclitaxel (PTX).  Compared with non-glucosylated nanoparticles (NP), a significantly higher amt. of dGlu-NP was internalized by RG-2 glioma cells through caveolae-mediated and clathrin-mediated endocytosis.  Both of the transport ratios across the in vitro BBB model and the cytotoxicity of RG-2 cells after crossing the BBB were significantly greater of dGlu-NP/PTX than that of NP/PTX.  In vivo fluorescent image indicated that dGlu-NP had high specificity and efficiency in intracranial tumor accumulation.  The anti-glioblastoma efficacy of dGlu-NP/PTX was significantly enhanced in comparison with that of Taxol and NP/PTX.  Preliminary safety tests showed no acute toxicity to hematol. system, liver, kidney, heart, lung and spleen in mice after i.v. administration at a dose of 100 mg/kg blank dGlu-NP per day for a week.  Therefore, these results indicated that dGlu-NP developed in this study could be a potential dual-targeted vehicle for brain glioma therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOeiuVV6tqybVg90H21EOLACvtfcHk0ljpy30QsdOZeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Sku7rE&md5=5144f99c38a5f230470ea1379fa87d8e</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.biomaterials.2013.09.094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biomaterials.2013.09.094%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DXin%26aufirst%3DH.%26aulast%3DRen%26aufirst%3DQ.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DDu%26aufirst%3DF.%26aulast%3DFeng%26aufirst%3DC.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DSha%26aufirst%3DX.%26aulast%3DFang%26aufirst%3DX.%26atitle%3DNanoparticles%2520of%25202-Deoxy-D-Glucose%2520Functionalized%2520Poly%2520%2528Ethylene%2520Glycol%2529-Co-Poly%2520%2528Trimethylene%2520Carbonate%2529%2520for%2520Dual-Targeted%2520Drug%2520Delivery%2520in%2520Glioma%2520Treatment%26jtitle%3DBiomaterials%26date%3D2014%26volume%3D35%26spage%3D518%26epage%3D529%26doi%3D10.1016%2Fj.biomaterials.2013.09.094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mamaeva, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niemi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Özliseli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gronroos, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kronqvist, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettersen, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormack, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenholm, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linden, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahlgren, C.</span></span> <span> </span><span class="NLM_article-title">Inhibiting Notch Activity in Breast Cancer Stem Cells by Glucose Functionalized Nanoparticles Carrying Γ-Secretase Inhibitors</span>. <i>Mol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">926</span>– <span class="NLM_lpage">936</span>, <span class="refDoi"> DOI: 10.1038/mt.2016.42</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1038%2Fmt.2016.42" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=26916284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC28XltVaqsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=926-936&author=V.+Mamaevaauthor=R.+Niemiauthor=M.+Beckauthor=E.+%C3%96zliseliauthor=D.+Desaiauthor=S.+Landorauthor=T.+Gronroosauthor=P.+Kronqvistauthor=I.+K.+Pettersenauthor=E.+McCormackauthor=J.+M.+Rosenholmauthor=M.+Lindenauthor=C.+Sahlgren&title=Inhibiting+Notch+Activity+in+Breast+Cancer+Stem+Cells+by+Glucose+Functionalized+Nanoparticles+Carrying+%CE%93-Secretase+Inhibitors&doi=10.1038%2Fmt.2016.42"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting Notch Activity in Breast Cancer Stem Cells by Glucose Functionalized Nanoparticles Carrying γ-secretase Inhibitors</span></div><div class="casAuthors">Mamaeva, Veronika; Niemi, Rasmus; Beck, Michaela; Ozliseli, Ezgi; Desai, Diti; Landor, Sebastian; Gronroos, Tove; Kronqvist, Pauliina; Pettersen, Ina K. N.; McCormack, Emmet; Rosenholm, Jessica M.; Linden, Mika; Sahlgren, Cecilia</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">926-936</span>CODEN:
                <span class="NLM_cas:coden">MTOHCK</span>;
        ISSN:<span class="NLM_cas:issn">1525-0016</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cancer stem cells (CSCs) are a challenge in cancer treatment due to their therapy resistance.  We demonstrated that enhanced Notch signaling in breast cancer promotes self-renewal of CSCs that display high glycolytic activity and aggressive hormone-independent tumor growth in vivo.  We took advantage of the glycolytic phenotype and the dependence on Notch activity of the CSCs and designed nanoparticles to target the CSCs.  Mesoporous silica nanoparticles were functionalized with glucose moieties and loaded with a γ-secretase inhibitor, a potent interceptor of Notch signaling.  Cancer cells and CSCs in vitro and in vivo efficiently internalized these particles, and particle uptake correlated with the glycolytic profile of the cells.  Nanoparticle treatment of breast cancer transplants on chick embryo chorioallantoic membranes efficiently reduced the cancer stem cell population of the tumor.  Our data reveal that specific CSC characteristics can be utilized in nanoparticle design to improve CSC-targeted drug delivery and therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN16-R4Gx5yLVg90H21EOLACvtfcHk0ljpy30QsdOZeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XltVaqsrc%253D&md5=b0248b6ef6953d9b6db9cce815914cc6</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1038%2Fmt.2016.42&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmt.2016.42%26sid%3Dliteratum%253Aachs%26aulast%3DMamaeva%26aufirst%3DV.%26aulast%3DNiemi%26aufirst%3DR.%26aulast%3DBeck%26aufirst%3DM.%26aulast%3D%25C3%2596zliseli%26aufirst%3DE.%26aulast%3DDesai%26aufirst%3DD.%26aulast%3DLandor%26aufirst%3DS.%26aulast%3DGronroos%26aufirst%3DT.%26aulast%3DKronqvist%26aufirst%3DP.%26aulast%3DPettersen%26aufirst%3DI.%2BK.%26aulast%3DMcCormack%26aufirst%3DE.%26aulast%3DRosenholm%26aufirst%3DJ.%2BM.%26aulast%3DLinden%26aufirst%3DM.%26aulast%3DSahlgren%26aufirst%3DC.%26atitle%3DInhibiting%2520Notch%2520Activity%2520in%2520Breast%2520Cancer%2520Stem%2520Cells%2520by%2520Glucose%2520Functionalized%2520Nanoparticles%2520Carrying%2520%25CE%2593-Secretase%2520Inhibitors%26jtitle%3DMol.%2520Ther.%26date%3D2016%26volume%3D24%26spage%3D926%26epage%3D936%26doi%3D10.1038%2Fmt.2016.42" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puri, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, N.</span></span> <span> </span><span class="NLM_article-title">Mannanases: Microbial Sources, Production, Properties and Potential Biotechnological Applications</span>. <i>Appl. Microbiol. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">1817</span>– <span class="NLM_lpage">1830</span>, <span class="refDoi"> DOI: 10.1007/s00253-012-3887-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1007%2Fs00253-012-3887-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=22314515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC38Xisl2qt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2012&pages=1817-1830&author=P.+S.+Chauhanauthor=N.+Puriauthor=P.+Sharmaauthor=N.+Gupta&title=Mannanases%3A+Microbial+Sources%2C+Production%2C+Properties+and+Potential+Biotechnological+Applications&doi=10.1007%2Fs00253-012-3887-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Mannanases: microbial sources, production, properties and potential biotechnological applications</span></div><div class="casAuthors">Chauhan, Prakram Singh; Puri, Neena; Sharma, Prince; Gupta, Naveen</div><div class="citationInfo"><span class="NLM_cas:title">Applied Microbiology and Biotechnology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1817-1830</span>CODEN:
                <span class="NLM_cas:coden">AMBIDG</span>;
        ISSN:<span class="NLM_cas:issn">0175-7598</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Mannans are the major constituents of the hemicellulose fraction in softwoods and show widespread distribution in plant tissues.  The major mannan-degrading enzymes are β-mannanases, β-mannosidases and β-glucosidases.  In addn. to these, other enzymes such as α-galactosidases and acetyl mannan esterases, are required to remove the side chain substituents.  The mannanases are known to be produced by a variety of bacteria, fungi, actinomycetes, plants and animals.  Microbial mannanases are mainly extracellular and can act in wide range of pH and temp. because of which they have found applications in pulp and paper, pharmaceutical, food, feed, oil and textile industries.  This review summarizes the studies on mannanases reported in recent years in terms of important microbial sources, prodn. conditions, enzyme properties, heterologous expression and potential industrial applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwf5-BsOk0JbVg90H21EOLACvtfcHk0li0hpRVNPCTFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xisl2qt7o%253D&md5=b16cd1228136901eac74c1e581d730ae</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1007%2Fs00253-012-3887-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00253-012-3887-5%26sid%3Dliteratum%253Aachs%26aulast%3DChauhan%26aufirst%3DP.%2BS.%26aulast%3DPuri%26aufirst%3DN.%26aulast%3DSharma%26aufirst%3DP.%26aulast%3DGupta%26aufirst%3DN.%26atitle%3DMannanases%253A%2520Microbial%2520Sources%252C%2520Production%252C%2520Properties%2520and%2520Potential%2520Biotechnological%2520Applications%26jtitle%3DAppl.%2520Microbiol.%2520Biotechnol.%26date%3D2012%26volume%3D93%26spage%3D1817%26epage%3D1830%26doi%3D10.1007%2Fs00253-012-3887-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Budzynska, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nevozhay, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanska, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jagiello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opolski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wietrzyk, J.</span></span> <span> </span><span class="NLM_article-title">Boratynski, Antitumor Activity of Mannan–Methotrexate Conjugate In-Vitro and In-Vivo</span>. <i>J. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">415</span>– <span class="NLM_lpage">421</span>, <span class="refDoi"> DOI: 10.3727/000000007783980837</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.3727%2F000000007783980837" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2007&pages=415-421&author=R.+Budzynskaauthor=D.+Nevozhayauthor=U.+Kanskaauthor=M.+Jagielloauthor=A.+Opolskiauthor=J.+Wietrzyk&title=Boratynski%2C+Antitumor+Activity+of+Mannan%E2%80%93Methotrexate+Conjugate+In-Vitro+and+In-Vivo&doi=10.3727%2F000000007783980837"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.3727%2F000000007783980837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3727%252F000000007783980837%26sid%3Dliteratum%253Aachs%26aulast%3DBudzynska%26aufirst%3DR.%26aulast%3DNevozhay%26aufirst%3DD.%26aulast%3DKanska%26aufirst%3DU.%26aulast%3DJagiello%26aufirst%3DM.%26aulast%3DOpolski%26aufirst%3DA.%26aulast%3DWietrzyk%26aufirst%3DJ.%26atitle%3DBoratynski%252C%2520Antitumor%2520Activity%2520of%2520Mannan%25E2%2580%2593Methotrexate%2520Conjugate%2520In-Vitro%2520and%2520In-Vivo%26jtitle%3DJ.%2520Ther.%26date%3D2007%26volume%3D16%26spage%3D415%26epage%3D421%26doi%3D10.3727%2F000000007783980837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampaio, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coutinho, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gama, F. M.</span></span> <span> </span><span class="NLM_article-title">Supramolecular Assembled Nanogel Made of Mannan</span>. <i>J. Colloid Interface Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>361</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">108</span>, <span class="refDoi"> DOI: 10.1016/j.jcis.2011.05.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.jcis.2011.05.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=21658701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotleks7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2011&pages=97-108&author=S.+A.+Ferreiraauthor=P.+Pereiraauthor=P.+Sampaioauthor=P.+J.+Coutinhoauthor=F.+M.+Gama&title=Supramolecular+Assembled+Nanogel+Made+of+Mannan&doi=10.1016%2Fj.jcis.2011.05.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Supramolecular assembled nanogel made of mannan</span></div><div class="casAuthors">Ferreira, Silvia A.; Pereira, Paula; Sampaio, Paula; Coutinho, Paulo J. G.; Gama, Francisco M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Colloid and Interface Science</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">97-108</span>CODEN:
                <span class="NLM_cas:coden">JCISA5</span>;
        ISSN:<span class="NLM_cas:issn">0021-9797</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The supramol. assembly of amphiphilic mannan, synthesized by the Michael addn. of hydrophobic 1-hexadecanethiol to vinyl methacrylated mannan, originates in aq. medium the formation of a nanogel, stabilized by hydrophobic interactions among alkyl chains.  The crit. aggregation concn., calcd. by fluorescence spectroscopy ranged between 0.002 and 0.01 mg/mL, depending on the polymer degree of substitution.  The cryo-field emission SEM showed spherical macromol. micelles with diams. between 100 and 500 nm.  The dynamic light scattering anal. revealed a polydisperse colloidal system, with mean hydrodynamic diam. between 50 and 140 nm, depending on the polymer degree of substitution.  The nanogel is neg. charged, stable over a 6 mo storage period, and stable at pH 3-8, salt or urea solns.  Bovine serum albumin and curcumin were spontaneously incorporated in the nanogel, being stabilized by the hydrophobic domains, opening the possibility for future applications as potential delivery systems for therapeutic mols.  In vitro assays were carried out to characterize the biocompatibility of the nanogel.  A toxic effect of mannan-C16 was obsd., specific to mouse macrophage-like cell line J774, not affecting mouse embryo fibroblast cell line 3T3 viability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_GE146OubtrVg90H21EOLACvtfcHk0li0hpRVNPCTFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotleks7c%253D&md5=e96c39dfcaacfed0042c9d62b6331767</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1016%2Fj.jcis.2011.05.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jcis.2011.05.020%26sid%3Dliteratum%253Aachs%26aulast%3DFerreira%26aufirst%3DS.%2BA.%26aulast%3DPereira%26aufirst%3DP.%26aulast%3DSampaio%26aufirst%3DP.%26aulast%3DCoutinho%26aufirst%3DP.%2BJ.%26aulast%3DGama%26aufirst%3DF.%2BM.%26atitle%3DSupramolecular%2520Assembled%2520Nanogel%2520Made%2520of%2520Mannan%26jtitle%3DJ.%2520Colloid%2520Interface%2520Sci.%26date%3D2011%26volume%3D361%26spage%3D97%26epage%3D108%26doi%3D10.1016%2Fj.jcis.2011.05.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvalho, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teixeira, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilanova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gama, F. M.</span></span> <span> </span><span class="NLM_article-title">Self-Assembled Mannan Nanogel: Cytocompatibility and Cell Localization</span>. <i>J. Biomed. Nanotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">473</span>– <span class="NLM_lpage">481</span>, <span class="refDoi"> DOI: 10.1166/jbn.2012.1408</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1166%2Fjbn.2012.1408" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=22764417" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC38XotFWmtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=473-481&author=S.+A.+Ferreiraauthor=V.+Carvalhoauthor=C.+Costaauthor=J.+P.+Teixeiraauthor=M.+Vilanovaauthor=F.+M.+Gama&title=Self-Assembled+Mannan+Nanogel%3A+Cytocompatibility+and+Cell+Localization&doi=10.1166%2Fjbn.2012.1408"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Self-assembled mannan nanogel: cytocompatibility and cell localization</span></div><div class="casAuthors">Ferreira, Silvia A.; Carvalho, Vera; Costa, Carla; Teixeira, Joao Paulo; Vilanova, Manuel; Gama, Francisco M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomedical Nanotechnology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">473-481</span>CODEN:
                <span class="NLM_cas:coden">JBNOAB</span>;
        ISSN:<span class="NLM_cas:issn">1550-7033</span>.
    
            (<span class="NLM_cas:orgname">American Scientific Publishers</span>)
        </div><div class="casAbstract">Amphiphilic mannan, produced by the Michael addn. of hydrophobic 1-hexadecanethiol to vinyl methacrylated mannan, self-assembles in aq. medium through hydrophobic interactions among alkyl chains.  The resultant nanogel is stable, spherical, polydisperse, with 50-140 nm mean hydrodynamic diam. depending on the polymer degree of substitution, and nearly neutral neg. surface charge.  No cytotoxicity of mannan nanogel is detected up to about 0.4 mg/mL in mouse embryo fibroblast cell line 3T3 and mouse bone marrow-derived macrophages (BMDM) using cell proliferation, lactate dehydrogenase and Live/Dead assays.  Comet assay, under the tested conditions, reveals no DNA damage in fibroblasts but possible in BMDM.  BMDM internalize the mannan nanogel, which is obsd. in vesicles in the cytoplasm by confocal laser scanning microscopy.  Confocal colocalization image anal. denotes that the entrance and exit of nanogel and FM 4-64 might occur by the same processes, endocytosis and exocytosis, in BMDM.  Physicochem. characteristics, in vitro cytocompatibility and uptake of self-assembled mannan nanogel by mouse BMDM are great signals of the potential applicability of this nanosystem for macrophages targeted delivery of vaccines or drugs, acting as potential nanomedicines, always with the key goal of preventing and/or treating diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqb7GFGjPO-6LVg90H21EOLACvtfcHk0li0hpRVNPCTFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotFWmtb0%253D&md5=7ab7e1fcc2ecba4d7b2f2579c1b0e6ed</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1166%2Fjbn.2012.1408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1166%252Fjbn.2012.1408%26sid%3Dliteratum%253Aachs%26aulast%3DFerreira%26aufirst%3DS.%2BA.%26aulast%3DCarvalho%26aufirst%3DV.%26aulast%3DCosta%26aufirst%3DC.%26aulast%3DTeixeira%26aufirst%3DJ.%2BP.%26aulast%3DVilanova%26aufirst%3DM.%26aulast%3DGama%26aufirst%3DF.%2BM.%26atitle%3DSelf-Assembled%2520Mannan%2520Nanogel%253A%2520Cytocompatibility%2520and%2520Cell%2520Localization%26jtitle%3DJ.%2520Biomed.%2520Nanotechnol.%26date%3D2012%26volume%3D8%26spage%3D473%26epage%3D481%26doi%3D10.1166%2Fjbn.2012.1408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Apostolopoulos, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietersz, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsibanis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsikkinis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drakaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loveland, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piddlesden, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plebanski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pouniotis, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexis, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenzie, I. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vassilaros, S.</span></span> <span> </span><span class="NLM_article-title">Pilot Phase III Immunotherapy Study in Early-Stage Breast Cancer Patients Using Oxidized Mannan-MUC1</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">R27</span>, <span class="refDoi"> DOI: 10.1186/bcr1505</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1186%2Fbcr1505" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=16776849" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2006&pages=R27&author=V.+Apostolopoulosauthor=G.+A.+Pieterszauthor=A.+Tsibanisauthor=A.+Tsikkinisauthor=H.+Drakakiauthor=B.+E.+Lovelandauthor=S.+J.+Piddlesdenauthor=M.+Plebanskiauthor=D.+S.+Pouniotisauthor=M.+N.+Alexisauthor=I.+F.+McKenzieauthor=S.+Vassilaros&title=Pilot+Phase+III+Immunotherapy+Study+in+Early-Stage+Breast+Cancer+Patients+Using+Oxidized+Mannan-MUC1&doi=10.1186%2Fbcr1505"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1186%2Fbcr1505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fbcr1505%26sid%3Dliteratum%253Aachs%26aulast%3DApostolopoulos%26aufirst%3DV.%26aulast%3DPietersz%26aufirst%3DG.%2BA.%26aulast%3DTsibanis%26aufirst%3DA.%26aulast%3DTsikkinis%26aufirst%3DA.%26aulast%3DDrakaki%26aufirst%3DH.%26aulast%3DLoveland%26aufirst%3DB.%2BE.%26aulast%3DPiddlesden%26aufirst%3DS.%2BJ.%26aulast%3DPlebanski%26aufirst%3DM.%26aulast%3DPouniotis%26aufirst%3DD.%2BS.%26aulast%3DAlexis%26aufirst%3DM.%2BN.%26aulast%3DMcKenzie%26aufirst%3DI.%2BF.%26aulast%3DVassilaros%26aufirst%3DS.%26atitle%3DPilot%2520Phase%2520III%2520Immunotherapy%2520Study%2520in%2520Early-Stage%2520Breast%2520Cancer%2520Patients%2520Using%2520Oxidized%2520Mannan-MUC1%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2006%26volume%3D8%26spage%3DR27%26doi%3D10.1186%2Fbcr1505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. M.</span></span> <span> </span><span class="NLM_article-title">Development of a Mucin4-Targeting SPIO Contrast Agent for Effective Detection of Pancreatic Tumor Cells In-Vitro and In-Vivo</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">9100</span>– <span class="NLM_lpage">9109</span>, <span class="refDoi"> DOI: 10.1021/jm401060z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401060z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1KktL7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=9100-9109&author=S.+C.+Wuauthor=Y.+J.+Chenauthor=Y.+J.+Linauthor=T.+H.+Wuauthor=Y.+M.+Wang&title=Development+of+a+Mucin4-Targeting+SPIO+Contrast+Agent+for+Effective+Detection+of+Pancreatic+Tumor+Cells+In-Vitro+and+In-Vivo&doi=10.1021%2Fjm401060z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Mucin4-Targeting SPIO Contrast Agent for Effective Detection of Pancreatic Tumor Cells in Vitro and in Vivo</span></div><div class="casAuthors">Wu, Shou-Cheng; Chen, Yu-Jen; Lin, Yi-Jan; Wu, Tung-Ho; Wang, Yun-Ming</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9100-9109</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In search of a unique and reliable contrast agent targeting pancreatic adenocarcinoma, new multifunctional nanoparticles (MnMEIO-silane-NH2-(MUC4)-mPEG NPs) were successfully developed in this study.  Mucin4-expression levels were detd. through different imaging studies in a panel of pancreatic tumor cells (HPAC, BxPC-3, and Panc-1) both in vitro and in vivo studies.  The in vitro T2-weighted MR imaging study in HPAC and Panc-1 tumor cells treated with NPs showed -89.1 ± 5.7% and -0.9 ± 0.2% contrast enhancement, whereas in in vivo study, it is found to be -81.5 ± 4.5% vs. -19.6 ± 5.2% (24 h postinjection, 7.0 T), resp.  The T2-weighted MR and optical imaging studies revealed that the novel contrast agent can specifically and effectively target to mucin4-expressing tumors in nude mice.  Hence, it is suggested that MnMEIO-silane-NH2-(MUC4)-mPEG NPs are able to provide an efficient and targeted delivery of MUC4 antibodies to mucin4-expressing pancreatic tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqENH9lGC6ElbVg90H21EOLACvtfcHk0lj_saWER-DWZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1KktL7M&md5=e926b9a0772536ef00ee769d43a15796</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1021%2Fjm401060z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401060z%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DS.%2BC.%26aulast%3DChen%26aufirst%3DY.%2BJ.%26aulast%3DLin%26aufirst%3DY.%2BJ.%26aulast%3DWu%26aufirst%3DT.%2BH.%26aulast%3DWang%26aufirst%3DY.%2BM.%26atitle%3DDevelopment%2520of%2520a%2520Mucin4-Targeting%2520SPIO%2520Contrast%2520Agent%2520for%2520Effective%2520Detection%2520of%2520Pancreatic%2520Tumor%2520Cells%2520In-Vitro%2520and%2520In-Vivo%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D9100%26epage%3D9109%26doi%3D10.1021%2Fjm401060z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dufresne, A.</span></span> <span> </span><span class="NLM_article-title">Nanocellulose in Biomedicine: Current Status and Future Prospect</span>. <i>Eur. Polym. J.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">302</span>– <span class="NLM_lpage">325</span>, <span class="refDoi"> DOI: 10.1016/j.eurpolymj.2014.07.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.eurpolymj.2014.07.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Kgs7%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2014&pages=302-325&author=N.+Linauthor=A.+Dufresne&title=Nanocellulose+in+Biomedicine%3A+Current+Status+and+Future+Prospect&doi=10.1016%2Fj.eurpolymj.2014.07.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Nanocellulose in biomedicine: Current status and future prospect</span></div><div class="casAuthors">Lin, Ning; Dufresne, Alain</div><div class="citationInfo"><span class="NLM_cas:title">European Polymer Journal</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">302-325</span>CODEN:
                <span class="NLM_cas:coden">EUPJAG</span>;
        ISSN:<span class="NLM_cas:issn">0014-3057</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Nanocellulose, a unique and promising natural material extd. from native cellulose, has gained much attention for its use as biomedical material, because of its remarkable phys. properties, special surface chem. and excellent biol. properties (biocompatibility, biodegradability and low toxicity).  Three different types of nanocellulose, viz. cellulose nanocrystals (CNC), cellulose nanofibrils (CNF) and bacterial cellulose (BC), are introduced and compared in terms of prodn., properties and biomedical applications in this article.  The advancement of nanocellulose-based biomedical materials is summarized and discussed on the anal. of latest studies (esp. reports from the past five years).  Selected studies with significant findings are emphasized, and focused topics for nanocellulose in biomedicine research in this article include the discussion at the level of mol. (e.g. tissue bioscaffolds for cellular culture; drug excipient and drug delivery; and immobilization and recognition of enzyme/protein) as well as at the level of macroscopic biomaterials (e.g. blood vessel and soft tissue substitutes; skin and bone tissue repair materials; and antimicrobial materials).  Functional modification of nanocellulose will det. the potential biomedical application for nanocellulose, which is also introduced as a sepd. section in the article.  Finally, future perspectives and possible research points are proposed in Section 5.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdLSCasVlR8rVg90H21EOLACvtfcHk0lj_saWER-DWZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Kgs7%252FF&md5=2b35e7c586aaf5fdc2f5cb7675dd62c2</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2Fj.eurpolymj.2014.07.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.eurpolymj.2014.07.025%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DN.%26aulast%3DDufresne%26aufirst%3DA.%26atitle%3DNanocellulose%2520in%2520Biomedicine%253A%2520Current%2520Status%2520and%2520Future%2520Prospect%26jtitle%3DEur.%2520Polym.%2520J.%26date%3D2014%26volume%3D59%26spage%3D302%26epage%3D325%26doi%3D10.1016%2Fj.eurpolymj.2014.07.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Souza Lima, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borsali, R.</span></span> <span> </span><span class="NLM_article-title">Rodlike Cellulose Microcrystals: Structure, Properties, and Applications</span>. <i>Macromol. Rapid Commun.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">771</span>– <span class="NLM_lpage">787</span>, <span class="refDoi"> DOI: 10.1002/marc.200300268</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1002%2Fmarc.200300268" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjt1Smsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2004&pages=771-787&author=M.+M.+De%0ASouza+Limaauthor=R.+Borsali&title=Rodlike+Cellulose+Microcrystals%3A+Structure%2C+Properties%2C+and+Applications&doi=10.1002%2Fmarc.200300268"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Rodlike cellulose microcrystals: structure, properties, and applications</span></div><div class="casAuthors">De Souza Lima, M. Miriam; Borsali, Redouane</div><div class="citationInfo"><span class="NLM_cas:title">Macromolecular Rapid Communications</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">771-787</span>CODEN:
                <span class="NLM_cas:coden">MRCOE3</span>;
        ISSN:<span class="NLM_cas:issn">1022-1336</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  In this article we present some interesting properties of rodlike cellulose microcrystals (so-called "whiskers").  These microcrystals can be obtained from different cellulose sources such as wood, cotton, or animal origin.  When submitted to acid hydrolysis, the cellulose fibers yield stable aq. suspensions because of the presence of neg. charges on the surface of the microcrystallites during the hydrolysis process.  The obtained microcrystals are rod-shaped particles, the dimensions of which depend on the cellulose origin.  For instance, the cotton whiskers have typical dimensions varying from 100 to 300 nm in length, L, and 8 to 10 nm in diam., d, while those of the tunicate whiskers range from 100 nm to few micrometers in length and 10 to 20 nm in diam.  At very low concns., these whiskers are randomly suspended in water and form an isotropic phase.  When the concn. reaches a crit. value, the whiskers spontaneously display ordered phases showing interesting liq. crystal properties (nematic and chiral nematic).  The chiral nematic orders can be retained after evapn. of the solvent (generally water), leaving iridescent films.  The reflected color can be controlled by changing either the ionic strength or by applying an elec. field.  These colloidal particles have been investigated using several techniques including small-angle neutron scattering (SANS), small angle X-ray scattering, rheol., and more recently dynamic and static light scattering techniques (DLS and SLS) to highlight their static and dynamic behavior.  Because of their geometry, important axis ratio (L/d), and high crystallinity, these rods have been also extensively used to process nanocomposites based on polymer matrixes, to reinforce their mech. properties.  All these properties are discussed in this contribution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqW6BHsoNSKHrVg90H21EOLACvtfcHk0lj_saWER-DWZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjt1Smsbk%253D&md5=efc89570dff19fc3ff258d6b95e2b5ab</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1002%2Fmarc.200300268&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmarc.200300268%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BSouza%2BLima%26aufirst%3DM.%2BM.%26aulast%3DBorsali%26aufirst%3DR.%26atitle%3DRodlike%2520Cellulose%2520Microcrystals%253A%2520Structure%252C%2520Properties%252C%2520and%2520Applications%26jtitle%3DMacromol.%2520Rapid%2520Commun.%26date%3D2004%26volume%3D25%26spage%3D771%26epage%3D787%26doi%3D10.1002%2Fmarc.200300268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Colacino, K.</span></span> <i>Potential of Cellulose Nanocrystals in the Detection and Treatment of Cancer</i>. Doctoral Dissertation. <span class="NLM_publisher-name">Virginia Tech University</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=K.+Colacino&title=Potential+of+Cellulose+Nanocrystals+in+the+Detection+and+Treatment+of+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DColacino%26aufirst%3DK.%26jtitle%3DPotential%2520of%2520Cellulose%2520Nanocrystals%2520in%2520the%2520Detection%2520and%2520Treatment%2520of%2520Cancer%26pub%3DVirginia%2520Tech%2520University%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sivakumar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aswathy, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagaoka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maekawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakthikumar, D. N.</span></span> <span> </span><span class="NLM_article-title">Multifunctional Carboxymethyl Cellulose-Based Magnetic Nanovector as a Theragnostic System for Folate Receptor Targeted Chemotherapy, Imaging, and Hyperthermia Against Cancer</span>. <i>Langmuir</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">3453</span>– <span class="NLM_lpage">3466</span>, <span class="refDoi"> DOI: 10.1021/la305048m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/la305048m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC3sXisV2iu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2013&pages=3453-3466&author=B.+Sivakumarauthor=R.+G.+Aswathyauthor=Y.+Nagaokaauthor=M.+Suzukiauthor=T.+Fukudaauthor=Y.+Yoshidaauthor=T.+Maekawaauthor=D.+N.+Sakthikumar&title=Multifunctional+Carboxymethyl+Cellulose-Based+Magnetic+Nanovector+as+a+Theragnostic+System+for+Folate+Receptor+Targeted+Chemotherapy%2C+Imaging%2C+and+Hyperthermia+Against+Cancer&doi=10.1021%2Fla305048m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Multifunctional Carboxymethyl Cellulose-Based Magnetic Nanovector as a Theragnostic System for Folate Receptor Targeted Chemotherapy, Imaging, and Hyperthermia against Cancer</span></div><div class="casAuthors">Sivakumar, Balasubramanian; Aswathy, Ravindran Girija; Nagaoka, Yutaka; Suzuki, Masashi; Fukuda, Takahiro; Yoshida, Yasuhiko; Maekawa, Toru; Sakthikumar, Dasappan Nair</div><div class="citationInfo"><span class="NLM_cas:title">Langmuir</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3453-3466</span>CODEN:
                <span class="NLM_cas:coden">LANGD5</span>;
        ISSN:<span class="NLM_cas:issn">0743-7463</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A multifunctional biocompatible nanovector based on magnetic nanoparticle and CM-cellulose (CMC) was developed.  The nanoparticles have been characterized using TEM, SEM, DLS, FT-IR spectra, VSM, and TGA studies.  We found that the synthesized CM-cellulose magnetic nanoparticles (CMC MNPs) were spherical in shape with an av. size of 150 nm having low aggregation and superparamagnetic properties.  We found that the folate-tagged CMC MNPs were delivered to cancer cells by a folate-receptor-mediated endocytosis mechanism. 5-FU was encapsulated as a model drug for delivering cytotoxicity, and we could demonstrate the sustained release of 5-FU.  It was also obsd. that the FITC-labeled CMC MNPs could effectively enter cells, and the fate of nanoparticles was tracked with Lysotracker.  The CMC MNPs could induce significant cell death when an alternating magnetic field was applied.  These results indicate that the multifunctional CMC MNPs possess a high drug loading efficiency and high biocompatibility and with low cell cytotoxicity and can be considered to be promising candidates for CMC-based targeted drug delivery, cellular imaging, and magnetic hyperthermia (MHT).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0fr7LR-YMurVg90H21EOLACvtfcHk0lhkOuMbSstXWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXisV2iu70%253D&md5=f28c4cb20c7e3c06ee65a8970db7f5ce</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1021%2Fla305048m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fla305048m%26sid%3Dliteratum%253Aachs%26aulast%3DSivakumar%26aufirst%3DB.%26aulast%3DAswathy%26aufirst%3DR.%2BG.%26aulast%3DNagaoka%26aufirst%3DY.%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DFukuda%26aufirst%3DT.%26aulast%3DYoshida%26aufirst%3DY.%26aulast%3DMaekawa%26aufirst%3DT.%26aulast%3DSakthikumar%26aufirst%3DD.%2BN.%26atitle%3DMultifunctional%2520Carboxymethyl%2520Cellulose-Based%2520Magnetic%2520Nanovector%2520as%2520a%2520Theragnostic%2520System%2520for%2520Folate%2520Receptor%2520Targeted%2520Chemotherapy%252C%2520Imaging%252C%2520and%2520Hyperthermia%2520Against%2520Cancer%26jtitle%3DLangmuir%26date%3D2013%26volume%3D29%26spage%3D3453%26epage%3D3466%26doi%3D10.1021%2Fla305048m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohan
Yallapu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray Dobberpuhl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michele Maher, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaggi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chand Chauhan, S.</span></span> <span> </span><span class="NLM_article-title">Design of Curcumin Loaded Cellulose Nanoparticles for Prostate Cancer</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">120</span>– <span class="NLM_lpage">128</span>, <span class="refDoi"> DOI: 10.2174/138920012798356952</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.2174%2F138920012798356952" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=21892919" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=120-128&author=M.+Mohan%0AYallapuauthor=M.+Ray+Dobberpuhlauthor=D.+Michele+Maherauthor=M.+Jaggiauthor=S.+Chand+Chauhan&title=Design+of+Curcumin+Loaded+Cellulose+Nanoparticles+for+Prostate+Cancer&doi=10.2174%2F138920012798356952"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.2174%2F138920012798356952&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920012798356952%26sid%3Dliteratum%253Aachs%26aulast%3DMohan%2BYallapu%26aufirst%3DM.%26aulast%3DRay%2BDobberpuhl%26aufirst%3DM.%26aulast%3DMichele%2BMaher%26aufirst%3DD.%26aulast%3DJaggi%26aufirst%3DM.%26aulast%3DChand%2BChauhan%26aufirst%3DS.%26atitle%3DDesign%2520of%2520Curcumin%2520Loaded%2520Cellulose%2520Nanoparticles%2520for%2520Prostate%2520Cancer%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2012%26volume%3D13%26spage%3D120%26epage%3D128%26doi%3D10.2174%2F138920012798356952" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arruebo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valladares, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González-Fernández, Á.</span></span> <span> </span><span class="NLM_article-title">Antibody-Conjugated Nanoparticles for Biomedical Applications</span>. <i>J. Nanomater.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>2009</i></span> (<span class="NLM_issue">37</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1155/2009/439389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1155%2F2009%2F439389" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2009&publication_year=2009&pages=1-24&issue=37&author=M.+Arrueboauthor=M.+Valladaresauthor=%C3%81.+Gonz%C3%A1lez-Fern%C3%A1ndez&title=Antibody-Conjugated+Nanoparticles+for+Biomedical+Applications&doi=10.1155%2F2009%2F439389"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1155%2F2009%2F439389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2009%252F439389%26sid%3Dliteratum%253Aachs%26aulast%3DArruebo%26aufirst%3DM.%26aulast%3DValladares%26aufirst%3DM.%26aulast%3DGonz%25C3%25A1lez-Fern%25C3%25A1ndez%26aufirst%3D%25C3%2581.%26atitle%3DAntibody-Conjugated%2520Nanoparticles%2520for%2520Biomedical%2520Applications%26jtitle%3DJ.%2520Nanomater.%26date%3D2009%26volume%3D2009%26issue%3D37%26spage%3D1%26epage%3D24%26doi%3D10.1155%2F2009%2F439389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Voltan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Secchiero, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruozi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agostinis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caruso, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandelli, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zauli, G.</span></span> <span> </span><span class="NLM_article-title">Nanoparticles Engineered with Rituximab and Loaded with Nutlin-3 Show Promising Therapeutic Activity in B-Leukemic Xenografts</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">3871</span>– <span class="NLM_lpage">3880</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-0015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1158%2F1078-0432.CCR-13-0015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=23719263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFSrtbbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=3871-3880&author=R.+Voltanauthor=P.+Secchieroauthor=B.+Ruoziauthor=F.+Forniauthor=C.+Agostinisauthor=L.+Carusoauthor=M.+A.+Vandelliauthor=G.+Zauli&title=Nanoparticles+Engineered+with+Rituximab+and+Loaded+with+Nutlin-3+Show+Promising+Therapeutic+Activity+in+B-Leukemic+Xenografts&doi=10.1158%2F1078-0432.CCR-13-0015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Nanoparticles Engineered with Rituximab and Loaded with Nutlin-3 Show Promising Therapeutic Activity in B-Leukemic Xenografts</span></div><div class="casAuthors">Voltan, Rebecca; Secchiero, Paola; Ruozi, Barbara; Forni, Flavio; Agostinis, Chiara; Caruso, Lorenzo; Vandelli, Maria Angela; Zauli, Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3871-3880</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Because the nongenotoxic inhibitor of the p53/MDM2 interactions Nutlin-3 has shown promising in vitro therapeutic activity against a variety of p53wild-type cancer cells, in this study we evaluated an innovative strategy able to specifically target Nutlin-3 toward CD20+ malignant cells.  Exptl. Design: The cytotoxic effects of Nutlin-3 encapsulated into poly(lactide-co-glycolide) nanoparticles (NP-Nut) and into rituximab (anti-CD20 antibody)-engineered NP (NP-Rt-Nut) as well as of NPs engineered with rituximab alone (NP-Rt) were initially analyzed in vitro in JVM-2 B-leukemic cells, by assessing both the functional activation of the p53 pathway (by Nutlin-3) and/or the activation of the complement cascade (by rituximab).  Moreover, the potential therapeutic efficacy of NP-Nut, NP-Rt, and NP-Rt-Nut were comparatively assessed in vivo in CD20+ JVM-2 leukemic xenograft SCID mice.  Results: Functional in vitro assays showed that NP-Nut and NP-Rt-Nut exhibited a comparable ability to activate the p53 pathway in the p53wild-type JVM-2 leukemic cells.  On the other hand, NP-Rt and NP-Rt-Nut, but not NP nor NP-Nut, were able to promote activation of the complement cascade.  Of note, the in vivo intratumoral injection in JVM-2 B-leukemic/xenograft mice showed that NP-Rt-Nut displayed the maximal therapeutic activity promoting a survival rate significantly higher not only with respect to control animals, treated either with vehicle or with empty NP, but also with respect to animals treated with NP-Nut or NP-Rt.  Conclusions: Our data show for the first time the potential antileukemic activity of rituximab-engineered Nutlin-3-loaded NPs in xenograft SCID mice.  Clin Cancer Res; 19(14); 3871-80. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4AHlUfDjFV7Vg90H21EOLACvtfcHk0lhkOuMbSstXWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFSrtbbJ&md5=ae48d72062bf4b7d560ddf69dc42bace</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0015%26sid%3Dliteratum%253Aachs%26aulast%3DVoltan%26aufirst%3DR.%26aulast%3DSecchiero%26aufirst%3DP.%26aulast%3DRuozi%26aufirst%3DB.%26aulast%3DForni%26aufirst%3DF.%26aulast%3DAgostinis%26aufirst%3DC.%26aulast%3DCaruso%26aufirst%3DL.%26aulast%3DVandelli%26aufirst%3DM.%2BA.%26aulast%3DZauli%26aufirst%3DG.%26atitle%3DNanoparticles%2520Engineered%2520with%2520Rituximab%2520and%2520Loaded%2520with%2520Nutlin-3%2520Show%2520Promising%2520Therapeutic%2520Activity%2520in%2520B-Leukemic%2520Xenografts%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D3871%26epage%3D3880%26doi%3D10.1158%2F1078-0432.CCR-13-0015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span> <span> </span><span class="NLM_article-title">Intracellular pH-Responsive and Rituximab-Conjugated Mesoporous Silica Nanoparticles for Targeted Drug Delivery to Lymphoma B Cells</span>. <i>J. Exp. Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">14</span>, <span class="refDoi"> DOI: 10.1186/s13046-017-0492-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1186%2Fs13046-017-0492-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=28049532" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2017&pages=1-14&issue=24&author=S.+Zhouauthor=D.+Wuauthor=X.+Yinauthor=X.+Jinauthor=X.+Zhangauthor=S.+Zhengauthor=C.+Wangauthor=Y.+Liu&title=Intracellular+pH-Responsive+and+Rituximab-Conjugated+Mesoporous+Silica+Nanoparticles+for+Targeted+Drug+Delivery+to+Lymphoma+B+Cells&doi=10.1186%2Fs13046-017-0492-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1186%2Fs13046-017-0492-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13046-017-0492-6%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DYin%26aufirst%3DX.%26aulast%3DJin%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DY.%26atitle%3DIntracellular%2520pH-Responsive%2520and%2520Rituximab-Conjugated%2520Mesoporous%2520Silica%2520Nanoparticles%2520for%2520Targeted%2520Drug%2520Delivery%2520to%2520Lymphoma%2520B%2520Cells%26jtitle%3DJ.%2520Exp.%2520Clin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D36%26issue%3D24%26spage%3D1%26epage%3D14%26doi%3D10.1186%2Fs13046-017-0492-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranganathan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, S.-S.</span></span> <span> </span><span class="NLM_article-title">Multifunctional Poly (D, L-Lactide-Co-Glycolide)/Montmorillonite (PLGA/MMT) Nanoparticles Decorated by Trastuzumab for Targeted Chemotherapy of Breast Cancer</span>. <i>Biomaterials</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">475</span>– <span class="NLM_lpage">486</span>, <span class="refDoi"> DOI: 10.1016/j.biomaterials.2007.09.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.biomaterials.2007.09.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=17953985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A280%3ADC%252BD2snosVKjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2008&pages=475-486&author=B.+Sunauthor=B.+Ranganathanauthor=S.-S.+Feng&title=Multifunctional+Poly+%28D%2C+L-Lactide-Co-Glycolide%29%2FMontmorillonite+%28PLGA%2FMMT%29+Nanoparticles+Decorated+by+Trastuzumab+for+Targeted+Chemotherapy+of+Breast+Cancer&doi=10.1016%2Fj.biomaterials.2007.09.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Multifunctional poly(D,L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer</span></div><div class="casAuthors">Sun Bingfeng; Ranganathan Balu; Feng Si-Shen</div><div class="citationInfo"><span class="NLM_cas:title">Biomaterials</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">475-86</span>
        ISSN:<span class="NLM_cas:issn">0142-9612</span>.
    </div><div class="casAbstract">This paper continued our earlier work on the poly(D,L-lactide-co-glycolide)/montmorillonite nanoparticles (PLGA/MMT NPs), which were further decorated by human epidermal growth factor receptor-2 (HER2) antibody Trastuzumab for targeted breast cancer chemotherapy with paclitaxel as a model anticancer drug.  Such a NP system is multifunctional, which formulates anticancer drugs with no harmful adjuvant, reduces the side effects of the formulated anticancer drug, promotes synergistic therapeutic effects, and achieves targeted delivery of the therapy.  The paclitaxel-loaded PLGA/MMT NPs were prepared by a modified solvent extraction/evaporation technique, which were then decorated with Trastuzumab.  The effects of the surface decoration on particle size and size distribution, surface morphology, drug encapsulation efficiency, as well as the drug release kinetics, were investigated.  The NP formulation exhibited a biphasic drug release with a moderate initial burst followed by a sustained release profile.  The surface decoration speeded the drug release.  Surface chemistry analysis was conducted by X-ray photoelectron spectroscopy (XPS), which confirmed the presence of Trastuzumab on the NP surface.  Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis showed the stability of the antibody in the NP preparation process.  Internalization of the coumarin-6-loaded PLGA/MMT NPs with or without the antibody decoration by both of Caco-2 colon adeno carcinoma cells and SK-BR-3 breast cancer cells was visualized by confocal laser scanning microscopy and quantitatively analyzed, which shows that the antibody decoration achieved significantly higher cellular uptake of the NPs.  The results of in vitro cytotoxicity experiment on SK-BR-3 cells further proved the targeting effects of the antibody decoration.  Judged by IC50 after 24h culture, the therapeutic effects of the drug formulated in the NPs with surface decoration could be 12.74 times higher than that of the bare NPs and 13.11 times higher than Taxol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT9V8O6sKsTrNbHMBt0mMIXfW6udTcc2eZda7JoGZkU2bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2snosVKjtQ%253D%253D&md5=94686aed4f3cf8e05fee0feb49b3baab</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1016%2Fj.biomaterials.2007.09.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biomaterials.2007.09.038%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DB.%26aulast%3DRanganathan%26aufirst%3DB.%26aulast%3DFeng%26aufirst%3DS.-S.%26atitle%3DMultifunctional%2520Poly%2520%2528D%252C%2520L-Lactide-Co-Glycolide%2529%252FMontmorillonite%2520%2528PLGA%252FMMT%2529%2520Nanoparticles%2520Decorated%2520by%2520Trastuzumab%2520for%2520Targeted%2520Chemotherapy%2520of%2520Breast%2520Cancer%26jtitle%3DBiomaterials%26date%3D2008%26volume%3D29%26spage%3D475%26epage%3D486%26doi%3D10.1016%2Fj.biomaterials.2007.09.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ito, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuga, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikkawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horiuchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span> <span> </span><span class="NLM_article-title">Magnetite Nanoparticle-Loaded Anti-HER2 Immunoliposomes for Combination of Antibody Therapy with Hyperthermia</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>212</i></span>,  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">175</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2004.03.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.canlet.2004.03.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=15279897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlvFyqtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=212&publication_year=2004&pages=167-175&author=A.+Itoauthor=Y.+Kugaauthor=H.+Hondaauthor=H.+Kikkawaauthor=A.+Horiuchiauthor=Y.+Watanabeauthor=T.+Kobayashi&title=Magnetite+Nanoparticle-Loaded+Anti-HER2+Immunoliposomes+for+Combination+of+Antibody+Therapy+with+Hyperthermia&doi=10.1016%2Fj.canlet.2004.03.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Magnetite nanoparticle-loaded anti-HER2 immunoliposomes for combination of antibody therapy with hyperthermia</span></div><div class="casAuthors">Ito, Akira; Kuga, Yuko; Honda, Hiroyuki; Kikkawa, Hiroyuki; Horiuchi, Atsushi; Watanabe, Yuji; Kobayashi, Takeshi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">212</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">167-175</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Anti-HER2 antibody can induce antitumor responses, and can be used in delivering drugs to HER2-overexressing cancer.  Previously, we produced hyperthermia using magnetite nanoparticles that generate heat in an alternating magnetic field.  In the present study, we constructed anti-HER2 immunoliposomes contg. magnetite nanoparticles, which act as tumor-targeting vehicles, combining anti-HER2 antibody therapy with hyperthermia.  The magnetite nanoparticle-loaded anti-HER2 immunoliposomes exerted HER2-mediated antiproliferative effects on SKBr3 breast cancer cells in vitro.  Moreover, 60% of magnetite nanoparticles were incorporated into SKBr3, and the cells were then heated at 42.5° under an alternating magnetic field, resulting in strong cytotoxic effects.  These results suggest that this novel therapeutic tool is applicable to treatment of HER2-overexpressing cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnJ8DF3mOMf7Vg90H21EOLACvtfcHk0lglwsZMr8pfvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlvFyqtLk%253D&md5=caa7728b68f61abfaf4b1ef12b3f8c52</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2004.03.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2004.03.038%26sid%3Dliteratum%253Aachs%26aulast%3DIto%26aufirst%3DA.%26aulast%3DKuga%26aufirst%3DY.%26aulast%3DHonda%26aufirst%3DH.%26aulast%3DKikkawa%26aufirst%3DH.%26aulast%3DHoriuchi%26aufirst%3DA.%26aulast%3DWatanabe%26aufirst%3DY.%26aulast%3DKobayashi%26aufirst%3DT.%26atitle%3DMagnetite%2520Nanoparticle-Loaded%2520Anti-HER2%2520Immunoliposomes%2520for%2520Combination%2520of%2520Antibody%2520Therapy%2520with%2520Hyperthermia%26jtitle%3DCancer%2520Lett.%26date%3D2004%26volume%3D212%26spage%3D167%26epage%3D175%26doi%3D10.1016%2Fj.canlet.2004.03.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arya, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acharya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahoo, S. K.</span></span> <span> </span><span class="NLM_article-title">EnhancedAntiproliferative Activity of Herceptin (HER2)-Conjugated Gemcitabine-Loaded Chitosan Nanoparticle in Pancreatic Cancer Therapy</span>. <i>Nanomedicine</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">859</span>– <span class="NLM_lpage">870</span>, <span class="refDoi"> DOI: 10.1016/j.nano.2011.03.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.nano.2011.03.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=21550422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWmu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=859-870&author=G.+Aryaauthor=M.+Vandanaauthor=S.+Acharyaauthor=S.+K.+Sahoo&title=EnhancedAntiproliferative+Activity+of+Herceptin+%28HER2%29-Conjugated+Gemcitabine-Loaded+Chitosan+Nanoparticle+in+Pancreatic+Cancer+Therapy&doi=10.1016%2Fj.nano.2011.03.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced antiproliferative activity of Herceptin (HER2)-conjugated gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapy</span></div><div class="casAuthors">Arya, Geetanjali; Vandana, Mallaredy; Acharya, Sarbari; Sahoo, Sanjeeb K.</div><div class="citationInfo"><span class="NLM_cas:title">Nanomedicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">859-870</span>CODEN:
                <span class="NLM_cas:coden">NANOBF</span>;
        ISSN:<span class="NLM_cas:issn">1549-9634</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Currently, effective drug delivery in pancreatic cancer treatment is a major challenge.  Nanomedicine plays an essential role by delivering anticancer drugs in a targeted manner to the malignant tumor cells, leading to increased efficacy by reducing the toxicity of anticancer drugs to normal, sensitive sites.  This study investigated the prepn. and characterization of a targeted system represented by Herceptin-conjugated gemcitabine-loaded chitosan nanoparticles (HER2-Gem-CS-NPs) for pancreatic cancer therapy.  The targeted NPs displayed superior antiproliferative activity along with an enhanced S-phase arrest, leading to apoptosis in comparison with unconjugated gemcitabine-loaded nanoparticles and free gemcitabine due to higher cellular binding with eventual uptake and prolonged intracellular retention.  Thus, HER2-Gem-CS-NPs are able to provide an efficient and targeted delivery of gemcitabine for pancreatic cancer treatment.  From the Clin. Editor: This study investigated the prepn. and characterization of a targeted drug delivery system consisting of Herceptin-conjugated gemcitabine-loaded chitosan nanoparticles for pancreatic cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsHQiMBrj2krVg90H21EOLACvtfcHk0lglwsZMr8pfvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWmu78%253D&md5=63d515bd07ae04d8e75f3080d76cd8bb</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2Fj.nano.2011.03.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nano.2011.03.009%26sid%3Dliteratum%253Aachs%26aulast%3DArya%26aufirst%3DG.%26aulast%3DVandana%26aufirst%3DM.%26aulast%3DAcharya%26aufirst%3DS.%26aulast%3DSahoo%26aufirst%3DS.%2BK.%26atitle%3DEnhancedAntiproliferative%2520Activity%2520of%2520Herceptin%2520%2528HER2%2529-Conjugated%2520Gemcitabine-Loaded%2520Chitosan%2520Nanoparticle%2520in%2520Pancreatic%2520Cancer%2520Therapy%26jtitle%3DNanomedicine%26date%3D2011%26volume%3D7%26spage%3D859%26epage%3D870%26doi%3D10.1016%2Fj.nano.2011.03.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamann, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinman, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollander, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beyer, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holcomb, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallett, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsou, H.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upeslacis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shochat, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mountain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flowers, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernstein, I.</span></span> <span> </span><span class="NLM_article-title">Gemtuzumab Ozogamicin, a Potent and Selective Anti-CD33 Antibody- Calicheamicin Conjugate for Treatment of Acute Myeloid Leukemia</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">47</span>– <span class="NLM_lpage">58</span>, <span class="refDoi"> DOI: 10.1021/bc010021y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc010021y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD3MXptFanurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2002&pages=47-58&author=P.+R.+Hamannauthor=L.+M.+Hinmanauthor=I.+Hollanderauthor=C.+F.+Beyerauthor=D.+Lindhauthor=R.+Holcombauthor=W.+Hallettauthor=H.-R.+Tsouauthor=J.+Upeslacisauthor=D.+Shochatauthor=A.+Mountainauthor=D.+A.+Flowersauthor=I.+Bernstein&title=Gemtuzumab+Ozogamicin%2C+a+Potent+and+Selective+Anti-CD33+Antibody-+Calicheamicin+Conjugate+for+Treatment+of+Acute+Myeloid+Leukemia&doi=10.1021%2Fbc010021y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Gemtuzumab Ozogamicin, A Potent and Selective Anti-CD33 Antibody-Calicheamicin Conjugate for Treatment of Acute Myeloid Leukemia</span></div><div class="casAuthors">Hamann, Philip R.; Hinman, Lois M.; Hollander, Irwin; Beyer, Carl F.; Lindh, Delores; Holcomb, Ryan; Hallett, William; Tsou, Hwei-Ru; Upeslacis, Janis; Shochat, Dan; Mountain, Andrew; Flowers, David A.; Bernstein, Irwin</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">47-58</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">CD33 is expressed by acute myeloid leukemia (AML) cells in >80% of patients but not by normal hematopoietic stem cells, suggesting that elimination of CD33+ cells may be therapeutically beneficial.  A conjugate of a calicheamicin hydrazide deriv. attached via hydrazone formation to the oxidized carbohydrates of the anti-CD33 murine antibody P67.6 had been chosen for use in AML prior to humanization of this antibody.  However, the CDR-grafted humanized P67.6 could not be used to make the carbohydrate conjugate because of the unexpected sensitivity of this antibody to periodate oxidn.  Exploration of a series of bifunctional linkers resulted in a new class of calicheamicin conjugates, termed the hybrid conjugates, that allows for the attachment of the calicheamicin to lysines but incorporates the site of hydrolytic release, a hydrazone, previously shown to be required for activity.  The optimized conjugate chosen for clin. trials, gemtuzumab ozogamicin ("gem-ozo", Mylotarg, formerly designated CMA-676), was significantly more potent and selective than the carbohydrate conjugate it replaced.  It was selectively cytotoxic to HL-60 leukemia cells in tissue culture with an IC50 in the low to sub-pg cal/mL range (cal = calicheamicin equiv.).  Doses of gem-ozo as low as 50 μg cal/kg given three times to mice bearing HL-60 xenografts routinely resulted in long-term, tumor-free survivors, while a nonbinding control conjugate was relatively inactive.  Gem-ozo at a concn. of 2 to 10 ng cal/mL selectively inhibited leukemia colony formation by marrow cells from a significant proportion of AML patients.  Gem-ozo has also shown significant activity against AML in Phase II trials and is the first antibody-targeted chemotherapeutic agent approved by the FDA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUzPmqKMIOx7Vg90H21EOLACvtfcHk0lisDbjUbsNgcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXptFanurg%253D&md5=56f273f4975fa6ebfa81e28f23111e8a</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1021%2Fbc010021y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc010021y%26sid%3Dliteratum%253Aachs%26aulast%3DHamann%26aufirst%3DP.%2BR.%26aulast%3DHinman%26aufirst%3DL.%2BM.%26aulast%3DHollander%26aufirst%3DI.%26aulast%3DBeyer%26aufirst%3DC.%2BF.%26aulast%3DLindh%26aufirst%3DD.%26aulast%3DHolcomb%26aufirst%3DR.%26aulast%3DHallett%26aufirst%3DW.%26aulast%3DTsou%26aufirst%3DH.-R.%26aulast%3DUpeslacis%26aufirst%3DJ.%26aulast%3DShochat%26aufirst%3DD.%26aulast%3DMountain%26aufirst%3DA.%26aulast%3DFlowers%26aufirst%3DD.%2BA.%26aulast%3DBernstein%26aufirst%3DI.%26atitle%3DGemtuzumab%2520Ozogamicin%252C%2520a%2520Potent%2520and%2520Selective%2520Anti-CD33%2520Antibody-%2520Calicheamicin%2520Conjugate%2520for%2520Treatment%2520of%2520Acute%2520Myeloid%2520Leukemia%26jtitle%3DBioconjugate%2520Chem.%26date%3D2002%26volume%3D13%26spage%3D47%26epage%3D58%26doi%3D10.1021%2Fbc010021y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yung, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, Y.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muthusamy, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcucci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. J.</span></span> <span> </span><span class="NLM_article-title">CD33-Targeted Lipid Nanoparticles (Acd33lns) for Therapeutic Delivery of GTI-2040 to Acute Myelogenous Leukemia</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2010</span>– <span class="NLM_lpage">2018</span>, <span class="refDoi"> DOI: 10.1021/mp5008212</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp5008212" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsVSkt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=2010-2018&author=H.+Liauthor=S.+Xuauthor=J.+Quanauthor=B.+C.+Yungauthor=J.+Pangauthor=C.+Zhouauthor=Y.-A.+Choauthor=M.+Zhangauthor=S.+Liuauthor=N.+Muthusamyauthor=K.+K.+Chanauthor=J.+C.+Byrdauthor=L.+J.+Leeauthor=G.+Marcucciauthor=R.+J.+Lee&title=CD33-Targeted+Lipid+Nanoparticles+%28Acd33lns%29+for+Therapeutic+Delivery+of+GTI-2040+to+Acute+Myelogenous+Leukemia&doi=10.1021%2Fmp5008212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">CD33-Targeted Lipid Nanoparticles (aCD33LNs) for Therapeutic Delivery of GTI-2040 to Acute Myelogenous Leukemia</span></div><div class="casAuthors">Li, Hong; Xu, Songlin; Quan, Jishan; Yung, Bryant C.; Pang, Jiuxia; Zhou, Chenguang; Cho, Young-Ah; Zhang, Mengzi; Liu, Shujun; Muthusamy, Natarajan; Chan, Kenneth K.; Byrd, John C.; Lee, L. James; Marcucci, Guido; Lee, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2010-2018</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">CD33-targeted lipid nanoparticles (aCD33LNs) were synthesized for delivery of GTI-2040, an antisense oligonucleotide (ASO) against the R2 subunit of ribonucleotide reductase, to acute myelogenous leukemia (AML).  These LNs incorporated a deoxycholate-polyethylenimine (DOC-PEI) conjugate, which has shown significant activity to facilitate oligonucleotide delivery.  Anti-CD33 scFv (aCD33) was added as a targeting ligand.  The delivery efficiency of this system was investigated both in vitro and in vivo.  When cells were treated with aCD33LN/GTI-2040, significant uptake was obsd. in CD33 pos. Kasumi-1 cells. aCD33LNs loaded with GTI-2040 induced significant down-regulation of R2 mRNA and protein levels in AML cells.  Moreover, aCD33LN/GTI-2040 showed a 15-fold redn. in the IC50 of antileukemic drug Ara-C in Kasumi-1 cells.  In Kasumi-1 xenograft model, aCD33LN/GTI-2040 showed significant R2 downregulation compared to LN/GTI-2040.  Furthermore, aCD33LN/GTI-2040 coadministered with Ara-C was shown to be highly effective in tumor growth inhibition and to greatly increase survival time of mice bearing Kasumi-1 xenograft tumors.  The conjugate DOC-PEI has shown an ability to include calcein release from lipid nanoparticles, suggesting a potential mechanism contributing to efficient endosome release by DOC-PEI2K.  These results indicate that aCD33LNs are a highly effective vehicle for the therapeutic delivery of antisense agents to AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKbLCR7_N-eLVg90H21EOLACvtfcHk0lisDbjUbsNgcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsVSkt7g%253D&md5=7646ea983c5471a86d7da6cf255c4ef7</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1021%2Fmp5008212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp5008212%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DQuan%26aufirst%3DJ.%26aulast%3DYung%26aufirst%3DB.%2BC.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DCho%26aufirst%3DY.-A.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DMuthusamy%26aufirst%3DN.%26aulast%3DChan%26aufirst%3DK.%2BK.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DLee%26aufirst%3DL.%2BJ.%26aulast%3DMarcucci%26aufirst%3DG.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26atitle%3DCD33-Targeted%2520Lipid%2520Nanoparticles%2520%2528Acd33lns%2529%2520for%2520Therapeutic%2520Delivery%2520of%2520GTI-2040%2520to%2520Acute%2520Myelogenous%2520Leukemia%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2015%26volume%3D12%26spage%3D2010%26epage%3D2018%26doi%3D10.1021%2Fmp5008212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trail, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofstead, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casazza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellstrom, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellstrom, K.</span></span> <span> </span><span class="NLM_article-title">Cure of Xenografted Human Carcinomas by BR96-Doxorubicin Immunoconjugates</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>261</i></span>,  <span class="NLM_fpage">212</span>– <span class="NLM_lpage">212</span>, <span class="refDoi"> DOI: 10.1126/science.8327892</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1126%2Fscience.8327892" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=8327892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADyaK3sXltlWjtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=261&publication_year=1993&pages=212-212&author=P.+Trailauthor=D.+Willnerauthor=S.+Laschauthor=A.+Hendersonauthor=S.+Hofsteadauthor=A.+Casazzaauthor=R.+Firestoneauthor=I.+Hellstromauthor=K.+Hellstrom&title=Cure+of+Xenografted+Human+Carcinomas+by+BR96-Doxorubicin+Immunoconjugates&doi=10.1126%2Fscience.8327892"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates</span></div><div class="casAuthors">Trail, P. A.; Willner, D.; Lasch, S. J.; Henderson, A. J.; Hofstead, S.; Casazza, A. M.; Firestone, R. A.; Hellstrom, I.; Hellstrom, K. E.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">261</span>
        (<span class="NLM_cas:issue">5118</span>),
    <span class="NLM_cas:pages">212-15</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">Immunoconjugates (BR96-DOX) were prepd. between chimeric monoclonal antibody BR96 and the anticancer drug doxorubicin.  The monoclonal antibody binds an antigen related to Lewis Y that is abundantly expressed at the surface of cells from many human carcinomas; it has a high degree of tumor selectivity and is internalized after binding.  BR96-DOX induced complete regressions and cures of xenografted human lung, breast, and colon carcinomas growing s.c. in athymic mice and cured 70 percent of mice bearing extensive metastasis of a human lung carcinoma.  Also, BR96-DOX cured 94 percent of athymic rats with s.c. human lung carcinoma, even though the rats, like humans and in contrast to mice, expressed the BR96 target antigen in normal tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkJ15RWFve9rVg90H21EOLACvtfcHk0lisDbjUbsNgcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXltlWjtLk%253D&md5=3a366cdac960b3324fd1100c1dc97653</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1126%2Fscience.8327892&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.8327892%26sid%3Dliteratum%253Aachs%26aulast%3DTrail%26aufirst%3DP.%26aulast%3DWillner%26aufirst%3DD.%26aulast%3DLasch%26aufirst%3DS.%26aulast%3DHenderson%26aufirst%3DA.%26aulast%3DHofstead%26aufirst%3DS.%26aulast%3DCasazza%26aufirst%3DA.%26aulast%3DFirestone%26aufirst%3DR.%26aulast%3DHellstrom%26aufirst%3DI.%26aulast%3DHellstrom%26aufirst%3DK.%26atitle%3DCure%2520of%2520Xenografted%2520Human%2520Carcinomas%2520by%2520BR96-Doxorubicin%2520Immunoconjugates%26jtitle%3DScience%26date%3D1993%26volume%3D261%26spage%3D212%26epage%3D212%26doi%3D10.1126%2Fscience.8327892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofstead, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braslawsky, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenfield, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trail, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casazza, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellstrom, I</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellstrom, K. E.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Antitumor Activity of the Immunoconjugate Br96-Dox</span>. <i>J. Controlled Release</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">251</span>– <span class="NLM_lpage">259</span>, <span class="refDoi"> DOI: 10.1016/0168-3659(95)00160-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2F0168-3659%2895%2900160-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADyaK28Xjt1ykur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=251-259&author=R.+Firestoneauthor=D.+Willnerauthor=S.+Hofsteadauthor=H.+Kingauthor=T.+Kanekoauthor=G.+Braslawskyauthor=R.+Greenfieldauthor=P.+Trailauthor=S.+Laschauthor=A.+Hendersonauthor=A.+M.+Casazzaauthor=I+Hellstromauthor=K.+E.+Hellstrom&title=Synthesis+and+Antitumor+Activity+of+the+Immunoconjugate+Br96-Dox&doi=10.1016%2F0168-3659%2895%2900160-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antitumor activity of the immunoconjugate BR96-Dox</span></div><div class="casAuthors">Firestone, R. A.; Willner, D.; Hofstead, S. J.; King, H. D.; Kaneko, T.; Braslawsky, G. R.; Greenfield, R. S.; Trail, P. A.; Lasch, S. J.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">2,3</span>),
    <span class="NLM_cas:pages">251-259</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">BR96-Dox is an immunoconjugate (IC) in which doxorubicin (8 equiv) is linked via an acid-labile hydrazone to the chimeric MAb BR96.  It binds to a modified Ley Ag on tumor cells, which then internalize it via endocytosis into lysosomes.  There, the acidic milieu hydrolyzes the hydrazone link, releasing free Dox.  In vivo, it is more active and less toxic than untargeted Dox, producing complete remissions and many cures of s.c. human breast, lung and colon tumors, as well as disseminated lung tumors.  In vivo, only BR96+ and not BR96- tumors respond, and ICs with nonbinding Abs are inactive.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYEwDzjerWBrVg90H21EOLACvtfcHk0lgoEZGrEudz-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xjt1ykur8%253D&md5=c43ccc0822602ace371c3bae490b4090</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1016%2F0168-3659%2895%2900160-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0168-3659%252895%252900160-3%26sid%3Dliteratum%253Aachs%26aulast%3DFirestone%26aufirst%3DR.%26aulast%3DWillner%26aufirst%3DD.%26aulast%3DHofstead%26aufirst%3DS.%26aulast%3DKing%26aufirst%3DH.%26aulast%3DKaneko%26aufirst%3DT.%26aulast%3DBraslawsky%26aufirst%3DG.%26aulast%3DGreenfield%26aufirst%3DR.%26aulast%3DTrail%26aufirst%3DP.%26aulast%3DLasch%26aufirst%3DS.%26aulast%3DHenderson%26aufirst%3DA.%26aulast%3DCasazza%26aufirst%3DA.%2BM.%26aulast%3DHellstrom%26aufirst%3DI%26aulast%3DHellstrom%26aufirst%3DK.%2BE.%26atitle%3DSynthesis%2520and%2520Antitumor%2520Activity%2520of%2520the%2520Immunoconjugate%2520Br96-Dox%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D1996%26volume%3D39%26spage%3D251%26epage%3D259%26doi%3D10.1016%2F0168-3659%2895%2900160-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saleh, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugarman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostroff, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Healey, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeBherz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brewer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onetto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LoBuglio, A. F.</span></span> <span> </span><span class="NLM_article-title">Phase I Trial of the Anti–Lewis Y Drug Immunoconjugate Br96-Doxorubicin in Patients with Lewis Y–Expressing Epithelial Tumors</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2282</span>– <span class="NLM_lpage">2292</span>, <span class="refDoi"> DOI: 10.1200/JCO.2000.18.11.2282</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1200%2FJCO.2000.18.11.2282" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10829049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD3cXktlagsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2000&pages=2282-2292&author=M.+N.+Salehauthor=S.+Sugarmanauthor=J.+Murrayauthor=J.+B.+Ostroffauthor=D.+Healeyauthor=D.+Jonesauthor=C.+R.+Danielauthor=D.+LeBherzauthor=H.+Brewerauthor=N.+Onettoauthor=A.+F.+LoBuglio&title=Phase+I+Trial+of+the+Anti%E2%80%93Lewis+Y+Drug+Immunoconjugate+Br96-Doxorubicin+in+Patients+with+Lewis+Y%E2%80%93Expressing+Epithelial+Tumors&doi=10.1200%2FJCO.2000.18.11.2282"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with Lewis Y-expressing epithelial tumors</span></div><div class="casAuthors">Saleh, Mansoor N.; Sugarman, Steve; Murray, James; Ostroff, Joy B.; Healey, Diane; Jones, Dennie; Daniel, Carol R.; LeBherz, Donna; Brewer, Hannah; Onetto, Nicole; LoBuglio, Albert F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2282-2292</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">We conducted a phase I clin. trial of BR96-Doxorubicin (BR96-Dox), a chimeric anti-Lewis Y (LeY) monoclonal antibody conjugated to doxorubicin, in patients whose tumors expressed the LeY antigen.  The study aimed to det. the toxicity, max.-tolerated dose, pharmacokinetics, and immunogenicity of BR96-Dox.  This was a phase I dose escalation study.  BR96-Dox was initially administered alone as a 2-h infusion every 3 wk.  The occurrence of gastrointestinal (GI) toxicity necessitated the administration of BR96-Dox as a continuous infusion over 24 h and use of antiemetics and antigastritis premedication.  Patients experiencing severe GI toxicity underwent GI endoscopy.  All patients underwent restaging after two cycles.  A total of 66 patients predominantly with metastatic colon and breast cancer were enrolled onto the study.  The most common side effects were GI toxicity, fever, and elevation of pancreatic lipase.  At higher doses, BR96-Dox was assocd. with nausea, vomiting, and endoscopically documented exudative gastritis of the upper GI tract, which was dose-limiting at a max. dose of 875 mg/m2 (doxorubicin equiv., 25 mg/m2) administered every 3 wk.  Toxicity was reversible and generally of short duration.  Premedication with the antiemetic Kytril (granisetron hydrochloride; SmithKline Beecham, Philadelphia, PA), the antacid omeprazole, and dexamethasone was most effective in ameliorating GI toxicity.  A dose of 700 mg/m2 BR96-Dox (doxorubicin equiv., 19 mg/m2) every 3 wk was detd. to be the optimal phase II dose when administered with antiemetic and antigastritis prophylaxis.  BR96-Dox deposition on tumor tissue was documented immunohistochem. and by confocal microscopy.  At the 550-mg/m2 dose, the half-life (mean ± SD) of BR96 and doxorubicin was 300 ± 95 h and 43 ± 4 h, resp.  BR96-Dox elicited a weak immune response in 37% of patients.  Objective clin. responses were seen in two patients.  BR96-Dox provides a unique strategy to deliver doxorubicin to LeY-expressing tumor and was well tolerated at doses of 700 mg/m2 every 3 wk.  BR96-Dox was not assocd. with the typical side-effect profile of native doxorubicin and can potentially deliver high doses of doxorubicin to antigen-expressing tumors.  A phase II study in doxorubicin-sensitive tumors is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3mPMC7pov2LVg90H21EOLACvtfcHk0lgoEZGrEudz-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXktlagsbs%253D&md5=eb75070cfb7fb18828e22732f712f7b7</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1200%2FJCO.2000.18.11.2282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2000.18.11.2282%26sid%3Dliteratum%253Aachs%26aulast%3DSaleh%26aufirst%3DM.%2BN.%26aulast%3DSugarman%26aufirst%3DS.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DOstroff%26aufirst%3DJ.%2BB.%26aulast%3DHealey%26aufirst%3DD.%26aulast%3DJones%26aufirst%3DD.%26aulast%3DDaniel%26aufirst%3DC.%2BR.%26aulast%3DLeBherz%26aufirst%3DD.%26aulast%3DBrewer%26aufirst%3DH.%26aulast%3DOnetto%26aufirst%3DN.%26aulast%3DLoBuglio%26aufirst%3DA.%2BF.%26atitle%3DPhase%2520I%2520Trial%2520of%2520the%2520Anti%25E2%2580%2593Lewis%2520Y%2520Drug%2520Immunoconjugate%2520Br96-Doxorubicin%2520in%2520Patients%2520with%2520Lewis%2520Y%25E2%2580%2593Expressing%2520Epithelial%2520Tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2000%26volume%3D18%26spage%3D2282%26epage%3D2292%26doi%3D10.1200%2FJCO.2000.18.11.2282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schlesinger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendas, G.</span></span> <span> </span><span class="NLM_article-title">Vascular Cell Adhesion Molecule-1 (Vcam-1)—An Increasing Insight into its Role in Tumorigenicity and Metastasis</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">2504</span>– <span class="NLM_lpage">2514</span>, <span class="refDoi"> DOI: 10.1002/ijc.28927</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1002%2Fijc.28927" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=24771582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntlyit7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2015&pages=2504-2514&author=M.+Schlesingerauthor=G.+Bendas&title=Vascular+Cell+Adhesion+Molecule-1+%28Vcam-1%29%E2%80%94An+Increasing+Insight+into+its+Role+in+Tumorigenicity+and+Metastasis&doi=10.1002%2Fijc.28927"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular cell adhesion molecule-1 (VCAM-1)-An increasing insight into its role in tumorigenicity and metastasis</span></div><div class="casAuthors">Schlesinger, Martin; Bendas, Gerd</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2504-2514</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Vascular cell adhesion mol.-1 (VCAM-1) first attracted attention more than two decades ago as endothelial adhesion receptor with key function for leukocyte recruitment in term of cellular immune response.  The early finding of VCAM-1 binding to melanoma cells, and thus a suggested mechanistic contribution to metastatic spread, was the first and for a long time the only link of VCAM-1 to cancer sciences.  In the last few years, hallmarked by a growing insight into the mol. understanding of tumorigenicity and metastasis, an impressive variety of VCAM-1 functionalities in cancer have been elucidated.  The present review aims to provide a current overview of VCAM-1 relevance for tumor growth, metastasis, angiogenesis, and related processes.  By illustrating the intriguing role of VCAM-1 in cancer disease, VCAM-1 is suggested as a new and up to now underestimated target in cancer treatment and in clin. diagnosis of malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwO6-JE65ryrVg90H21EOLACvtfcHk0lgoEZGrEudz-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntlyit7w%253D&md5=cbf415ecbccb83b4f88885ef898bd11a</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1002%2Fijc.28927&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.28927%26sid%3Dliteratum%253Aachs%26aulast%3DSchlesinger%26aufirst%3DM.%26aulast%3DBendas%26aufirst%3DG.%26atitle%3DVascular%2520Cell%2520Adhesion%2520Molecule-1%2520%2528Vcam-1%2529%25E2%2580%2594An%2520Increasing%2520Insight%2520into%2520its%2520Role%2520in%2520Tumorigenicity%2520and%2520Metastasis%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2015%26volume%3D136%26spage%3D2504%26epage%3D2514%26doi%3D10.1002%2Fijc.28927" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gosk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moos, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottstein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendas, G.</span></span> <span> </span><span class="NLM_article-title">VCAM-1 Directed Immunoliposomes Selectively Target Tumor Vasculature In-Vivo</span>. <i>Biochim. Biophys. Acta, Biomembr.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>1778</i></span>,  <span class="NLM_fpage">854</span>– <span class="NLM_lpage">863</span>, <span class="refDoi"> DOI: 10.1016/j.bbamem.2007.12.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.bbamem.2007.12.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=18211818" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD1cXktVGrsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1778&publication_year=2008&pages=854-863&author=S.+Goskauthor=T.+Moosauthor=C.+Gottsteinauthor=G.+Bendas&title=VCAM-1+Directed+Immunoliposomes+Selectively+Target+Tumor+Vasculature+In-Vivo&doi=10.1016%2Fj.bbamem.2007.12.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">VCAM-1 directed immunoliposomes selectively target tumor vasculature in vivo</span></div><div class="casAuthors">Gosk, Sara; Moos, Torben; Gottstein, Claudia; Bendas, Gerd</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Biomembranes</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">1778</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">854-863</span>CODEN:
                <span class="NLM_cas:coden">BBBMBS</span>;
        ISSN:<span class="NLM_cas:issn">0005-2736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Targeting the tumor vasculature and selectively modifying endothelial functions is an attractive anti-tumor strategy.  We prepd. polyethyleneglycol modified immunoliposomes (IL) directed against vascular cell adhesion mol. 1 (VCAM-1), a surface receptor over-expressed on tumor vessels, and investigated the liposomal targetability in vitro and in vivo.  In vitro, anti-VCAM-1 liposomes displayed specific binding to activated endothelial cells under static conditions, as well as under simulated blood flow conditions.  The in vivo targeting of IL was analyzed in mice bearing human Colo 677 tumor xenografts 30 min and 24 h post i.v. injection.  Whereas biodistribution studies using [3H]-labeled liposomes displayed only marginal higher tumor accumulation of VCAM-1 targeted vs. unspecific ILs, fluorescence microscopy evaluation revealed that their localizations within tumors differed strongly.  VCAM-1 targeted ILs accumulated in tumor vessels with increasing intensities from 30 min to 24 h, while control ILs accumulated in the tumor tissue by passive diffusion.  ILs that accumulated in non-affected organs, mainly liver and spleen, primarily co-localized with macrophages.  This is the first morphol. evidence for selective in vivo targeting of tumor vessels using ILs.  VCAM-directed ILs are candidate drug delivery systems for therapeutic anti-cancer approaches designed to alter endothelial function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJcdK6ha6dnLVg90H21EOLACvtfcHk0ljAK2bV346PCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXktVGrsbg%253D&md5=e275299e262e93a75e0b7d59bae01a98</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamem.2007.12.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamem.2007.12.021%26sid%3Dliteratum%253Aachs%26aulast%3DGosk%26aufirst%3DS.%26aulast%3DMoos%26aufirst%3DT.%26aulast%3DGottstein%26aufirst%3DC.%26aulast%3DBendas%26aufirst%3DG.%26atitle%3DVCAM-1%2520Directed%2520Immunoliposomes%2520Selectively%2520Target%2520Tumor%2520Vasculature%2520In-Vivo%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Biomembr.%26date%3D2008%26volume%3D1778%26spage%3D854%26epage%3D863%26doi%3D10.1016%2Fj.bbamem.2007.12.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hagan, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medik, Y. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A. Z.</span></span> <span> </span><span class="NLM_article-title">Nanotechnology Approaches to Improving Cancer Immunotherapy</span>. <i>Adv. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">35</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1016/bs.acr.2018.05.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fbs.acr.2018.05.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=29941106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252Fhs1Ghuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2018&pages=35-56&author=C.+T.+Haganauthor=Y.+B.+Medikauthor=A.+Z.+Wang&title=Nanotechnology+Approaches+to+Improving+Cancer+Immunotherapy&doi=10.1016%2Fbs.acr.2018.05.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Nanotechnology Approaches to Improving Cancer Immunotherapy</span></div><div class="casAuthors">Hagan C Tilden 4th; Medik Yusra B; Wang Andrew Z</div><div class="citationInfo"><span class="NLM_cas:title">Advances in cancer research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">35-56</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cancer immunotherapy is a powerful, growing treatment approach to cancer that can be combined with chemotherapy, radiotherapy, and oncosurgery.  Modulating the immune system to enhance anticancer response by several strategies has yielded improved cancer survival.  Despite this progress, the success rate for immunotherapy has been below expectations due to unpredictable efficacy and off-target side effects from systemic dosing.  Nanotechnology offers numerous different materials and targeting properties to overcome many of these challenges in immunotherapy.  In this chapter, we review current immunotherapy and its challenges as well as the latest nanotechnology applications in cancer immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRh-u_uJ3fLMAMthz5_Rx5rfW6udTcc2eavEr-nRGjJrrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252Fhs1Ghuw%253D%253D&md5=f7cb5bd4a4c456c8b69a719b22168c07</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1016%2Fbs.acr.2018.05.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.acr.2018.05.003%26sid%3Dliteratum%253Aachs%26aulast%3DHagan%26aufirst%3DC.%2BT.%26aulast%3DMedik%26aufirst%3DY.%2BB.%26aulast%3DWang%26aufirst%3DA.%2BZ.%26atitle%3DNanotechnology%2520Approaches%2520to%2520Improving%2520Cancer%2520Immunotherapy%26jtitle%3DAdv.%2520Cancer%2520Res.%26date%3D2018%26volume%3D139%26spage%3D35%26epage%3D56%26doi%3D10.1016%2Fbs.acr.2018.05.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minn, A.</span></span> <span> </span><span class="NLM_article-title">Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">417</span>– <span class="NLM_lpage">433</span>, <span class="refDoi"> DOI: 10.1016/j.immuni.2018.03.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.immuni.2018.03.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=29562193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlt1Wis7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2018&pages=417-433&author=S.+A.+Patelauthor=A.+Minn&title=Combination+Cancer+Therapy+with+Immune+Checkpoint+Blockade%3A+Mechanisms+and+Strategies&doi=10.1016%2Fj.immuni.2018.03.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies</span></div><div class="casAuthors">Patel, Shetal A.; Minn, Andy J.</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">417-433</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The success of immune checkpoint blockade in patients with a wide variety of malignancies has changed the treatment paradigm in oncol.  However, combination therapies with immune checkpoint blockade will be needed to overcome resistance and broaden the clin. utility of immunotherapy.  Here we discuss a framework for rationally designing combination therapy strategies based on enhancing major discriminatory functions of the immune system that are corrupted by cancer-namely, antigenicity, adjuvanticity, and homeostatic feedback inhibition.  We review recent advances on how conventional genotoxic cancer therapies, molecularly targeted therapies, epigenetic agents, and immune checkpoint inhibitors can restore these discriminatory functions.  Potential barriers that can impede response despite combination therapy are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5pMPa8TU5SLVg90H21EOLACvtfcHk0ljAK2bV346PCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlt1Wis7c%253D&md5=2301162790d8dbf631e96d3f2a2465d4</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2018.03.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2018.03.007%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DS.%2BA.%26aulast%3DMinn%26aufirst%3DA.%26atitle%3DCombination%2520Cancer%2520Therapy%2520with%2520Immune%2520Checkpoint%2520Blockade%253A%2520Mechanisms%2520and%2520Strategies%26jtitle%3DImmunity%26date%3D2018%26volume%3D48%26spage%3D417%26epage%3D433%26doi%3D10.1016%2Fj.immuni.2018.03.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bangayan, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pariva, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vashisht, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corey, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graeber, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wohlschlegel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, O. N.</span></span> <span> </span><span class="NLM_article-title">Systemic Surfaceome Profiling Identifies Target Antigens for Immune-Based Therapy in Subtypes of Advanced Prostate Cancer</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">E4473</span>– <span class="NLM_lpage">E4482</span>, <span class="refDoi"> DOI: 10.1073/pnas.1802354115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1073%2Fpnas.1802354115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=29686080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVGhtL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2018&pages=E4473-E4482&author=J.+K.+Leeauthor=N.+J.+Bangayanauthor=T.+Chaiauthor=B.+A.+Smithauthor=T.+E.+Parivaauthor=S.+Yunauthor=A.+Vashishtauthor=Q.+Zhangauthor=J.+W.+Parkauthor=E.+Coreyauthor=J.+Huangauthor=T.+G.+Graeberauthor=J.+Wohlschlegelauthor=O.+N.+Witte&title=Systemic+Surfaceome+Profiling+Identifies+Target+Antigens+for+Immune-Based+Therapy+in+Subtypes+of+Advanced+Prostate+Cancer&doi=10.1073%2Fpnas.1802354115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer</span></div><div class="casAuthors">Lee, John K.; Bangayan, Nathanael J.; Chai, Timothy; Smith, Bryan A.; Pariva, Tiffany E.; Yun, Sangwon; Vashisht, Ajay; Zhang, Qingfu; Park, Jung Wook; Corey, Eva; Huang, Jiaoti; Graeber, Thomas G.; Wohlschlegel, James; Witte, Owen N.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">E4473-E4482</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Prostate cancer is a heterogeneous disease composed of divergent mol. and histol. subtypes, including prostate adenocarcinoma (PrAd) and neuroendocrine prostate cancer (NEPC).  While PrAd is the major histol. in prostate cancer, NEPC can evolve from PrAd as a mechanism of treatment resistance that involves a transition from an epithelial to a neurosecretory cancer phenotype.  Cell surface markers are often assocd. with specific cell lineages and differentiation states in normal development and cancer.  Here, we show that PrAd and NEPC can be broadly discriminated by cell-surface profiles based on the anal. of prostate cancer gene expression datasets.  To overcome a dependence on predictions of human cell-surface genes and an assumed correlation between mRNA levels and protein expression, we integrated transcriptomic and cell-surface proteomic data generated from a panel of prostate cancer cell lines to nominate cell-surface markers assocd. with these cancer subtypes.  FXYD3 and CEACAM5 were validated as cell-surface antigens enriched in PrAd and NEPC, resp.  Given the lack of effective treatments for NEPC, CEACAM5 appeared to be a promising target for cell-based immunotherapy.  As a proof of concept, engineered chimeric antigen receptor T cells targeting CEACAM5 induced antigen-specific cytotoxicity in NEPC cell lines.  Our findings demonstrate that the surfaceomes of PrAd and NEPC reflect unique cancer differentiation states and broadly represent vulnerabilities amenable to therapeutic targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonth2rGS7qbbVg90H21EOLACvtfcHk0lig13Jas1aejw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVGhtL7I&md5=3066ed1ab1ab67c0948ea5d0c46fe761</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1802354115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1802354115%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BK.%26aulast%3DBangayan%26aufirst%3DN.%2BJ.%26aulast%3DChai%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DB.%2BA.%26aulast%3DPariva%26aufirst%3DT.%2BE.%26aulast%3DYun%26aufirst%3DS.%26aulast%3DVashisht%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DPark%26aufirst%3DJ.%2BW.%26aulast%3DCorey%26aufirst%3DE.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DGraeber%26aufirst%3DT.%2BG.%26aulast%3DWohlschlegel%26aufirst%3DJ.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26atitle%3DSystemic%2520Surfaceome%2520Profiling%2520Identifies%2520Target%2520Antigens%2520for%2520Immune-Based%2520Therapy%2520in%2520Subtypes%2520of%2520Advanced%2520Prostate%2520Cancer%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2018%26volume%3D115%26spage%3DE4473%26epage%3DE4482%26doi%3D10.1073%2Fpnas.1802354115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weiden, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figdor, C. G.</span></span> <span> </span><span class="NLM_article-title">Synthetic Immune Niches for Cancer Immunotherapy</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">212</span>– <span class="NLM_lpage">219</span>, <span class="refDoi"> DOI: 10.1038/nri.2017.89</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1038%2Fnri.2017.89" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=28853444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtl2ru7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=212-219&author=J.+Weidenauthor=J.+Telauthor=C.+G.+Figdor&title=Synthetic+Immune+Niches+for+Cancer+Immunotherapy&doi=10.1038%2Fnri.2017.89"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic immune niches for cancer immunotherapy</span></div><div class="casAuthors">Weiden, Jorieke; Tel, Jurjen; Figdor, Carl G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">212-219</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Cancer immunotherapy can successfully promote long-term anticancer immune responses, although there is still only a limited no. of patients who benefit from such treatment, and it can sometimes have severe treatment-assocd. adverse events.  Compared with systemic immunomodulation, local immunomodulation may enable more effective treatment at lower doses and, at the same time, prevent systemic toxicity.  Local delivery of engineered three-dimensional scaffolds may fulfil this role by acting as synthetic immune niches that boost anticancer immunity.  In this Opinion article, we highlight the potential of scaffold-based adoptive cell transfer and scaffold-based cancer vaccines that, although applied locally, can promote systemic antitumor immunity.  Furthermore, we discuss how scaffold-based cancer immunotherapy may contribute to the development of the next generation of cancer treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVYKyP4D8ttbVg90H21EOLACvtfcHk0lig13Jas1aejw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtl2ru7fP&md5=6ebda3d13095e6125c682308e5bdd566</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1038%2Fnri.2017.89&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri.2017.89%26sid%3Dliteratum%253Aachs%26aulast%3DWeiden%26aufirst%3DJ.%26aulast%3DTel%26aufirst%3DJ.%26aulast%3DFigdor%26aufirst%3DC.%2BG.%26atitle%3DSynthetic%2520Immune%2520Niches%2520for%2520Cancer%2520Immunotherapy%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2018%26volume%3D18%26spage%3D212%26epage%3D219%26doi%3D10.1038%2Fnri.2017.89" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooney, D. J.</span></span> <span> </span><span class="NLM_article-title">Biomaterial-Assisted Targeted Modulation of Immune Cells in Cancer Treatment</span>. <i>Nat. Mater.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">761</span>– <span class="NLM_lpage">772</span>, <span class="refDoi"> DOI: 10.1038/s41563-018-0147-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1038%2Fs41563-018-0147-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=30104668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFahsr7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=761-772&author=H.+Wangauthor=D.+J.+Mooney&title=Biomaterial-Assisted+Targeted+Modulation+of+Immune+Cells+in+Cancer+Treatment&doi=10.1038%2Fs41563-018-0147-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Biomaterial-assisted targeted modulation of immune cells in cancer treatment</span></div><div class="casAuthors">Wang, Hua; Mooney, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Materials</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">761-772</span>CODEN:
                <span class="NLM_cas:coden">NMAACR</span>;
        ISSN:<span class="NLM_cas:issn">1476-1122</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  The past decade has witnessed the accelerating development of immunotherapies for cancer treatment.  Immune checkpoint blockade therapies and chimeric antigen receptor (CAR)-T cell therapies have demonstrated clin. efficacy against a variety of cancers.  However, issues including life-threatening off-target side effects, long processing times, limited patient responses and high cost still limit the clin. utility of cancer immunotherapies.  Biomaterial carriers of these therapies, though, enable one to troubleshoot the delivery issues, amplify immunomodulatory effects, integrate the synergistic effect of different mols. and, more importantly, home and manipulate immune cells in vivo.  In this Review, we will analyze thus-far developed immunomaterials for targeted modulation of dendritic cells, T cells, tumor-assocd. macrophages, myeloid-derived suppressor cells, B cells and natural killer cells, and summarize the promises and challenges of cell-targeted immunomodulation for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyiKlYW1t2T7Vg90H21EOLACvtfcHk0lig13Jas1aejw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFahsr7O&md5=04c9d71f21b6a6287a44f6c3918ba286</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1038%2Fs41563-018-0147-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41563-018-0147-9%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DMooney%26aufirst%3DD.%2BJ.%26atitle%3DBiomaterial-Assisted%2520Targeted%2520Modulation%2520of%2520Immune%2520Cells%2520in%2520Cancer%2520Treatment%26jtitle%3DNat.%2520Mater.%26date%3D2018%26volume%3D17%26spage%3D761%26epage%3D772%26doi%3D10.1038%2Fs41563-018-0147-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, D.</span></span> <span> </span><span class="NLM_article-title">Allogenic Dendritic Cell and Tumor Cell Fused Vaccine for Targeted Imaging and Enhanced Immunotherapeutic Efficacy of Gastric Cancer</span>. <i>Biomaterials</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">177</span>– <span class="NLM_lpage">187</span>, <span class="refDoi"> DOI: 10.1016/j.biomaterials.2015.03.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.biomaterials.2015.03.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=25907051" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltlKntb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=177-187&author=C.+Liauthor=S.+Liangauthor=C.+Zhangauthor=Y.+Liuauthor=M.+Yangauthor=J.+Zhangauthor=X.+Zhiauthor=F.+Panauthor=D.+Cui&title=Allogenic+Dendritic+Cell+and+Tumor+Cell+Fused+Vaccine+for+Targeted+Imaging+and+Enhanced+Immunotherapeutic+Efficacy+of+Gastric+Cancer&doi=10.1016%2Fj.biomaterials.2015.03.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Allogenic dendritic cell and tumor cell fused vaccine for targeted imaging and enhanced immunotherapeutic efficacy of gastric cancer</span></div><div class="casAuthors">Li, Chao; Liang, Shujing; Zhang, Chunlei; Liu, Yanlei; Yang, Meng; Zhang, Jingpu; Zhi, Xiao; Pan, Fei; Cui, Daxiang</div><div class="citationInfo"><span class="NLM_cas:title">Biomaterials</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">177-187</span>CODEN:
                <span class="NLM_cas:coden">BIMADU</span>;
        ISSN:<span class="NLM_cas:issn">0142-9612</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Dendritic cells (DCs) have displayed the promising potential in cancer immunity.  How to enhance DCs immunotherapeutic effect in cancer targeted immunotherapy and prevention is still a great challenge.  Herein, we report for the first time the allogenic DCs and tumor cell fused vaccine combined with cytokine induced killing cells (CIKs) for targeted imaging and enhanced immunotherapeutic efficacy of gastric cancer (GC).  The fused vaccine was prepd. by PEG mediated fusion between mature DCs and inactive gastric cancer MGC803 cells.  The immunotherapeutic and prophylactic potential of the fused cells (FCs) were evaluated in tumor-bearing, post-surgery and tumor free mice models.  The migration and homing process of near IR region quantum dots (NIR-QDs) labeled FCs were investigated by real-time animal imaging system.  Results showed that the FCs and FC + CIKs could trigger the tumor-specific CTLs against GC cells, target the tumor tissue initiatively and enhance the prophylactic effects, suppress the tumor growth remarkably in vivo.  The potential mechanism is also investigated.  In conclusion, allogenic DCs and tumor cell fused vaccine can be used for targeted imaging and enhanced immunotherapeutic efficacy of GC, and the FC + CIKs strategy own great potential in clin. applications such as early therapy and prevention of tumor-metastasis and relapse in near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqObEDVw46DDLVg90H21EOLACvtfcHk0lig13Jas1aejw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltlKntb0%253D&md5=626109626d0e826f9b03fea926c8cee5</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1016%2Fj.biomaterials.2015.03.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biomaterials.2015.03.024%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLiang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhi%26aufirst%3DX.%26aulast%3DPan%26aufirst%3DF.%26aulast%3DCui%26aufirst%3DD.%26atitle%3DAllogenic%2520Dendritic%2520Cell%2520and%2520Tumor%2520Cell%2520Fused%2520Vaccine%2520for%2520Targeted%2520Imaging%2520and%2520Enhanced%2520Immunotherapeutic%2520Efficacy%2520of%2520Gastric%2520Cancer%26jtitle%3DBiomaterials%26date%3D2015%26volume%3D54%26spage%3D177%26epage%3D187%26doi%3D10.1016%2Fj.biomaterials.2015.03.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ursula, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jana, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katarina, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petra, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ondrej, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juraj, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martina, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanda, R.</span></span> <span> </span><span class="NLM_article-title">Prodrug Suicide Gene Therapy for Cancer Targeted Intracellular by Mesenchymal Stem Cell Exosomes</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">897</span>– <span class="NLM_lpage">908</span>, <span class="refDoi"> DOI: 10.1002/ijc.31792</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1002%2Fijc.31792" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=30098225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVSmsb%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2019&pages=897-908&author=A.+Ursulaauthor=J.+Janaauthor=B.+Katarinaauthor=P.+Petraauthor=P.+Martinauthor=P.+Pavelauthor=T.+Ondrejauthor=K.+Jurajauthor=Z.+Martinaauthor=R.+Vanda&title=Prodrug+Suicide+Gene+Therapy+for+Cancer+Targeted+Intracellular+by+Mesenchymal+Stem+Cell+Exosomes&doi=10.1002%2Fijc.31792"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Prodrug suicide gene therapy for cancer targeted intracellular by mesenchymal stem cell exosomes</span></div><div class="casAuthors">Ursula, Altanerova; Jana, Jakubechova; Katarina, Benejova; Petra, Priscakova; Martin, Pesta; Pavel, Pitule; Ondrej, Topolcan; Juraj, Kausitz; Martina, Zduriencikova; Vanda, Repiska; Cestmir, Altaner</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">897-908</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The natural behavior of mesenchymal stem cells (MSCs) and their exosomes in targeting tumors is a promising approach for curative therapy.  Human tumor tropic mesenchymal stem cells (MSCs) isolated from various tissues and MSCs engineered to express the yeast cytosine deaminase::uracil phosphoribosyl transferase suicide fusion gene (yCD::UPRT-MSCs) released exosomes in conditional medium (CM).  Exosomes from all tissue specific yCD::UPRT-MSCs contained mRNA of the suicide gene in the exosome's cargo.  When the CM was applied to tumor cells, the exosomes were internalized by recipient tumor cells and in the presence of the prodrug 5-fluorocytosine (5-FC) effectively triggered dose-dependent tumor cell death by endocytosed exosomes via an intracellular conversion of the prodrug 5-FC to 5-fluorouracil.  Exosomes were found to be responsible for the tumor inhibitory activity.  The presence of microRNAs in exosomes produced from naive MSCs and from suicide gene transduced MSCs did not differ significantly.  MicroRNAs from yCD::UPRT-MSCs were not assocd. with therapeutic effect.  MSC suicide gene exosomes represent a new class of tumor cell targeting drug acting intracellular with curative potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-SkUhiyV_PrVg90H21EOLACvtfcHk0ljywKq8pcy1vQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVSmsb%252FN&md5=b01a26c8ca9342a8941627789043bcaf</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1002%2Fijc.31792&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.31792%26sid%3Dliteratum%253Aachs%26aulast%3DUrsula%26aufirst%3DA.%26aulast%3DJana%26aufirst%3DJ.%26aulast%3DKatarina%26aufirst%3DB.%26aulast%3DPetra%26aufirst%3DP.%26aulast%3DMartin%26aufirst%3DP.%26aulast%3DPavel%26aufirst%3DP.%26aulast%3DOndrej%26aufirst%3DT.%26aulast%3DJuraj%26aufirst%3DK.%26aulast%3DMartina%26aufirst%3DZ.%26aulast%3DVanda%26aufirst%3DR.%26atitle%3DProdrug%2520Suicide%2520Gene%2520Therapy%2520for%2520Cancer%2520Targeted%2520Intracellular%2520by%2520Mesenchymal%2520Stem%2520Cell%2520Exosomes%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2019%26volume%3D144%26spage%3D897%26epage%3D908%26doi%3D10.1002%2Fijc.31792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, D.</span></span> <span> </span><span class="NLM_article-title">Human CIK Cells Loaded with Au Nanorods as a Theranostic Platform for Targeted Photoacoustic Imaging and Enhanced Immunotherapy and Photothermal Therapy</span>. <i>Nanoscale Res. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">285</span>, <span class="refDoi"> DOI: 10.1186/s11671-016-1468-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1186%2Fs11671-016-1468-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=27271853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252FnvFKnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=285&author=Y.+Yangauthor=J.+Zhangauthor=F.+Xiaauthor=C.+Zhangauthor=Q.+Qianauthor=X.+Zhiauthor=C.+Yueauthor=R.+Sunauthor=S.+Chengauthor=S.+Fangauthor=W.+Jinauthor=Y.+Yangauthor=D.+Cui&title=Human+CIK+Cells+Loaded+with+Au+Nanorods+as+a+Theranostic+Platform+for+Targeted+Photoacoustic+Imaging+and+Enhanced+Immunotherapy+and+Photothermal+Therapy&doi=10.1186%2Fs11671-016-1468-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Human CIK Cells Loaded with Au Nanorods as a Theranostic Platform for Targeted Photoacoustic Imaging and Enhanced Immunotherapy and Photothermal Therapy</span></div><div class="casAuthors">Yang Yao; Fang Shan; Cui Daxiang; Zhang Jingjing; Xia Fangfang; Zhang Chunlei; Zhi Xiao; Yue Caixia; Sun Rongjin; Cheng Shangli; Jin Weilin; Yang Yuming; Cui Daxiang; Qian Qirong; Cui Daxiang</div><div class="citationInfo"><span class="NLM_cas:title">Nanoscale research letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">285</span>
        ISSN:<span class="NLM_cas:issn">1931-7573</span>.
    </div><div class="casAbstract">How to realize targeted photoacoustic imaging, enhanced immunotherapy, and photothermal therapy of gastric cancer has become a great challenge.  Herein, we reported for the first time that human cytokine-induced killer cells (CIK) loaded with gold nanorods were used for targeted photoacoustic imaging, enhanced immunotherapy, and photothermal therapy of gastric cancer.  Silica-modified gold nanorods were prepared; then incubated with human cytokine-induced killer cells (CIK), resultant human CIK cells loaded with Au nanorods were evaluated for their cytotoxicity, targeted ability of gastric cancer in vitro and in vivo, immunotherapy, and photothermal therapy efficacy.  In vitro cell experiment shows that human CIK cells labeled with gold nanorods actively target gastric cancer MGC803 cells, inhibit growth of MGC803 cells by inducing cell apoptosis, and kill MGC803 cells under low power density near-infrared (NIR) laser treatment (808-nm continuous wave laser, 1.5 W/cm(2), 3 min).  In vivo experiment results showed that human CIK cells labeled with gold nanorods could target actively and image subcutaneous gastric cancer vessels via photoacoustic imaging at 4 h post-injection, could enhance immunotherapy efficacy by up-regulating cytokines such as IL-1, IL-12, IL-2, IL-4, IL-17, and IFN-γ, and kill gastric cancer tissues by photothermal therapy via direct injection into tumor site under near-infrared (NIR) laser irradiation.  High-performance human CIK cells labeled with Au nanorods are a good novel theranostic platform to exhibit great potential in applications such as tumor-targeted photoacoustic imaging, enhanced immunotherapy, and photothermal therapy in the near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRFBHW9ajsjmFf1XRtfYM0dfW6udTcc2ebzABxijJom-rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252FnvFKnsQ%253D%253D&md5=d1c93a038e4b3647e09e613feaef29ad</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1186%2Fs11671-016-1468-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs11671-016-1468-8%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DXia%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DQian%26aufirst%3DQ.%26aulast%3DZhi%26aufirst%3DX.%26aulast%3DYue%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DR.%26aulast%3DCheng%26aufirst%3DS.%26aulast%3DFang%26aufirst%3DS.%26aulast%3DJin%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DCui%26aufirst%3DD.%26atitle%3DHuman%2520CIK%2520Cells%2520Loaded%2520with%2520Au%2520Nanorods%2520as%2520a%2520Theranostic%2520Platform%2520for%2520Targeted%2520Photoacoustic%2520Imaging%2520and%2520Enhanced%2520Immunotherapy%2520and%2520Photothermal%2520Therapy%26jtitle%3DNanoscale%2520Res.%2520Lett.%26date%3D2016%26volume%3D11%26spage%3D285%26doi%3D10.1186%2Fs11671-016-1468-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez de la Fuente, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, D.</span></span> <span> </span><span class="NLM_article-title">Cytokine Induced Killer Cells-Assisted Delivery of Chlorin E6Mediated Self-Assembled Gold Nanoclusters to Tumors for Imaging and Immuno-Photodynamic Therapy</span>. <i>Biomaterials</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>170</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">11</span>, <span class="refDoi"> DOI: 10.1016/j.biomaterials.2018.03.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.biomaterials.2018.03.048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=29635107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntFyls7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2018&pages=1-11&author=F.+Xiaauthor=W.+Houauthor=Y.+Liuauthor=W.+Wangauthor=Y.+Hanauthor=M.+Yangauthor=X.+Zhiauthor=C.+Liauthor=D.+Qiauthor=T.+Liauthor=J.+Martinez+de+la+Fuenteauthor=C.+Zhangauthor=J.+Songauthor=D.+Cui&title=Cytokine+Induced+Killer+Cells-Assisted+Delivery+of+Chlorin+E6Mediated+Self-Assembled+Gold+Nanoclusters+to+Tumors+for+Imaging+and+Immuno-Photodynamic+Therapy&doi=10.1016%2Fj.biomaterials.2018.03.048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Cytokine induced killer cells-assisted delivery of chlorin e6 mediated self-assembled gold nanoclusters to tumors for imaging and immuno-photodynamic therapy</span></div><div class="casAuthors">Xia, Fangfang; Hou, Wenxiu; Liu, Yanlei; Wang, Wentao; Han, Yu; Yang, Meng; Zhi, Xiao; Li, Chenlu; Qi, Daizong; Li, Tianliang; Martinez de la Fuente, Jesus; Zhang, Chunlei; Song, Jie; Cui, Daxiang</div><div class="citationInfo"><span class="NLM_cas:title">Biomaterials</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-11</span>CODEN:
                <span class="NLM_cas:coden">BIMADU</span>;
        ISSN:<span class="NLM_cas:issn">0142-9612</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The cytotoxicity and unique tumor-tropic properties of cytokine-induced killer (CIK) cells render them promising in the field of cancer immunotherapy and delivery systems.  Here, we report a novel and facile approach to assemble gold nanoclusters (GNCs) into stable and monodispersed nanoparticles (NPs) using Chlorin e6 (Ce6) mols.  Notably, the fluorescence intensity of the GNCs-Ce6 NPs was about 4.5 folds stronger than the GNCs counterparts.  The as-prepd. GNCs-Ce6 NPs were conjugated with CD3 antibody (Ab) and further employed to label CIK cells to create a CIK cell-based drug delivery system (Ce6-GNCs-Ab-CIK).  The Ce6-GNCs-Ab-CIK exhibited high tumor-targeting efficiency and excellent therapeutic efficacy toward MGC-803 tumor-bearing mice.  Benefiting from the synergistic therapeutic effect between GNCs-Ce6-Ab NPs and CIK cells, the GNCs-Ce6-Ab-CIK strategy may present an ideal cancer theranostic platform for tumor targeted imaging and combination therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbkTGhHmQye7Vg90H21EOLACvtfcHk0lgeKOn2lpjghA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntFyls7g%253D&md5=2858a16fd527f92d1a294eebc0037639</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2Fj.biomaterials.2018.03.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biomaterials.2018.03.048%26sid%3Dliteratum%253Aachs%26aulast%3DXia%26aufirst%3DF.%26aulast%3DHou%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DZhi%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DQi%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DMartinez%2Bde%2Bla%2BFuente%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DCui%26aufirst%3DD.%26atitle%3DCytokine%2520Induced%2520Killer%2520Cells-Assisted%2520Delivery%2520of%2520Chlorin%2520E6Mediated%2520Self-Assembled%2520Gold%2520Nanoclusters%2520to%2520Tumors%2520for%2520Imaging%2520and%2520Immuno-Photodynamic%2520Therapy%26jtitle%3DBiomaterials%26date%3D2018%26volume%3D170%26spage%3D1%26epage%3D11%26doi%3D10.1016%2Fj.biomaterials.2018.03.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rotte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhandaru, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McElwee, K. J.</span></span> <span> </span><span class="NLM_article-title">Immunotherapy of Melanoma: Present Options and Future Promises</span>. <i>Cancer Metastasis Rev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">128</span>, <span class="refDoi"> DOI: 10.1007/s10555-014-9542-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1007%2Fs10555-014-9542-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=25589384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVOmtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2015&pages=115-128&author=A.+Rotteauthor=M.+Bhandaruauthor=Y.+Zhouauthor=K.+J.+McElwee&title=Immunotherapy+of+Melanoma%3A+Present+Options+and+Future+Promises&doi=10.1007%2Fs10555-014-9542-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Immunotherapy of melanoma: Present options and future promises</span></div><div class="casAuthors">Rotte, Anand; Bhandaru, Madhuri; Zhou, Youwen; McElwee, Kevin J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer and Metastasis Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">115-128</span>CODEN:
                <span class="NLM_cas:coden">CMRED4</span>;
        ISSN:<span class="NLM_cas:issn">0167-7659</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Metastatic melanoma is notorious for its immune evasion and resistance to conventional chemotherapy.  The recent success of ipilimumab, a human monoclonal antibody against cytotoxic T-lymphocyte-assocd. antigen 4 (CTLA-4), in increasing the median survival time and stabilizing the disease progression renewed, hopes in treatment for melanoma.  Currently, ipilimumab and high-dose interleukin-2 (IL-2; Aldesleukin) are approved as monotherapies for the treatment of patients with unresectable advanced melanoma, and pegylated interferon-α2b (p-IFN-α2b) is approved as an adjuvant for the treatment of patients with surgically resected high-risk melanoma.  The present review describes the currently approved immune-modulators and the promising immune-based interventions that are currently in clin. trials.  We present the four commonly used strategies to boost immune responses against the tumors; monoclonal antibodies, cytokines, cancer vaccines, and adoptive T cell transfer.  The corresponding lists of ongoing clin. trials include details of the trial phase, target patients, intervention details, status of the study, and expected date of completion.  Further, our review discusses the challenges faced by immunotherapy and the various strategies adopted to overcome them.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptvc-D5REioLVg90H21EOLACvtfcHk0lgeKOn2lpjghA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVOmtbg%253D&md5=285f6156c8539af05e79d5699c74b930</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1007%2Fs10555-014-9542-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10555-014-9542-0%26sid%3Dliteratum%253Aachs%26aulast%3DRotte%26aufirst%3DA.%26aulast%3DBhandaru%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DMcElwee%26aufirst%3DK.%2BJ.%26atitle%3DImmunotherapy%2520of%2520Melanoma%253A%2520Present%2520Options%2520and%2520Future%2520Promises%26jtitle%3DCancer%2520Metastasis%2520Rev.%26date%3D2015%26volume%3D34%26spage%3D115%26epage%3D128%26doi%3D10.1007%2Fs10555-014-9542-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span> <span> </span><span class="NLM_article-title">Photothermal Therapy with Immune-Adjuvant Nanoparticles Together with Checkpoint Blockade for Effective Cancer Immunotherapy</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">13193</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">13</span>, <span class="refDoi"> DOI: 10.1038/ncomms13193</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1038%2Fncomms13193" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=1-13&issue=13193&author=Q.+Chenauthor=L.+Xuauthor=C.+Liangauthor=C.+Wangauthor=R.+Pengauthor=Z.+Liu&title=Photothermal+Therapy+with+Immune-Adjuvant+Nanoparticles+Together+with+Checkpoint+Blockade+for+Effective+Cancer+Immunotherapy&doi=10.1038%2Fncomms13193"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1038%2Fncomms13193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms13193%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DPeng%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DZ.%26atitle%3DPhotothermal%2520Therapy%2520with%2520Immune-Adjuvant%2520Nanoparticles%2520Together%2520with%2520Checkpoint%2520Blockade%2520for%2520Effective%2520Cancer%2520Immunotherapy%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26issue%3D13193%26spage%3D1%26epage%3D13%26doi%3D10.1038%2Fncomms13193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Velpurisiva, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jadia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rai, P.</span></span> <span> </span><span class="NLM_article-title">Nanoparticle Design Strategies for Effective Cancer Immunotherapy</span>. <i>J. Biomed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">64</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.7150/jbm.18877</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.7150%2Fjbm.18877" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2017&pages=1-26&issue=64&author=P.+Velpurisivaauthor=A.+Gadauthor=B.+Pielauthor=R.+Jadiaauthor=P.+Rai&title=Nanoparticle+Design+Strategies+for+Effective+Cancer+Immunotherapy&doi=10.7150%2Fjbm.18877"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.7150%2Fjbm.18877&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fjbm.18877%26sid%3Dliteratum%253Aachs%26aulast%3DVelpurisiva%26aufirst%3DP.%26aulast%3DGad%26aufirst%3DA.%26aulast%3DPiel%26aufirst%3DB.%26aulast%3DJadia%26aufirst%3DR.%26aulast%3DRai%26aufirst%3DP.%26atitle%3DNanoparticle%2520Design%2520Strategies%2520for%2520Effective%2520Cancer%2520Immunotherapy%26jtitle%3DJ.%2520Biomed.%26date%3D2017%26volume%3D2%26issue%3D64%26spage%3D1%26epage%3D26%26doi%3D10.7150%2Fjbm.18877" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meir, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shamalov, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motiei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yaari, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popovtzer, R.</span></span> <span> </span><span class="NLM_article-title">Fast Image-Guided Stratification Using Anti-Programmed Death Ligand-1 Gold Nanoparticles for Cancer Immunotherapy</span>. <i>ACS Nano</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">11127</span>– <span class="NLM_lpage">11134</span>, <span class="refDoi"> DOI: 10.1021/acsnano.7b05299</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsnano.7b05299" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Grur%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=11127-11134&author=R.+Meirauthor=K.+Shamalovauthor=T.+Sadanauthor=M.+Motieiauthor=G.+Yaariauthor=C.+J.+Cohenauthor=R.+Popovtzer&title=Fast+Image-Guided+Stratification+Using+Anti-Programmed+Death+Ligand-1+Gold+Nanoparticles+for+Cancer+Immunotherapy&doi=10.1021%2Facsnano.7b05299"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Fast Image-Guided Stratification Using Anti-Programmed Death Ligand 1 Gold Nanoparticles for Cancer Immunotherapy</span></div><div class="casAuthors">Meir, Rinat; Shamalov, Katerina; Sadan, Tamar; Motiei, Menachem; Yaari, Gur; Cohen, Cyrille J.; Popovtzer, Rachela</div><div class="citationInfo"><span class="NLM_cas:title">ACS Nano</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">11127-11134</span>CODEN:
                <span class="NLM_cas:coden">ANCAC3</span>;
        ISSN:<span class="NLM_cas:issn">1936-0851</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cancer immunotherapy has made enormous progress in offering safer and more effective treatments for the disease.  Specifically, programmed death ligand 1 antibody (αPDL1), designed to perform immune checkpoint blockade (ICB), is now considered a pillar in cancer immunotherapy.  However, due to the complexity and heterogeneity of tumors, as well as the diversity in patient response, ICB therapy only has a 30% success rate, at most; moreover, the efficacy of ICB can be evaluated only two months after start of treatment.  Therefore, early identification of potential responders and nonresponders to therapy, using noninvasive means, is crucial for improving treatment decisions.  Here, we report a straightforward approach for fast, image-guided prediction of therapeutic response to ICB.  In a colon cancer mouse model, we demonstrate that the combination of computed tomog. imaging and gold nanoparticles conjugated to αPDL1 allowed prediction of therapeutic response, as early as 48 h after treatment.  This was achieved by noninvasive measurement of nanoparticle accumulation levels within the tumors.  Moreover, we show that the nanoparticles efficiently prevented tumor growth with only a fifth of the std. dosage of clin. care.  This technol. may be developed into a powerful tool for early and noninvasive patient stratification as responders or nonresponders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdM2b1IJd6P7Vg90H21EOLACvtfcHk0lgeKOn2lpjghA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Grur%252FJ&md5=6dfea4e2cc9c9011eca18510172c9bcc</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1021%2Facsnano.7b05299&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsnano.7b05299%26sid%3Dliteratum%253Aachs%26aulast%3DMeir%26aufirst%3DR.%26aulast%3DShamalov%26aufirst%3DK.%26aulast%3DSadan%26aufirst%3DT.%26aulast%3DMotiei%26aufirst%3DM.%26aulast%3DYaari%26aufirst%3DG.%26aulast%3DCohen%26aufirst%3DC.%2BJ.%26aulast%3DPopovtzer%26aufirst%3DR.%26atitle%3DFast%2520Image-Guided%2520Stratification%2520Using%2520Anti-Programmed%2520Death%2520Ligand-1%2520Gold%2520Nanoparticles%2520for%2520Cancer%2520Immunotherapy%26jtitle%3DACS%2520Nano%26date%3D2017%26volume%3D11%26spage%3D11127%26epage%3D11134%26doi%3D10.1021%2Facsnano.7b05299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cano-Mejia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burga, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollard, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandler, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, C. R. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, R.</span></span> <span> </span><span class="NLM_article-title">Prussian Blue Nanoparticle-Based Photothermal Therapy Combined with Checkpoint Inhibition for Photothermal Immunotherapy of Neuroblastoma</span>. <i>Nanomedicine</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">771</span>– <span class="NLM_lpage">781</span>, <span class="refDoi"> DOI: 10.1016/j.nano.2016.10.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.nano.2016.10.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=27826115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjs1Onu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=771-781&author=J.+Cano-Mejiaauthor=R.+A.+Burgaauthor=E.+E.+Sweeneyauthor=J.+P.+Fisherauthor=C.+M.+Bollardauthor=A.+D.+Sandlerauthor=C.+R.+Y.+Cruzauthor=R.+Fernandes&title=Prussian+Blue+Nanoparticle-Based+Photothermal+Therapy+Combined+with+Checkpoint+Inhibition+for+Photothermal+Immunotherapy+of+Neuroblastoma&doi=10.1016%2Fj.nano.2016.10.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Prussian blue nanoparticle-based photothermal therapy combined with checkpoint inhibition for photothermal immunotherapy of neuroblastoma</span></div><div class="casAuthors">Cano-Mejia, Juliana; Burga, Rachel A.; Sweeney, Elizabeth E.; Fisher, John P.; Bollard, Catherine M.; Sandler, Anthony D.; Cruz, Conrad Russell Y.; Fernandes, Rohan</div><div class="citationInfo"><span class="NLM_cas:title">Nanomedicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">771-781</span>CODEN:
                <span class="NLM_cas:coden">NANOBF</span>;
        ISSN:<span class="NLM_cas:issn">1549-9634</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">We describe "photothermal immunotherapy," which combines Prussian blue nanoparticle (PBNP)-based photothermal therapy (PTT) with anti-CTLA-4 checkpoint inhibition for treating neuroblastoma, a common, hard-to-treat pediatric cancer.  PBNPs exhibit pH-dependent stability, which makes them suitable for intratumorally-administered PTT.  PBNP-based PTT is able to lower tumor burden and prime an immune response, specifically an increased infiltration of lymphocytes and T cells to the tumor area, which is complemented by the antitumor effects of anti-CTLA-4 immunotherapy, providing a more durable treatment against neuroblastoma in an animal model.  We observe 55.5% survival in photothermal immunotherapy-treated mice at 100 days compared to 12.5%, 0%, 0%, and 0% survival in mice receiving: anti-CTLA-4 alone, PBNPs alone, PTT alone, and no treatment, resp.  Addnl., long-term surviving, photothermal immunotherapy-treated mice exhibit protection against neuroblastoma rechallenge, suggesting the development of immunity against these tumors.  Our findings suggest the potential of photothermal immunotherapy in improving treatments for neuroblastoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonO8vFz11ZQ7Vg90H21EOLACvtfcHk0ljhZD8jD0dRdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjs1Onu74%253D&md5=80a981875ccf60f26dbd94524642f6a6</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2Fj.nano.2016.10.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nano.2016.10.015%26sid%3Dliteratum%253Aachs%26aulast%3DCano-Mejia%26aufirst%3DJ.%26aulast%3DBurga%26aufirst%3DR.%2BA.%26aulast%3DSweeney%26aufirst%3DE.%2BE.%26aulast%3DFisher%26aufirst%3DJ.%2BP.%26aulast%3DBollard%26aufirst%3DC.%2BM.%26aulast%3DSandler%26aufirst%3DA.%2BD.%26aulast%3DCruz%26aufirst%3DC.%2BR.%2BY.%26aulast%3DFernandes%26aufirst%3DR.%26atitle%3DPrussian%2520Blue%2520Nanoparticle-Based%2520Photothermal%2520Therapy%2520Combined%2520with%2520Checkpoint%2520Inhibition%2520for%2520Photothermal%2520Immunotherapy%2520of%2520Neuroblastoma%26jtitle%3DNanomedicine%26date%3D2017%26volume%3D13%26spage%3D771%26epage%3D781%26doi%3D10.1016%2Fj.nano.2016.10.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heo, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, D. K.</span></span> <span> </span><span class="NLM_article-title">New Opportunities for Nanoparticles in Cancer Immunotherapy</span>. <i>Biomater. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1186/s40824-018-0133-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1186%2Fs40824-018-0133-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=29308274" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1MXivVCrtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2018&pages=1-10&issue=24&author=W.+Parkauthor=Y.-J.+Heoauthor=D.+K.+Han&title=New+Opportunities+for+Nanoparticles+in+Cancer+Immunotherapy&doi=10.1186%2Fs40824-018-0133-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced osteogenic commitment of murine mesenchymal stem cells on graphene oxide substrate</span></div><div class="casAuthors">Kim, Jiyong; Kim, Hwan D.; Park, Jungha; Lee, Eun-seo; Kim, Eugene; Lee, Seunghun S.; Yang, Jin-Kyung; Lee, Yoon-Sik; Hwang, Nathaniel S.</div><div class="citationInfo"><span class="NLM_cas:title">Biomaterials Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1/1-1/9</span>CODEN:
                <span class="NLM_cas:coden">BRIEFJ</span>;
        ISSN:<span class="NLM_cas:issn">2055-7124</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Tissue engineering is an interdisciplinary field that attempts to restore or regenerate tissues and organs through biomimetic fabrication of scaffolds with specific functionality.  In recent years, graphene oxide (GO) is considered as promising biomaterial due to its nontoxicity, high dispersity, and hydrophilic interaction, and these characteristics are key to stimulating the interactions between substrates and cells.  In this study, GO substrates were fabricated via chem. immobilizing GO at 1.0 mg/mL on glass slides.  Furthermore, we examd. the osteogenic responses of murine mesenchymal-like stem cells, C3H10T1/2 cells, on GO substrates.  C3H10T1/2 cells on GO substrates resulted in increased cell surface area, enhanced cellular adhesions, and instigated osteogenic differentiation.  Furthermore, priming of C3H10T1/2 cells with chondrocyte-conditioned medium (CM) could further induce a synergistic effect of osteogenesis on GO substrates.  All of these data suggest that GO substrate along with CM is suitable for upregulating osteogenic responses of mesenchymal stem cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyRcm4CmNstbVg90H21EOLACvtfcHk0ljhZD8jD0dRdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXivVCrtbs%253D&md5=0365d2deebd72344e59c7e0cf77f03e5</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1186%2Fs40824-018-0133-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40824-018-0133-y%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DW.%26aulast%3DHeo%26aufirst%3DY.-J.%26aulast%3DHan%26aufirst%3DD.%2BK.%26atitle%3DNew%2520Opportunities%2520for%2520Nanoparticles%2520in%2520Cancer%2520Immunotherapy%26jtitle%3DBiomater.%2520Res.%26date%3D2018%26volume%3D22%26issue%3D24%26spage%3D1%26epage%3D10%26doi%3D10.1186%2Fs40824-018-0133-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hagan, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medik, Y. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A. Z.</span></span> <span> </span><span class="NLM_article-title">Nanotechnology Approaches to Improving Cancer Immunotherapy</span>. <i>Adv. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">35</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1016/bs.acr.2018.05.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fbs.acr.2018.05.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=29941106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252Fhs1Ghuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2018&pages=35-56&author=C.+T.+Haganauthor=Y.+B.+Medikauthor=A.+Z.+Wang&title=Nanotechnology+Approaches+to+Improving+Cancer+Immunotherapy&doi=10.1016%2Fbs.acr.2018.05.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Nanotechnology Approaches to Improving Cancer Immunotherapy</span></div><div class="casAuthors">Hagan C Tilden 4th; Medik Yusra B; Wang Andrew Z</div><div class="citationInfo"><span class="NLM_cas:title">Advances in cancer research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">35-56</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cancer immunotherapy is a powerful, growing treatment approach to cancer that can be combined with chemotherapy, radiotherapy, and oncosurgery.  Modulating the immune system to enhance anticancer response by several strategies has yielded improved cancer survival.  Despite this progress, the success rate for immunotherapy has been below expectations due to unpredictable efficacy and off-target side effects from systemic dosing.  Nanotechnology offers numerous different materials and targeting properties to overcome many of these challenges in immunotherapy.  In this chapter, we review current immunotherapy and its challenges as well as the latest nanotechnology applications in cancer immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRh-u_uJ3fLMAMthz5_Rx5rfW6udTcc2eaPKlejZK52crntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252Fhs1Ghuw%253D%253D&md5=f7cb5bd4a4c456c8b69a719b22168c07</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1016%2Fbs.acr.2018.05.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.acr.2018.05.003%26sid%3Dliteratum%253Aachs%26aulast%3DHagan%26aufirst%3DC.%2BT.%26aulast%3DMedik%26aufirst%3DY.%2BB.%26aulast%3DWang%26aufirst%3DA.%2BZ.%26atitle%3DNanotechnology%2520Approaches%2520to%2520Improving%2520Cancer%2520Immunotherapy%26jtitle%3DAdv.%2520Cancer%2520Res.%26date%3D2018%26volume%3D139%26spage%3D35%26epage%3D56%26doi%3D10.1016%2Fbs.acr.2018.05.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ansari, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raza, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, R.</span></span> <span> </span><span class="NLM_article-title">Zinc Gluconate-Loaded Chitosan Nanoparticles Reduce Severity of Collagen-Induced Arthritis in Wistar Rats</span>. <i>ACS Biomater. Sci. Eng.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">3380</span>– <span class="NLM_lpage">3397</span>, <span class="refDoi"> DOI: 10.1021/acsbiomaterials.9b00427</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsbiomaterials.9b00427" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVehurrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2019&pages=3380-3397&issue=7&author=M.+M.+Ansariauthor=A.+Ahmadauthor=R.+K.+Mishraauthor=S.+S.+Razaauthor=R.+Khan&title=Zinc+Gluconate-Loaded+Chitosan+Nanoparticles+Reduce+Severity+of+Collagen-Induced+Arthritis+in+Wistar+Rats&doi=10.1021%2Facsbiomaterials.9b00427"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Zinc gluconate-loaded chitosan nanoparticles reduce severity of collagen-induced arthritis in Wistar Rats</span></div><div class="casAuthors">Ansari, Md. Meraj; Ahmad, Anas; Mishra, Rakesh Kumar; Raza, Syed Shadab; Khan, Rehan</div><div class="citationInfo"><span class="NLM_cas:title">ACS Biomaterials Science & Engineering</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3380-3397</span>CODEN:
                <span class="NLM_cas:coden">ABSEBA</span>;
        ISSN:<span class="NLM_cas:issn">2373-9878</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Rheumatoid arthritis (RA) is the most prevalent autoimmune disease affecting about 1% world population.  Zinc (Zn) is necessary for the maintenance of bone homeostasis and the level of Zn was reported to be decreased in RA patients and collagen-induced arthritic rats.  Effective delivery of Zn has been reported using zinc gluconate but oral absorption of Zn from zinc gluconate (ZG) is very low in humans.  Zn supplementation reduces disease severity in patients suffering from chronic, refractory RA and exerts mild and transient side effects.  The aim of this study was to synthesize and characterize zinc gluconate-loaded chitosan nanoparticles (ZG-Chit NPs) and to evaluate and compare therapeutic efficacy of ZG-Chit NPs and zinc gluconate against collagen-induced RA in Wistar rats.  The nanoparticles were formulated by ionic gelation method and the hydrodynamic diam. was 106.5 ± 79.55 nm as measured using DLS.  The particle size, shape, and surface morphol. was further confirmed by transmission electron microscopy, SEM, and at. force microscopy.  These nanoparticles showed good cytocompatibility against foreskin fibroblasts (BJ) and L929 cells.  Arthritic rats were treated with ZG (20 mg/kg body wt., i.p.) and equiv. doses of ZG-Chit NPs.  The treatment of both ZG and ZG-Chit NPs reduced the severity of arthritis as evidenced by reduced joint swelling, erythema, and edema but ZG-Chit NPs exhibited superior efficacy.  Furthermore, it was found that ZG and ZG-Chit NPs attenuate biomarkers of inflammation (C-reactive protein, myeloperoxidase, nitric oxide, TNF-α, and IL-1β) and oxidative stress (articular elastase, lipid peroxidn., catalase, glutathione, and superoxide dismutase).  The results of the histopathol. further confirmed that ZG-Chit NPs markedly suppressed infiltration of inflammatory cells as compared to ZG at the ankle joint tissue.  Immunohistochem. anal. also revealed that treatment with ZG-Chit NPs resulted in reduced pro-inflammatory marker (TNF-α, IL-6, and iNOS) expression and enhanced SOD1 expression.  Overall, this study suggests that ZG and ZG-Chit NPs suppressed the severity of arthritis plausibly mediated by attenuation of inflammation and oxidative stress and more importantly ZG-Chit NPs exhibited superior efficacy as compared to ZG.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpzCEMCGdsvLVg90H21EOLACvtfcHk0lj3Zw4tRNML5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVehurrL&md5=d694d19695f50d23b1ff3b1d70cbb1f6</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1021%2Facsbiomaterials.9b00427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsbiomaterials.9b00427%26sid%3Dliteratum%253Aachs%26aulast%3DAnsari%26aufirst%3DM.%2BM.%26aulast%3DAhmad%26aufirst%3DA.%26aulast%3DMishra%26aufirst%3DR.%2BK.%26aulast%3DRaza%26aufirst%3DS.%2BS.%26aulast%3DKhan%26aufirst%3DR.%26atitle%3DZinc%2520Gluconate-Loaded%2520Chitosan%2520Nanoparticles%2520Reduce%2520Severity%2520of%2520Collagen-Induced%2520Arthritis%2520in%2520Wistar%2520Rats%26jtitle%3DACS%2520Biomater.%2520Sci.%2520Eng.%26date%3D2019%26volume%3D5%26issue%3D7%26spage%3D3380%26epage%3D3397%26doi%3D10.1021%2Facsbiomaterials.9b00427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fauzia, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raza, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, R.</span></span> <span> </span><span class="NLM_article-title">Engineering. Gelatin-Coated Polycaprolactone Nanoparticle-Mediated Naringenin Delivery Rescues Human Mesenchymal Stem Cells from Oxygen Glucose Deprivation-Induced Inflammatory Stress</span>. <i>ACS Biomater. Sci. Eng.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">683</span>– <span class="NLM_lpage">695</span>, <span class="refDoi"> DOI: 10.1021/acsbiomaterials.8b01081</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsbiomaterials.8b01081" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVCisb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2019&pages=683-695&author=A.+Ahmadauthor=E.+Fauziaauthor=M.+Kumarauthor=R.+K.+Mishraauthor=A.+Kumarauthor=M.+A.+Khanauthor=S.+S.+Razaauthor=R.+Khan&title=Engineering.+Gelatin-Coated+Polycaprolactone+Nanoparticle-Mediated+Naringenin+Delivery+Rescues+Human+Mesenchymal+Stem+Cells+from+Oxygen+Glucose+Deprivation-Induced+Inflammatory+Stress&doi=10.1021%2Facsbiomaterials.8b01081"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Gelatin-Coated Polycaprolactone Nanoparticle-Mediated Naringenin Delivery Rescue Human Mesenchymal Stem Cells from Oxygen Glucose Deprivation-Induced Inflammatory Stress</span></div><div class="casAuthors">Ahmad, Anas; Fauzia, Eram; Kumar, Manish; Mishra, Rakesh Kumar; Kumar, Ajay; Khan, Mohsin Ali; Raza, Syed Shadab; Khan, Rehan</div><div class="citationInfo"><span class="NLM_cas:title">ACS Biomaterials Science & Engineering</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">683-695</span>CODEN:
                <span class="NLM_cas:coden">ABSEBA</span>;
        ISSN:<span class="NLM_cas:issn">2373-9878</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Ischemic stroke involves pro-inflammatory species, which implicates inflammation in the disease mechanism.  Recent studies indicate that the prevalence of therapeutic choice such as stem cell transplantation has seen an upsurge in ischemic stroke.  However, after transplantation the fate of transplanted cells is largely unknown.  Human mesenchymal stem cells (MSCs), due to their robust survival rate upon transplantation in brain tissue, are being widely employed to treat ischemic stroke.  In the present study, we have evaluated naringenin-loaded gelatin-coated polycaprolactone nanoparticles (nar-gel-c-PCL NPs) to rescue MSCs against oxygen glucose deprived insult.  Naringenin, due to its strong anti-inflammatory effects, remains a therapeutic choice in neurol. disorders.  Though, the low soly. and inefficient delivery remain challenges in using naringenin as a therapeutic drug.  The present study showed that inflammation occurred in MSCs during their treatment with oxygen glucose deprivation (OGD) and was well overturned by treatment with nar-gel-c-PCL NPs.  In brief, the results indicated that nar-gel-c-PCL NPs were able to protect the loss of cell membrane integrity and restored neuronal morphol.  Then nar-gel-c-PCL NPs successfully protected the human MSCs against OGD-induced inflammation as evident by reduced level of pro-inflammatory cytokine (TNF-α, IFN-γ, and IL-1β) and other inflammatory biomarkers (COX2, iNOS, and MPO activity).  Therefore, the modulation of inflammation by treatment with nar-gel-c-PCL NPs in MSCs could provide a novel strategy to improve MSC-based therapy, and thus, our nanoformulation may find a wide therapeutic application in ischemic stroke and other neuro-inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquDn8OxnaxjrVg90H21EOLACvtfcHk0lj3Zw4tRNML5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVCisb7O&md5=5e3c2fbfbe53dbf9a763fe65bf2f1a5e</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1021%2Facsbiomaterials.8b01081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsbiomaterials.8b01081%26sid%3Dliteratum%253Aachs%26aulast%3DAhmad%26aufirst%3DA.%26aulast%3DFauzia%26aufirst%3DE.%26aulast%3DKumar%26aufirst%3DM.%26aulast%3DMishra%26aufirst%3DR.%2BK.%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DKhan%26aufirst%3DM.%2BA.%26aulast%3DRaza%26aufirst%3DS.%2BS.%26aulast%3DKhan%26aufirst%3DR.%26atitle%3DEngineering.%2520Gelatin-Coated%2520Polycaprolactone%2520Nanoparticle-Mediated%2520Naringenin%2520Delivery%2520Rescues%2520Human%2520Mesenchymal%2520Stem%2520Cells%2520from%2520Oxygen%2520Glucose%2520Deprivation-Induced%2520Inflammatory%2520Stress%26jtitle%3DACS%2520Biomater.%2520Sci.%2520Eng.%26date%3D2019%26volume%3D5%26spage%3D683%26epage%3D695%26doi%3D10.1021%2Facsbiomaterials.8b01081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez de la Fuente, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, D.</span></span> <span> </span><span class="NLM_article-title">Martinez de la Fuentea, Human Induced Pluripotent Stem Cells for Tumor Targeted Delivery of Gold Nanorods and Enhanced Photothermal Therapy</span>. <i>ACS Nano</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2375</span>– <span class="NLM_lpage">2385</span>, <span class="refDoi"> DOI: 10.1021/acsnano.5b07172</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsnano.5b07172" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvFCnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=2375-2385&author=Y.+Liuauthor=M.+Yangauthor=J.+Zhangauthor=X.+Zhiauthor=C.+Liauthor=C.+Zhangauthor=F.+Panauthor=K.+Wangauthor=Y.+Yangauthor=J.+Martinez+de+la+Fuenteauthor=D.+Cui&title=Martinez+de+la+Fuentea%2C+Human+Induced+Pluripotent+Stem+Cells+for+Tumor+Targeted+Delivery+of+Gold+Nanorods+and+Enhanced+Photothermal+Therapy&doi=10.1021%2Facsnano.5b07172"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Human Induced Pluripotent Stem Cells for Tumor Targeted Delivery of Gold Nanorods and Enhanced Photothermal Therapy</span></div><div class="casAuthors">Liu, Yanlei; Yang, Meng; Zhang, Jingpu; Zhi, Xiao; Li, Chao; Zhang, Chunlei; Pan, Fei; Wang, Kan; Yang, Yuming; Martinez de la Fuentea, Jesus; Cui, Daxiang</div><div class="citationInfo"><span class="NLM_cas:title">ACS Nano</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">2375-2385</span>CODEN:
                <span class="NLM_cas:coden">ANCAC3</span>;
        ISSN:<span class="NLM_cas:issn">1936-0851</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">How to improve effective accumulation and intratumoral distribution of plasmonic gold nanoparticles has become a great challenge for photothermal therapy of tumors.  Herein, we reported a nanoplatform with photothermal therapeutic effects by fabricating Au <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="d5bbb4bbbaa7bab1a69586bc9ae7">[email protected]</a>@CXCR4 nanoparticles and loading the prepd. nanoparticles into the human induced pluripotent stem cells(AuNRs-iPS).  In virtue of the prominent optical properties of Au <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="c4aaa5aaabb6aba0b78497ad8bf6">[email protected]</a>@CXCR4 and remarkable tumor target migration ability of iPS cells, the Au nanorods delivery mediated by iPS cells via the nanoplatform AuNRs-iPS was found to have a prolonged retention time and spatially even distribution in MGC803 tumor-bearing nude mice obsd. by photoacoustic tomog. and two-photon luminescence.  On the basis of these improvements, the nanoplatform displayed a robust migration capacity to target the tumor site and to improve photothermal therapeutic efficacy on inhibiting the growth of tumors in xenograft mice under a low laser power d.  The combination of gold nanorods with human iPS cells as a theranostic platform paves an alternative road for cancer theranostics and holds great promise for clin. translation in the near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnNNHynfNaZLVg90H21EOLACvtfcHk0lj3Zw4tRNML5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvFCnsA%253D%253D&md5=703a918880b938efe6f91658b3a7f8a6</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1021%2Facsnano.5b07172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsnano.5b07172%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhi%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DPan%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DMartinez%2Bde%2Bla%2BFuente%26aufirst%3DJ.%26aulast%3DCui%26aufirst%3DD.%26atitle%3DMartinez%2520de%2520la%2520Fuentea%252C%2520Human%2520Induced%2520Pluripotent%2520Stem%2520Cells%2520for%2520Tumor%2520Targeted%2520Delivery%2520of%2520Gold%2520Nanorods%2520and%2520Enhanced%2520Photothermal%2520Therapy%26jtitle%3DACS%2520Nano%26date%3D2016%26volume%3D10%26spage%3D2375%26epage%3D2385%26doi%3D10.1021%2Facsnano.5b07172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gasch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ffrench, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Leary, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallagher, M. F.</span></span> <span> </span><span class="NLM_article-title">Catching Moving Targets: Cancer Stem Cell Hierarchies, Therapy-Resistance & Considerations for Clinical Intervention</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">43</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1186/s12943-017-0601-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1186%2Fs12943-017-0601-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=28093071" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=1-15&issue=43&author=C.+Gaschauthor=B.+Ffrenchauthor=J.+J.+O%E2%80%99Learyauthor=M.+F.+Gallagher&title=Catching+Moving+Targets%3A+Cancer+Stem+Cell+Hierarchies%2C+Therapy-Resistance+%26+Considerations+for+Clinical+Intervention&doi=10.1186%2Fs12943-017-0601-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1186%2Fs12943-017-0601-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-017-0601-3%26sid%3Dliteratum%253Aachs%26aulast%3DGasch%26aufirst%3DC.%26aulast%3DFfrench%26aufirst%3DB.%26aulast%3DO%25E2%2580%2599Leary%26aufirst%3DJ.%2BJ.%26aulast%3DGallagher%26aufirst%3DM.%2BF.%26atitle%3DCatching%2520Moving%2520Targets%253A%2520Cancer%2520Stem%2520Cell%2520Hierarchies%252C%2520Therapy-Resistance%2520%2526%2520Considerations%2520for%2520Clinical%2520Intervention%26jtitle%3DMol.%2520Cancer%26date%3D2017%26volume%3D16%26issue%3D43%26spage%3D1%26epage%3D15%26doi%3D10.1186%2Fs12943-017-0601-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suryaprakash, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lao, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leong, K. W.</span></span> <span> </span><span class="NLM_article-title">Graphene Oxide Cellular Patches for Mesenchymal Stem Cell-Based Cancer Therapy</span>. <i>Carbon</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">863</span>– <span class="NLM_lpage">868</span>, <span class="refDoi"> DOI: 10.1016/j.carbon.2017.12.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.carbon.2017.12.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvF2ks7nM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2018&pages=863-868&author=S.+Suryaprakashauthor=M.+Liauthor=Y.-H.+Laoauthor=H.-X.+Wangauthor=K.+W.+Leong&title=Graphene+Oxide+Cellular+Patches+for+Mesenchymal+Stem+Cell-Based+Cancer+Therapy&doi=10.1016%2Fj.carbon.2017.12.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Graphene oxide cellular patches for mesenchymal stem cell-based cancer therapy</span></div><div class="casAuthors">Suryaprakash, Smruthi; Li, Mingqiang; Lao, Yeh-Hsing; Wang, Hong-Xia; Leong, Kam W.</div><div class="citationInfo"><span class="NLM_cas:title">Carbon</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">863-868</span>CODEN:
                <span class="NLM_cas:coden">CRBNAH</span>;
        ISSN:<span class="NLM_cas:issn">0008-6223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Graphene oxide (GO) is a versatile platform for drug delivery, but poor accumulation at the tumor site limits the translation of this technol.  Mesenchymal stem cells (MSC) on the other hand is tumor trophic but is limited to delivering only protein-based drugs.  Our soln. is to combine the individual attributes of GO and MSC by loading GO on the surface of MSC to create a unique drug delivery platform wherein, GO can be used to load a range of therapeutics and MSC can carry the drug effectively to the site of the tumor.  Here, we demonstrated that GO can be loaded with two types of chemo drugs, doxorubicin and mitoxantrone, with similar efficiency (>30%).  The drug-GO complex was loaded on MSC without affecting the MSC viability significantly.  On exposure to GO-mitoxantrone, 87% of MSC survived while only 28% of the cancer cells (LN18) survived, demonstrating the selective killing of the cancer cells but not MSC.  Furthermore, drug-GO loading did not affect the tumor trophic property of MSC, and coculture of the drug-GO loaded MSC with LN18 showed a dose-dependent killing of LN18.  Together, these results show the feasibility of using drug-GO loaded MSC as an effective carrier for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQKyWZ4T-BxbVg90H21EOLACvtfcHk0lgehsqt3wpt7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvF2ks7nM&md5=3e5ac45c92070d6efb53c30a92e8497d</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1016%2Fj.carbon.2017.12.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.carbon.2017.12.031%26sid%3Dliteratum%253Aachs%26aulast%3DSuryaprakash%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DLao%26aufirst%3DY.-H.%26aulast%3DWang%26aufirst%3DH.-X.%26aulast%3DLeong%26aufirst%3DK.%2BW.%26atitle%3DGraphene%2520Oxide%2520Cellular%2520Patches%2520for%2520Mesenchymal%2520Stem%2520Cell-Based%2520Cancer%2520Therapy%26jtitle%3DCarbon%26date%3D2018%26volume%3D129%26spage%3D863%26epage%3D868%26doi%3D10.1016%2Fj.carbon.2017.12.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwacka, R.</span></span> <span> </span><span class="NLM_article-title">The Future of Mesenchymal Stem Cell-Based Therapeutic Approaches for Cancer–From Cells to Ghosts</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>414</i></span>,  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">249</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2017.11.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.canlet.2017.11.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=29175461" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFWhurzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=414&publication_year=2018&pages=239-249&author=A.+Mohrauthor=R.+Zwacka&title=The+Future+of+Mesenchymal+Stem+Cell-Based+Therapeutic+Approaches+for+Cancer%E2%80%93From+Cells+to+Ghosts&doi=10.1016%2Fj.canlet.2017.11.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">The future of mesenchymal stem cell-based therapeutic approaches for cancer - From cells to ghosts</span></div><div class="casAuthors">Mohr, Andrea; Zwacka, Ralf</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">414</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">239-249</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Mesenchymal stem cells (MSCs) are multipotent stromal cells which can differentiate into a variety of cell types including osteoblasts, adipocytes and chondrocytes.  They are normally resident in adipose tissue, bone marrow and the umbilical cord, but can also be found in other tissues and are known to be recruited to sites of wound healing as well as growing tumors.  The therapeutic potential of MSCs has been explored in a no. of phase I/II and III clin. trials, of which several were targeted against graft-vs.-host disease and to support engraftment of haematopoietic stem cells (HSCs), but currently only very few in the oncol. field.  There are now three clin. trials either ongoing or recruiting patients that use MSCs to treat tumor disease.  In these, MSCs target gastrointestinal, lung and ovarian cancer, resp.  The first study uses MSCs loaded with a HSV-TK expression construct under the control of the CCL5 promoter, and has recently reported successful completion of Phase I/II.  While no adverse side effects were seen during this study, no outcomes with respect to therapeutic benefits have been published.  The other clin. trials targeting lung and ovarian cancer will be using MSCs expressing cytokines as therapeutic payload.  Despite these encouraging early steps towards their clin. use, many questions are still unanswered regarding the biol. of MSCs in normal and pathophysiol. settings.  In this review, in addn. to summarising the current state of MSC-based therapeutic approaches for cancer, we will describe the remaining questions, obstacles and risks, as well as novel developments such as MSC-derived nanoghosts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrALBOMlqeCX7Vg90H21EOLACvtfcHk0lgehsqt3wpt7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFWhurzJ&md5=d246250bcbcf66ffe7e0af0084d0ac2f</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2017.11.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2017.11.025%26sid%3Dliteratum%253Aachs%26aulast%3DMohr%26aufirst%3DA.%26aulast%3DZwacka%26aufirst%3DR.%26atitle%3DThe%2520Future%2520of%2520Mesenchymal%2520Stem%2520Cell-Based%2520Therapeutic%2520Approaches%2520for%2520Cancer%25E2%2580%2593From%2520Cells%2520to%2520Ghosts%26jtitle%3DCancer%2520Lett.%26date%3D2018%26volume%3D414%26spage%3D239%26epage%3D249%26doi%3D10.1016%2Fj.canlet.2017.11.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sehl, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wicha, M. S.</span></span> <span> </span><span class="NLM_article-title">Modeling of Interactions Between Cancer Stem Cells and Their Microenvironment: Predicting Clinical Response</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>1711</i></span>,  <span class="NLM_fpage">333</span>– <span class="NLM_lpage">349</span>, <span class="refDoi"> DOI: 10.1007/978-1-4939-7493-1_16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1007%2F978-1-4939-7493-1_16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=29344897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFKrsL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1711&publication_year=2018&pages=333-349&author=M.+E.+Sehlauthor=M.+S.+Wicha&title=Modeling+of+Interactions+Between+Cancer+Stem+Cells+and+Their+Microenvironment%3A+Predicting+Clinical+Response&doi=10.1007%2F978-1-4939-7493-1_16"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Modeling of interactions between cancer stem cells and their microenvironment: predicting clinical response</span></div><div class="casAuthors">Sehl, Mary E.; Wicha, Max S.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">1711</span>
        (<span class="NLM_cas:issue">Cancer Systems Biology</span>),
    <span class="NLM_cas:pages">333-349</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1940-6029</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Math. models of cancer stem cells are useful in translational cancer research for facilitating the understanding of tumor growth dynamics and for predicting treatment response and resistance to combined targeted therapies.  In this chapter, we describe appealing aspects of different methods used in math. oncol. and discuss compelling questions in oncol. that can be addressed with these modeling techniques.  We describe a simplified version of a model of the breast cancer stem cell niche, illustrate the visualization of the model, and apply stochastic simulation to generate full distributions and av. trajectories of cell type populations over time.  We further discuss the advent of single-cell data in studying cancer stem cell heterogeneity and how these data can be integrated with modeling to advance understanding of the dynamics of invasive and proliferative populations during cancer progression and response to therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGAJtUHRE5yLVg90H21EOLACvtfcHk0lgehsqt3wpt7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFKrsL3L&md5=6ae71c9ee33c9cb398fbde019e5ad05f</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-7493-1_16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4939-7493-1_16%26sid%3Dliteratum%253Aachs%26aulast%3DSehl%26aufirst%3DM.%2BE.%26aulast%3DWicha%26aufirst%3DM.%2BS.%26atitle%3DModeling%2520of%2520Interactions%2520Between%2520Cancer%2520Stem%2520Cells%2520and%2520Their%2520Microenvironment%253A%2520Predicting%2520Clinical%2520Response%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2018%26volume%3D1711%26spage%3D333%26epage%3D349%26doi%3D10.1007%2F978-1-4939-7493-1_16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, M.</span></span> <span> </span><span class="NLM_article-title">Exosome-Based Cancer Therapy: Implication for Targeting Cancer Stem Cells</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">533</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">11</span>, <span class="refDoi"> DOI: 10.3389/fphar.2016.00533</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.3389%2Ffphar.2016.00533" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=1-11&issue=533&author=J.+Wangauthor=Y.+Zhengauthor=M.+Zhao&title=Exosome-Based+Cancer+Therapy%3A+Implication+for+Targeting+Cancer+Stem+Cells&doi=10.3389%2Ffphar.2016.00533"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2016.00533&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2016.00533%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DM.%26atitle%3DExosome-Based%2520Cancer%2520Therapy%253A%2520Implication%2520for%2520Targeting%2520Cancer%2520Stem%2520Cells%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D7%26issue%3D533%26spage%3D1%26epage%3D11%26doi%3D10.3389%2Ffphar.2016.00533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Nanomaterials in Targeting Cancer Stem Cells for Cancer Therapy</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.3389/fphar.2017.00001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.3389%2Ffphar.2017.00001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=28149278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtl2mtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1-15&author=W.+Qinauthor=G.+Huangauthor=Z.+Chenauthor=Y.+Zhang&title=Nanomaterials+in+Targeting+Cancer+Stem+Cells+for+Cancer+Therapy&doi=10.3389%2Ffphar.2017.00001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Nanomaterials in targeting cancer stem cells for cancer therapy</span></div><div class="casAuthors">Qin, Weiwei; Huang, Guan; Chen, Zuanguang; Zhang, Yuanqing</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-15</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Cancer stem cells (CSCs) have been identified in almost all cancers and give rise to metastases and can also act as a reservoir of cancer cells that may cause a relapse after surgery, radiation, or chemotherapy.  Thus they are obvious targets in therapeutic approaches and also a great challenge in cancer treatment.  The threat presented by CSCs lies in their unlimited proliferative ability and multidrug resistance.  These findings have necessitated an effective novel strategy to target CSCs for cancer treatment.  Nanomaterials are on the route to providing novel methods in cancer therapies.  Although, there have been a large no. of excellent work in the field of targeted cancer therapy, it remains an open question how nanomaterials can meet future demands for targeting and eradicating of CSCs.  In this review, we summarized recent and highlighted future prospects for targeting CSCs for cancer therapies by using a variety of nanomaterials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogBDr6a6L-CbVg90H21EOLACvtfcHk0lj_VkaA2ONvAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtl2mtb0%253D&md5=18c8fcfe71cacd450e98eb61967ade02</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00001%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DNanomaterials%2520in%2520Targeting%2520Cancer%2520Stem%2520Cells%2520for%2520Cancer%2520Therapy%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D1%26epage%3D15%26doi%3D10.3389%2Ffphar.2017.00001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kong, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mäkilä, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salonen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hai, M.</span></span> <span> </span><span class="NLM_article-title">Gold Nanorods, DNA Origami, and Porous Silicon Nanoparticle-Functionalized Biocompatible Double Emulsion for Versatile Targeted Therapeutics and Antibody Combination Therapy</span>. <i>Adv. Mater.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">10195</span>– <span class="NLM_lpage">10203</span>, <span class="refDoi"> DOI: 10.1002/adma.201602763</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1002%2Fadma.201602763" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=27689681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1SlsrrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2016&pages=10195-10203&author=F.+Kongauthor=H.+Zhangauthor=X.+Quauthor=X.+Zhangauthor=D.+Chenauthor=R.+Dingauthor=E.+M%C3%A4kil%C3%A4author=J.+Salonenauthor=H.+A.+Santosauthor=M.+Hai&title=Gold+Nanorods%2C+DNA+Origami%2C+and+Porous+Silicon+Nanoparticle-Functionalized+Biocompatible+Double+Emulsion+for+Versatile+Targeted+Therapeutics+and+Antibody+Combination+Therapy&doi=10.1002%2Fadma.201602763"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Gold Nanorods, DNA Origami, and Porous Silicon Nanoparticle-functionalized Biocompatible Double Emulsion for Versatile Targeted Therapeutics and Antibody Combination Therapy</span></div><div class="casAuthors">Kong, Feng; Zhang, Hongbo; Qu, Xiangmeng; Zhang, Xu; Chen, Dong; Ding, Ruihua; Maekilae, Ermei; Salonen, Jarno; Santos, Helder A.; Hai, Mingtan</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Materials (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">10195-10203</span>CODEN:
                <span class="NLM_cas:coden">ADVMEW</span>;
        ISSN:<span class="NLM_cas:issn">0935-9648</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Gold nanorods, DNA origami, and porous silicon nanoparticle-functionalized biocompatible double emulsion are developed for versatile mol. targeted therapeutics and antibody combination therapy.  This advanced photothermal responsive all-in-one biocompatible platform can be easily formed with great therapeutics loading capacity for different cancer treatments with synergism and multidrug resistance inhibition, which has great potential in advancing biomedical applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkywVMIALbz7Vg90H21EOLACvtfcHk0lj_VkaA2ONvAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1SlsrrF&md5=8e70e2a810acd265d95e829904a00e23</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1002%2Fadma.201602763&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fadma.201602763%26sid%3Dliteratum%253Aachs%26aulast%3DKong%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DQu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DDing%26aufirst%3DR.%26aulast%3DM%25C3%25A4kil%25C3%25A4%26aufirst%3DE.%26aulast%3DSalonen%26aufirst%3DJ.%26aulast%3DSantos%26aufirst%3DH.%2BA.%26aulast%3DHai%26aufirst%3DM.%26atitle%3DGold%2520Nanorods%252C%2520DNA%2520Origami%252C%2520and%2520Porous%2520Silicon%2520Nanoparticle-Functionalized%2520Biocompatible%2520Double%2520Emulsion%2520for%2520Versatile%2520Targeted%2520Therapeutics%2520and%2520Antibody%2520Combination%2520Therapy%26jtitle%3DAdv.%2520Mater.%26date%3D2016%26volume%3D28%26spage%3D10195%26epage%3D10203%26doi%3D10.1002%2Fadma.201602763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palazzolo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadla, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo Spena, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo Re, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adeel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caligiuri, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romano, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corona, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canzonieri, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toffoli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzolio, F.</span></span> <span> </span><span class="NLM_article-title">A Proof-of-Concept Multi-Stage Biomimetic Liposomal DNA Origami Nanosystem for the Remote Loading of Doxorubicin</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">517</span>– <span class="NLM_lpage">521</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00557</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00557" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1Cisro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=517-521&issue=4&author=S.+Palazzoloauthor=M.+Hadlaauthor=C.+Russo+Spenaauthor=S.+Baydaauthor=V.+Kumarauthor=F.+Lo+Reauthor=M.+Adeelauthor=I.+Caligiuriauthor=F.+Romanoauthor=G.+Coronaauthor=V.+Canzonieriauthor=G.+Toffoliauthor=F.+Rizzolio&title=A+Proof-of-Concept+Multi-Stage+Biomimetic+Liposomal+DNA+Origami+Nanosystem+for+the+Remote+Loading+of+Doxorubicin&doi=10.1021%2Facsmedchemlett.8b00557"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Proof-of-Concept Multistage Biomimetic Liposomal DNA Origami Nanosystem for the Remote Loading of Doxorubicin</span></div><div class="casAuthors">Palazzolo, Stefano; Hadla, Mohamad; Spena, Concetta Russo; Bayda, Samer; Kumar, Vinit; Lo Re, Francesco; Adeel, Muhammad; Caligiuri, Isabella; Romano, Flavio; Corona, Giuseppe; Canzonieri, Vincenzo; Toffoli, Giuseppe; Rizzolio, Flavio</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">517-521</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">One of the most promising applications of DNA origami is its use as an excellent evolution of nanostructured intelligent systems for drug delivery, but short in vivo lifetime and immune-activation are still major challenges to overcome.  On the contrary, stealth liposomes have long-circulation time and are well tolerated by the immune system.  To overcome DNA origami limitations, we have designed and synthesized a compact short tube DNA origami (STDO) of approx. 30 nm in length and 10 nm in width.  These STDO are highly stable ≥48 h in physiol. conditions without any postsynthetic modifications.  The compact size of STDO precisely fits inside a stealthy liposome of about 150 nm and could efficiently remotely load doxorubicin in liposomes (LSTDO) without a pH driven gradient.  We demonstrated that this innovative drug delivery system (DDS) has an optimal tumoral release and high biocompatible profiles opening up new horizons to encapsulate many other hydrophobic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQgk2vYEQxY7Vg90H21EOLACvtfcHk0lj_VkaA2ONvAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1Cisro%253D&md5=5444e0fa2b8fd5b6b3279be9d01f7e06</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00557&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00557%26sid%3Dliteratum%253Aachs%26aulast%3DPalazzolo%26aufirst%3DS.%26aulast%3DHadla%26aufirst%3DM.%26aulast%3DRusso%2BSpena%26aufirst%3DC.%26aulast%3DBayda%26aufirst%3DS.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DLo%2BRe%26aufirst%3DF.%26aulast%3DAdeel%26aufirst%3DM.%26aulast%3DCaligiuri%26aufirst%3DI.%26aulast%3DRomano%26aufirst%3DF.%26aulast%3DCorona%26aufirst%3DG.%26aulast%3DCanzonieri%26aufirst%3DV.%26aulast%3DToffoli%26aufirst%3DG.%26aulast%3DRizzolio%26aufirst%3DF.%26atitle%3DA%2520Proof-of-Concept%2520Multi-Stage%2520Biomimetic%2520Liposomal%2520DNA%2520Origami%2520Nanosystem%2520for%2520the%2520Remote%2520Loading%2520of%2520Doxorubicin%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26issue%3D4%26spage%3D517%26epage%3D521%26doi%3D10.1021%2Facsmedchemlett.8b00557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gurunathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.-H.</span></span> <span> </span><span class="NLM_article-title">Biocompatible Gold Nanoparticles Ameliorate Retinoic Acid-Induced Cell Death and Induce Differentiation in F9 Teratocarcinoma Stem Cells</span>. <i>Nanomaterials</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">396</span>, <span class="refDoi"> DOI: 10.3390/nano8060396</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.3390%2Fnano8060396" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlOmt7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=396&author=S.+Gurunathanauthor=J.-H.+Kim&title=Biocompatible+Gold+Nanoparticles+Ameliorate+Retinoic+Acid-Induced+Cell+Death+and+Induce+Differentiation+in+F9+Teratocarcinoma+Stem+Cells&doi=10.3390%2Fnano8060396"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Biocompatible gold nanoparticles ameliorate retinoic acid-induced cell death and induce differentiation in F9 teratocarcinoma stem cells</span></div><div class="casAuthors">Gurunathan, Sangiliyandi; Kim, Jin-Hoi</div><div class="citationInfo"><span class="NLM_cas:title">Nanomaterials</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">396/1-396/21</span>CODEN:
                <span class="NLM_cas:coden">NANOKO</span>;
        ISSN:<span class="NLM_cas:issn">2079-4991</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The unique properties of gold nanoparticles (AuNPs) have attracted much interest for a range of applications, including biomedical applications in the cosmetic industry.  The current study assessed the anti-oxidative effect of AuNPs against retinoic acid (RA)-induced loss of cell viability; cell proliferation; expression of oxidative and anti-oxidative stress markers, pro- and anti-apoptotic genes, and differentiation markers; and mitochondrial dysfunction in F9 teratocarcinoma stem cells.  AuNPs were prepd. by redn. of gold salts using luteolin as a reducing and stabilizing agent.  The prepd. AuNPs were spherical in shape with an av. diam. of 18 nm.  F9 cells exposed to various concns. of these AuNPs were not harmed, whereas cells exposed to RA exhibited a dose-dependent change in cell viability and cell proliferation.  The RA-mediated toxicity was assocd. with increased leakage of lactate dehydrogenase, reactive oxygen species, increased levels of malondialdehyde and nitric oxide, loss of mitochondrial membrane potential, and a reduced level of ATP.  Finally, RA increased the level of pro-apoptotic gene expression and decreased the expression of anti-apoptotic genes.  Interestingly, the toxic effect of RA appeared to be decreased in cells treated with RA in the presence of AuNPs, which was coincident with the increased levels of anti-oxidant markers including thioredoxin, glutathione peroxidases, glutathione, glutathione disulfide, catalase, and superoxide dismutase.  Concomitantly, AuNPs ameliorated the apoptotic response by decreasing the mRNA expression of p53, p21, Bax, Bak, caspase-3, caspase-9, and increasing the expressions of Bcl-2 and Bcl-Xl.  Interestingly, AuNPs not only ameliorated oxidative stress but also induced differentiation in F9 cells by increasing the expression of differentiation markers including retinoic acid binding protein, laminin 1, collagen type IV, and Gata 6 and decreasing the expressions of markers of stem cell pluripotency including Nanog, Rex1, octamer-binding transcription factor 4, and Sox-2.  These consistent cellular and biochem. data suggest that AuNPs could ameliorate RA-induced cell death and facilitate F9 cell differentiation.  AuNPs could be suitable therapeutic agents for the treatment of oxidative stress-related diseases such as atherosclerosis, cancer, diabetes, rheumatoid arthritis, and neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozX-U_84A5qLVg90H21EOLACvtfcHk0lhmqS46kQs-bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlOmt7fP&md5=ad42f557c452dfbc6d9e3bd15bc5ec98</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.3390%2Fnano8060396&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fnano8060396%26sid%3Dliteratum%253Aachs%26aulast%3DGurunathan%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DJ.-H.%26atitle%3DBiocompatible%2520Gold%2520Nanoparticles%2520Ameliorate%2520Retinoic%2520Acid-Induced%2520Cell%2520Death%2520and%2520Induce%2520Differentiation%2520in%2520F9%2520Teratocarcinoma%2520Stem%2520Cells%26jtitle%3DNanomaterials%26date%3D2018%26volume%3D8%26spage%3D396%26doi%3D10.3390%2Fnano8060396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mooney, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batalla-Covello, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdul Majid, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aboody, K. S.</span></span> <span> </span><span class="NLM_article-title">Concise Review: Neural Stem Cell-Mediated Targeted Cancer Therapies</span>. <i>Stem Cells Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">740</span>– <span class="NLM_lpage">747</span>, <span class="refDoi"> DOI: 10.1002/sctm.18-0003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1002%2Fsctm.18-0003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=30133188" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A280%3ADC%252BB3c3gs1Cjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2018&pages=740-747&author=R.+Mooneyauthor=M.+Hammadauthor=J.+Batalla-Covelloauthor=A.+Abdul+Majidauthor=K.+S.+Aboody&title=Concise+Review%3A+Neural+Stem+Cell-Mediated+Targeted+Cancer+Therapies&doi=10.1002%2Fsctm.18-0003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Concise Review: Neural Stem Cell-Mediated Targeted Cancer Therapies</span></div><div class="casAuthors">Mooney Rachael; Hammad Mohamed; Batalla-Covello Jennifer; Abdul Majid Asma; Aboody Karen S; Mooney Rachael; Batalla-Covello Jennifer</div><div class="citationInfo"><span class="NLM_cas:title">Stem cells translational medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">740-747</span>
        ISSN:<span class="NLM_cas:issn">2157-6564</span>.
    </div><div class="casAbstract">Cancer is one of the leading causes of morbidity and mortality worldwide, with 1,688,780 new cancer cases and 600,920 cancer deaths projected to occur in 2017 in the U.S. alone.  Conventional cancer treatments including surgical, chemo-, and radiation therapies can be effective, but are often limited by tumor invasion, off-target toxicities, and acquired resistance.  To improve clinical outcomes and decrease toxic side effects, more targeted, tumor-specific therapies are being developed.  Delivering anticancer payloads using tumor-tropic cells can greatly increase therapeutic distribution to tumor sites, while sparing non-tumor tissues therefore minimizing toxic side effects.  Neural stem cells (NSCs) are tumor-tropic cells that can pass through normal organs quickly, localize to invasive and metastatic tumor foci throughout the body, and cross the blood-brain barrier to reach tumors in the brain.  This review focuses on the potential use of NSCs as vehicles to deliver various anticancer payloads selectively to tumor sites.  The use of NSCs in cancer treatment has been studied most extensively in the brain, but the findings are applicable to other metastatic solid tumors, which will be described in this review.  Strategies include NSC-mediated enzyme/prodrug gene therapy, oncolytic virotherapy, and delivery of antibodies, nanoparticles, and extracellular vesicles containing oligonucleotides.  Preclinical discovery and translational studies, as well as early clinical trials, will be discussed.  Stem Cells Translational Medicine 2018;7:740-747.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQr9VjUb_7DjbmQt-ICR3qNfW6udTcc2eZcO9AJi_OuAbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c3gs1Cjsw%253D%253D&md5=3471fefe5a2d5f2b391637ca41238e81</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1002%2Fsctm.18-0003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fsctm.18-0003%26sid%3Dliteratum%253Aachs%26aulast%3DMooney%26aufirst%3DR.%26aulast%3DHammad%26aufirst%3DM.%26aulast%3DBatalla-Covello%26aufirst%3DJ.%26aulast%3DAbdul%2BMajid%26aufirst%3DA.%26aulast%3DAboody%26aufirst%3DK.%2BS.%26atitle%3DConcise%2520Review%253A%2520Neural%2520Stem%2520Cell-Mediated%2520Targeted%2520Cancer%2520Therapies%26jtitle%3DStem%2520Cells%2520Transl.%2520Med.%26date%3D2018%26volume%3D7%26spage%3D740%26epage%3D747%26doi%3D10.1002%2Fsctm.18-0003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Bertoni, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozielski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lal, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaughan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mihelson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberhart, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laterra, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, J.</span></span> <span> </span><span class="NLM_article-title">Bioreducible Polymeric Nanoparticles Containing Multiplexed Cancer Stem Cell-Regulating MiRNAs Inhibit Glioblastoma Growth and Prolong Survival</span>. <i>Nano Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4086</span>– <span class="NLM_lpage">4094</span>, <span class="refDoi"> DOI: 10.1021/acs.nanolett.8b00390</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.nanolett.8b00390" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFyqt7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=4086-4094&author=H.+Lopez-Bertoniauthor=K.+Kozielskiauthor=Y.+Ruiauthor=B.+Lalauthor=H.+Vaughanauthor=D.+Wilsonauthor=N.+Mihelsonauthor=C.+Eberhartauthor=J.+Laterraauthor=J.+Green&title=Bioreducible+Polymeric+Nanoparticles+Containing+Multiplexed+Cancer+Stem+Cell-Regulating+MiRNAs+Inhibit+Glioblastoma+Growth+and+Prolong+Survival&doi=10.1021%2Facs.nanolett.8b00390"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Bioreducible Polymeric Nanoparticles Containing Multiplexed Cancer Stem Cell Regulating miRNAs Inhibit Glioblastoma Growth and Prolong Survival</span></div><div class="casAuthors">Lopez-Bertoni, Hernando; Kozielski, Kristen L.; Rui, Yuan; Lal, Bachchu; Vaughan, Hannah; Wilson, David R.; Mihelson, Nicole; Eberhart, Charles G.; Laterra, John; Green, Jordan J.</div><div class="citationInfo"><span class="NLM_cas:title">Nano Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">4086-4094</span>CODEN:
                <span class="NLM_cas:coden">NALEFD</span>;
        ISSN:<span class="NLM_cas:issn">1530-6984</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Despite our growing mol.-level understanding of glioblastoma (GBM), treatment modalities remain limited.  Recent developments in the mechanisms of cell fate regulation and nanomedicine provide new avenues by which to treat and manage brain tumors via the delivery of mol. therapeutics.  Here, we have developed bioreducible poly(β-amino ester) nanoparticles that demonstrate high intracellular delivery efficacy, low cytotoxicity, escape from endosomes, and promotion of cytosol-targeted environmentally triggered cargo release for miRNA delivery to tumor-propagating human cancer stem cells.  In this report, we combined this nanobiotechnol. with newly discovered cancer stem cell inhibiting miRNAs to develop self-assembled miRNA-contg. polymeric nanoparticles (nano-miRs) to treat gliomas.  We show that these nano-miRs effectively intracellularly deliver single and combination miRNA mimics that inhibit the stem cell phenotype of human GBM cells in vitro.  Following direct intratumoral infusion, these nano-miRs were found to distribute through the tumors, inhibit the growth of established orthotopic human GBM xenografts, and cooperatively enhance the response to std.-of-care γ radiation.  Co-delivery of two miRNAs, miR-148a and miR-296-5p, within the bioreducible nano-miR particles enabled long-term survival from GBM in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzu2F4Tq9m87Vg90H21EOLACvtfcHk0lhmqS46kQs-bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFyqt7rN&md5=980ccb688441948880685d5c69fc898a</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1021%2Facs.nanolett.8b00390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.nanolett.8b00390%26sid%3Dliteratum%253Aachs%26aulast%3DLopez-Bertoni%26aufirst%3DH.%26aulast%3DKozielski%26aufirst%3DK.%26aulast%3DRui%26aufirst%3DY.%26aulast%3DLal%26aufirst%3DB.%26aulast%3DVaughan%26aufirst%3DH.%26aulast%3DWilson%26aufirst%3DD.%26aulast%3DMihelson%26aufirst%3DN.%26aulast%3DEberhart%26aufirst%3DC.%26aulast%3DLaterra%26aufirst%3DJ.%26aulast%3DGreen%26aufirst%3DJ.%26atitle%3DBioreducible%2520Polymeric%2520Nanoparticles%2520Containing%2520Multiplexed%2520Cancer%2520Stem%2520Cell-Regulating%2520MiRNAs%2520Inhibit%2520Glioblastoma%2520Growth%2520and%2520Prolong%2520Survival%26jtitle%3DNano%2520Lett.%26date%3D2018%26volume%3D18%26spage%3D4086%26epage%3D4094%26doi%3D10.1021%2Facs.nanolett.8b00390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hua, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Matos, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metselaar, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storm, G.</span></span> <span> </span><span class="NLM_article-title">Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">790</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">14</span>, <span class="refDoi"> DOI: 10.3389/fphar.2018.00790</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.3389%2Ffphar.2018.00790" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=29387012" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1-14&issue=790&author=S.+Huaauthor=M.+B.+de+Matosauthor=J.+M.+Metselaarauthor=G.+Storm&title=Current+Trends+and+Challenges+in+the+Clinical+Translation+of+Nanoparticulate+Nanomedicines%3A+Pathways+for+Translational+Development+and+Commercialization&doi=10.3389%2Ffphar.2018.00790"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2018.00790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2018.00790%26sid%3Dliteratum%253Aachs%26aulast%3DHua%26aufirst%3DS.%26aulast%3Dde%2BMatos%26aufirst%3DM.%2BB.%26aulast%3DMetselaar%26aufirst%3DJ.%2BM.%26aulast%3DStorm%26aufirst%3DG.%26atitle%3DCurrent%2520Trends%2520and%2520Challenges%2520in%2520the%2520Clinical%2520Translation%2520of%2520Nanoparticulate%2520Nanomedicines%253A%2520Pathways%2520for%2520Translational%2520Development%2520and%2520Commercialization%26jtitle%3DFront.%2520Pharmacol.%26date%3D2018%26volume%3D9%26issue%3D790%26spage%3D1%26epage%3D14%26doi%3D10.3389%2Ffphar.2018.00790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Youn, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bae, Y. H.</span></span> <span> </span><span class="NLM_article-title">Perspectives on the Past, Present, and Future of Cancer Nanomedicine</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">11</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2018.05.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.addr.2018.05.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=29778902" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVantbjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2018&pages=3-11&author=Y.+S.+Younauthor=Y.+H.+Bae&title=Perspectives+on+the+Past%2C+Present%2C+and+Future+of+Cancer+Nanomedicine&doi=10.1016%2Fj.addr.2018.05.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Perspectives on the past, present, and future of cancer nanomedicine</span></div><div class="casAuthors">Youn, Yu Seok; Bae, You Han</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3-11</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The justification of cancer nanomedicine relies on enhanced permeation (EP) and retention (R) effect and the capability of intracellular targeting due primarily to size after internalization (endocytosis) into the individual target cells.  The EPR effect implies improved efficacy.  Affinity targeting for solid tumors only occur after delivery to individual cells, which help internalization and/or retention.  The design principles have been supported by animal results in numerous publications, but hardly translated.  The natures of EP and R, such as frequency of large openings in tumor vasculature and their dynamics, are not understood, in particular, in clin. settings.  Although various attempts to address the issues related to EP and delivery, by modifying design factors and manipulating tumor microenvironment, are being reported, they are still verified in artificial rodent tumors which do not mimic the nature of human tumor physiol./pathol. in terms of transport and delivery.  The clin. trials of exptl. nanomedicine have experienced unexpected adverse effects with modest improvement in efficacy when compared to current frontline therapy.  Future nanomedicine may require new design principles without consideration of EP and affinity targeting.  A possible direction is to set new approaches to intentionally minimize adverse effects, rather than aiming at better efficacy, which can widen the therapeutic window of an anticancer drug of interest.  Broadening indications and administration routes of developed therapeutic nanotechnol. would benefit patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3h7U16UUscbVg90H21EOLACvtfcHk0li-KpWLRAlHsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVantbjN&md5=19e61fff4b7e3f4b6ef55bb97cdbfcae</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2018.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2018.05.008%26sid%3Dliteratum%253Aachs%26aulast%3DYoun%26aufirst%3DY.%2BS.%26aulast%3DBae%26aufirst%3DY.%2BH.%26atitle%3DPerspectives%2520on%2520the%2520Past%252C%2520Present%252C%2520and%2520Future%2520of%2520Cancer%2520Nanomedicine%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2018%26volume%3D130%26spage%3D3%26epage%3D11%26doi%3D10.1016%2Fj.addr.2018.05.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herrera, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colby, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz-Opazo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grinstaff, M. W.</span></span> <span> </span><span class="NLM_article-title">Nucleic Acid Nanomedicines in Phase II/III Clinical Trials: Translation of Nucleic Acid Therapies for Reprogramming Cells</span>. <i>Nanomedicine</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">2083</span>– <span class="NLM_lpage">2098</span>, <span class="refDoi"> DOI: 10.2217/nnm-2018-0122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.2217%2Fnnm-2018-0122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=30204054" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVaqt7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=2083-2098&author=V.+L.+Herreraauthor=A.+H.+Colbyauthor=N.+Ruiz-Opazoauthor=D.+G.+Colemanauthor=M.+W.+Grinstaff&title=Nucleic+Acid+Nanomedicines+in+Phase+II%2FIII+Clinical+Trials%3A+Translation+of+Nucleic+Acid+Therapies+for+Reprogramming+Cells&doi=10.2217%2Fnnm-2018-0122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Nucleic acid nanomedicines in Phase II/III clinical trials: translation of nucleic acid therapies for reprogramming cells</span></div><div class="casAuthors">Herrera, Victoria L. M.; Colby, Aaron H.; Ruiz-Opazo, Nelson; Coleman, David G.; Grinstaff, Mark W.</div><div class="citationInfo"><span class="NLM_cas:title">Nanomedicine (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2083-2098</span>CODEN:
                <span class="NLM_cas:coden">NLUKAC</span>;
        ISSN:<span class="NLM_cas:issn">1748-6963</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">This review presents an integrated anal. of the current-state-of-the-art in nucleic acid nanotherapies and highlights the importance of nanotechnol. in the delivery of nucleic acid therapies.  While there is no one dominant nanodesign, the diversity of nanodesigns and delivery of different siRNAs, miRNA and DNA to inhibit more than 20 targets in seven disease states in Phase II/III clin. trials reflects the potential of nucleic acid therapies to treat intractable diseases and non-druggable targets.  We provide benchmarks to aid in comparing the design, proof-of-concept studies and clin. trials.  From this, we demonstrate the importance of generating a strategic framework for integrating clin. 'wish lists' for a means to treat intractable diseases with engineering 'design checklists' for nucleic acid nanotherapies.  Lay abstr. : The application of nanotechnol. to medicine - nanomedicine - offers an unprecedented opportunity to improve patient outcomes.  This integrated review of emerging clin. successes and failures in Phase II/III clin. trials provides insight into how best to design new technologies for the delivery of nucleic acid therapies.  An integrated anal. of the current-state-of-the-art in nucleic acid nanotherapies is presented with an emphasis on medical perspectives in nanomedicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocwN-TsJHvXbVg90H21EOLACvtfcHk0li-KpWLRAlHsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVaqt7nE&md5=c3ae325b9d6bbd7a86f96a4d075418e3</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.2217%2Fnnm-2018-0122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fnnm-2018-0122%26sid%3Dliteratum%253Aachs%26aulast%3DHerrera%26aufirst%3DV.%2BL.%26aulast%3DColby%26aufirst%3DA.%2BH.%26aulast%3DRuiz-Opazo%26aufirst%3DN.%26aulast%3DColeman%26aufirst%3DD.%2BG.%26aulast%3DGrinstaff%26aufirst%3DM.%2BW.%26atitle%3DNucleic%2520Acid%2520Nanomedicines%2520in%2520Phase%2520II%252FIII%2520Clinical%2520Trials%253A%2520Translation%2520of%2520Nucleic%2520Acid%2520Therapies%2520for%2520Reprogramming%2520Cells%26jtitle%3DNanomedicine%26date%3D2018%26volume%3D13%26spage%3D2083%26epage%3D2098%26doi%3D10.2217%2Fnnm-2018-0122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caster, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span> <span> </span><span class="NLM_article-title">Investigational Nanomedicines in 2016: A Review of Nanotherapeutics Currently Undergoing Clinical Trials</span>. <i>Nanomedicine</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">e1416</span>– <span class="NLM_lpage">e1434</span>, <span class="refDoi"> DOI: 10.1002/wnan.1416</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1002%2Fwnan.1416" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=e1416-e1434&author=J.+M.+Casterauthor=A.+N.+Patelauthor=T.+Zhangauthor=A.+Wang&title=Investigational+Nanomedicines+in+2016%3A+A+Review+of+Nanotherapeutics+Currently+Undergoing+Clinical+Trials&doi=10.1002%2Fwnan.1416"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1002%2Fwnan.1416&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fwnan.1416%26sid%3Dliteratum%253Aachs%26aulast%3DCaster%26aufirst%3DJ.%2BM.%26aulast%3DPatel%26aufirst%3DA.%2BN.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DA.%26atitle%3DInvestigational%2520Nanomedicines%2520in%25202016%253A%2520A%2520Review%2520of%2520Nanotherapeutics%2520Currently%2520Undergoing%2520Clinical%2520Trials%26jtitle%3DNanomedicine%26date%3D2017%26volume%3D9%26spage%3De1416%26epage%3De1434%26doi%3D10.1002%2Fwnan.1416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papoian, T.</span></span> <span> </span><span class="NLM_article-title">Safety of Antisense Oligonucleotide and SiRNA-Based Therapeutics</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">823</span>– <span class="NLM_lpage">833</span>, 144. <span class="refDoi"> DOI: 10.1016/j.drudis.2017.01.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.drudis.2017.01.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=28159625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2sXit1eqs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=823-833&author=X.+Chiauthor=P.+Gattiauthor=T.+Papoian&title=Safety+of+Antisense+Oligonucleotide+and+SiRNA-Based+Therapeutics&doi=10.1016%2Fj.drudis.2017.01.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Safety of antisense oligonucleotide and siRNA-based therapeutics</span></div><div class="casAuthors">Chi, Xuan; Gatti, Philip; Papoian, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">823-833</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Oligonucleotide-based therapy is an active area of drug development designed to treat a variety of gene-specific diseases.  Two of the more promising platforms are the antisense oligonucleotides (ASOs) and short interfering RNAs (siRNAs), both of which are often directed against similar targets.  In light of recent reports on clin. trials of severe thrombocytopenia with two different ASO drugs and increased peripheral neuropathy with an siRNA drug, we compared and contrasted the specific safety characteristics of these two classes of oligonucleotide therapeutic.  The objectives were to assess factors that could contribute to the specific toxicities obsd. with these two classes of promising drugs, and get a better understanding of the potential mechanism(s) responsible for these rare, but serious, adverse events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2Ej7iOK40PbVg90H21EOLACvtfcHk0li-KpWLRAlHsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXit1eqs70%253D&md5=40ef4591957b37ab501c95f53b6aa07b</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2017.01.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2017.01.013%26sid%3Dliteratum%253Aachs%26aulast%3DChi%26aufirst%3DX.%26aulast%3DGatti%26aufirst%3DP.%26aulast%3DPapoian%26aufirst%3DT.%26atitle%3DSafety%2520of%2520Antisense%2520Oligonucleotide%2520and%2520SiRNA-Based%2520Therapeutics%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2017%26volume%3D22%26spage%3D823%26epage%3D833%26doi%3D10.1016%2Fj.drudis.2017.01.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ventola, C. L.</span></span> <span> </span><span class="NLM_article-title">Progress in Nanomedicine: Approved and Investigational Nanodrugs</span>. <i>Pharm. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">742</span>– <span class="NLM_lpage">755</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2017&pages=742-755&author=C.+L.+Ventola&title=Progress+in+Nanomedicine%3A+Approved+and+Investigational+Nanodrugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVentola%26aufirst%3DC.%2BL.%26atitle%3DProgress%2520in%2520Nanomedicine%253A%2520Approved%2520and%2520Investigational%2520Nanodrugs%26jtitle%3DPharm.%2520Ther.%26date%3D2017%26volume%3D42%26spage%3D742%26epage%3D755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Erdoǧar, N.</span>; <span class="NLM_string-name">Bilensoy, E.</span></span> <span> </span><span class="NLM_article-title">Cyclodextrin-Based Nanosystems in Targeted Cancer Therapy</span>. In  <i>Cyclodextrin Applications in Medicine, Food, Environment and Liquid Crystals</i>; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">Gewerbestrasse 11, 6330 Cham, Switzerland</span>, <span class="NLM_year">2018</span>; pp  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">80</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1007%2F978-3-319-76162-6_3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&pages=59-80&author=N.+Erdo%C7%A7ar&author=E.+Bilensoy&title=Cyclodextrin+Applications+in+Medicine%2C+Food%2C+Environment+and+Liquid+Crystals"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1007%2F978-3-319-76162-6_3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-3-319-76162-6_3%26sid%3Dliteratum%253Aachs%26aulast%3DErdo%25C7%25A7ar%26aufirst%3DN.%26atitle%3DCyclodextrin-Based%2520Nanosystems%2520in%2520Targeted%2520Cancer%2520Therapy%26btitle%3DCyclodextrin%2520Applications%2520in%2520Medicine%252C%2520Food%252C%2520Environment%2520and%2520Liquid%2520Crystals%26pub%3DSpringer%26date%3D2018%26spage%3D59%26epage%3D80" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bor, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mat Azmi, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yaghmur, A.</span></span> <span> </span><span class="NLM_article-title">Nanomedicines for Cancer Therapy: Current Status, Challenges and Future Prospects</span>. <i>Ther. Delivery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.4155/tde-2018-0062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.4155%2Ftde-2018-0062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=30678550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisFWgsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=113-132&author=G.+Borauthor=I.+D.+Mat+Azmiauthor=A.+Yaghmur&title=Nanomedicines+for+Cancer+Therapy%3A+Current+Status%2C+Challenges+and+Future+Prospects&doi=10.4155%2Ftde-2018-0062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Nanomedicines for cancer therapy: current status, challenges and future prospects</span></div><div class="casAuthors">Bor, Gizem; Mat Azmi, Intan Diana; Yaghmur, Anan</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Delivery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">113-132</span>CODEN:
                <span class="NLM_cas:coden">TDHEA7</span>;
        ISSN:<span class="NLM_cas:issn">2041-5990</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The emergence of nanomedicine as an innovative and promising alternative technol. shows many advantages over conventional cancer therapies and provides new opportunities for early detection, improved treatment, and diagnosis of cancer.  Despite the cancer nanomedicines capability of delivering chemotherapeutic agents while providing lower systemic toxicity, it is paramount to consider the cancer complexity and dynamics for bridging the translational bench-to-bedside gap.  It is important to conduct appropriate investigations for exploiting the tumor microenvironment, and achieving a more comprehensive understanding of the fundamental biol. processes in cancer and their roles in modulating nanoparticle-protein interactions, blood circulation, and tumor penetration.  This review provides an overview of the current cancer nanomedicines, the major challenges, and the future opportunities in this research area.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7xUAn3El1QbVg90H21EOLACvtfcHk0lhao3UVwIPD2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisFWgsbY%253D&md5=8b826e36413b87761c551032560dd9e5</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.4155%2Ftde-2018-0062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ftde-2018-0062%26sid%3Dliteratum%253Aachs%26aulast%3DBor%26aufirst%3DG.%26aulast%3DMat%2BAzmi%26aufirst%3DI.%2BD.%26aulast%3DYaghmur%26aufirst%3DA.%26atitle%3DNanomedicines%2520for%2520Cancer%2520Therapy%253A%2520Current%2520Status%252C%2520Challenges%2520and%2520Future%2520Prospects%26jtitle%3DTher.%2520Delivery%26date%3D2019%26volume%3D10%26spage%3D113%26epage%3D132%26doi%3D10.4155%2Ftde-2018-0062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeGiovanni, P.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rai, P.</span></span> <span> </span><span class="NLM_article-title">Cancer Nanomedicine: A Review of Recent Success in Drug Delivery</span>. <i>Clin. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">44</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1186/s40169-017-0175-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1186%2Fs40169-017-0175-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=28044245" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2017&pages=1-21&issue=44&author=S.+Tranauthor=P.-J.+DeGiovanniauthor=B.+Pielauthor=P.+Rai&title=Cancer+Nanomedicine%3A+A+Review+of+Recent+Success+in+Drug+Delivery&doi=10.1186%2Fs40169-017-0175-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1186%2Fs40169-017-0175-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40169-017-0175-0%26sid%3Dliteratum%253Aachs%26aulast%3DTran%26aufirst%3DS.%26aulast%3DDeGiovanni%26aufirst%3DP.-J.%26aulast%3DPiel%26aufirst%3DB.%26aulast%3DRai%26aufirst%3DP.%26atitle%3DCancer%2520Nanomedicine%253A%2520A%2520Review%2520of%2520Recent%2520Success%2520in%2520Drug%2520Delivery%26jtitle%3DClin.%2520Transl.%2520Med.%26date%3D2017%26volume%3D6%26issue%3D44%26spage%3D1%26epage%3D21%26doi%3D10.1186%2Fs40169-017-0175-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pooja, D.</span>; <span class="NLM_string-name">Kadari, A.</span>; <span class="NLM_string-name">Kulhari, H.</span>; <span class="NLM_string-name">Sistla, R.</span></span> <span> </span><span class="NLM_article-title">Lipid-Based Nanomedicines: Current Clinical Status and Future Perspectives</span>.  <i>Lipid Nanocarriers for Drug Targeting</i>; <span class="NLM_publisher-name">Elsevier</span>: <span class="NLM_year">2018</span>; pp  <span class="NLM_fpage">509</span>– <span class="NLM_lpage">528</span>, <span class="refDoi"> DOI: 10.1016/B978-0-12-813687-4.00013-X</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2FB978-0-12-813687-4.00013-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&pages=509-528&author=D.+Pooja&author=A.+Kadari&author=H.+Kulhari&author=R.+Sistla&title=Lipid+Nanocarriers+for+Drug+Targeting"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-813687-4.00013-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-0-12-813687-4.00013-X%26sid%3Dliteratum%253Aachs%26aulast%3DPooja%26aufirst%3DD.%26atitle%3DLipid-Based%2520Nanomedicines%253A%2520Current%2520Clinical%2520Status%2520and%2520Future%2520Perspectives%26btitle%3DLipid%2520Nanocarriers%2520for%2520Drug%2520Targeting%26pub%3DElsevier%26date%3D2018%26spage%3D509%26epage%3D528%26doi%3D10.1016%2FB978-0-12-813687-4.00013-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Asadian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhaenens, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onyshchenko, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Waele, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Declercq, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cools, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devreese, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deforce, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morent, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Geyter, N.</span></span> <span> </span><span class="NLM_article-title">Plasma Functionalization of Polycaprolactone Nanofibers Changes Protein Interactions with Cells, Resulting in Increased Cell Viability</span>. <i>ACS Appl. Mater. Interfaces</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">41962</span>– <span class="NLM_lpage">41977</span>, <span class="refDoi"> DOI: 10.1021/acsami.8b14995</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsami.8b14995" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1artb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=41962-41977&author=M.+Asadianauthor=M.+Dhaenensauthor=I.+Onyshchenkoauthor=S.+De+Waeleauthor=H.+Declercqauthor=P.+Coolsauthor=B.+Devreeseauthor=D.+Deforceauthor=R.+Morentauthor=N.+De+Geyter&title=Plasma+Functionalization+of+Polycaprolactone+Nanofibers+Changes+Protein+Interactions+with+Cells%2C+Resulting+in+Increased+Cell+Viability&doi=10.1021%2Facsami.8b14995"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Plasma Functionalization of Polycaprolactone Nanofibers Changes Protein Interactions with Cells, Resulting in Increased Cell Viability</span></div><div class="casAuthors">Asadian, Mahtab; Dhaenens, Maarten; Onyshchenko, Iuliia; De Waele, Stijn; Declercq, Heidi; Cools, Pieter; Devreese, Bart; Deforce, Dieter; Morent, Rino; De Geyter, Nathalie</div><div class="citationInfo"><span class="NLM_cas:title">ACS Applied Materials & Interfaces</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">41962-41977</span>CODEN:
                <span class="NLM_cas:coden">AAMICK</span>;
        ISSN:<span class="NLM_cas:issn">1944-8244</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The surface properties of electrospun scaffolds can greatly influence protein adsorption and, thus, strongly dictate cell-material interactions.  In this study, we aim to investigate possible correlations between the surface properties of argon, nitrogen, and ammonia and helium plasma-functionalized polycaprolactone (PCL) nanofibers (NFs) and their cellular interactions by examg. the protein corona patterns of the plasma-treated NFs as well as the cell membrane proteins involved in cell proliferation.  As a result of the performed plasma treatments, PCL NFs morphol. was preserved, while wettability was improved profoundly after all treatments because of the incorporation of polar surface groups.  Depending on the discharge gas, different types of groups are incorporated, which influenced the resultant cell-material interactions.  Argon plasma-functionalized PCL NFs, only enriched by oxygen-contg. functional groups, were found to show the best cell-material interactions, followed by N2 and He/NH3 plasma-treated samples.  Sodium dodecyl sulfate polyacrylamide gel electrophoresis and liq. chromatog.-mass spectrometry clearly indicated an increased protein retention compared with non-treated PCL NFs.  The nine proteins retained best on plasma-treated NF are important mediators of extracellular matrix interaction, illustrating the importance thereof for cell proliferation and the viability of cells.  Finally, 92 proteins that can be used to differentiate how the different plasma treatments are clustered and subjected to a gene ontol. study, illustrating the importance of keratinization and extracellular matrix organization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3KeF8cqssqbVg90H21EOLACvtfcHk0lgRU5FOHq1VAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1artb7O&md5=3e44be3a8b70048554bbc659cfad37e6</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1021%2Facsami.8b14995&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsami.8b14995%26sid%3Dliteratum%253Aachs%26aulast%3DAsadian%26aufirst%3DM.%26aulast%3DDhaenens%26aufirst%3DM.%26aulast%3DOnyshchenko%26aufirst%3DI.%26aulast%3DDe%2BWaele%26aufirst%3DS.%26aulast%3DDeclercq%26aufirst%3DH.%26aulast%3DCools%26aufirst%3DP.%26aulast%3DDevreese%26aufirst%3DB.%26aulast%3DDeforce%26aufirst%3DD.%26aulast%3DMorent%26aufirst%3DR.%26aulast%3DDe%2BGeyter%26aufirst%3DN.%26atitle%3DPlasma%2520Functionalization%2520of%2520Polycaprolactone%2520Nanofibers%2520Changes%2520Protein%2520Interactions%2520with%2520Cells%252C%2520Resulting%2520in%2520Increased%2520Cell%2520Viability%26jtitle%3DACS%2520Appl.%2520Mater.%2520Interfaces%26date%3D2018%26volume%3D10%26spage%3D41962%26epage%3D41977%26doi%3D10.1021%2Facsami.8b14995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corbo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molinaro, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parodi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toledano
Furman, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvatore, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tasciotti, E.</span></span> <span> </span><span class="NLM_article-title">The impact of Nanoparticle Protein Corona on Cytotoxicity, Immunotoxicity and Target Drug Delivery</span>. <i>Nanomedicine</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">81</span>– <span class="NLM_lpage">100</span>, <span class="refDoi"> DOI: 10.2217/nnm.15.188</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.2217%2Fnnm.15.188" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=26653875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVejtb7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=81-100&author=C.+Corboauthor=R.+Molinaroauthor=A.+Parodiauthor=N.+E.+Toledano%0AFurmanauthor=F.+Salvatoreauthor=E.+Tasciotti&title=The+impact+of+Nanoparticle+Protein+Corona+on+Cytotoxicity%2C+Immunotoxicity+and+Target+Drug+Delivery&doi=10.2217%2Fnnm.15.188"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">The impact of nanoparticle protein corona on cytotoxicity, immunotoxicity and target drug delivery</span></div><div class="casAuthors">Corbo, Claudia; Molinaro, Roberto; Parodi, Alessandro; Toledano Furman, Naama E.; Salvatore, Francesco; Tasciotti, Ennio</div><div class="citationInfo"><span class="NLM_cas:title">Nanomedicine (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">81-100</span>CODEN:
                <span class="NLM_cas:coden">NLUKAC</span>;
        ISSN:<span class="NLM_cas:issn">1743-5889</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">In a perfect sequence of events, nanoparticles (NPs) are injected into the bloodstream where they circulate until they reach the target tissue.  The ligand on the NP surface recognizes its specific receptor expressed on the target tissue and the drug is released in a controlled manner.  However, once injected in a physiol. environment, NPs interact with biol. components and are surrounded by a protein corona (PC).  This can trigger an immune response and affect NP toxicity and targeting capabilities.  In this review, we provide a survey of recent findings on the NP-PC interactions and discuss how the PC can be used to modulate both cytotoxicity and the immune response as well as to improve the efficacy of targeted delivery of nanocarriers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIXwVKlfiRp7Vg90H21EOLACvtfcHk0lgRU5FOHq1VAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVejtb7K&md5=541d052dabe708f6970385fdbdf8238b</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.2217%2Fnnm.15.188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fnnm.15.188%26sid%3Dliteratum%253Aachs%26aulast%3DCorbo%26aufirst%3DC.%26aulast%3DMolinaro%26aufirst%3DR.%26aulast%3DParodi%26aufirst%3DA.%26aulast%3DToledano%2BFurman%26aufirst%3DN.%2BE.%26aulast%3DSalvatore%26aufirst%3DF.%26aulast%3DTasciotti%26aufirst%3DE.%26atitle%3DThe%2520impact%2520of%2520Nanoparticle%2520Protein%2520Corona%2520on%2520Cytotoxicity%252C%2520Immunotoxicity%2520and%2520Target%2520Drug%2520Delivery%26jtitle%3DNanomedicine%26date%3D2016%26volume%3D11%26spage%3D81%26epage%3D100%26doi%3D10.2217%2Fnnm.15.188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span> <span> </span><span class="NLM_article-title">Ligand Size and Conformation Affects the Behavior of Nanoparticles Coated with In-Vitro and In-Vivo Protein Corona</span>. <i>ACS Appl. Mater. Interfaces</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">9094</span>– <span class="NLM_lpage">9103</span>, <span class="refDoi"> DOI: 10.1021/acsami.7b16096</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsami.7b16096" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtlOnsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=9094-9103&author=H.+Zhangauthor=T.+Wuauthor=W.+Yuauthor=S.+Ruanauthor=Q.+Heauthor=H.+Gao&title=Ligand+Size+and+Conformation+Affects+the+Behavior+of+Nanoparticles+Coated+with+In-Vitro+and+In-Vivo+Protein+Corona&doi=10.1021%2Facsami.7b16096"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand size and conformation affect the behavior of nanoparticles coated with in vitro and in vivo protein corona</span></div><div class="casAuthors">Zhang, Huajin; Wu, Tianmu; Yu, Wenqi; Ruan, Shaobo; He, Qin; Gao, Huile</div><div class="citationInfo"><span class="NLM_cas:title">ACS Applied Materials & Interfaces</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">9094-9103</span>CODEN:
                <span class="NLM_cas:coden">AAMICK</span>;
        ISSN:<span class="NLM_cas:issn">1944-8244</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Protein corona is immediately established on the surface of nanoparticles upon their introduction into biol. milieu.  Several studies have shown that the targeting efficiency of ligand-modified nanoparticles is attenuated or abolished owing to the protein adsorption.  Here, transferrin receptor-targeting ligands, including LT7 (CHAIYPRH), DT7 (hrpyiahc, all D-form amino acids), and transferrin, were used to identify the influence of the ligand size and conformation on protein corona formation.  The results showed that the targeting capacity of ligand-modified nanoparticles was lost after incubation with plasma in vitro, whereas it was partially retained after in vivo corona formation.  Results from sodium dodecyl sulfate polyacrylamide gel electrophoresis and liq. chromatog.-mass spectrometry revealed the difference in the compn. of in vitro and in vivo corona, wherein the ligand size and conformation played a crit. role.  Differences were obsd. in cellular internalization and exocytosis profiles on the basis of the ligand and corona source.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhsaHUdzBEOLVg90H21EOLACvtfcHk0lgRU5FOHq1VAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtlOnsrs%253D&md5=81c7e3a9515800776053a9bdfccabc58</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1021%2Facsami.7b16096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsami.7b16096%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DRuan%26aufirst%3DS.%26aulast%3DHe%26aufirst%3DQ.%26aulast%3DGao%26aufirst%3DH.%26atitle%3DLigand%2520Size%2520and%2520Conformation%2520Affects%2520the%2520Behavior%2520of%2520Nanoparticles%2520Coated%2520with%2520In-Vitro%2520and%2520In-Vivo%2520Protein%2520Corona%26jtitle%3DACS%2520Appl.%2520Mater.%2520Interfaces%26date%3D2018%26volume%3D10%26spage%3D9094%26epage%3D9103%26doi%3D10.1021%2Facsami.7b16096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span> <span> </span><span class="NLM_article-title">Electrical-Charge-Mediated Cancer Cell Targeting via Protein Corona-Decorated Superparamagnetic Nanoparticles an a Simulated Physiological Environment</span>. <i>ACS Appl. Mater. Interfaces</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">41986</span>– <span class="NLM_lpage">41998</span>, <span class="refDoi"> DOI: 10.1021/acsami.8b15098</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsami.8b15098" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitF2qtrfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=41986-41998&author=J.+Zhaoauthor=S.+Wuauthor=J.+Qinauthor=D.+Shiauthor=Y.+Wang&title=Electrical-Charge-Mediated+Cancer+Cell+Targeting+via+Protein+Corona-Decorated+Superparamagnetic+Nanoparticles+an+a+Simulated+Physiological+Environment&doi=10.1021%2Facsami.8b15098"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Electrical-Charge-Mediated Cancer Cell Targeting via Protein Corona-Decorated Superparamagnetic Nanoparticles in a Simulated Physiological Environment</span></div><div class="casAuthors">Zhao, Jian; Wu, Shengming; Qin, Jingwen; Shi, Donglu; Wang, Yilong</div><div class="citationInfo"><span class="NLM_cas:title">ACS Applied Materials & Interfaces</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">41986-41998</span>CODEN:
                <span class="NLM_cas:coden">AAMICK</span>;
        ISSN:<span class="NLM_cas:issn">1944-8244</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A crit. issue in nanomedicine is on the understanding of nano-bio interface behaviors, particularly when the nanoparticles are inevitably decorated by protein coronas in the physiol. fluids.  In this study, the effects of particle surface corona on cancer cell targeting were investigated in simulated physiol. fluids.  Cell targeting was achieved by two strategies: (1) using conventional epithelial cell adhesion mol. antibody-functionalized Fe3O4 nanoparticles and (2) rendering the same but naked magnetic nanoparticles elec. pos. charged, enabling them to electrostatically bind onto the neg. charged cancer cells.  The cell-particle electrostatic binding was found to be much stronger with faster reaction kinetics than the immunol. interactions even at 4 nC.  Both types of nanoparticles were decorated with various protein coronas by administration in a simulated physiol. system.  Well-decorated by protein coronas, the elec. charged particles retained strong electrostatic interactions with cancer cells, even upon reversal of the particle zeta potential from pos. to neg.  This behavior was explained by a nonuniform corona modulation of the particle surface charge distributions, exposing locally pos. charged regions, capable of strong electrostatic cell binding and magnetic capturing in a physiol. environment.  This fundamental discovery paves new way for sensitive detection of circulating tumor cells in whole blood in clin. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiwq7S_-e1iLVg90H21EOLACvtfcHk0ljf5iJQXDOE1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitF2qtrfL&md5=e5f09271a3ebfe9f97955f869e669267</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1021%2Facsami.8b15098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsami.8b15098%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DQin%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DY.%26atitle%3DElectrical-Charge-Mediated%2520Cancer%2520Cell%2520Targeting%2520via%2520Protein%2520Corona-Decorated%2520Superparamagnetic%2520Nanoparticles%2520an%2520a%2520Simulated%2520Physiological%2520Environment%26jtitle%3DACS%2520Appl.%2520Mater.%2520Interfaces%26date%3D2018%26volume%3D10%26spage%3D41986%26epage%3D41998%26doi%3D10.1021%2Facsami.8b15098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Westmeier, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauber, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Docter, D.</span></span> <span> </span><span class="NLM_article-title">The Concept of Bio-Corona in Modulating the Toxicity of Engineered Nanomaterials (ENM)</span>. <i>Toxicol. Appl. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>299</i></span>,  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">57</span>, <span class="refDoi"> DOI: 10.1016/j.taap.2015.11.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.taap.2015.11.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=26592323" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFeqsr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=299&publication_year=2016&pages=53-57&author=D.+Westmeierauthor=R.+H.+Stauberauthor=D.+Docter&title=The+Concept+of+Bio-Corona+in+Modulating+the+Toxicity+of+Engineered+Nanomaterials+%28ENM%29&doi=10.1016%2Fj.taap.2015.11.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">The concept of bio-corona in modulating the toxicity of engineered nanomaterials (ENM)</span></div><div class="casAuthors">Westmeier, Dana; Stauber, Roland H.; Docter, Dominic</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">299</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">53-57</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Besides the wide use of engineered nanomaterials (ENM) in tech. products, their application spectrum in biotechnol. and biomedicine is steadily increasing.  In complex physiol. environments the physico-chem. properties and the behavior of nanoparticles (NPs) are challenging to characterize.  Biomols. rapidly adsorb to the nanomaterial, leading to the formation of the protein/biomol. corona, which critically affects the nanomaterials' (patho)biol. and tech. identities.  This formation can trigger an immune response and affect nanoparticles' toxicity and targeting capabilities.  In this review, we provide a survey of recent findings on the (protein)corona-nanoparticle interaction and discuss how the corona modulates both cytotoxicity and the immune response as well as to improve the efficacy of targeted delivery of nanocarriers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosmfxIZQo8abVg90H21EOLACvtfcHk0ljf5iJQXDOE1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFeqsr7I&md5=a315836d5baee92935e5314dfe89f179</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1016%2Fj.taap.2015.11.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.taap.2015.11.008%26sid%3Dliteratum%253Aachs%26aulast%3DWestmeier%26aufirst%3DD.%26aulast%3DStauber%26aufirst%3DR.%2BH.%26aulast%3DDocter%26aufirst%3DD.%26atitle%3DThe%2520Concept%2520of%2520Bio-Corona%2520in%2520Modulating%2520the%2520Toxicity%2520of%2520Engineered%2520Nanomaterials%2520%2528ENM%2529%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D2016%26volume%3D299%26spage%3D53%26epage%3D57%26doi%3D10.1016%2Fj.taap.2015.11.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salvati, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitek, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monopoli, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prapainop, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bombelli, F. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hristov, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Åberg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, K. A.</span></span> <span> </span><span class="NLM_article-title">Transferrin-Functionalized Nanoparticles Lose Their Targeting Capabilities When a Biomolecule Corona Adsorbs on the Surface</span>. <i>Nat. Nanotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">137</span>– <span class="NLM_lpage">143</span>, <span class="refDoi"> DOI: 10.1038/nnano.2012.237</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1038%2Fnnano.2012.237" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=23334168" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFSjtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=137-143&author=A.+Salvatiauthor=A.+S.+Pitekauthor=M.+P.+Monopoliauthor=K.+Prapainopauthor=F.+B.+Bombelliauthor=D.+R.+Hristovauthor=P.+M.+Kellyauthor=C.+%C3%85bergauthor=E.+Mahonauthor=K.+A.+Dawson&title=Transferrin-Functionalized+Nanoparticles+Lose+Their+Targeting+Capabilities+When+a+Biomolecule+Corona+Adsorbs+on+the+Surface&doi=10.1038%2Fnnano.2012.237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface</span></div><div class="casAuthors">Salvati, Anna; Pitek, Andrzej S.; Monopoli, Marco P.; Prapainop, Kanlaya; Bombelli, Francesca Baldelli; Hristov, Delyan R.; Kelly, Philip M.; Aberg, Christoffer; Mahon, Eugene; Dawson, Kenneth A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Nanotechnology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">137-143</span>CODEN:
                <span class="NLM_cas:coden">NNAABX</span>;
        ISSN:<span class="NLM_cas:issn">1748-3387</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Nanoparticles have been proposed as carriers for drugs, genes and therapies to treat various diseases.  Many strategies have been developed to target nanomaterials to specific or over-expressed receptors in diseased cells, and these typically involve functionalizing the surface of nanoparticles with proteins, antibodies or other biomols.  Here, we show that the targeting ability of such functionalized nanoparticles may disappear when they are placed in a biol. environment.  Using transferrin-conjugated nanoparticles, we found that proteins in the media can shield transferrin from binding to both its targeted receptors on cells and sol. transferrin receptors.  Although nanoparticles continue to enter cells, the targeting specificity of transferrin is lost.  Our results suggest that when nanoparticles are placed in a complex biol. environment, interaction with other proteins in the medium and the formation of a protein corona can 'screen' the targeting mols. on the surface of nanoparticles and cause loss of specificity in targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEAjBW1PnMK7Vg90H21EOLACvtfcHk0ljf5iJQXDOE1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFSjtLg%253D&md5=cf3fbdf4d460fc8f016bbc2337719d96</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1038%2Fnnano.2012.237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnnano.2012.237%26sid%3Dliteratum%253Aachs%26aulast%3DSalvati%26aufirst%3DA.%26aulast%3DPitek%26aufirst%3DA.%2BS.%26aulast%3DMonopoli%26aufirst%3DM.%2BP.%26aulast%3DPrapainop%26aufirst%3DK.%26aulast%3DBombelli%26aufirst%3DF.%2BB.%26aulast%3DHristov%26aufirst%3DD.%2BR.%26aulast%3DKelly%26aufirst%3DP.%2BM.%26aulast%3D%25C3%2585berg%26aufirst%3DC.%26aulast%3DMahon%26aufirst%3DE.%26aulast%3DDawson%26aufirst%3DK.%2BA.%26atitle%3DTransferrin-Functionalized%2520Nanoparticles%2520Lose%2520Their%2520Targeting%2520Capabilities%2520When%2520a%2520Biomolecule%2520Corona%2520Adsorbs%2520on%2520the%2520Surface%26jtitle%3DNat.%2520Nanotechnol.%26date%3D2013%26volume%3D8%26spage%3D137%26epage%3D143%26doi%3D10.1038%2Fnnano.2012.237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dai, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ang, C.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kempe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamphuis, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodds, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caruso, F.</span></span> <span> </span><span class="NLM_article-title">Monoclonal Antibody-Functionalized Multilayered Particles: Targeting Cancer Cells in the Presence of Protein Coronas</span>. <i>ACS Nano</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">2876</span>– <span class="NLM_lpage">2885</span>, <span class="refDoi"> DOI: 10.1021/nn506929e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/nn506929e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtlChsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=2876-2885&author=Q.+Daiauthor=Y.+Yanauthor=C.-S.+Angauthor=K.+Kempeauthor=M.+M.+Kamphuisauthor=S.+J.+Doddsauthor=F.+Caruso&title=Monoclonal+Antibody-Functionalized+Multilayered+Particles%3A+Targeting+Cancer+Cells+in+the+Presence+of+Protein+Coronas&doi=10.1021%2Fnn506929e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Monoclonal Antibody-Functionalized Multilayered Particles: Targeting Cancer Cells in the Presence of Protein Coronas</span></div><div class="casAuthors">Dai, Qiong; Yan, Yan; Ang, Ching-Seng; Kempe, Kristian; Kamphuis, Marloes M. J.; Dodds, Sarah J.; Caruso, Frank</div><div class="citationInfo"><span class="NLM_cas:title">ACS Nano</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">2876-2885</span>CODEN:
                <span class="NLM_cas:coden">ANCAC3</span>;
        ISSN:<span class="NLM_cas:issn">1936-0851</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Engineered particles adsorb biomols. (e.g., proteins) when introduced in a biol. medium to form a layer called a "corona".  Coronas, in particular the protein corona, play an important role in detg. the surface properties of particles and their targeting abilities.  This study examines the influence of protein coronas on the targeting ability of layer-by-layer (LbL)-assembled polymer capsules and core-shell particles functionalized with monoclonal antibodies.  Upon exposure of humanized A33 monoclonal antibody (huA33 mAb)-functionalized poly(methacrylic acid) (PMA) capsules or huA33 mAb-PMA particles to human serum, a total of 83 or 65 proteins were identified in the protein coronas, resp.  Human serum of varying concns. altered the compn. of the protein corona.  The antibody-driven specific cell membrane binding was qual. and quant. assessed by flow cytometry and fluorescence microscopy in both the absence and presence of a protein corona.  The findings show that although different protein coronas formed in human serum (at different concns.), the targeting ability of both the huA33 mAb-functionalized PMA capsules and particles toward human colon cancer cells was retained, demonstrating no significant difference compared with capsules and particles in the absence of protein coronas: ∼70% and ∼90% A33-expressing cells were targeted by the huA33 mAb-PMA capsules and particles, resp., in a mixed cell population.  This result demonstrates that the formation of protein coronas did not significantly influence the targeting ability of antibody-functionalized LbL-polymer carriers, indicating that the surface functionality of engineered particles in the presence of protein coronas can be preserved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGru61EZOY1VE7Vg90H21EOLACvtfcHk0ljz3scs-3qs0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtlChsLg%253D&md5=f1a4822e298052519b11980e337dff9b</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1021%2Fnn506929e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fnn506929e%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DQ.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DAng%26aufirst%3DC.-S.%26aulast%3DKempe%26aufirst%3DK.%26aulast%3DKamphuis%26aufirst%3DM.%2BM.%26aulast%3DDodds%26aufirst%3DS.%2BJ.%26aulast%3DCaruso%26aufirst%3DF.%26atitle%3DMonoclonal%2520Antibody-Functionalized%2520Multilayered%2520Particles%253A%2520Targeting%2520Cancer%2520Cells%2520in%2520the%2520Presence%2520of%2520Protein%2520Coronas%26jtitle%3DACS%2520Nano%26date%3D2015%26volume%3D9%26spage%3D2876%26epage%3D2885%26doi%3D10.1021%2Fnn506929e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Safavi-Sohi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maghari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raoufi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jalali, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hajipour, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghassempour, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahmoudi, M.</span></span> <span> </span><span class="NLM_article-title">Bypassing Protein Corona Issue on Active Targeting: Zwitterionic Coatings Dictate Specific Interactions of Targeting Moieties and Cell Receptors</span>. <i>ACS Appl. Mater. Interfaces</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">22808</span>– <span class="NLM_lpage">22818</span>, <span class="refDoi"> DOI: 10.1021/acsami.6b05099</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsami.6b05099" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlehsrnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=22808-22818&author=R.+Safavi-Sohiauthor=S.+Maghariauthor=M.+Raoufiauthor=S.+A.+Jalaliauthor=M.+J.+Hajipourauthor=A.+Ghassempourauthor=M.+Mahmoudi&title=Bypassing+Protein+Corona+Issue+on+Active+Targeting%3A+Zwitterionic+Coatings+Dictate+Specific+Interactions+of+Targeting+Moieties+and+Cell+Receptors&doi=10.1021%2Facsami.6b05099"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Bypassing Protein Corona Issue on Active Targeting: Zwitterionic Coatings Dictate Specific Interactions of Targeting Moieties and Cell Receptors</span></div><div class="casAuthors">Safavi-Sohi, Reihaneh; Maghari, Shokoofeh; Raoufi, Mohammad; Jalali, Seyed Amir; Hajipour, Mohammad J.; Ghassempour, Alireza; Mahmoudi, Morteza</div><div class="citationInfo"><span class="NLM_cas:title">ACS Applied Materials & Interfaces</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">22808-22818</span>CODEN:
                <span class="NLM_cas:coden">AAMICK</span>;
        ISSN:<span class="NLM_cas:issn">1944-8244</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Surface functionalization strategies for targeting nanoparticles (NP) to specific organs, cells, or organelles, is the foundation for new applications of nanomedicine to drug delivery and biomedical imaging.  Interaction of NPs with biol. media leads to the formation of a biomol. layer at the surface of NPs so called as "protein corona".  This corona layer can shield active mols. at the surface of NPs and cause mistargeting or unintended scavenging by the liver, kidney or spleen.  To overcome this corona issue, we have designed biotin-cysteine conjugated silica NPs (biotin was employed as a targeting mol. and cysteine was used as a zwitterionic ligand) to inhibit corona-induced mistargeting and thus significantly enhance the active targeting capability of NPs in complex biol. media.  To probe the targeting yield of our engineered NPs, we employed both modified silicon wafer substrates with streptavidin (i.e., biotin receptor) to simulate a target and a cell-based model platform using tumor cell lines that overexpress biotin receptors.  In both cases, after incubation with human plasma (thus forming a protein corona), cellular uptake/substrate attachment of the targeted NPs with zwitterionic coatings were significantly higher than the same NPs without zwitterionic coating.  Our results demonstrated that NPs with a zwitterionic surface can considerably facilitate targeting yield of NPs and provide a promising new type of nanocarriers in biol. applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4WQu-uOT6HrVg90H21EOLACvtfcHk0ljz3scs-3qs0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlehsrnJ&md5=115c6eea9dfadcff81979cbf7e972809</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1021%2Facsami.6b05099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsami.6b05099%26sid%3Dliteratum%253Aachs%26aulast%3DSafavi-Sohi%26aufirst%3DR.%26aulast%3DMaghari%26aufirst%3DS.%26aulast%3DRaoufi%26aufirst%3DM.%26aulast%3DJalali%26aufirst%3DS.%2BA.%26aulast%3DHajipour%26aufirst%3DM.%2BJ.%26aulast%3DGhassempour%26aufirst%3DA.%26aulast%3DMahmoudi%26aufirst%3DM.%26atitle%3DBypassing%2520Protein%2520Corona%2520Issue%2520on%2520Active%2520Targeting%253A%2520Zwitterionic%2520Coatings%2520Dictate%2520Specific%2520Interactions%2520of%2520Targeting%2520Moieties%2520and%2520Cell%2520Receptors%26jtitle%3DACS%2520Appl.%2520Mater.%2520Interfaces%26date%3D2016%26volume%3D8%26spage%3D22808%26epage%3D22818%26doi%3D10.1021%2Facsami.6b05099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neagu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piperigkou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karamanou, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engin, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Docea, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Constantin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negrei, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikitovic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsatsakis, A.</span></span> <span> </span><span class="NLM_article-title">Protein Bio-Corona: Critical Issue in Immune Nanotoxicology</span>. <i>Arch. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">1031</span>– <span class="NLM_lpage">1048</span>, <span class="refDoi"> DOI: 10.1007/s00204-016-1797-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1007%2Fs00204-016-1797-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=27438349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Sgsr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2017&pages=1031-1048&author=M.+Neaguauthor=Z.+Piperigkouauthor=K.+Karamanouauthor=A.+B.+Enginauthor=A.+O.+Doceaauthor=C.+Constantinauthor=C.+Negreiauthor=D.+Nikitovicauthor=A.+Tsatsakis&title=Protein+Bio-Corona%3A+Critical+Issue+in+Immune+Nanotoxicology&doi=10.1007%2Fs00204-016-1797-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Protein bio-corona: critical issue in immune nanotoxicology</span></div><div class="casAuthors">Neagu, Monica; Piperigkou, Zoi; Karamanou, Konstantina; Engin, Ayse Basak; Docea, Anca Oana; Constantin, Carolina; Negrei, Carolina; Nikitovic, Dragana; Tsatsakis, Aristidis</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Toxicology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1031-1048</span>CODEN:
                <span class="NLM_cas:coden">ARTODN</span>;
        ISSN:<span class="NLM_cas:issn">0340-5761</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  With the expansion of the nanomedicine field, the knowledge focusing on the behavior of nanoparticles in the biol. milieu has rapidly escalated.  Upon introduction to a complex biol. system, nanomaterials dynamically interact with all the encountered biomols. and form the protein "bio-corona.".  The decoration with these surface biomols. endows nanoparticles with new properties.  The present review will address updates of the protein bio-corona characteristics as influenced by nanoparticle's physicochem. properties and by the particularities of the encountered biol. milieu.  Undeniably, bio-corona generation influences the efficacy of the nanodrug and guides the actions of innate and adaptive immunity.  Exploiting the dynamic process of protein bio-corona development in combination with the new engineered horizons of drugs linked to nanoparticles could lead to innovative functional nanotherapies.  Therefore, bio-medical nanotechnologies should focus on the interactions of nanoparticles with the immune system for both safety and efficacy reasons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2WVdIGRRKQrVg90H21EOLACvtfcHk0ljz3scs-3qs0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Sgsr%252FM&md5=d9c11c551cbe5e4a5c8f428175ea680f</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1007%2Fs00204-016-1797-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00204-016-1797-5%26sid%3Dliteratum%253Aachs%26aulast%3DNeagu%26aufirst%3DM.%26aulast%3DPiperigkou%26aufirst%3DZ.%26aulast%3DKaramanou%26aufirst%3DK.%26aulast%3DEngin%26aufirst%3DA.%2BB.%26aulast%3DDocea%26aufirst%3DA.%2BO.%26aulast%3DConstantin%26aufirst%3DC.%26aulast%3DNegrei%26aufirst%3DC.%26aulast%3DNikitovic%26aufirst%3DD.%26aulast%3DTsatsakis%26aufirst%3DA.%26atitle%3DProtein%2520Bio-Corona%253A%2520Critical%2520Issue%2520in%2520Immune%2520Nanotoxicology%26jtitle%3DArch.%2520Toxicol.%26date%3D2017%26volume%3D91%26spage%3D1031%26epage%3D1048%26doi%3D10.1007%2Fs00204-016-1797-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tonigold, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estupiñán, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokkinopoulou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinholz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kintzel, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaltbeitzel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domogalla, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbrink, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieberwirth, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crespy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landfester, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mailander, V.</span></span> <span> </span><span class="NLM_article-title">Pre-Adsorption of Antibodies Enables Targeting of Nanocarriers Despite a Biomolecular Corona</span>. <i>Nat. Nanotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">862</span>– <span class="NLM_lpage">869</span>, <span class="refDoi"> DOI: 10.1038/s41565-018-0171-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1038%2Fs41565-018-0171-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=29915272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFGksLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=862-869&author=M.+Tonigoldauthor=J.+Simonauthor=D.+Estupi%C3%B1%C3%A1nauthor=M.+Kokkinopoulouauthor=J.+Reinholzauthor=U.+Kintzelauthor=A.+Kaltbeitzelauthor=P.+Renzauthor=M.+P.+Domogallaauthor=K.+Steinbrinkauthor=I.+Lieberwirthauthor=D.+Crespyauthor=K.+Landfesterauthor=V.+Mailander&title=Pre-Adsorption+of+Antibodies+Enables+Targeting+of+Nanocarriers+Despite+a+Biomolecular+Corona&doi=10.1038%2Fs41565-018-0171-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Pre-adsorption of antibodies enables targeting of nanocarriers despite a biomolecular corona</span></div><div class="casAuthors">Tonigold, Manuel; Simon, Johanna; Estupinan, Diego; Kokkinopoulou, Maria; Reinholz, Jonas; Kintzel, Ulrike; Kaltbeitzel, Anke; Renz, Patricia; Domogalla, Matthias P.; Steinbrink, Kerstin; Lieberwirth, Ingo; Crespy, Daniel; Landfester, Katharina; Mailaender, Volker</div><div class="citationInfo"><span class="NLM_cas:title">Nature Nanotechnology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">862-869</span>CODEN:
                <span class="NLM_cas:coden">NNAABX</span>;
        ISSN:<span class="NLM_cas:issn">1748-3387</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">To promote drug delivery to exact sites and cell types, the surface of nanocarriers is functionalized with targeting antibodies or ligands, typically coupled by covalent chem.  Once the nanocarrier is exposed to biol. fluid such as plasma, however, its surface is inevitably covered with various biomols. forming the protein corona, which masks the targeting ability of the nanoparticle.  Here, we show that we can use a pre-adsorption process to attach targeting antibodies to the surface of the nanocarrier.  Pre-adsorbed antibodies remain functional and are not completely exchanged or covered by the biomol. corona, whereas coupled antibodies are more affected by this shielding.  We conclude that pre-adsorption is potentially a versatile, efficient and rapid method of attaching targeting moieties to the surface of nanocarriers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7KwxlOIkCW7Vg90H21EOLACvtfcHk0lh36bgkBZ_eOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFGksLjP&md5=3cadadfffbc7c3caefecbec690ebcf9f</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1038%2Fs41565-018-0171-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41565-018-0171-6%26sid%3Dliteratum%253Aachs%26aulast%3DTonigold%26aufirst%3DM.%26aulast%3DSimon%26aufirst%3DJ.%26aulast%3DEstupi%25C3%25B1%25C3%25A1n%26aufirst%3DD.%26aulast%3DKokkinopoulou%26aufirst%3DM.%26aulast%3DReinholz%26aufirst%3DJ.%26aulast%3DKintzel%26aufirst%3DU.%26aulast%3DKaltbeitzel%26aufirst%3DA.%26aulast%3DRenz%26aufirst%3DP.%26aulast%3DDomogalla%26aufirst%3DM.%2BP.%26aulast%3DSteinbrink%26aufirst%3DK.%26aulast%3DLieberwirth%26aufirst%3DI.%26aulast%3DCrespy%26aufirst%3DD.%26aulast%3DLandfester%26aufirst%3DK.%26aulast%3DMailander%26aufirst%3DV.%26atitle%3DPre-Adsorption%2520of%2520Antibodies%2520Enables%2520Targeting%2520of%2520Nanocarriers%2520Despite%2520a%2520Biomolecular%2520Corona%26jtitle%3DNat.%2520Nanotechnol.%26date%3D2018%26volume%3D13%26spage%3D862%26epage%3D869%26doi%3D10.1038%2Fs41565-018-0171-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahmoudi, M.</span></span> <span> </span><span class="NLM_article-title">Antibody Orientation Determines Corona Mistargeting Capability</span>. <i>Nat. Nanotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">775</span>– <span class="NLM_lpage">776</span>, <span class="refDoi"> DOI: 10.1038/s41565-018-0147-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1038%2Fs41565-018-0147-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=29915270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFGksLjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=775-776&author=M.+Mahmoudi&title=Antibody+Orientation+Determines+Corona+Mistargeting+Capability&doi=10.1038%2Fs41565-018-0147-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody orientation determines corona mistargeting capability</span></div><div class="casAuthors">Mahmoudi, Morteza</div><div class="citationInfo"><span class="NLM_cas:title">Nature Nanotechnology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">775-776</span>CODEN:
                <span class="NLM_cas:coden">NNAABX</span>;
        ISSN:<span class="NLM_cas:issn">1748-3387</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Antibody pre-adsorption can reduce the adverse effects of the biomol. corona.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBQG8-zd4iUrVg90H21EOLACvtfcHk0lh36bgkBZ_eOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFGksLjL&md5=03b8fe46098e8edf59cc5ffed88a0799</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1038%2Fs41565-018-0147-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41565-018-0147-6%26sid%3Dliteratum%253Aachs%26aulast%3DMahmoudi%26aufirst%3DM.%26atitle%3DAntibody%2520Orientation%2520Determines%2520Corona%2520Mistargeting%2520Capability%26jtitle%3DNat.%2520Nanotechnol.%26date%3D2018%26volume%3D13%26spage%3D775%26epage%3D776%26doi%3D10.1038%2Fs41565-018-0147-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, H.</span></span> <span> </span><span class="NLM_article-title">The potential of Protein–Nanomaterial Interaction for Advanced Drug Delivery</span>. <i>J. Controlled Release</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>225</i></span>,  <span class="NLM_fpage">121</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1016/j.jconrel.2016.01.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.jconrel.2016.01.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=26812004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhslyhu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=225&publication_year=2016&pages=121-132&author=Q.+Pengauthor=H.+Mu&title=The+potential+of+Protein%E2%80%93Nanomaterial+Interaction+for+Advanced+Drug+Delivery&doi=10.1016%2Fj.jconrel.2016.01.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">The potential of protein-nanomaterial interaction for advanced drug delivery</span></div><div class="casAuthors">Peng, Qiang; Mu, Huiling</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">225</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">121-132</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Nanomaterials, like nanoparticles, micelles, nano-sheets, nanotubes and quantum dots, have great potentials in biomedical fields.  However, their delivery is highly limited by the formation of protein corona upon interaction with endogenous proteins.  This new identity, instead of nanomaterial itself, would be the real substance the organs and cells firstly encounter.  Consequently, the behavior of nanomaterials in vivo is uncontrollable and some undesired effects may occur, like rapid clearance from blood stream; risk of capillary blockage; loss of targeting capacity; and potential toxicity.  Therefore, protein-nanomaterial interaction is a great challenge for nanomaterial systems and should be inhibited.  However, this interaction can also be used to functionalize nanomaterials by forming a selected protein corona.  Unlike other decoration using exogenous mols., nanomaterials functionalized by selected protein corona using endogenous proteins would have greater promise for clin. use.  In this review, we aim to provide a comprehensive understanding of protein-nanomaterial interaction.  Importantly, a discussion about how to use such interaction is launched and some possible applications of such interaction for advanced drug delivery are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqZitagPA6rrVg90H21EOLACvtfcHk0lh36bgkBZ_eOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhslyhu7Y%253D&md5=51f036bc4814aa2a71b2f9ebc9ebd97d</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2016.01.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2016.01.041%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DQ.%26aulast%3DMu%26aufirst%3DH.%26atitle%3DThe%2520potential%2520of%2520Protein%25E2%2580%2593Nanomaterial%2520Interaction%2520for%2520Advanced%2520Drug%2520Delivery%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2016%26volume%3D225%26spage%3D121%26epage%3D132%26doi%3D10.1016%2Fj.jconrel.2016.01.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miclaus, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murugadoss, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takamiya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scavenius, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kjaer-Sorensen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enghild, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strähle, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oxvig, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherland, D. S.</span></span> <span> </span><span class="NLM_article-title">Female Versus Male Biological Identities of Nanoparticles Determine the Interaction with Immune Cells in Fish</span>. <i>Environ. Sci.: Nano</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">895</span>– <span class="NLM_lpage">906</span>, <span class="refDoi"> DOI: 10.1039/C7EN00071E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1039%2FC7EN00071E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjs1GktLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2017&pages=895-906&author=Y.+Hayashiauthor=T.+Miclausauthor=S.+Murugadossauthor=M.+Takamiyaauthor=C.+Scaveniusauthor=K.+Kjaer-Sorensenauthor=J.+J.+Enghildauthor=U.+Str%C3%A4hleauthor=C.+Oxvigauthor=C.+Weissauthor=D.+S.+Sutherland&title=Female+Versus+Male+Biological+Identities+of+Nanoparticles+Determine+the+Interaction+with+Immune+Cells+in+Fish&doi=10.1039%2FC7EN00071E"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Female versus male biological identities of nanoparticles determine the interaction with immune cells in fish</span></div><div class="casAuthors">Hayashi, Yuya; Miclaus, Teodora; Murugadoss, Sivakumar; Takamiya, Masanari; Scavenius, Carsten; Kjaer-Sorensen, Kasper; Enghild, Jan J.; Strahle, Uwe; Oxvig, Claus; Weiss, Carsten; Sutherland, Duncan S.</div><div class="citationInfo"><span class="NLM_cas:title">Environmental Science: Nano</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">895-906</span>CODEN:
                <span class="NLM_cas:coden">ESNNA4</span>;
        ISSN:<span class="NLM_cas:issn">2051-8161</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Biomol. decoration of nanoparticles provides a corona that modulates how the nanoparticles interact with biol. milieus.  The corona compn. has proved to reflect the differences in the repertoire of proteins to which the nanoparticles are exposed, and as a result the same nanoparticles can acquire a differential biol. identity.  Here we examd. whether a unique biol. identity acquired from sex-specific protein repertoires could alter the degree of nanoparticle uptake by cognate immune cells.  We chose zebrafish as a model species of which blood plasma is sexually contrasted by the unique presence/absence of the egg yolk precursor protein vitellogenin.  Sex-specific protein coronas were thus formed around 70 nm SiO2 nanoparticles using female/male blood plasma from zebrafish or fetal bovine serum as a non-native ref.  In contrast to protein coronas formed of male blood plasma, a "female" biol. identity of the nanoparticles was represented by prevailing contribution of vitellogenins to the corona proteome.  We then exposed zebrafish blood cells to the three types of pre-formed nanoparticle-protein complexes and compared nanoparticle uptake using flow cytometry.  Lymphoid and myeloid populations of the blood cells preferentially accumulated the nanoparticles with a female biol. identity, irresp. of the sex of the fish from which the cells were obtained.  The concept of repertoire differences in the corona proteome therefore deserves further attention, as various factors such as sex-specific biol. conditions exemplified in this study could alter the nanoparticle-cell interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8X4Lcw_LbY7Vg90H21EOLACvtfcHk0ljhGFJpp_p9Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjs1GktLs%253D&md5=f825c6816fa7cfa3a38ba891d54dd6db</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1039%2FC7EN00071E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7EN00071E%26sid%3Dliteratum%253Aachs%26aulast%3DHayashi%26aufirst%3DY.%26aulast%3DMiclaus%26aufirst%3DT.%26aulast%3DMurugadoss%26aufirst%3DS.%26aulast%3DTakamiya%26aufirst%3DM.%26aulast%3DScavenius%26aufirst%3DC.%26aulast%3DKjaer-Sorensen%26aufirst%3DK.%26aulast%3DEnghild%26aufirst%3DJ.%2BJ.%26aulast%3DStr%25C3%25A4hle%26aufirst%3DU.%26aulast%3DOxvig%26aufirst%3DC.%26aulast%3DWeiss%26aufirst%3DC.%26aulast%3DSutherland%26aufirst%3DD.%2BS.%26atitle%3DFemale%2520Versus%2520Male%2520Biological%2520Identities%2520of%2520Nanoparticles%2520Determine%2520the%2520Interaction%2520with%2520Immune%2520Cells%2520in%2520Fish%26jtitle%3DEnviron.%2520Sci.%253A%2520Nano%26date%3D2017%26volume%3D4%26spage%3D895%26epage%3D906%26doi%3D10.1039%2FC7EN00071E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Serpooshan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheibani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pushparaj, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wojcik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoso, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safavi-Sohi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haghjoo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nejadnik, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aghaverdi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vali, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinsella, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Presley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P. C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahmoudi, M.</span></span> <span> </span><span class="NLM_article-title">Effect of Cell Sex on Uptake of Nanoparticles: The Overlooked Factor at the Nanobio Interface</span>. <i>ACS Nano</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2253</span>– <span class="NLM_lpage">2266</span>, <span class="refDoi"> DOI: 10.1021/acsnano.7b06212</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsnano.7b06212" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktlKhsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2018&pages=2253-2266&author=V.+Serpooshanauthor=S.+Sheibaniauthor=P.+Pushparajauthor=M.+Wojcikauthor=A.+Y.+Jangauthor=M.+R.+Santosoauthor=J.+H.+Jangauthor=H.+Huangauthor=R.+Safavi-Sohiauthor=N.+Haghjooauthor=H.+Nejadnikauthor=H.+Aghaverdiauthor=H.+Valiauthor=J.+M.+Kinsellaauthor=J.+Presleyauthor=K.+Xuauthor=P.+C.-M.+Yangauthor=M.+Mahmoudi&title=Effect+of+Cell+Sex+on+Uptake+of+Nanoparticles%3A+The+Overlooked+Factor+at+the+Nanobio+Interface&doi=10.1021%2Facsnano.7b06212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of Cell Sex on Uptake of Nanoparticles: The Overlooked Factor at the Nanobio Interface</span></div><div class="casAuthors">Serpooshan, Vahid; Sheibani, Sara; Pushparaj, Pooja; Wojcik, Michal; Jang, Albert Y.; Santoso, Michelle R.; Jang, Joyce H.; Huang, Haina; Safavi-Sohi, Reihaneh; Haghjoo, Niloofar; Nejadnik, Hossein; Aghaverdi, Haniyeh; Vali, Hojatollah; Kinsella, Joseph Matthew; Presley, John; Xu, Ke; Yang, Phillip Chung-Ming; Mahmoudi, Morteza</div><div class="citationInfo"><span class="NLM_cas:title">ACS Nano</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">2253-2266</span>CODEN:
                <span class="NLM_cas:coden">ANCAC3</span>;
        ISSN:<span class="NLM_cas:issn">1936-0851</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cellular uptake of nanoparticles (NPs) depends on the nature of the nanobio system including the solid nanocomponents (e.g., physicochem. properties of NPs), nanobio interfaces (e.g., protein corona compn.), and the cellular characteristics (e.g., cell type).  In this study, we document the role of sex in cellular uptake of NPs as an "overlooked" factor in nanobio interface investigations.  We demonstrate that cell sex leads to differences in NP uptake between male and female human amniotic stem cells (hAMSCs), with greater uptake by female cells. hAMSCs are one of the earliest sources of somatic stem cells.  The expts. were replicated with primary fibroblasts isolated from the salivary gland of adult male and female donors of similar ages, and again the extent of NP uptake was altered by cell sex.  However, in contrast to hAMSCs, uptake was greater in male cells.  We also found out that female vs. male amniotic stem cells exhibited different responses to reprogramming into induced pluripotent stem cells (iPSCs) by the Yamanaka factors.  Thus, future studies should consider the effect of sex on the nanobio interactions to optimize clin. translation of NPs and iPSC biol. and to help researchers to better design and produce safe and efficient therapeutic sex-specific NPs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcunRw1WljebVg90H21EOLACvtfcHk0ljhGFJpp_p9Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktlKhsro%253D&md5=6a2dc803b0c39122e1786b052d918ccd</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1021%2Facsnano.7b06212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsnano.7b06212%26sid%3Dliteratum%253Aachs%26aulast%3DSerpooshan%26aufirst%3DV.%26aulast%3DSheibani%26aufirst%3DS.%26aulast%3DPushparaj%26aufirst%3DP.%26aulast%3DWojcik%26aufirst%3DM.%26aulast%3DJang%26aufirst%3DA.%2BY.%26aulast%3DSantoso%26aufirst%3DM.%2BR.%26aulast%3DJang%26aufirst%3DJ.%2BH.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DSafavi-Sohi%26aufirst%3DR.%26aulast%3DHaghjoo%26aufirst%3DN.%26aulast%3DNejadnik%26aufirst%3DH.%26aulast%3DAghaverdi%26aufirst%3DH.%26aulast%3DVali%26aufirst%3DH.%26aulast%3DKinsella%26aufirst%3DJ.%2BM.%26aulast%3DPresley%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DP.%2BC.-M.%26aulast%3DMahmoudi%26aufirst%3DM.%26atitle%3DEffect%2520of%2520Cell%2520Sex%2520on%2520Uptake%2520of%2520Nanoparticles%253A%2520The%2520Overlooked%2520Factor%2520at%2520the%2520Nanobio%2520Interface%26jtitle%3DACS%2520Nano%26date%3D2018%26volume%3D12%26spage%3D2253%26epage%3D2266%26doi%3D10.1021%2Facsnano.7b06212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, S.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.-D.</span></span> <span> </span><span class="NLM_article-title">Sex Differences in the Toxicity of Polyethylene Glycol-Coated Gold Nanoparticles in Mice</span>. <i>Int. J. Nanomed.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">2409</span>– <span class="NLM_lpage">2419</span>, <span class="refDoi"> DOI: 10.2147/IJN.S46376</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.2147%2FIJN.S46376" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=23861586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A280%3ADC%252BC3sfhtleruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=2409-2419&author=J.+Chenauthor=H.+Wangauthor=W.+Longauthor=X.+Shenauthor=D.+Wuauthor=S.-S.+Songauthor=Y.-M.+Sunauthor=P.-X.+Liuauthor=S.+Fanauthor=F.+Fanauthor=X.-D.+Zhang&title=Sex+Differences+in+the+Toxicity+of+Polyethylene+Glycol-Coated+Gold+Nanoparticles+in+Mice&doi=10.2147%2FIJN.S46376"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Sex differences in the toxicity of polyethylene glycol-coated gold nanoparticles in mice</span></div><div class="casAuthors">Chen Jie; Wang Hao; Long Wei; Shen Xiu; Wu Di; Song Sha-Sha; Sun Yuan-Ming; Liu Pei-Xun; Fan Saijun; Fan Feiyue; Zhang Xiao-Dong</div><div class="citationInfo"><span class="NLM_cas:title">International journal of nanomedicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2409-19</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Gold nanoparticles have received wide interest in disease diagnosis and therapy, but one of the important issues is their toxicological effects in vivo.  Sex differences in the toxicity of gold nanoparticles are not clear.  In this work, body weight, organ weight, hematology, and biochemistry were used to evaluate sex differences in immune response and liver and kidney damage.  Pathology was used to observe the general toxicity of reproductive organs.  The immune response was influenced significantly in female mice, with obvious changes in spleen and thymus index.  Hematology results showed that male mice treated with 22.5 nm gold nanoparticles received more significant infection and inflammation than female mice.  Meanwhile, the biochemistry results showed that 4.4 and 22.5 nm gold nanoparticles caused more significant liver damage in male mice than female mice, while 22.5, 29.3, and 36.1 nm gold nanoparticles caused more significant kidney damage in female mice than male mice.  No significant toxicological response was found in the reproductive system for female or male mice.  It was found that gold nanoparticles caused more serious liver toxicity and infection in male mice than female mice.  These findings indicated that sex differences may be one of the important elements for in vivo toxicity of gold nanoparticles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRcle_nAtSdN4JKJbLTgsvCfW6udTcc2eZUkkwjHAeqI7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sfhtleruw%253D%253D&md5=1f4e7421673de77b2c3bf596762a9c2a</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.2147%2FIJN.S46376&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIJN.S46376%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLong%26aufirst%3DW.%26aulast%3DShen%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DSong%26aufirst%3DS.-S.%26aulast%3DSun%26aufirst%3DY.-M.%26aulast%3DLiu%26aufirst%3DP.-X.%26aulast%3DFan%26aufirst%3DS.%26aulast%3DFan%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DX.-D.%26atitle%3DSex%2520Differences%2520in%2520the%2520Toxicity%2520of%2520Polyethylene%2520Glycol-Coated%2520Gold%2520Nanoparticles%2520in%2520Mice%26jtitle%3DInt.%2520J.%2520Nanomed.%26date%3D2013%26volume%3D8%26spage%3D2409%26epage%3D2419%26doi%3D10.2147%2FIJN.S46376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahmoudi, M.</span></span> <span> </span><span class="NLM_article-title">Debugging Nano–Bio Interfaces: Systematic Strategies to Accelerate Clinical Translation of Nanotechnologies</span>. <i>Trends Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">755</span>– <span class="NLM_lpage">769</span>, <span class="refDoi"> DOI: 10.1016/j.tibtech.2018.02.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.tibtech.2018.02.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=29559165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXks1yrt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=755-769&author=M.+Mahmoudi&title=Debugging+Nano%E2%80%93Bio+Interfaces%3A+Systematic+Strategies+to+Accelerate+Clinical+Translation+of+Nanotechnologies&doi=10.1016%2Fj.tibtech.2018.02.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Debugging Nano-Bio Interfaces: Systematic Strategies to Accelerate Clinical Translation of Nanotechnologies</span></div><div class="casAuthors">Mahmoudi, Morteza</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biotechnology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">755-769</span>CODEN:
                <span class="NLM_cas:coden">TRBIDM</span>;
        ISSN:<span class="NLM_cas:issn">0167-7799</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Despite considerable efforts in the field of nanomedicine that have been made by researchers, funding agencies, entrepreneurs, and the media, fewer nanoparticle (NP) technologies than expected have made it to clin. trials.  The wide gap between the efforts and effective clin. translation is, at least in part, due to multiple overlooked factors in both in vitro and in vivo environments, a poor understanding of the nano-bio interface, and misinterpretation of the data collected in vitro, all of which reduce the accuracy of predictions regarding the NPs' fate and safety in humans.  To minimize this bench-to-clinic gap, which may accelerate successful clin. translation of NPs, this opinion paper aims to introduce strategies for systematic debugging of nano-bio interfaces in the current literature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9y9myq9nI3rVg90H21EOLACvtfcHk0lhw-hyFgSekeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXks1yrt7Y%253D&md5=abc95b1de26771b846ebef773399965f</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1016%2Fj.tibtech.2018.02.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tibtech.2018.02.014%26sid%3Dliteratum%253Aachs%26aulast%3DMahmoudi%26aufirst%3DM.%26atitle%3DDebugging%2520Nano%25E2%2580%2593Bio%2520Interfaces%253A%2520Systematic%2520Strategies%2520to%2520Accelerate%2520Clinical%2520Translation%2520of%2520Nanotechnologies%26jtitle%3DTrends%2520Biotechnol.%26date%3D2018%26volume%3D36%26spage%3D755%26epage%3D769%26doi%3D10.1016%2Fj.tibtech.2018.02.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fragiadakis, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjornson-Hooper, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madhireddy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sachs, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitzer, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendall, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolan, G. P.</span></span> <span> </span><span class="NLM_article-title">Variation of Immune Cell Responses in Humans Reveals Sex-Specific Coordinated Signaling Across Cell Types</span>. <i>Bio Rxiv</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>567784</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">11</span>, <span class="refDoi"> DOI: 10.1101/567784</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1101%2F567784" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=567784&publication_year=2019&pages=1-11&author=G.+K.+Fragiadakisauthor=Z.+B.+Bjornson-Hooperauthor=D.+Madhireddyauthor=K.+Sachsauthor=M.+H.+Spitzerauthor=S.+C.+Bendallauthor=G.+P.+Nolan&title=Variation+of+Immune+Cell+Responses+in+Humans+Reveals+Sex-Specific+Coordinated+Signaling+Across+Cell+Types&doi=10.1101%2F567784"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1101%2F567784&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252F567784%26sid%3Dliteratum%253Aachs%26aulast%3DFragiadakis%26aufirst%3DG.%2BK.%26aulast%3DBjornson-Hooper%26aufirst%3DZ.%2BB.%26aulast%3DMadhireddy%26aufirst%3DD.%26aulast%3DSachs%26aufirst%3DK.%26aulast%3DSpitzer%26aufirst%3DM.%2BH.%26aulast%3DBendall%26aufirst%3DS.%2BC.%26aulast%3DNolan%26aufirst%3DG.%2BP.%26atitle%3DVariation%2520of%2520Immune%2520Cell%2520Responses%2520in%2520Humans%2520Reveals%2520Sex-Specific%2520Coordinated%2520Signaling%2520Across%2520Cell%2520Types%26jtitle%3DBio%2520Rxiv%26date%3D2019%26volume%3D567784%26spage%3D1%26epage%3D11%26doi%3D10.1101%2F567784" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joossens, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macko, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palosaari, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerloff, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ojea-Jiménez, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrent, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gineste, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Römer, I.</span></span> <span> </span><span class="NLM_article-title">A High Throughput Imaging Database of Toxicological Effects of Nanomaterials Tested on HepaRG Cells</span>. <i>Sci. Data</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">46</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1038/s41597-019-0053-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1038%2Fs41597-019-0053-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=30647409" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2019&pages=1-10&issue=46&author=E.+Joossensauthor=P.+Mackoauthor=T.+Palosaariauthor=K.+Gerloffauthor=I.+Ojea-Jim%C3%A9nezauthor=D.+Gillilandauthor=J.+Novakauthor=S.+F.+Torrentauthor=J.-M.+Ginesteauthor=I.+R%C3%B6mer&title=A+High+Throughput+Imaging+Database+of+Toxicological+Effects+of+Nanomaterials+Tested+on+HepaRG+Cells&doi=10.1038%2Fs41597-019-0053-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1038%2Fs41597-019-0053-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41597-019-0053-2%26sid%3Dliteratum%253Aachs%26aulast%3DJoossens%26aufirst%3DE.%26aulast%3DMacko%26aufirst%3DP.%26aulast%3DPalosaari%26aufirst%3DT.%26aulast%3DGerloff%26aufirst%3DK.%26aulast%3DOjea-Jim%25C3%25A9nez%26aufirst%3DI.%26aulast%3DGilliland%26aufirst%3DD.%26aulast%3DNovak%26aufirst%3DJ.%26aulast%3DTorrent%26aufirst%3DS.%2BF.%26aulast%3DGineste%26aufirst%3DJ.-M.%26aulast%3DR%25C3%25B6mer%26aufirst%3DI.%26atitle%3DA%2520High%2520Throughput%2520Imaging%2520Database%2520of%2520Toxicological%2520Effects%2520of%2520Nanomaterials%2520Tested%2520on%2520HepaRG%2520Cells%26jtitle%3DSci.%2520Data%26date%3D2019%26volume%3D6%26issue%3D46%26spage%3D1%26epage%3D10%26doi%3D10.1038%2Fs41597-019-0053-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kermanizadeh, A.</span>; <span class="NLM_string-name">Brown, D. M.</span>; <span class="NLM_string-name">Møller, P.</span></span> <span> </span><span class="NLM_article-title">Toxicological Hazard Analysis of Nanomaterials with Potential for Utilization in Consumer Goods</span>. In  <i>Nanomaterials for Food Applications</i>; <span class="NLM_publisher-name">Elsevier</span>: <span class="NLM_publisher-loc">Valencia, Spain</span>, <span class="NLM_year">2019</span>; pp  <span class="NLM_fpage">355</span>– <span class="NLM_lpage">380</span>, <span class="refDoi"> DOI: 10.1016/B978-0-12-814130-4.00012-9</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2FB978-0-12-814130-4.00012-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&pages=355-380&author=A.+Kermanizadeh&author=D.+M.+Brown&author=P.+M%C3%B8ller&title=Nanomaterials+for+Food+Applications"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-814130-4.00012-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-0-12-814130-4.00012-9%26sid%3Dliteratum%253Aachs%26aulast%3DKermanizadeh%26aufirst%3DA.%26atitle%3DToxicological%2520Hazard%2520Analysis%2520of%2520Nanomaterials%2520with%2520Potential%2520for%2520Utilization%2520in%2520Consumer%2520Goods%26btitle%3DNanomaterials%2520for%2520Food%2520Applications%26pub%3DElsevier%26date%3D2019%26spage%3D355%26epage%3D380%26doi%3D10.1016%2FB978-0-12-814130-4.00012-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blázquez, M.</span>; <span class="NLM_string-name">Fernández-Cruz, M.</span>; <span class="NLM_string-name">Gajewicz, A.</span>; <span class="NLM_string-name">Puzyn, T.</span>; <span class="NLM_string-name">Benfenati, E.</span></span> <span> </span><span class="NLM_article-title">In On the Uses of Predictive Toxicology to Approve the Use of Engineered Nanomaterials as Biocidal Active Substances Under the Biocidal Products Regulation</span>. In  <i>IOP Conference Series: Materials Science and Engineering, 2019</i>; <span class="NLM_publisher-name">IOP Publishing</span>, <span class="NLM_year">2019</span>;  <span class="NLM_volume">012007</span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1088/1757-899X/499/1/012007</span> .</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&pages=1-8&author=M.+Bl%C3%A1zquez&author=M.+Fern%C3%A1ndez-Cruz&author=A.+Gajewicz&author=T.+Puzyn&author=E.+Benfenati&title=In+On+the+Uses+of+Predictive+Toxicology+to+Approve+the+Use+of+Engineered+Nanomaterials+as+Biocidal+Active+Substances+Under+the+Biocidal+Products+Regulation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DBl%25C3%25A1zquez%26aufirst%3DM.%26atitle%3DIn%2520On%2520the%2520Uses%2520of%2520Predictive%2520Toxicology%2520to%2520Approve%2520the%2520Use%2520of%2520Engineered%2520Nanomaterials%2520as%2520Biocidal%2520Active%2520Substances%2520Under%2520the%2520Biocidal%2520Products%2520Regulation%26jtitle%3DIOP%2520Conference%2520Series%253A%2520Materials%2520Science%2520and%2520Engineering%252C%25202019%26pub%3DIOP%2520Publishing%26date%3D2019%26volume%3D012007%26spage%3D1%26epage%3D8%26doi%3D10.1088%2F1757-899X%2F499%2F1%2F012007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span> <span> </span><span class="NLM_article-title">A Safe-By-Design Strategy Towards Safer Nanomaterials in Nanomedicines</span>. <i>Adv. Mater.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_fpage">1805391</span>, <span class="refDoi"> DOI: 10.1002/adma.201805391</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1002%2Fadma.201805391" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1Cgtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&pages=1805391&author=L.+Yanauthor=F.+Zhaoauthor=J.+Wangauthor=Y.+Zuauthor=Z.+Guauthor=Y.+Zhao&title=A+Safe-By-Design+Strategy+Towards+Safer+Nanomaterials+in+Nanomedicines&doi=10.1002%2Fadma.201805391"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">A safe-by-design strategy towards safer nanomaterials in nanomedicines</span></div><div class="casAuthors">Yan, Liang; Zhao, Feng; Wang, Jing; Zu, Yan; Gu, Zhanjun; Zhao, Yuliang</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Materials (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">1805391</span>CODEN:
                <span class="NLM_cas:coden">ADVMEW</span>;
        ISSN:<span class="NLM_cas:issn">0935-9648</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The marriage of nanotechnol. and medicine offers new opportunities to fight against human diseases.  Benefiting from their unique optical, thermal, magnetic, or redox properties, a wide range of nanomaterials have shown potential in applications such as diagnosis, drug delivery, or tissue repair and regeneration.  Despite the considerable success achieved over the past decades, the newly emerging nanomedicines still suffer from an incomplete understanding of their safety risks, and of the relationships between their physicochem. characteristics and safety profiles.  Herein, the most important categories of nanomaterials with clin. potential and their toxicol. mechanisms are summarized, and then, based on this available information, an overview of the principles in developing safe-by-design nanomaterials for medical applications and of the recent progress in this field is provided.  These principles may serve as a starting point to guide the development of more effective safe-by-design strategies and to help identify the major knowledge and skill gaps.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1tB-7kw0vmbVg90H21EOLACvtfcHk0lhw-hyFgSekeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1Cgtb4%253D&md5=a69bffdab372e5db5436e681260d0fbb</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1002%2Fadma.201805391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fadma.201805391%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZu%26aufirst%3DY.%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DZhao%26aufirst%3DY.%26atitle%3DA%2520Safe-By-Design%2520Strategy%2520Towards%2520Safer%2520Nanomaterials%2520in%2520Nanomedicines%26jtitle%3DAdv.%2520Mater.%26date%3D2019%26spage%3D1805391%26doi%3D10.1002%2Fadma.201805391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hodson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastlake, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbers, R.</span></span> <span> </span><span class="NLM_article-title">An Evaluation of Engineered Nanomaterial Safety Data Sheets for Safety and Health Information Post Implementation of the Revised Hazard Communication Standard</span>. <i>J. Chem. Health Saf.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">12</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1016/j.jchas.2018.10.002</span> </span><div class="citationLinks">[<a href="/doi/10.1016/j.jchas.2018.10.002" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=12-18&author=L.+Hodsonauthor=A.+Eastlakeauthor=R.+Herbers&title=An+Evaluation+of+Engineered+Nanomaterial+Safety+Data+Sheets+for+Safety+and+Health+Information+Post+Implementation+of+the+Revised+Hazard+Communication+Standard&doi=10.1016%2Fj.jchas.2018.10.002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1016%2Fj.jchas.2018.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jchas.2018.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DHodson%26aufirst%3DL.%26aulast%3DEastlake%26aufirst%3DA.%26aulast%3DHerbers%26aufirst%3DR.%26atitle%3DAn%2520Evaluation%2520of%2520Engineered%2520Nanomaterial%2520Safety%2520Data%2520Sheets%2520for%2520Safety%2520and%2520Health%2520Information%2520Post%2520Implementation%2520of%2520the%2520Revised%2520Hazard%2520Communication%2520Standard%26jtitle%3DJ.%2520Chem.%2520Health%2520Saf.%26date%3D2019%26volume%3D26%26spage%3D12%26epage%3D18%26doi%3D10.1016%2Fj.jchas.2018.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benchimol, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourne, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moghimi, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simberg, D.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic Analysis Reveals Limitations and Opportunities for Nanomedicine Targeting of Endothelial and Extravascular Compartments of Tumours</span>. <i>J. Drug Targeting</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">690</span>– <span class="NLM_lpage">698</span>, <span class="refDoi"> DOI: 10.1080/1061186X.2019.1566339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1080%2F1061186X.2019.1566339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=30614276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlGis7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=690-698&author=M.+J.+Benchimolauthor=D.+Bourneauthor=S.+M.+Moghimiauthor=D.+Simberg&title=Pharmacokinetic+Analysis+Reveals+Limitations+and+Opportunities+for+Nanomedicine+Targeting+of+Endothelial+and+Extravascular+Compartments+of+Tumours&doi=10.1080%2F1061186X.2019.1566339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic analysis reveals limitations and opportunities for nanomedicine targeting of endothelial and extravascular compartments of tumours</span></div><div class="casAuthors">Benchimol, Michael J.; Bourne, David; Moghimi, Seyed Moein; Simberg, Dmitri</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Drug Targeting</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">690-698</span>CODEN:
                <span class="NLM_cas:coden">JDTAEH</span>;
        ISSN:<span class="NLM_cas:issn">1026-7158</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Targeting of nanoparticles to tumors can potentially improve the specificity of imaging and treatments.  We have developed a multicompartmental pharmacokinetic model in order to analyze some of the factors that control efficiency of targeting to intravascular (endothelium) and extravascular (tumor cells and stroma) compartments.  We make the assumption that transport across tumor endothelium is an important step for subsequent nanoparticle accumulation in the tumor (area-under-the-curve, AUC) regardless of entry route (interendothelial and transendothelial routes) and study this through a multicompartmental simulation.  Our model reveals that increasing endothelial targeting efficiency has a much stronger effect on the AUC than increasing extravascular targeting efficiency.  Furthermore, our anal. reveals that both extravasation and intratumoral diffusion rates need to be increased in order to significantly increase the AUC of extravascular-targeted nanoparticles.  Increasing the nanoparticle circulation half-life increases the AUC independently of extravasation and intratumoral diffusion.  Targeting the extravascular compartment leads to a buildup in the first layer surrounding blood vessels at the expense of deeper layers (binding site barrier).  This model explains some of the limitations of tumor targeting and provides important guidelines for the design of targeted nanomedicines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_DGPfsbvZNrVg90H21EOLACvtfcHk0lgqC0hR3H6LlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlGis7c%253D&md5=f4154e7feef28c8aaf6debb1f0e55d34</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1080%2F1061186X.2019.1566339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F1061186X.2019.1566339%26sid%3Dliteratum%253Aachs%26aulast%3DBenchimol%26aufirst%3DM.%2BJ.%26aulast%3DBourne%26aufirst%3DD.%26aulast%3DMoghimi%26aufirst%3DS.%2BM.%26aulast%3DSimberg%26aufirst%3DD.%26atitle%3DPharmacokinetic%2520Analysis%2520Reveals%2520Limitations%2520and%2520Opportunities%2520for%2520Nanomedicine%2520Targeting%2520of%2520Endothelial%2520and%2520Extravascular%2520Compartments%2520of%2520Tumours%26jtitle%3DJ.%2520Drug%2520Targeting%26date%3D2019%26volume%3D27%26spage%3D690%26epage%3D698%26doi%3D10.1080%2F1061186X.2019.1566339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosenblum, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karp, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peer, D.</span></span> <span> </span><span class="NLM_article-title">Progress and Challenges Towards Targeted Delivery of Cancer Therapeutics</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1410</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-03705-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1038%2Fs41467-018-03705-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=29317637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVOitLjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1-12&issue=1410&author=D.+Rosenblumauthor=N.+Joshiauthor=W.+Taoauthor=J.+M.+Karpauthor=D.+Peer&title=Progress+and+Challenges+Towards+Targeted+Delivery+of+Cancer+Therapeutics&doi=10.1038%2Fs41467-018-03705-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes</span></div><div class="casAuthors">Veiga, Nuphar; Goldsmith, Meir; Granot, Yasmin; Rosenblum, Daniel; Dammes, Niels; Kedmi, Ranit; Ramishetti, Srinivas; Peer, Dan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-9</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Therapeutic alteration of gene expression in vivo can be achieved by delivering nucleic acids (e.g., mRNA, siRNA) using nanoparticles.  Recent progress in modified mRNA (mmRNA) synthesis facilitated the development of lipid nanoparticles (LNPs) loaded with mmRNA as a promising tool for in vivo protein expression.  Although progress have been made with mmRNA-LNPs based protein expression in hepatocytes, cell specificity is still a major challenge.  Moreover, selective protein expression is essential for an improved therapeutic effect, due to the heterogeneous nature of diseases.  Here, we present a precision protein expression strategy in Ly6c+ inflammatory leukocytes in inflammatory bowel disease (IBD) induced mice.  We demonstrate a therapeutic effect in an IBD model by targeted expression of the interleukin 10 in Ly6c+ inflammatory leukocytes.  A selective mmRNA expression strategy has tremendous therapeutic potential in IBD and can ultimately become a novel therapeutic modality in many other diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEExH7iEJNeLVg90H21EOLACvtfcHk0lgqC0hR3H6LlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVOitLjM&md5=007a9ad4f420a1e35857b73a9064133d</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-03705-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-03705-y%26sid%3Dliteratum%253Aachs%26aulast%3DRosenblum%26aufirst%3DD.%26aulast%3DJoshi%26aufirst%3DN.%26aulast%3DTao%26aufirst%3DW.%26aulast%3DKarp%26aufirst%3DJ.%2BM.%26aulast%3DPeer%26aufirst%3DD.%26atitle%3DProgress%2520and%2520Challenges%2520Towards%2520Targeted%2520Delivery%2520of%2520Cancer%2520Therapeutics%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26issue%3D1410%26spage%3D1%26epage%3D12%26doi%3D10.1038%2Fs41467-018-03705-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantoff, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wooster, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farokhzad, O. C.</span></span> <span> </span><span class="NLM_article-title">Cancer Nanomedicine: Progress, Challenges and Opportunities</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">20</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.1038/nrc.2016.108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1038%2Fnrc.2016.108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=27834398" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVGisr%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=20-37&author=J.+Shiauthor=P.+W.+Kantoffauthor=R.+Woosterauthor=O.+C.+Farokhzad&title=Cancer+Nanomedicine%3A+Progress%2C+Challenges+and+Opportunities&doi=10.1038%2Fnrc.2016.108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer nanomedicine: progress, challenges and opportunities</span></div><div class="casAuthors">Shi, Jinjun; Kantoff, Philip W.; Wooster, Richard; Farokhzad, Omid C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">20-37</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The intrinsic limits of conventional cancer therapies prompted the development and application of various nanotechnologies for more effective and safer cancer treatment, herein referred to as cancer nanomedicine.  Considerable technol. success has been achieved in this field, but the main obstacles to nanomedicine becoming a new paradigm in cancer therapy stem from the complexities and heterogeneity of tumor biol., an incomplete understanding of nano-bio interactions and the challenges regarding chem., manufg. and controls required for clin. translation and commercialization.  This Review highlights the progress, challenges and opportunities in cancer nanomedicine and discusses novel engineering approaches that capitalize on our growing understanding of tumor biol. and nano-bio interactions to develop more effective nanotherapeutics for cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvEyH3WmeaOLVg90H21EOLACvtfcHk0lgRnUeWBpL2tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVGisr%252FK&md5=58ce4c202687ce16c66de979c5b185e4</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1038%2Fnrc.2016.108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc.2016.108%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DKantoff%26aufirst%3DP.%2BW.%26aulast%3DWooster%26aufirst%3DR.%26aulast%3DFarokhzad%26aufirst%3DO.%2BC.%26atitle%3DCancer%2520Nanomedicine%253A%2520Progress%252C%2520Challenges%2520and%2520Opportunities%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2017%26volume%3D17%26spage%3D20%26epage%3D37%26doi%3D10.1038%2Fnrc.2016.108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raucher, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dragojevic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, J.</span></span> <span> </span><span class="NLM_article-title">Macromolecular Drug Carriers for Targeted Glioblastoma Therapy: Preclinical Studies, Challenges and Future Perspectives</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">624</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.3389/fonc.2018.00624</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.3389%2Ffonc.2018.00624" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=29404275" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=1-15&issue=624&author=D.+Raucherauthor=S.+Dragojevicauthor=J.+Ryu&title=Macromolecular+Drug+Carriers+for+Targeted+Glioblastoma+Therapy%3A+Preclinical+Studies%2C+Challenges+and+Future+Perspectives&doi=10.3389%2Ffonc.2018.00624"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2018.00624&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2018.00624%26sid%3Dliteratum%253Aachs%26aulast%3DRaucher%26aufirst%3DD.%26aulast%3DDragojevic%26aufirst%3DS.%26aulast%3DRyu%26aufirst%3DJ.%26atitle%3DMacromolecular%2520Drug%2520Carriers%2520for%2520Targeted%2520Glioblastoma%2520Therapy%253A%2520Preclinical%2520Studies%252C%2520Challenges%2520and%2520Future%2520Perspectives%26jtitle%3DFront.%2520Oncol.%26date%3D2018%26volume%3D8%26issue%3D624%26spage%3D1%26epage%3D15%26doi%3D10.3389%2Ffonc.2018.00624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haque, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jasinski, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binzel, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, P.</span></span> <span> </span><span class="NLM_article-title">Favorable Biodistribution, Specific Targeting and Conditional Endosomal Escape of RNA Nanoparticles in Cancer Therapy</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>414</i></span>,  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2017.09.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.canlet.2017.09.043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=28987384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1aisrbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=414&publication_year=2018&pages=57-70&author=C.+Xuauthor=F.+Haqueauthor=D.+L.+Jasinskiauthor=D.+W.+Binzelauthor=D.+Shuauthor=P.+Guo&title=Favorable+Biodistribution%2C+Specific+Targeting+and+Conditional+Endosomal+Escape+of+RNA+Nanoparticles+in+Cancer+Therapy&doi=10.1016%2Fj.canlet.2017.09.043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Favorable biodistribution, specific targeting and conditional endosomal escape of RNA nanoparticles in cancer therapy</span></div><div class="casAuthors">Xu, Congcong; Haque, Farzin; Jasinski, Daniel L.; Binzel, Daniel W.; Shu, Dan; Guo, Peixuan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">414</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">57-70</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The past decades have witnessed the successful transition of several nanotechnol. platforms into the clin. trials.  However, specific delivery of therapeutics to tumors is hindered by several barriers including cancer recognition and tissue penetration, particle heterogeneity and aggregation, and unfavorable pharmacokinetic profiles such as fast clearance and organ accumulation.  With the advent of RNA nanotechnol., a series of RNA nanoparticles have been successfully constructed to overcome many of the aforementioned challenges for in vivo cancer targeting with favorable biodistribution profiles.  Compared to other nanodelivery platforms, the physiochem. properties of RNA nanoparticles can be tuned with relative ease for investigating the in vivo behavior of nanoparticles upon systemic injection.  The size, shape, and surface chem., esp. hydrophobic modifications, exert significant impacts on the in vivo fate of RNA nanoparticles.  Rationally designed RNA nanoparticles with defined stoichiometry and high homogeneity have been demonstrated to specifically target tumor cells while avoiding accumulation in healthy vital organs after systemic injection.  RNA nanoparticles were proven to deliver therapeutics such as siRNA and anti-miRNA to block tumor growth in several animal models.  Although the release of anti-miRNA from the RNA nanoparticles has achieved high efficiency of tumor regression in multiple animal models, the efficiency of endosomal escape for siRNA delivery needs further improvement.  This review focuses on the advances and perspectives of this promising RNA nanotechnol. platform for cancer targeting and therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYAA8rGnWqIbVg90H21EOLACvtfcHk0lgRnUeWBpL2tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1aisrbL&md5=241ceed5006262c0ada21e1e3a62673d</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2017.09.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2017.09.043%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DC.%26aulast%3DHaque%26aufirst%3DF.%26aulast%3DJasinski%26aufirst%3DD.%2BL.%26aulast%3DBinzel%26aufirst%3DD.%2BW.%26aulast%3DShu%26aufirst%3DD.%26aulast%3DGuo%26aufirst%3DP.%26atitle%3DFavorable%2520Biodistribution%252C%2520Specific%2520Targeting%2520and%2520Conditional%2520Endosomal%2520Escape%2520of%2520RNA%2520Nanoparticles%2520in%2520Cancer%2520Therapy%26jtitle%3DCancer%2520Lett.%26date%3D2018%26volume%3D414%26spage%3D57%26epage%3D70%26doi%3D10.1016%2Fj.canlet.2017.09.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maniam, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mai, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zulkefeli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dufes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, D. M.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J. Y.</span></span> <span> </span><span class="NLM_article-title">Challenges and Opportunities of Nanotechnology as Delivery Platform for Tocotrienols in Cancer Therapy</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1358</span>, <span class="refDoi"> DOI: 10.3389/fphar.2018.01358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.3389%2Ffphar.2018.01358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=30534071" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVGmtb7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1358&author=G.+Maniamauthor=C.+W.+Maiauthor=M.+Zulkefeliauthor=C.+Dufesauthor=D.+M.-Y.+Tanauthor=J.+Y.+Fu&title=Challenges+and+Opportunities+of+Nanotechnology+as+Delivery+Platform+for+Tocotrienols+in+Cancer+Therapy&doi=10.3389%2Ffphar.2018.01358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Challenges and opportunities of nanotechnology as delivery platform for tocotrienols in cancer therapy</span></div><div class="casAuthors">Maniam, Geetha; Mai, Chun-Wai; Zulkefeli, Mohd; Dufes, Christine; Tan, Doryn Meam-Yee; Fu, Ju-Yen</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1358</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Plant-derived phytonutrients have emerged as health enhancers.  Tocotrienols from the vitamin E family gained high attention in recent years due to their multi-targeted biol. properties, including lipid-lowering, neuroprotection, anti-inflammatory, antioxidant, and anticancer effects.  Despite well-defined mechanism of action as an anti-cancer agent, their clin. use is hampered by poor pharmacokinetic profile and low oral bioavailability.  Delivery systems based on nanotechnol. were proven to be advantageous in elevating the delivery of tocotrienols to tumor sites for enhanced efficacy.  To date, preclin. development of nanocarriers for tocotrienols include niosomes, lipid nanoemulsions, nanostructured lipid carriers (NLCs) and polymeric nanoparticles.  Active targeting was explored via the use of transferrin as targeting ligand in niosomes.  In vitro, nanocarriers were shown to enhance the anti-proliferative efficacy and cellular uptake of tocotrienols in cancer cells.  In vivo, improved bioavailability of tocotrienols were reported with NLCs while marked tumor regression was obsd. with transferrin-targeted niosomes.  In this review, the advantages and limitations of each nanocarriers were critically analyzed.  Furthermore, a no. of key challenges were identified including scale-up prodn., biol. barriers, and toxicity profiles.  To overcome these challenges, three research opportunities were highlighted based on rapid advancements in the field of nanomedicine.  This review aims to provide a wholesome perspective for tocotrienol nanoformulations in cancer therapy directed toward effective clin. translation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqk68OnOyFcvLVg90H21EOLACvtfcHk0lghSzWwLa5aVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVGmtb7J&md5=84afd2f1436b5db303325067c972b31f</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2018.01358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2018.01358%26sid%3Dliteratum%253Aachs%26aulast%3DManiam%26aufirst%3DG.%26aulast%3DMai%26aufirst%3DC.%2BW.%26aulast%3DZulkefeli%26aufirst%3DM.%26aulast%3DDufes%26aufirst%3DC.%26aulast%3DTan%26aufirst%3DD.%2BM.-Y.%26aulast%3DFu%26aufirst%3DJ.%2BY.%26atitle%3DChallenges%2520and%2520Opportunities%2520of%2520Nanotechnology%2520as%2520Delivery%2520Platform%2520for%2520Tocotrienols%2520in%2520Cancer%2520Therapy%26jtitle%3DFront.%2520Pharmacol.%26date%3D2018%26volume%3D9%26spage%3D1358%26doi%3D10.3389%2Ffphar.2018.01358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Belfiore, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurecht, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storm, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vine, K. L.</span></span> <span> </span><span class="NLM_article-title">Towards Clinical Translation of Ligand-Functionalized Liposomes in Targeted Cancer Therapy: Challenges and Opportunities</span>. <i>J. Controlled Release</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">13</span>, <span class="refDoi"> DOI: 10.1016/j.jconrel.2018.02.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.jconrel.2018.02.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=29501721" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltVKlu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2018&pages=1-13&author=L.+Belfioreauthor=D.+N.+Saundersauthor=M.+Ransonauthor=K.+J.+Thurechtauthor=G.+Stormauthor=K.+L.+Vine&title=Towards+Clinical+Translation+of+Ligand-Functionalized+Liposomes+in+Targeted+Cancer+Therapy%3A+Challenges+and+Opportunities&doi=10.1016%2Fj.jconrel.2018.02.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and opportunities</span></div><div class="casAuthors">Belfiore, Lisa; Saunders, Darren N.; Ranson, Marie; Thurecht, Kristofer J.; Storm, Gert; Vine, Kara L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-13</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The development of therapeutic resistance to targeted anticancer therapies remains a significant clin. problem, with intratumoral heterogeneity playing a key role.  In this context, improving the therapeutic outcome through simultaneous targeting of multiple tumor cell subtypes within a heterogeneous tumor is a promising approach.  Liposomes have emerged as useful drug carriers that can reduce systemic toxicity and increase drug delivery to the tumor site.  While clin. used liposomal drug formulations show marked therapeutic advantages over free drug formulations, ligand-functionalized liposomes that can target multiple tumor cell subtypes may further improve the therapeutic efficacy by facilitating drug delivery to a broader population of tumor cells making up the heterogeneous tumor tissue.  Ligand-directed liposomes enable the so-called active targeting of cell receptors via surface-attached ligands that direct drug uptake into tumor cells or tumor-assocd. stromal cells, and so can increase the selectivity of drug delivery.  Despite promising preclin. results demonstrating improved targeting and anti-tumor effects of ligand-directed liposomes, there has been limited translation of this approach to the clinic.  Key challenges for translation include the lack of established methods to scale up prodn. and comprehensively characterize ligand-functionalized liposome formulations, as well as the inadequate recapitulation of in vivo tumors in the preclin. models currently used to evaluate their performance.  Herein, we discuss the utility of recent ligand-directed liposome approaches, with a focus on dual-ligand liposomes, for the treatment of solid tumors and examine the drawbacks limiting their progression to clin. adoption.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2lasK_w_g3LVg90H21EOLACvtfcHk0ljC4Bg27PYPbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltVKlu7c%253D&md5=feca6592e27d7bc3f5a4f3081d82f045</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2018.02.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2018.02.040%26sid%3Dliteratum%253Aachs%26aulast%3DBelfiore%26aufirst%3DL.%26aulast%3DSaunders%26aufirst%3DD.%2BN.%26aulast%3DRanson%26aufirst%3DM.%26aulast%3DThurecht%26aufirst%3DK.%2BJ.%26aulast%3DStorm%26aufirst%3DG.%26aulast%3DVine%26aufirst%3DK.%2BL.%26atitle%3DTowards%2520Clinical%2520Translation%2520of%2520Ligand-Functionalized%2520Liposomes%2520in%2520Targeted%2520Cancer%2520Therapy%253A%2520Challenges%2520and%2520Opportunities%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2018%26volume%3D277%26spage%3D1%26epage%3D13%26doi%3D10.1016%2Fj.jconrel.2018.02.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Akhter, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizwanullah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahsan, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mujtaba, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amin, S.</span></span> <span> </span><span class="NLM_article-title">Nanocarriers in Advanced Drug Targeting: Setting Novel Paradigm in Cancer Therapeutics</span>. <i>Artif. Cells, Nanomed., Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">873</span>– <span class="NLM_lpage">884</span>, <span class="refDoi"> DOI: 10.1080/21691401.2017.1366333</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1080%2F21691401.2017.1366333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=28830262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVans7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=873-884&author=M.+H.+Akhterauthor=M.+Rizwanullahauthor=J.+Ahmadauthor=M.+J.+Ahsanauthor=M.+A.+Mujtabaauthor=S.+Amin&title=Nanocarriers+in+Advanced+Drug+Targeting%3A+Setting+Novel+Paradigm+in+Cancer+Therapeutics&doi=10.1080%2F21691401.2017.1366333"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Nanocarriers in advanced drug targeting: setting novel paradigm in cancer therapeutics</span></div><div class="casAuthors">Akhter, Md. Habban; Rizwanullah, Md.; Ahmad, Javed; Ahsan, Mohamed Jawed; Mujtaba, Md. Ali; Amin, Saima</div><div class="citationInfo"><span class="NLM_cas:title">Artificial Cells, Nanomedicine, and Biotechnology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">873-884</span>CODEN:
                <span class="NLM_cas:coden">ACNBCI</span>;
        ISSN:<span class="NLM_cas:issn">2169-141X</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Cancer has been growing nowadays consequently high no. of death ascertained worldwide.  The medical intervention involves chemotherapy, radiation therapy and surgical removal.  This conventional technique lacking targeting potential and harm the normal cells.  In drug treatment regimen, the combination therapy is preferred than single drug treatment module due to higher internalization of chemotherapeutics in the cancer cells both by enhance permeation retention effect and by direct cell apoptosis.  The cancer therapeutics involves different methodologies of delivering active moiety to the target site.  The active and passive transport mode of chemotherapeutic targeting utilizes advance nanocarriers.  The nanotechnol. strategic treatment applying advance nanocarrier greatly helps in mitigating the cancer prevalence.  The nanocarrier-incorporating nanodrug directed for specific area appealed scientist across the globe and issues to be addressed in this regard.  Therefore, various techniques and approaches invented to meet the objectives.  With the advances in nanomedicine and drug delivery, this review briefly focused on various modes of nanodrug delivery including nanoparticles, liposomes, dendrimer, quantum dots, carbon nanotubes, metallic nanoparticles, nanolipid carrier (NLC), gold nanoshell, nanosize cantilevers and nanowire that looks promising and generates a novel horizon in cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOyP9-YsodZLVg90H21EOLACvtfcHk0ljC4Bg27PYPbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVans7zK&md5=8064ddb463a4b39e309cfe7e167abc81</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1080%2F21691401.2017.1366333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F21691401.2017.1366333%26sid%3Dliteratum%253Aachs%26aulast%3DAkhter%26aufirst%3DM.%2BH.%26aulast%3DRizwanullah%26aufirst%3DM.%26aulast%3DAhmad%26aufirst%3DJ.%26aulast%3DAhsan%26aufirst%3DM.%2BJ.%26aulast%3DMujtaba%26aufirst%3DM.%2BA.%26aulast%3DAmin%26aufirst%3DS.%26atitle%3DNanocarriers%2520in%2520Advanced%2520Drug%2520Targeting%253A%2520Setting%2520Novel%2520Paradigm%2520in%2520Cancer%2520Therapeutics%26jtitle%3DArtif.%2520Cells%252C%2520Nanomed.%252C%2520Biotechnol.%26date%3D2018%26volume%3D46%26spage%3D873%26epage%3D884%26doi%3D10.1080%2F21691401.2017.1366333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 32 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Vanna Sanna, <span class="NLM_string-name hlFld-ContribAuthor">Mario Sechi</span>. </span><span class="cited-content_cbyCitation_article-title">Therapeutic Potential of Targeted Nanoparticles and Perspective on Nanotherapies. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (6)
                                     , 1069-1073. <a href="https://doi.org/10.1021/acsmedchemlett.0c00075" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00075</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00075%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DTherapeutic%252BPotential%252Bof%252BTargeted%252BNanoparticles%252Band%252BPerspective%252Bon%252BNanotherapies%26aulast%3DSanna%26aufirst%3DVanna%26date%3D2020%26date%3D2020%26date%3D02042020%26volume%3D11%26issue%3D6%26spage%3D1069%26epage%3D1073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Vanna Sanna, Mohamed Fathy Youssef, Nicolino Pala, Dominga Rogolino, Mauro Carcelli, Pankaj Kumar Singh, Tino Sanchez, Nouri Neamati, <span class="NLM_string-name hlFld-ContribAuthor">Mario Sechi</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibition of Human Immunodeficiency Virus-1 Integrase by β-Diketo Acid Coated Gold Nanoparticles. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (5)
                                     , 857-861. <a href="https://doi.org/10.1021/acsmedchemlett.9b00648" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00648</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00648%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DInhibition%252Bof%252BHuman%252BImmunodeficiency%252BVirus-1%252BIntegrase%252Bby%252B%2525CE%2525B2-Diketo%252BAcid%252BCoated%252BGold%252BNanoparticles%26aulast%3DSanna%26aufirst%3DVanna%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D24122019%26date%3D20032020%26date%3D25032020%26date%3D20032020%26volume%3D11%26issue%3D5%26spage%3D857%26epage%3D861" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Anas Ahmad, Anuradha Gupta, Md. Meraj Ansari, Akshay Vyawahare, Govindasamy Jayamurugan, <span class="NLM_string-name hlFld-ContribAuthor">Rehan Khan</span>. </span><span class="cited-content_cbyCitation_article-title">Hyperbranched Polymer-Functionalized Magnetic Nanoparticle-Mediated Hyperthermia and Niclosamide Bimodal Therapy of Colorectal Cancer Cells. </span><span class="cited-content_cbyCitation_journal-name">ACS Biomaterials Science & Engineering</span><span> <strong>2020,</strong> <em>6 </em>
                                    (2)
                                     , 1102-1111. <a href="https://doi.org/10.1021/acsbiomaterials.9b01947" title="DOI URL">https://doi.org/10.1021/acsbiomaterials.9b01947</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsbiomaterials.9b01947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsbiomaterials.9b01947%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Biomaterials%2520Science%2520%2526%2520Engineering%26atitle%3DHyperbranched%252BPolymer-Functionalized%252BMagnetic%252BNanoparticle-Mediated%252BHyperthermia%252Band%252BNiclosamide%252BBimodal%252BTherapy%252Bof%252BColorectal%252BCancer%252BCells%26aulast%3DAhmad%26aufirst%3DAnas%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D20122019%26date%3D31122019%26date%3D28012020%26date%3D31122019%26volume%3D6%26issue%3D2%26spage%3D1102%26epage%3D1111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xin  Li</span>, <span class="hlFld-ContribAuthor ">Yu  Zhen</span>, <span class="hlFld-ContribAuthor ">Shanshan  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Review on combination strategy of immune checkpoint blockade, photodynamic therapy and nanomedicine against solid tumor. </span><span class="cited-content_cbyCitation_journal-name">Materials & Design</span><span> <strong>2021,</strong> <em>209 </em>, 109958. <a href="https://doi.org/10.1016/j.matdes.2021.109958" title="DOI URL">https://doi.org/10.1016/j.matdes.2021.109958</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.matdes.2021.109958&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.matdes.2021.109958%26sid%3Dliteratum%253Aachs%26jtitle%3DMaterials%2520%2526%2520Design%26atitle%3DReview%252Bon%252Bcombination%252Bstrategy%252Bof%252Bimmune%252Bcheckpoint%252Bblockade%25252C%252Bphotodynamic%252Btherapy%252Band%252Bnanomedicine%252Bagainst%252Bsolid%252Btumor%26aulast%3DLi%26aufirst%3DXin%26date%3D2021%26volume%3D209%26spage%3D109958" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Poonam  Jain</span>, <span class="hlFld-ContribAuthor ">Krunal  Patel</span>, <span class="hlFld-ContribAuthor ">Ashok Kumar  Jangid</span>, <span class="hlFld-ContribAuthor ">Anupam  Guleria</span>, <span class="hlFld-ContribAuthor ">Sunita  Patel</span>, <span class="hlFld-ContribAuthor ">Deep  Pooja</span>, <span class="hlFld-ContribAuthor ">Hitesh  Kulhari</span>. </span><span class="cited-content_cbyCitation_article-title">Biotinylated Mn3O4 nanocuboids for targeted delivery of gemcitabine hydrochloride to breast cancer and MRI applications. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Pharmaceutics</span><span> <strong>2021,</strong> <em>606 </em>, 120895. <a href="https://doi.org/10.1016/j.ijpharm.2021.120895" title="DOI URL">https://doi.org/10.1016/j.ijpharm.2021.120895</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ijpharm.2021.120895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ijpharm.2021.120895%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Pharmaceutics%26atitle%3DBiotinylated%252BMn3O4%252Bnanocuboids%252Bfor%252Btargeted%252Bdelivery%252Bof%252Bgemcitabine%252Bhydrochloride%252Bto%252Bbreast%252Bcancer%252Band%252BMRI%252Bapplications%26aulast%3DJain%26aufirst%3DPoonam%26date%3D2021%26volume%3D606%26spage%3D120895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maeva  Chaupard</span>, <span class="hlFld-ContribAuthor ">Marta  de Frutos</span>, <span class="hlFld-ContribAuthor ">Ruxandra  Gref</span>. </span><span class="cited-content_cbyCitation_article-title">Deciphering the Structure and Chemical Composition of Drug Nanocarriers: From Bulk Approaches to Individual Nanoparticle Characterization. </span><span class="cited-content_cbyCitation_journal-name">Particle & Particle Systems Characterization</span><span> <strong>2021,</strong> <em>143 </em>, 2100022. <a href="https://doi.org/10.1002/ppsc.202100022" title="DOI URL">https://doi.org/10.1002/ppsc.202100022</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ppsc.202100022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fppsc.202100022%26sid%3Dliteratum%253Aachs%26jtitle%3DParticle%2520%2526%2520Particle%2520Systems%2520Characterization%26atitle%3DDeciphering%252Bthe%252BStructure%252Band%252BChemical%252BComposition%252Bof%252BDrug%252BNanocarriers%25253A%252BFrom%252BBulk%252BApproaches%252Bto%252BIndividual%252BNanoparticle%252BCharacterization%26aulast%3DChaupard%26aufirst%3DMaeva%26date%3D2021%26date%3D2021%26volume%3D143%26spage%3D2100022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">N.A.  Bhaskaran</span>, <span class="hlFld-ContribAuthor ">L.  Kumar</span>. </span><span class="cited-content_cbyCitation_article-title">Treating colon cancers with a non-conventional yet strategic approach: An overview of various nanoparticulate systems. </span><span class="cited-content_cbyCitation_journal-name">Journal of Controlled Release</span><span> <strong>2021,</strong> <em>336 </em>, 16-39. <a href="https://doi.org/10.1016/j.jconrel.2021.06.008" title="DOI URL">https://doi.org/10.1016/j.jconrel.2021.06.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jconrel.2021.06.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jconrel.2021.06.008%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Controlled%2520Release%26atitle%3DTreating%252Bcolon%252Bcancers%252Bwith%252Ba%252Bnon-conventional%252Byet%252Bstrategic%252Bapproach%25253A%252BAn%252Boverview%252Bof%252Bvarious%252Bnanoparticulate%252Bsystems%26aulast%3DBhaskaran%26aufirst%3DN.A.%26date%3D2021%26volume%3D336%26spage%3D16%26epage%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qimei  Gu</span>, <span class="hlFld-ContribAuthor ">Lance  Dockery</span>, <span class="hlFld-ContribAuthor ">Marie-Christine  Daniel</span>, <span class="hlFld-ContribAuthor ">Charles J.  Bieberich</span>, <span class="hlFld-ContribAuthor ">Ronghui  Ma</span>, <span class="hlFld-ContribAuthor ">Liang  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Nanoparticle Delivery in Prostate Tumors Implanted in Mice Facilitated by Either Local or Whole-Body Heating. </span><span class="cited-content_cbyCitation_journal-name">Fluids</span><span> <strong>2021,</strong> <em>6 </em>
                                    (8)
                                     , 272. <a href="https://doi.org/10.3390/fluids6080272" title="DOI URL">https://doi.org/10.3390/fluids6080272</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/fluids6080272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Ffluids6080272%26sid%3Dliteratum%253Aachs%26jtitle%3DFluids%26atitle%3DNanoparticle%252BDelivery%252Bin%252BProstate%252BTumors%252BImplanted%252Bin%252BMice%252BFacilitated%252Bby%252BEither%252BLocal%252Bor%252BWhole-Body%252BHeating%26aulast%3DGu%26aufirst%3DQimei%26date%3D2021%26date%3D2021%26volume%3D6%26issue%3D8%26spage%3D272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sankha  Bhattacharya</span>, <span class="hlFld-ContribAuthor ">Kapil  Gore</span>. </span><span class="cited-content_cbyCitation_article-title">Targeted Cancer Therapy Using Nanoparticles and Antibody Fragments. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.5772/intechopen.96550" title="DOI URL">https://doi.org/10.5772/intechopen.96550</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.5772/intechopen.96550&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.5772%2Fintechopen.96550%26sid%3Dliteratum%253Aachs%26atitle%3DTargeted%252BCancer%252BTherapy%252BUsing%252BNanoparticles%252Band%252BAntibody%252BFragments%26aulast%3DBhattacharya%26aufirst%3DSankha%26date%3D2021%26date%3D2021%26pub%3DIntechOpen%26atitle%3DAdvances%252Bin%252BPrecision%252BMedicine%252BOncology%26aulast%3DArnouk%26aufirst%3DHilal%26date%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Enrique  Niza</span>, <span class="hlFld-ContribAuthor ">Alberto  Ocaña</span>, <span class="hlFld-ContribAuthor ">José Antonio  Castro-Osma</span>, <span class="hlFld-ContribAuthor ">Iván  Bravo</span>, <span class="hlFld-ContribAuthor ">Carlos  Alonso-Moreno</span>. </span><span class="cited-content_cbyCitation_article-title">Polyester Polymeric Nanoparticles as Platforms in the Development of Novel Nanomedicines for Cancer Treatment. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (14)
                                     , 3387. <a href="https://doi.org/10.3390/cancers13143387" title="DOI URL">https://doi.org/10.3390/cancers13143387</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13143387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13143387%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DPolyester%252BPolymeric%252BNanoparticles%252Bas%252BPlatforms%252Bin%252Bthe%252BDevelopment%252Bof%252BNovel%252BNanomedicines%252Bfor%252BCancer%252BTreatment%26aulast%3DNiza%26aufirst%3DEnrique%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D14%26spage%3D3387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">M.  Madakka</span>, <span class="hlFld-ContribAuthor ">N.  Jayaraju</span>, <span class="hlFld-ContribAuthor ">N.  Rajesh</span>. </span><span class="cited-content_cbyCitation_article-title">Evaluating the antimicrobial activity and antitumor screening of green synthesized silver nanoparticles compounds, using Syzygium jambolanum, towards MCF7 cell line (Breast cancer cell line). </span><span class="cited-content_cbyCitation_journal-name">Journal of Photochemistry and Photobiology</span><span> <strong>2021,</strong> <em>6 </em>, 100028. <a href="https://doi.org/10.1016/j.jpap.2021.100028" title="DOI URL">https://doi.org/10.1016/j.jpap.2021.100028</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jpap.2021.100028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jpap.2021.100028%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Photochemistry%2520and%2520Photobiology%26atitle%3DEvaluating%252Bthe%252Bantimicrobial%252Bactivity%252Band%252Bantitumor%252Bscreening%252Bof%252Bgreen%252Bsynthesized%252Bsilver%252Bnanoparticles%252Bcompounds%25252C%252Busing%252BSyzygium%252Bjambolanum%25252C%252Btowards%252BMCF7%252Bcell%252Bline%252B%252528Breast%252Bcancer%252Bcell%252Bline%252529%26aulast%3DMadakka%26aufirst%3DM.%26date%3D2021%26volume%3D6%26spage%3D100028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gui-Ling  Fan</span>, <span class="hlFld-ContribAuthor ">Fu-An  Deng</span>, <span class="hlFld-ContribAuthor ">Xiang  Zhou</span>, <span class="hlFld-ContribAuthor ">Ling-Shan  Liu</span>, <span class="hlFld-ContribAuthor ">Jia-Qi  Huang</span>, <span class="hlFld-ContribAuthor ">Da-Wei  Zhang</span>, <span class="hlFld-ContribAuthor ">Yun-Xia  Sun</span>, <span class="hlFld-ContribAuthor ">A-Li  Chen</span>, <span class="hlFld-ContribAuthor ">Hong  Cheng</span>, <span class="hlFld-ContribAuthor ">Shi-Ying  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Plasma membrane targeted photodynamic O2 economizer for hypoxic tumor therapy. </span><span class="cited-content_cbyCitation_journal-name">Biomaterials</span><span> <strong>2021,</strong> <em>273 </em>, 120854. <a href="https://doi.org/10.1016/j.biomaterials.2021.120854" title="DOI URL">https://doi.org/10.1016/j.biomaterials.2021.120854</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.biomaterials.2021.120854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.biomaterials.2021.120854%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomaterials%26atitle%3DPlasma%252Bmembrane%252Btargeted%252Bphotodynamic%252BO2%252Beconomizer%252Bfor%252Bhypoxic%252Btumor%252Btherapy%26aulast%3DFan%26aufirst%3DGui-Ling%26date%3D2021%26volume%3D273%26spage%3D120854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Reza  Eivazzadeh-Keihan</span>, <span class="hlFld-ContribAuthor ">Ali  Maleki</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of a new magnetic aromatic organo-silane star polymer with unique nanoplate morphology and hyperthermia application. </span><span class="cited-content_cbyCitation_journal-name">Journal of Nanostructure in Chemistry</span><span> <strong>2021,</strong> <em>116 </em><a href="https://doi.org/10.1007/s40097-021-00401-0" title="DOI URL">https://doi.org/10.1007/s40097-021-00401-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40097-021-00401-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40097-021-00401-0%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Nanostructure%2520in%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Ba%252Bnew%252Bmagnetic%252Baromatic%252Borgano-silane%252Bstar%252Bpolymer%252Bwith%252Bunique%252Bnanoplate%252Bmorphology%252Band%252Bhyperthermia%252Bapplication%26aulast%3DEivazzadeh-Keihan%26aufirst%3DReza%26date%3D2021%26date%3D2021%26volume%3D116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rakesh Kumar  Mishra</span>, <span class="hlFld-ContribAuthor ">Anas  Ahmad</span>, <span class="hlFld-ContribAuthor ">Akshay  Vyawahare</span>, <span class="hlFld-ContribAuthor ">Pravej  Alam</span>, <span class="hlFld-ContribAuthor ">Tajdar Hussain  Khan</span>, <span class="hlFld-ContribAuthor ">Rehan  Khan</span>. </span><span class="cited-content_cbyCitation_article-title">Biological effects of formation of protein corona onto nanoparticles. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Biological Macromolecules</span><span> <strong>2021,</strong> <em>175 </em>, 1-18. <a href="https://doi.org/10.1016/j.ijbiomac.2021.01.152" title="DOI URL">https://doi.org/10.1016/j.ijbiomac.2021.01.152</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ijbiomac.2021.01.152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ijbiomac.2021.01.152%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Biological%2520Macromolecules%26atitle%3DBiological%252Beffects%252Bof%252Bformation%252Bof%252Bprotein%252Bcorona%252Bonto%252Bnanoparticles%26aulast%3DMishra%26aufirst%3DRakesh%2BKumar%26date%3D2021%26volume%3D175%26spage%3D1%26epage%3D18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mayara K  Uchiyama</span>, <span class="hlFld-ContribAuthor ">Cristina B  Hebeda</span>, <span class="hlFld-ContribAuthor ">Silvana  Sandri</span>, <span class="hlFld-ContribAuthor ">Marina de  Paula-Silva</span>, <span class="hlFld-ContribAuthor ">Mariana  Romano</span>, <span class="hlFld-ContribAuthor ">Roberta M  Cardoso</span>, <span class="hlFld-ContribAuthor ">Sergio H  Toma</span>, <span class="hlFld-ContribAuthor ">Koiti  Araki</span>, <span class="hlFld-ContribAuthor ">Sandra HP  Farsky</span>. </span><span class="cited-content_cbyCitation_article-title">In vivo
              evaluation of toxicity and anti-inflammatory activity of iron oxide nanoparticles conjugated with ibuprofen. </span><span class="cited-content_cbyCitation_journal-name">Nanomedicine</span><span> <strong>2021,</strong> <em>16 </em>
                                    (9)
                                     , 741-758. <a href="https://doi.org/10.2217/nnm-2020-0459" title="DOI URL">https://doi.org/10.2217/nnm-2020-0459</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2217/nnm-2020-0459&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2217%2Fnnm-2020-0459%26sid%3Dliteratum%253Aachs%26jtitle%3DNanomedicine%26atitle%3DIn%252Bvivo%252Bevaluation%252Bof%252Btoxicity%252Band%252Banti-inflammatory%252Bactivity%252Bof%252Biron%252Boxide%252Bnanoparticles%252Bconjugated%252Bwith%252Bibuprofen%26aulast%3DUchiyama%26aufirst%3DMayara%2BK%26date%3D2021%26volume%3D16%26issue%3D9%26spage%3D741%26epage%3D758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yingcai  Meng</span>, <span class="hlFld-ContribAuthor ">Yuan  Chen</span>, <span class="hlFld-ContribAuthor ">Jiaojiao  Zhu</span>, <span class="hlFld-ContribAuthor ">Yan  Qi</span>, <span class="hlFld-ContribAuthor ">Jinsong  Ding</span>, <span class="hlFld-ContribAuthor ">Wenhu  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Polarity control of DNA adsorption enabling the surface functionalization of CuO nanozymes for targeted tumor therapy. </span><span class="cited-content_cbyCitation_journal-name">Materials Horizons</span><span> <strong>2021,</strong> <em>8 </em>
                                    (3)
                                     , 972-986. <a href="https://doi.org/10.1039/D0MH01372B" title="DOI URL">https://doi.org/10.1039/D0MH01372B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0MH01372B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0MH01372B%26sid%3Dliteratum%253Aachs%26jtitle%3DMaterials%2520Horizons%26atitle%3DPolarity%252Bcontrol%252Bof%252BDNA%252Badsorption%252Benabling%252Bthe%252Bsurface%252Bfunctionalization%252Bof%252BCuO%252Bnanozymes%252Bfor%252Btargeted%252Btumor%252Btherapy%26aulast%3DMeng%26aufirst%3DYingcai%26date%3D2021%26date%3D2021%26volume%3D8%26issue%3D3%26spage%3D972%26epage%3D986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maria Victoria  Cano-Cortes</span>, <span class="hlFld-ContribAuthor ">Patricia  Altea-Manzano</span>, <span class="hlFld-ContribAuthor ">Jose Antonio  Laz-Ruiz</span>, <span class="hlFld-ContribAuthor ">Juan Diego  Unciti-Broceta</span>, <span class="hlFld-ContribAuthor ">Francisco Javier  Lopez-Delgado</span>, <span class="hlFld-ContribAuthor ">Jose Manuel  Espejo-Roman</span>, <span class="hlFld-ContribAuthor ">Juan Jose  Diaz-Mochon</span>, <span class="hlFld-ContribAuthor ">Rosario M.  Sanchez-Martin</span>. </span><span class="cited-content_cbyCitation_article-title">An effective polymeric nanocarrier that allows for active targeting and selective drug delivery in cell coculture systems. </span><span class="cited-content_cbyCitation_journal-name">Nanoscale</span><span> <strong>2021,</strong> <em>13 </em>
                                    (6)
                                     , 3500-3511. <a href="https://doi.org/10.1039/D0NR07145E" title="DOI URL">https://doi.org/10.1039/D0NR07145E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0NR07145E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0NR07145E%26sid%3Dliteratum%253Aachs%26jtitle%3DNanoscale%26atitle%3DAn%252Beffective%252Bpolymeric%252Bnanocarrier%252Bthat%252Ballows%252Bfor%252Bactive%252Btargeting%252Band%252Bselective%252Bdrug%252Bdelivery%252Bin%252Bcell%252Bcoculture%252Bsystems%26aulast%3DCano-Cortes%26aufirst%3DMaria%2BVictoria%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D6%26spage%3D3500%26epage%3D3511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yue  Yan</span>, <span class="hlFld-ContribAuthor ">Binlong  Chen</span>, <span class="hlFld-ContribAuthor ">Zenghui  Wang</span>, <span class="hlFld-ContribAuthor ">Qingqing  Yin</span>, <span class="hlFld-ContribAuthor ">Yaoqi  Wang</span>, <span class="hlFld-ContribAuthor ">Fangjie  Wan</span>, <span class="hlFld-ContribAuthor ">Yulin  Mo</span>, <span class="hlFld-ContribAuthor ">Bo  Xu</span>, <span class="hlFld-ContribAuthor ">Qiang  Zhang</span>, <span class="hlFld-ContribAuthor ">Siling  Wang</span>, <span class="hlFld-ContribAuthor ">Yiguang  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Sequential Modulations of Tumor Vasculature and Stromal Barriers Augment the Active Targeting Efficacy of Antibody‐Modified Nanophotosensitizer in Desmoplastic Ovarian Carcinoma. </span><span class="cited-content_cbyCitation_journal-name">Advanced Science</span><span> <strong>2021,</strong> <em>8 </em>
                                    (3)
                                     , 2002253. <a href="https://doi.org/10.1002/advs.202002253" title="DOI URL">https://doi.org/10.1002/advs.202002253</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/advs.202002253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadvs.202002253%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Science%26atitle%3DSequential%252BModulations%252Bof%252BTumor%252BVasculature%252Band%252BStromal%252BBarriers%252BAugment%252Bthe%252BActive%252BTargeting%252BEfficacy%252Bof%252BAntibody%2525E2%252580%252590Modified%252BNanophotosensitizer%252Bin%252BDesmoplastic%252BOvarian%252BCarcinoma%26aulast%3DYan%26aufirst%3DYue%26date%3D2021%26date%3D2020%26volume%3D8%26issue%3D3%26spage%3D2002253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael J.  Mitchell</span>, <span class="hlFld-ContribAuthor ">Margaret M.  Billingsley</span>, <span class="hlFld-ContribAuthor ">Rebecca M.  Haley</span>, <span class="hlFld-ContribAuthor ">Marissa E.  Wechsler</span>, <span class="hlFld-ContribAuthor ">Nicholas A.  Peppas</span>, <span class="hlFld-ContribAuthor ">Robert  Langer</span>. </span><span class="cited-content_cbyCitation_article-title">Engineering precision nanoparticles for drug delivery. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Drug Discovery</span><span> <strong>2021,</strong> <em>20 </em>
                                    (2)
                                     , 101-124. <a href="https://doi.org/10.1038/s41573-020-0090-8" title="DOI URL">https://doi.org/10.1038/s41573-020-0090-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41573-020-0090-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41573-020-0090-8%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Drug%2520Discovery%26atitle%3DEngineering%252Bprecision%252Bnanoparticles%252Bfor%252Bdrug%252Bdelivery%26aulast%3DMitchell%26aufirst%3DMichael%2BJ.%26date%3D2021%26date%3D2020%26volume%3D20%26issue%3D2%26spage%3D101%26epage%3D124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Junjie  Liu</span>, <span class="hlFld-ContribAuthor ">Jinjin  Shi</span>, <span class="hlFld-ContribAuthor ">Weimin  Nie</span>, <span class="hlFld-ContribAuthor ">Sijie  Wang</span>, <span class="hlFld-ContribAuthor ">Genhua  Liu</span>, <span class="hlFld-ContribAuthor ">Kaiyong  Cai</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Progress in the Development of Multifunctional Nanoplatform for Precise Tumor Phototherapy. </span><span class="cited-content_cbyCitation_journal-name">Advanced Healthcare Materials</span><span> <strong>2021,</strong> <em>10 </em>
                                    (1)
                                     , 2001207. <a href="https://doi.org/10.1002/adhm.202001207" title="DOI URL">https://doi.org/10.1002/adhm.202001207</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adhm.202001207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadhm.202001207%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Healthcare%2520Materials%26atitle%3DRecent%252BProgress%252Bin%252Bthe%252BDevelopment%252Bof%252BMultifunctional%252BNanoplatform%252Bfor%252BPrecise%252BTumor%252BPhototherapy%26aulast%3DLiu%26aufirst%3DJunjie%26date%3D2021%26date%3D2020%26volume%3D10%26issue%3D1%26spage%3D2001207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mohmmad Younus  Wani</span>, <span class="hlFld-ContribAuthor ">Manzoor Ahmad  Malik</span>. </span><span class="cited-content_cbyCitation_article-title">Non-platinum Anticancer Agents. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 51-68. <a href="https://doi.org/10.1007/978-981-33-6314-4_6" title="DOI URL">https://doi.org/10.1007/978-981-33-6314-4_6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-981-33-6314-4_6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-981-33-6314-4_6%26sid%3Dliteratum%253Aachs%26atitle%3DNon-platinum%252BAnticancer%252BAgents%26aulast%3DWani%26aufirst%3DMohmmad%2BYounus%26date%3D2021%26date%3D2021%26spage%3D51%26epage%3D68%26pub%3DSpringer%2520Singapore%26atitle%3DGold%252Band%252Bits%252BComplexes%252Bin%252BAnticancer%252BChemotherapy%26aulast%3DWani%26aufirst%3DMohmmad%2BYounus%26date%3D2021%26volume%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Manzar  Abbas</span>, <span class="hlFld-ContribAuthor ">Muhammad  Ovais</span>, <span class="hlFld-ContribAuthor ">Sudip  Mukherjee</span>, <span class="hlFld-ContribAuthor ">Arbab  Ali</span>, <span class="hlFld-ContribAuthor ">Muhammad  Hanif</span>, <span class="hlFld-ContribAuthor ">Chunying  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Nanotechnology for cancer drug design, delivery, and theranostics applications. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-26. <a href="https://doi.org/10.1016/B978-0-12-821467-1.00004-5" title="DOI URL">https://doi.org/10.1016/B978-0-12-821467-1.00004-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-821467-1.00004-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-821467-1.00004-5%26sid%3Dliteratum%253Aachs%26atitle%3DNanotechnology%252Bfor%252Bcancer%252Bdrug%252Bdesign%25252C%252Bdelivery%25252C%252Band%252Btheranostics%252Bapplications%26aulast%3DAbbas%26aufirst%3DManzar%26date%3D2021%26spage%3D1%26epage%3D26%26pub%3DElsevier%26atitle%3DBiogenic%252BNanoparticles%252Bfor%252BCancer%252BTheranostics%26date%3D2021%26volume%3D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guiying  Jiang</span>, <span class="hlFld-ContribAuthor ">Xueqian  Wang</span>, <span class="hlFld-ContribAuthor ">Ying  Zhou</span>, <span class="hlFld-ContribAuthor ">Chenming  Zou</span>, <span class="hlFld-ContribAuthor ">Ling  Wang</span>, <span class="hlFld-ContribAuthor ">Wei  Wang</span>, <span class="hlFld-ContribAuthor ">Danya  Zhang</span>, <span class="hlFld-ContribAuthor ">Hanjie  Xu</span>, <span class="hlFld-ContribAuthor ">Jie  Li</span>, <span class="hlFld-ContribAuthor ">Fei  Li</span>, <span class="hlFld-ContribAuthor ">Danfeng  Luo</span>, <span class="hlFld-ContribAuthor ">Xiangyi  Ma</span>, <span class="hlFld-ContribAuthor ">Ding  Ma</span>, <span class="hlFld-ContribAuthor ">Songwei  Tan</span>, <span class="hlFld-ContribAuthor ">Rui  Wei</span>, <span class="hlFld-ContribAuthor ">Ling  Xi</span>. </span><span class="cited-content_cbyCitation_article-title">TMTP1-Modified, Tumor Microenvironment Responsive Nanoparticles Co-Deliver Cisplatin and Paclitaxel Prodrugs for Effective Cervical Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Nanomedicine</span><span> <strong>2021,</strong> <em>Volume 16 </em>, 4087-4104. <a href="https://doi.org/10.2147/IJN.S298252" title="DOI URL">https://doi.org/10.2147/IJN.S298252</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2147/IJN.S298252&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2147%2FIJN.S298252%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Nanomedicine%26atitle%3DTMTP1-Modified%25252C%252BTumor%252BMicroenvironment%252BResponsive%252BNanoparticles%252BCo-Deliver%252BCisplatin%252Band%252BPaclitaxel%252BProdrugs%252Bfor%252BEffective%252BCervical%252BCancer%252BTherapy%26aulast%3DJiang%26aufirst%3DGuiying%26date%3D2021%26date%3D2021%26volume%3DVolume%252016%26spage%3D4087%26epage%3D4104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yurena  Luengo Morato</span>, <span class="hlFld-ContribAuthor ">Marzia  Marciello</span>, <span class="hlFld-ContribAuthor ">Laura  Lozano Chamizo</span>, <span class="hlFld-ContribAuthor ">Karina  Ovejero Paredes</span>, <span class="hlFld-ContribAuthor ">Marco  Filice</span>. </span><span class="cited-content_cbyCitation_article-title">Hybrid magnetic nanoparticles for multimodal molecular imaging of cancer. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 343-386. <a href="https://doi.org/10.1016/B978-0-12-823688-8.00008-9" title="DOI URL">https://doi.org/10.1016/B978-0-12-823688-8.00008-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-823688-8.00008-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-823688-8.00008-9%26sid%3Dliteratum%253Aachs%26atitle%3DHybrid%252Bmagnetic%252Bnanoparticles%252Bfor%252Bmultimodal%252Bmolecular%252Bimaging%252Bof%252Bcancer%26aulast%3DLuengo%2BMorato%26aufirst%3DYurena%26date%3D2021%26spage%3D343%26epage%3D386%26pub%3DElsevier%26atitle%3DMagnetic%252BNanoparticle-Based%252BHybrid%252BMaterials%26date%3D2021%26volume%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anas  Ahmad</span>, <span class="hlFld-ContribAuthor ">Haseeb  Ahsan</span>. </span><span class="cited-content_cbyCitation_article-title">Lipid-based formulations in cosmeceuticals and biopharmaceuticals. </span><span class="cited-content_cbyCitation_journal-name">Biomedical Dermatology</span><span> <strong>2020,</strong> <em>4 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s41702-020-00062-9" title="DOI URL">https://doi.org/10.1186/s41702-020-00062-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s41702-020-00062-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs41702-020-00062-9%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomedical%2520Dermatology%26atitle%3DLipid-based%252Bformulations%252Bin%252Bcosmeceuticals%252Band%252Bbiopharmaceuticals%26aulast%3DAhmad%26aufirst%3DAnas%26date%3D2020%26date%3D2020%26volume%3D4%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lulu  Yue</span>, <span class="hlFld-ContribAuthor ">Wen  Jin</span>, <span class="hlFld-ContribAuthor ">Shaoming  Chi</span>, <span class="hlFld-ContribAuthor ">Tong  Yang</span>, <span class="hlFld-ContribAuthor ">Ze  Lei</span>, <span class="hlFld-ContribAuthor ">Hongyou  Zhu</span>, <span class="hlFld-ContribAuthor ">Yan  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">pH‐responsive
              chitosan/sulfobutyl ether‐β‐cyclodextrin supramolecular nanoparticles for controlled release of sodium ferulate. </span><span class="cited-content_cbyCitation_journal-name">Polymer Engineering & Science</span><span> <strong>2020,</strong> <em>60 </em>
                                    (10)
                                     , 2403-2413. <a href="https://doi.org/10.1002/pen.25479" title="DOI URL">https://doi.org/10.1002/pen.25479</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/pen.25479&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fpen.25479%26sid%3Dliteratum%253Aachs%26jtitle%3DPolymer%2520Engineering%2520%2526%2520Science%26atitle%3DpH%2525E2%252580%252590responsive%252Bchitosan%25252Fsulfobutyl%252Bether%2525E2%252580%252590%2525CE%2525B2%2525E2%252580%252590cyclodextrin%252Bsupramolecular%252Bnanoparticles%252Bfor%252Bcontrolled%252Brelease%252Bof%252Bsodium%252Bferulate%26aulast%3DYue%26aufirst%3DLulu%26date%3D2020%26date%3D2020%26volume%3D60%26issue%3D10%26spage%3D2403%26epage%3D2413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shujing  Liang</span>, <span class="hlFld-ContribAuthor ">Menglin  Sun</span>, <span class="hlFld-ContribAuthor ">Yonglin  Lu</span>, <span class="hlFld-ContribAuthor ">Shuo  Shi</span>, <span class="hlFld-ContribAuthor ">Yiting  Yang</span>, <span class="hlFld-ContribAuthor ">Yun  Lin</span>, <span class="hlFld-ContribAuthor ">Chan  Feng</span>, <span class="hlFld-ContribAuthor ">Jie  Liu</span>, <span class="hlFld-ContribAuthor ">Chunyan  Dong</span>. </span><span class="cited-content_cbyCitation_article-title">Cytokine-induced killer cells-assisted tumor-targeting delivery of Her-2 monoclonal antibody-conjugated gold nanostars with NIR photosensitizer for enhanced therapy of cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Materials Chemistry B</span><span> <strong>2020,</strong> <em>8 </em>
                                    (36)
                                     , 8368-8382. <a href="https://doi.org/10.1039/D0TB01391A" title="DOI URL">https://doi.org/10.1039/D0TB01391A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0TB01391A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0TB01391A%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Materials%2520Chemistry%2520B%26atitle%3DCytokine-induced%252Bkiller%252Bcells-assisted%252Btumor-targeting%252Bdelivery%252Bof%252BHer-2%252Bmonoclonal%252Bantibody-conjugated%252Bgold%252Bnanostars%252Bwith%252BNIR%252Bphotosensitizer%252Bfor%252Benhanced%252Btherapy%252Bof%252Bcancer%26aulast%3DLiang%26aufirst%3DShujing%26date%3D2020%26date%3D2020%26volume%3D8%26issue%3D36%26spage%3D8368%26epage%3D8382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rakesh Kumar  Mishra</span>, <span class="hlFld-ContribAuthor ">Anas  Ahmad</span>, <span class="hlFld-ContribAuthor ">Akshay  Vyawahare</span>, <span class="hlFld-ContribAuthor ">Ajay  Kumar</span>, <span class="hlFld-ContribAuthor ">Rehan  Khan</span>. </span><span class="cited-content_cbyCitation_article-title">Understanding the Monoclonal Antibody Involvement in Targeting the Activation of Tumor Suppressor Genes. </span><span class="cited-content_cbyCitation_journal-name">Current Topics in Medicinal Chemistry</span><span> <strong>2020,</strong> <em>20 </em>
                                    (20)
                                     , 1810-1823. <a href="https://doi.org/10.2174/1568026620666200616133814" title="DOI URL">https://doi.org/10.2174/1568026620666200616133814</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1568026620666200616133814&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1568026620666200616133814%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Topics%2520in%2520Medicinal%2520Chemistry%26atitle%3DUnderstanding%252Bthe%252BMonoclonal%252BAntibody%252BInvolvement%252Bin%252BTargeting%252Bthe%252BActivation%252Bof%252BTumor%252BSuppressor%252BGenes%26aulast%3DMishra%26aufirst%3DRakesh%2BKumar%26date%3D2020%26volume%3D20%26issue%3D20%26spage%3D1810%26epage%3D1823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Belén  Begines</span>, <span class="hlFld-ContribAuthor ">Tamara  Ortiz</span>, <span class="hlFld-ContribAuthor ">María  Pérez-Aranda</span>, <span class="hlFld-ContribAuthor ">Guillermo  Martínez</span>, <span class="hlFld-ContribAuthor ">Manuel  Merinero</span>, <span class="hlFld-ContribAuthor ">Federico  Argüelles-Arias</span>, <span class="hlFld-ContribAuthor ">Ana  Alcudia</span>. </span><span class="cited-content_cbyCitation_article-title">Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects. </span><span class="cited-content_cbyCitation_journal-name">Nanomaterials</span><span> <strong>2020,</strong> <em>10 </em>
                                    (7)
                                     , 1403. <a href="https://doi.org/10.3390/nano10071403" title="DOI URL">https://doi.org/10.3390/nano10071403</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/nano10071403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fnano10071403%26sid%3Dliteratum%253Aachs%26jtitle%3DNanomaterials%26atitle%3DPolymeric%252BNanoparticles%252Bfor%252BDrug%252BDelivery%25253A%252BRecent%252BDevelopments%252Band%252BFuture%252BProspects%26aulast%3DBegines%26aufirst%3DBel%25C3%25A9n%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D7%26spage%3D1403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bin  Tu</span>, <span class="hlFld-ContribAuthor ">Meng  Zhang</span>, <span class="hlFld-ContribAuthor ">Tuanbing  Liu</span>, <span class="hlFld-ContribAuthor ">Yongzhuo  Huang</span>. </span><span class="cited-content_cbyCitation_article-title">Nanotechnology-Based Histone Deacetylase Inhibitors for Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Cell and Developmental Biology</span><span> <strong>2020,</strong> <em>8 </em><a href="https://doi.org/10.3389/fcell.2020.00400" title="DOI URL">https://doi.org/10.3389/fcell.2020.00400</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fcell.2020.00400&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffcell.2020.00400%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Cell%2520and%2520Developmental%2520Biology%26atitle%3DNanotechnology-Based%252BHistone%252BDeacetylase%252BInhibitors%252Bfor%252BCancer%252BTherapy%26aulast%3DTu%26aufirst%3DBin%26date%3D2020%26date%3D2020%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ajay  Kumar</span>, <span class="hlFld-ContribAuthor ">Anas  Ahmad</span>, <span class="hlFld-ContribAuthor ">Akshay  Vyawahare</span>, <span class="hlFld-ContribAuthor ">Rehan  Khan</span>. </span><span class="cited-content_cbyCitation_article-title">Membrane Trafficking and Subcellular Drug Targeting Pathways. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2020,</strong> <em>11 </em><a href="https://doi.org/10.3389/fphar.2020.00629" title="DOI URL">https://doi.org/10.3389/fphar.2020.00629</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2020.00629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2020.00629%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DMembrane%252BTrafficking%252Band%252BSubcellular%252BDrug%252BTargeting%252BPathways%26aulast%3DKumar%26aufirst%3DAjay%26date%3D2020%26date%3D2020%26volume%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rulin  Sun</span>, <span class="hlFld-ContribAuthor ">Xujun  He</span>, <span class="hlFld-ContribAuthor ">Xiaoting  Jiang</span>, <span class="hlFld-ContribAuthor ">Houquan  Tao</span>. </span><span class="cited-content_cbyCitation_article-title">The new role of riluzole in the treatment of pancreatic cancer through the apoptosis and autophagy pathways. </span><span class="cited-content_cbyCitation_journal-name">Journal of Cellular Biochemistry</span><span> <strong>2019,</strong> <em>68 </em><a href="https://doi.org/10.1002/jcb.29533" title="DOI URL">https://doi.org/10.1002/jcb.29533</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jcb.29533&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjcb.29533%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Cellular%2520Biochemistry%26atitle%3DThe%252Bnew%252Brole%252Bof%252Briluzole%252Bin%252Bthe%252Btreatment%252Bof%252Bpancreatic%252Bcancer%252Bthrough%252Bthe%252Bapoptosis%252Band%252Bautophagy%252Bpathways%26aulast%3DSun%26aufirst%3DRulin%26date%3D2019%26date%3D2019%26volume%3D68" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00511/20191205/images/medium/jm9b00511_0004.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00511/20191205/images/large/jm9b00511_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00511&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00511/20191205/images/medium/jm9b00511_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00511/20191205/images/large/jm9b00511_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Active and passive targeting in tumor and adjacent normal tissues.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00511/20191205/images/large/jm9b00511_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00511&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00511/20191205/images/medium/jm9b00511_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00511/20191205/images/large/jm9b00511_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Active targeting of cancer cell by various targeting moieties.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00511/20191205/images/large/jm9b00511_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00511&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00511/20191205/images/medium/jm9b00511_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00511/20191205/images/large/jm9b00511_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Schematic illustration for cancer stem cell active targeting and cancer immune cell active targeting.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-23/acs.jmedchem.9b00511/20191205/images/large/jm9b00511_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00511&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i40">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88414" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88414" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 180 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jemal, A.</span></span> <span> </span><span class="NLM_article-title">Cancer Statistics, 2016</span>. <i>Ca-Cancer J. Clin.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.3322/caac.21332</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.3322%2Fcaac.21332" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=26742998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A280%3ADC%252BC28rot1Kjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2016&pages=7-30&author=R.+L.+Siegelauthor=K.+D.+Millerauthor=A.+Jemal&title=Cancer+Statistics%2C+2016&doi=10.3322%2Fcaac.21332"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer statistics, 2016</span></div><div class="casAuthors">Siegel Rebecca L; Miller Kimberly D; Jemal Ahmedin</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival.  Incidence data were collected by the National Cancer Institute (Surveillance, Epidemiology, and End Results [SEER] Program), the Centers for Disease Control and Prevention (National Program of Cancer Registries), and the North American Association of Central Cancer Registries.  Mortality data were collected by the National Center for Health Statistics.  In 2016, 1,685,210 new cancer cases and 595,690 cancer deaths are projected to occur in the United States.  Overall cancer incidence trends (13 oldest SEER registries) are stable in women, but declining by 3.1% per year in men (from 2009-2012), much of which is because of recent rapid declines in prostate cancer diagnoses.  The cancer death rate has dropped by 23% since 1991, translating to more than 1.7 million deaths averted through 2012.  Despite this progress, death rates are increasing for cancers of the liver, pancreas, and uterine corpus, and cancer is now the leading cause of death in 21 states, primarily due to exceptionally large reductions in death from heart disease.  Among children and adolescents (aged birth-19 years), brain cancer has surpassed leukemia as the leading cause of cancer death because of the dramatic therapeutic advances against leukemia.  Accelerating progress against cancer requires both increased national investment in cancer research and the application of existing cancer control knowledge across all segments of the population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSKAn5ROFAaRS86Js-BCLiifW6udTcc2eaFGCPcyh6rOLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rot1Kjug%253D%253D&md5=2d4030a531945c5ebaaab181bfd80457</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3322%2Fcaac.21332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.21332%26sid%3Dliteratum%253Aachs%26aulast%3DSiegel%26aufirst%3DR.%2BL.%26aulast%3DMiller%26aufirst%3DK.%2BD.%26aulast%3DJemal%26aufirst%3DA.%26atitle%3DCancer%2520Statistics%252C%25202016%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2016%26volume%3D66%26spage%3D7%26epage%3D30%26doi%3D10.3322%2Fcaac.21332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holohan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Schaeybroeck, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longley, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, P. G.</span></span> <span> </span><span class="NLM_article-title">Cancer Drug Resistance: An Evolving Paradigm</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">714</span>– <span class="NLM_lpage">726</span>, <span class="refDoi"> DOI: 10.1038/nrc3599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1038%2Fnrc3599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=24060863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVyqurnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=714-726&author=C.+Holohanauthor=S.+Van+Schaeybroeckauthor=D.+B.+Longleyauthor=P.+G.+Johnston&title=Cancer+Drug+Resistance%3A+An+Evolving+Paradigm&doi=10.1038%2Fnrc3599"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer drug resistance: an evolving paradigm</span></div><div class="casAuthors">Holohan, Caitriona; Van Schaeybroeck, Sandra; Longley, Daniel B.; Johnston, Patrick G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">714-726</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Resistance to chemotherapy and molecularly targeted therapies is a major problem facing current cancer research.  The mechanisms of resistance to 'classical' cytotoxic chemotherapeutics and to therapies that are designed to be selective for specific mol. targets share many features, such as alterations in the drug target, activation of prosurvival pathways and ineffective induction of cell death.  With the increasing arsenal of anticancer agents, improving preclin. models and the advent of powerful high-throughput screening techniques, there are now unprecedented opportunities to understand and overcome drug resistance through the clin. assessment of rational therapeutic drug combinations and the use of predictive biomarkers to enable patient stratification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrykBEUSgvv7Vg90H21EOLACvtfcHk0lgh2kcJjOrGaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVyqurnE&md5=b497a823bbd968904ce1591b918d0679</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc3599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3599%26sid%3Dliteratum%253Aachs%26aulast%3DHolohan%26aufirst%3DC.%26aulast%3DVan%2BSchaeybroeck%26aufirst%3DS.%26aulast%3DLongley%26aufirst%3DD.%2BB.%26aulast%3DJohnston%26aufirst%3DP.%2BG.%26atitle%3DCancer%2520Drug%2520Resistance%253A%2520An%2520Evolving%2520Paradigm%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2013%26volume%3D13%26spage%3D714%26epage%3D726%26doi%3D10.1038%2Fnrc3599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Byrne, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betancourt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brannon-Peppas, L.</span></span> <span> </span><span class="NLM_article-title">Active Targeting Schemes for Nanoparticle Systems in Cancer Therapeutics</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1615</span>– <span class="NLM_lpage">1626</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2008.08.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.addr.2008.08.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=18840489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVSjsL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2008&pages=1615-1626&author=J.+D.+Byrneauthor=T.+Betancourtauthor=L.+Brannon-Peppas&title=Active+Targeting+Schemes+for+Nanoparticle+Systems+in+Cancer+Therapeutics&doi=10.1016%2Fj.addr.2008.08.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Active targeting schemes for nanoparticle systems in cancer therapeutics</span></div><div class="casAuthors">Byrne, James D.; Betancourt, Tania; Brannon-Peppas, Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1615-1626</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The objective of this review is to outline current major cancer targets for nanoparticle systems and give insight into the direction of the field.  The major targeting strategies that have been used for the delivery of therapeutic or imaging agents to cancer have been broken into three sections.  These sections are angiogenesis-assocd. targeting, targeting to uncontrolled cell proliferation markers, and tumor cell targeting.  The targeting schemes explored for many of the reported nanoparticle systems suggest the great potential of targeted delivery to revolutionize cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7soOyI6FoYLVg90H21EOLACvtfcHk0lgh2kcJjOrGaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVSjsL%252FP&md5=aeeb388245fec939e63fda98fb154d99</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2008.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2008.08.005%26sid%3Dliteratum%253Aachs%26aulast%3DByrne%26aufirst%3DJ.%2BD.%26aulast%3DBetancourt%26aufirst%3DT.%26aulast%3DBrannon-Peppas%26aufirst%3DL.%26atitle%3DActive%2520Targeting%2520Schemes%2520for%2520Nanoparticle%2520Systems%2520in%2520Cancer%2520Therapeutics%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2008%26volume%3D60%26spage%3D1615%26epage%3D1626%26doi%3D10.1016%2Fj.addr.2008.08.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, R.</span></span> <span> </span><span class="NLM_article-title">Selective Targeting of Cancer Cells Using Personalized Nanomedicine</span>. <i>Toxicol Forensic Med. Open J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">e12</span>– <span class="NLM_lpage">e13</span>, <span class="refDoi"> DOI: 10.17140/TFMOJ-1-e005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.17140%2FTFMOJ-1-e005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2016&pages=e12-e13&author=A.+Guptaauthor=A.+Ahmadauthor=A.+Darauthor=A.+Bhattauthor=R.+Khan&title=Selective+Targeting+of+Cancer+Cells+Using+Personalized+Nanomedicine&doi=10.17140%2FTFMOJ-1-e005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.17140%2FTFMOJ-1-e005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.17140%252FTFMOJ-1-e005%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DAhmad%26aufirst%3DA.%26aulast%3DDar%26aufirst%3DA.%26aulast%3DBhatt%26aufirst%3DA.%26aulast%3DKhan%26aufirst%3DR.%26atitle%3DSelective%2520Targeting%2520of%2520Cancer%2520Cells%2520Using%2520Personalized%2520Nanomedicine%26jtitle%3DToxicol%2520Forensic%2520Med.%2520Open%2520J.%26date%3D2016%26volume%3D1%26spage%3De12%26epage%3De13%26doi%3D10.17140%2FTFMOJ-1-e005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prabhu, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patravale, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, M. D.</span></span> <span> </span><span class="NLM_article-title">Polymeric Nanoparticles for Targeted Treatment in Oncology: Current Insights</span>. <i>Int. J. Nanomed.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1001</span>– <span class="NLM_lpage">1018</span>, <span class="refDoi"> DOI: 10.2147/IJN.S56932</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.2147%2FIJN.S56932" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=25678788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktl2qt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1001-1018&author=R.+H.+Prabhuauthor=V.+B.+Patravaleauthor=M.+D.+Joshi&title=Polymeric+Nanoparticles+for+Targeted+Treatment+in+Oncology%3A+Current+Insights&doi=10.2147%2FIJN.S56932"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Polymeric nanoparticles for targeted treatment in oncology: current insights</span></div><div class="casAuthors">Prabhu, Rashmi H.; Patravale, Vandana B.; Joshi, Medha D.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Nanomedicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1001-1018</span>CODEN:
                <span class="NLM_cas:coden">IJNNHQ</span>;
        ISSN:<span class="NLM_cas:issn">1178-2013</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Chemotherapy, a major strategy for cancer treatment, lacks the specificity to localize the cancer therapeutics in the tumor site, thereby affecting normal healthy tissues and advocating toxic adverse effects.  Nanotechnol. intervention has greatly revolutionized the therapy of cancer by surmounting the current limitations in conventional chemotherapy, which include undesirable biodistribution, cancer cell drug resistance, and severe systemic side effects.  Nanoparticles (NPs) achieve preferential accumulation in the tumor site by virtue of their passive and ligand-based targeting mechanisms.  Polymer-based nanomedicine, an arena that entails the use of polymeric NPs, polymer micelles, dendrimers, polymersomes, polyplexes, polymer-lipid hybrid systems, and polymer-drug/protein conjugates for improvement in efficacy of cancer therapeutics, has been widely explored.  The broad scope for chem. modifying the polymer into desired construct makes it a versatile delivery system.  Several polymer-based therapeutic NPs have been approved for clin. use.  This review provides an insight into the advances in polymer-based targeted nanocarriers with focus on therapeutic aspects in the field of oncol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTKOWCqQFfKrVg90H21EOLACvtfcHk0liHT8PQoXHugw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktl2qt7s%253D&md5=23a5f2583db59d156fe6cf9954c00ac3</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.2147%2FIJN.S56932&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIJN.S56932%26sid%3Dliteratum%253Aachs%26aulast%3DPrabhu%26aufirst%3DR.%2BH.%26aulast%3DPatravale%26aufirst%3DV.%2BB.%26aulast%3DJoshi%26aufirst%3DM.%2BD.%26atitle%3DPolymeric%2520Nanoparticles%2520for%2520Targeted%2520Treatment%2520in%2520Oncology%253A%2520Current%2520Insights%26jtitle%3DInt.%2520J.%2520Nanomed.%26date%3D2015%26volume%3D10%26spage%3D1001%26epage%3D1018%26doi%3D10.2147%2FIJN.S56932" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haeri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osouli, M.</span></span> <span> </span><span class="NLM_article-title">EGFR Targeted Nanocarriers for Cancer Diagnosis and Therapy</span>. <i>Trends Pept. Protein Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">55</span>, <span class="refDoi"> DOI: 10.22037/tpps.v1i2.13611</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.22037%2Ftpps.v1i2.13611" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2017&pages=41-55&author=A.+Haeriauthor=M.+Osouli&title=EGFR+Targeted+Nanocarriers+for+Cancer+Diagnosis+and+Therapy&doi=10.22037%2Ftpps.v1i2.13611"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.22037%2Ftpps.v1i2.13611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.22037%252Ftpps.v1i2.13611%26sid%3Dliteratum%253Aachs%26aulast%3DHaeri%26aufirst%3DA.%26aulast%3DOsouli%26aufirst%3DM.%26atitle%3DEGFR%2520Targeted%2520Nanocarriers%2520for%2520Cancer%2520Diagnosis%2520and%2520Therapy%26jtitle%3DTrends%2520Pept.%2520Protein%2520Sci.%26date%3D2017%26volume%3D1%26spage%3D41%26epage%3D55%26doi%3D10.22037%2Ftpps.v1i2.13611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Strebhardt, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullrich, A.</span></span> <span> </span><span class="NLM_article-title">Paul Ehrlich’s Magic Bullet Concept: 100 Years of Progress</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">473</span>– <span class="NLM_lpage">480</span>, <span class="refDoi"> DOI: 10.1038/nrc2394</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1038%2Fnrc2394" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=18469827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmt1Oksbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=473-480&author=K.+Strebhardtauthor=A.+Ullrich&title=Paul+Ehrlich%E2%80%99s+Magic+Bullet+Concept%3A+100+Years+of+Progress&doi=10.1038%2Fnrc2394"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Paul Ehrlich's magic bullet concept: 100 years of progress</span></div><div class="casAuthors">Strebhardt, Klaus; Ullrich, Axel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">473-480</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">One hundred years ago, Paul Ehrlich received the Nobel Prize for Physiol. or Medicine.  His idea of creating 'magic bullets' for use in the fight against human diseases has inspired generations of scientists to devise powerful mol. cancer therapeutics.  Exceptional advances in mol. biol. and genetic research have expedited cancer drug development tremendously.  The declared paradigm is the development of 'personalized and tailored drugs' that precisely target the specific mol. defects of a cancer patient.  It is therefore appropriate to revisit the intellectual foundations of the development of such agents, as many have shown great clin. success.  One hundred years ago, Paul Ehrlich, the founder of chemotherapy, received the Nobel Prize for Physiol. or Medicine.  His postulate of creating 'magic bullets' for use in the fight against human diseases inspired generations of scientists to devise powerful mol. cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA71zae_BVCbVg90H21EOLACvtfcHk0liHT8PQoXHugw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmt1Oksbw%253D&md5=e56fb7160426e409a7cb48ecf56a4483</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrc2394&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2394%26sid%3Dliteratum%253Aachs%26aulast%3DStrebhardt%26aufirst%3DK.%26aulast%3DUllrich%26aufirst%3DA.%26atitle%3DPaul%2520Ehrlich%25E2%2580%2599s%2520Magic%2520Bullet%2520Concept%253A%2520100%2520Years%2520of%2520Progress%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2008%26volume%3D8%26spage%3D473%26epage%3D480%26doi%3D10.1038%2Fnrc2394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ambade, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savariar, E. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thayumanavan, S.</span></span> <span> </span><span class="NLM_article-title">Dendrimeric Micelles for Controlled Drug Release and Targeted Delivery</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">264</span>– <span class="NLM_lpage">272</span>, <span class="refDoi"> DOI: 10.1021/mp050020d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp050020d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkslSltL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=264-272&author=A.+V.+Ambadeauthor=E.+N.+Savariarauthor=S.+Thayumanavan&title=Dendrimeric+Micelles+for+Controlled+Drug+Release+and+Targeted+Delivery&doi=10.1021%2Fmp050020d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Dendrimeric micelles for controlled drug release and targeted delivery</span></div><div class="casAuthors">Ambade, Ashootosh V.; Savariar, Elamprakash N.; Thayumanavan, S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">264-272</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This review highlights the developments in dendrimer-based micelles for drug delivery.  Dendrimers, the perfectly branched monodisperse macromols., have certain structural advantages that make them attractive candidates as drug carriers for controlled release or targeted delivery.  As polymeric micelle-based approaches precede the work in dendrimers, these are also discussed briefly.  The review concludes with a perspective on possible applications of biaryl-based dendrimeric micelles that exhibit environment-dependent conformations, in drug delivery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6H0x54VbddLVg90H21EOLACvtfcHk0liHT8PQoXHugw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkslSltL4%253D&md5=05e7a1fdee6ec635bef9d85f7608bc6c</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fmp050020d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp050020d%26sid%3Dliteratum%253Aachs%26aulast%3DAmbade%26aufirst%3DA.%2BV.%26aulast%3DSavariar%26aufirst%3DE.%2BN.%26aulast%3DThayumanavan%26aufirst%3DS.%26atitle%3DDendrimeric%2520Micelles%2520for%2520Controlled%2520Drug%2520Release%2520and%2520Targeted%2520Delivery%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2005%26volume%3D2%26spage%3D264%26epage%3D272%26doi%3D10.1021%2Fmp050020d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">K M, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ansari, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayamurugan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, R.</span></span> <span> </span><span class="NLM_article-title">Nanocarrier Composed of Magnetite Core Coated with Three Polymeric Shells Mediates LCS-1 Delivery for Synthetic Lethal Therapy of BLM-Defective Colorectal Cancer Cells</span>. <i>Biomacromolecules</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">803</span>– <span class="NLM_lpage">815</span>, <span class="refDoi"> DOI: 10.1021/acs.biomac.7b01607</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biomac.7b01607" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivVais7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=803-815&author=A.+Guptaauthor=A.+Ahmadauthor=H.+Singhauthor=S.+Kaurauthor=N.+K+Mauthor=M.+M.+Ansariauthor=G.+Jayamuruganauthor=R.+Khan&title=Nanocarrier+Composed+of+Magnetite+Core+Coated+with+Three+Polymeric+Shells+Mediates+LCS-1+Delivery+for+Synthetic+Lethal+Therapy+of+BLM-Defective+Colorectal+Cancer+Cells&doi=10.1021%2Facs.biomac.7b01607"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Nanocarrier composed of magnetite core coated with three polymeric shells mediates LCS-1 delivery for synthetic lethal therapy of BLM-defective colorectal cancer cells</span></div><div class="casAuthors">Gupta, Anuradha; Ahmad, Anas; Singh, Hardeep; Kaur, Sharanjeet; Neethu, K. M.; Ansari, Md. Meraj; Jayamurugan, Govindasamy; Khan, Rehan</div><div class="citationInfo"><span class="NLM_cas:title">Biomacromolecules</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">803-815</span>CODEN:
                <span class="NLM_cas:coden">BOMAF6</span>;
        ISSN:<span class="NLM_cas:issn">1525-7797</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Synthetic lethality is a mol.-targeted therapy for selective killing of cancer cells.  We exploited a lethal interaction between superoxide dismutase 1 inhibition and Bloom syndrome gene product (BLM) defect for the treatment of colorectal cancer (CRC) cells (HCT 116) with a customized lung cancer screen-1-loaded nanocarrier (LCS-1-NC).  The drug LCS-1 has poor aq. soly.  To overcome its limitations, a customized NC, composed of a magnetite core coated with three polymeric shells, namely, aminocellulose (AC), branched poly(amidoamine), and paraben-PEG, was developed for encapsulating LCS-1.  Encapsulation efficiency and drug loading were found to be 74% and 8.2%, resp.  LCS-1-NC exhibited sustained release, with ∼85% of drug release in 24 h.  Blank NC (0.5 mg/mL) exhibited cytocompatibility toward normal cells, mainly due to the AC layer.  LCS-1-NC demonstrated high killing selectivity (104 times) toward BLM-deficient HCT 116 cells over BLM-proficient HCT 116 cells.  Due to enhanced efficacy of the drug using NC, the sensitivity difference for BLM-deficient cells increased to 1.7 times in comparison to that with free LCS-1.  LCS-1-NC induced persistent DNA damage and apoptosis, which demonstrates that LCS-1-NC effectively and preferentially killed BLM-deficient CRC cells.  This is the first report on the development of a potential drug carrier to improve the therapeutic efficacy of LCS-1 for specific killing of CRC cells having BLM defects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjpxH-q-AazbVg90H21EOLACvtfcHk0lhG-b2Nrkiv-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivVais7g%253D&md5=3dd493e08c0a3212138ed4ba465909fb</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Facs.biomac.7b01607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biomac.7b01607%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DAhmad%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DH.%26aulast%3DKaur%26aufirst%3DS.%26aulast%3DK%2BM%26aufirst%3DN.%26aulast%3DAnsari%26aufirst%3DM.%2BM.%26aulast%3DJayamurugan%26aufirst%3DG.%26aulast%3DKhan%26aufirst%3DR.%26atitle%3DNanocarrier%2520Composed%2520of%2520Magnetite%2520Core%2520Coated%2520with%2520Three%2520Polymeric%2520Shells%2520Mediates%2520LCS-1%2520Delivery%2520for%2520Synthetic%2520Lethal%2520Therapy%2520of%2520BLM-Defective%2520Colorectal%2520Cancer%2520Cells%26jtitle%3DBiomacromolecules%26date%3D2018%26volume%3D19%26spage%3D803%26epage%3D815%26doi%3D10.1021%2Facs.biomac.7b01607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dar, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, R.</span></span> <span> </span><span class="NLM_article-title">Synthetic Lethality: From Research to Precision Cancer Nanomedicine</span>. <i>Curr. Cancer Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">337</span>– <span class="NLM_lpage">346</span>, <span class="refDoi"> DOI: 10.2174/1568009617666170630141931</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.2174%2F1568009617666170630141931" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=28669337" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnvFejtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=337-346&author=A.+Guptaauthor=A.+Ahmadauthor=A.+I.+Darauthor=R.+Khan&title=Synthetic+Lethality%3A+From+Research+to+Precision+Cancer+Nanomedicine&doi=10.2174%2F1568009617666170630141931"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic Lethality: From Research to Precision Cancer Nanomedicine</span></div><div class="casAuthors">Gupta, Anuradha; Ahmad, Anas; Dar, Aqib Iqbal; Khan, Rehan</div><div class="citationInfo"><span class="NLM_cas:title">Current Cancer Drug Targets</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">337-346</span>CODEN:
                <span class="NLM_cas:coden">CCDTB9</span>;
        ISSN:<span class="NLM_cas:issn">1568-0096</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Cancer is an evolutionary disease with multiple genetic alterations, accumulated due to chromosomal instability and/or aneuploidy and it sometimes acquires drug-resistant phenotype also.  Whole genome sequencing and mutational anal. helped in understanding the differences among persons for predisposition of a disease and its treatment non-responsiveness.  Thus, mol. targeted therapies came into existence.  Among them, the concept of synthetic lethality have enthralled great attention as it is a pragmatic approach towards exploiting cancer cell specific mutations to specifically kill cancer cells without affecting normal cells and thus enhancing anti-cancer drug therapeutic index.  Thus, this approach helped in discovering new therapeutic mols. for development of precision medicine.  Nanotechnol. helped in delivering these mols. to the target site in an effective concn. thus reducing off target effects of drugs, dose and dosage frequency drugs.  Researchers have tried to deliver siRNA targeting synthetic lethal partner for target cancer cell killing by incorporating it in nanoparticles and it has shown efficacy by preventing tumor progression.  This review summarizes the brief introduction of synthetic lethality, and synthetic lethal gene interactions, with a major focus on its therapeutic anticancer potential with the application of nanotechnol. for development of personalized medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNT60k7B0777Vg90H21EOLACvtfcHk0lhG-b2Nrkiv-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnvFejtbc%253D&md5=a2385841eda520b634f1f6ab2eaa885a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2174%2F1568009617666170630141931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568009617666170630141931%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DAhmad%26aufirst%3DA.%26aulast%3DDar%26aufirst%3DA.%2BI.%26aulast%3DKhan%26aufirst%3DR.%26atitle%3DSynthetic%2520Lethality%253A%2520From%2520Research%2520to%2520Precision%2520Cancer%2520Nanomedicine%26jtitle%3DCurr.%2520Cancer%2520Drug%2520Targets%26date%3D2018%26volume%3D18%26spage%3D337%26epage%3D346%26doi%3D10.2174%2F1568009617666170630141931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayamurugan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, R.</span></span> <span> </span><span class="NLM_article-title">Applying Synthetic Lethality to Nanomedicine: LCS-1 Loaded Magnetite and Polymeric Nanoparticles for the Treatment of BLM and CHEK2-Deficient Colorectal Cancer Cells</span>. <i>Cancer Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">28</span>, <span class="refDoi"> DOI: 10.1186/s12964-018-0238-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1186%2Fs12964-018-0238-x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2018&pages=27-28&author=A.+Ahmadauthor=A.+Guptaauthor=G.+Jayamuruganauthor=R.+Khan&title=Applying+Synthetic+Lethality+to+Nanomedicine%3A+LCS-1+Loaded+Magnetite+and+Polymeric+Nanoparticles+for+the+Treatment+of+BLM+and+CHEK2-Deficient+Colorectal+Cancer+Cells&doi=10.1186%2Fs12964-018-0238-x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1186%2Fs12964-018-0238-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12964-018-0238-x%26sid%3Dliteratum%253Aachs%26aulast%3DAhmad%26aufirst%3DA.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DJayamurugan%26aufirst%3DG.%26aulast%3DKhan%26aufirst%3DR.%26atitle%3DApplying%2520Synthetic%2520Lethality%2520to%2520Nanomedicine%253A%2520LCS-1%2520Loaded%2520Magnetite%2520and%2520Polymeric%2520Nanoparticles%2520for%2520the%2520Treatment%2520of%2520BLM%2520and%2520CHEK2-Deficient%2520Colorectal%2520Cancer%2520Cells%26jtitle%3DCancer%2520Med.%26date%3D2018%26volume%3D7%26spage%3D27%26epage%3D28%26doi%3D10.1186%2Fs12964-018-0238-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blanco, M.</span>; <span class="NLM_string-name">Teijón, C.</span>; <span class="NLM_string-name">Olmo, R.</span>; <span class="NLM_string-name">Teijón, J.</span></span> <span> </span><span class="NLM_article-title">Targeted Nanoparticles for Cancer Therapy</span>. In  <i>Recent Advances in Novel Drug Carrier Systems</i>; <span class="NLM_publisher-name">InTech</span>: <span class="NLM_publisher-loc">Janeza Trdine 9, 51000 Rijeka, Croatia</span>, <span class="NLM_year">2012</span>; <span class="refDoi"> DOI: 10.5772/51382</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.5772%2F51382" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=M.+Blanco&author=C.+Teij%C3%B3n&author=R.+Olmo&author=J.+Teij%C3%B3n&title=Recent+Advances+in+Novel+Drug+Carrier+Systems"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.5772%2F51382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.5772%252F51382%26sid%3Dliteratum%253Aachs%26aulast%3DBlanco%26aufirst%3DM.%26atitle%3DTargeted%2520Nanoparticles%2520for%2520Cancer%2520Therapy%26btitle%3DRecent%2520Advances%2520in%2520Novel%2520Drug%2520Carrier%2520Systems%26pub%3DInTech%26date%3D2012%26doi%3D10.5772%2F51382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haley, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frenkel, E.</span></span> <span> </span><span class="NLM_article-title">In Nanoparticles for Drug Delivery in Cancer Treatment</span>. <i>Urol. Oncol.: Semin. Orig. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">64</span>, <span class="refDoi"> DOI: 10.1016/j.urolonc.2007.03.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.urolonc.2007.03.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=18190833" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlsVWqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=57-64&author=B.+Haleyauthor=E.+Frenkel&title=In+Nanoparticles+for+Drug+Delivery+in+Cancer+Treatment&doi=10.1016%2Fj.urolonc.2007.03.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Nanoparticles for drug delivery in cancer treatment</span></div><div class="casAuthors">Haley, Barbara; Frenkel, Eugene</div><div class="citationInfo"><span class="NLM_cas:title">Urologic Oncology: Seminars and Original Investigations</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-64</span>CODEN:
                <span class="NLM_cas:coden">UOSOAA</span>;
        ISSN:<span class="NLM_cas:issn">1078-1439</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Nanoparticles (size in nanometer range) provide a new mode of cancer drug delivery functioning as a carrier for entry through fenestrations in tumor vasculature allowing direct cell access.  These particles allow exquisite modification for binding to cancer cell membranes, the microenvironment, or to cytoplasmic or nuclear receptor sites.  This results in delivery of high drug concns. to the targeted cancer cell, with reduced toxicity of normal tissue.  Several such engineered drugs are in clin. practice, including liposomal doxorubicin and albumin conjugate paclitaxel.  The carrier mediated paclitaxel has already shown significant efficacy in taxane resistant cancers, an approach highly relevant in prostate cancer, where taxanes are the treatment of choice.  Other modifications including transferrin receptor and folate receptor targeted drug delivery mols. are in study.  This new technol. provides many exciting therapeutic approaches for targeted high concn. drug delivery to cancer cells with reduced injury of normal cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJHhEKhqrLzrVg90H21EOLACvtfcHk0li9feCueLPeFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlsVWqtQ%253D%253D&md5=2e9523ea06f91249f9b0cee8440837b6</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.urolonc.2007.03.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.urolonc.2007.03.015%26sid%3Dliteratum%253Aachs%26aulast%3DHaley%26aufirst%3DB.%26aulast%3DFrenkel%26aufirst%3DE.%26atitle%3DIn%2520Nanoparticles%2520for%2520Drug%2520Delivery%2520in%2520Cancer%2520Treatment%26jtitle%3DUrol.%2520Oncol.%253A%2520Semin.%2520Orig.%2520Invest.%26date%3D2008%26volume%3D26%26spage%3D57%26epage%3D64%26doi%3D10.1016%2Fj.urolonc.2007.03.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Torchilin, V.</span></span> <span> </span><span class="NLM_article-title">Tumor Delivery of Macromolecular Drugs Based on the EPR Effect</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">131</span>– <span class="NLM_lpage">135</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2010.03.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.addr.2010.03.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=20304019" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktF2jur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2011&pages=131-135&author=V.+Torchilin&title=Tumor+Delivery+of+Macromolecular+Drugs+Based+on+the+EPR+Effect&doi=10.1016%2Fj.addr.2010.03.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor delivery of macromolecular drugs based on the EPR effect</span></div><div class="casAuthors">Torchilin, Vladimir</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">131-135</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Enhanced permeability and retention (EPR) effect is the physiol.-based principal mechanism of tumor accumulation of large mols. and small particles.  This specific issue of Advanced Drug Delivery Reviews is summing up multiple data on the EPR effect-based drug design and clin. outcome.  In this commentary, the role of the EPR effect in the intratumoral delivery of protein and peptide drugs, macromol. drugs and drug-loaded long-circulating pharmaceutical nanocarriers is briefly discussed together with some addnl. opportunities for drug delivery arising from the initial EPR effect-mediated accumulation of drug-contg. macromol. systems in tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosnNJqwkqLNLVg90H21EOLACvtfcHk0lgynXA3JJhgSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktF2jur4%253D&md5=25ea755afea49f20c4301756bf15c6a1</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2010.03.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2010.03.011%26sid%3Dliteratum%253Aachs%26aulast%3DTorchilin%26aufirst%3DV.%26atitle%3DTumor%2520Delivery%2520of%2520Macromolecular%2520Drugs%2520Based%2520on%2520the%2520EPR%2520Effect%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2011%26volume%3D63%26spage%3D131%26epage%3D135%26doi%3D10.1016%2Fj.addr.2010.03.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sutradhar, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amin, M. L.</span></span> <span> </span><span class="NLM_article-title">Nanotechnology in Cancer Drug Delivery and Selective Targeting</span>. <i>ISRN Nanotechnol</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>2014</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1155/2014/939378</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1155%2F2014%2F939378" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2014&publication_year=2014&pages=1-12&author=K.+B.+Sutradharauthor=M.+L.+Amin&title=Nanotechnology+in+Cancer+Drug+Delivery+and+Selective+Targeting&doi=10.1155%2F2014%2F939378"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1155%2F2014%2F939378&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2014%252F939378%26sid%3Dliteratum%253Aachs%26aulast%3DSutradhar%26aufirst%3DK.%2BB.%26aulast%3DAmin%26aufirst%3DM.%2BL.%26atitle%3DNanotechnology%2520in%2520Cancer%2520Drug%2520Delivery%2520and%2520Selective%2520Targeting%26jtitle%3DISRN%2520Nanotechnol%26date%3D2014%26volume%3D2014%26spage%3D1%26epage%3D12%26doi%3D10.1155%2F2014%2F939378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, H.</span></span> <span> </span><span class="NLM_article-title">The Enhanced Permeability and Retention (EPR) Effect in Tumor Vasculature: The Key Role of Tumor-Selective Macromolecular Drug Targeting</span>. <i>Adv. Enzyme Regul.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">189</span>– <span class="NLM_lpage">207</span>, <span class="refDoi"> DOI: 10.1016/S0065-2571(00)00013-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2FS0065-2571%2800%2900013-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=11384745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmtlekt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2001&pages=189-207&author=H.+Maeda&title=The+Enhanced+Permeability+and+Retention+%28EPR%29+Effect+in+Tumor+Vasculature%3A+The+Key+Role+of+Tumor-Selective+Macromolecular+Drug+Targeting&doi=10.1016%2FS0065-2571%2800%2900013-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting</span></div><div class="casAuthors">Maeda, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Enzyme Regulation</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">189-207</span>CODEN:
                <span class="NLM_cas:coden">AEZRA2</span>;
        ISSN:<span class="NLM_cas:issn">0065-2571</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review, with 59 refs., describes the vascular permeability effect in tumor tissues, macromol. drug delivery, and pathophysiol. of tumor vessels.  Tumor vasculature can be an excellent target for delivery of macromol. anticancer drugs, the most beneficial class of drugs in view of tumor-selective targeting based on the enhanced permeability and retention effect in solid tumor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtl5whieMPvbVg90H21EOLACvtfcHk0lgynXA3JJhgSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmtlekt7k%253D&md5=9be9d39fe75e3765a7907669fd354536</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2FS0065-2571%2800%2900013-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0065-2571%252800%252900013-3%26sid%3Dliteratum%253Aachs%26aulast%3DMaeda%26aufirst%3DH.%26atitle%3DThe%2520Enhanced%2520Permeability%2520and%2520Retention%2520%2528EPR%2529%2520Effect%2520in%2520Tumor%2520Vasculature%253A%2520The%2520Key%2520Role%2520of%2520Tumor-Selective%2520Macromolecular%2520Drug%2520Targeting%26jtitle%3DAdv.%2520Enzyme%2520Regul.%26date%3D2001%26volume%3D41%26spage%3D189%26epage%3D207%26doi%3D10.1016%2FS0065-2571%2800%2900013-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drummond, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benz, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirpgtin, D. B.</span></span> <span> </span><span class="NLM_article-title">Liposome Targeting to Tumors Using Vitamin and Growth Factor Receptors</span>. <i>Vitam. Horm.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">332</span>, <span class="refDoi"> DOI: 10.1016/S0083-6729(00)60022-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2FS0083-6729%2800%2960022-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=11037627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A280%3ADC%252BD3cvovVagtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2000&pages=285-332&author=D.+C.+Drummondauthor=K.+Hongauthor=J.+W.+Parkauthor=C.+C.+Benzauthor=D.+B.+Kirpgtin&title=Liposome+Targeting+to+Tumors+Using+Vitamin+and+Growth+Factor+Receptors&doi=10.1016%2FS0083-6729%2800%2960022-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Liposome targeting to tumors using vitamin and growth factor receptors</span></div><div class="casAuthors">Drummond D C; Hong K; Park J W; Benz C C; Kirpotin D B</div><div class="citationInfo"><span class="NLM_cas:title">Vitamins and hormones</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">285-332</span>
        ISSN:<span class="NLM_cas:issn">0083-6729</span>.
    </div><div class="casAbstract">Liposome-encapsulated anticancer drugs reveal their potential for increased therapeutic efficacy and decreased nonspecific toxicities due to their ability to enhance the delivery of chemotherapeutic agents to solid tumors.  Advances in liposome technology have resulted in the development of ligand-targeted liposomes capable of selectively increasing the efficacy of carried agents against receptor-bearing tumor cells.  Receptors for vitamins and growth factors have become attractive targets for ligand-directed liposomal therapies due to their high expression levels on various forms of cancer and their ability to internalize after binding to the liposomes conjugated to receptors' natural ligands (vitamins) or synthetic agonists (receptor-specific antibodies and synthetic peptides).  This chapter summarizes various strategies and advances in targeting liposomes to vitamin and growth factor receptors in vitro and in vivo with special emphasis on two extensively studied liposome-targeting systems utilizing folate receptor and HER2/neu growth factor receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQKMqKy8820ZJQHPYJuLg8TfW6udTcc2eZGC0j3gmC0Tbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3cvovVagtg%253D%253D&md5=e0f876c862b4df692898e0d9bab05fb5</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS0083-6729%2800%2960022-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0083-6729%252800%252960022-5%26sid%3Dliteratum%253Aachs%26aulast%3DDrummond%26aufirst%3DD.%2BC.%26aulast%3DHong%26aufirst%3DK.%26aulast%3DPark%26aufirst%3DJ.%2BW.%26aulast%3DBenz%26aufirst%3DC.%2BC.%26aulast%3DKirpgtin%26aufirst%3DD.%2BB.%26atitle%3DLiposome%2520Targeting%2520to%2520Tumors%2520Using%2520Vitamin%2520and%2520Growth%2520Factor%2520Receptors%26jtitle%3DVitam.%2520Horm.%26date%3D2000%26volume%3D60%26spage%3D285%26epage%3D332%26doi%3D10.1016%2FS0083-6729%2800%2960022-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iinuma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maruyama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okinaga, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekine, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishida, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogiwara, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johkura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yonemura, Y.</span></span> <span> </span><span class="NLM_article-title">Intracellular Targeting Therapy of Cisplatin-Encapsulated Transferrin-Polyethylene Glycol Liposome on Peritoneal Dissemination of Gastric Cancer</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">130</span>– <span class="NLM_lpage">137</span>, <span class="refDoi"> DOI: 10.1002/ijc.10242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1002%2Fijc.10242" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=11948504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD38XivVCgsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=130-137&author=H.+Iinumaauthor=K.+Maruyamaauthor=K.+Okinagaauthor=K.+Sasakiauthor=T.+Sekineauthor=O.+Ishidaauthor=N.+Ogiwaraauthor=K.+Johkuraauthor=Y.+Yonemura&title=Intracellular+Targeting+Therapy+of+Cisplatin-Encapsulated+Transferrin-Polyethylene+Glycol+Liposome+on+Peritoneal+Dissemination+of+Gastric+Cancer&doi=10.1002%2Fijc.10242"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Intracellular targeting therapy of cisplatin-encapsulated transferrin-polyethylene glycol liposome on peritoneal dissemination of gastric cancer</span></div><div class="casAuthors">Iinuma, Hisae; Maruyama, Kazuo; Okinaga, Kota; Sasaki, Katsunori; Sekine, Toshiyuki; Ishida, Osamu; Ogiwara, Naoko; Johkura, Kohei; Yonemura, Yutaka</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">130-137</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Peritoneal dissemination in gastric cancer is a common fatal clin. condition with few effective therapies available.  The authors studied the therapeutic effect of a tumor-targeting drug delivery system that uses cisplatin-encapsulated and Tf-conjugated PEG liposomes (Tf-PEG liposomes) in nude mice with peritoneal dissemination of human gastric cancer cells.  Small unilamellar Tf-PEG, PEG or DSPC/CH liposomes (bare liposomes) encapsulating cisplatin were prepd. by reverse-phase evapn. followed by extrusion.  Electron microscopic studies revealed that Tf-PEG liposomes were internalized into tumor cells by receptor-mediated endocytosis.  To examine the biodistribution of each liposome and cisplatin level, nude mice were inoculated i.p. with 107 MKN45P human gastric tumor cells.  On the fourth day after tumor inoculation, 3H-CHE-labeled and cisplatin-encapsulated Tf-PEG, PEG or bare liposome were inoculated i.p.  The Tf-PEG liposome-administered group maintained high liposome and cisplatin levels in ascites and showed a prolonged residence time in the peripheral circulation.  Uptake of Tf-PEG liposomes into the liver and spleen was significantly lower than that of bare liposomes.  Uptake of Tf-PEG liposomes in disseminated tumor cells of ascites and the greater omentum was significantly higher than that of PEG or bare liposomes and a significant increase in cisplatin levels was obsd. in these tumor cells.  Mice receiving Tf-PEG liposomes 1 and 4 days after the day of tumor inoculation showed significantly higher survival rates compared with those receiving PEG liposomes without Tf, bare liposomes or free cisplatin soln.  These results suggest that cisplatin-encapsulated Tf-PEG liposomes may be useful as a new intracellular targeting carrier for treatment of gastric cancer with peritoneal dissemination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquaA71UaqPMbVg90H21EOLACvtfcHk0li8k1m5PGg2hQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XivVCgsL4%253D&md5=1b6fb36bc94650ed008ebde0fc9a17d7</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1002%2Fijc.10242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.10242%26sid%3Dliteratum%253Aachs%26aulast%3DIinuma%26aufirst%3DH.%26aulast%3DMaruyama%26aufirst%3DK.%26aulast%3DOkinaga%26aufirst%3DK.%26aulast%3DSasaki%26aufirst%3DK.%26aulast%3DSekine%26aufirst%3DT.%26aulast%3DIshida%26aufirst%3DO.%26aulast%3DOgiwara%26aufirst%3DN.%26aulast%3DJohkura%26aufirst%3DK.%26aulast%3DYonemura%26aufirst%3DY.%26atitle%3DIntracellular%2520Targeting%2520Therapy%2520of%2520Cisplatin-Encapsulated%2520Transferrin-Polyethylene%2520Glycol%2520Liposome%2520on%2520Peritoneal%2520Dissemination%2520of%2520Gastric%2520Cancer%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2002%26volume%3D99%26spage%3D130%26epage%3D137%26doi%3D10.1002%2Fijc.10242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamaly, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farokhzad, O. C.</span></span> <span> </span><span class="NLM_article-title">Cancer Nanotechnology: The Impact of Passive and Active Targeting in the Era of Modern Cancer Biology</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">2</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2013.11.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.addr.2013.11.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=24270007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisV2hug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2014&pages=2-25&author=N.+Bertrandauthor=J.+Wuauthor=X.+Xuauthor=N.+Kamalyauthor=O.+C.+Farokhzad&title=Cancer+Nanotechnology%3A+The+Impact+of+Passive+and+Active+Targeting+in+the+Era+of+Modern+Cancer+Biology&doi=10.1016%2Fj.addr.2013.11.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology</span></div><div class="casAuthors">Bertrand, Nicolas; Wu, Jun; Xu, Xiaoyang; Kamaly, Nazila; Farokhzad, Omid C.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2-25</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Cancer nanotherapeutics are progressing at a steady rate; research and development in the field has experienced an exponential growth since early 2000's.  The path to the commercialization of oncol. drugs is long and carries significant risk; however, there is considerable excitement that nanoparticle technologies may contribute to the success of cancer drug development.  The pace at which pharmaceutical companies have formed partnerships to use proprietary nanoparticle technologies has considerably accelerated.  It is now recognized that by enhancing the efficacy and/or tolerability of new drug candidates, nanotechnol. can meaningfully contribute to create differentiated products and improve clin. outcome.  This review describes the lessons learned since the commercialization of the first-generation nanomedicines including DOXIL and Abraxane.  It explores our current understanding of targeted and non-targeted nanoparticles that are under various stages of development, including BIND-014 and MM-398.  It highlights the opportunities and challenges faced by nanomedicines in contemporary oncol., where personalized medicine is increasingly the mainstay of cancer therapy.  We revisit the fundamental concepts of enhanced permeability and retention effect (EPR) and explore the mechanisms proposed to enhance preferential "retention" in the tumor, whether using active targeting of nanoparticles, binding of drugs to their tumoral targets or the presence of tumor assocd. macrophages.  The overall objective of this review is to enhance our understanding in the design and development of therapeutic nanoparticles for treatment of cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrO44x5Hz86PrVg90H21EOLACvtfcHk0li8k1m5PGg2hQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisV2hug%253D%253D&md5=0980da1a1b75cde64cc1cf82184e01b7</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2013.11.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2013.11.009%26sid%3Dliteratum%253Aachs%26aulast%3DBertrand%26aufirst%3DN.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DKamaly%26aufirst%3DN.%26aulast%3DFarokhzad%26aufirst%3DO.%2BC.%26atitle%3DCancer%2520Nanotechnology%253A%2520The%2520Impact%2520of%2520Passive%2520and%2520Active%2520Targeting%2520in%2520the%2520Era%2520of%2520Modern%2520Cancer%2520Biology%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2014%26volume%3D66%26spage%3D2%26epage%3D25%26doi%3D10.1016%2Fj.addr.2013.11.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span> <span> </span><span class="NLM_article-title">AMP-Guided Tumour-Specific Nanoparticle Delivery via Adenosine A1 Receptor</span>. <i>Biomaterials</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">37</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1016/j.biomaterials.2016.01.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.biomaterials.2016.01.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=26773664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC28Xks1Wkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2016&pages=37-50&author=T.+Daiauthor=N.+Liauthor=F.+Hanauthor=H.+Zhangauthor=Y.+Zhangauthor=Q.+Liu&title=AMP-Guided+Tumour-Specific+Nanoparticle+Delivery+via+Adenosine+A1+Receptor&doi=10.1016%2Fj.biomaterials.2016.01.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">AMP-guided tumour-specific nanoparticle delivery via adenosine A1 receptor</span></div><div class="casAuthors">Dai, Tongcheng; Li, Na; Han, Fajun; Zhang, Hua; Zhang, Yuanxing; Liu, Qin</div><div class="citationInfo"><span class="NLM_cas:title">Biomaterials</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">37-50</span>CODEN:
                <span class="NLM_cas:coden">BIMADU</span>;
        ISSN:<span class="NLM_cas:issn">0142-9612</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Active targeting-ligands have been increasingly used to functionalize nanoparticles for tumor-specific clin. applications.  Here we utilize nucleotide AMP as a novel ligand to functionalize polymer-based fluorescent nanoparticles (NPs) for tumor-targeted imaging.  We demonstrate that AMP-conjugated NPs (NPs-AMP) efficiently bind to and are following internalized into colon cancer cell CW-2 and breast cancer cell MDA-MB-468 in vitro.  RNA interference and inhibitor assays reveal that the targeting effects mainly rely on the specific binding of AMP to adenosine A1 receptor (A1R), which is greatly up-regulated in cancer cells than in matched normal cells.  More importantly, NPs-AMP specifically accumulate in the tumor site of colon and breast tumor xenografts and are further internalized into the tumor cells in vivo via tail vein injection, confirming that the high in vitro specificity of AMP can be successfully translated into the in vivo efficacy.  Furthermore, NPs-AMP exhibit an active tumor-targeting behavior in various colon and breast cancer cells, which is pos. related to the up-regulation level of A1R in cancer cells, suggesting that AMP potentially suits for more extensive A1R-overexpressing cancer models.  This work establishes AMP to be a novel tumor-targeting ligand and provides a promising strategy for future diagnostic or therapeutic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjfCiknuemWrVg90H21EOLACvtfcHk0lj7fEJTfsDGHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xks1Wkuw%253D%253D&md5=47b3e0c6d28d2266fca5297209a1fb56</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.biomaterials.2016.01.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biomaterials.2016.01.011%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DHan%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DAMP-Guided%2520Tumour-Specific%2520Nanoparticle%2520Delivery%2520via%2520Adenosine%2520A1%2520Receptor%26jtitle%3DBiomaterials%26date%3D2016%26volume%3D83%26spage%3D37%26epage%3D50%26doi%3D10.1016%2Fj.biomaterials.2016.01.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Danhier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feron, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Préat, V.</span></span> <span> </span><span class="NLM_article-title">To Exploit the Tumor Microenvironment: Passive and Active Tumor Targeting of Nanocarriers for Anti-Cancer Drug Delivery</span>. <i>J. Controlled Release</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">135</span>– <span class="NLM_lpage">146</span>, <span class="refDoi"> DOI: 10.1016/j.jconrel.2010.08.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.jconrel.2010.08.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=20797419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVCmsrzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2010&pages=135-146&author=F.+Danhierauthor=O.+Feronauthor=V.+Pr%C3%A9at&title=To+Exploit+the+Tumor+Microenvironment%3A+Passive+and+Active+Tumor+Targeting+of+Nanocarriers+for+Anti-Cancer+Drug+Delivery&doi=10.1016%2Fj.jconrel.2010.08.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery</span></div><div class="casAuthors">Danhier, Fabienne; Feron, Olivier; Preat, Veronique</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">135-146</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Because of the particular characteristics of the tumor microenvironment and tumor angiogenesis, it is possible to design drug delivery systems that specifically target anti-cancer drugs to tumors.  Most of the conventional chemotherapeutic agents have poor pharmacokinetics profiles and are distributed non-specifically in the body leading to systemic toxicity assocd. with serious side effects.  Therefore, the development of drug delivery systems able to target the tumor site is becoming a real challenge that is currently addressed.  Nanomedicine can reach tumor passively through the leaky vasculature surrounding the tumors by the enhanced permeability and retention effect whereas ligands grafted at the surface of nanocarriers allow active targeting by binding to the receptors overexpressed by cancer cells or angiogenic endothelial cells.  This review is divided into 2 parts: the first one describes the tumor microenvironment and the second one focuses on the exploitation and the understanding of these characteristics to design new drug delivery systems targeting the tumor.  Delivery of conventional chemotherapeutic anti-cancer drugs is mainly discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgLX-Ce0wBO7Vg90H21EOLACvtfcHk0lj7fEJTfsDGHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVCmsrzF&md5=04d79d93a1828d379bfde830da737608</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2010.08.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2010.08.027%26sid%3Dliteratum%253Aachs%26aulast%3DDanhier%26aufirst%3DF.%26aulast%3DFeron%26aufirst%3DO.%26aulast%3DPr%25C3%25A9at%26aufirst%3DV.%26atitle%3DTo%2520Exploit%2520the%2520Tumor%2520Microenvironment%253A%2520Passive%2520and%2520Active%2520Tumor%2520Targeting%2520of%2520Nanocarriers%2520for%2520Anti-Cancer%2520Drug%2520Delivery%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2010%26volume%3D148%26spage%3D135%26epage%3D146%26doi%3D10.1016%2Fj.jconrel.2010.08.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kirpotin, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drummond, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shalaby, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, U. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benz, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. W.</span></span> <span> </span><span class="NLM_article-title">Antibody Targeting of Long-Circulating Lipidic Nanoparticles Does Not Increase Tumor Localization But Does Increase Internalization in Animal Models</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">6732</span>– <span class="NLM_lpage">6740</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-05-4199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1158%2F0008-5472.CAN-05-4199" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=16818648" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD28XmsVamu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=6732-6740&author=D.+B.+Kirpotinauthor=D.+C.+Drummondauthor=Y.+Shaoauthor=M.+R.+Shalabyauthor=K.+Hongauthor=U.+B.+Nielsenauthor=J.+D.+Marksauthor=C.+C.+Benzauthor=J.+W.+Park&title=Antibody+Targeting+of+Long-Circulating+Lipidic+Nanoparticles+Does+Not+Increase+Tumor+Localization+But+Does+Increase+Internalization+in+Animal+Models&doi=10.1158%2F0008-5472.CAN-05-4199"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody Targeting of Long-Circulating Lipidic Nanoparticles Does Not Increase Tumor Localization but Does Increase Internalization in Animal Models</span></div><div class="casAuthors">Kirpotin, Dmitri B.; Drummond, Daryl C.; Shao, Yi; Shalaby, M. Refaat; Hong, Keelung; Nielsen, Ulrik B.; Marks, James D.; Benz, Christopher C.; Park, John W.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6732-6740</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">We describe evidence for a novel mechanism of monoclonal antibody (MAb)-directed nanoparticle (immunoliposome) targeting to solid tumors in vivo.  Long-circulating immunoliposomes targeted to HER2 (ErbB2, Neu) were prepd. by the conjugation of anti-HER2 MAb fragments (Fab' or single chain Fv) to liposome-grafted polyethylene glycol chains.  MAb fragment conjugation did not affect the biodistribution or long-circulating properties of i.v.-administered liposomes.  However, antibody-directed targeting also did not increase the tumor localization of immunoliposomes, as both targeted and nontargeted liposomes achieved similarly high levels (7-8% injected dose/g tumor tissue) of tumor tissue accumulation in HER2-overexpressing breast cancer xenografts (BT-474).  Studies using colloidal gold-labeled liposomes showed the accumulation of anti-HER2 immunoliposomes within cancer cells, whereas matched nontargeted liposomes were located predominantly in extracellular stroma or within macrophages.  A similar pattern of stromal accumulation without cancer cell internalization was obsd. for anti-HER2 immunoliposomes in non-HER2-overexpressing breast cancer xenografts (MCF-7).  Flow cytometry of disaggregated tumors posttreatment with either liposomes or immunoliposomes showed up to 6-fold greater intracellular uptake in cancer cells due to targeting.  Thus, in contrast to nontargeted liposomes, anti-HER2 immunoliposomes achieved intracellular drug delivery via MAb-mediated endocytosis, and this, rather than increased uptake in tumor tissue, was correlated with superior antitumor activity.  Immunoliposomes capable of selective internalization in cancer cells in vivo may provide new opportunities for drug delivery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQlkzKL-iioLVg90H21EOLACvtfcHk0lgcZQdasQuK-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmsVamu7Y%253D&md5=20bd18c2355cc8a328aa8cc51153bc44</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-05-4199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-05-4199%26sid%3Dliteratum%253Aachs%26aulast%3DKirpotin%26aufirst%3DD.%2BB.%26aulast%3DDrummond%26aufirst%3DD.%2BC.%26aulast%3DShao%26aufirst%3DY.%26aulast%3DShalaby%26aufirst%3DM.%2BR.%26aulast%3DHong%26aufirst%3DK.%26aulast%3DNielsen%26aufirst%3DU.%2BB.%26aulast%3DMarks%26aufirst%3DJ.%2BD.%26aulast%3DBenz%26aufirst%3DC.%2BC.%26aulast%3DPark%26aufirst%3DJ.%2BW.%26atitle%3DAntibody%2520Targeting%2520of%2520Long-Circulating%2520Lipidic%2520Nanoparticles%2520Does%2520Not%2520Increase%2520Tumor%2520Localization%2520But%2520Does%2520Increase%2520Internalization%2520in%2520Animal%2520Models%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D6732%26epage%3D6740%26doi%3D10.1158%2F0008-5472.CAN-05-4199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cochran, J. R.</span></span> <span> </span><span class="NLM_article-title">Targeting Ligand–Receptor Interactions for Development of Cancer Therapeutics</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">62</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2017.03.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.cbpa.2017.03.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=28371692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlvVGjs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2017&pages=62-69&author=J.+W.+Kimauthor=J.+R.+Cochran&title=Targeting+Ligand%E2%80%93Receptor+Interactions+for+Development+of+Cancer+Therapeutics&doi=10.1016%2Fj.cbpa.2017.03.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting ligand-receptor interactions for development of cancer therapeutics</span></div><div class="casAuthors">Kim, Jun Woo; Cochran, Jennifer R.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">62-69</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The biol. importance and druggable properties of receptors and their cognate ligands have designated them as esp. useful clin. targets.  This significance continues to expand as new mol. insights underlying disease pathophysiol. are uncovered.  While both ligands and receptors have been exploited as drug targets, their differing biochem. properties require nuanced considerations for drug development, including where in the body they are located and how they are regulated on a cellular and mol. level.  In this review we will discuss ligands and receptors as therapeutics targets, including their biodistribution and biol. function.  We provide examples of monoclonal antibodies (mAbs) used to modulate the activity of these targets, and discuss approaches for using engineered versions of ligands and receptors themselves for therapeutic intervention in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5_8FhF3LTGrVg90H21EOLACvtfcHk0lgcZQdasQuK-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlvVGjs7Y%253D&md5=a9aa41f641165205f47ca9227ea16206</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2017.03.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2017.03.010%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DJ.%2BW.%26aulast%3DCochran%26aufirst%3DJ.%2BR.%26atitle%3DTargeting%2520Ligand%25E2%2580%2593Receptor%2520Interactions%2520for%2520Development%2520of%2520Cancer%2520Therapeutics%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2017%26volume%3D38%26spage%3D62%26epage%3D69%26doi%3D10.1016%2Fj.cbpa.2017.03.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Q. C.</span></span> <span> </span><span class="NLM_article-title">Ligand-Based Targeted Therapy: A Novel Strategy for Hepatocellular Carcinoma</span>. <i>Int. J. Nanomed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">5645</span>– <span class="NLM_lpage">5669</span>, <span class="refDoi"> DOI: 10.2147/IJN.S115727</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.2147%2FIJN.S115727" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=27920520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXot1eisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=5645-5669&author=M.+Liauthor=W.+Zhangauthor=B.+Wangauthor=Y.+Gaoauthor=Z.+Songauthor=Q.+C.+Zheng&title=Ligand-Based+Targeted+Therapy%3A+A+Novel+Strategy+for+Hepatocellular+Carcinoma&doi=10.2147%2FIJN.S115727"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma</span></div><div class="casAuthors">Li, Min; Zhang, Weiyue; Wang, Birong; Gao, Yang; Song, Zifang; Zheng, Qi Chang</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Nanomedicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">5645-5669</span>CODEN:
                <span class="NLM_cas:coden">IJNNHQ</span>;
        ISSN:<span class="NLM_cas:issn">1178-2013</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Hepatocellular carcinoma (HCC) is the most common primary liver cancer with high morbidity and mortality worldwide.  Chemotherapy is recommended to patients with intermediate or advanced stage cancer.  However, the conventional chemotherapy yields low desired response rates due to multidrug resistance, fast clearance rate, nonspecific delivery, severe side effects, low drug concn. in cancer cells, and so on.  Nanoparticle-mediated targeted drug delivery system can surmount the aforementioned obstacles through enhanced permeability and retention effect and active targeting as a novel approach of therapeutics for HCC in recent years.  The active targeting is triggered by ligands on the delivery system, which recognize with and internalize into hepatoma cells with high specificity and efficiency.  This review focuses on the latest targeted delivery systems for HCC and summarizes the ligands that can enhance the capacity of active targeting, to provide some insight into future research in nanomedicine for HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoS3qkbh1aM97Vg90H21EOLACvtfcHk0lh7Pakb2d9NVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXot1eisQ%253D%253D&md5=44586aff848cab79a4df79c0c52ebdfc</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.2147%2FIJN.S115727&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIJN.S115727%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DZheng%26aufirst%3DQ.%2BC.%26atitle%3DLigand-Based%2520Targeted%2520Therapy%253A%2520A%2520Novel%2520Strategy%2520for%2520Hepatocellular%2520Carcinoma%26jtitle%3DInt.%2520J.%2520Nanomed.%26date%3D2016%26volume%3D11%26spage%3D5645%26epage%3D5669%26doi%3D10.2147%2FIJN.S115727" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Assaraf, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leamon, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, J. A.</span></span> <span> </span><span class="NLM_article-title">The Folate Receptor as a Rational Therapeutic Target for Personalized Cancer Treatment</span>. <i>Drug Resist. Updates</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">89</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1016/j.drup.2014.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.drup.2014.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=25457975" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A280%3ADC%252BC2MzjtFyisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2014&pages=89-95&author=Y.+G.+Assarafauthor=C.+P.+Leamonauthor=J.+A.+Reddy&title=The+Folate+Receptor+as+a+Rational+Therapeutic+Target+for+Personalized+Cancer+Treatment&doi=10.1016%2Fj.drup.2014.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The folate receptor as a rational therapeutic target for personalized cancer treatment</span></div><div class="casAuthors">Assaraf Yehuda G; Leamon Christopher P; Reddy Joseph A</div><div class="citationInfo"><span class="NLM_cas:title">Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4-6</span>),
    <span class="NLM_cas:pages">89-95</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Conventional cancer treatment modalities have several limitations including lack of sufficient efficacy, serious untoward toxicity, as well as innate and acquired drug resistance.  In contrast, targeted imaging agents can identify patients with receptors overexpressed on the surface of cancer cells, thus allowing appropriate selection of patients for personalized treatment with a desirable targeted therapeutic.  The folate receptor (FR) has been identified as a new molecularly targeted entity, which is highly overexpressed on the surface of a spectrum of solid tumor cells, including ovarian, kidney, lung, brain, endometrial, colorectal, pancreatic, gastric, prostate, testicular, bladder, head and neck, breast, and non-small cell lung cancer.  Folic acid conjugation is a novel approach for targeting FR-expressing tissues for personalized treatment.  With the development of FRα-targeted therapies comes a concomitant prerequisite for reliable methods for the quantification of FRα tissue expression.  Therefore, attaching a radioactive probe to folic acid to target diseased tissue has become a novel and powerful imaging technique.  Currently available diagnostic tools frequently require invasive surgical biopsy.  In contrast, the noninvasive single-photon emission computed tomography-based companion imaging agent, (99m)Tc-etarfolatide ((99m)Tc-EC20), is in development for use as a companion diagnostic with the FRα-targeted folate conjugate, vintafolide (EC145), to identify patients whose tumors express FRα.  Vintafolide is a folic acid conjugate of Vinca alkaloid (desacetylvinblastine hydrazide) that targets FRα-expressing tumors, thereby disrupting microtubule polymerization. (99m)Tc-etarfolatide is taken up by FR-positive tumors and allows for noninvasive, whole-body monitoring of FRα expression status throughout treatment.  The combination of vintafolide plus etarfolatide has been evaluated in three Phase 2 studies for the treatment of various solid tumors, including ovarian, endometrial, peritoneal, and platinum-resistant ovarian cancer, as well as lung cancer.  Patients with FR-positive tumors, as identified by etarfolatide uptake, have had better clinical outcomes than patients with FR-negative tumors, indicating the potential of etarfolatide as a companion biomarker for predicting vintafolide response.  Targeted therapies combined with a reliable companion diagnostic test represent a novel approach toward efficient personalized medicine for malignant and nonmalignant disorders.  Furthermore, the recent availability of the crystal structures of FRα and FRβ in complex with folates and antifolates forms a realistic basis for the rational design and implementation of novel FR-targeted drugs for the treatment of cancer and inflammatory disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRJfpf2NhY2spPq5LRczm8ffW6udTcc2eaSipPv0snFjLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MzjtFyisw%253D%253D&md5=95dd062e28385ab37836a4545dbd197f</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.drup.2014.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drup.2014.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DAssaraf%26aufirst%3DY.%2BG.%26aulast%3DLeamon%26aufirst%3DC.%2BP.%26aulast%3DReddy%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520Folate%2520Receptor%2520as%2520a%2520Rational%2520Therapeutic%2520Target%2520for%2520Personalized%2520Cancer%2520Treatment%26jtitle%3DDrug%2520Resist.%2520Updates%26date%3D2014%26volume%3D17%26spage%3D89%26epage%3D95%26doi%3D10.1016%2Fj.drup.2014.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanna, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nurra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pala, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marceddu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pathania, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neamati, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sechi, M.</span></span> <span> </span><span class="NLM_article-title">Targeted Nanoparticles for The Delivery of Novel Bioactive Molecules to Pancreatic Cancer Cells</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">5209</span>– <span class="NLM_lpage">5220</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01571</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01571" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC28XntFCjs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=5209-5220&author=V.+Sannaauthor=S.+Nurraauthor=N.+Palaauthor=S.+Marcedduauthor=D.+Pathaniaauthor=N.+Neamatiauthor=M.+Sechi&title=Targeted+Nanoparticles+for+The+Delivery+of+Novel+Bioactive+Molecules+to+Pancreatic+Cancer+Cells&doi=10.1021%2Facs.jmedchem.5b01571"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted Nanoparticles for the Delivery of Novel Bioactive Molecules to Pancreatic Cancer Cells</span></div><div class="casAuthors">Sanna, Vanna; Nurra, Salvatore; Pala, Nicolino; Marceddu, Salvatore; Pathania, Divya; Neamati, Nouri; Sechi, Mario</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5209-5220</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with poor prognosis and limited therapeutic options.  Therefore, there is an urgent need to identify new, safe, and targeted therapeutics for effective treatment of late as well as early stage disease.  Plectin-1 (Plec-1) was recently identified as specific biomarker for detecting PDAC at an early stage.  We envisioned that multivalent attachment of nanocarriers incorporating certain drugs to Plec-1-derived peptide would increase specific binding affinity and impart high specificity for PDAC cells.  Previously, we discovered a novel class of compds. (e.g., quinazolinediones, QDs) that exert their cytotoxic effects by modulating ROS-mediated cell signaling.  Herein, we prepd. novel QD242-encapsulated polymeric nanoparticles (NPs) functionalized with a peptide to selectively bind to Plec-1.  Similarly, we prepd. QD-based NPs densely decorated with an isatoic anhydride deriv.  Furthermore, we evaluated their impact on ligand binding and antiproliferative activity against PDAC cells.  The targeted NPs were more potent than the nontargeted constructs in PDAC cells warranting further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoU4vXa1piLRLVg90H21EOLACvtfcHk0lg1045LcuXuJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntFCjs7s%253D&md5=68751c7a9d5f15e158df8aa0b5324373</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01571%26sid%3Dliteratum%253Aachs%26aulast%3DSanna%26aufirst%3DV.%26aulast%3DNurra%26aufirst%3DS.%26aulast%3DPala%26aufirst%3DN.%26aulast%3DMarceddu%26aufirst%3DS.%26aulast%3DPathania%26aufirst%3DD.%26aulast%3DNeamati%26aufirst%3DN.%26aulast%3DSechi%26aufirst%3DM.%26atitle%3DTargeted%2520Nanoparticles%2520for%2520The%2520Delivery%2520of%2520Novel%2520Bioactive%2520Molecules%2520to%2520Pancreatic%2520Cancer%2520Cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D5209%26epage%3D5220%26doi%3D10.1021%2Facs.jmedchem.5b01571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xue, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozlovskaya, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherwani, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratnayaka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habib, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manuvakhova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klampfer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yusuf, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kharlampieva, E.</span></span> <span> </span><span class="NLM_article-title">Peptide-Functionalized Hydrogel Cubes for Active Tumor Cell Targeting</span>. <i>Biomacromolecules</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">4084</span>– <span class="NLM_lpage">4097</span>, <span class="refDoi"> DOI: 10.1021/acs.biomac.8b01088</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biomac.8b01088" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1WksbfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=4084-4097&author=B.+Xueauthor=V.+Kozlovskayaauthor=M.+A.+Sherwaniauthor=S.+Ratnayakaauthor=S.+Habibauthor=T.+Andersonauthor=M.+Manuvakhovaauthor=L.+Klampferauthor=N.+Yusufauthor=E.+Kharlampieva&title=Peptide-Functionalized+Hydrogel+Cubes+for+Active+Tumor+Cell+Targeting&doi=10.1021%2Facs.biomac.8b01088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide-Functionalized Hydrogel Cubes for Active Tumor Cell Targeting</span></div><div class="casAuthors">Xue, Bing; Kozlovskaya, Veronika; Sherwani, Mohammad Asif; Ratnayaka, Sithira; Habib, Shahriar; Anderson, Theron; Manuvakhova, Marina; Klampfer, Lidija; Yusuf, Nabiha; Kharlampieva, Eugenia</div><div class="citationInfo"><span class="NLM_cas:title">Biomacromolecules</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4084-4097</span>CODEN:
                <span class="NLM_cas:coden">BOMAF6</span>;
        ISSN:<span class="NLM_cas:issn">1525-7797</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Conjugation of bioactive targeting mols. to nano- or micrometer-sized drug carriers is a pivotal strategy to improve their therapeutic efficiency.  Herein, we developed pH- and redox-sensitive hydrogel particles with a surface-conjugated cancer cell targeting ligand for specific tumor-targeting and controlled release of the anticancer drug doxorubicin.  The poly(methacrylic acid) (PMAA) hydrogel cubes of 700 nm and 2 μm with a hepsin-targeting (IPLVVPL) surface peptide are produced through multilayer polymer assembly on sacrificial cubical mesoporous cores.  Direct peptide conjugation to the disulfide-stabilized hydrogels through a thiol-amine reaction does not compromise the structural integrity, hydrophilicity, stability in serum, or pH/redox sensitivity but does affect internalization by cancer cells.  The cell uptake kinetics and the ultimate extent of internalization are controlled by the cell type and hydrogel size.  The peptide modification significantly promotes the uptake of the 700 nm hydrogels by hepsin-pos. MCF-7 cells due to ligand-receptor recognition but has a negligible effect on the uptake of 2 μm PMAA hydrogels.  The selectivity of 700 nm IPLVVPL-PMAA hydrogel cubes to hepsin-overexpressing tumor cells is further confirmed by a 3-10-fold higher particle internalization by hepsin-pos. MCF-7 and SK-OV-3 compared to that of hepsin-neg. PC-3 cells.  This work provides a facile method to fabricate enhanced tumor-targeting carriers of submicrometer size and improves the general understanding of particle design parameters for targeted drug delivery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobs2I6YCcPv7Vg90H21EOLACvtfcHk0lg1045LcuXuJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1WksbfI&md5=f327450acbe2018737eb3ed76dafab16</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facs.biomac.8b01088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biomac.8b01088%26sid%3Dliteratum%253Aachs%26aulast%3DXue%26aufirst%3DB.%26aulast%3DKozlovskaya%26aufirst%3DV.%26aulast%3DSherwani%26aufirst%3DM.%2BA.%26aulast%3DRatnayaka%26aufirst%3DS.%26aulast%3DHabib%26aufirst%3DS.%26aulast%3DAnderson%26aufirst%3DT.%26aulast%3DManuvakhova%26aufirst%3DM.%26aulast%3DKlampfer%26aufirst%3DL.%26aulast%3DYusuf%26aufirst%3DN.%26aulast%3DKharlampieva%26aufirst%3DE.%26atitle%3DPeptide-Functionalized%2520Hydrogel%2520Cubes%2520for%2520Active%2520Tumor%2520Cell%2520Targeting%26jtitle%3DBiomacromolecules%26date%3D2018%26volume%3D19%26spage%3D4084%26epage%3D4097%26doi%3D10.1021%2Facs.biomac.8b01088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fishman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bar-Yehuda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohn, I.</span></span> <span> </span><span class="NLM_article-title">A3 Adenosine Receptor as a Target for Cancer Therapy</span>. <i>Anti-Cancer Drugs</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">437</span>– <span class="NLM_lpage">443</span>, <span class="refDoi"> DOI: 10.1097/00001813-200206000-00001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1097%2F00001813-200206000-00001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=12045454" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD38Xks12hsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2002&pages=437-443&author=P.+Fishmanauthor=S.+Bar-Yehudaauthor=L.+Madiauthor=I.+Cohn&title=A3+Adenosine+Receptor+as+a+Target+for+Cancer+Therapy&doi=10.1097%2F00001813-200206000-00001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">A3 adenosine receptor as a target for cancer therapy</span></div><div class="casAuthors">Fishman, Pnina; Bar-Yehuda, Sara; Madi, Lea; Cohn, Ilan</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Drugs</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">437-443</span>CODEN:
                <span class="NLM_cas:coden">ANTDEV</span>;
        ISSN:<span class="NLM_cas:issn">0959-4973</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Targeting the A3 adenosine receptor (A3AR) by adenosine or a synthetic agonist to this receptor (IB-MECA and CI-IB-MECA) results in a differential effect on tumor and on normal cells.  Both the adenosine and the agonists inhibit the growth of various tumor cell types such as melanoma, colon or prostate carcinoma and lymphoma.  This effect is specific and is exerted on tumor cells only.  Moreover, exposure of peripheral blood mononuclear cells to adenosine or the agonists leads to the induction of granulocyte colony stimulating factor (G-CSF) prodn.  When given orally to mice, the agonists suppress the growth of melanoma, colon and prostate carcinoma in these animals, while inducing a myeloprotective effect via the induction of G-CSF prodn.  The de-regulation of the Wnt signaling pathway was involved in the anticancer effect.  Receptor activation induces inhibition of adenylyl cyclase with a subsequent decrease in the level of protein kinase A and protein kinase B/Akt leading to activation of glycogen synthase kinase-3β, a key element in the Wnt pathway.  The oral bioavailability of the synthetic A3AR agonists, and their induced systemic anticancer and myeloprotective effect, renders them potentially useful in three different modes of treatment: as a stand-alone anticancer treatment, in combination with chemotherapy to enhance its therapeutic index and myelprotection.  It is evident that use of the A3AR agonist for increasing the therapeutic index of chemotherapy may also invariably give rise to myeloprotection and vice versa.  The A3AR agonists are thus a promising new class of agents for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMRGo7OpTcU7Vg90H21EOLACvtfcHk0lhH8rPFDNhwLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xks12hsL8%253D&md5=d034dcf99d0f2ca90e63ae8a08df82ea</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1097%2F00001813-200206000-00001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00001813-200206000-00001%26sid%3Dliteratum%253Aachs%26aulast%3DFishman%26aufirst%3DP.%26aulast%3DBar-Yehuda%26aufirst%3DS.%26aulast%3DMadi%26aufirst%3DL.%26aulast%3DCohn%26aufirst%3DI.%26atitle%3DA3%2520Adenosine%2520Receptor%2520as%2520a%2520Target%2520for%2520Cancer%2520Therapy%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2002%26volume%3D13%26spage%3D437%26epage%3D443%26doi%3D10.1097%2F00001813-200206000-00001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swami, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeengar, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naidu, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sistla, R.</span></span> <span> </span><span class="NLM_article-title">Adenosine Conjugated Lipidic Nanoparticles for Enhanced Tumor Targeting</span>. <i>Int. J. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>486</i></span>,  <span class="NLM_fpage">287</span>– <span class="NLM_lpage">296</span>, <span class="refDoi"> DOI: 10.1016/j.ijpharm.2015.03.065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.ijpharm.2015.03.065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=25839415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2MXls1ejt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=486&publication_year=2015&pages=287-296&author=R.+Swamiauthor=I.+Singhauthor=M.+K.+Jeengarauthor=V.+Naiduauthor=W.+Khanauthor=R.+Sistla&title=Adenosine+Conjugated+Lipidic+Nanoparticles+for+Enhanced+Tumor+Targeting&doi=10.1016%2Fj.ijpharm.2015.03.065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine conjugated lipidic nanoparticles for enhanced tumor targeting</span></div><div class="casAuthors">Swami, Rajan; Singh, Indu; Jeengar, Manish Kumar; Naidu, V. G. M.; Khan, Wahid; Sistla, Ramakrishna</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">486</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">287-296</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Delivering chemotherapeutics by nanoparticles into tumor is impeded majorly by two factors: nonspecific targeting and inefficient penetration.  Targeted delivery of anti-cancer agents solely to tumor cells introduces a smart strategy because it enhances the therapeutic index compared with untargeted drugs.  The present study was performed to investigate the efficiency of adenosine (ADN) to target solid lipid nanoparticles (SLN) to over expressing adenosine receptor cell lines such as human breast cancer and prostate cancer (MCF-7 and DU-145 cells), resp.  SLN were prepd. by emulsification and solvent evapn. process using docetaxel (DTX) as drug and were characterized by various techniques like dynamic light scattering, differential scanning calorimeter and transmission electron microscopy.  DTX loaded SLNs were surface modified with ADN, an adenosine receptors ligand using carbodiimide coupling.  Conjugation was confirmed using IR spectroscopy and quantified using phenol-sulfuric acid method.  Conjugated SLN were shown to have sustained drug release as compared to unconjugated nanoparticles and drug suspension.  Compared with free DTX and unconjugated SLN, ADN conjugated SLN showed significantly higher cytotoxicity of loaded DTX, as evidenced by in vitro cell expts.  The IC50 was 0.41 μg/mL for native DTX, 0.30 μg/mL for unconjugated SLN formulation, and 0.09 μg/mL for ADN conjugated SLN formulation in MCF-7 cell lines.  Whereas, in DU-145, there was 2 fold change in IC50 of ADN-SLN as compared to DTX.  IC50 was found to be 0.44 μg/mL for free DTX, 0.39 μg/mL for unconjugated SLN and 0.22 μg/mL for ADN-SLN.  Annexin assay and cell cycle anal. assay further substantiated the cell cytotoxicity.  Fluorescent cell uptake and competitive ligand-receptor binding assay corroborated the receptor mediated endocytosis pathway indicated role of adenosine receptors in internalization of conjugated particles.  Pharmacokinetic studies of lipidic formulations depicted significant improvement in pharmacokinetic parameters than marketed formulation.  ADN conjugated SLN proved to be an efficient drug delivery vehicle.  Hence, ADN can be used as a potential ligand to target breast and prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZmJphk2UznbVg90H21EOLACvtfcHk0lhH8rPFDNhwLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXls1ejt7k%253D&md5=870d5af504d546fc65b27133c74dde41</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpharm.2015.03.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpharm.2015.03.065%26sid%3Dliteratum%253Aachs%26aulast%3DSwami%26aufirst%3DR.%26aulast%3DSingh%26aufirst%3DI.%26aulast%3DJeengar%26aufirst%3DM.%2BK.%26aulast%3DNaidu%26aufirst%3DV.%26aulast%3DKhan%26aufirst%3DW.%26aulast%3DSistla%26aufirst%3DR.%26atitle%3DAdenosine%2520Conjugated%2520Lipidic%2520Nanoparticles%2520for%2520Enhanced%2520Tumor%2520Targeting%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D2015%26volume%3D486%26spage%3D287%26epage%3D296%26doi%3D10.1016%2Fj.ijpharm.2015.03.065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, H.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, P.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Iron Oxide Nanoparticles Coated with Nonpolymeric Azidopropyl-Uracil Triphosphate (UTP) and Adenosine Triphosphate (ATP) for Multimodality Imaging</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">1218</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2016&pages=1218&author=H.-S.+Jeongauthor=D.+H.+Kimauthor=I.+S.+Kimauthor=H.+Hwangauthor=P.-S.+Ohauthor=E.-M.+Kimauthor=J.-H.+Choiauthor=J.+Kwonauthor=H.+S.+Kimauthor=M.+Kim&title=Synthesis+of+Iron+Oxide+Nanoparticles+Coated+with+Nonpolymeric+Azidopropyl-Uracil+Triphosphate+%28UTP%29+and+Adenosine+Triphosphate+%28ATP%29+for+Multimodality+Imaging"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJeong%26aufirst%3DH.-S.%26aulast%3DKim%26aufirst%3DD.%2BH.%26aulast%3DKim%26aufirst%3DI.%2BS.%26aulast%3DHwang%26aufirst%3DH.%26aulast%3DOh%26aufirst%3DP.-S.%26aulast%3DKim%26aufirst%3DE.-M.%26aulast%3DChoi%26aufirst%3DJ.-H.%26aulast%3DKwon%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DH.%2BS.%26aulast%3DKim%26aufirst%3DM.%26atitle%3DSynthesis%2520of%2520Iron%2520Oxide%2520Nanoparticles%2520Coated%2520with%2520Nonpolymeric%2520Azidopropyl-Uracil%2520Triphosphate%2520%2528UTP%2529%2520and%2520Adenosine%2520Triphosphate%2520%2528ATP%2529%2520for%2520Multimodality%2520Imaging%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2016%26volume%3D57%26spage%3D1218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Durand, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storz, P.</span></span> <span> </span><span class="NLM_article-title">Targeting Reactive Oxygen Species in Development and Progression of Pancreatic Cancer</span>. <i>Expert Rev. Anticancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.1080/14737140.2017.1261017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1080%2F14737140.2017.1261017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=27841037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFCgtbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=19-31&author=N.+Durandauthor=P.+Storz&title=Targeting+Reactive+Oxygen+Species+in+Development+and+Progression+of+Pancreatic+Cancer&doi=10.1080%2F14737140.2017.1261017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting reactive oxygen species in development and progression of pancreatic cancer</span></div><div class="casAuthors">Durand, Nisha; Storz, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-31</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Pancreatic ductal adenocarcinoma (PDA) is characterized by expression of oncogenic KRas which drives all aspects of tumorigenesis.  Oncogenic KRas induces the formation of reactive oxygen species (ROS) which have been implicated in initiation and progression of PDA.  To facilitate tumor promoting levels and to avoid oncogene-induced senescence or cytotoxicity, ROS homeostasis in PDA cells is balanced by addnl. up-regulation of antioxidant systems.  We examine the sources of ROS in PDA, the mechanisms by which ROS homeostasis is maintained, and the biol. consequences of ROS in PDA.  Addnl., we discuss the potential mechanisms for targeting ROS homoeostasis as a point of therapeutic intervention.  An extensive review of the relevant literature as it relates to the topic was conducted using PubMed. Even though oncogenic mutations in the KRAS gene have been detected in over 95% of human pancreatic adenocarcinoma, targeting its gene product, KRas, has been difficult.  The dependency of PDA cells on balancing ROS homeostasis could be an angle for new prevention or treatment strategies.  These include use of antioxidants to prevent formation or progression of precancerous lesions, or methods to increase ROS in tumor cells to toxic levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGcAyB4qAqGbVg90H21EOLACvtfcHk0lgX7YemdckIaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFCgtbfO&md5=dd51ffe392d672754074fc7afa8ec44e</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1080%2F14737140.2017.1261017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14737140.2017.1261017%26sid%3Dliteratum%253Aachs%26aulast%3DDurand%26aufirst%3DN.%26aulast%3DStorz%26aufirst%3DP.%26atitle%3DTargeting%2520Reactive%2520Oxygen%2520Species%2520in%2520Development%2520and%2520Progression%2520of%2520Pancreatic%2520Cancer%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2017%26volume%3D17%26spage%3D19%26epage%3D31%26doi%3D10.1080%2F14737140.2017.1261017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nogueira-Librelotto, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Codevilla, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farooqi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolim, C. M.</span></span> <span> </span><span class="NLM_article-title">Transferrin-Conjugated Nanocarriers as Active-Targeted Drug Delivery Platforms for Cancer Therapy</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">454</span>– <span class="NLM_lpage">466</span>, <span class="refDoi"> DOI: 10.2174/1381612822666161026162347</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.2174%2F1381612822666161026162347" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=27784246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjslSjsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=454-466&author=D.+R.+Nogueira-Librelottoauthor=C.+F.+Codevillaauthor=A.+Farooqiauthor=C.+M.+Rolim&title=Transferrin-Conjugated+Nanocarriers+as+Active-Targeted+Drug+Delivery+Platforms+for+Cancer+Therapy&doi=10.2174%2F1381612822666161026162347"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Transferrin-Conjugated Nanocarriers as Active-Targeted Drug Delivery Platforms for Cancer Therapy</span></div><div class="casAuthors">Nogueira-Librelotto, Daniele R.; Codevilla, Cristiane F.; Farooqi, Ammad; Rolim, Clarice M. B.</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">454-466</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  A lot of effort has been devoted to achieving active targeting for cancer therapy in order to reach the right cells.  Hence, increasingly it is being realized that active-targeted nanocarriers notably reduce off-target effects, mainly because of targeted localization in tumors and active cellular uptake.  In this context, by taking advantage of the overexpression of transferrin receptors on the surface of tumor cells, transferrin-conjugated nanodevices have been designed, in hope that the biomarker grafting would help to maximize the therapeutic benefit and to minimize the side effects.  Notably, active targeting nanoparticles have shown improved therapeutic performances in different tumor models as compared to their passive targeting counterparts.  In this review, current development of nano-based devices conjugated with transferrin for active tumor-targeting drug delivery are highlighted and discussed.  The main objective of this review is to provide a summary of the vast types of nanomaterials that have been used to deliver different chemotherapeutics into tumor cells, and to ultimately evaluate the progression on the strategies for cancer therapy in view of the future research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoU-f_yBvZ307Vg90H21EOLACvtfcHk0lgX7YemdckIaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjslSjsLo%253D&md5=21dc2ce1c79777c40883a9c0b8c9f0ec</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.2174%2F1381612822666161026162347&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612822666161026162347%26sid%3Dliteratum%253Aachs%26aulast%3DNogueira-Librelotto%26aufirst%3DD.%2BR.%26aulast%3DCodevilla%26aufirst%3DC.%2BF.%26aulast%3DFarooqi%26aufirst%3DA.%26aulast%3DRolim%26aufirst%3DC.%2BM.%26atitle%3DTransferrin-Conjugated%2520Nanocarriers%2520as%2520Active-Targeted%2520Drug%2520Delivery%2520Platforms%2520for%2520Cancer%2520Therapy%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2017%26volume%3D23%26spage%3D454%26epage%3D466%26doi%3D10.2174%2F1381612822666161026162347" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levin, A. A.</span></span> <span> </span><span class="NLM_article-title">Targeting Therapeutic Oligonucleotides</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>376</i></span>,  <span class="NLM_fpage">86</span>– <span class="NLM_lpage">88</span>, <span class="refDoi"> DOI: 10.1056/NEJMcibr1613559</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1056%2FNEJMcibr1613559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=28052219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A280%3ADC%252BC1c7it1amsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=2017&pages=86-88&author=A.+A.+Levin&title=Targeting+Therapeutic+Oligonucleotides&doi=10.1056%2FNEJMcibr1613559"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Therapeutic Oligonucleotides</span></div><div class="casAuthors">Levin Arthur A</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">376</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">86-88</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT7RKT9ESs8MENoizSOkG_FfW6udTcc2eY7PUdP_G35o7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7it1amsA%253D%253D&md5=b812c708430de18b6902ce1380829e4e</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1056%2FNEJMcibr1613559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMcibr1613559%26sid%3Dliteratum%253Aachs%26aulast%3DLevin%26aufirst%3DA.%2BA.%26atitle%3DTargeting%2520Therapeutic%2520Oligonucleotides%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D376%26spage%3D86%26epage%3D88%26doi%3D10.1056%2FNEJMcibr1613559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarisozen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torchilin, V. P.</span></span> <span> </span><span class="NLM_article-title">The Reversal of Multidrug Resistance in Ovarian Carcinoma Cells by Co-Application of Tariquidar and Paclitaxel in Transferrin-Targeted Polymeric Micelles</span>. <i>J. Drug Targeting</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">234</span>, <span class="refDoi"> DOI: 10.1080/1061186X.2016.1236113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1080%2F1061186X.2016.1236113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=27616277" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1Wnu7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=225-234&author=W.+Zouauthor=C.+Sarisozenauthor=V.+P.+Torchilin&title=The+Reversal+of+Multidrug+Resistance+in+Ovarian+Carcinoma+Cells+by+Co-Application+of+Tariquidar+and+Paclitaxel+in+Transferrin-Targeted+Polymeric+Micelles&doi=10.1080%2F1061186X.2016.1236113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The reversal of multidrug resistance in ovarian carcinoma cells by co-application of tariquidar and paclitaxel in transferrin-targeted polymeric micelles</span></div><div class="casAuthors">Zou, Wanting; Sarisozen, Can; Torchilin, Vladimir P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Drug Targeting</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">225-234</span>CODEN:
                <span class="NLM_cas:coden">JDTAEH</span>;
        ISSN:<span class="NLM_cas:issn">1026-7158</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">In this study, a transferrin (Tf)-modified polyethylene glycol-phosphatidyl ethanolamine (PEG-PE)-based micellar delivery system contg. paclitaxel (PTX) and tariquidar (TRQ), a potent third generation P-gp inhibitor, was prepd.  The nanoformulation was evaluated by targeting efficiency, cellular assocn., cellular internalization pathway and cytotoxicity for reversal of PTX resistance on two multidrug resistant (MDR) ovarian carcinoma cell lines, SKOV-3TR and A2780-Adr.  PTX and TRQ are both hydrophobic compds.  They were successfully encapsulated into the micellar structure contg. vitamin E as the encapsulation enhancer.  The Tf-targeted micelles were internalized mainly via clathrin-dependent endocytosis by both cell lines.  For SKOV-3TR, addnl. mechanisms including caveolin-dependent endocytosis and macropinocytosis were found to play a significant role.  The PTX cytotoxicity against the SKOV-3TR and A2780-Adr MDR cells was increased significantly in the presence of micellar encapsulation.  However, unlike the A2780-Adr cell line, the Tf-targeting effect was significant on SKOV-3TR cells when co-administrated with TRQ.  Penetration of the Tf-targeted micelles in a cancer cell spheroid culture was also investigated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKCUPXXfrcKrVg90H21EOLACvtfcHk0li0y_-MwtiLww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1Wnu7%252FM&md5=60ca58f49d51a3c624963d1161029dac</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1080%2F1061186X.2016.1236113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F1061186X.2016.1236113%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DW.%26aulast%3DSarisozen%26aufirst%3DC.%26aulast%3DTorchilin%26aufirst%3DV.%2BP.%26atitle%3DThe%2520Reversal%2520of%2520Multidrug%2520Resistance%2520in%2520Ovarian%2520Carcinoma%2520Cells%2520by%2520Co-Application%2520of%2520Tariquidar%2520and%2520Paclitaxel%2520in%2520Transferrin-Targeted%2520Polymeric%2520Micelles%26jtitle%3DJ.%2520Drug%2520Targeting%26date%3D2017%26volume%3D25%26spage%3D225%26epage%3D234%26doi%3D10.1080%2F1061186X.2016.1236113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, J.</span></span> <span> </span><span class="NLM_article-title">Self-Assembled Targeted Nanoparticles Based on Transferrin-Modified Eight-Arm-Polyethylene Glycol–Dihydroartemisinin Conjugate</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">29461</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1038/srep29461</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1038%2Fsrep29461" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=28442746" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslGmu77L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=1-12&issue=29461&author=K.+Liuauthor=L.+Daiauthor=C.+Liauthor=J.+Liuauthor=L.+Wangauthor=J.+Lei&title=Self-Assembled+Targeted+Nanoparticles+Based+on+Transferrin-Modified+Eight-Arm-Polyethylene+Glycol%E2%80%93Dihydroartemisinin+Conjugate&doi=10.1038%2Fsrep29461"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Evolution of the intrinsic electronic phase separation in La0.6Er0.1Sr0.3MnO3 perovskite</span></div><div class="casAuthors">Chen, Lili; Fan, Jiyu; Tong, Wei; Hu, Dazhi; Ji, Yanda; Liu, Jindong; Zhang, Lei; Pi, Li; Zhang, Yuheng; Yang, Hao</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-9</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Magnetic and electronic transport properties of perovskite manganite La0.6Er0.1Sr0.3MnO3 have been thoroughly examd. through the measurements of magnetization, ESR(EPR), and resistivity.  It was found that the substitution of Er3+ for La3+ ions introduced the chem. disorder and addnl. strain in this sample.  An extra resonance signal occurred in EPR spectra at high temps. well above TC gives a strong evidence of electronic phase sepn.(EPS).  The anal. of resistivity enable us to identify the polaronic transport mechanism in the paramagnetic region.  At low temp., a new ferromagnetic interaction generates in the microdomains of Er3+-disorder causing the second increase of magnetization.  However, the new ferromagnetic interaction does not improve but decreases electronic transport due to the enhancement of interface resistance among neighboring domains.  In view of a really wide temp. region for the EPS existence, this sample provides an ideal platform to uncover the evolution law of different magnetic structures in perovskite manganites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEVtObrKK5DLVg90H21EOLACvtfcHk0li0y_-MwtiLww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslGmu77L&md5=3ea2f182469394f5b72ed446be3960ad</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fsrep29461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep29461%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DDai%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLei%26aufirst%3DJ.%26atitle%3DSelf-Assembled%2520Targeted%2520Nanoparticles%2520Based%2520on%2520Transferrin-Modified%2520Eight-Arm-Polyethylene%2520Glycol%25E2%2580%2593Dihydroartemisinin%2520Conjugate%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26issue%3D29461%26spage%3D1%26epage%3D12%26doi%3D10.1038%2Fsrep29461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohan
Yallapu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray Dobberpuhl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michele Maher, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaggi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chand Chauhan, S.</span></span> <span> </span><span class="NLM_article-title">Design of Curcumin Loaded Cellulose Nanoparticles for Prostate Cancer</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">120</span>– <span class="NLM_lpage">128</span>, <span class="refDoi"> DOI: 10.2174/138920012798356952</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.2174%2F138920012798356952" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=21892919" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=120-128&author=M.+Mohan%0AYallapuauthor=M.+Ray+Dobberpuhlauthor=D.+Michele+Maherauthor=M.+Jaggiauthor=S.+Chand+Chauhan&title=Design+of+Curcumin+Loaded+Cellulose+Nanoparticles+for+Prostate+Cancer&doi=10.2174%2F138920012798356952"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.2174%2F138920012798356952&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920012798356952%26sid%3Dliteratum%253Aachs%26aulast%3DMohan%2BYallapu%26aufirst%3DM.%26aulast%3DRay%2BDobberpuhl%26aufirst%3DM.%26aulast%3DMichele%2BMaher%26aufirst%3DD.%26aulast%3DJaggi%26aufirst%3DM.%26aulast%3DChand%2BChauhan%26aufirst%3DS.%26atitle%3DDesign%2520of%2520Curcumin%2520Loaded%2520Cellulose%2520Nanoparticles%2520for%2520Prostate%2520Cancer%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2012%26volume%3D13%26spage%3D120%26epage%3D128%26doi%3D10.2174%2F138920012798356952" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span> <span> </span><span class="NLM_article-title">Co-Delivery of Doxorubicin and pH-Sensitive Curcumin Prodrug by Transferrin-Targeted Nanoparticles for Breast Cancer Treatment</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1253</span>– <span class="NLM_lpage">1260</span>, <span class="refDoi"> DOI: 10.3892/or.2017.5345</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.3892%2For.2017.5345" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=28075466" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFyis7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2017&pages=1253-1260&author=T.+Cuiauthor=S.+Zhangauthor=H.+Sun&title=Co-Delivery+of+Doxorubicin+and+pH-Sensitive+Curcumin+Prodrug+by+Transferrin-Targeted+Nanoparticles+for+Breast+Cancer+Treatment&doi=10.3892%2For.2017.5345"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Co-delivery of doxorubicin and pH-sensitive curcumin prodrug by transferrin-targeted nanoparticles for breast cancer treatment</span></div><div class="casAuthors">Cui, Tongxing; Zhang, Sihao; Sun, Hong</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1253-1260</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1791-2431</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">The natural product curcumin and the chemotherapeutic agent doxorubicin have been used in the treatment of many cancers, including breast cancer.  However, fast clearance and unspecific distribution in the body after i.v. injection are still challenges to be overcome by an ideal nanosized drug delivery system in cancer treatment.  In this study we design transferrin (Tf) decorated nanoparticles (NPs) to co-deliver CUR and DOX for breast cancer treatment.  A pH-sensitive prodrug, transferrin-poly(ethylene glycol)-curcumin (Tf-PEG-CUR), was synthesized and used for the self-assembling of NPs (Tf-PEG-CUR NPs).  DOX is incorporated into the Tf-PEG-CUR NPs to obtain Tf-PEG-CUR/DOX NPs.  In vitro cytotoxicity studies and in vivo antitumor activity were carried out using MCF-7 cells and mice bearing MCF-7 cells, resp.  Tf-PEG-CUR/DOX NPs has a particle size of 89 nm and a zeta potential of -15.6 mV.  This system displayed remarkably higher efficiency than other systems both in vitro and in vivo.  DOX and CUR were successfully loaded into nanocarriers.  The in vitro cell viability assays revealed the combination of Tf-PEG-CUR and DOX NPs exhibited higher cytotoxicity in vitro in MCF-7 cells compared with Tf-PEG-CUR NPs alone.  Using the breast cancer xenograft mouse model, we demonstrate that this co-encapsulation approach resulted in an efficient tumor-targeted drug delivery, decreased cytotoxic effects and exhibited stronger antitumor effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCI__DprrsWbVg90H21EOLACvtfcHk0liIdNtQdx_6eA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFyis7s%253D&md5=90d2f1f9453e0511987b192fd60ab173</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.3892%2For.2017.5345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2017.5345%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DH.%26atitle%3DCo-Delivery%2520of%2520Doxorubicin%2520and%2520pH-Sensitive%2520Curcumin%2520Prodrug%2520by%2520Transferrin-Targeted%2520Nanoparticles%2520for%2520Breast%2520Cancer%2520Treatment%26jtitle%3DOncol.%2520Rep.%26date%3D2017%26volume%3D37%26spage%3D1253%26epage%3D1260%26doi%3D10.3892%2For.2017.5345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deshpande, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhaveri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattni, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biswas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torchilin, V.</span></span> <span> </span><span class="NLM_article-title">Transferrin and Octaarginine Modified Dual-Functional Liposomes with Improved Cancer Cell Targeting and Enhanced Intracellular Delivery for the Treatment of Ovarian Cancer</span>. <i>Drug Delivery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">517</span>– <span class="NLM_lpage">532</span>, <span class="refDoi"> DOI: 10.1080/10717544.2018.1435747</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1080%2F10717544.2018.1435747" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=29433357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXis1Oksrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=517-532&author=P.+Deshpandeauthor=A.+Jhaveriauthor=B.+Pattniauthor=S.+Biswasauthor=V.+Torchilin&title=Transferrin+and+Octaarginine+Modified+Dual-Functional+Liposomes+with+Improved+Cancer+Cell+Targeting+and+Enhanced+Intracellular+Delivery+for+the+Treatment+of+Ovarian+Cancer&doi=10.1080%2F10717544.2018.1435747"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Transferrin and octaarginine modified dual-functional liposomes with improved cancer cell targeting and enhanced intracellular delivery for the treatment of ovarian cancer</span></div><div class="casAuthors">Deshpande, Pranali; Jhaveri, Aditi; Pattni, Bhushan; Biswas, Swati; Torchilin, Vladimir</div><div class="citationInfo"><span class="NLM_cas:title">Drug Delivery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">517-532</span>CODEN:
                <span class="NLM_cas:coden">DDELEB</span>;
        ISSN:<span class="NLM_cas:issn">1071-7544</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Off-target effects of drugs severely limit cancer therapy.  Targeted nanocarriers are promising to enhance the delivery of therapeutics to tumors.  Among many approaches for active tumor-targeting, arginine-rich cell penetrating peptides (AR-CPP) and ligands specific to target over-expressed receptors on cancer-cell surfaces, are popular.  Earlier, we showed that the attachment of an AR-CPP octaarginine (R8) to the surface of DOXIL (Doxorubicin encapsulated PEGylated liposomes) improved cytoplasmic and nuclear DOX delivery that enhanced the cytotoxic effect in vitro and improved therapeutic efficacy in vivo.  Here, we report on DOX-loaded liposomes, surface-modified with, R8 and transferrin (Tf) (Dual DOX-L), to improve targeting of A2780 ovarian carcinoma cells via the over-expressed transferrin receptors (TfRs) with R8-mediated intracellular DOX delivery.  Flow cytometry anal. with fluorescently labeled DualL (without DOX) showed two-fold higher cancer-cell assocn. than other treatments after 4 h treatment.  Blocking entry pathways of R8 (macropinocytosis) and Tf (receptor-mediated endocytosis, RME) resulted in a decreased cancer-cell assocn. of DualL.  Confocal microscopy confirmed involvement of both entry pathways and cytoplasmic liposome accumulation with nuclear DOX delivery for Dual DOX-L.  Dual DOX-L exhibited enhanced cytotoxicity in vitro and was most effective in controlling tumor growth in vivo in an A2780 ovarian xenograft model compared to other treatments.  A pilot biodistribution study showed improved DOX accumulation in tumors after Dual DOX-L treatment.  All results collectively presented a clear advantage of the R8 and Tf combination to elevate the therapeutic potential of DOX-L by exploiting TfR over-expression imparting specificity followed by endosomal escape and intracellular delivery via R8.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5wsXPrjATArVg90H21EOLACvtfcHk0liIdNtQdx_6eA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXis1Oksrw%253D&md5=1e986de2158d956e56e31195dbb87a41</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1080%2F10717544.2018.1435747&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10717544.2018.1435747%26sid%3Dliteratum%253Aachs%26aulast%3DDeshpande%26aufirst%3DP.%26aulast%3DJhaveri%26aufirst%3DA.%26aulast%3DPattni%26aufirst%3DB.%26aulast%3DBiswas%26aufirst%3DS.%26aulast%3DTorchilin%26aufirst%3DV.%26atitle%3DTransferrin%2520and%2520Octaarginine%2520Modified%2520Dual-Functional%2520Liposomes%2520with%2520Improved%2520Cancer%2520Cell%2520Targeting%2520and%2520Enhanced%2520Intracellular%2520Delivery%2520for%2520the%2520Treatment%2520of%2520Ovarian%2520Cancer%26jtitle%3DDrug%2520Delivery%26date%3D2018%26volume%3D25%26spage%3D517%26epage%3D532%26doi%3D10.1080%2F10717544.2018.1435747" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haeri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalba, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ten Hagen, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dadashzadeh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koning, G. A.</span></span> <span> </span><span class="NLM_article-title">EGFR Targeted Thermosensitive Liposomes: ANovel Multifunctional Platform for Simultaneous Tumor Targeted and Stimulus Responsive Drug Delivery</span>. <i>Colloids Surf., B</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">657</span>– <span class="NLM_lpage">669</span>, <span class="refDoi"> DOI: 10.1016/j.colsurfb.2016.06.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.colsurfb.2016.06.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=27434152" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFyntb3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2016&pages=657-669&author=A.+Haeriauthor=S.+Zalbaauthor=T.+L.+Ten+Hagenauthor=S.+Dadashzadehauthor=G.+A.+Koning&title=EGFR+Targeted+Thermosensitive+Liposomes%3A+ANovel+Multifunctional+Platform+for+Simultaneous+Tumor+Targeted+and+Stimulus+Responsive+Drug+Delivery&doi=10.1016%2Fj.colsurfb.2016.06.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR targeted thermosensitive liposomes: A novel multifunctional platform for simultaneous tumor targeted and stimulus responsive drug delivery</span></div><div class="casAuthors">Haeri, Azadeh; Zalba, Sara; ten Hagen, Timo L. M.; Dadashzadeh, Simin; Koning, Gerben A.</div><div class="citationInfo"><span class="NLM_cas:title">Colloids and Surfaces, B: Biointerfaces</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">657-669</span>CODEN:
                <span class="NLM_cas:coden">CSBBEQ</span>;
        ISSN:<span class="NLM_cas:issn">0927-7765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) is a promising target for anti-cancer therapy.  The aim of this study was to design thermosensitive liposomes (TSL), functionalized with anti-EGFR ligands for targeted delivery and localized triggered release of chemotherapy.  For targeting, EGFR specific peptide (GE11) and Fab' fragments of cetuximab were used and the effect of ligand d. on in vitro tumor targeting was investigated.  Ligand conjugation did not significantly change the physicochem. characteristics of liposomes.  Fab'-decorated TSL (Fab'-TSL) can specifically and more efficiently bind to the EGFR overexpressed cancer cells as compared to GE11 modified TSL.  Calcein labeled Fab'-TSL showed adequate stability at 37 °C in serum (<4% calcein released after 1 h) and a temp. dependent release at above 40 °C.  FACS anal. and live cell imaging showed efficient and EGFR mediated cellular assocn. as well as dramatic intracellular cargo release upon hyperthermia.  Fab'-conjugation and hyperthermia induced enhanced tumor cell cytotoxicity of doxorubicin loaded TSL.  The relative cytotoxicity of Fab'-TSL was also correlated to EGFR d. on the tumor cells.  These results suggest that Fab'-TSL showed great potential for combinational targeted and triggered release drug delivery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0ZPfYPxO7NLVg90H21EOLACvtfcHk0lhuRps5llDGAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFyntb3E&md5=6a182679690f77684459b2e9ad914707</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.colsurfb.2016.06.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.colsurfb.2016.06.012%26sid%3Dliteratum%253Aachs%26aulast%3DHaeri%26aufirst%3DA.%26aulast%3DZalba%26aufirst%3DS.%26aulast%3DTen%2BHagen%26aufirst%3DT.%2BL.%26aulast%3DDadashzadeh%26aufirst%3DS.%26aulast%3DKoning%26aufirst%3DG.%2BA.%26atitle%3DEGFR%2520Targeted%2520Thermosensitive%2520Liposomes%253A%2520ANovel%2520Multifunctional%2520Platform%2520for%2520Simultaneous%2520Tumor%2520Targeted%2520and%2520Stimulus%2520Responsive%2520Drug%2520Delivery%26jtitle%3DColloids%2520Surf.%252C%2520B%26date%3D2016%26volume%3D146%26spage%3D657%26epage%3D669%26doi%3D10.1016%2Fj.colsurfb.2016.06.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mamot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drummond, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greiser, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirpotin, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. W.</span></span> <span> </span><span class="NLM_article-title">Epidermal Growth Factor Receptor (EGFR)-Targeted Immunoliposomes Mediate Specific and Efficient Drug Delivery to EGFR-and EGFRvIII-Overexpressing Tumor Cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">3154</span>– <span class="NLM_lpage">3161</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=12810643" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD3sXks1eiur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=3154-3161&author=C.+Mamotauthor=D.+C.+Drummondauthor=U.+Greiserauthor=K.+Hongauthor=D.+B.+Kirpotinauthor=J.+D.+Marksauthor=J.+W.+Park&title=Epidermal+Growth+Factor+Receptor+%28EGFR%29-Targeted+Immunoliposomes+Mediate+Specific+and+Efficient+Drug+Delivery+to+EGFR-and+EGFRvIII-Overexpressing+Tumor+Cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells</span></div><div class="casAuthors">Mamot, Christoph; Drummond, Daryl C.; Greiser, Udo; Hong, Keelung; Kirpotin, Dmitri B.; Marks, James D.; Park, John W.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3154-3161</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">We hypothesized that immunoliposomes (ILs) that target epidermal growth factor receptor (EGFR) and/or its truncated variant EGFRvIII can be constructed to provide efficient intracellular drug delivery in tumor cells overexpressing these receptors.  Monoclonal antibody fragments included Fab' fragments derived from C225, which binds both EGFR and EGFRvIII, or novel anti-EGFR scFv C10, which binds EGFR only.  Monoclonal antibody fragments were covalently linked to liposomes contg. various reporters or drugs.  ILs were evaluated for specific binding, internalization, and cytotoxicity in EGFR/EGFRvIII-overexpressing cell lines in vitro.  Flow cytometry and fluorescence microscopy showed that EGFR-targeted ILs, but not nontargeted liposomes or irrelevant ILs, were efficiently bound and internalized by EGFR-overexpressing cells, including glioma cells (U-87), carcinoma cells (A-431 and MDA-MB-468), and EGFRvIII stable transfectants (NR-6M).  Furthermore, EGFR-targeted ILs did not bind to non-EGFR-overexpressing cells (MCF-7 and parental NR-6).  ILs showed 3 orders of magnitude greater accumulation in NR-6-EGFRvIII stable transfectants vs. parental NR-6 cells.  Quant. internalization studies indicated binding of EGFR-targeted ILs to target cells within 5 min, followed by intracellular accumulation beginning at 15 min; total uptake reached ∼13,000 ILs/cell.  ILs were used to deliver cytotoxic drugs doxorubicin, vinorelbine, or methotrexate to EGFR/EGFRvIII-overexpressing target cells in vitro.  In each case, the IL agent was significantly more cytotoxic than the corresponding nontargeted liposomal drug in target cells, whereas it was equiv. in cells lacking EGFR/EGFRvIII overexpression.  We conclude that EGFR-targeted ILs provide efficient and targeted delivery of anticancer drugs in cells overexpressing EGFR or EGFRvIII.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWh4lD4DzGIbVg90H21EOLACvtfcHk0lhuRps5llDGAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXks1eiur4%253D&md5=1c5ac0e83ffa20720d9c1c0347706bad</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMamot%26aufirst%3DC.%26aulast%3DDrummond%26aufirst%3DD.%2BC.%26aulast%3DGreiser%26aufirst%3DU.%26aulast%3DHong%26aufirst%3DK.%26aulast%3DKirpotin%26aufirst%3DD.%2BB.%26aulast%3DMarks%26aufirst%3DJ.%2BD.%26aulast%3DPark%26aufirst%3DJ.%2BW.%26atitle%3DEpidermal%2520Growth%2520Factor%2520Receptor%2520%2528EGFR%2529-Targeted%2520Immunoliposomes%2520Mediate%2520Specific%2520and%2520Efficient%2520Drug%2520Delivery%2520to%2520EGFR-and%2520EGFRvIII-Overexpressing%2520Tumor%2520Cells%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D3154%26epage%3D3161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, S.-i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takanashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuyama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizutani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohgi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochiya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotoh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuroda, M.</span></span> <span> </span><span class="NLM_article-title">Systemically Injected Exosomes Targeted to EGFR Deliver Antitumor Microrna to Breast Cancer Cells</span>. <i>Mol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">191</span>, <span class="refDoi"> DOI: 10.1038/mt.2012.180</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1038%2Fmt.2012.180" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=23032975" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVegsb7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=185-191&author=S.-i.+Ohnoauthor=M.+Takanashiauthor=K.+Sudoauthor=S.+Uedaauthor=A.+Ishikawaauthor=N.+Matsuyamaauthor=K.+Fujitaauthor=T.+Mizutaniauthor=T.+Ohgiauthor=T.+Ochiyaauthor=N.+Gotohauthor=M.+Kuroda&title=Systemically+Injected+Exosomes+Targeted+to+EGFR+Deliver+Antitumor+Microrna+to+Breast+Cancer+Cells&doi=10.1038%2Fmt.2012.180"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells</span></div><div class="casAuthors">Ohno, Shin-ichiro; Takanashi, Masakatsu; Sudo, Katsuko; Ueda, Shinobu; Ishikawa, Akio; Matsuyama, Nagahisa; Fujita, Koji; Mizutani, Takayuki; Ohgi, Tadaaki; Ochiya, Takahiro; Gotoh, Noriko; Kuroda, Masahiko</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">185-191</span>CODEN:
                <span class="NLM_cas:coden">MTOHCK</span>;
        ISSN:<span class="NLM_cas:issn">1525-0016</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Despite the therapeutic potential of nucleic acid drugs, their clin. application has been limited in part by a lack of appropriate delivery systems.  Exosomes or microvesicles are small endosomally derived vesicles that are secreted by a variety of cell types and tissues.  Here, we show that exosomes can efficiently deliver microRNA (miRNA) to epidermal growth factor receptor (EGFR)-expressing breast cancer cells.  Targeting was achieved by engineering the donor cells to express the transmembrane domain of platelet-derived growth factor receptor fused to the GE11 peptide.  I.v. injected exosomes delivered let-7a miRNA to EGFR-expressing xenograft breast cancer tissue in RAG2-/- mice.  Our results suggest that exosomes can be used therapeutically to target EGFR-expressing cancerous tissues with nucleic acid drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRVVvNb0XOhLVg90H21EOLACvtfcHk0lgXmPibDq72wA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVegsb7P&md5=4b0a2eac9cf0e73f090b1bb5a9b6928d</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2Fmt.2012.180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmt.2012.180%26sid%3Dliteratum%253Aachs%26aulast%3DOhno%26aufirst%3DS.-i.%26aulast%3DTakanashi%26aufirst%3DM.%26aulast%3DSudo%26aufirst%3DK.%26aulast%3DUeda%26aufirst%3DS.%26aulast%3DIshikawa%26aufirst%3DA.%26aulast%3DMatsuyama%26aufirst%3DN.%26aulast%3DFujita%26aufirst%3DK.%26aulast%3DMizutani%26aufirst%3DT.%26aulast%3DOhgi%26aufirst%3DT.%26aulast%3DOchiya%26aufirst%3DT.%26aulast%3DGotoh%26aufirst%3DN.%26aulast%3DKuroda%26aufirst%3DM.%26atitle%3DSystemically%2520Injected%2520Exosomes%2520Targeted%2520to%2520EGFR%2520Deliver%2520Antitumor%2520Microrna%2520to%2520Breast%2520Cancer%2520Cells%26jtitle%3DMol.%2520Ther.%26date%3D2013%26volume%3D21%26spage%3D185%26epage%3D191%26doi%3D10.1038%2Fmt.2012.180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Costa, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mozhdehi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dzuricky, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaacs, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brustad, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chilkoti, A.</span></span> <span> </span><span class="NLM_article-title">Active Targeting of Cancer Cells by Nanobody Decorated Polypeptide Micelle with Bio-Orthogonally Conjugated Drug</span>. <i>Nano Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">247</span>– <span class="NLM_lpage">254</span>, <span class="refDoi"> DOI: 10.1021/acs.nanolett.8b03837</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.nanolett.8b03837" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFWhtr%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=247-254&author=S.+A.+Costaauthor=D.+Mozhdehiauthor=M.+J.+Dzurickyauthor=F.+J.+Isaacsauthor=E.+M.+Brustadauthor=A.+Chilkoti&title=Active+Targeting+of+Cancer+Cells+by+Nanobody+Decorated+Polypeptide+Micelle+with+Bio-Orthogonally+Conjugated+Drug&doi=10.1021%2Facs.nanolett.8b03837"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Active Targeting of Cancer Cells by Nanobody Decorated Polypeptide Micelle with Bio-orthogonally Conjugated Drug</span></div><div class="casAuthors">Costa, Simone A.; Mozhdehi, Davoud; Dzuricky, Michael J.; Isaacs, Farren J.; Brustad, Eric M.; Chilkoti, Ashutosh</div><div class="citationInfo"><span class="NLM_cas:title">Nano Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">247-254</span>CODEN:
                <span class="NLM_cas:coden">NALEFD</span>;
        ISSN:<span class="NLM_cas:issn">1530-6984</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Polypeptides are promising carriers for chemotherapeutics: they have minimal toxicity, can be recombinantly synthesized with precise control over mol. wt., and enhance drug pharmacokinetics as self-assembled nanoparticles.  Polypeptide-based systems also provide the ability to achieve active targeting with genetically encoded targeting ligands.  While passive targeting promotes accumulation of nanocarriers in solid tumors, active targeting provides an addnl. layer of tunable control and widens the therapeutic window.  However, fusion of most targeting proteins to polypeptide carriers exposes the limitations of this approach: the residues that are used for drug attachment are also promiscuously distributed on protein surfaces.  We present here a universal methodol. to solve this problem by the site-specific attachment of extrinsic moieties to polypeptide drug delivery systems without cross-reactivity to fused targeting domains.  We incorporate an unnatural amino acid, p-acetylphenylalanine, to provide a biorthogonal ketone for attachment of doxorubicin in the presence of reactive amino acids in a nanobody-targeted, elastin-like polypeptide nanoparticle.  These nanoparticles exhibit significantly greater cytotoxicity than nontargeted controls in multiple cancer cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN4KqSVn3PObVg90H21EOLACvtfcHk0lgXmPibDq72wA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFWhtr%252FI&md5=5e0340cfc5fc4902770ab3e7ed66dd15</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Facs.nanolett.8b03837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.nanolett.8b03837%26sid%3Dliteratum%253Aachs%26aulast%3DCosta%26aufirst%3DS.%2BA.%26aulast%3DMozhdehi%26aufirst%3DD.%26aulast%3DDzuricky%26aufirst%3DM.%2BJ.%26aulast%3DIsaacs%26aufirst%3DF.%2BJ.%26aulast%3DBrustad%26aufirst%3DE.%2BM.%26aulast%3DChilkoti%26aufirst%3DA.%26atitle%3DActive%2520Targeting%2520of%2520Cancer%2520Cells%2520by%2520Nanobody%2520Decorated%2520Polypeptide%2520Micelle%2520with%2520Bio-Orthogonally%2520Conjugated%2520Drug%26jtitle%3DNano%2520Lett.%26date%3D2019%26volume%3D19%26spage%3D247%26epage%3D254%26doi%3D10.1021%2Facs.nanolett.8b03837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patil, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amitay, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohana, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shmeeda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabizon, A.</span></span> <span> </span><span class="NLM_article-title">Targeting of Pegylated Liposomal Mitomycin-C Prodrug to the Folate Receptor of Cancer Cells: Intracellular Activation and Enhanced Cytotoxicity</span>. <i>J. Controlled Release</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>225</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1016/j.jconrel.2016.01.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.jconrel.2016.01.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=26809007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1Gjt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=225&publication_year=2016&pages=87-95&author=Y.+Patilauthor=Y.+Amitayauthor=P.+Ohanaauthor=H.+Shmeedaauthor=A.+Gabizon&title=Targeting+of+Pegylated+Liposomal+Mitomycin-C+Prodrug+to+the+Folate+Receptor+of+Cancer+Cells%3A+Intracellular+Activation+and+Enhanced+Cytotoxicity&doi=10.1016%2Fj.jconrel.2016.01.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting of pegylated liposomal mitomycin-C prodrug to the folate receptor of cancer cells: Intracellular activation and enhanced cytotoxicity</span></div><div class="casAuthors">Patil, Yogita; Amitay, Yasmine; Ohana, Patricia; Shmeeda, Hilary; Gabizon, Alberto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">225</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">87-95</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Mitomycin C (MMC) is a powerful anti-bacterial, anti-fungal and anti-tumor antibiotic, often active against multidrug resistant cells.  Despite a broad spectrum of antitumor activity, MMC clin. use is relatively limited due to its fast clearance and dose-limiting toxicity.  To exploit the potential antitumor activity of MMC and reduce its toxicity we have previously developed a formulation of pegylated liposomes with a lipophilic prodrug of MMC (PL-MLP), activated by endogenous reducing agents which are abundant in the tumor cell environment in the form of different thiols.  PL-MLP has minimal in vitro cytotoxicity unless reducing agents are added to the cell culture to activate the prodrug.  In the present study, we hypothesized that targeting PL-MLP via folate receptors will facilitate intracellular activation of prodrug and enhance cytotoxic activity without added reducing agents.  We grafted a lipophilic folate conjugate (folate-PEG(5000)-DSPE) to formulate folate targeted liposomes (FT-PL-MLP) and examd. in vitro cell uptake and cytotoxic activity in cancer cell lines with high folate receptors (HiFR). 3H-cholesterol-hexadecyl ether (3H-Chol)-radiolabeled liposomes were prepd. to study liposome-cell binding in parallel to cellular uptake of prodrug MLP. 3H-Chol and MLP cell uptake levels were 4-fold and 9-fold greater in KB HiFR cells when FT-PL-MLP is compared to non-targeted PL-MLP liposomes.  The cytotoxic activity of FT-PL-MLP liposomes was significantly increased up to ∼ 5-fold compared with PL-MLP liposomes in all tested HiFR expressing cell lines.  The enhanced uptake and intracytoplasmic liposome delivery was confirmed by confocal fluorescence studies with Rhodamine-labeled liposomes.  In vivo, no significant differences in pharmacokinetics and biodistribution were obsd. when PL-MLP was compared to FT-PL-MLP by the i.v. route.  However, when liposomes were directly injected into the peritoneal cavity of mice with malignant ascites of J6456 HiFR lymphoma cells, the tumor cell levels of MLP were significantly greater with the folate-targeted liposomes.  Thus, folate targeting enhances liposome uptake by tumor cells enabling intracellular activation of prodrug in the absence of exogenous reducing agents, and leading to increased cytotoxicity.  These results may be particularly relevant to the application of folate-targeted PL-MLP in intracavitary or intravesical treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGre2whzZITQELVg90H21EOLACvtfcHk0libdbUoBbhZmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1Gjt7k%253D&md5=b7879ef5119375335a1c1f2c3d6dd3b6</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2016.01.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2016.01.039%26sid%3Dliteratum%253Aachs%26aulast%3DPatil%26aufirst%3DY.%26aulast%3DAmitay%26aufirst%3DY.%26aulast%3DOhana%26aufirst%3DP.%26aulast%3DShmeeda%26aufirst%3DH.%26aulast%3DGabizon%26aufirst%3DA.%26atitle%3DTargeting%2520of%2520Pegylated%2520Liposomal%2520Mitomycin-C%2520Prodrug%2520to%2520the%2520Folate%2520Receptor%2520of%2520Cancer%2520Cells%253A%2520Intracellular%2520Activation%2520and%2520Enhanced%2520Cytotoxicity%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2016%26volume%3D225%26spage%3D87%26epage%3D95%26doi%3D10.1016%2Fj.jconrel.2016.01.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tacha, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremer, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Da, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skinner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicks, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, P.</span></span> <span> </span><span class="NLM_article-title">Medicine, L. Folate Receptor-A Associated with Triple-Negative Breast Cancer and Poor Prognosis</span>. <i>Arch. Pathol. Lab. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">890</span>– <span class="NLM_lpage">895</span>, <span class="refDoi"> DOI: 10.5858/arpa.2013-0309-OA</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.5858%2Farpa.2013-0309-OA" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=24028341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A280%3ADC%252BC3sbnsV2itg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2014&pages=890-895&author=Z.+Zhangauthor=J.+Wangauthor=D.+E.+Tachaauthor=P.+Liauthor=R.+E.+Bremerauthor=H.+Chenauthor=B.+Weiauthor=X.+Xiaoauthor=J.+Daauthor=K.+Skinnerauthor=D.+G.+Hicksauthor=H.+Buauthor=P.+Tang&title=Medicine%2C+L.+Folate+Receptor-A+Associated+with+Triple-Negative+Breast+Cancer+and+Poor+Prognosis&doi=10.5858%2Farpa.2013-0309-OA"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Folate receptor α associated with triple-negative breast cancer and poor prognosis</span></div><div class="casAuthors">Zhang Zhang; Wang Jianmin; Tacha David E; Li Pamela; Bremer Ryan E; Chen Huijiao; Wei Bing; Xiao Xiuli; Da Jiping; Skinner Kristin; Hicks David G; Bu Hong; Tang Ping</div><div class="citationInfo"><span class="NLM_cas:title">Archives of pathology & laboratory medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">890-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">CONTEXT:  Folate receptor α (FRA) has been shown to be selectively expressed in several types of human cancer, including breast cancer.  Currently, several FRA target therapies are under intensive study.  OBJECTIVE:  To investigate the expression pattern of FRA in a large cohort of patients with breast cancer and analyze its relationship with different clinicopathologic features, with expression of several key biomarkers, and with clinical outcome.  DESIGN:  Four hundred forty-seven cases of infiltrating ductal carcinoma diagnosed between 1997 and 2008 at the University of Rochester Medical Center were identified and reviewed, and 25 blocks of tissue microassays were constructed.  The association between expression of FRA and clinicopathologic features; expression of estrogen receptor (ER), progesterone receptor (PR), HER2/neu, and Ki-67; and clinical outcome of these tumors were evaluated.  RESULTS:  The expression of FRA was significantly associated with tumors with high histologic grade, higher nodal stages, ER/PR negativity, and high proliferative activity (Ki-67 ≥ 15%), and was independent of HER2/neu overexpression.  In all, 74% of ER/PR-negative and 80% of triple-negative breast cancers expressed FRA.  The expression of FRA was significantly associated with a worse disease-free survival.  CONCLUSIONS:  Our data demonstrate that a significant subgroup of ER/PR-negative and triple-negative breast cancers express FRA, and its expression is associated with worse clinical outcome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQcfU0t4X4JDNts4TFFB11gfW6udTcc2ea0i6cVYwYoprntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sbnsV2itg%253D%253D&md5=314882f46da416cf2f23fcc3a75330fe</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.5858%2Farpa.2013-0309-OA&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5858%252Farpa.2013-0309-OA%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DTacha%26aufirst%3DD.%2BE.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DBremer%26aufirst%3DR.%2BE.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DXiao%26aufirst%3DX.%26aulast%3DDa%26aufirst%3DJ.%26aulast%3DSkinner%26aufirst%3DK.%26aulast%3DHicks%26aufirst%3DD.%2BG.%26aulast%3DBu%26aufirst%3DH.%26aulast%3DTang%26aufirst%3DP.%26atitle%3DMedicine%252C%2520L.%2520Folate%2520Receptor-A%2520Associated%2520with%2520Triple-Negative%2520Breast%2520Cancer%2520and%2520Poor%2520Prognosis%26jtitle%3DArch.%2520Pathol.%2520Lab.%2520Med.%26date%3D2014%26volume%3D138%26spage%3D890%26epage%3D895%26doi%3D10.5858%2Farpa.2013-0309-OA" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xia, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, P. S.</span></span> <span> </span><span class="NLM_article-title">Folate-Targeted Therapies for Cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">6811</span>– <span class="NLM_lpage">6824</span>, <span class="refDoi"> DOI: 10.1021/jm100509v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100509v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVCit7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=6811-6824&author=W.+Xiaauthor=P.+S.+Low&title=Folate-Targeted+Therapies+for+Cancer&doi=10.1021%2Fjm100509v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Folate-Targeted Therapies for Cancer</span></div><div class="casAuthors">Xia, Wei; Low, Philip S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6811-6824</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This article discusses the use of folic acid as a ligand to target therapeutic cargos of many sizes, shapes, mechanisms of action to tumor cells both in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpihPD6hMJ_77Vg90H21EOLACvtfcHk0lj0f1vgf3rjGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVCit7w%253D&md5=8d302235e47b742beed54f482c637c49</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjm100509v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100509v%26sid%3Dliteratum%253Aachs%26aulast%3DXia%26aufirst%3DW.%26aulast%3DLow%26aufirst%3DP.%2BS.%26atitle%3DFolate-Targeted%2520Therapies%2520for%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D6811%26epage%3D6824%26doi%3D10.1021%2Fjm100509v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weil, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, R. L.</span></span> <span> </span><span class="NLM_article-title">Farletuzumab (AMonoclonal Antibody Against Folate Receptor Alpha) in Relapsed Platinum-Sensitive Ovarian Cancer</span>. <i>Gynecol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">452</span>– <span class="NLM_lpage">458</span>, <span class="refDoi"> DOI: 10.1016/j.ygyno.2013.03.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.ygyno.2013.03.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=23474348" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC3sXls1Sns78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2013&pages=452-458&author=D.+K.+Armstrongauthor=A.+J.+Whiteauthor=S.+C.+Weilauthor=M.+Phillipsauthor=R.+L.+Coleman&title=Farletuzumab+%28AMonoclonal+Antibody+Against+Folate+Receptor+Alpha%29+in+Relapsed+Platinum-Sensitive+Ovarian+Cancer&doi=10.1016%2Fj.ygyno.2013.03.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer</span></div><div class="casAuthors">Armstrong, Deborah K.; White, Allen J.; Weil, Susan C.; Phillips, Martin; Coleman, Robert L.</div><div class="citationInfo"><span class="NLM_cas:title">Gynecologic Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">452-458</span>CODEN:
                <span class="NLM_cas:coden">GYNOA3</span>;
        ISSN:<span class="NLM_cas:issn">0090-8258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Objective: Farletuzumab is a humanized monoclonal antibody to folate receptor-α, which is over-expressed in most epithelial ovarian cancers but largely absent on normal tissue.  We evaluated clin. activity of farletuzumab, alone and combined with chemotherapy, in women with first-relapse, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancers.  Methods: Fifty-four eligible subjects received open-label farletuzumab weekly, single agent or combined with carboplatin (AUC5-6) and taxane (paclitaxel 175 mg/m2 or docetaxel 75 mg/m2), every 21 days for 6 cycles, followed by farletuzumab maintenance until progression.  Twenty-eight subjects with asymptomatic CA125 relapse received single-agent farletuzumab and could receive platinum/taxane chemotherapy plus farletuzumab after single-agent progression.  Twenty-six subjects with symptomatic relapse entered the combination arm directly; 21 subjects entered after single agent.  Primary endpoints included normalized CA125 and Overall Response Rate (ORR).  Duration of each subject's second progression-free interval (PFI2) was compared with her own first response interval (PFI1).  Results: Farletuzumab was well-tolerated as single agent, without additive toxicity when administered with chemotherapy.  Of 47 subjects who received farletuzumab with chemotherapy, 38 (80.9%) normalized CA125.  In 9/42 (21%) evaluable subjects, PFI2 was ≥ PFI1, better than the historical rate (3%).  There was a high response rate among subjects with PFI1 < 12 mo (75%), comparable to that in subjects with PFI1 ≥ 12 mo (84%).  Complete or partial ORR was 75% with combination therapy.  Conclusions: Based on this study, farletuzumab with carboplatin and taxane may enhance the response rate and duration of response in platinum-sensitive ovarian cancer patients with first relapse after remission of 6-18 mo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9MihV5zqvabVg90H21EOLACvtfcHk0ljdG6amsw11hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXls1Sns78%253D&md5=d9190e9c360045d3a15f580f3be2789c</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.ygyno.2013.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ygyno.2013.03.002%26sid%3Dliteratum%253Aachs%26aulast%3DArmstrong%26aufirst%3DD.%2BK.%26aulast%3DWhite%26aufirst%3DA.%2BJ.%26aulast%3DWeil%26aufirst%3DS.%2BC.%26aulast%3DPhillips%26aufirst%3DM.%26aulast%3DColeman%26aufirst%3DR.%2BL.%26atitle%3DFarletuzumab%2520%2528AMonoclonal%2520Antibody%2520Against%2520Folate%2520Receptor%2520Alpha%2529%2520in%2520Relapsed%2520Platinum-Sensitive%2520Ovarian%2520Cancer%26jtitle%3DGynecol.%2520Oncol.%26date%3D2013%26volume%3D129%26spage%3D452%26epage%3D458%26doi%3D10.1016%2Fj.ygyno.2013.03.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span> <span> </span><span class="NLM_article-title">Microencapsulation of Coupled Folate and Chitosan Nanoparticles for Targeted Delivery of Combination Drugs to Colon</span>. <i>J. Microencapsulation</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">40</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.3109/02652048.2014.944947</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.3109%2F02652048.2014.944947" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=25198909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFSmsb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2015&pages=40-45&author=P.+Liauthor=Z.+Yangauthor=Y.+Wangauthor=Z.+Pengauthor=S.+Liauthor=L.+Kongauthor=Q.+Wang&title=Microencapsulation+of+Coupled+Folate+and+Chitosan+Nanoparticles+for+Targeted+Delivery+of+Combination+Drugs+to+Colon&doi=10.3109%2F02652048.2014.944947"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Microencapsulation of coupled folate and chitosan nanoparticles for targeted delivery of combination drugs to colon</span></div><div class="casAuthors">Li, Puwang; Yang, Ziming; Wang, Yichao; Peng, Zheng; Li, Sidong; Kong, Lingxue; Wang, Qinghuang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Microencapsulation</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">40-45</span>CODEN:
                <span class="NLM_cas:coden">JOMIEF</span>;
        ISSN:<span class="NLM_cas:issn">0265-2048</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Folate-chitosan nanoparticles, co-loaded with 5-fluourouacil (5-FU) and leucovorin (LV) and prepd. by ionic gelation technol. were phys. microencapsulated by enteric polymer using a solvent evapn. method.  Av. particle size of the microencapsulated particles was in the range of 15 to 35 μm.  High drug encapsulation efficiency was obtained for both 5-FU and LV in the microencapsulated particles.  Both drugs were in amorphous state in the microencapsulated particles.  By enteric coating, excellent pH-dependent release profile was achieved and no drug release was obsd. in simulated gastric and intestinal fluids.  However, when the pH value reached the sol. threshold of Eudragit S-100, a const. and slow drug release was obsd.  The results indicated that these microencapsulated particles are a promising vehicle for selectively targeting drugs to colon in the chemotherapy of colon cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGre9RWRJOdz4rVg90H21EOLACvtfcHk0ljdG6amsw11hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFSmsb7O&md5=0ba026c8118deb382e3057af80b9f423</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.3109%2F02652048.2014.944947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F02652048.2014.944947%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DPeng%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DKong%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DQ.%26atitle%3DMicroencapsulation%2520of%2520Coupled%2520Folate%2520and%2520Chitosan%2520Nanoparticles%2520for%2520Targeted%2520Delivery%2520of%2520Combination%2520Drugs%2520to%2520Colon%26jtitle%3DJ.%2520Microencapsulation%26date%3D2015%26volume%3D32%26spage%3D40%26epage%3D45%26doi%3D10.3109%2F02652048.2014.944947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Desgrosellier, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheresh, D. A.</span></span> <span> </span><span class="NLM_article-title">Integrins in Cancer: Biological Implications and Therapeutic Opportunities</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.1038/nrc2748</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1038%2Fnrc2748" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=20029421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsF2hsLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=9-22&author=J.+S.+Desgrosellierauthor=D.+A.+Cheresh&title=Integrins+in+Cancer%3A+Biological+Implications+and+Therapeutic+Opportunities&doi=10.1038%2Fnrc2748"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Integrins in cancer: biological implications and therapeutic opportunities</span></div><div class="casAuthors">Desgrosellier, Jay S.; Cheresh, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-22</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The integrin family of cell adhesion receptors regulates a diverse array of cellular functions crucial to the initiation, progression and metastasis of solid tumors.  The importance of integrins in several cell types that affect tumor progression has made them an appealing target for cancer therapy.  Integrin antagonists, including the αvβ3 and αvβ5 inhibitor cilengitide, have shown encouraging activity in Phase II clin. trials and cilengitide is currently being tested in a Phase III trial in patients with glioblastoma.  These exciting clin. developments emphasize the need to identify how integrin antagonists influence the tumor and its microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL2sajdsDI07Vg90H21EOLACvtfcHk0liavUYuSwff8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsF2hsLzI&md5=43d0b526ca38021e780aba991a58451b</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fnrc2748&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2748%26sid%3Dliteratum%253Aachs%26aulast%3DDesgrosellier%26aufirst%3DJ.%2BS.%26aulast%3DCheresh%26aufirst%3DD.%2BA.%26atitle%3DIntegrins%2520in%2520Cancer%253A%2520Biological%2520Implications%2520and%2520Therapeutic%2520Opportunities%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D9%26epage%3D22%26doi%3D10.1038%2Fnrc2748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brannon-Peppas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchette, J. O.</span></span> <span> </span><span class="NLM_article-title">Nanoparticle and Targeted Systems for Cancer Therapy</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">206</span>– <span class="NLM_lpage">212</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2012.09.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.addr.2012.09.033" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2012&pages=206-212&author=L.+Brannon-Peppasauthor=J.+O.+Blanchette&title=Nanoparticle+and+Targeted+Systems+for+Cancer+Therapy&doi=10.1016%2Fj.addr.2012.09.033"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2012.09.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2012.09.033%26sid%3Dliteratum%253Aachs%26aulast%3DBrannon-Peppas%26aufirst%3DL.%26aulast%3DBlanchette%26aufirst%3DJ.%2BO.%26atitle%3DNanoparticle%2520and%2520Targeted%2520Systems%2520for%2520Cancer%2520Therapy%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2012%26volume%3D64%26spage%3D206%26epage%3D212%26doi%3D10.1016%2Fj.addr.2012.09.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nam, J.-O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, R.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, I.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, S. Y.</span></span> <span> </span><span class="NLM_article-title">Self-Assembled Nanoparticles Based on Glycol Chitosan Bearing 5β-Cholanic Acid for RGD Peptide Delivery</span>. <i>J. Controlled Release</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">579</span>– <span class="NLM_lpage">588</span>, <span class="refDoi"> DOI: 10.1016/j.jconrel.2003.12.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.jconrel.2003.12.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=15023468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitVKgt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2004&pages=579-588&author=J.+H.+Parkauthor=S.+Kwonauthor=J.-O.+Namauthor=R.-W.+Parkauthor=H.+Chungauthor=S.+B.+Seoauthor=I.-S.+Kimauthor=I.+C.+Kwonauthor=S.+Y.+Jeong&title=Self-Assembled+Nanoparticles+Based+on+Glycol+Chitosan+Bearing+5%CE%B2-Cholanic+Acid+for+RGD+Peptide+Delivery&doi=10.1016%2Fj.jconrel.2003.12.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Self-assembled nanoparticles based on glycol chitosan bearing 5β-cholanic acid for RGD peptide delivery</span></div><div class="casAuthors">Park, Jae Hyung; Kwon, Seunglee; Nam, Ju-Ock; Park, Rang-Woon; Chung, Hesson; Seo, Sang Bong; Kim, In-San; Kwon, Ick Chan; Jeong, Seo Young</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">579-588</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The synthetic peptide bearing Arg-Gly-Asp (RGD) sequence is considered to specifically bind to αvβ3 integrin expressed on endothelial cells in the angiogenic blood vessels, which provides a potential to inhibit the tumor growth.  As a carrier for the RGD peptide, hydrophobically modified glycol chitosan (HGC) capable of forming nano-sized self-aggregates was prepd. by the chem. conjugation of 5β-cholanic acid to the main backbone of glycol chitosan.  The RGD peptide labeled with fluorescein isothiocyanate (FITC-GRGDS) was loaded into self-aggregates in three different conditions: simple mixing, sonication, and solvent evapn. methods.  Of different methods applied, solvent evapn. method showed the most promising results for peptide loading, as judged by the yield (>70%) and loading efficiency (>75%).  It was found that the presence of FITC-labeled peptides makes the self-aggregates to be compact, possibly due to the role of both hydrophobic FITC and peptides contg. carboxylic acids that allow hydrogen bonding and electrostatic interaction with the primary amino groups in the main backbone of glycol chitosan.  FITC-labeled peptides were released from self-aggregates in a physiol. soln. (pH 7.4) for up to 1 day.  From the cell adhesion and migration assays, it was demonstrated that FITC labeling of peptides does not significantly deteriorate biol. activity of the parent peptide drug (GRGDS).  Overall, the self-aggregates loaded with FITC-GRGDS might be useful for monitoring or destroying the angiogenic vessels surrounding the tumor tissue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpglbBn1FC4b7Vg90H21EOLACvtfcHk0liavUYuSwff8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitVKgt70%253D&md5=3a46df347d9d27b98c177fa446177530</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2003.12.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2003.12.020%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.%2BH.%26aulast%3DKwon%26aufirst%3DS.%26aulast%3DNam%26aufirst%3DJ.-O.%26aulast%3DPark%26aufirst%3DR.-W.%26aulast%3DChung%26aufirst%3DH.%26aulast%3DSeo%26aufirst%3DS.%2BB.%26aulast%3DKim%26aufirst%3DI.-S.%26aulast%3DKwon%26aufirst%3DI.%2BC.%26aulast%3DJeong%26aufirst%3DS.%2BY.%26atitle%3DSelf-Assembled%2520Nanoparticles%2520Based%2520on%2520Glycol%2520Chitosan%2520Bearing%25205%25CE%25B2-Cholanic%2520Acid%2520for%2520RGD%2520Peptide%2520Delivery%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2004%26volume%3D95%26spage%3D579%26epage%3D588%26doi%3D10.1016%2Fj.jconrel.2003.12.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span> <span> </span><span class="NLM_article-title">Enhanced Antitumor Effect of Novel Dual-Targeted Paclitaxel Liposomes</span>. <i>Nanotechnology</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">415103</span>, <span class="refDoi"> DOI: 10.1088/0957-4484/21/41/415103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1088%2F0957-4484%2F21%2F41%2F415103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=20852356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVygt7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2010&pages=415103&author=S.+Mengauthor=B.+Suauthor=W.+Liauthor=Y.+Dingauthor=L.+Tangauthor=W.+Zhouauthor=Y.+Songauthor=H.+Liauthor=C.+Zhou&title=Enhanced+Antitumor+Effect+of+Novel+Dual-Targeted+Paclitaxel+Liposomes&doi=10.1088%2F0957-4484%2F21%2F41%2F415103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced antitumor effect of novel dual-targeted paclitaxel liposomes</span></div><div class="casAuthors">Meng, Shuyan; Su, Bo; Li, Wei; Ding, Yongmei; Tang, Liang; Zhou, Wei; Song, Yin; Li, Heyan; Zhou, Caicun</div><div class="citationInfo"><span class="NLM_cas:title">Nanotechnology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">415103/1-415103/7</span>CODEN:
                <span class="NLM_cas:coden">NNOTER</span>;
        ISSN:<span class="NLM_cas:issn">1361-6528</span>.
    
            (<span class="NLM_cas:orgname">Institute of Physics Publishing</span>)
        </div><div class="casAbstract">A novel dual-targeted peptide contg. an alpha V integrins specific ligand and a neuropilin-1 specific motif was developed which showed an increased specific targeting affinity to tumors.  Active dual-targeted liposomes were then produced with this peptide and exhibited greater binding activity than single-targeted liposomes in vitro.  Paclitaxel entrapped in this formulation greatly increased the uptake of paclitaxel in the targeting cells and significantly suppressed the growth of HUVEC and A549 cells compared with general paclitaxel injections (Taxol) and single-targeted paclitaxel liposomes.  The treatment of tumor xenograft models with dual-targeted paclitaxel liposomes also resulted in better tumor growth inhibition than any other treatment groups.  Therefore, the dual-targeted paclitaxel liposomes prepd. in the present study might be a more promising drug for cancer treatment.  Therefore, Furthermore, the dual-targeting approach may produce synergistic effects that can be applied in the development of new drug delivery systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDH1k9TGynn7Vg90H21EOLACvtfcHk0lgrmDdu7y_Oaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVygt7fM&md5=a9d721a7bb45e63605bf7646c094bbcc</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1088%2F0957-4484%2F21%2F41%2F415103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1088%252F0957-4484%252F21%252F41%252F415103%26sid%3Dliteratum%253Aachs%26aulast%3DMeng%26aufirst%3DS.%26aulast%3DSu%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DDing%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DC.%26atitle%3DEnhanced%2520Antitumor%2520Effect%2520of%2520Novel%2520Dual-Targeted%2520Paclitaxel%2520Liposomes%26jtitle%3DNanotechnology%26date%3D2010%26volume%3D21%26spage%3D415103%26doi%3D10.1088%2F0957-4484%2F21%2F41%2F415103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, X.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, K.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, F.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.-T.</span></span> <span> </span><span class="NLM_article-title">Glioma-Targeted Therapy Using Cilengitide Nanoparticles Combined with UTMD Enhanced Delivery</span>. <i>J. Controlled Release</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>224</i></span>,  <span class="NLM_fpage">112</span>– <span class="NLM_lpage">125</span>, <span class="refDoi"> DOI: 10.1016/j.jconrel.2016.01.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.jconrel.2016.01.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=26792571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC28XovFCntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=224&publication_year=2016&pages=112-125&author=Y.-Z.+Zhaoauthor=Q.+Linauthor=H.+L.+Wongauthor=X.-T.+Shenauthor=W.+Yangauthor=H.-L.+Xuauthor=K.-L.+Maoauthor=F.-R.+Tianauthor=J.-J.+Yangauthor=J.+Xuauthor=J.+Xiaoauthor=C.-T.+Lu&title=Glioma-Targeted+Therapy+Using+Cilengitide+Nanoparticles+Combined+with+UTMD+Enhanced+Delivery&doi=10.1016%2Fj.jconrel.2016.01.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Glioma-targeted therapy using Cilengitide nanoparticles combined with UTMD enhanced delivery</span></div><div class="casAuthors">Zhao, Ying-Zheng; Lin, Qian; Wong, Ho Lun; Shen, Xiao-Tong; Yang, Wei; Xu, He-Lin; Mao, Kai-Li; Tian, Fu-Rong; Yang, Jing-Jing; Xu, Jie; Xiao, Jian; Lu, Cui-Tao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">224</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112-125</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Malignant gliomas esp. glioblastoma (GBM) are poorly responsive to the current treatments.  Cilengitide (CGT) is a cyclic pentapeptide that demonstrated efficacy for GBM treatment by targeting the integrins avβ3 and avβ5 over-expressed on GBM cells.  However, clin. translation of this therapy has been limited by issues including fast blood clearance, high kidney and liver uptake, poor blood-brain barrier (BBB) penetration, low tumor specificity and rapid washout from tumors.  In this study, these issues were tackled in an integrated manner using a multi-stage strategy combining ultrasound-targeted microbubble destruction (UTMD) with CGT nanotherapy.  CGT nanoparticles (CGT-NP) prepd. using gelatin and Poloxamer 188-grafted heparin copolymer demonstrated significant apoptotic and cytotoxic effects in C6 GBM cells.  Biodistribution study in a rat GBM model demonstrated buildup of high CGT level in tumors subjected to CGT-NP + UTMD combined therapy.  The tumor CGT level in these animals was increased over 3-fold, tumor retention of CGT prolonged and renal clearance significantly reduced when compared with free CGT with or without UTMD.  CGT-NP + UTMD treatment was further shown to extend the median survival period from less than 20 days in the control and about 30 days in free CGT group to about 80 days.  This was achieved with low CGT dosing level (2 mg/kg twice weekly).  In situ monitoring of GFAP, Ki67, caspase-3, Beclin-1, and LC-3 in the tumor samples together with TUNEL assay, transmission electron microscope imaging and Western blot assay all demonstrated high apoptotic and autophagy activities induced by the combined therapy.  In conclusion, this study has provided extensive preclin. data supporting the use of this combined therapy to overcome the limitations of std. CGT treatment of gliomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoe14j1RuKTibVg90H21EOLACvtfcHk0ljV6S4p0cUPCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XovFCntw%253D%253D&md5=f4b92cef3e3eafca4491a5ad77502a1e</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2016.01.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2016.01.015%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DY.-Z.%26aulast%3DLin%26aufirst%3DQ.%26aulast%3DWong%26aufirst%3DH.%2BL.%26aulast%3DShen%26aufirst%3DX.-T.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DXu%26aufirst%3DH.-L.%26aulast%3DMao%26aufirst%3DK.-L.%26aulast%3DTian%26aufirst%3DF.-R.%26aulast%3DYang%26aufirst%3DJ.-J.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DXiao%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DC.-T.%26atitle%3DGlioma-Targeted%2520Therapy%2520Using%2520Cilengitide%2520Nanoparticles%2520Combined%2520with%2520UTMD%2520Enhanced%2520Delivery%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2016%26volume%3D224%26spage%3D112%26epage%3D125%26doi%3D10.1016%2Fj.jconrel.2016.01.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ai, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Y.</span></span> <span> </span><span class="NLM_article-title">Novel Linear Peptides with High Affinity to Avβ3 Integrin for Precise Tumor Identification</span>. <i>Theranostics</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1511</span>– <span class="NLM_lpage">1523</span>, <span class="refDoi"> DOI: 10.7150/thno.18401</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.7150%2Fthno.18401" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=28529634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtV2rt77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=1511-1523&author=Y.+Maauthor=G.+Aiauthor=C.+Zhangauthor=M.+Zhaoauthor=X.+Dongauthor=Z.+Hanauthor=Z.+Wangauthor=M.+Zhangauthor=Y.+Liuauthor=W.+Gaoauthor=S.+Liauthor=Y.+Gu&title=Novel+Linear+Peptides+with+High+Affinity+to+Av%CE%B23+Integrin+for+Precise+Tumor+Identification&doi=10.7150%2Fthno.18401"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Novel linear peptides with high affinity to αvβ3 integrin for precise tumor identification</span></div><div class="casAuthors">Ma, Yi; Ai, Guanhua; Zhang, Congying; Zhao, Menglu; Dong, Xue; Han, Zhihao; Wang, Zhaohui; Zhang, Min; Liu, Yuxi; Gao, Weidong; Li, Siwen; Gu, Yueqing</div><div class="citationInfo"><span class="NLM_cas:title">Theranostics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1511-1523</span>CODEN:
                <span class="NLM_cas:coden">THERDS</span>;
        ISSN:<span class="NLM_cas:issn">1838-7640</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">Development of alternative linear peptides for targeting αvβ3 integrin has attracted much attention, as the traditional peptide ligand, cyclic RGD, is limited by inferior water-soly. and complex synthesis.  Using pharmacophore-based virtual screening and high-throughput mol. docking, we identified two novel linear small peptides RWr and RWrNM with high affinity and specificity to αvβ3 integrin.  The competitive binding with cyclic RGD (c(RGDyK)) and cellular uptake related to the integrin expression levels verified their affinity to αvβ3 integrin.  The intermol. interaction measurement and dynamics simulation demonstrated the high binding affinity and stability, esp. for RWrNM.  In vivo peptide-guided tumor imaging and targeted therapy further confirmed their specificity.  Results indicated that the newly identified small linear peptide RWrNM, with high affinity and specificity to αvβ3 integrin, better water-soly., and simplified synthetic process, could overcome limitations of the current cyclic RGD peptides, paving the way for diverse use in diagnosis and therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpqcHMImewU7Vg90H21EOLACvtfcHk0ljV6S4p0cUPCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtV2rt77I&md5=247b1d9e2663c1aacfb0b1f157231d4a</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.7150%2Fthno.18401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fthno.18401%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DY.%26aulast%3DAi%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DDong%26aufirst%3DX.%26aulast%3DHan%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DGu%26aufirst%3DY.%26atitle%3DNovel%2520Linear%2520Peptides%2520with%2520High%2520Affinity%2520to%2520Av%25CE%25B23%2520Integrin%2520for%2520Precise%2520Tumor%2520Identification%26jtitle%3DTheranostics%26date%3D2017%26volume%3D7%26spage%3D1511%26epage%3D1523%26doi%3D10.7150%2Fthno.18401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.</span></span> <span> </span><span class="NLM_article-title">Multifunctional Dendrimer-Entrapped Gold Nanoparticles Modified with RGD Peptide for Targeted Computed Tomography/Magnetic Resonance Dual-Modal Imaging of Tumors</span>. <i>Anal. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">3949</span>– <span class="NLM_lpage">3956</span>, <span class="refDoi"> DOI: 10.1021/acs.analchem.5b00135</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.analchem.5b00135" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2MXksVOktr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2015&pages=3949-3956&author=Q.+Chenauthor=H.+Wangauthor=H.+Liuauthor=S.+Wenauthor=C.+Pengauthor=M.+Shenauthor=G.+Zhangauthor=X.+Shi&title=Multifunctional+Dendrimer-Entrapped+Gold+Nanoparticles+Modified+with+RGD+Peptide+for+Targeted+Computed+Tomography%2FMagnetic+Resonance+Dual-Modal+Imaging+of+Tumors&doi=10.1021%2Facs.analchem.5b00135"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Multifunctional Dendrimer-Entrapped Gold Nanoparticles Modified with RGD Peptide for Targeted Computed Tomography/Magnetic Resonance Dual-Modal Imaging of Tumors</span></div><div class="casAuthors">Chen, Qian; Wang, Han; Liu, Hui; Wen, Shihui; Peng, Chen; Shen, Mingwu; Zhang, Guixiang; Shi, Xiangyang</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Chemistry (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3949-3956</span>CODEN:
                <span class="NLM_cas:coden">ANCHAM</span>;
        ISSN:<span class="NLM_cas:issn">0003-2700</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report the use of multifunctional dendrimer-entrapped gold nanoparticles (Au DENPs) loaded with gadolinium (Gd) chelator/Gd(III) complexes and surface-modified with thiolated cyclo(Arg-Gly-Asp-Phe-Lys(mpa)) (RGD) peptide for targeted dual-mode computed tomog. (CT)/magnetic resonance (MR) imaging of small tumors.  In this study, amine-terminated generation 5 poly(amidoamine) dendrimers were used as a nanoplatform to be covalently modified with Gd chelator, RGD via a polyethylene glycol (PEG) spacer, and PEG monomethyl ether.  Then the multifunctional dendrimers were used as templates to entrap gold nanoparticles, followed by chelating Gd(III) ions and acetylation of the remaining dendrimer terminal amines.  The thus-formed multifunctional Au DENPs (in short, Gd-Au DENPs-RGD) were characterized via different techniques.  We show that the multifunctional Au DENPs with a Au core size of 3.8 nm are water-dispersible, stable under different pH (5-8) and temp. conditions (4-50 °C), and noncytotoxic at a Au concn. up to 100 μM.  With the displayed X-ray attenuation property and the r1 relaxivity (2.643 mM-1s-1), the developed Gd-Au DENPs-RGD are able to be used as a dual-mode nanoprobe for targeted CT/MR imaging of an αvβ3 integrin-overexpressing xenografted small tumor model in vivo via RGD-mediated active targeting pathway.  The developed multifunctional Gd-Au DENPs-RGD may be used as a promising dual-mode nanoprobe for targeted CT/MR imaging of different types of αvβ3 integrin-overexpressing cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovu9WBepJIuLVg90H21EOLACvtfcHk0ljVEhUAay1xMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXksVOktr0%253D&md5=44ea751128488a605a6a1c45481cb021</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Facs.analchem.5b00135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.analchem.5b00135%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DWen%26aufirst%3DS.%26aulast%3DPeng%26aufirst%3DC.%26aulast%3DShen%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DShi%26aufirst%3DX.%26atitle%3DMultifunctional%2520Dendrimer-Entrapped%2520Gold%2520Nanoparticles%2520Modified%2520with%2520RGD%2520Peptide%2520for%2520Targeted%2520Computed%2520Tomography%252FMagnetic%2520Resonance%2520Dual-Modal%2520Imaging%2520of%2520Tumors%26jtitle%3DAnal.%2520Chem.%26date%3D2015%26volume%3D87%26spage%3D3949%26epage%3D3956%26doi%3D10.1021%2Facs.analchem.5b00135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauth, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X. Y.</span></span> <span> </span><span class="NLM_article-title">RGD-Conjugated Solid Lipid Nanoparticles Inhibit Adhesion and Invasion of Avβ3 Integrin-Overexpressing Breast Cancer Cells</span>. <i>Drug Delivery Transl. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1007/s13346-014-0210-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1007%2Fs13346-014-0210-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=25787336" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFSqurjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=15-26&author=D.+Shanauthor=J.+Liauthor=P.+Caiauthor=P.+Prasadauthor=F.+Liuauthor=A.+M.+Rauthauthor=X.+Y.+Wu&title=RGD-Conjugated+Solid+Lipid+Nanoparticles+Inhibit+Adhesion+and+Invasion+of+Av%CE%B23+Integrin-Overexpressing+Breast+Cancer+Cells&doi=10.1007%2Fs13346-014-0210-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">RGD-conjugated solid lipid nanoparticles inhibit adhesion and invasion of αvβ3 integrin-overexpressing breast cancer cells</span></div><div class="casAuthors">Shan, Dan; Li, Jason; Cai, Ping; Prasad, Preethy; Liu, Franky; Rauth, Andrew Michael; Wu, Xiao Yu</div><div class="citationInfo"><span class="NLM_cas:title">Drug Delivery and Translational Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-26</span>CODEN:
                <span class="NLM_cas:coden">DDTRCY</span>;
        ISSN:<span class="NLM_cas:issn">2190-3948</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">αvβ3 Integrin receptors expressed on cancer cell surfaces play a crucial role in promoting tumor angiogenesis and cancer cell metastasis.  Thus, cyclic arginyl-glycyl-aspartic acid (cRGD) peptides have been explored as a αvβ3 integrin receptor-specific targeting moiety for the targeted delivery of nanoparticle-loaded therapeutics.  However, our previous study showed that cyclic RGD could act as a double-edged sword that, on one hand, extended the retention of cRGD-modified solid lipid nanoparticles (RGD-SLNs) at αvβ3 integrin receptor overexpressing breast carcinoma, and yet on the other hand, decreased the amt. of tumor accumulation of RGD-SLNs attributable to the greater uptake by the mononuclear phagocyte system (MPS).  Therefore, we aimed to optimize the RGD-decorated nanoparticle systems for (1) inhibiting αvβ3 integrin receptor overexpressing tumor cell metastasis and (2) increasing nanoparticle accumulation to tumor site.  SLNs with cRGD content ranging from 0 to 10 % mol of total polyethyleneglycol (PEG) chains were synthesized.  The binding of RGD-SLNs with αvβ3 integrin receptors increased with increasing cRGD concn. on the nanoparticles.  RGD-SLNs were demonstrated to inhibit MDA-MB-231 cell adhesion to fibronectin and invasion through Matrigel.  In vivo whole-body fluorescence imaging revealed that 1 % cRGD on the SLNs' surface had max. tumor accumulation with extended tumor retention among all formulations tested in an orthotopic MDA-MB-231/EGFP breast tumor model.  This work has laid a foundation for further development of anticancer drug-loaded optimized cRGD nanoparticle formulations for the treatment of breast cancer metastasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsVjZUfCe6XLVg90H21EOLACvtfcHk0ljVEhUAay1xMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFSqurjP&md5=00ac02d020650fefd627f270f403c9ef</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1007%2Fs13346-014-0210-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13346-014-0210-2%26sid%3Dliteratum%253Aachs%26aulast%3DShan%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DCai%26aufirst%3DP.%26aulast%3DPrasad%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DRauth%26aufirst%3DA.%2BM.%26aulast%3DWu%26aufirst%3DX.%2BY.%26atitle%3DRGD-Conjugated%2520Solid%2520Lipid%2520Nanoparticles%2520Inhibit%2520Adhesion%2520and%2520Invasion%2520of%2520Av%25CE%25B23%2520Integrin-Overexpressing%2520Breast%2520Cancer%2520Cells%26jtitle%3DDrug%2520Delivery%2520Transl.%2520Res.%26date%3D2015%26volume%3D5%26spage%3D15%26epage%3D26%26doi%3D10.1007%2Fs13346-014-0210-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Graf, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielenberg, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolishetti, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muus, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banyard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farokhzad, O. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span> <span> </span><span class="NLM_article-title">Avβ3 Integrin-Targeted PLGA-PEG Nanoparticles for Enhanced Anti-Tumor Efficacy of aPt (IV) Prodrug</span>. <i>ACS Nano</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">4530</span>– <span class="NLM_lpage">4539</span>, <span class="refDoi"> DOI: 10.1021/nn301148e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/nn301148e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC38XmvFGhu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2012&pages=4530-4539&author=N.+Grafauthor=D.+R.+Bielenbergauthor=N.+Kolishettiauthor=C.+Muusauthor=J.+Banyardauthor=O.+C.+Farokhzadauthor=S.+J.+Lippard&title=Av%CE%B23+Integrin-Targeted+PLGA-PEG+Nanoparticles+for+Enhanced+Anti-Tumor+Efficacy+of+aPt+%28IV%29+Prodrug&doi=10.1021%2Fnn301148e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">αVβ3 Integrin-Targeted PLGA-PEG Nanoparticles for Enhanced Anti-tumor Efficacy of a Pt(IV) Prodrug</span></div><div class="casAuthors">Graf, Nora; Bielenberg, Diane R.; Kolishetti, Nagesh; Muus, Christoph; Banyard, Jacqueline; Farokhzad, Omid C.; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Nano</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">4530-4539</span>CODEN:
                <span class="NLM_cas:coden">ANCAC3</span>;
        ISSN:<span class="NLM_cas:issn">1936-0851</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Targeted delivery of therapeutics to tumor neovasculature is potentially a powerful approach for selective cancer treatment.  Integrins are heterodimeric transmembrane proteins involved in cell adhesion and cell signaling, and their expression is commonly upregulated in cancers and inflammatory diseases.  The αvβ3 integrin is differentially upregulated on angiogenic endothelial cells as well as on many cancer cells.  Here we demonstrate the differential targeting of cisplatin prodrug-encapsulated poly(D,L-lactic-co-glycolic acid)-block-polyethylene glycol (PLGA-PEG) nanoparticles (NPs) to the αvβ3 integrin on cancer cells using the cyclic pentapeptide c(RGDfK).  Cisplatin is one of the most widely used anticancer drugs, and approaches that can improve its therapeutic index are of broad importance.  The RGD-targeted Pt(IV)-encapsulated NPs displayed enhanced cytotoxicity as compared to cisplatin administered in its conventional dosage form in model prostate and breast cancer epithelial cells in vitro.  Cytotoxicities were also elevated in comparison to those of previously reported systems, a small mol. Pt(IV)-RGD conjugate and a Pt(IV) nanoscale coordination polymer carrying RGD moieties.  This result encouraged us also to evaluate the anticancer effect of the new construct in an animal model.  The RGD-targeted PLGA-PEG NPs were more efficacious and better tolerated by comparison to cisplatin in an orthotopic human breast cancer xenograft model in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMAV6ynbyup7Vg90H21EOLACvtfcHk0liPnBLAhV2nFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmvFGhu70%253D&md5=7650624390ad2befa90ce40577b2edcd</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fnn301148e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fnn301148e%26sid%3Dliteratum%253Aachs%26aulast%3DGraf%26aufirst%3DN.%26aulast%3DBielenberg%26aufirst%3DD.%2BR.%26aulast%3DKolishetti%26aufirst%3DN.%26aulast%3DMuus%26aufirst%3DC.%26aulast%3DBanyard%26aufirst%3DJ.%26aulast%3DFarokhzad%26aufirst%3DO.%2BC.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DAv%25CE%25B23%2520Integrin-Targeted%2520PLGA-PEG%2520Nanoparticles%2520for%2520Enhanced%2520Anti-Tumor%2520Efficacy%2520of%2520aPt%2520%2528IV%2529%2520Prodrug%26jtitle%3DACS%2520Nano%26date%3D2012%26volume%3D6%26spage%3D4530%26epage%3D4539%26doi%3D10.1021%2Fnn301148e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montet, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montet-Abou, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissleder, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josephson, L.</span></span> <span> </span><span class="NLM_article-title">Nanoparticle Imaging of Integrins on Tumor Cells</span>. <i>Neoplasia</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">214</span>– <span class="NLM_lpage">222</span>, <span class="refDoi"> DOI: 10.1593/neo.05769</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1593%2Fneo.05769" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=16611415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD28XovVKlurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2006&pages=214-222&author=X.+Montetauthor=K.+Montet-Abouauthor=F.+Reynoldsauthor=R.+Weisslederauthor=L.+Josephson&title=Nanoparticle+Imaging+of+Integrins+on+Tumor+Cells&doi=10.1593%2Fneo.05769"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Nanoparticle imaging of integrins on tumor cells</span></div><div class="casAuthors">Montet, Xavier; Montet-Abou, Karin; Reynolds, Fred; Weissleder, Ralph; Josephson, Lee</div><div class="citationInfo"><span class="NLM_cas:title">Neoplasia (Ann Arbor, MI, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">214-222</span>CODEN:
                <span class="NLM_cas:coden">NEOPFL</span>;
        ISSN:<span class="NLM_cas:issn">1522-8002</span>.
    
            (<span class="NLM_cas:orgname">Neoplasia Press Inc.</span>)
        </div><div class="casAbstract">Nanoparticles 10 to 100 nm in size can deliver large payloads to mol. targets, but undergo slow diffusion and/or slow transport through delivery barriers.  To examine the feasibility of nanoparticles targeting a marker expressed in tumor cells, we used the binding of cyclic arginine-glycine-aspartic acid (RGD) nanoparticle targeting integrins on BT-20 tumor as a model system.  The goals of this study were: (1) to use nanoparticles to image αvβ3 integrins expressed in BT-20 tumor cells by fluorescence-based imaging and magnetic resonance imaging, and, (2) to identify factors assocd. with the ability of nanoparticles to target tumor cell integrins.  Three factors were identified: (1) tumor cell integrin expression (the αvβ3 integrin was expressed in BT-20 cells, but not in 9L cells); (2) nanoparticle pharmacokinetics (the cyclic RGD peptide cross-linked iron oxide had a blood half-life of 180 min and was able to escape from the vasculature over its long circulation time); and (3) tumor vascularization the tumor had a dense capillary bed, with distances of <100 μm between capillaries.  These results suggest that nanoparticles could be targeted to the cell surface markers expressed in tumor cells, at least in the case wherein the nanoparticles and the tumor model have characteristics similar to those of the BT-20 tumor employed here.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryyuzlfn7Pn7Vg90H21EOLACvtfcHk0liPnBLAhV2nFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XovVKlurY%253D&md5=83f23d8309416bf17b6565213400e9f7</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1593%2Fneo.05769&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1593%252Fneo.05769%26sid%3Dliteratum%253Aachs%26aulast%3DMontet%26aufirst%3DX.%26aulast%3DMontet-Abou%26aufirst%3DK.%26aulast%3DReynolds%26aufirst%3DF.%26aulast%3DWeissleder%26aufirst%3DR.%26aulast%3DJosephson%26aufirst%3DL.%26atitle%3DNanoparticle%2520Imaging%2520of%2520Integrins%2520on%2520Tumor%2520Cells%26jtitle%3DNeoplasia%26date%3D2006%26volume%3D8%26spage%3D214%26epage%3D222%26doi%3D10.1593%2Fneo.05769" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haubner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beer, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vabuliene, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reim, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarbia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, K.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goebel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wester, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwaiger, M.</span></span> <span> </span><span class="NLM_article-title">Noninvasive Visualization of the Activated Avβ3 Integrin in Cancer Patients by Positron Emission Tomography and [18F] Galacto-RGD</span>. <i>PLoS Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">244</span>– <span class="NLM_lpage">252</span>, <span class="refDoi"> DOI: 10.1371/journal.pmed.0020070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1371%2Fjournal.pmed.0020070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFyhsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=244-252&author=R.+Haubnerauthor=W.+A.+Weberauthor=A.+J.+Beerauthor=E.+Vabulieneauthor=D.+Reimauthor=M.+Sarbiaauthor=K.-F.+Beckerauthor=M.+Goebelauthor=R.+Heinauthor=H.-J.+Westerauthor=H.+Kesslerauthor=M.+Schwaiger&title=Noninvasive+Visualization+of+the+Activated+Av%CE%B23+Integrin+in+Cancer+Patients+by+Positron+Emission+Tomography+and+%5B18F%5D+Galacto-RGD&doi=10.1371%2Fjournal.pmed.0020070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Noninvasive visualization of the activated αvβ3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD</span></div><div class="casAuthors">Haubner, Roland; Weber, Wolfgang A.; Beer, Ambros J.; Vabuliene, Eugenija; Reim, Daniel; Sarbia, Mario; Becker, Karl-Friedrich; Goebel, Michael; Hein, Ruediger; Wester, Hans-Juergen; Kessler, Horst; Schwaiger, Markus</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">244-252</span>CODEN:
                <span class="NLM_cas:coden">PMLEAC</span>;
        ISSN:<span class="NLM_cas:issn">1549-1277</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background The integrin αvβ3 plays an important role in angiogenesis and tumor cell metastasis, and is currently being evaluated as a target for new therapeutic approaches.  Several techniques are being studied to enable noninvasive detn. of αvβ3 expression.  We developed [18F]Galacto-RGD, a 18F-labeled glycosylated αvβ3 antagonist, allowing monitoring of αvβ3 expression with positron emission tomog. (PET).  Methods and Findings Here we show by quant. anal. of images resulting from a small-animal PET scanner that uptake of [18F]Galacto-RGD in the tumor correlates with αvβ3 expression subsequently detd. by Western blot analyses.  Moreover, using the A431 human squamous cell carcinoma model we demonstrate that this approach is sensitive enough to visualize αvβ3 expression resulting exclusively from the tumor vasculature.  Most important, this study shows, that [18F]Galacto-RGD with PET enables noninvasive quant. assessment of the αvβ3 expression pattern on tumor and endothelial cells in patients with malignant tumors.  Conclusions Mol. imaging with [18F]Galacto-RGD and PET can provide important information for planning and monitoring anti-angiogenic therapies targeting the αvβ3 integrins and can reveal the involvement and role of this integrin in metastatic and angiogenic processes in various diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUO_C1ztS9H7Vg90H21EOLACvtfcHk0liZd7dEOgh3CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFyhsLg%253D&md5=edef779afc8302d55bff67877e21ea17</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pmed.0020070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pmed.0020070%26sid%3Dliteratum%253Aachs%26aulast%3DHaubner%26aufirst%3DR.%26aulast%3DWeber%26aufirst%3DW.%2BA.%26aulast%3DBeer%26aufirst%3DA.%2BJ.%26aulast%3DVabuliene%26aufirst%3DE.%26aulast%3DReim%26aufirst%3DD.%26aulast%3DSarbia%26aufirst%3DM.%26aulast%3DBecker%26aufirst%3DK.-F.%26aulast%3DGoebel%26aufirst%3DM.%26aulast%3DHein%26aufirst%3DR.%26aulast%3DWester%26aufirst%3DH.-J.%26aulast%3DKessler%26aufirst%3DH.%26aulast%3DSchwaiger%26aufirst%3DM.%26atitle%3DNoninvasive%2520Visualization%2520of%2520the%2520Activated%2520Av%25CE%25B23%2520Integrin%2520in%2520Cancer%2520Patients%2520by%2520Positron%2520Emission%2520Tomography%2520and%2520%255B18F%255D%2520Galacto-RGD%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26spage%3D244%26epage%3D252%26doi%3D10.1371%2Fjournal.pmed.0020070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soroceanu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillespie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khazaeli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sontheimer, H.</span></span> <span> </span><span class="NLM_article-title">Use of Chlorotoxin for Targeting of Primary Brain Tumors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4871</span>– <span class="NLM_lpage">4879</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=9809993" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADyaK1cXnt1yis7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1998&pages=4871-4879&author=L.+Soroceanuauthor=Y.+Gillespieauthor=M.+Khazaeliauthor=H.+Sontheimer&title=Use+of+Chlorotoxin+for+Targeting+of+Primary+Brain+Tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Use of chlorotoxin for targeting of primary brain tumors</span></div><div class="casAuthors">Soroceanu, Liliana; Gillespie, Yancey; Khazaeli, M. B.; Sontheimer, Harald</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4871-4879</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">AACR Subscription Office</span>)
        </div><div class="casAbstract">Gliomas are primary brain tumors that arise from differentiated glial cells through a poorly understood malignant transformation.  Although glioma cells retain some genetic and antigenic features common to glial cells, they show a remarkable degree of antigenic heterogeneity and variable mutations in their genome.  Glioma cells have recently been shown to express a glioma-specific chloride ion channel (GCC) that is sensitive to chlorotoxin (CTX), a small peptide purified from Leiurus quinquestriatus scorpion venom.  Using native and recombinant 125I-labeled CTX, we show that toxin binding to glioma cells is specific and involves high affinity [dissocn. const. (Kd) = 4.2 nM] and low affinity (Kd = 660 nM) binding sites.  In radioreceptor assays, 125I-labeled CTX binds to a protein with Mr = 72,000, presumably GCC or a receptor that modulates GCC activity.  In vivo targeting and biodistribution expts. were obtained using 125I- and 131I-labeled CTX injected into severe combined immunodeficient mice bearing xenografted gliomas.  CTX selectively accumulated in the brain of tumor-bearing mice with calcd. brain: muscle ratios of 36.4% of injected dose/g (ID/g), as compared to 12.4% ID/g in control animals.  In the tumor-bearing severe combined immunodeficient mice, the vast majority of the brain-assocd. radioactivity was localized within the tumor (tumor:muscle ratio, 39.13% ID/g; contralateral brain:muscle ratio, 6.68% ID/g).  Moreover, 131I-labeled CTX distribution, visualized through in vivo imaging by gamma ray camera scans, demonstrates specific and persistent intratumoral localization of the radioactive ligand.  Immunohistochem. studies using biotinylated and fluorescently tagged CTX show highly selective staining of glioma cells in vitro, in situ, and in sections of patient biopsies.  Comparison tissues including normal human brain, kidney, and colon were consistently neg. for CTX immunostaining.  These data suggest that CTX and CTX-conjugated mols. may serve as glioma-specific markers with diagnostic and therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5ZrYqlVfEVrVg90H21EOLACvtfcHk0liZd7dEOgh3CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnt1yis7s%253D&md5=e7eba505cd6d39156fe9161a2543407d</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSoroceanu%26aufirst%3DL.%26aulast%3DGillespie%26aufirst%3DY.%26aulast%3DKhazaeli%26aufirst%3DM.%26aulast%3DSontheimer%26aufirst%3DH.%26atitle%3DUse%2520of%2520Chlorotoxin%2520for%2520Targeting%2520of%2520Primary%2520Brain%2520Tumors%26jtitle%3DCancer%2520Res.%26date%3D1998%26volume%3D58%26spage%3D4871%26epage%3D4879" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jon, S.</span></span> <span> </span><span class="NLM_article-title">Targeting Strategies for Multifunctional Nanoparticles in Cancer Imaging and Therapy</span>. <i>Theranostics</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.7150/thno.3463</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.7150%2Fthno.3463" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=22272217" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A280%3ADC%252BC387nt1Wnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=3-44&author=M.+K.+Yuauthor=J.+Parkauthor=S.+Jon&title=Targeting+Strategies+for+Multifunctional+Nanoparticles+in+Cancer+Imaging+and+Therapy&doi=10.7150%2Fthno.3463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy</span></div><div class="casAuthors">Yu Mi Kyung; Park Jinho; Jon Sangyong</div><div class="citationInfo"><span class="NLM_cas:title">Theranostics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-44</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Nanomaterials offer new opportunities for cancer diagnosis and treatment.  Multifunctional nanoparticles harboring various functions including targeting, imaging, therapy, and etc have been intensively studied aiming to overcome limitations associated with conventional cancer diagnosis and therapy.  Of various nanoparticles, magnetic iron oxide nanoparticles with superparamagnetic property have shown potential as multifunctional nanoparticles for clinical translation because they have been used asmagnetic resonance imaging (MRI) constrast agents in clinic and their features could be easily tailored by including targeting moieties, fluorescence dyes, or therapeutic agents.  This review summarizes targeting strategies for construction of multifunctional nanoparticles including magnetic nanoparticles-based theranostic systems, and the various surface engineering strategies of nanoparticles for in vivo applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTtHCiTxwHPpTToTC3aBaesfW6udTcc2eanANBJwzxZK7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC387nt1Wnsg%253D%253D&md5=d842af826431047f6cfd6be7b8d3054b</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.7150%2Fthno.3463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fthno.3463%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DM.%2BK.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DJon%26aufirst%3DS.%26atitle%3DTargeting%2520Strategies%2520for%2520Multifunctional%2520Nanoparticles%2520in%2520Cancer%2520Imaging%2520and%2520Therapy%26jtitle%3DTheranostics%26date%3D2012%26volume%3D2%26spage%3D3%26epage%3D44%26doi%3D10.7150%2Fthno.3463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sontheimer, H.</span></span> <span> </span><span class="NLM_article-title">Chlorotoxin, A Scorpion-Derived Peptide, Specifically Binds to Gliomas and Tumors of Neuroectodermal Origin</span>. <i>Glia</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">162</span>– <span class="NLM_lpage">173</span>, <span class="refDoi"> DOI: 10.1002/glia.10083</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1002%2Fglia.10083" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=12112367" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A280%3ADC%252BD38zms1KjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2002&pages=162-173&author=S.+A.+Lyonsauthor=J.+O%E2%80%99Nealauthor=H.+Sontheimer&title=Chlorotoxin%2C+A+Scorpion-Derived+Peptide%2C+Specifically+Binds+to+Gliomas+and+Tumors+of+Neuroectodermal+Origin&doi=10.1002%2Fglia.10083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Chlorotoxin, a scorpion-derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin</span></div><div class="casAuthors">Lyons Susan A; O'Neal Jeffrey; Sontheimer Harald</div><div class="citationInfo"><span class="NLM_cas:title">Glia</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">162-73</span>
        ISSN:<span class="NLM_cas:issn">0894-1491</span>.
    </div><div class="casAbstract">Highly migratory neuroectodermal cells share a common embryonic origin with cells of the central nervous system (CNS).  They include enteric, parasympathetic, sympathoadrenal, and sensory neurons of the peripheral nervous system, Schwann cells, melanocytes, endocrine cells, and cells forming connective tissue of the face and neck.  Because of their common embryologic origin, these cells and the tumors that derive from them can share genetic and antigenic phenotypes with gliomas, tumors derived from CNS glia.  We recently discovered that chlorotoxin (ClTx), a 4-kD peptide purified from Leiurus quinquestriatus scorpion, is a highly specific marker for glioma cells in biopsy tissues (Soroceanu et al.  Cancer Res 58:4871-4879, 1998) that can target tumors in animal models.  We report on the specificity of ClTx as a marker for tumors of neuroectodermal origin that include peripheral neuroectodermal tumors (PNET) and gliomas.  Specifically, we histochemically stained frozen and paraffin tissue sections of human biopsy tissues from 262 patients with a synthetically manufactured and biologically active ClTx bearing an N-terminal biotin.  The vast majority (74 of 79) of primary human brain tumors investigated showed abundant binding of ClTx with greater than 90% ClTx-positive cells in each section.  By comparison, 32 biopsies of uninvolved brain used for comparison were largely ClTx-negative, with only a few isolated reactive astrocytes showing some ClTx binding.  However, as with gliomas, the vast majority of PNETs examined showed specific ClTx binding (31 of 34).  These include medulloblastomas (4 of 4), neuroblastomas (6 of 7), ganglioneuromas (4 of 4), melanomas (7 of 7), adrenal pheochromocytomas (5 of 6), primitive PNET (1), small cell lung carcinoma (2 of 3), and Ewing's sarcoma (2 of 2).  Under identical staining conditions, normal tissues from brain, skin, kidney, and lung were consistently negative for ClTx.  These results suggest that chlorotoxin is a reliable and specific histopathological marker for tumors of neuroectodermal origin and that chlorotoxin derivatives with cytolytic activity may have therapeutic potential for these cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQTkuSPR0MIXvEeosoOnpOLfW6udTcc2eanANBJwzxZK7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38zms1KjtQ%253D%253D&md5=479e66a95551cf8f3cddffeaceba6c48</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1002%2Fglia.10083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fglia.10083%26sid%3Dliteratum%253Aachs%26aulast%3DLyons%26aufirst%3DS.%2BA.%26aulast%3DO%25E2%2580%2599Neal%26aufirst%3DJ.%26aulast%3DSontheimer%26aufirst%3DH.%26atitle%3DChlorotoxin%252C%2520A%2520Scorpion-Derived%2520Peptide%252C%2520Specifically%2520Binds%2520to%2520Gliomas%2520and%2520Tumors%2520of%2520Neuroectodermal%2520Origin%26jtitle%3DGlia%26date%3D2002%26volume%3D39%26spage%3D162%26epage%3D173%26doi%3D10.1002%2Fglia.10083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Veiseh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabikian, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahrami, S.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veiseh, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackman, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravanpay, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroud, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusuma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, S.</span></span> <span> </span><span class="NLM_article-title">Tumor Paint: A Chlorotoxin: Cy5.5 Bioconjugate for Intraoperative Visualization of Cancer Foci</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">6882</span>– <span class="NLM_lpage">6888</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-3948</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1158%2F0008-5472.CAN-06-3948" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=17638899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslOisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=6882-6888&author=M.+Veisehauthor=P.+Gabikianauthor=S.-B.+Bahramiauthor=O.+Veisehauthor=M.+Zhangauthor=R.+C.+Hackmanauthor=A.+C.+Ravanpayauthor=M.+R.+Stroudauthor=Y.+Kusumaauthor=S.+Hansen&title=Tumor+Paint%3A+A+Chlorotoxin%3A+Cy5.5+Bioconjugate+for+Intraoperative+Visualization+of+Cancer+Foci&doi=10.1158%2F0008-5472.CAN-06-3948"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor Paint: A Chlorotoxin:Cy5.5 Bioconjugate for Intraoperative Visualization of Cancer Foci</span></div><div class="casAuthors">Veiseh, Mandana; Gabikian, Patrik; Bahrami, S-Bahram; Veiseh, Omid; Zhang, Miqin; Hackman, Robert C.; Ravanpay, Ali C.; Stroud, Mark R.; Kusuma, Yumiko; Hansen, Stacey J.; Kwok, Deborah; Munoz, Nina M.; Sze, Raymond W.; Grady, William M.; Greenberg, Norman M.; Ellenbogen, Richard G.; Olson, James M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6882-6888</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Toward the goal of developing an optical imaging contrast agent that will enable surgeons to intraoperatively distinguish cancer foci from adjacent normal tissue, we developed a chlorotoxin:Cy5.5 (CTX:Cy5.5) bioconjugate that emits near-IR fluorescent signal.  The probe delineates malignant glioma, medulloblastoma, prostate cancer, intestinal cancer, and sarcoma from adjacent non-neoplastic tissue in mouse models.  Metastatic cancer foci as small as a few hundred cells were detected in lymph channels.  Specific binding to cancer cells is facilitated by matrix metalloproteinase-2 (MMP-2) as evidenced by redn. of CTX:Cy5.5 binding in vitro and in vivo by a pharmacol. blocker of MMP-2 and induction of CTX:Cy5.5 binding in MCF-7 cells following transfection with a plasmid encoding MMP-2.  Mouse studies revealed that CTX:Cy5.5 has favorable biodistribution and toxicity profiles.  These studies show that CTX:Cy5.5 has the potential to fundamentally improve intraoperative detection and resection of malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo04sI0a6cQdLVg90H21EOLACvtfcHk0liKVvzHhu7BWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslOisb8%253D&md5=9f9bbe1bf8df8b3ef12fa79df5e671e0</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-3948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-3948%26sid%3Dliteratum%253Aachs%26aulast%3DVeiseh%26aufirst%3DM.%26aulast%3DGabikian%26aufirst%3DP.%26aulast%3DBahrami%26aufirst%3DS.-B.%26aulast%3DVeiseh%26aufirst%3DO.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DHackman%26aufirst%3DR.%2BC.%26aulast%3DRavanpay%26aufirst%3DA.%2BC.%26aulast%3DStroud%26aufirst%3DM.%2BR.%26aulast%3DKusuma%26aufirst%3DY.%26aulast%3DHansen%26aufirst%3DS.%26atitle%3DTumor%2520Paint%253A%2520A%2520Chlorotoxin%253A%2520Cy5.5%2520Bioconjugate%2520for%2520Intraoperative%2520Visualization%2520of%2520Cancer%2520Foci%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D6882%26epage%3D6888%26doi%3D10.1158%2F0008-5472.CAN-06-3948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">Necroptotic Cancer Cells-Mimicry Nanovaccine Boosts Anti-Tumor Immunity with Tailored Immune-Stimulatory Modality</span>. <i>Biomaterials</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>164</i></span>,  <span class="NLM_fpage">80</span>– <span class="NLM_lpage">97</span>, <span class="refDoi"> DOI: 10.1016/j.biomaterials.2018.02.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.biomaterials.2018.02.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=29499438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjsVGnsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2018&pages=80-97&author=T.+Kangauthor=Y.+Huangauthor=Q.+Zhuauthor=H.+Chengauthor=Y.+Peiauthor=J.+Fengauthor=M.+Xuauthor=G.+Jiangauthor=Q.+Songauthor=T.+Jiangauthor=H.+Chenauthor=X.+Gaoauthor=J.+Chen&title=Necroptotic+Cancer+Cells-Mimicry+Nanovaccine+Boosts+Anti-Tumor+Immunity+with+Tailored+Immune-Stimulatory+Modality&doi=10.1016%2Fj.biomaterials.2018.02.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Necroptotic cancer cells-mimicry nanovaccine boosts anti-tumor immunity with tailored immune-stimulatory modality</span></div><div class="casAuthors">Kang, Ting; Huang, Yukun; Zhu, Qianqian; Cheng, Hao; Pei, Yuanyuan; Feng, Jingxian; Xu, Minjun; Jiang, Gan; Song, Qingxiang; Jiang, Tianze; Chen, Hongzhuan; Gao, Xiaoling; Chen, Jun</div><div class="citationInfo"><span class="NLM_cas:title">Biomaterials</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">80-97</span>CODEN:
                <span class="NLM_cas:coden">BIMADU</span>;
        ISSN:<span class="NLM_cas:issn">0142-9612</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Recent breakthroughs in cancer immunotherapy offer new paradigm-shifting therapeutic options for combating cancer.  Personalized therapeutic anti-cancer vaccines training T cells to directly fight against tumor cells endogenously offer tremendous benefits in working synergistically with immune checkpoint inhibitors.  Biomimetic nanotechnol. offers a versatile platform to boost anticancer immunity by efficiently co-delivering optimized immunogenic antigen materials and adjuvants to antigen presenting cells (APC).  Necroptotic tumor cells can release danger assocd. mol. patterns (DAMPs) like heat shock proteins, being more immunogenic than naive tumor cells.  Here, nano-size "artificial necroptotic cancer cell" (αHSP70p-CM-CaP) composing of phospholipid bilayer and a phosphate calcium core was designed as a flexible vaccine platform for co-delivering cancer membrane proteins (CM), DAMPs signal-augmenting element α-helix HSP70 functional peptide (αHSP70p) and CpG to both natural killer (NK) cells and APC.  Mech., immunogenic B16OVA tumor cells membrane-assocd. antigens and αHSP70p were reconstituted in artificial outer phospholipid bilayer membrane via one-step hydration and CpG encapsulated in the phosphate calcium core.  The resulted αHSP70p-CM-CaP exhibited 30 nm in diam. with the immunogenic membrane proteins reserved in the particles to produce synergistic effect on bone marrow derived dendritic cells maturation and antigen-presentation.  Following αHSP70p-CM-CaP vaccination, efficient lymph node trafficking and multi-epitope-T cells response was obsd. in mice.  Vitally, αHSP70p-CM-CaP was also able to induce expansion of IFN-γ-expressing CD8+ T cells and NKG2D+ NK cells subsets.  Most promisingly, αHSP70p-CM-CaP vaccination led to the killing of target cells and tumor regression in vivo when combined with anti-PD-1 antibody treatment on mice B16OVA melanoma models.  Altogether, we demonstrated proof-of-concept evidence for the feasibility, capability and safety of a nanovaccine platform towards efficient personalized anticancer application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpArZnnpxP1xLVg90H21EOLACvtfcHk0liKVvzHhu7BWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjsVGnsbc%253D&md5=bca7d0b132925bbef99ef63fa7f52010</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.biomaterials.2018.02.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biomaterials.2018.02.033%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DQ.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DPei%26aufirst%3DY.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DJiang%26aufirst%3DG.%26aulast%3DSong%26aufirst%3DQ.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DNecroptotic%2520Cancer%2520Cells-Mimicry%2520Nanovaccine%2520Boosts%2520Anti-Tumor%2520Immunity%2520with%2520Tailored%2520Immune-Stimulatory%2520Modality%26jtitle%3DBiomaterials%26date%3D2018%26volume%3D164%26spage%3D80%26epage%3D97%26doi%3D10.1016%2Fj.biomaterials.2018.02.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mok, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veiseh, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kievit, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span> <span> </span><span class="NLM_article-title">pH-Sensitive siRNA Nanovector for Targeted Gene Silencing and Cytotoxic Effect in Cancer Cells</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1930</span>– <span class="NLM_lpage">1939</span>, <span class="refDoi"> DOI: 10.1021/mp100221h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp100221h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFGrtbbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=1930-1939&author=H.+Mokauthor=O.+Veisehauthor=C.+Fangauthor=F.+M.+Kievitauthor=F.+Y.+Wangauthor=J.+O.+Parkauthor=M.+Zhang&title=pH-Sensitive+siRNA+Nanovector+for+Targeted+Gene+Silencing+and+Cytotoxic+Effect+in+Cancer+Cells&doi=10.1021%2Fmp100221h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">pH-Sensitive siRNA Nanovector for Targeted Gene Silencing and Cytotoxic Effect in Cancer Cells</span></div><div class="casAuthors">Mok, Hyejung; Veiseh, Omid; Fang, Chen; Kievit, Forrest M.; Wang, Freddy Y.; Park, James O.; Zhang, Miqin</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1930-1939</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A small interfering RNA (siRNA) nanovector with dual targeting specificity and dual therapeutic effect is developed for targeted cancer imaging and therapy.  The nanovector is composed of an iron oxide magnetic nanoparticle core coated with three different functional mols.: polyethyleneimine (PEI), siRNA, and chlorotoxin (CTX).  The primary amine group of PEI is blocked with citraconic anhydride that is removable at acidic conditions, not only to increase its biocompatibility at physiol. conditions but also to elicit a pH-sensitive cytotoxic effect in the acidic tumor microenvironment.  The PEI is covalently immobilized on the nanovector via a disulfide linkage that is cleavable after cellular internalization of the nanovector.  CTX as a tumor-specific targeting ligand and siRNA as a therapeutic payload are conjugated on the nanovector via a flexible and hydrophilic PEG linker for targeted gene silencing in cancer cells.  With a size of ∼60 nm, the nanovector exhibits long-term stability and good magnetic property for magnetic resonance imaging.  The multifunctional nanovector exhibits both significant cytotoxic and gene silencing effects at acidic pH conditions for C6 glioma cells, but not at physiol. pH conditions.  Our results suggest that this nanovector system could be safely used as a potential therapeutic agent for targeted treatment of glioma as well as other cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpit6qK7PZ_HbVg90H21EOLACvtfcHk0lifnHa5quhpmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFGrtbbI&md5=b89b0fbf2a9dc796621ee7ab76b90104</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1021%2Fmp100221h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp100221h%26sid%3Dliteratum%253Aachs%26aulast%3DMok%26aufirst%3DH.%26aulast%3DVeiseh%26aufirst%3DO.%26aulast%3DFang%26aufirst%3DC.%26aulast%3DKievit%26aufirst%3DF.%2BM.%26aulast%3DWang%26aufirst%3DF.%2BY.%26aulast%3DPark%26aufirst%3DJ.%2BO.%26aulast%3DZhang%26aufirst%3DM.%26atitle%3DpH-Sensitive%2520siRNA%2520Nanovector%2520for%2520Targeted%2520Gene%2520Silencing%2520and%2520Cytotoxic%2520Effect%2520in%2520Cancer%2520Cells%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2010%26volume%3D7%26spage%3D1930%26epage%3D1939%26doi%3D10.1021%2Fmp100221h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Veiseh, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kievit, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunn, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratner, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span> <span> </span><span class="NLM_article-title">Ligand-Mediated Nanovector for Targeted Gene Delivery and Transfection in Cancer Cells</span>. <i>Biomaterials</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">649</span>– <span class="NLM_lpage">657</span>, <span class="refDoi"> DOI: 10.1016/j.biomaterials.2008.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.biomaterials.2008.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=18990439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A280%3ADC%252BD1cjnt1Chsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=649-657&author=O.+Veisehauthor=F.+M.+Kievitauthor=J.+W.+Gunnauthor=B.+D.+Ratnerauthor=M.+Zhang&title=Ligand-Mediated+Nanovector+for+Targeted+Gene+Delivery+and+Transfection+in+Cancer+Cells&doi=10.1016%2Fj.biomaterials.2008.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">A ligand-mediated nanovector for targeted gene delivery and transfection in cancer cells</span></div><div class="casAuthors">Veiseh Omid; Kievit Forrest M; Gunn Jonathan W; Ratner Buddy D; Zhang Miqin</div><div class="citationInfo"><span class="NLM_cas:title">Biomaterials</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">649-57</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">As conventional cancer therapies struggle with toxicity issues and irregular remedial efficacy, the preparation of novel gene therapy vectors could offer clinicians the tools for addressing the genetic errors of diseased tissue.  The transfer of gene therapy to the clinic has proven difficult due to safety, target specificity, and transfection efficiency concerns.  Polyethylenimine (PEI) nanoparticles have been identified as promising gene carriers that induce gene transfection with high efficiency.  However, the inherent toxicity of the material and non-selective delivery are the major concerns in applying these particles clinically.  Here, a non-viral nanovector has been developed by PEGylation of DNA-complexing PEI in nanoparticles functionalized with an Alexa Fluor 647 near infrared fluorophore, and the chlorotoxin (CTX) peptide which binds specifically to many forms of cancer.  With this nanovector, the potential toxicity to healthy cells is minimized by both the reduction of the toxicity of PEI with the biocompatible copolymer and the targeted delivery of the nanovector to cancer cells, as evaluated by viability studies.  The nanovector demonstrated high levels of targeting specificity and gene transfection efficiency with both C6 glioma and DAOY medulloblastoma tumor cells.  Significantly, with the CTX as the targeting ligand, the nanovector may serve as a widely applicable gene delivery system for a broad array of cancer types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSRn5vRovxvJ-b6AVA-44PTfW6udTcc2eai9OWQ_Fy6vbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cjnt1Chsg%253D%253D&md5=70fac702d68745ab4bffee9cc35fea6a</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.biomaterials.2008.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biomaterials.2008.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DVeiseh%26aufirst%3DO.%26aulast%3DKievit%26aufirst%3DF.%2BM.%26aulast%3DGunn%26aufirst%3DJ.%2BW.%26aulast%3DRatner%26aufirst%3DB.%2BD.%26aulast%3DZhang%26aufirst%3DM.%26atitle%3DLigand-Mediated%2520Nanovector%2520for%2520Targeted%2520Gene%2520Delivery%2520and%2520Transfection%2520in%2520Cancer%2520Cells%26jtitle%3DBiomaterials%26date%3D2009%26volume%3D30%26spage%3D649%26epage%3D657%26doi%3D10.1016%2Fj.biomaterials.2008.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bharti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dey, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dey, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parida, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pal, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukherjee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pradhan, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emdad, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandal, M.</span></span> <span> </span><span class="NLM_article-title">Somatostatin Receptor Targeted Liposomes with Diacerein Inhibit IL-6 for Breast Cancer Therapy</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>388</i></span>,  <span class="NLM_fpage">292</span>– <span class="NLM_lpage">302</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2016.12.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.canlet.2016.12.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=28025102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFKru77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=388&publication_year=2017&pages=292-302&author=R.+Bhartiauthor=G.+Deyauthor=I.+Banerjeeauthor=K.+K.+Deyauthor=S.+Paridaauthor=P.+B.+Kumarauthor=C.+K.+Dasauthor=I.+Palauthor=M.+Mukherjeeauthor=M.+Misraauthor=A.+J.+Pradhanauthor=L.+Emdadauthor=S.+K.+Dasauthor=P.+B.+Fisherauthor=M.+Mandal&title=Somatostatin+Receptor+Targeted+Liposomes+with+Diacerein+Inhibit+IL-6+for+Breast+Cancer+Therapy&doi=10.1016%2Fj.canlet.2016.12.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Somatostatin receptor targeted liposomes with Diacerein inhibit IL-6 for breast cancer therapy</span></div><div class="casAuthors">Bharti, Rashmi; Dey, Goutam; Banerjee, Indranil; Dey, Kaushik Kumar; Parida, Sheetal; Kumar, B. N. Prashanth; Das, Chandan Kanta; Pal, Ipsita; Mukherjee, Manabendra; Misra, Mridula; Pradhan, Anjan K.; Emdad, Luni; Das, Swadesh K.; Fisher, Paul B.; Mandal, Mahitosh</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">388</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">292-302</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Selective targeting to the tumor niche remains a major challenge in successful cancer therapy.  Somatostatin receptor 2 (SSTR2) is overexpressed in breast cancer cells thus making this receptor an attractive target for selective guidance of ligand-conjugated drug liposomes to the tumor site.  In this study, a synthetic somatostatin analog (SST) was used as SSTR2 targeting agent and Diacerein was employed as therapeutic mol.  Diacerein loaded liposomes (DNL) were prepd. and they were further decorated with the synthetic and stable analog of somatostatin (SST-DNL).  Fabricated liposomes were nano-size in range and biocompatible.  SST-DNL displayed significantly better anti-tumor efficacy as compared to free Diacerein (DN) and DNL in breast cancer models.  Enhanced apoptosis in breast cancer cells was detected in SST-DNL treated groups as monitored by cell cycle anal. and changes in expression level of apoptotic/anti-apoptotic proteins Bcl-2, Bax, cleaved Caspase 3 and PARP.  SST-DNL more effectively inhibited the oncogenic IL-6/IL-6R/STAT3/MAPK/Akt signalling pathways as compared to DN or DNL in cancer cells.  In addn., SST-DNL effectively suppressed angiogenesis and cancer cell invasion.  In vivo tumor growth in a MDA-MB-231 mouse xenograft model was significantly suppressed following SST-DNL treatment.  In xenograft model, immunohistochem. of Ki-67 and CD-31 indicated that SST-DNL improved the anti-proliferative and anti-angiogenic impacts of Diacerein.  In vivo pharmacokinetic studies in rats showed enhanced circulation time in the DNL or SST-DNL treated groups as compared to free DN.  Considering all of these findings, we conclude that SST-DNL provides a novel strategy with better efficacy for breast cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxN_W9iylZ6rVg90H21EOLACvtfcHk0lhtyzNT4uZqbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFKru77J&md5=ca6703ff79681e6ce8d56a43258c6129</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2016.12.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2016.12.021%26sid%3Dliteratum%253Aachs%26aulast%3DBharti%26aufirst%3DR.%26aulast%3DDey%26aufirst%3DG.%26aulast%3DBanerjee%26aufirst%3DI.%26aulast%3DDey%26aufirst%3DK.%2BK.%26aulast%3DParida%26aufirst%3DS.%26aulast%3DKumar%26aufirst%3DP.%2BB.%26aulast%3DDas%26aufirst%3DC.%2BK.%26aulast%3DPal%26aufirst%3DI.%26aulast%3DMukherjee%26aufirst%3DM.%26aulast%3DMisra%26aufirst%3DM.%26aulast%3DPradhan%26aufirst%3DA.%2BJ.%26aulast%3DEmdad%26aufirst%3DL.%26aulast%3DDas%26aufirst%3DS.%2BK.%26aulast%3DFisher%26aufirst%3DP.%2BB.%26aulast%3DMandal%26aufirst%3DM.%26atitle%3DSomatostatin%2520Receptor%2520Targeted%2520Liposomes%2520with%2520Diacerein%2520Inhibit%2520IL-6%2520for%2520Breast%2520Cancer%2520Therapy%26jtitle%3DCancer%2520Lett.%26date%3D2017%26volume%3D388%26spage%3D292%26epage%3D302%26doi%3D10.1016%2Fj.canlet.2016.12.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veiseh, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellenbogen, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span> <span> </span><span class="NLM_article-title">Tumor-Targeted Drug Delivery and MRI Contrast Enhancement by Chlorotoxin-Conjugated Iron Oxide Nanoparticles</span>. <i>Nanomedicine</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">495</span>– <span class="NLM_lpage">505</span>, <span class="refDoi"> DOI: 10.2217/17435889.3.4.495</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.2217%2F17435889.3.4.495" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=18694312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVWnsL7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=495-505&author=C.+Sunauthor=C.+Fangauthor=Z.+Stephenauthor=O.+Veisehauthor=S.+Hansenauthor=D.+Leeauthor=R.+G.+Ellenbogenauthor=J.+Olsonauthor=M.+Zhang&title=Tumor-Targeted+Drug+Delivery+and+MRI+Contrast+Enhancement+by+Chlorotoxin-Conjugated+Iron+Oxide+Nanoparticles&doi=10.2217%2F17435889.3.4.495"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor-targeted drug delivery and MRI contrast enhancement by chlorotoxin-conjugated iron oxide nanoparticles</span></div><div class="casAuthors">Sun, Conroy; Fang, Chen; Stephen, Zachary; Veiseh, Omid; Hansen, Stacey; Lee, Donghoon; Ellenbogen, Richard G.; Olson, Jim; Zhang, Miqin</div><div class="citationInfo"><span class="NLM_cas:title">Nanomedicine (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">495-505</span>CODEN:
                <span class="NLM_cas:coden">NLUKAC</span>;
        ISSN:<span class="NLM_cas:issn">1743-5889</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">This study examines the capabilities of an actively targeting superparamagnetic nanoparticle to specifically deliver therapeutic and MRI contrast agents to cancer cells.  Iron oxide nanoparticles were synthesized and conjugated to both a chemotherapeutic agent, methotrexate, and a targeting ligand, chlorotoxin, through a poly(ethylene glycol) linker.  Cytotoxicity of this nanoparticle conjugate was evaluated by Alamar Blue cell viability assays, while tumor-cell specificity was examd. in vitro and in vivo by MRI.  Characterization of these multifunctional nanoparticles confirms the successful attachment of both drug and targeting ligands.  The targeting nanoparticle demonstrated preferential accumulation and increased cytotoxicity in tumor cells.  Furthermore, prolonged retention of these nanoparticles was obsd. within tumors in vivo.  The improved specificity, extended particle retention and increased cytotoxicity toward tumor cells demonstrated by this multifunctional nanoparticle system suggest that it possesses potential for applications in cancer diagnosis and treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH3qeR-YOfPrVg90H21EOLACvtfcHk0ljgiCqiMYp13w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVWnsL7K&md5=1778124206b94c18414389dcb6b23879</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.2217%2F17435889.3.4.495&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252F17435889.3.4.495%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DC.%26aulast%3DFang%26aufirst%3DC.%26aulast%3DStephen%26aufirst%3DZ.%26aulast%3DVeiseh%26aufirst%3DO.%26aulast%3DHansen%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DD.%26aulast%3DEllenbogen%26aufirst%3DR.%2BG.%26aulast%3DOlson%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DM.%26atitle%3DTumor-Targeted%2520Drug%2520Delivery%2520and%2520MRI%2520Contrast%2520Enhancement%2520by%2520Chlorotoxin-Conjugated%2520Iron%2520Oxide%2520Nanoparticles%26jtitle%3DNanomedicine%26date%3D2008%26volume%3D3%26spage%3D495%26epage%3D505%26doi%3D10.2217%2F17435889.3.4.495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Veiseh, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunn, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kievit, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Tumor-Cell Invasion with Chlorotoxin-Bound Superparamagnetic Nanoparticles</span>. <i>Small</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">256</span>– <span class="NLM_lpage">264</span>, <span class="refDoi"> DOI: 10.1002/smll.200800646</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1002%2Fsmll.200800646" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=19089837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvVWlsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=256-264&author=O.+Veisehauthor=J.+W.+Gunnauthor=F.+M.+Kievitauthor=C.+Sunauthor=C.+Fangauthor=J.+S.+Leeauthor=M.+Zhang&title=Inhibition+of+Tumor-Cell+Invasion+with+Chlorotoxin-Bound+Superparamagnetic+Nanoparticles&doi=10.1002%2Fsmll.200800646"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of tumor-cell invasion with chlorotoxin-bound superparamagnetic nanoparticles</span></div><div class="casAuthors">Veiseh, Omid; Gunn, Jonathan W.; Kievit, Forrest M.; Sun, Conroy; Fang, Chen; Lee, Jerry S. H.; Zhang, Miqin</div><div class="citationInfo"><span class="NLM_cas:title">Small</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">256-264</span>CODEN:
                <span class="NLM_cas:coden">SMALBC</span>;
        ISSN:<span class="NLM_cas:issn">1613-6810</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Nanoparticles have been investigated as drug delivery vehicles, contrast agents, and multifunctional devices for patient care.  Current nanoparticle-based therapeutic strategies for cancer treatment are mainly based on delivery of chemotherapeutic agents to induce apoptosis or DNA/siRNA to regulate oncogene expression.  Here, a nanoparticle system that demonstrates an alternative approach to the treatment of cancers through the inhibition of cell invasion, while serving as a magnetic resonance and optical imaging contrast agent, is presented.  The nanoparticle comprises an iron oxide nanoparticle core conjugated with an amine-functionalized poly (ethylene glycol) silane and a small peptide, chlorotoxin (CTX), which enables the tumor cell-specific binding of the nanoparticle.  It is shown that the nanoparticle exhibits substantially enhanced cellular uptake and an invasion inhibition rate of ∼98% compared to unbound CTX (∼45%).  Significantly, the investigation from flow cytometry anal., transmission electron microscopy, and fluorescent imaging reveals that the CTX-enabled nanoparticles deactivated the membrane-bound matrix metalloproteinase 2 (MMP-2) and induced increased internalization of lipid rafts that contain surface-expressed MMP-2 and vol.-regulating ion channels through receptor-mediated endocytosis, leading to enhanced prohibitory effects.  Since upregulation and activity of MMP-2 have been obsd. in tumors of neuroectodermal origin, and in cancers of the breast, colon, skin, lung, prostate, ovaries, and a host of others, this nanoparticle system can be potentially used for non-invasive diagnosis and treatment of a variety of cancer types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowRagWbq7a9LVg90H21EOLACvtfcHk0lhKDmAYm4XdpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvVWlsLo%253D&md5=d4886bab53a03e00ffb5688edfb175ee</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1002%2Fsmll.200800646&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fsmll.200800646%26sid%3Dliteratum%253Aachs%26aulast%3DVeiseh%26aufirst%3DO.%26aulast%3DGunn%26aufirst%3DJ.%2BW.%26aulast%3DKievit%26aufirst%3DF.%2BM.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DFang%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DZhang%26aufirst%3DM.%26atitle%3DInhibition%2520of%2520Tumor-Cell%2520Invasion%2520with%2520Chlorotoxin-Bound%2520Superparamagnetic%2520Nanoparticles%26jtitle%3DSmall%26date%3D2009%26volume%3D5%26spage%3D256%26epage%3D264%26doi%3D10.1002%2Fsmll.200800646" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veiseh, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kievit, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattarai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellenbogen, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span> <span> </span><span class="NLM_article-title">Functionalization of Iron Oxide Magnetic Nanoparticles with Targeting Ligands: Their Physicochemical Properties and In-Vivo Behavior</span>. <i>Nanomedicine</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1357</span>– <span class="NLM_lpage">1369</span>, <span class="refDoi"> DOI: 10.2217/nnm.10.55</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.2217%2Fnnm.10.55" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=21128719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFWjs7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=1357-1369&author=C.+Fangauthor=O.+Veisehauthor=F.+Kievitauthor=N.+Bhattaraiauthor=F.+Wangauthor=Z.+Stephenauthor=C.+Liauthor=D.+Leeauthor=R.+G.+Ellenbogenauthor=M.+Zhang&title=Functionalization+of+Iron+Oxide+Magnetic+Nanoparticles+with+Targeting+Ligands%3A+Their+Physicochemical+Properties+and+In-Vivo+Behavior&doi=10.2217%2Fnnm.10.55"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Functionalization of iron oxide magnetic nanoparticles with targeting ligands: their physicochemical properties and in vivo behavior</span></div><div class="casAuthors">Fang, Chen; Veiseh, Omid; Kievit, Forrest; Bhattarai, Narayan; Wang, Freddy; Stephen, Zach; Li, Chun; Lee, Donghoon; Ellenbogen, Richard G.; Zhang, Miqin</div><div class="citationInfo"><span class="NLM_cas:title">Nanomedicine (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1357-1369</span>CODEN:
                <span class="NLM_cas:coden">NLUKAC</span>;
        ISSN:<span class="NLM_cas:issn">1743-5889</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">Aim: To develop and evaluate two tumor-specific nanoprobes by functionalization of a polyethylene glycol-immobilized nanoparticle with arginine-glycine-aspartic acid (RGD) or chlorotoxin ligand that targets αvβ3 integrin and matrix metalloproteinase-2 receptors, resp.  Materials & methods: The nanoprobes were made of iron oxide cores, biocompatible polymer coating, and surface-conjugated RGD or chlorotoxin peptide.  The tumor-targeting specificity of the nanoprobes was evaluated both in vitro and in vivo.  Results & discussion: Both nanoprobes were highly dispersive and exhibited excellent long-term stability in cell culture media.  The RGD-conjugated nanoprobe displayed a strong initial accumulation near neovasculatures in tumors followed by quick clearance.  Conversely, the chlorotoxin-enabled nanoprobe exhibited sustained accumulation throughout the tumor.  Conclusion: These findings revealed the influence of the targeting ligands on the intratumoral distribution of the ligand-enabled nanoprobes.  With flexible surface chem., our nanoparticle platform can be used in a modular fashion to conjugate biomols. for intended applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAev-QcazH7rVg90H21EOLACvtfcHk0lhKDmAYm4XdpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFWjs7vO&md5=d307d69e73d4894dfaae16ed52a56c06</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.2217%2Fnnm.10.55&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fnnm.10.55%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DC.%26aulast%3DVeiseh%26aufirst%3DO.%26aulast%3DKievit%26aufirst%3DF.%26aulast%3DBhattarai%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DStephen%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DD.%26aulast%3DEllenbogen%26aufirst%3DR.%2BG.%26aulast%3DZhang%26aufirst%3DM.%26atitle%3DFunctionalization%2520of%2520Iron%2520Oxide%2520Magnetic%2520Nanoparticles%2520with%2520Targeting%2520Ligands%253A%2520Their%2520Physicochemical%2520Properties%2520and%2520In-Vivo%2520Behavior%26jtitle%3DNanomedicine%26date%3D2010%26volume%3D5%26spage%3D1357%26epage%3D1369%26doi%3D10.2217%2Fnnm.10.55" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, M.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephen, Z. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span> <span> </span><span class="NLM_article-title">Hexanoyl-Chitosan-PEG Copolymer Coated Iron Oxide Nanoparticles for Hydrophobic Drug Delivery</span>. <i>ACS Macro Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">403</span>– <span class="NLM_lpage">407</span>, <span class="refDoi"> DOI: 10.1021/acsmacrolett.5b00091</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmacrolett.5b00091" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltFSlsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=403-407&author=M.-H.+Hsiaoauthor=Q.+Muauthor=Z.+R.+Stephenauthor=C.+Fangauthor=M.+Zhang&title=Hexanoyl-Chitosan-PEG+Copolymer+Coated+Iron+Oxide+Nanoparticles+for+Hydrophobic+Drug+Delivery&doi=10.1021%2Facsmacrolett.5b00091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Hexanoyl-chitosan-PEG copolymer coated iron oxide nanoparticles for hydrophobic drug delivery</span></div><div class="casAuthors">Hsiao, Meng-Hsuan; Mu, Qingxin; Stephen, Zachary R.; Fang, Chen; Zhang, Miqin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Macro Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">403-407</span>CODEN:
                <span class="NLM_cas:coden">AMLCCD</span>;
        ISSN:<span class="NLM_cas:issn">2161-1653</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nanoparticle (NP) formulations may be used to improve in vivo efficacy of hydrophobic drugs by circumventing soly. issues and providing targeted delivery.  In this study, we developed a hexanoyl-chitosan-PEG (CP6C) copolymer coated, paclitaxel (PTX)-loaded, and chlorotoxin (CTX) conjugated iron oxide NP (CTX-PTX-NP) for targeted delivery of PTX to human glioblastoma (GBM) cells.  We modified chitosan with polyethylene glycol (PEG) and hexanoyl groups to obtain the amphiphilic CP6C.  The resultant copolymer was then coated onto oleic acid-stabilized iron oxide NPs (OA-IONP) via hydrophobic interactions.  PTX, a model hydrophobic drug, was loaded into the hydrophobic region of IONPs.  CTX-PTX-NP showed high drug loading efficiency (>30%), slow drug release in PBS and the CTX-conjugated NP was shown to successfully target GBM cells.  Importantly, the NPs showed great therapeutic efficacy when evaluated in GBM cell line U-118 MG.  Our results indicate that this nanoparticle platform could be used for loading and targeted delivery of hydrophobic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx9qKeUyVy57Vg90H21EOLACvtfcHk0lhKDmAYm4XdpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltFSlsrw%253D&md5=11356590e2fbb0ffb3d487abededbb55</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1021%2Facsmacrolett.5b00091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmacrolett.5b00091%26sid%3Dliteratum%253Aachs%26aulast%3DHsiao%26aufirst%3DM.-H.%26aulast%3DMu%26aufirst%3DQ.%26aulast%3DStephen%26aufirst%3DZ.%2BR.%26aulast%3DFang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DM.%26atitle%3DHexanoyl-Chitosan-PEG%2520Copolymer%2520Coated%2520Iron%2520Oxide%2520Nanoparticles%2520for%2520Hydrophobic%2520Drug%2520Delivery%26jtitle%3DACS%2520Macro%2520Lett.%26date%3D2015%26volume%3D4%26spage%3D403%26epage%3D407%26doi%3D10.1021%2Facsmacrolett.5b00091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patton, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Press, O. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span> <span> </span><span class="NLM_article-title">Gemcitabine and Chlorotoxin Conjugated Iron Oxide Nanoparticles for Glioblastoma Therapy</span>. <i>J. Mater. Chem. B</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.1039/C5TB02123E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1039%2FC5TB02123E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=26835125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvV2jsr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2016&pages=32-36&author=Q.+Muauthor=G.+Linauthor=V.+K.+Pattonauthor=K.+Wangauthor=O.+W.+Pressauthor=M.+Zhang&title=Gemcitabine+and+Chlorotoxin+Conjugated+Iron+Oxide+Nanoparticles+for+Glioblastoma+Therapy&doi=10.1039%2FC5TB02123E"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Gemcitabine and chlorotoxin conjugated iron oxide nanoparticles for glioblastoma therapy</span></div><div class="casAuthors">Mu, Qingxin; Lin, Guanyou; Patton, Victoria K.; Wang, Kui; Press, Oliver W.; Zhang, Miqin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Materials Chemistry B: Materials for Biology and Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-36</span>CODEN:
                <span class="NLM_cas:coden">JMCBDV</span>;
        ISSN:<span class="NLM_cas:issn">2050-7518</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Many small-mol. anti-cancer drugs have short blood half-lives and toxicity issues due to non-specificity.  Nanotechnol. has shown great promise in addressing these issues.  Here, we report the development of anti-cancer drug gemcitabine-conjugated iron oxide nanoparticles for glioblastoma therapy.  A glioblastoma targeting peptide, chlorotoxin, was attached after drug conjugation.  The nanoparticles have a small size (∼32 nm) and uniform size distribution (PDI ≈ 0.1), and are stable in biol. medium.  The nanoparticles effectively enter cancer cells without losing potency compared to the free drug.  Significantly, the nanoparticles showed a prolonged blood half-life and the ability to cross the blood-brain barrier in wild type mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7XXHozRQDdLVg90H21EOLACvtfcHk0lhe3pm4p0O-8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvV2jsr%252FN&md5=211b9c1916eb46d9607cb72c4ad97600</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1039%2FC5TB02123E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5TB02123E%26sid%3Dliteratum%253Aachs%26aulast%3DMu%26aufirst%3DQ.%26aulast%3DLin%26aufirst%3DG.%26aulast%3DPatton%26aufirst%3DV.%2BK.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DPress%26aufirst%3DO.%2BW.%26aulast%3DZhang%26aufirst%3DM.%26atitle%3DGemcitabine%2520and%2520Chlorotoxin%2520Conjugated%2520Iron%2520Oxide%2520Nanoparticles%2520for%2520Glioblastoma%2520Therapy%26jtitle%3DJ.%2520Mater.%2520Chem.%2520B%26date%3D2016%26volume%3D4%26spage%3D32%26epage%3D36%26doi%3D10.1039%2FC5TB02123E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Breeman, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwekkeboom, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valkema, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakker, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kooij, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visser, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krenning, E. P.</span></span> <span> </span><span class="NLM_article-title">Somatostatin Receptor-Mediated Imaging and Therapy: Basic Science, Current Knowledge, Limitations and Future Perspectives</span>. <i>Eur. J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1421</span>– <span class="NLM_lpage">1429</span>, <span class="refDoi"> DOI: 10.1007/s002590100502</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1007%2Fs002590100502" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=11585303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmt1GntLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2001&pages=1421-1429&author=W.+A.+Breemanauthor=M.+de+Jongauthor=D.+J.+Kwekkeboomauthor=R.+Valkemaauthor=W.+H.+Bakkerauthor=P.+P.+Kooijauthor=T.+J.+Visserauthor=E.+P.+Krenning&title=Somatostatin+Receptor-Mediated+Imaging+and+Therapy%3A+Basic+Science%2C+Current+Knowledge%2C+Limitations+and+Future+Perspectives&doi=10.1007%2Fs002590100502"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives</span></div><div class="casAuthors">Breeman, Wout A. P.; de Jong, Marion; Kwekkeboom, Dik J.; Valkema, Roelf; Bakker, Willem H.; Kooij, Peter P. M.; Visser, Theo J.; Krenning, Eric P.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1421-1429</span>CODEN:
                <span class="NLM_cas:coden">EJNMD9</span>;
        ISSN:<span class="NLM_cas:issn">0340-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">A review.  In vivo somatostatin receptor-mediated scintigraphy has proven to be a valuable method for the visualization of neuroendocrine tumors and their metastases.  A new application is the use of radiolabeled analogs for somatostatin receptor-mediated therapy.  This paper presents a review on the basic science, historical background and current knowledge of somatostatin receptor subtypes and their expression in neuroendocrine tumors.  New somatostatin analogs, new chelators, "new" radionuclides and combinations thereof are also discussed.  Due attention is given to limitations and future perspectives of somatostatin receptor-mediated imaging and therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrE-Y8-1DzeMrVg90H21EOLACvtfcHk0lj8RRBpTREQ9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmt1GntLo%253D&md5=d56f38d0e22c4acc65d7e5aca49ee86d</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1007%2Fs002590100502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs002590100502%26sid%3Dliteratum%253Aachs%26aulast%3DBreeman%26aufirst%3DW.%2BA.%26aulast%3Dde%2BJong%26aufirst%3DM.%26aulast%3DKwekkeboom%26aufirst%3DD.%2BJ.%26aulast%3DValkema%26aufirst%3DR.%26aulast%3DBakker%26aufirst%3DW.%2BH.%26aulast%3DKooij%26aufirst%3DP.%2BP.%26aulast%3DVisser%26aufirst%3DT.%2BJ.%26aulast%3DKrenning%26aufirst%3DE.%2BP.%26atitle%3DSomatostatin%2520Receptor-Mediated%2520Imaging%2520and%2520Therapy%253A%2520Basic%2520Science%252C%2520Current%2520Knowledge%252C%2520Limitations%2520and%2520Future%2520Perspectives%26jtitle%3DEur.%2520J.%2520Nucl.%2520Med.%26date%3D2001%26volume%3D28%26spage%3D1421%26epage%3D1429%26doi%3D10.1007%2Fs002590100502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abdellatif, A. A.</span></span> <span> </span><span class="NLM_article-title">Targeting of Somatostatin Receptors Using Quantum Dots Nanoparticles Decorated with Octreotide</span>. <i>J. Nanomed. Nanotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>S6</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">1</span>, <span class="refDoi"> DOI: 10.4172/2157-7439.S6-005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.4172%2F2157-7439.S6-005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=S6&publication_year=2015&pages=1-1&author=A.+A.+Abdellatif&title=Targeting+of+Somatostatin+Receptors+Using+Quantum+Dots+Nanoparticles+Decorated+with+Octreotide&doi=10.4172%2F2157-7439.S6-005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.4172%2F2157-7439.S6-005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4172%252F2157-7439.S6-005%26sid%3Dliteratum%253Aachs%26aulast%3DAbdellatif%26aufirst%3DA.%2BA.%26atitle%3DTargeting%2520of%2520Somatostatin%2520Receptors%2520Using%2520Quantum%2520Dots%2520Nanoparticles%2520Decorated%2520with%2520Octreotide%26jtitle%3DJ.%2520Nanomed.%2520Nanotechnol.%26date%3D2015%26volume%3DS6%26spage%3D1%26epage%3D1%26doi%3D10.4172%2F2157-7439.S6-005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sreenivasan, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodchild, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvyagin, A. V.</span></span> <span> </span><span class="NLM_article-title">Targeting Somatostatin Receptors Using In-Situ Bioconjugated Fluorescent Nanoparticles</span>. <i>Nanomedicine</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1551</span>– <span class="NLM_lpage">1560</span>, <span class="refDoi"> DOI: 10.2217/nnm.12.42</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.2217%2Fnnm.12.42" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=22812712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1GlsLnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=1551-1560&author=V.+K.+Sreenivasanauthor=E.+J.+Kimauthor=A.+K.+Goodchildauthor=M.+Connorauthor=A.+V.+Zvyagin&title=Targeting+Somatostatin+Receptors+Using+In-Situ+Bioconjugated+Fluorescent+Nanoparticles&doi=10.2217%2Fnnm.12.42"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting somatostatin receptors using in situ-bioconjugated fluorescent nanoparticles</span></div><div class="casAuthors">Sreenivasan, Varun K. A.; Kim, Eun J.; Goodchild, Ann K.; Connor, Mark; Zvyagin, Andrei V.</div><div class="citationInfo"><span class="NLM_cas:title">Nanomedicine (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1551-1560</span>CODEN:
                <span class="NLM_cas:coden">NLUKAC</span>;
        ISSN:<span class="NLM_cas:issn">1743-5889</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">Aim: The author's group report, for the first time, on the development of a quantum dot (QD)-based fluorescent somatostatin (somatotropin release-inhibiting factor [SRIF]) probe that enables specific targeting of somatostatin receptors.  Receptor-mediated endocytosis of SRIF was imaged using this probe.  Materials & methods: Biotinylated SRIF-analog (SRIF-B) and streptavidin (Sav)-coated QDs were used for the probe synthesis.  A dye-labeled streptavidin complex was used to evaluate the effect of Sav binding on the activity of SRIF-B.  Results: A preconjugated probe of the form SRIF-B:Sav-QD, was inactive and unable to undergo receptor-mediated endocytosis.  An alternative in situ bioconjugation strategy, where SRIF-B and Sav-QD were added in two consecutive steps, enabled visualization of the receptor-mediated endocytosis.  The process of Sav binding appeared to be responsible for the inactivity in the first case.  Conclusion: The in situ two-step bioconjugation strategy allowed QDs to be targeted to somatostatin receptors.  This strategy should enable flexible fluorescent tagging of SRIF for the investigation of mol. trafficking in cells and targeted delivery in live animals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCYCNT1wgkrrVg90H21EOLACvtfcHk0ljrCQWoURZ4pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1GlsLnN&md5=644ce9dae87354bc7eda222014bed874</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.2217%2Fnnm.12.42&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fnnm.12.42%26sid%3Dliteratum%253Aachs%26aulast%3DSreenivasan%26aufirst%3DV.%2BK.%26aulast%3DKim%26aufirst%3DE.%2BJ.%26aulast%3DGoodchild%26aufirst%3DA.%2BK.%26aulast%3DConnor%26aufirst%3DM.%26aulast%3DZvyagin%26aufirst%3DA.%2BV.%26atitle%3DTargeting%2520Somatostatin%2520Receptors%2520Using%2520In-Situ%2520Bioconjugated%2520Fluorescent%2520Nanoparticles%26jtitle%3DNanomedicine%26date%3D2012%26volume%3D7%26spage%3D1551%26epage%3D1560%26doi%3D10.2217%2Fnnm.12.42" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barak, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goike, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panaretakis, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einarsson, R.</span></span> <span> </span><span class="NLM_article-title">Clinical Utility of Cytokeratins as Tumor Markers</span>. <i>Clin. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">529</span>– <span class="NLM_lpage">540</span>, <span class="refDoi"> DOI: 10.1016/j.clinbiochem.2004.05.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.clinbiochem.2004.05.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=15234234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD2cXltl2gtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2004&pages=529-540&author=V.+Barakauthor=H.+Goikeauthor=K.+W.+Panaretakisauthor=R.+Einarsson&title=Clinical+Utility+of+Cytokeratins+as+Tumor+Markers&doi=10.1016%2Fj.clinbiochem.2004.05.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical utility of cytokeratins as tumor markers</span></div><div class="casAuthors">Barak, Vivian; Goike, Helena; Panaretakis, Katja W.; Einarsson, Roland</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Biochemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">529-540</span>CODEN:
                <span class="NLM_cas:coden">CLBIAS</span>;
        ISSN:<span class="NLM_cas:issn">0009-9120</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Cytokeratins, belonging to the intermediate filament (IF) protein family, are particularly useful tools in oncol. diagnostics.  At present, more than 20 different cytokeratins have been identified, of which cytokeratins 8, 18, and 19 are the most abundant in simple epithelial cells.  Upon release from proliferating or apoptotic cells, cytokeratins provide useful markers for epithelial malignancies, distinctly reflecting ongoing cell activity.  It appears that motifs in certain cytokeratins make them likely substrates for caspase degrdn., and their subsequent release occurs during the intermediate events in apoptosis.  The clin. value of detg. sol. cytokeratin protein fragments in body fluids lies in the early detection of recurrence and the fast assessment of the efficacy of therapy response in epithelial cell carcinomas.  The three most applied cytokeratin markers used in the clinic are tissue polypeptide antigen (TPA), tissue polypeptide specific antigen (TPS), and CYFRA 21-1.  TPA is a broad spectrum test that measures cytokeratins 8, 18, and 19.  TPS and CYFRA 21-1 assays are more specific and measure cytokeratin 18 and cytokeratin 19, resp.  By following patients with repeated testing during management, the oncologist may obtain crit. information regarding the growth activity in symptomatic patients.  Although their main use is to monitor treatment and evaluate response to therapy, early prognostic information particularly on tumor progression and metastasis formation is also provided for several types of cancers.  Cytokeratin tumor markers can accurately predict disease status before conventional methods and offer a simple, noninvasive, cheap, and reliable tool for more efficient management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsEQvH8gCQZrVg90H21EOLACvtfcHk0ljrCQWoURZ4pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXltl2gtLc%253D&md5=f123b3dd99548a29ead48f23e07ebac7</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.clinbiochem.2004.05.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clinbiochem.2004.05.009%26sid%3Dliteratum%253Aachs%26aulast%3DBarak%26aufirst%3DV.%26aulast%3DGoike%26aufirst%3DH.%26aulast%3DPanaretakis%26aufirst%3DK.%2BW.%26aulast%3DEinarsson%26aufirst%3DR.%26atitle%3DClinical%2520Utility%2520of%2520Cytokeratins%2520as%2520Tumor%2520Markers%26jtitle%3DClin.%2520Biochem.%26date%3D2004%26volume%3D37%26spage%3D529%26epage%3D540%26doi%3D10.1016%2Fj.clinbiochem.2004.05.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herrmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bär, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreplak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strelkov, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aebi, U.</span></span> <span> </span><span class="NLM_article-title">Intermediate Filaments: From Cell Architecture to Nanomechanics</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">562</span>– <span class="NLM_lpage">573</span>, <span class="refDoi"> DOI: 10.1038/nrm2197</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1038%2Fnrm2197" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=17551517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmvVaktLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=562-573&author=H.+Herrmannauthor=H.+B%C3%A4rauthor=L.+Kreplakauthor=S.+V.+Strelkovauthor=U.+Aebi&title=Intermediate+Filaments%3A+From+Cell+Architecture+to+Nanomechanics&doi=10.1038%2Fnrm2197"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Intermediate filaments: from cell architecture to nanomechanics</span></div><div class="casAuthors">Herrmann, Harald; Baer, Harald; Kreplak, Laurent; Strelkov, Sergei V.; Aebi, Ueli</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">562-573</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Intermediate filaments (IFs) constitute a major structural element of animal cells.  IFs build 2 distinct systems, one in the nucleus and one in the cytoplasm.  In both cases, their major function is assumed to be that of a mech. stress absorber and an integrating device for the entire cytoskeleton.  In line with this, recent disease mutations in human IF proteins indicate that the nanomech. properties of cell-type-specific IFs are central to the pathogenesis of diseases as diverse as muscular dystrophy and premature aging.  However, the anal. of these various diseases suggests that IFs also have an important role in cell-type-specific physiol. functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQxp0AlM747rVg90H21EOLACvtfcHk0ljrCQWoURZ4pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmvVaktLg%253D&md5=22a72f84bf1a8403ca4c90af97bfc4eb</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1038%2Fnrm2197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2197%26sid%3Dliteratum%253Aachs%26aulast%3DHerrmann%26aufirst%3DH.%26aulast%3DB%25C3%25A4r%26aufirst%3DH.%26aulast%3DKreplak%26aufirst%3DL.%26aulast%3DStrelkov%26aufirst%3DS.%2BV.%26aulast%3DAebi%26aufirst%3DU.%26atitle%3DIntermediate%2520Filaments%253A%2520From%2520Cell%2520Architecture%2520to%2520Nanomechanics%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2007%26volume%3D8%26spage%3D562%26epage%3D573%26doi%3D10.1038%2Fnrm2197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kocbek, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermajer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cegnar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kristl, J.</span></span> <span> </span><span class="NLM_article-title">Targeting Cancer Cells Using PLGA Nanoparticles Surface Modified with Monoclonal Antibody</span>. <i>J. Controlled Release</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">18</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1016/j.jconrel.2007.03.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.jconrel.2007.03.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=17509712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmt1Gls7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2007&pages=18-26&author=P.+Kocbekauthor=N.+Obermajerauthor=M.+Cegnarauthor=J.+Kosauthor=J.+Kristl&title=Targeting+Cancer+Cells+Using+PLGA+Nanoparticles+Surface+Modified+with+Monoclonal+Antibody&doi=10.1016%2Fj.jconrel.2007.03.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody</span></div><div class="casAuthors">Kocbek, Petra; Obermajer, Natasa; Cegnar, Mateja; Kos, Janko; Kristl, Julijana</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">18-26</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Targeting drugs to their sites of action is still a major challenge in pharmaceutical research.  In this study, polylactic-co-glycolic acid (PLGA) immuno-nanoparticles were prepd. for targeting invasive epithelial breast tumor cells.  Monoclonal antibody (mAb) was used as a homing ligand and was attached to the nanoparticle surface either covalently or non-covalently.  The presence of mAb on the nanoparticle surface, its stability and recognition properties were tested.  Protein assay, surface plasmon resonance, flow cytometry and fluorescence-immunostaining confirmed the presence of mAb on nanoparticles in both cases.  However, a binding assay using cell lysate revealed that the recognition properties were preserved only for nanoparticles with adsorbed mAb.  These nanoparticles were more likely to be bound to the targeted cells than non-coated nanoparticles.  Both types of nanoparticles entered the target MCF-10A neoT cells in mono-culture.  In co-culture of MCF-10A neoT and Caco-2 cells immuno-nanoparticles were localized solely to MCF-10A neoT cells, whereas non-coated nanoparticles were distributed randomly.  Immuno-nanoparticles entered only MCF-10A neoT cells, while non-coated nanoparticles were taken up by both cell types, indicating specific targeting of the immuno-nanoparticles.  In conclusion, we demonstrate a method by which mAbs can be bound to nanoparticles without detriment to their targeting ability.  Furthermore, the results show the effectiveness of the new carrier system for targeted delivery of small or large active substances into cells or tissues of interest.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8ctO-ZaMI3rVg90H21EOLACvtfcHk0ljrCQWoURZ4pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmt1Gls7g%253D&md5=dcf085731137e0433b4a8e9da491a507</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2007.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2007.03.012%26sid%3Dliteratum%253Aachs%26aulast%3DKocbek%26aufirst%3DP.%26aulast%3DObermajer%26aufirst%3DN.%26aulast%3DCegnar%26aufirst%3DM.%26aulast%3DKos%26aufirst%3DJ.%26aulast%3DKristl%26aufirst%3DJ.%26atitle%3DTargeting%2520Cancer%2520Cells%2520Using%2520PLGA%2520Nanoparticles%2520Surface%2520Modified%2520with%2520Monoclonal%2520Antibody%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2007%26volume%3D120%26spage%3D18%26epage%3D26%26doi%3D10.1016%2Fj.jconrel.2007.03.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, G.</span></span> <span> </span><span class="NLM_article-title">Targeting Cells for Drug and Gene Delivery: Emerging Applicationsof Mannans and Mannan Binding Lectins</span>. <i>J. Sci. Ind. Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">465</span>– <span class="NLM_lpage">483</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1OksLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2009&pages=465-483&author=A.+Guptaauthor=R.+K.+Guptaauthor=G.+Gupta&title=Targeting+Cells+for+Drug+and+Gene+Delivery%3A+Emerging+Applicationsof+Mannans+and+Mannan+Binding+Lectins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cells for drug and gene delivery: emerging applications of mannans and mannan binding lectins</span></div><div class="casAuthors">Gupta, Anita; Gupta, Rajesh K.; Gupta, G. S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Scientific & Industrial Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">465-483</span>CODEN:
                <span class="NLM_cas:coden">JSIRAC</span>;
        ISSN:<span class="NLM_cas:issn">0022-4456</span>.
    
            (<span class="NLM_cas:orgname">National Institute of Science Communication and Information Resources</span>)
        </div><div class="casAbstract">This review outlines exclusive applications of mannose, mannan conjugates, and their specific interacting proteins (macrophage mannose receptors, dendritic cell receptors) in gene delivery and drug targeting, and their scope in development of targeted delivery systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIRfKfxrgc5rVg90H21EOLACvtfcHk0lijZ4vZpjd8hA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1OksLc%253D&md5=ce63e9349732075ea7d966d6ee74c000</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DGupta%26aufirst%3DR.%2BK.%26aulast%3DGupta%26aufirst%3DG.%26atitle%3DTargeting%2520Cells%2520for%2520Drug%2520and%2520Gene%2520Delivery%253A%2520Emerging%2520Applicationsof%2520Mannans%2520and%2520Mannan%2520Binding%2520Lectins%26jtitle%3DJ.%2520Sci.%2520Ind.%2520Res.%26date%3D2009%26volume%3D68%26spage%3D465%26epage%3D483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span> <span> </span><span class="NLM_article-title">Targeted Polysaccharide Nanoparticle for Adamplatin Prodrug Delivery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">9725</span>– <span class="NLM_lpage">9736</span>, <span class="refDoi"> DOI: 10.1021/jm4014168</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4014168" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVShsL7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=9725-9736&author=Y.+Yangauthor=Y.+M.+Zhangauthor=Y.+Chenauthor=J.+T.+Chenauthor=Y.+Liu&title=Targeted+Polysaccharide+Nanoparticle+for+Adamplatin+Prodrug+Delivery&doi=10.1021%2Fjm4014168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted Polysaccharide Nanoparticle for Adamplatin Prodrug Delivery</span></div><div class="casAuthors">Yang, Yang; Zhang, Ying-Ming; Chen, Yong; Chen, Jia-Tong; Liu, Yu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9725-9736</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of conjugated hyaluronic acid particles (HAP), composed of a hydrophobic anticancer drug core and hydrophilic cyclodextrin/hyaluronic acid shell, were prepd. through self-assembling and characterized by 1H NMR titrn., electron microscopy, zeta potential, and dynamic light-scattering expts.  The nanometer-sized HAP thus prepd. was biocompatible and biodegradable and was well-recognized by the hyaluronic acid receptors overexpressed on the surface of cancer cells, which enabled us to exploit HAP as an efficient targeted delivery system for anticancer drugs.  Indeed, HAP exhibited anticancer activities comparable to the com. anticancer drug cisplatin but with lower side effects both in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplSUSSw7s3k7Vg90H21EOLACvtfcHk0lijZ4vZpjd8hA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVShsL7O&md5=dc1c697d34fbd6f8c0e32e68ed7a447c</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1021%2Fjm4014168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4014168%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%2BM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DJ.%2BT.%26aulast%3DLiu%26aufirst%3DY.%26atitle%3DTargeted%2520Polysaccharide%2520Nanoparticle%2520for%2520Adamplatin%2520Prodrug%2520Delivery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D9725%26epage%3D9736%26doi%3D10.1021%2Fjm4014168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kojima, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bovin, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabius, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabius, H.-J.</span></span> <span> </span><span class="NLM_article-title">Endogenous Lectins as Targets for Drug Delivery</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">244</span>, <span class="refDoi"> DOI: 10.1016/S0169-409X(00)00071-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2FS0169-409X%2800%2900071-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10967228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmtVClu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=225-244&author=N.+Yamazakiauthor=S.+Kojimaauthor=N.+V.+Bovinauthor=S.+Andreauthor=S.+Gabiusauthor=H.-J.+Gabius&title=Endogenous+Lectins+as+Targets+for+Drug+Delivery&doi=10.1016%2FS0169-409X%2800%2900071-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Endogenous lectins as targets for drug delivery</span></div><div class="casAuthors">Yamazaki, N.; Kojima, S.; Bovin, N. V.; Andre, S.; Gabius, S.; Gabius, H.-J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">225-244</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">A review with 110 refs.  To minimize side effects of drugs it would be ideal to target them exclusively to those cell types which require treatment.  As a means to this end prototypical cellular recognition systems pique our interest to devise biomimetic strategies.  Since oligosaccharides of glycoconjugates outmatch other information-carrying biomols. (proteins, nucleic acids) in theor. storage capacity by far, work on the sugar code can spark off development of effective targeting devices.  Conjugation of custom-made glycan epitopes to proteins or biocompatible non-immunogenic polymeric scaffolds produces neoglycoconjugates with purpose-adaptable properties.  In the interplay with endogenous receptors such as lectins, suitable oligosaccharides such as histo-blood group trisaccharides as parts of neoglycoconjugates have already proven their practical applications in histopathol.  Elucidation of the structure of cell lectins with currently five main families aids to tailor ligand characteristics rationally.  They include the types of functional groups and their topol. presentation to optimize the bimol. binding as well as the optimal spatial clustering and spacer characteristics to exploit cooperativity.  Indeed, the potent trivalent cluster glycosides designed for the C-type asialoglycoprotein receptors furnish an instructive example how to turn the theor. guideline on ligand modification into nM-affinity.  By placing emphasis on tissue lectins as targets of neoglycoconjugate-mediated drug delivery, the long-term perspective is opened to likewise test members of these families themselves for routing of therapeutic payloads, aiming at cell addressins.  This review illustrates the conceivable potential which work on the sugar code with custom-made neoglycoconjugates and tissue lectins can have in store for drug delivery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4gcIIbPwwf7Vg90H21EOLACvtfcHk0lijZ4vZpjd8hA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmtVClu7o%253D&md5=7d6c735f008c58f354b0d9fc9284cba4</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2800%2900071-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252800%252900071-5%26sid%3Dliteratum%253Aachs%26aulast%3DYamazaki%26aufirst%3DN.%26aulast%3DKojima%26aufirst%3DS.%26aulast%3DBovin%26aufirst%3DN.%2BV.%26aulast%3DAndre%26aufirst%3DS.%26aulast%3DGabius%26aufirst%3DS.%26aulast%3DGabius%26aufirst%3DH.-J.%26atitle%3DEndogenous%2520Lectins%2520as%2520Targets%2520for%2520Drug%2520Delivery%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2000%26volume%3D43%26spage%3D225%26epage%3D244%26doi%3D10.1016%2FS0169-409X%2800%2900071-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Minko, T.</span></span> <span> </span><span class="NLM_article-title">Drug Targeting to the Colon with Lectins and Neoglycoconjugates</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">491</span>– <span class="NLM_lpage">509</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2003.10.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.addr.2003.10.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=14969755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD2cXht1KnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2004&pages=491-509&author=T.+Minko&title=Drug+Targeting+to+the+Colon+with+Lectins+and+Neoglycoconjugates&doi=10.1016%2Fj.addr.2003.10.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Drug targeting to the colon with lectins and neoglycoconjugates</span></div><div class="casAuthors">Minko, Tamara</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">491-509</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review and discussion.  Targeting of drugs to specific sites of action provides several advantages over non-targeted drugs.  These include the prevention of side effects of drugs on healthy tissues and enhancement of drug uptake by targeted cells.  This review will cover traditional approaches of colon drug targeting as well as the use of lectins and neoglycoconjugates for the targeted delivery.  Direct and reverse targeting strategies, potential mol. targets and targeting moieties for colon drug delivery, targeted drug delivery systems (DDS) for colon delivery, anticancer DDS targeted to colon cancer are examd.  Directions of future development are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWXcDEhZJQjLVg90H21EOLACvtfcHk0lhVkvLUvUVVcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXht1KnsLc%253D&md5=ffad4ef76afc8e2d31d4ef8b2013bead</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2003.10.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2003.10.017%26sid%3Dliteratum%253Aachs%26aulast%3DMinko%26aufirst%3DT.%26atitle%3DDrug%2520Targeting%2520to%2520the%2520Colon%2520with%2520Lectins%2520and%2520Neoglycoconjugates%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2004%26volume%3D56%26spage%3D491%26epage%3D509%26doi%3D10.1016%2Fj.addr.2003.10.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ertl, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabor, F.</span></span> <span> </span><span class="NLM_article-title">Lectin-Mediated Drug Targeting: Preparation, Binding Characteristics, and Antiproliferative Activity of Wheat Germ Agglutinin Conjugated Doxorubicin on Caco-2 Cells</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1031</span>– <span class="NLM_lpage">1037</span>, <span class="refDoi"> DOI: 10.1023/A:1011926026653</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1023%2FA%3A1011926026653" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=9688056" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADyaK1cXkvVWgtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1998&pages=1031-1037&author=M.+Wirthauthor=A.+Fuchsauthor=M.+Wolfauthor=B.+Ertlauthor=F.+Gabor&title=Lectin-Mediated+Drug+Targeting%3A+Preparation%2C+Binding+Characteristics%2C+and+Antiproliferative+Activity+of+Wheat+Germ+Agglutinin+Conjugated+Doxorubicin+on+Caco-2+Cells&doi=10.1023%2FA%3A1011926026653"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Lectin-mediated drug targeting: preparation, binding characteristics, and antiproliferative activity of wheat germ agglutinin conjugated doxorubicin on Caco-2 cells</span></div><div class="casAuthors">Wirth, Michael; Fuchs, Andrea; Wolf, Michaela; Ertl, Bernhard; Gabor, Franz</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1031-1037</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Plenum Publishing Corp.</span>)
        </div><div class="casAbstract">To investigate the usefulness of wheat germ agglutinin as a targeting carrier protein for an acid-labile chemotherapeutic prodrug directed against colon carcinoma cells in vitro.  Cis-aconityl-linked doxorubicin-wheat germ agglutinin was prepd. by a two step procedure and the conjugate-binding capacity of target- and non-target cells was assayed by flow cytometry.  The antiproliferative activity of the prodrug on Caco-2 and MOLT-4 cells was detd. by the XTT- and BrdU-test and compared with that of the parent drug and the lectin alone.  At pH 4.0, about 50% of the conjugated doxorubicin were released within 24 h from the water sol. prodrug exhibiting a conjugation no. of 24 (mol doxorubicin/mol WGA).  The prodrug-binding capacity of colon carcinoma cells exceeded that of human colonocytes and lymphoblastic MOLT-4 cells 4.5-fold.  Addnl., the antiproliferative effect of the conjugate on Caco-2 cells was 39% as opposed to 5% in case of MOLT-4 cells.  As the unmodified carrier protein inhibited or stimulated Caco-2 cell growth in a concn.-dependent manner, the cytostatic activity of the conjugate was detd. at WGA concns. without an effect on cell-proliferation.  Considering 50% release of conjugated drug at the most, the prodrug yielded 160% of the cytostatic activity of free doxorubicin.  WGA-prodrug targeting offers new perspectives for site specific, cytoinvading drug delivery in colon cancer chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2Y8vaYwhUurVg90H21EOLACvtfcHk0lhVkvLUvUVVcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXkvVWgtbk%253D&md5=a5f5fc4cdbf10a5c911164f7b6424f24</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1023%2FA%3A1011926026653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1011926026653%26sid%3Dliteratum%253Aachs%26aulast%3DWirth%26aufirst%3DM.%26aulast%3DFuchs%26aufirst%3DA.%26aulast%3DWolf%26aufirst%3DM.%26aulast%3DErtl%26aufirst%3DB.%26aulast%3DGabor%26aufirst%3DF.%26atitle%3DLectin-Mediated%2520Drug%2520Targeting%253A%2520Preparation%252C%2520Binding%2520Characteristics%252C%2520and%2520Antiproliferative%2520Activity%2520of%2520Wheat%2520Germ%2520Agglutinin%2520Conjugated%2520Doxorubicin%2520on%2520Caco-2%2520Cells%26jtitle%3DPharm.%2520Res.%26date%3D1998%26volume%3D15%26spage%3D1031%26epage%3D1037%26doi%3D10.1023%2FA%3A1011926026653" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Venturelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nappini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bulfoni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gianfranceschi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dal Zilio, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coceano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Ben, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turetta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scoles, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaccari, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cesselli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cojoc, D.</span></span> <span> </span><span class="NLM_article-title">Glucose is a Key Driver for GLUT1-Mediated Nanoparticles Internalization in Breast Cancer Cells</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">21629</span>, <span class="refDoi"> DOI: 10.1038/srep21629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1038%2Fsrep21629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=26899926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC28XivFKhtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=21629&author=L.+Venturelliauthor=S.+Nappiniauthor=M.+Bulfoniauthor=G.+Gianfranceschiauthor=S.+Dal+Zilioauthor=G.+Coceanoauthor=F.+Del+Benauthor=M.+Turettaauthor=G.+Scolesauthor=L.+Vaccariauthor=D.+Cesselliauthor=D.+Cojoc&title=Glucose+is+a+Key+Driver+for+GLUT1-Mediated+Nanoparticles+Internalization+in+Breast+Cancer+Cells&doi=10.1038%2Fsrep21629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Glucose is a key driver for GLUT1-mediated nanoparticles internalization in breast cancer cells</span></div><div class="casAuthors">Venturelli, Leonardo; Nappini, Silvia; Bulfoni, Michela; Gianfranceschi, Giuseppe; Dal Zilio, Simone; Coceano, Giovanna; Del Ben, Fabio; Turetta, Matteo; Scoles, Giacinto; Vaccari, Lisa; Cesselli, Daniela; Cojoc, Dan</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">21629</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The mesenchymal state in cancer is usually assocd. with poor prognosis due to the metastatic predisposition and the hyper-activated metab.  Exploiting cell glucose metab. we propose a new method to detect mesenchymal-like cancer cells.  We demonstrate that the uptake of glucose-coated magnetic nanoparticles (MNPs) by mesenchymal-like cells remains const. when the glucose in the medium is increased from low (5.5 mM) to high (25 mM) concn., while the MNPs uptake by epithelial-like cells is significantly reduced.  These findings reveal that the glucose-shell of MNPs plays a major role in recognition of cells with high-metabolic activity.  By selectively blocking the glucose transporter 1 channels we showed its involvement in the internalization process of glucose-coated MNPs.  Our results suggest that glucose-coated MNPs can be used for metabolic-based assays aimed at detecting cancer cells and that can be used to selectively target cancer cells taking advantage, for instance, of the magnetic-thermotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTx-GhEtVkM7Vg90H21EOLACvtfcHk0lhVkvLUvUVVcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XivFKhtb8%253D&md5=395719c191fc8b17dabc028e35e5f30d</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1038%2Fsrep21629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep21629%26sid%3Dliteratum%253Aachs%26aulast%3DVenturelli%26aufirst%3DL.%26aulast%3DNappini%26aufirst%3DS.%26aulast%3DBulfoni%26aufirst%3DM.%26aulast%3DGianfranceschi%26aufirst%3DG.%26aulast%3DDal%2BZilio%26aufirst%3DS.%26aulast%3DCoceano%26aufirst%3DG.%26aulast%3DDel%2BBen%26aufirst%3DF.%26aulast%3DTuretta%26aufirst%3DM.%26aulast%3DScoles%26aufirst%3DG.%26aulast%3DVaccari%26aufirst%3DL.%26aulast%3DCesselli%26aufirst%3DD.%26aulast%3DCojoc%26aufirst%3DD.%26atitle%3DGlucose%2520is%2520a%2520Key%2520Driver%2520for%2520GLUT1-Mediated%2520Nanoparticles%2520Internalization%2520in%2520Breast%2520Cancer%2520Cells%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D21629%26doi%3D10.1038%2Fsrep21629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gromnicova, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sreekanthreddy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lund, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roitt, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Male, D. K.</span></span> <span> </span><span class="NLM_article-title">Glucose-Coated Gold Nanoparticles Transfer Across Human Brain Endothelium and Enter Astrocytes in Vitro</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">e81043</span> 1–10 <span class="refDoi"> DOI: 10.1371/journal.pone.0081043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1371%2Fjournal.pone.0081043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=24339894" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltl2rsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&author=R.+Gromnicovaauthor=H.+A.+Daviesauthor=P.+Sreekanthreddyauthor=I.+A.+Romeroauthor=T.+Lundauthor=I.+M.+Roittauthor=J.+B.+Phillipsauthor=D.+K.+Male&title=Glucose-Coated+Gold+Nanoparticles+Transfer+Across+Human+Brain+Endothelium+and+Enter+Astrocytes+in+Vitro&doi=10.1371%2Fjournal.pone.0081043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Glucose-coated gold nanoparticles transfer across human brain endothelium and enter astrocytes in vitro</span></div><div class="casAuthors">Gromnicova, Radka; Davies, Heather A.; Sreekanthreddy, Peddagangannagari; Romero, Ignacio A.; Lund, Torben; Roitt, Ivan M.; Phillips, James B.; Male, David K.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e81043/1-e81043/10, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The blood-brain barrier prevents the entry of many therapeutic agents into the brain.  Various nanocarriers have been developed to help agents to cross this barrier, but they all have limitations, with regard to tissue-selectivity and their ability to cross the endothelium.  This study investigated the potential for 4 nm coated gold nanoparticles to act as selective carriers across human brain endothelium and subsequently to enter astrocytes.  The transfer rate of glucose-coated gold nanoparticles across primary human brain endothelium was at least three times faster than across non-brain endothelia.  Movement of these nanoparticles occurred across the apical and basal plasma membranes via the cytosol with relatively little vesicular or paracellular migration; antibiotics that interfere with vesicular transport did not block migration.  The transfer rate was also dependent on the surface coating of the nanoparticle and incubation temp.  Using a novel 3-dimensional co-culture system, which includes primary human astrocytes and a brain endothelial cell line hCMEC/D3, we demonstrated that the glucose-coated nanoparticles traverse the endothelium, move through the extracellular matrix and localize in astrocytes.  The movement of the nanoparticles through the matrix was >10 μm/h and they appeared in the nuclei of the astrocytes in considerable nos.  These nanoparticles have the correct properties for efficient and selective carriers of therapeutic agents across the blood-brain barrier.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfS2FgUtqjpLVg90H21EOLACvtfcHk0ljzsUxsKuwAcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltl2rsrw%253D&md5=3448a63d0dbf90ccbf49227264e2f384</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0081043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0081043%26sid%3Dliteratum%253Aachs%26aulast%3DGromnicova%26aufirst%3DR.%26aulast%3DDavies%26aufirst%3DH.%2BA.%26aulast%3DSreekanthreddy%26aufirst%3DP.%26aulast%3DRomero%26aufirst%3DI.%2BA.%26aulast%3DLund%26aufirst%3DT.%26aulast%3DRoitt%26aufirst%3DI.%2BM.%26aulast%3DPhillips%26aufirst%3DJ.%2BB.%26aulast%3DMale%26aufirst%3DD.%2BK.%26atitle%3DGlucose-Coated%2520Gold%2520Nanoparticles%2520Transfer%2520Across%2520Human%2520Brain%2520Endothelium%2520and%2520Enter%2520Astrocytes%2520in%2520Vitro%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26doi%3D10.1371%2Fjournal.pone.0081043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sha, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, X.</span></span> <span> </span><span class="NLM_article-title">Nanoparticles of 2-Deoxy-D-Glucose Functionalized Poly (Ethylene Glycol)-Co-Poly (Trimethylene Carbonate) for Dual-Targeted Drug Delivery in Glioma Treatment</span>. <i>Biomaterials</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">518</span>– <span class="NLM_lpage">529</span>, <span class="refDoi"> DOI: 10.1016/j.biomaterials.2013.09.094</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.biomaterials.2013.09.094" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=24125772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Sku7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2014&pages=518-529&author=X.+Jiangauthor=H.+Xinauthor=Q.+Renauthor=J.+Guauthor=L.+Zhuauthor=F.+Duauthor=C.+Fengauthor=Y.+Xieauthor=X.+Shaauthor=X.+Fang&title=Nanoparticles+of+2-Deoxy-D-Glucose+Functionalized+Poly+%28Ethylene+Glycol%29-Co-Poly+%28Trimethylene+Carbonate%29+for+Dual-Targeted+Drug+Delivery+in+Glioma+Treatment&doi=10.1016%2Fj.biomaterials.2013.09.094"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Nanoparticles of 2-deoxy-d-glucose functionalized poly(ethylene glycol)-co-poly(trimethylene carbonate) for dual-targeted drug delivery in glioma treatment</span></div><div class="casAuthors">Jiang, Xinyi; Xin, Hongliang; Ren, Qiuyue; Gu, Jijin; Zhu, Lingjun; Du, Fengyi; Feng, Chunlai; Xie, Yike; Sha, Xianyi; Fang, Xiaoling</div><div class="citationInfo"><span class="NLM_cas:title">Biomaterials</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">518-529</span>CODEN:
                <span class="NLM_cas:coden">BIMADU</span>;
        ISSN:<span class="NLM_cas:issn">0142-9612</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Based on the facilitative glucose transporter (GLUT) over-expression on both blood-brain barrier (BBB) and glioma cells, 2-deoxy-d-glucose modified poly(ethylene glycol)-co-poly(trimethylene carbonate) nanoparticles (dGlu-NP) were developed as a potential dual-targeted drug delivery system for enhancing the BBB penetration via GLUT-mediated transcytosis and improving the drug accumulation in the glioma via GLUT-mediated endocytosis.  In vitro physicochem. characterization of the dual-targeted nanoparticulate system presented satisfactory size of 71 nm with uniform distribution, high encapsulation efficiency and adequate loading capacity of paclitaxel (PTX).  Compared with non-glucosylated nanoparticles (NP), a significantly higher amt. of dGlu-NP was internalized by RG-2 glioma cells through caveolae-mediated and clathrin-mediated endocytosis.  Both of the transport ratios across the in vitro BBB model and the cytotoxicity of RG-2 cells after crossing the BBB were significantly greater of dGlu-NP/PTX than that of NP/PTX.  In vivo fluorescent image indicated that dGlu-NP had high specificity and efficiency in intracranial tumor accumulation.  The anti-glioblastoma efficacy of dGlu-NP/PTX was significantly enhanced in comparison with that of Taxol and NP/PTX.  Preliminary safety tests showed no acute toxicity to hematol. system, liver, kidney, heart, lung and spleen in mice after i.v. administration at a dose of 100 mg/kg blank dGlu-NP per day for a week.  Therefore, these results indicated that dGlu-NP developed in this study could be a potential dual-targeted vehicle for brain glioma therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOeiuVV6tqybVg90H21EOLACvtfcHk0ljzsUxsKuwAcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Sku7rE&md5=5144f99c38a5f230470ea1379fa87d8e</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.biomaterials.2013.09.094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biomaterials.2013.09.094%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DXin%26aufirst%3DH.%26aulast%3DRen%26aufirst%3DQ.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DDu%26aufirst%3DF.%26aulast%3DFeng%26aufirst%3DC.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DSha%26aufirst%3DX.%26aulast%3DFang%26aufirst%3DX.%26atitle%3DNanoparticles%2520of%25202-Deoxy-D-Glucose%2520Functionalized%2520Poly%2520%2528Ethylene%2520Glycol%2529-Co-Poly%2520%2528Trimethylene%2520Carbonate%2529%2520for%2520Dual-Targeted%2520Drug%2520Delivery%2520in%2520Glioma%2520Treatment%26jtitle%3DBiomaterials%26date%3D2014%26volume%3D35%26spage%3D518%26epage%3D529%26doi%3D10.1016%2Fj.biomaterials.2013.09.094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mamaeva, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niemi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Özliseli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gronroos, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kronqvist, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettersen, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormack, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenholm, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linden, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahlgren, C.</span></span> <span> </span><span class="NLM_article-title">Inhibiting Notch Activity in Breast Cancer Stem Cells by Glucose Functionalized Nanoparticles Carrying Γ-Secretase Inhibitors</span>. <i>Mol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">926</span>– <span class="NLM_lpage">936</span>, <span class="refDoi"> DOI: 10.1038/mt.2016.42</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1038%2Fmt.2016.42" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=26916284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC28XltVaqsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=926-936&author=V.+Mamaevaauthor=R.+Niemiauthor=M.+Beckauthor=E.+%C3%96zliseliauthor=D.+Desaiauthor=S.+Landorauthor=T.+Gronroosauthor=P.+Kronqvistauthor=I.+K.+Pettersenauthor=E.+McCormackauthor=J.+M.+Rosenholmauthor=M.+Lindenauthor=C.+Sahlgren&title=Inhibiting+Notch+Activity+in+Breast+Cancer+Stem+Cells+by+Glucose+Functionalized+Nanoparticles+Carrying+%CE%93-Secretase+Inhibitors&doi=10.1038%2Fmt.2016.42"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting Notch Activity in Breast Cancer Stem Cells by Glucose Functionalized Nanoparticles Carrying γ-secretase Inhibitors</span></div><div class="casAuthors">Mamaeva, Veronika; Niemi, Rasmus; Beck, Michaela; Ozliseli, Ezgi; Desai, Diti; Landor, Sebastian; Gronroos, Tove; Kronqvist, Pauliina; Pettersen, Ina K. N.; McCormack, Emmet; Rosenholm, Jessica M.; Linden, Mika; Sahlgren, Cecilia</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">926-936</span>CODEN:
                <span class="NLM_cas:coden">MTOHCK</span>;
        ISSN:<span class="NLM_cas:issn">1525-0016</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cancer stem cells (CSCs) are a challenge in cancer treatment due to their therapy resistance.  We demonstrated that enhanced Notch signaling in breast cancer promotes self-renewal of CSCs that display high glycolytic activity and aggressive hormone-independent tumor growth in vivo.  We took advantage of the glycolytic phenotype and the dependence on Notch activity of the CSCs and designed nanoparticles to target the CSCs.  Mesoporous silica nanoparticles were functionalized with glucose moieties and loaded with a γ-secretase inhibitor, a potent interceptor of Notch signaling.  Cancer cells and CSCs in vitro and in vivo efficiently internalized these particles, and particle uptake correlated with the glycolytic profile of the cells.  Nanoparticle treatment of breast cancer transplants on chick embryo chorioallantoic membranes efficiently reduced the cancer stem cell population of the tumor.  Our data reveal that specific CSC characteristics can be utilized in nanoparticle design to improve CSC-targeted drug delivery and therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN16-R4Gx5yLVg90H21EOLACvtfcHk0lhxqHSgnED13g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XltVaqsrc%253D&md5=b0248b6ef6953d9b6db9cce815914cc6</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1038%2Fmt.2016.42&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmt.2016.42%26sid%3Dliteratum%253Aachs%26aulast%3DMamaeva%26aufirst%3DV.%26aulast%3DNiemi%26aufirst%3DR.%26aulast%3DBeck%26aufirst%3DM.%26aulast%3D%25C3%2596zliseli%26aufirst%3DE.%26aulast%3DDesai%26aufirst%3DD.%26aulast%3DLandor%26aufirst%3DS.%26aulast%3DGronroos%26aufirst%3DT.%26aulast%3DKronqvist%26aufirst%3DP.%26aulast%3DPettersen%26aufirst%3DI.%2BK.%26aulast%3DMcCormack%26aufirst%3DE.%26aulast%3DRosenholm%26aufirst%3DJ.%2BM.%26aulast%3DLinden%26aufirst%3DM.%26aulast%3DSahlgren%26aufirst%3DC.%26atitle%3DInhibiting%2520Notch%2520Activity%2520in%2520Breast%2520Cancer%2520Stem%2520Cells%2520by%2520Glucose%2520Functionalized%2520Nanoparticles%2520Carrying%2520%25CE%2593-Secretase%2520Inhibitors%26jtitle%3DMol.%2520Ther.%26date%3D2016%26volume%3D24%26spage%3D926%26epage%3D936%26doi%3D10.1038%2Fmt.2016.42" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puri, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, N.</span></span> <span> </span><span class="NLM_article-title">Mannanases: Microbial Sources, Production, Properties and Potential Biotechnological Applications</span>. <i>Appl. Microbiol. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">1817</span>– <span class="NLM_lpage">1830</span>, <span class="refDoi"> DOI: 10.1007/s00253-012-3887-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1007%2Fs00253-012-3887-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=22314515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC38Xisl2qt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2012&pages=1817-1830&author=P.+S.+Chauhanauthor=N.+Puriauthor=P.+Sharmaauthor=N.+Gupta&title=Mannanases%3A+Microbial+Sources%2C+Production%2C+Properties+and+Potential+Biotechnological+Applications&doi=10.1007%2Fs00253-012-3887-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Mannanases: microbial sources, production, properties and potential biotechnological applications</span></div><div class="casAuthors">Chauhan, Prakram Singh; Puri, Neena; Sharma, Prince; Gupta, Naveen</div><div class="citationInfo"><span class="NLM_cas:title">Applied Microbiology and Biotechnology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1817-1830</span>CODEN:
                <span class="NLM_cas:coden">AMBIDG</span>;
        ISSN:<span class="NLM_cas:issn">0175-7598</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Mannans are the major constituents of the hemicellulose fraction in softwoods and show widespread distribution in plant tissues.  The major mannan-degrading enzymes are β-mannanases, β-mannosidases and β-glucosidases.  In addn. to these, other enzymes such as α-galactosidases and acetyl mannan esterases, are required to remove the side chain substituents.  The mannanases are known to be produced by a variety of bacteria, fungi, actinomycetes, plants and animals.  Microbial mannanases are mainly extracellular and can act in wide range of pH and temp. because of which they have found applications in pulp and paper, pharmaceutical, food, feed, oil and textile industries.  This review summarizes the studies on mannanases reported in recent years in terms of important microbial sources, prodn. conditions, enzyme properties, heterologous expression and potential industrial applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwf5-BsOk0JbVg90H21EOLACvtfcHk0lhxqHSgnED13g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xisl2qt7o%253D&md5=b16cd1228136901eac74c1e581d730ae</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1007%2Fs00253-012-3887-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00253-012-3887-5%26sid%3Dliteratum%253Aachs%26aulast%3DChauhan%26aufirst%3DP.%2BS.%26aulast%3DPuri%26aufirst%3DN.%26aulast%3DSharma%26aufirst%3DP.%26aulast%3DGupta%26aufirst%3DN.%26atitle%3DMannanases%253A%2520Microbial%2520Sources%252C%2520Production%252C%2520Properties%2520and%2520Potential%2520Biotechnological%2520Applications%26jtitle%3DAppl.%2520Microbiol.%2520Biotechnol.%26date%3D2012%26volume%3D93%26spage%3D1817%26epage%3D1830%26doi%3D10.1007%2Fs00253-012-3887-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Budzynska, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nevozhay, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanska, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jagiello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opolski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wietrzyk, J.</span></span> <span> </span><span class="NLM_article-title">Boratynski, Antitumor Activity of Mannan–Methotrexate Conjugate In-Vitro and In-Vivo</span>. <i>J. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">415</span>– <span class="NLM_lpage">421</span>, <span class="refDoi"> DOI: 10.3727/000000007783980837</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.3727%2F000000007783980837" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2007&pages=415-421&author=R.+Budzynskaauthor=D.+Nevozhayauthor=U.+Kanskaauthor=M.+Jagielloauthor=A.+Opolskiauthor=J.+Wietrzyk&title=Boratynski%2C+Antitumor+Activity+of+Mannan%E2%80%93Methotrexate+Conjugate+In-Vitro+and+In-Vivo&doi=10.3727%2F000000007783980837"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.3727%2F000000007783980837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3727%252F000000007783980837%26sid%3Dliteratum%253Aachs%26aulast%3DBudzynska%26aufirst%3DR.%26aulast%3DNevozhay%26aufirst%3DD.%26aulast%3DKanska%26aufirst%3DU.%26aulast%3DJagiello%26aufirst%3DM.%26aulast%3DOpolski%26aufirst%3DA.%26aulast%3DWietrzyk%26aufirst%3DJ.%26atitle%3DBoratynski%252C%2520Antitumor%2520Activity%2520of%2520Mannan%25E2%2580%2593Methotrexate%2520Conjugate%2520In-Vitro%2520and%2520In-Vivo%26jtitle%3DJ.%2520Ther.%26date%3D2007%26volume%3D16%26spage%3D415%26epage%3D421%26doi%3D10.3727%2F000000007783980837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampaio, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coutinho, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gama, F. M.</span></span> <span> </span><span class="NLM_article-title">Supramolecular Assembled Nanogel Made of Mannan</span>. <i>J. Colloid Interface Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>361</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">108</span>, <span class="refDoi"> DOI: 10.1016/j.jcis.2011.05.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.jcis.2011.05.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=21658701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotleks7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2011&pages=97-108&author=S.+A.+Ferreiraauthor=P.+Pereiraauthor=P.+Sampaioauthor=P.+J.+Coutinhoauthor=F.+M.+Gama&title=Supramolecular+Assembled+Nanogel+Made+of+Mannan&doi=10.1016%2Fj.jcis.2011.05.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Supramolecular assembled nanogel made of mannan</span></div><div class="casAuthors">Ferreira, Silvia A.; Pereira, Paula; Sampaio, Paula; Coutinho, Paulo J. G.; Gama, Francisco M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Colloid and Interface Science</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">97-108</span>CODEN:
                <span class="NLM_cas:coden">JCISA5</span>;
        ISSN:<span class="NLM_cas:issn">0021-9797</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The supramol. assembly of amphiphilic mannan, synthesized by the Michael addn. of hydrophobic 1-hexadecanethiol to vinyl methacrylated mannan, originates in aq. medium the formation of a nanogel, stabilized by hydrophobic interactions among alkyl chains.  The crit. aggregation concn., calcd. by fluorescence spectroscopy ranged between 0.002 and 0.01 mg/mL, depending on the polymer degree of substitution.  The cryo-field emission SEM showed spherical macromol. micelles with diams. between 100 and 500 nm.  The dynamic light scattering anal. revealed a polydisperse colloidal system, with mean hydrodynamic diam. between 50 and 140 nm, depending on the polymer degree of substitution.  The nanogel is neg. charged, stable over a 6 mo storage period, and stable at pH 3-8, salt or urea solns.  Bovine serum albumin and curcumin were spontaneously incorporated in the nanogel, being stabilized by the hydrophobic domains, opening the possibility for future applications as potential delivery systems for therapeutic mols.  In vitro assays were carried out to characterize the biocompatibility of the nanogel.  A toxic effect of mannan-C16 was obsd., specific to mouse macrophage-like cell line J774, not affecting mouse embryo fibroblast cell line 3T3 viability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_GE146OubtrVg90H21EOLACvtfcHk0ljBOECjrpOI6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotleks7c%253D&md5=e96c39dfcaacfed0042c9d62b6331767</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1016%2Fj.jcis.2011.05.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jcis.2011.05.020%26sid%3Dliteratum%253Aachs%26aulast%3DFerreira%26aufirst%3DS.%2BA.%26aulast%3DPereira%26aufirst%3DP.%26aulast%3DSampaio%26aufirst%3DP.%26aulast%3DCoutinho%26aufirst%3DP.%2BJ.%26aulast%3DGama%26aufirst%3DF.%2BM.%26atitle%3DSupramolecular%2520Assembled%2520Nanogel%2520Made%2520of%2520Mannan%26jtitle%3DJ.%2520Colloid%2520Interface%2520Sci.%26date%3D2011%26volume%3D361%26spage%3D97%26epage%3D108%26doi%3D10.1016%2Fj.jcis.2011.05.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvalho, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teixeira, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilanova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gama, F. M.</span></span> <span> </span><span class="NLM_article-title">Self-Assembled Mannan Nanogel: Cytocompatibility and Cell Localization</span>. <i>J. Biomed. Nanotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">473</span>– <span class="NLM_lpage">481</span>, <span class="refDoi"> DOI: 10.1166/jbn.2012.1408</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1166%2Fjbn.2012.1408" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=22764417" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC38XotFWmtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=473-481&author=S.+A.+Ferreiraauthor=V.+Carvalhoauthor=C.+Costaauthor=J.+P.+Teixeiraauthor=M.+Vilanovaauthor=F.+M.+Gama&title=Self-Assembled+Mannan+Nanogel%3A+Cytocompatibility+and+Cell+Localization&doi=10.1166%2Fjbn.2012.1408"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Self-assembled mannan nanogel: cytocompatibility and cell localization</span></div><div class="casAuthors">Ferreira, Silvia A.; Carvalho, Vera; Costa, Carla; Teixeira, Joao Paulo; Vilanova, Manuel; Gama, Francisco M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomedical Nanotechnology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">473-481</span>CODEN:
                <span class="NLM_cas:coden">JBNOAB</span>;
        ISSN:<span class="NLM_cas:issn">1550-7033</span>.
    
            (<span class="NLM_cas:orgname">American Scientific Publishers</span>)
        </div><div class="casAbstract">Amphiphilic mannan, produced by the Michael addn. of hydrophobic 1-hexadecanethiol to vinyl methacrylated mannan, self-assembles in aq. medium through hydrophobic interactions among alkyl chains.  The resultant nanogel is stable, spherical, polydisperse, with 50-140 nm mean hydrodynamic diam. depending on the polymer degree of substitution, and nearly neutral neg. surface charge.  No cytotoxicity of mannan nanogel is detected up to about 0.4 mg/mL in mouse embryo fibroblast cell line 3T3 and mouse bone marrow-derived macrophages (BMDM) using cell proliferation, lactate dehydrogenase and Live/Dead assays.  Comet assay, under the tested conditions, reveals no DNA damage in fibroblasts but possible in BMDM.  BMDM internalize the mannan nanogel, which is obsd. in vesicles in the cytoplasm by confocal laser scanning microscopy.  Confocal colocalization image anal. denotes that the entrance and exit of nanogel and FM 4-64 might occur by the same processes, endocytosis and exocytosis, in BMDM.  Physicochem. characteristics, in vitro cytocompatibility and uptake of self-assembled mannan nanogel by mouse BMDM are great signals of the potential applicability of this nanosystem for macrophages targeted delivery of vaccines or drugs, acting as potential nanomedicines, always with the key goal of preventing and/or treating diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqb7GFGjPO-6LVg90H21EOLACvtfcHk0ljBOECjrpOI6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotFWmtb0%253D&md5=7ab7e1fcc2ecba4d7b2f2579c1b0e6ed</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1166%2Fjbn.2012.1408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1166%252Fjbn.2012.1408%26sid%3Dliteratum%253Aachs%26aulast%3DFerreira%26aufirst%3DS.%2BA.%26aulast%3DCarvalho%26aufirst%3DV.%26aulast%3DCosta%26aufirst%3DC.%26aulast%3DTeixeira%26aufirst%3DJ.%2BP.%26aulast%3DVilanova%26aufirst%3DM.%26aulast%3DGama%26aufirst%3DF.%2BM.%26atitle%3DSelf-Assembled%2520Mannan%2520Nanogel%253A%2520Cytocompatibility%2520and%2520Cell%2520Localization%26jtitle%3DJ.%2520Biomed.%2520Nanotechnol.%26date%3D2012%26volume%3D8%26spage%3D473%26epage%3D481%26doi%3D10.1166%2Fjbn.2012.1408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Apostolopoulos, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietersz, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsibanis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsikkinis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drakaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loveland, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piddlesden, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plebanski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pouniotis, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexis, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenzie, I. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vassilaros, S.</span></span> <span> </span><span class="NLM_article-title">Pilot Phase III Immunotherapy Study in Early-Stage Breast Cancer Patients Using Oxidized Mannan-MUC1</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">R27</span>, <span class="refDoi"> DOI: 10.1186/bcr1505</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1186%2Fbcr1505" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=16776849" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2006&pages=R27&author=V.+Apostolopoulosauthor=G.+A.+Pieterszauthor=A.+Tsibanisauthor=A.+Tsikkinisauthor=H.+Drakakiauthor=B.+E.+Lovelandauthor=S.+J.+Piddlesdenauthor=M.+Plebanskiauthor=D.+S.+Pouniotisauthor=M.+N.+Alexisauthor=I.+F.+McKenzieauthor=S.+Vassilaros&title=Pilot+Phase+III+Immunotherapy+Study+in+Early-Stage+Breast+Cancer+Patients+Using+Oxidized+Mannan-MUC1&doi=10.1186%2Fbcr1505"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1186%2Fbcr1505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fbcr1505%26sid%3Dliteratum%253Aachs%26aulast%3DApostolopoulos%26aufirst%3DV.%26aulast%3DPietersz%26aufirst%3DG.%2BA.%26aulast%3DTsibanis%26aufirst%3DA.%26aulast%3DTsikkinis%26aufirst%3DA.%26aulast%3DDrakaki%26aufirst%3DH.%26aulast%3DLoveland%26aufirst%3DB.%2BE.%26aulast%3DPiddlesden%26aufirst%3DS.%2BJ.%26aulast%3DPlebanski%26aufirst%3DM.%26aulast%3DPouniotis%26aufirst%3DD.%2BS.%26aulast%3DAlexis%26aufirst%3DM.%2BN.%26aulast%3DMcKenzie%26aufirst%3DI.%2BF.%26aulast%3DVassilaros%26aufirst%3DS.%26atitle%3DPilot%2520Phase%2520III%2520Immunotherapy%2520Study%2520in%2520Early-Stage%2520Breast%2520Cancer%2520Patients%2520Using%2520Oxidized%2520Mannan-MUC1%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2006%26volume%3D8%26spage%3DR27%26doi%3D10.1186%2Fbcr1505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. M.</span></span> <span> </span><span class="NLM_article-title">Development of a Mucin4-Targeting SPIO Contrast Agent for Effective Detection of Pancreatic Tumor Cells In-Vitro and In-Vivo</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">9100</span>– <span class="NLM_lpage">9109</span>, <span class="refDoi"> DOI: 10.1021/jm401060z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401060z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1KktL7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=9100-9109&author=S.+C.+Wuauthor=Y.+J.+Chenauthor=Y.+J.+Linauthor=T.+H.+Wuauthor=Y.+M.+Wang&title=Development+of+a+Mucin4-Targeting+SPIO+Contrast+Agent+for+Effective+Detection+of+Pancreatic+Tumor+Cells+In-Vitro+and+In-Vivo&doi=10.1021%2Fjm401060z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Mucin4-Targeting SPIO Contrast Agent for Effective Detection of Pancreatic Tumor Cells in Vitro and in Vivo</span></div><div class="casAuthors">Wu, Shou-Cheng; Chen, Yu-Jen; Lin, Yi-Jan; Wu, Tung-Ho; Wang, Yun-Ming</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9100-9109</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In search of a unique and reliable contrast agent targeting pancreatic adenocarcinoma, new multifunctional nanoparticles (MnMEIO-silane-NH2-(MUC4)-mPEG NPs) were successfully developed in this study.  Mucin4-expression levels were detd. through different imaging studies in a panel of pancreatic tumor cells (HPAC, BxPC-3, and Panc-1) both in vitro and in vivo studies.  The in vitro T2-weighted MR imaging study in HPAC and Panc-1 tumor cells treated with NPs showed -89.1 ± 5.7% and -0.9 ± 0.2% contrast enhancement, whereas in in vivo study, it is found to be -81.5 ± 4.5% vs. -19.6 ± 5.2% (24 h postinjection, 7.0 T), resp.  The T2-weighted MR and optical imaging studies revealed that the novel contrast agent can specifically and effectively target to mucin4-expressing tumors in nude mice.  Hence, it is suggested that MnMEIO-silane-NH2-(MUC4)-mPEG NPs are able to provide an efficient and targeted delivery of MUC4 antibodies to mucin4-expressing pancreatic tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqENH9lGC6ElbVg90H21EOLACvtfcHk0ljBOECjrpOI6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1KktL7M&md5=e926b9a0772536ef00ee769d43a15796</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1021%2Fjm401060z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401060z%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DS.%2BC.%26aulast%3DChen%26aufirst%3DY.%2BJ.%26aulast%3DLin%26aufirst%3DY.%2BJ.%26aulast%3DWu%26aufirst%3DT.%2BH.%26aulast%3DWang%26aufirst%3DY.%2BM.%26atitle%3DDevelopment%2520of%2520a%2520Mucin4-Targeting%2520SPIO%2520Contrast%2520Agent%2520for%2520Effective%2520Detection%2520of%2520Pancreatic%2520Tumor%2520Cells%2520In-Vitro%2520and%2520In-Vivo%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D9100%26epage%3D9109%26doi%3D10.1021%2Fjm401060z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dufresne, A.</span></span> <span> </span><span class="NLM_article-title">Nanocellulose in Biomedicine: Current Status and Future Prospect</span>. <i>Eur. Polym. J.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">302</span>– <span class="NLM_lpage">325</span>, <span class="refDoi"> DOI: 10.1016/j.eurpolymj.2014.07.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.eurpolymj.2014.07.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Kgs7%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2014&pages=302-325&author=N.+Linauthor=A.+Dufresne&title=Nanocellulose+in+Biomedicine%3A+Current+Status+and+Future+Prospect&doi=10.1016%2Fj.eurpolymj.2014.07.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Nanocellulose in biomedicine: Current status and future prospect</span></div><div class="casAuthors">Lin, Ning; Dufresne, Alain</div><div class="citationInfo"><span class="NLM_cas:title">European Polymer Journal</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">302-325</span>CODEN:
                <span class="NLM_cas:coden">EUPJAG</span>;
        ISSN:<span class="NLM_cas:issn">0014-3057</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Nanocellulose, a unique and promising natural material extd. from native cellulose, has gained much attention for its use as biomedical material, because of its remarkable phys. properties, special surface chem. and excellent biol. properties (biocompatibility, biodegradability and low toxicity).  Three different types of nanocellulose, viz. cellulose nanocrystals (CNC), cellulose nanofibrils (CNF) and bacterial cellulose (BC), are introduced and compared in terms of prodn., properties and biomedical applications in this article.  The advancement of nanocellulose-based biomedical materials is summarized and discussed on the anal. of latest studies (esp. reports from the past five years).  Selected studies with significant findings are emphasized, and focused topics for nanocellulose in biomedicine research in this article include the discussion at the level of mol. (e.g. tissue bioscaffolds for cellular culture; drug excipient and drug delivery; and immobilization and recognition of enzyme/protein) as well as at the level of macroscopic biomaterials (e.g. blood vessel and soft tissue substitutes; skin and bone tissue repair materials; and antimicrobial materials).  Functional modification of nanocellulose will det. the potential biomedical application for nanocellulose, which is also introduced as a sepd. section in the article.  Finally, future perspectives and possible research points are proposed in Section 5.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdLSCasVlR8rVg90H21EOLACvtfcHk0ljrCoBcKlVPWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Kgs7%252FF&md5=2b35e7c586aaf5fdc2f5cb7675dd62c2</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2Fj.eurpolymj.2014.07.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.eurpolymj.2014.07.025%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DN.%26aulast%3DDufresne%26aufirst%3DA.%26atitle%3DNanocellulose%2520in%2520Biomedicine%253A%2520Current%2520Status%2520and%2520Future%2520Prospect%26jtitle%3DEur.%2520Polym.%2520J.%26date%3D2014%26volume%3D59%26spage%3D302%26epage%3D325%26doi%3D10.1016%2Fj.eurpolymj.2014.07.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Souza Lima, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borsali, R.</span></span> <span> </span><span class="NLM_article-title">Rodlike Cellulose Microcrystals: Structure, Properties, and Applications</span>. <i>Macromol. Rapid Commun.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">771</span>– <span class="NLM_lpage">787</span>, <span class="refDoi"> DOI: 10.1002/marc.200300268</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1002%2Fmarc.200300268" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjt1Smsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2004&pages=771-787&author=M.+M.+De%0ASouza+Limaauthor=R.+Borsali&title=Rodlike+Cellulose+Microcrystals%3A+Structure%2C+Properties%2C+and+Applications&doi=10.1002%2Fmarc.200300268"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Rodlike cellulose microcrystals: structure, properties, and applications</span></div><div class="casAuthors">De Souza Lima, M. Miriam; Borsali, Redouane</div><div class="citationInfo"><span class="NLM_cas:title">Macromolecular Rapid Communications</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">771-787</span>CODEN:
                <span class="NLM_cas:coden">MRCOE3</span>;
        ISSN:<span class="NLM_cas:issn">1022-1336</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  In this article we present some interesting properties of rodlike cellulose microcrystals (so-called "whiskers").  These microcrystals can be obtained from different cellulose sources such as wood, cotton, or animal origin.  When submitted to acid hydrolysis, the cellulose fibers yield stable aq. suspensions because of the presence of neg. charges on the surface of the microcrystallites during the hydrolysis process.  The obtained microcrystals are rod-shaped particles, the dimensions of which depend on the cellulose origin.  For instance, the cotton whiskers have typical dimensions varying from 100 to 300 nm in length, L, and 8 to 10 nm in diam., d, while those of the tunicate whiskers range from 100 nm to few micrometers in length and 10 to 20 nm in diam.  At very low concns., these whiskers are randomly suspended in water and form an isotropic phase.  When the concn. reaches a crit. value, the whiskers spontaneously display ordered phases showing interesting liq. crystal properties (nematic and chiral nematic).  The chiral nematic orders can be retained after evapn. of the solvent (generally water), leaving iridescent films.  The reflected color can be controlled by changing either the ionic strength or by applying an elec. field.  These colloidal particles have been investigated using several techniques including small-angle neutron scattering (SANS), small angle X-ray scattering, rheol., and more recently dynamic and static light scattering techniques (DLS and SLS) to highlight their static and dynamic behavior.  Because of their geometry, important axis ratio (L/d), and high crystallinity, these rods have been also extensively used to process nanocomposites based on polymer matrixes, to reinforce their mech. properties.  All these properties are discussed in this contribution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqW6BHsoNSKHrVg90H21EOLACvtfcHk0ljrCoBcKlVPWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjt1Smsbk%253D&md5=efc89570dff19fc3ff258d6b95e2b5ab</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1002%2Fmarc.200300268&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmarc.200300268%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BSouza%2BLima%26aufirst%3DM.%2BM.%26aulast%3DBorsali%26aufirst%3DR.%26atitle%3DRodlike%2520Cellulose%2520Microcrystals%253A%2520Structure%252C%2520Properties%252C%2520and%2520Applications%26jtitle%3DMacromol.%2520Rapid%2520Commun.%26date%3D2004%26volume%3D25%26spage%3D771%26epage%3D787%26doi%3D10.1002%2Fmarc.200300268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Colacino, K.</span></span> <i>Potential of Cellulose Nanocrystals in the Detection and Treatment of Cancer</i>. Doctoral Dissertation. <span class="NLM_publisher-name">Virginia Tech University</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=K.+Colacino&title=Potential+of+Cellulose+Nanocrystals+in+the+Detection+and+Treatment+of+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DColacino%26aufirst%3DK.%26jtitle%3DPotential%2520of%2520Cellulose%2520Nanocrystals%2520in%2520the%2520Detection%2520and%2520Treatment%2520of%2520Cancer%26pub%3DVirginia%2520Tech%2520University%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sivakumar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aswathy, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagaoka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maekawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakthikumar, D. N.</span></span> <span> </span><span class="NLM_article-title">Multifunctional Carboxymethyl Cellulose-Based Magnetic Nanovector as a Theragnostic System for Folate Receptor Targeted Chemotherapy, Imaging, and Hyperthermia Against Cancer</span>. <i>Langmuir</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">3453</span>– <span class="NLM_lpage">3466</span>, <span class="refDoi"> DOI: 10.1021/la305048m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/la305048m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC3sXisV2iu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2013&pages=3453-3466&author=B.+Sivakumarauthor=R.+G.+Aswathyauthor=Y.+Nagaokaauthor=M.+Suzukiauthor=T.+Fukudaauthor=Y.+Yoshidaauthor=T.+Maekawaauthor=D.+N.+Sakthikumar&title=Multifunctional+Carboxymethyl+Cellulose-Based+Magnetic+Nanovector+as+a+Theragnostic+System+for+Folate+Receptor+Targeted+Chemotherapy%2C+Imaging%2C+and+Hyperthermia+Against+Cancer&doi=10.1021%2Fla305048m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Multifunctional Carboxymethyl Cellulose-Based Magnetic Nanovector as a Theragnostic System for Folate Receptor Targeted Chemotherapy, Imaging, and Hyperthermia against Cancer</span></div><div class="casAuthors">Sivakumar, Balasubramanian; Aswathy, Ravindran Girija; Nagaoka, Yutaka; Suzuki, Masashi; Fukuda, Takahiro; Yoshida, Yasuhiko; Maekawa, Toru; Sakthikumar, Dasappan Nair</div><div class="citationInfo"><span class="NLM_cas:title">Langmuir</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3453-3466</span>CODEN:
                <span class="NLM_cas:coden">LANGD5</span>;
        ISSN:<span class="NLM_cas:issn">0743-7463</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A multifunctional biocompatible nanovector based on magnetic nanoparticle and CM-cellulose (CMC) was developed.  The nanoparticles have been characterized using TEM, SEM, DLS, FT-IR spectra, VSM, and TGA studies.  We found that the synthesized CM-cellulose magnetic nanoparticles (CMC MNPs) were spherical in shape with an av. size of 150 nm having low aggregation and superparamagnetic properties.  We found that the folate-tagged CMC MNPs were delivered to cancer cells by a folate-receptor-mediated endocytosis mechanism. 5-FU was encapsulated as a model drug for delivering cytotoxicity, and we could demonstrate the sustained release of 5-FU.  It was also obsd. that the FITC-labeled CMC MNPs could effectively enter cells, and the fate of nanoparticles was tracked with Lysotracker.  The CMC MNPs could induce significant cell death when an alternating magnetic field was applied.  These results indicate that the multifunctional CMC MNPs possess a high drug loading efficiency and high biocompatibility and with low cell cytotoxicity and can be considered to be promising candidates for CMC-based targeted drug delivery, cellular imaging, and magnetic hyperthermia (MHT).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0fr7LR-YMurVg90H21EOLACvtfcHk0ljrCoBcKlVPWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXisV2iu70%253D&md5=f28c4cb20c7e3c06ee65a8970db7f5ce</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1021%2Fla305048m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fla305048m%26sid%3Dliteratum%253Aachs%26aulast%3DSivakumar%26aufirst%3DB.%26aulast%3DAswathy%26aufirst%3DR.%2BG.%26aulast%3DNagaoka%26aufirst%3DY.%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DFukuda%26aufirst%3DT.%26aulast%3DYoshida%26aufirst%3DY.%26aulast%3DMaekawa%26aufirst%3DT.%26aulast%3DSakthikumar%26aufirst%3DD.%2BN.%26atitle%3DMultifunctional%2520Carboxymethyl%2520Cellulose-Based%2520Magnetic%2520Nanovector%2520as%2520a%2520Theragnostic%2520System%2520for%2520Folate%2520Receptor%2520Targeted%2520Chemotherapy%252C%2520Imaging%252C%2520and%2520Hyperthermia%2520Against%2520Cancer%26jtitle%3DLangmuir%26date%3D2013%26volume%3D29%26spage%3D3453%26epage%3D3466%26doi%3D10.1021%2Fla305048m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohan
Yallapu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray Dobberpuhl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michele Maher, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaggi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chand Chauhan, S.</span></span> <span> </span><span class="NLM_article-title">Design of Curcumin Loaded Cellulose Nanoparticles for Prostate Cancer</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">120</span>– <span class="NLM_lpage">128</span>, <span class="refDoi"> DOI: 10.2174/138920012798356952</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.2174%2F138920012798356952" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=21892919" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=120-128&author=M.+Mohan%0AYallapuauthor=M.+Ray+Dobberpuhlauthor=D.+Michele+Maherauthor=M.+Jaggiauthor=S.+Chand+Chauhan&title=Design+of+Curcumin+Loaded+Cellulose+Nanoparticles+for+Prostate+Cancer&doi=10.2174%2F138920012798356952"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.2174%2F138920012798356952&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920012798356952%26sid%3Dliteratum%253Aachs%26aulast%3DMohan%2BYallapu%26aufirst%3DM.%26aulast%3DRay%2BDobberpuhl%26aufirst%3DM.%26aulast%3DMichele%2BMaher%26aufirst%3DD.%26aulast%3DJaggi%26aufirst%3DM.%26aulast%3DChand%2BChauhan%26aufirst%3DS.%26atitle%3DDesign%2520of%2520Curcumin%2520Loaded%2520Cellulose%2520Nanoparticles%2520for%2520Prostate%2520Cancer%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2012%26volume%3D13%26spage%3D120%26epage%3D128%26doi%3D10.2174%2F138920012798356952" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arruebo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valladares, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González-Fernández, Á.</span></span> <span> </span><span class="NLM_article-title">Antibody-Conjugated Nanoparticles for Biomedical Applications</span>. <i>J. Nanomater.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>2009</i></span> (<span class="NLM_issue">37</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1155/2009/439389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1155%2F2009%2F439389" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2009&publication_year=2009&pages=1-24&issue=37&author=M.+Arrueboauthor=M.+Valladaresauthor=%C3%81.+Gonz%C3%A1lez-Fern%C3%A1ndez&title=Antibody-Conjugated+Nanoparticles+for+Biomedical+Applications&doi=10.1155%2F2009%2F439389"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1155%2F2009%2F439389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2009%252F439389%26sid%3Dliteratum%253Aachs%26aulast%3DArruebo%26aufirst%3DM.%26aulast%3DValladares%26aufirst%3DM.%26aulast%3DGonz%25C3%25A1lez-Fern%25C3%25A1ndez%26aufirst%3D%25C3%2581.%26atitle%3DAntibody-Conjugated%2520Nanoparticles%2520for%2520Biomedical%2520Applications%26jtitle%3DJ.%2520Nanomater.%26date%3D2009%26volume%3D2009%26issue%3D37%26spage%3D1%26epage%3D24%26doi%3D10.1155%2F2009%2F439389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Voltan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Secchiero, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruozi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agostinis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caruso, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandelli, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zauli, G.</span></span> <span> </span><span class="NLM_article-title">Nanoparticles Engineered with Rituximab and Loaded with Nutlin-3 Show Promising Therapeutic Activity in B-Leukemic Xenografts</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">3871</span>– <span class="NLM_lpage">3880</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-0015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1158%2F1078-0432.CCR-13-0015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=23719263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFSrtbbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=3871-3880&author=R.+Voltanauthor=P.+Secchieroauthor=B.+Ruoziauthor=F.+Forniauthor=C.+Agostinisauthor=L.+Carusoauthor=M.+A.+Vandelliauthor=G.+Zauli&title=Nanoparticles+Engineered+with+Rituximab+and+Loaded+with+Nutlin-3+Show+Promising+Therapeutic+Activity+in+B-Leukemic+Xenografts&doi=10.1158%2F1078-0432.CCR-13-0015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Nanoparticles Engineered with Rituximab and Loaded with Nutlin-3 Show Promising Therapeutic Activity in B-Leukemic Xenografts</span></div><div class="casAuthors">Voltan, Rebecca; Secchiero, Paola; Ruozi, Barbara; Forni, Flavio; Agostinis, Chiara; Caruso, Lorenzo; Vandelli, Maria Angela; Zauli, Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3871-3880</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Because the nongenotoxic inhibitor of the p53/MDM2 interactions Nutlin-3 has shown promising in vitro therapeutic activity against a variety of p53wild-type cancer cells, in this study we evaluated an innovative strategy able to specifically target Nutlin-3 toward CD20+ malignant cells.  Exptl. Design: The cytotoxic effects of Nutlin-3 encapsulated into poly(lactide-co-glycolide) nanoparticles (NP-Nut) and into rituximab (anti-CD20 antibody)-engineered NP (NP-Rt-Nut) as well as of NPs engineered with rituximab alone (NP-Rt) were initially analyzed in vitro in JVM-2 B-leukemic cells, by assessing both the functional activation of the p53 pathway (by Nutlin-3) and/or the activation of the complement cascade (by rituximab).  Moreover, the potential therapeutic efficacy of NP-Nut, NP-Rt, and NP-Rt-Nut were comparatively assessed in vivo in CD20+ JVM-2 leukemic xenograft SCID mice.  Results: Functional in vitro assays showed that NP-Nut and NP-Rt-Nut exhibited a comparable ability to activate the p53 pathway in the p53wild-type JVM-2 leukemic cells.  On the other hand, NP-Rt and NP-Rt-Nut, but not NP nor NP-Nut, were able to promote activation of the complement cascade.  Of note, the in vivo intratumoral injection in JVM-2 B-leukemic/xenograft mice showed that NP-Rt-Nut displayed the maximal therapeutic activity promoting a survival rate significantly higher not only with respect to control animals, treated either with vehicle or with empty NP, but also with respect to animals treated with NP-Nut or NP-Rt.  Conclusions: Our data show for the first time the potential antileukemic activity of rituximab-engineered Nutlin-3-loaded NPs in xenograft SCID mice.  Clin Cancer Res; 19(14); 3871-80. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4AHlUfDjFV7Vg90H21EOLACvtfcHk0lia9_xFaWZPKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFSrtbbJ&md5=ae48d72062bf4b7d560ddf69dc42bace</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0015%26sid%3Dliteratum%253Aachs%26aulast%3DVoltan%26aufirst%3DR.%26aulast%3DSecchiero%26aufirst%3DP.%26aulast%3DRuozi%26aufirst%3DB.%26aulast%3DForni%26aufirst%3DF.%26aulast%3DAgostinis%26aufirst%3DC.%26aulast%3DCaruso%26aufirst%3DL.%26aulast%3DVandelli%26aufirst%3DM.%2BA.%26aulast%3DZauli%26aufirst%3DG.%26atitle%3DNanoparticles%2520Engineered%2520with%2520Rituximab%2520and%2520Loaded%2520with%2520Nutlin-3%2520Show%2520Promising%2520Therapeutic%2520Activity%2520in%2520B-Leukemic%2520Xenografts%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D3871%26epage%3D3880%26doi%3D10.1158%2F1078-0432.CCR-13-0015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span> <span> </span><span class="NLM_article-title">Intracellular pH-Responsive and Rituximab-Conjugated Mesoporous Silica Nanoparticles for Targeted Drug Delivery to Lymphoma B Cells</span>. <i>J. Exp. Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">14</span>, <span class="refDoi"> DOI: 10.1186/s13046-017-0492-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1186%2Fs13046-017-0492-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=28049532" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2017&pages=1-14&issue=24&author=S.+Zhouauthor=D.+Wuauthor=X.+Yinauthor=X.+Jinauthor=X.+Zhangauthor=S.+Zhengauthor=C.+Wangauthor=Y.+Liu&title=Intracellular+pH-Responsive+and+Rituximab-Conjugated+Mesoporous+Silica+Nanoparticles+for+Targeted+Drug+Delivery+to+Lymphoma+B+Cells&doi=10.1186%2Fs13046-017-0492-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1186%2Fs13046-017-0492-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13046-017-0492-6%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DYin%26aufirst%3DX.%26aulast%3DJin%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DY.%26atitle%3DIntracellular%2520pH-Responsive%2520and%2520Rituximab-Conjugated%2520Mesoporous%2520Silica%2520Nanoparticles%2520for%2520Targeted%2520Drug%2520Delivery%2520to%2520Lymphoma%2520B%2520Cells%26jtitle%3DJ.%2520Exp.%2520Clin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D36%26issue%3D24%26spage%3D1%26epage%3D14%26doi%3D10.1186%2Fs13046-017-0492-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranganathan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, S.-S.</span></span> <span> </span><span class="NLM_article-title">Multifunctional Poly (D, L-Lactide-Co-Glycolide)/Montmorillonite (PLGA/MMT) Nanoparticles Decorated by Trastuzumab for Targeted Chemotherapy of Breast Cancer</span>. <i>Biomaterials</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">475</span>– <span class="NLM_lpage">486</span>, <span class="refDoi"> DOI: 10.1016/j.biomaterials.2007.09.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.biomaterials.2007.09.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=17953985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A280%3ADC%252BD2snosVKjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2008&pages=475-486&author=B.+Sunauthor=B.+Ranganathanauthor=S.-S.+Feng&title=Multifunctional+Poly+%28D%2C+L-Lactide-Co-Glycolide%29%2FMontmorillonite+%28PLGA%2FMMT%29+Nanoparticles+Decorated+by+Trastuzumab+for+Targeted+Chemotherapy+of+Breast+Cancer&doi=10.1016%2Fj.biomaterials.2007.09.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Multifunctional poly(D,L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer</span></div><div class="casAuthors">Sun Bingfeng; Ranganathan Balu; Feng Si-Shen</div><div class="citationInfo"><span class="NLM_cas:title">Biomaterials</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">475-86</span>
        ISSN:<span class="NLM_cas:issn">0142-9612</span>.
    </div><div class="casAbstract">This paper continued our earlier work on the poly(D,L-lactide-co-glycolide)/montmorillonite nanoparticles (PLGA/MMT NPs), which were further decorated by human epidermal growth factor receptor-2 (HER2) antibody Trastuzumab for targeted breast cancer chemotherapy with paclitaxel as a model anticancer drug.  Such a NP system is multifunctional, which formulates anticancer drugs with no harmful adjuvant, reduces the side effects of the formulated anticancer drug, promotes synergistic therapeutic effects, and achieves targeted delivery of the therapy.  The paclitaxel-loaded PLGA/MMT NPs were prepared by a modified solvent extraction/evaporation technique, which were then decorated with Trastuzumab.  The effects of the surface decoration on particle size and size distribution, surface morphology, drug encapsulation efficiency, as well as the drug release kinetics, were investigated.  The NP formulation exhibited a biphasic drug release with a moderate initial burst followed by a sustained release profile.  The surface decoration speeded the drug release.  Surface chemistry analysis was conducted by X-ray photoelectron spectroscopy (XPS), which confirmed the presence of Trastuzumab on the NP surface.  Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis showed the stability of the antibody in the NP preparation process.  Internalization of the coumarin-6-loaded PLGA/MMT NPs with or without the antibody decoration by both of Caco-2 colon adeno carcinoma cells and SK-BR-3 breast cancer cells was visualized by confocal laser scanning microscopy and quantitatively analyzed, which shows that the antibody decoration achieved significantly higher cellular uptake of the NPs.  The results of in vitro cytotoxicity experiment on SK-BR-3 cells further proved the targeting effects of the antibody decoration.  Judged by IC50 after 24h culture, the therapeutic effects of the drug formulated in the NPs with surface decoration could be 12.74 times higher than that of the bare NPs and 13.11 times higher than Taxol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT9V8O6sKsTrNbHMBt0mMIXfW6udTcc2eYTyerSmuklObntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2snosVKjtQ%253D%253D&md5=94686aed4f3cf8e05fee0feb49b3baab</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1016%2Fj.biomaterials.2007.09.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biomaterials.2007.09.038%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DB.%26aulast%3DRanganathan%26aufirst%3DB.%26aulast%3DFeng%26aufirst%3DS.-S.%26atitle%3DMultifunctional%2520Poly%2520%2528D%252C%2520L-Lactide-Co-Glycolide%2529%252FMontmorillonite%2520%2528PLGA%252FMMT%2529%2520Nanoparticles%2520Decorated%2520by%2520Trastuzumab%2520for%2520Targeted%2520Chemotherapy%2520of%2520Breast%2520Cancer%26jtitle%3DBiomaterials%26date%3D2008%26volume%3D29%26spage%3D475%26epage%3D486%26doi%3D10.1016%2Fj.biomaterials.2007.09.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ito, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuga, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikkawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horiuchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span> <span> </span><span class="NLM_article-title">Magnetite Nanoparticle-Loaded Anti-HER2 Immunoliposomes for Combination of Antibody Therapy with Hyperthermia</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>212</i></span>,  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">175</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2004.03.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.canlet.2004.03.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=15279897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlvFyqtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=212&publication_year=2004&pages=167-175&author=A.+Itoauthor=Y.+Kugaauthor=H.+Hondaauthor=H.+Kikkawaauthor=A.+Horiuchiauthor=Y.+Watanabeauthor=T.+Kobayashi&title=Magnetite+Nanoparticle-Loaded+Anti-HER2+Immunoliposomes+for+Combination+of+Antibody+Therapy+with+Hyperthermia&doi=10.1016%2Fj.canlet.2004.03.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Magnetite nanoparticle-loaded anti-HER2 immunoliposomes for combination of antibody therapy with hyperthermia</span></div><div class="casAuthors">Ito, Akira; Kuga, Yuko; Honda, Hiroyuki; Kikkawa, Hiroyuki; Horiuchi, Atsushi; Watanabe, Yuji; Kobayashi, Takeshi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">212</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">167-175</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Anti-HER2 antibody can induce antitumor responses, and can be used in delivering drugs to HER2-overexressing cancer.  Previously, we produced hyperthermia using magnetite nanoparticles that generate heat in an alternating magnetic field.  In the present study, we constructed anti-HER2 immunoliposomes contg. magnetite nanoparticles, which act as tumor-targeting vehicles, combining anti-HER2 antibody therapy with hyperthermia.  The magnetite nanoparticle-loaded anti-HER2 immunoliposomes exerted HER2-mediated antiproliferative effects on SKBr3 breast cancer cells in vitro.  Moreover, 60% of magnetite nanoparticles were incorporated into SKBr3, and the cells were then heated at 42.5° under an alternating magnetic field, resulting in strong cytotoxic effects.  These results suggest that this novel therapeutic tool is applicable to treatment of HER2-overexpressing cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnJ8DF3mOMf7Vg90H21EOLACvtfcHk0lia9_xFaWZPKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlvFyqtLk%253D&md5=caa7728b68f61abfaf4b1ef12b3f8c52</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2004.03.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2004.03.038%26sid%3Dliteratum%253Aachs%26aulast%3DIto%26aufirst%3DA.%26aulast%3DKuga%26aufirst%3DY.%26aulast%3DHonda%26aufirst%3DH.%26aulast%3DKikkawa%26aufirst%3DH.%26aulast%3DHoriuchi%26aufirst%3DA.%26aulast%3DWatanabe%26aufirst%3DY.%26aulast%3DKobayashi%26aufirst%3DT.%26atitle%3DMagnetite%2520Nanoparticle-Loaded%2520Anti-HER2%2520Immunoliposomes%2520for%2520Combination%2520of%2520Antibody%2520Therapy%2520with%2520Hyperthermia%26jtitle%3DCancer%2520Lett.%26date%3D2004%26volume%3D212%26spage%3D167%26epage%3D175%26doi%3D10.1016%2Fj.canlet.2004.03.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arya, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acharya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahoo, S. K.</span></span> <span> </span><span class="NLM_article-title">EnhancedAntiproliferative Activity of Herceptin (HER2)-Conjugated Gemcitabine-Loaded Chitosan Nanoparticle in Pancreatic Cancer Therapy</span>. <i>Nanomedicine</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">859</span>– <span class="NLM_lpage">870</span>, <span class="refDoi"> DOI: 10.1016/j.nano.2011.03.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.nano.2011.03.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=21550422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWmu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=859-870&author=G.+Aryaauthor=M.+Vandanaauthor=S.+Acharyaauthor=S.+K.+Sahoo&title=EnhancedAntiproliferative+Activity+of+Herceptin+%28HER2%29-Conjugated+Gemcitabine-Loaded+Chitosan+Nanoparticle+in+Pancreatic+Cancer+Therapy&doi=10.1016%2Fj.nano.2011.03.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced antiproliferative activity of Herceptin (HER2)-conjugated gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapy</span></div><div class="casAuthors">Arya, Geetanjali; Vandana, Mallaredy; Acharya, Sarbari; Sahoo, Sanjeeb K.</div><div class="citationInfo"><span class="NLM_cas:title">Nanomedicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">859-870</span>CODEN:
                <span class="NLM_cas:coden">NANOBF</span>;
        ISSN:<span class="NLM_cas:issn">1549-9634</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Currently, effective drug delivery in pancreatic cancer treatment is a major challenge.  Nanomedicine plays an essential role by delivering anticancer drugs in a targeted manner to the malignant tumor cells, leading to increased efficacy by reducing the toxicity of anticancer drugs to normal, sensitive sites.  This study investigated the prepn. and characterization of a targeted system represented by Herceptin-conjugated gemcitabine-loaded chitosan nanoparticles (HER2-Gem-CS-NPs) for pancreatic cancer therapy.  The targeted NPs displayed superior antiproliferative activity along with an enhanced S-phase arrest, leading to apoptosis in comparison with unconjugated gemcitabine-loaded nanoparticles and free gemcitabine due to higher cellular binding with eventual uptake and prolonged intracellular retention.  Thus, HER2-Gem-CS-NPs are able to provide an efficient and targeted delivery of gemcitabine for pancreatic cancer treatment.  From the Clin. Editor: This study investigated the prepn. and characterization of a targeted drug delivery system consisting of Herceptin-conjugated gemcitabine-loaded chitosan nanoparticles for pancreatic cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsHQiMBrj2krVg90H21EOLACvtfcHk0lhmndO5OLtPGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWmu78%253D&md5=63d515bd07ae04d8e75f3080d76cd8bb</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2Fj.nano.2011.03.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nano.2011.03.009%26sid%3Dliteratum%253Aachs%26aulast%3DArya%26aufirst%3DG.%26aulast%3DVandana%26aufirst%3DM.%26aulast%3DAcharya%26aufirst%3DS.%26aulast%3DSahoo%26aufirst%3DS.%2BK.%26atitle%3DEnhancedAntiproliferative%2520Activity%2520of%2520Herceptin%2520%2528HER2%2529-Conjugated%2520Gemcitabine-Loaded%2520Chitosan%2520Nanoparticle%2520in%2520Pancreatic%2520Cancer%2520Therapy%26jtitle%3DNanomedicine%26date%3D2011%26volume%3D7%26spage%3D859%26epage%3D870%26doi%3D10.1016%2Fj.nano.2011.03.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamann, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinman, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollander, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beyer, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holcomb, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallett, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsou, H.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upeslacis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shochat, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mountain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flowers, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernstein, I.</span></span> <span> </span><span class="NLM_article-title">Gemtuzumab Ozogamicin, a Potent and Selective Anti-CD33 Antibody- Calicheamicin Conjugate for Treatment of Acute Myeloid Leukemia</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">47</span>– <span class="NLM_lpage">58</span>, <span class="refDoi"> DOI: 10.1021/bc010021y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc010021y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD3MXptFanurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2002&pages=47-58&author=P.+R.+Hamannauthor=L.+M.+Hinmanauthor=I.+Hollanderauthor=C.+F.+Beyerauthor=D.+Lindhauthor=R.+Holcombauthor=W.+Hallettauthor=H.-R.+Tsouauthor=J.+Upeslacisauthor=D.+Shochatauthor=A.+Mountainauthor=D.+A.+Flowersauthor=I.+Bernstein&title=Gemtuzumab+Ozogamicin%2C+a+Potent+and+Selective+Anti-CD33+Antibody-+Calicheamicin+Conjugate+for+Treatment+of+Acute+Myeloid+Leukemia&doi=10.1021%2Fbc010021y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Gemtuzumab Ozogamicin, A Potent and Selective Anti-CD33 Antibody-Calicheamicin Conjugate for Treatment of Acute Myeloid Leukemia</span></div><div class="casAuthors">Hamann, Philip R.; Hinman, Lois M.; Hollander, Irwin; Beyer, Carl F.; Lindh, Delores; Holcomb, Ryan; Hallett, William; Tsou, Hwei-Ru; Upeslacis, Janis; Shochat, Dan; Mountain, Andrew; Flowers, David A.; Bernstein, Irwin</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">47-58</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">CD33 is expressed by acute myeloid leukemia (AML) cells in >80% of patients but not by normal hematopoietic stem cells, suggesting that elimination of CD33+ cells may be therapeutically beneficial.  A conjugate of a calicheamicin hydrazide deriv. attached via hydrazone formation to the oxidized carbohydrates of the anti-CD33 murine antibody P67.6 had been chosen for use in AML prior to humanization of this antibody.  However, the CDR-grafted humanized P67.6 could not be used to make the carbohydrate conjugate because of the unexpected sensitivity of this antibody to periodate oxidn.  Exploration of a series of bifunctional linkers resulted in a new class of calicheamicin conjugates, termed the hybrid conjugates, that allows for the attachment of the calicheamicin to lysines but incorporates the site of hydrolytic release, a hydrazone, previously shown to be required for activity.  The optimized conjugate chosen for clin. trials, gemtuzumab ozogamicin ("gem-ozo", Mylotarg, formerly designated CMA-676), was significantly more potent and selective than the carbohydrate conjugate it replaced.  It was selectively cytotoxic to HL-60 leukemia cells in tissue culture with an IC50 in the low to sub-pg cal/mL range (cal = calicheamicin equiv.).  Doses of gem-ozo as low as 50 μg cal/kg given three times to mice bearing HL-60 xenografts routinely resulted in long-term, tumor-free survivors, while a nonbinding control conjugate was relatively inactive.  Gem-ozo at a concn. of 2 to 10 ng cal/mL selectively inhibited leukemia colony formation by marrow cells from a significant proportion of AML patients.  Gem-ozo has also shown significant activity against AML in Phase II trials and is the first antibody-targeted chemotherapeutic agent approved by the FDA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUzPmqKMIOx7Vg90H21EOLACvtfcHk0lhmndO5OLtPGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXptFanurg%253D&md5=56f273f4975fa6ebfa81e28f23111e8a</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1021%2Fbc010021y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc010021y%26sid%3Dliteratum%253Aachs%26aulast%3DHamann%26aufirst%3DP.%2BR.%26aulast%3DHinman%26aufirst%3DL.%2BM.%26aulast%3DHollander%26aufirst%3DI.%26aulast%3DBeyer%26aufirst%3DC.%2BF.%26aulast%3DLindh%26aufirst%3DD.%26aulast%3DHolcomb%26aufirst%3DR.%26aulast%3DHallett%26aufirst%3DW.%26aulast%3DTsou%26aufirst%3DH.-R.%26aulast%3DUpeslacis%26aufirst%3DJ.%26aulast%3DShochat%26aufirst%3DD.%26aulast%3DMountain%26aufirst%3DA.%26aulast%3DFlowers%26aufirst%3DD.%2BA.%26aulast%3DBernstein%26aufirst%3DI.%26atitle%3DGemtuzumab%2520Ozogamicin%252C%2520a%2520Potent%2520and%2520Selective%2520Anti-CD33%2520Antibody-%2520Calicheamicin%2520Conjugate%2520for%2520Treatment%2520of%2520Acute%2520Myeloid%2520Leukemia%26jtitle%3DBioconjugate%2520Chem.%26date%3D2002%26volume%3D13%26spage%3D47%26epage%3D58%26doi%3D10.1021%2Fbc010021y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yung, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, Y.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muthusamy, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcucci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. J.</span></span> <span> </span><span class="NLM_article-title">CD33-Targeted Lipid Nanoparticles (Acd33lns) for Therapeutic Delivery of GTI-2040 to Acute Myelogenous Leukemia</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2010</span>– <span class="NLM_lpage">2018</span>, <span class="refDoi"> DOI: 10.1021/mp5008212</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp5008212" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsVSkt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=2010-2018&author=H.+Liauthor=S.+Xuauthor=J.+Quanauthor=B.+C.+Yungauthor=J.+Pangauthor=C.+Zhouauthor=Y.-A.+Choauthor=M.+Zhangauthor=S.+Liuauthor=N.+Muthusamyauthor=K.+K.+Chanauthor=J.+C.+Byrdauthor=L.+J.+Leeauthor=G.+Marcucciauthor=R.+J.+Lee&title=CD33-Targeted+Lipid+Nanoparticles+%28Acd33lns%29+for+Therapeutic+Delivery+of+GTI-2040+to+Acute+Myelogenous+Leukemia&doi=10.1021%2Fmp5008212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">CD33-Targeted Lipid Nanoparticles (aCD33LNs) for Therapeutic Delivery of GTI-2040 to Acute Myelogenous Leukemia</span></div><div class="casAuthors">Li, Hong; Xu, Songlin; Quan, Jishan; Yung, Bryant C.; Pang, Jiuxia; Zhou, Chenguang; Cho, Young-Ah; Zhang, Mengzi; Liu, Shujun; Muthusamy, Natarajan; Chan, Kenneth K.; Byrd, John C.; Lee, L. James; Marcucci, Guido; Lee, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2010-2018</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">CD33-targeted lipid nanoparticles (aCD33LNs) were synthesized for delivery of GTI-2040, an antisense oligonucleotide (ASO) against the R2 subunit of ribonucleotide reductase, to acute myelogenous leukemia (AML).  These LNs incorporated a deoxycholate-polyethylenimine (DOC-PEI) conjugate, which has shown significant activity to facilitate oligonucleotide delivery.  Anti-CD33 scFv (aCD33) was added as a targeting ligand.  The delivery efficiency of this system was investigated both in vitro and in vivo.  When cells were treated with aCD33LN/GTI-2040, significant uptake was obsd. in CD33 pos. Kasumi-1 cells. aCD33LNs loaded with GTI-2040 induced significant down-regulation of R2 mRNA and protein levels in AML cells.  Moreover, aCD33LN/GTI-2040 showed a 15-fold redn. in the IC50 of antileukemic drug Ara-C in Kasumi-1 cells.  In Kasumi-1 xenograft model, aCD33LN/GTI-2040 showed significant R2 downregulation compared to LN/GTI-2040.  Furthermore, aCD33LN/GTI-2040 coadministered with Ara-C was shown to be highly effective in tumor growth inhibition and to greatly increase survival time of mice bearing Kasumi-1 xenograft tumors.  The conjugate DOC-PEI has shown an ability to include calcein release from lipid nanoparticles, suggesting a potential mechanism contributing to efficient endosome release by DOC-PEI2K.  These results indicate that aCD33LNs are a highly effective vehicle for the therapeutic delivery of antisense agents to AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKbLCR7_N-eLVg90H21EOLACvtfcHk0lhmndO5OLtPGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsVSkt7g%253D&md5=7646ea983c5471a86d7da6cf255c4ef7</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1021%2Fmp5008212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp5008212%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DQuan%26aufirst%3DJ.%26aulast%3DYung%26aufirst%3DB.%2BC.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DCho%26aufirst%3DY.-A.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DMuthusamy%26aufirst%3DN.%26aulast%3DChan%26aufirst%3DK.%2BK.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DLee%26aufirst%3DL.%2BJ.%26aulast%3DMarcucci%26aufirst%3DG.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26atitle%3DCD33-Targeted%2520Lipid%2520Nanoparticles%2520%2528Acd33lns%2529%2520for%2520Therapeutic%2520Delivery%2520of%2520GTI-2040%2520to%2520Acute%2520Myelogenous%2520Leukemia%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2015%26volume%3D12%26spage%3D2010%26epage%3D2018%26doi%3D10.1021%2Fmp5008212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trail, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofstead, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casazza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellstrom, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellstrom, K.</span></span> <span> </span><span class="NLM_article-title">Cure of Xenografted Human Carcinomas by BR96-Doxorubicin Immunoconjugates</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>261</i></span>,  <span class="NLM_fpage">212</span>– <span class="NLM_lpage">212</span>, <span class="refDoi"> DOI: 10.1126/science.8327892</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1126%2Fscience.8327892" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=8327892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADyaK3sXltlWjtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=261&publication_year=1993&pages=212-212&author=P.+Trailauthor=D.+Willnerauthor=S.+Laschauthor=A.+Hendersonauthor=S.+Hofsteadauthor=A.+Casazzaauthor=R.+Firestoneauthor=I.+Hellstromauthor=K.+Hellstrom&title=Cure+of+Xenografted+Human+Carcinomas+by+BR96-Doxorubicin+Immunoconjugates&doi=10.1126%2Fscience.8327892"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates</span></div><div class="casAuthors">Trail, P. A.; Willner, D.; Lasch, S. J.; Henderson, A. J.; Hofstead, S.; Casazza, A. M.; Firestone, R. A.; Hellstrom, I.; Hellstrom, K. E.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">261</span>
        (<span class="NLM_cas:issue">5118</span>),
    <span class="NLM_cas:pages">212-15</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">Immunoconjugates (BR96-DOX) were prepd. between chimeric monoclonal antibody BR96 and the anticancer drug doxorubicin.  The monoclonal antibody binds an antigen related to Lewis Y that is abundantly expressed at the surface of cells from many human carcinomas; it has a high degree of tumor selectivity and is internalized after binding.  BR96-DOX induced complete regressions and cures of xenografted human lung, breast, and colon carcinomas growing s.c. in athymic mice and cured 70 percent of mice bearing extensive metastasis of a human lung carcinoma.  Also, BR96-DOX cured 94 percent of athymic rats with s.c. human lung carcinoma, even though the rats, like humans and in contrast to mice, expressed the BR96 target antigen in normal tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkJ15RWFve9rVg90H21EOLACvtfcHk0linOu3idnrsuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXltlWjtLk%253D&md5=3a366cdac960b3324fd1100c1dc97653</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1126%2Fscience.8327892&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.8327892%26sid%3Dliteratum%253Aachs%26aulast%3DTrail%26aufirst%3DP.%26aulast%3DWillner%26aufirst%3DD.%26aulast%3DLasch%26aufirst%3DS.%26aulast%3DHenderson%26aufirst%3DA.%26aulast%3DHofstead%26aufirst%3DS.%26aulast%3DCasazza%26aufirst%3DA.%26aulast%3DFirestone%26aufirst%3DR.%26aulast%3DHellstrom%26aufirst%3DI.%26aulast%3DHellstrom%26aufirst%3DK.%26atitle%3DCure%2520of%2520Xenografted%2520Human%2520Carcinomas%2520by%2520BR96-Doxorubicin%2520Immunoconjugates%26jtitle%3DScience%26date%3D1993%26volume%3D261%26spage%3D212%26epage%3D212%26doi%3D10.1126%2Fscience.8327892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Firestone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofstead, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braslawsky, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenfield, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trail, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casazza, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellstrom, I</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellstrom, K. E.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Antitumor Activity of the Immunoconjugate Br96-Dox</span>. <i>J. Controlled Release</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">251</span>– <span class="NLM_lpage">259</span>, <span class="refDoi"> DOI: 10.1016/0168-3659(95)00160-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2F0168-3659%2895%2900160-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADyaK28Xjt1ykur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=251-259&author=R.+Firestoneauthor=D.+Willnerauthor=S.+Hofsteadauthor=H.+Kingauthor=T.+Kanekoauthor=G.+Braslawskyauthor=R.+Greenfieldauthor=P.+Trailauthor=S.+Laschauthor=A.+Hendersonauthor=A.+M.+Casazzaauthor=I+Hellstromauthor=K.+E.+Hellstrom&title=Synthesis+and+Antitumor+Activity+of+the+Immunoconjugate+Br96-Dox&doi=10.1016%2F0168-3659%2895%2900160-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antitumor activity of the immunoconjugate BR96-Dox</span></div><div class="casAuthors">Firestone, R. A.; Willner, D.; Hofstead, S. J.; King, H. D.; Kaneko, T.; Braslawsky, G. R.; Greenfield, R. S.; Trail, P. A.; Lasch, S. J.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">2,3</span>),
    <span class="NLM_cas:pages">251-259</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">BR96-Dox is an immunoconjugate (IC) in which doxorubicin (8 equiv) is linked via an acid-labile hydrazone to the chimeric MAb BR96.  It binds to a modified Ley Ag on tumor cells, which then internalize it via endocytosis into lysosomes.  There, the acidic milieu hydrolyzes the hydrazone link, releasing free Dox.  In vivo, it is more active and less toxic than untargeted Dox, producing complete remissions and many cures of s.c. human breast, lung and colon tumors, as well as disseminated lung tumors.  In vivo, only BR96+ and not BR96- tumors respond, and ICs with nonbinding Abs are inactive.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYEwDzjerWBrVg90H21EOLACvtfcHk0linOu3idnrsuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xjt1ykur8%253D&md5=c43ccc0822602ace371c3bae490b4090</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1016%2F0168-3659%2895%2900160-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0168-3659%252895%252900160-3%26sid%3Dliteratum%253Aachs%26aulast%3DFirestone%26aufirst%3DR.%26aulast%3DWillner%26aufirst%3DD.%26aulast%3DHofstead%26aufirst%3DS.%26aulast%3DKing%26aufirst%3DH.%26aulast%3DKaneko%26aufirst%3DT.%26aulast%3DBraslawsky%26aufirst%3DG.%26aulast%3DGreenfield%26aufirst%3DR.%26aulast%3DTrail%26aufirst%3DP.%26aulast%3DLasch%26aufirst%3DS.%26aulast%3DHenderson%26aufirst%3DA.%26aulast%3DCasazza%26aufirst%3DA.%2BM.%26aulast%3DHellstrom%26aufirst%3DI%26aulast%3DHellstrom%26aufirst%3DK.%2BE.%26atitle%3DSynthesis%2520and%2520Antitumor%2520Activity%2520of%2520the%2520Immunoconjugate%2520Br96-Dox%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D1996%26volume%3D39%26spage%3D251%26epage%3D259%26doi%3D10.1016%2F0168-3659%2895%2900160-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saleh, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugarman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostroff, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Healey, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeBherz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brewer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onetto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LoBuglio, A. F.</span></span> <span> </span><span class="NLM_article-title">Phase I Trial of the Anti–Lewis Y Drug Immunoconjugate Br96-Doxorubicin in Patients with Lewis Y–Expressing Epithelial Tumors</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2282</span>– <span class="NLM_lpage">2292</span>, <span class="refDoi"> DOI: 10.1200/JCO.2000.18.11.2282</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1200%2FJCO.2000.18.11.2282" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10829049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD3cXktlagsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2000&pages=2282-2292&author=M.+N.+Salehauthor=S.+Sugarmanauthor=J.+Murrayauthor=J.+B.+Ostroffauthor=D.+Healeyauthor=D.+Jonesauthor=C.+R.+Danielauthor=D.+LeBherzauthor=H.+Brewerauthor=N.+Onettoauthor=A.+F.+LoBuglio&title=Phase+I+Trial+of+the+Anti%E2%80%93Lewis+Y+Drug+Immunoconjugate+Br96-Doxorubicin+in+Patients+with+Lewis+Y%E2%80%93Expressing+Epithelial+Tumors&doi=10.1200%2FJCO.2000.18.11.2282"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with Lewis Y-expressing epithelial tumors</span></div><div class="casAuthors">Saleh, Mansoor N.; Sugarman, Steve; Murray, James; Ostroff, Joy B.; Healey, Diane; Jones, Dennie; Daniel, Carol R.; LeBherz, Donna; Brewer, Hannah; Onetto, Nicole; LoBuglio, Albert F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2282-2292</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">We conducted a phase I clin. trial of BR96-Doxorubicin (BR96-Dox), a chimeric anti-Lewis Y (LeY) monoclonal antibody conjugated to doxorubicin, in patients whose tumors expressed the LeY antigen.  The study aimed to det. the toxicity, max.-tolerated dose, pharmacokinetics, and immunogenicity of BR96-Dox.  This was a phase I dose escalation study.  BR96-Dox was initially administered alone as a 2-h infusion every 3 wk.  The occurrence of gastrointestinal (GI) toxicity necessitated the administration of BR96-Dox as a continuous infusion over 24 h and use of antiemetics and antigastritis premedication.  Patients experiencing severe GI toxicity underwent GI endoscopy.  All patients underwent restaging after two cycles.  A total of 66 patients predominantly with metastatic colon and breast cancer were enrolled onto the study.  The most common side effects were GI toxicity, fever, and elevation of pancreatic lipase.  At higher doses, BR96-Dox was assocd. with nausea, vomiting, and endoscopically documented exudative gastritis of the upper GI tract, which was dose-limiting at a max. dose of 875 mg/m2 (doxorubicin equiv., 25 mg/m2) administered every 3 wk.  Toxicity was reversible and generally of short duration.  Premedication with the antiemetic Kytril (granisetron hydrochloride; SmithKline Beecham, Philadelphia, PA), the antacid omeprazole, and dexamethasone was most effective in ameliorating GI toxicity.  A dose of 700 mg/m2 BR96-Dox (doxorubicin equiv., 19 mg/m2) every 3 wk was detd. to be the optimal phase II dose when administered with antiemetic and antigastritis prophylaxis.  BR96-Dox deposition on tumor tissue was documented immunohistochem. and by confocal microscopy.  At the 550-mg/m2 dose, the half-life (mean ± SD) of BR96 and doxorubicin was 300 ± 95 h and 43 ± 4 h, resp.  BR96-Dox elicited a weak immune response in 37% of patients.  Objective clin. responses were seen in two patients.  BR96-Dox provides a unique strategy to deliver doxorubicin to LeY-expressing tumor and was well tolerated at doses of 700 mg/m2 every 3 wk.  BR96-Dox was not assocd. with the typical side-effect profile of native doxorubicin and can potentially deliver high doses of doxorubicin to antigen-expressing tumors.  A phase II study in doxorubicin-sensitive tumors is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3mPMC7pov2LVg90H21EOLACvtfcHk0ljT4Y9EApXIXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXktlagsbs%253D&md5=eb75070cfb7fb18828e22732f712f7b7</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1200%2FJCO.2000.18.11.2282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2000.18.11.2282%26sid%3Dliteratum%253Aachs%26aulast%3DSaleh%26aufirst%3DM.%2BN.%26aulast%3DSugarman%26aufirst%3DS.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DOstroff%26aufirst%3DJ.%2BB.%26aulast%3DHealey%26aufirst%3DD.%26aulast%3DJones%26aufirst%3DD.%26aulast%3DDaniel%26aufirst%3DC.%2BR.%26aulast%3DLeBherz%26aufirst%3DD.%26aulast%3DBrewer%26aufirst%3DH.%26aulast%3DOnetto%26aufirst%3DN.%26aulast%3DLoBuglio%26aufirst%3DA.%2BF.%26atitle%3DPhase%2520I%2520Trial%2520of%2520the%2520Anti%25E2%2580%2593Lewis%2520Y%2520Drug%2520Immunoconjugate%2520Br96-Doxorubicin%2520in%2520Patients%2520with%2520Lewis%2520Y%25E2%2580%2593Expressing%2520Epithelial%2520Tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2000%26volume%3D18%26spage%3D2282%26epage%3D2292%26doi%3D10.1200%2FJCO.2000.18.11.2282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schlesinger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendas, G.</span></span> <span> </span><span class="NLM_article-title">Vascular Cell Adhesion Molecule-1 (Vcam-1)—An Increasing Insight into its Role in Tumorigenicity and Metastasis</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">2504</span>– <span class="NLM_lpage">2514</span>, <span class="refDoi"> DOI: 10.1002/ijc.28927</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1002%2Fijc.28927" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=24771582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntlyit7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2015&pages=2504-2514&author=M.+Schlesingerauthor=G.+Bendas&title=Vascular+Cell+Adhesion+Molecule-1+%28Vcam-1%29%E2%80%94An+Increasing+Insight+into+its+Role+in+Tumorigenicity+and+Metastasis&doi=10.1002%2Fijc.28927"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular cell adhesion molecule-1 (VCAM-1)-An increasing insight into its role in tumorigenicity and metastasis</span></div><div class="casAuthors">Schlesinger, Martin; Bendas, Gerd</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2504-2514</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Vascular cell adhesion mol.-1 (VCAM-1) first attracted attention more than two decades ago as endothelial adhesion receptor with key function for leukocyte recruitment in term of cellular immune response.  The early finding of VCAM-1 binding to melanoma cells, and thus a suggested mechanistic contribution to metastatic spread, was the first and for a long time the only link of VCAM-1 to cancer sciences.  In the last few years, hallmarked by a growing insight into the mol. understanding of tumorigenicity and metastasis, an impressive variety of VCAM-1 functionalities in cancer have been elucidated.  The present review aims to provide a current overview of VCAM-1 relevance for tumor growth, metastasis, angiogenesis, and related processes.  By illustrating the intriguing role of VCAM-1 in cancer disease, VCAM-1 is suggested as a new and up to now underestimated target in cancer treatment and in clin. diagnosis of malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwO6-JE65ryrVg90H21EOLACvtfcHk0ljT4Y9EApXIXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntlyit7w%253D&md5=cbf415ecbccb83b4f88885ef898bd11a</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1002%2Fijc.28927&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.28927%26sid%3Dliteratum%253Aachs%26aulast%3DSchlesinger%26aufirst%3DM.%26aulast%3DBendas%26aufirst%3DG.%26atitle%3DVascular%2520Cell%2520Adhesion%2520Molecule-1%2520%2528Vcam-1%2529%25E2%2580%2594An%2520Increasing%2520Insight%2520into%2520its%2520Role%2520in%2520Tumorigenicity%2520and%2520Metastasis%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2015%26volume%3D136%26spage%3D2504%26epage%3D2514%26doi%3D10.1002%2Fijc.28927" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gosk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moos, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottstein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendas, G.</span></span> <span> </span><span class="NLM_article-title">VCAM-1 Directed Immunoliposomes Selectively Target Tumor Vasculature In-Vivo</span>. <i>Biochim. Biophys. Acta, Biomembr.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>1778</i></span>,  <span class="NLM_fpage">854</span>– <span class="NLM_lpage">863</span>, <span class="refDoi"> DOI: 10.1016/j.bbamem.2007.12.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.bbamem.2007.12.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=18211818" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BD1cXktVGrsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1778&publication_year=2008&pages=854-863&author=S.+Goskauthor=T.+Moosauthor=C.+Gottsteinauthor=G.+Bendas&title=VCAM-1+Directed+Immunoliposomes+Selectively+Target+Tumor+Vasculature+In-Vivo&doi=10.1016%2Fj.bbamem.2007.12.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">VCAM-1 directed immunoliposomes selectively target tumor vasculature in vivo</span></div><div class="casAuthors">Gosk, Sara; Moos, Torben; Gottstein, Claudia; Bendas, Gerd</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Biomembranes</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">1778</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">854-863</span>CODEN:
                <span class="NLM_cas:coden">BBBMBS</span>;
        ISSN:<span class="NLM_cas:issn">0005-2736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Targeting the tumor vasculature and selectively modifying endothelial functions is an attractive anti-tumor strategy.  We prepd. polyethyleneglycol modified immunoliposomes (IL) directed against vascular cell adhesion mol. 1 (VCAM-1), a surface receptor over-expressed on tumor vessels, and investigated the liposomal targetability in vitro and in vivo.  In vitro, anti-VCAM-1 liposomes displayed specific binding to activated endothelial cells under static conditions, as well as under simulated blood flow conditions.  The in vivo targeting of IL was analyzed in mice bearing human Colo 677 tumor xenografts 30 min and 24 h post i.v. injection.  Whereas biodistribution studies using [3H]-labeled liposomes displayed only marginal higher tumor accumulation of VCAM-1 targeted vs. unspecific ILs, fluorescence microscopy evaluation revealed that their localizations within tumors differed strongly.  VCAM-1 targeted ILs accumulated in tumor vessels with increasing intensities from 30 min to 24 h, while control ILs accumulated in the tumor tissue by passive diffusion.  ILs that accumulated in non-affected organs, mainly liver and spleen, primarily co-localized with macrophages.  This is the first morphol. evidence for selective in vivo targeting of tumor vessels using ILs.  VCAM-directed ILs are candidate drug delivery systems for therapeutic anti-cancer approaches designed to alter endothelial function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJcdK6ha6dnLVg90H21EOLACvtfcHk0ljT4Y9EApXIXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXktVGrsbg%253D&md5=e275299e262e93a75e0b7d59bae01a98</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamem.2007.12.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamem.2007.12.021%26sid%3Dliteratum%253Aachs%26aulast%3DGosk%26aufirst%3DS.%26aulast%3DMoos%26aufirst%3DT.%26aulast%3DGottstein%26aufirst%3DC.%26aulast%3DBendas%26aufirst%3DG.%26atitle%3DVCAM-1%2520Directed%2520Immunoliposomes%2520Selectively%2520Target%2520Tumor%2520Vasculature%2520In-Vivo%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Biomembr.%26date%3D2008%26volume%3D1778%26spage%3D854%26epage%3D863%26doi%3D10.1016%2Fj.bbamem.2007.12.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hagan, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medik, Y. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A. Z.</span></span> <span> </span><span class="NLM_article-title">Nanotechnology Approaches to Improving Cancer Immunotherapy</span>. <i>Adv. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">35</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1016/bs.acr.2018.05.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fbs.acr.2018.05.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=29941106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252Fhs1Ghuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2018&pages=35-56&author=C.+T.+Haganauthor=Y.+B.+Medikauthor=A.+Z.+Wang&title=Nanotechnology+Approaches+to+Improving+Cancer+Immunotherapy&doi=10.1016%2Fbs.acr.2018.05.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Nanotechnology Approaches to Improving Cancer Immunotherapy</span></div><div class="casAuthors">Hagan C Tilden 4th; Medik Yusra B; Wang Andrew Z</div><div class="citationInfo"><span class="NLM_cas:title">Advances in cancer research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">35-56</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cancer immunotherapy is a powerful, growing treatment approach to cancer that can be combined with chemotherapy, radiotherapy, and oncosurgery.  Modulating the immune system to enhance anticancer response by several strategies has yielded improved cancer survival.  Despite this progress, the success rate for immunotherapy has been below expectations due to unpredictable efficacy and off-target side effects from systemic dosing.  Nanotechnology offers numerous different materials and targeting properties to overcome many of these challenges in immunotherapy.  In this chapter, we review current immunotherapy and its challenges as well as the latest nanotechnology applications in cancer immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRh-u_uJ3fLMAMthz5_Rx5rfW6udTcc2eY2kPe49rkOprntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252Fhs1Ghuw%253D%253D&md5=f7cb5bd4a4c456c8b69a719b22168c07</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1016%2Fbs.acr.2018.05.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.acr.2018.05.003%26sid%3Dliteratum%253Aachs%26aulast%3DHagan%26aufirst%3DC.%2BT.%26aulast%3DMedik%26aufirst%3DY.%2BB.%26aulast%3DWang%26aufirst%3DA.%2BZ.%26atitle%3DNanotechnology%2520Approaches%2520to%2520Improving%2520Cancer%2520Immunotherapy%26jtitle%3DAdv.%2520Cancer%2520Res.%26date%3D2018%26volume%3D139%26spage%3D35%26epage%3D56%26doi%3D10.1016%2Fbs.acr.2018.05.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minn, A.</span></span> <span> </span><span class="NLM_article-title">Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">417</span>– <span class="NLM_lpage">433</span>, <span class="refDoi"> DOI: 10.1016/j.immuni.2018.03.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.immuni.2018.03.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=29562193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlt1Wis7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2018&pages=417-433&author=S.+A.+Patelauthor=A.+Minn&title=Combination+Cancer+Therapy+with+Immune+Checkpoint+Blockade%3A+Mechanisms+and+Strategies&doi=10.1016%2Fj.immuni.2018.03.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies</span></div><div class="casAuthors">Patel, Shetal A.; Minn, Andy J.</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">417-433</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The success of immune checkpoint blockade in patients with a wide variety of malignancies has changed the treatment paradigm in oncol.  However, combination therapies with immune checkpoint blockade will be needed to overcome resistance and broaden the clin. utility of immunotherapy.  Here we discuss a framework for rationally designing combination therapy strategies based on enhancing major discriminatory functions of the immune system that are corrupted by cancer-namely, antigenicity, adjuvanticity, and homeostatic feedback inhibition.  We review recent advances on how conventional genotoxic cancer therapies, molecularly targeted therapies, epigenetic agents, and immune checkpoint inhibitors can restore these discriminatory functions.  Potential barriers that can impede response despite combination therapy are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5pMPa8TU5SLVg90H21EOLACvtfcHk0lgKe40TRLSbMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlt1Wis7c%253D&md5=2301162790d8dbf631e96d3f2a2465d4</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2018.03.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2018.03.007%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DS.%2BA.%26aulast%3DMinn%26aufirst%3DA.%26atitle%3DCombination%2520Cancer%2520Therapy%2520with%2520Immune%2520Checkpoint%2520Blockade%253A%2520Mechanisms%2520and%2520Strategies%26jtitle%3DImmunity%26date%3D2018%26volume%3D48%26spage%3D417%26epage%3D433%26doi%3D10.1016%2Fj.immuni.2018.03.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bangayan, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pariva, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vashisht, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corey, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graeber, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wohlschlegel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, O. N.</span></span> <span> </span><span class="NLM_article-title">Systemic Surfaceome Profiling Identifies Target Antigens for Immune-Based Therapy in Subtypes of Advanced Prostate Cancer</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">E4473</span>– <span class="NLM_lpage">E4482</span>, <span class="refDoi"> DOI: 10.1073/pnas.1802354115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1073%2Fpnas.1802354115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=29686080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVGhtL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2018&pages=E4473-E4482&author=J.+K.+Leeauthor=N.+J.+Bangayanauthor=T.+Chaiauthor=B.+A.+Smithauthor=T.+E.+Parivaauthor=S.+Yunauthor=A.+Vashishtauthor=Q.+Zhangauthor=J.+W.+Parkauthor=E.+Coreyauthor=J.+Huangauthor=T.+G.+Graeberauthor=J.+Wohlschlegelauthor=O.+N.+Witte&title=Systemic+Surfaceome+Profiling+Identifies+Target+Antigens+for+Immune-Based+Therapy+in+Subtypes+of+Advanced+Prostate+Cancer&doi=10.1073%2Fpnas.1802354115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer</span></div><div class="casAuthors">Lee, John K.; Bangayan, Nathanael J.; Chai, Timothy; Smith, Bryan A.; Pariva, Tiffany E.; Yun, Sangwon; Vashisht, Ajay; Zhang, Qingfu; Park, Jung Wook; Corey, Eva; Huang, Jiaoti; Graeber, Thomas G.; Wohlschlegel, James; Witte, Owen N.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">E4473-E4482</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Prostate cancer is a heterogeneous disease composed of divergent mol. and histol. subtypes, including prostate adenocarcinoma (PrAd) and neuroendocrine prostate cancer (NEPC).  While PrAd is the major histol. in prostate cancer, NEPC can evolve from PrAd as a mechanism of treatment resistance that involves a transition from an epithelial to a neurosecretory cancer phenotype.  Cell surface markers are often assocd. with specific cell lineages and differentiation states in normal development and cancer.  Here, we show that PrAd and NEPC can be broadly discriminated by cell-surface profiles based on the anal. of prostate cancer gene expression datasets.  To overcome a dependence on predictions of human cell-surface genes and an assumed correlation between mRNA levels and protein expression, we integrated transcriptomic and cell-surface proteomic data generated from a panel of prostate cancer cell lines to nominate cell-surface markers assocd. with these cancer subtypes.  FXYD3 and CEACAM5 were validated as cell-surface antigens enriched in PrAd and NEPC, resp.  Given the lack of effective treatments for NEPC, CEACAM5 appeared to be a promising target for cell-based immunotherapy.  As a proof of concept, engineered chimeric antigen receptor T cells targeting CEACAM5 induced antigen-specific cytotoxicity in NEPC cell lines.  Our findings demonstrate that the surfaceomes of PrAd and NEPC reflect unique cancer differentiation states and broadly represent vulnerabilities amenable to therapeutic targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonth2rGS7qbbVg90H21EOLACvtfcHk0lgKe40TRLSbMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVGhtL7I&md5=3066ed1ab1ab67c0948ea5d0c46fe761</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1802354115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1802354115%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BK.%26aulast%3DBangayan%26aufirst%3DN.%2BJ.%26aulast%3DChai%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DB.%2BA.%26aulast%3DPariva%26aufirst%3DT.%2BE.%26aulast%3DYun%26aufirst%3DS.%26aulast%3DVashisht%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DPark%26aufirst%3DJ.%2BW.%26aulast%3DCorey%26aufirst%3DE.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DGraeber%26aufirst%3DT.%2BG.%26aulast%3DWohlschlegel%26aufirst%3DJ.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26atitle%3DSystemic%2520Surfaceome%2520Profiling%2520Identifies%2520Target%2520Antigens%2520for%2520Immune-Based%2520Therapy%2520in%2520Subtypes%2520of%2520Advanced%2520Prostate%2520Cancer%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2018%26volume%3D115%26spage%3DE4473%26epage%3DE4482%26doi%3D10.1073%2Fpnas.1802354115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weiden, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figdor, C. G.</span></span> <span> </span><span class="NLM_article-title">Synthetic Immune Niches for Cancer Immunotherapy</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">212</span>– <span class="NLM_lpage">219</span>, <span class="refDoi"> DOI: 10.1038/nri.2017.89</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1038%2Fnri.2017.89" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=28853444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtl2ru7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=212-219&author=J.+Weidenauthor=J.+Telauthor=C.+G.+Figdor&title=Synthetic+Immune+Niches+for+Cancer+Immunotherapy&doi=10.1038%2Fnri.2017.89"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic immune niches for cancer immunotherapy</span></div><div class="casAuthors">Weiden, Jorieke; Tel, Jurjen; Figdor, Carl G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">212-219</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Cancer immunotherapy can successfully promote long-term anticancer immune responses, although there is still only a limited no. of patients who benefit from such treatment, and it can sometimes have severe treatment-assocd. adverse events.  Compared with systemic immunomodulation, local immunomodulation may enable more effective treatment at lower doses and, at the same time, prevent systemic toxicity.  Local delivery of engineered three-dimensional scaffolds may fulfil this role by acting as synthetic immune niches that boost anticancer immunity.  In this Opinion article, we highlight the potential of scaffold-based adoptive cell transfer and scaffold-based cancer vaccines that, although applied locally, can promote systemic antitumor immunity.  Furthermore, we discuss how scaffold-based cancer immunotherapy may contribute to the development of the next generation of cancer treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVYKyP4D8ttbVg90H21EOLACvtfcHk0lgKe40TRLSbMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtl2ru7fP&md5=6ebda3d13095e6125c682308e5bdd566</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1038%2Fnri.2017.89&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri.2017.89%26sid%3Dliteratum%253Aachs%26aulast%3DWeiden%26aufirst%3DJ.%26aulast%3DTel%26aufirst%3DJ.%26aulast%3DFigdor%26aufirst%3DC.%2BG.%26atitle%3DSynthetic%2520Immune%2520Niches%2520for%2520Cancer%2520Immunotherapy%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2018%26volume%3D18%26spage%3D212%26epage%3D219%26doi%3D10.1038%2Fnri.2017.89" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooney, D. J.</span></span> <span> </span><span class="NLM_article-title">Biomaterial-Assisted Targeted Modulation of Immune Cells in Cancer Treatment</span>. <i>Nat. Mater.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">761</span>– <span class="NLM_lpage">772</span>, <span class="refDoi"> DOI: 10.1038/s41563-018-0147-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1038%2Fs41563-018-0147-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=30104668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFahsr7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=761-772&author=H.+Wangauthor=D.+J.+Mooney&title=Biomaterial-Assisted+Targeted+Modulation+of+Immune+Cells+in+Cancer+Treatment&doi=10.1038%2Fs41563-018-0147-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Biomaterial-assisted targeted modulation of immune cells in cancer treatment</span></div><div class="casAuthors">Wang, Hua; Mooney, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Materials</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">761-772</span>CODEN:
                <span class="NLM_cas:coden">NMAACR</span>;
        ISSN:<span class="NLM_cas:issn">1476-1122</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  The past decade has witnessed the accelerating development of immunotherapies for cancer treatment.  Immune checkpoint blockade therapies and chimeric antigen receptor (CAR)-T cell therapies have demonstrated clin. efficacy against a variety of cancers.  However, issues including life-threatening off-target side effects, long processing times, limited patient responses and high cost still limit the clin. utility of cancer immunotherapies.  Biomaterial carriers of these therapies, though, enable one to troubleshoot the delivery issues, amplify immunomodulatory effects, integrate the synergistic effect of different mols. and, more importantly, home and manipulate immune cells in vivo.  In this Review, we will analyze thus-far developed immunomaterials for targeted modulation of dendritic cells, T cells, tumor-assocd. macrophages, myeloid-derived suppressor cells, B cells and natural killer cells, and summarize the promises and challenges of cell-targeted immunomodulation for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyiKlYW1t2T7Vg90H21EOLACvtfcHk0lg9XGeT_xLwvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFahsr7O&md5=04c9d71f21b6a6287a44f6c3918ba286</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1038%2Fs41563-018-0147-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41563-018-0147-9%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DMooney%26aufirst%3DD.%2BJ.%26atitle%3DBiomaterial-Assisted%2520Targeted%2520Modulation%2520of%2520Immune%2520Cells%2520in%2520Cancer%2520Treatment%26jtitle%3DNat.%2520Mater.%26date%3D2018%26volume%3D17%26spage%3D761%26epage%3D772%26doi%3D10.1038%2Fs41563-018-0147-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, D.</span></span> <span> </span><span class="NLM_article-title">Allogenic Dendritic Cell and Tumor Cell Fused Vaccine for Targeted Imaging and Enhanced Immunotherapeutic Efficacy of Gastric Cancer</span>. <i>Biomaterials</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">177</span>– <span class="NLM_lpage">187</span>, <span class="refDoi"> DOI: 10.1016/j.biomaterials.2015.03.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.biomaterials.2015.03.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=25907051" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltlKntb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=177-187&author=C.+Liauthor=S.+Liangauthor=C.+Zhangauthor=Y.+Liuauthor=M.+Yangauthor=J.+Zhangauthor=X.+Zhiauthor=F.+Panauthor=D.+Cui&title=Allogenic+Dendritic+Cell+and+Tumor+Cell+Fused+Vaccine+for+Targeted+Imaging+and+Enhanced+Immunotherapeutic+Efficacy+of+Gastric+Cancer&doi=10.1016%2Fj.biomaterials.2015.03.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Allogenic dendritic cell and tumor cell fused vaccine for targeted imaging and enhanced immunotherapeutic efficacy of gastric cancer</span></div><div class="casAuthors">Li, Chao; Liang, Shujing; Zhang, Chunlei; Liu, Yanlei; Yang, Meng; Zhang, Jingpu; Zhi, Xiao; Pan, Fei; Cui, Daxiang</div><div class="citationInfo"><span class="NLM_cas:title">Biomaterials</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">177-187</span>CODEN:
                <span class="NLM_cas:coden">BIMADU</span>;
        ISSN:<span class="NLM_cas:issn">0142-9612</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Dendritic cells (DCs) have displayed the promising potential in cancer immunity.  How to enhance DCs immunotherapeutic effect in cancer targeted immunotherapy and prevention is still a great challenge.  Herein, we report for the first time the allogenic DCs and tumor cell fused vaccine combined with cytokine induced killing cells (CIKs) for targeted imaging and enhanced immunotherapeutic efficacy of gastric cancer (GC).  The fused vaccine was prepd. by PEG mediated fusion between mature DCs and inactive gastric cancer MGC803 cells.  The immunotherapeutic and prophylactic potential of the fused cells (FCs) were evaluated in tumor-bearing, post-surgery and tumor free mice models.  The migration and homing process of near IR region quantum dots (NIR-QDs) labeled FCs were investigated by real-time animal imaging system.  Results showed that the FCs and FC + CIKs could trigger the tumor-specific CTLs against GC cells, target the tumor tissue initiatively and enhance the prophylactic effects, suppress the tumor growth remarkably in vivo.  The potential mechanism is also investigated.  In conclusion, allogenic DCs and tumor cell fused vaccine can be used for targeted imaging and enhanced immunotherapeutic efficacy of GC, and the FC + CIKs strategy own great potential in clin. applications such as early therapy and prevention of tumor-metastasis and relapse in near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqObEDVw46DDLVg90H21EOLACvtfcHk0lg9XGeT_xLwvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltlKntb0%253D&md5=626109626d0e826f9b03fea926c8cee5</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1016%2Fj.biomaterials.2015.03.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biomaterials.2015.03.024%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLiang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhi%26aufirst%3DX.%26aulast%3DPan%26aufirst%3DF.%26aulast%3DCui%26aufirst%3DD.%26atitle%3DAllogenic%2520Dendritic%2520Cell%2520and%2520Tumor%2520Cell%2520Fused%2520Vaccine%2520for%2520Targeted%2520Imaging%2520and%2520Enhanced%2520Immunotherapeutic%2520Efficacy%2520of%2520Gastric%2520Cancer%26jtitle%3DBiomaterials%26date%3D2015%26volume%3D54%26spage%3D177%26epage%3D187%26doi%3D10.1016%2Fj.biomaterials.2015.03.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ursula, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jana, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katarina, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petra, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ondrej, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juraj, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martina, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanda, R.</span></span> <span> </span><span class="NLM_article-title">Prodrug Suicide Gene Therapy for Cancer Targeted Intracellular by Mesenchymal Stem Cell Exosomes</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">897</span>– <span class="NLM_lpage">908</span>, <span class="refDoi"> DOI: 10.1002/ijc.31792</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1002%2Fijc.31792" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=30098225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVSmsb%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2019&pages=897-908&author=A.+Ursulaauthor=J.+Janaauthor=B.+Katarinaauthor=P.+Petraauthor=P.+Martinauthor=P.+Pavelauthor=T.+Ondrejauthor=K.+Jurajauthor=Z.+Martinaauthor=R.+Vanda&title=Prodrug+Suicide+Gene+Therapy+for+Cancer+Targeted+Intracellular+by+Mesenchymal+Stem+Cell+Exosomes&doi=10.1002%2Fijc.31792"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Prodrug suicide gene therapy for cancer targeted intracellular by mesenchymal stem cell exosomes</span></div><div class="casAuthors">Ursula, Altanerova; Jana, Jakubechova; Katarina, Benejova; Petra, Priscakova; Martin, Pesta; Pavel, Pitule; Ondrej, Topolcan; Juraj, Kausitz; Martina, Zduriencikova; Vanda, Repiska; Cestmir, Altaner</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">897-908</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The natural behavior of mesenchymal stem cells (MSCs) and their exosomes in targeting tumors is a promising approach for curative therapy.  Human tumor tropic mesenchymal stem cells (MSCs) isolated from various tissues and MSCs engineered to express the yeast cytosine deaminase::uracil phosphoribosyl transferase suicide fusion gene (yCD::UPRT-MSCs) released exosomes in conditional medium (CM).  Exosomes from all tissue specific yCD::UPRT-MSCs contained mRNA of the suicide gene in the exosome's cargo.  When the CM was applied to tumor cells, the exosomes were internalized by recipient tumor cells and in the presence of the prodrug 5-fluorocytosine (5-FC) effectively triggered dose-dependent tumor cell death by endocytosed exosomes via an intracellular conversion of the prodrug 5-FC to 5-fluorouracil.  Exosomes were found to be responsible for the tumor inhibitory activity.  The presence of microRNAs in exosomes produced from naive MSCs and from suicide gene transduced MSCs did not differ significantly.  MicroRNAs from yCD::UPRT-MSCs were not assocd. with therapeutic effect.  MSC suicide gene exosomes represent a new class of tumor cell targeting drug acting intracellular with curative potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-SkUhiyV_PrVg90H21EOLACvtfcHk0lg9XGeT_xLwvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVSmsb%252FN&md5=b01a26c8ca9342a8941627789043bcaf</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1002%2Fijc.31792&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.31792%26sid%3Dliteratum%253Aachs%26aulast%3DUrsula%26aufirst%3DA.%26aulast%3DJana%26aufirst%3DJ.%26aulast%3DKatarina%26aufirst%3DB.%26aulast%3DPetra%26aufirst%3DP.%26aulast%3DMartin%26aufirst%3DP.%26aulast%3DPavel%26aufirst%3DP.%26aulast%3DOndrej%26aufirst%3DT.%26aulast%3DJuraj%26aufirst%3DK.%26aulast%3DMartina%26aufirst%3DZ.%26aulast%3DVanda%26aufirst%3DR.%26atitle%3DProdrug%2520Suicide%2520Gene%2520Therapy%2520for%2520Cancer%2520Targeted%2520Intracellular%2520by%2520Mesenchymal%2520Stem%2520Cell%2520Exosomes%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2019%26volume%3D144%26spage%3D897%26epage%3D908%26doi%3D10.1002%2Fijc.31792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, D.</span></span> <span> </span><span class="NLM_article-title">Human CIK Cells Loaded with Au Nanorods as a Theranostic Platform for Targeted Photoacoustic Imaging and Enhanced Immunotherapy and Photothermal Therapy</span>. <i>Nanoscale Res. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">285</span>, <span class="refDoi"> DOI: 10.1186/s11671-016-1468-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1186%2Fs11671-016-1468-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=27271853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252FnvFKnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=285&author=Y.+Yangauthor=J.+Zhangauthor=F.+Xiaauthor=C.+Zhangauthor=Q.+Qianauthor=X.+Zhiauthor=C.+Yueauthor=R.+Sunauthor=S.+Chengauthor=S.+Fangauthor=W.+Jinauthor=Y.+Yangauthor=D.+Cui&title=Human+CIK+Cells+Loaded+with+Au+Nanorods+as+a+Theranostic+Platform+for+Targeted+Photoacoustic+Imaging+and+Enhanced+Immunotherapy+and+Photothermal+Therapy&doi=10.1186%2Fs11671-016-1468-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Human CIK Cells Loaded with Au Nanorods as a Theranostic Platform for Targeted Photoacoustic Imaging and Enhanced Immunotherapy and Photothermal Therapy</span></div><div class="casAuthors">Yang Yao; Fang Shan; Cui Daxiang; Zhang Jingjing; Xia Fangfang; Zhang Chunlei; Zhi Xiao; Yue Caixia; Sun Rongjin; Cheng Shangli; Jin Weilin; Yang Yuming; Cui Daxiang; Qian Qirong; Cui Daxiang</div><div class="citationInfo"><span class="NLM_cas:title">Nanoscale research letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">285</span>
        ISSN:<span class="NLM_cas:issn">1931-7573</span>.
    </div><div class="casAbstract">How to realize targeted photoacoustic imaging, enhanced immunotherapy, and photothermal therapy of gastric cancer has become a great challenge.  Herein, we reported for the first time that human cytokine-induced killer cells (CIK) loaded with gold nanorods were used for targeted photoacoustic imaging, enhanced immunotherapy, and photothermal therapy of gastric cancer.  Silica-modified gold nanorods were prepared; then incubated with human cytokine-induced killer cells (CIK), resultant human CIK cells loaded with Au nanorods were evaluated for their cytotoxicity, targeted ability of gastric cancer in vitro and in vivo, immunotherapy, and photothermal therapy efficacy.  In vitro cell experiment shows that human CIK cells labeled with gold nanorods actively target gastric cancer MGC803 cells, inhibit growth of MGC803 cells by inducing cell apoptosis, and kill MGC803 cells under low power density near-infrared (NIR) laser treatment (808-nm continuous wave laser, 1.5 W/cm(2), 3 min).  In vivo experiment results showed that human CIK cells labeled with gold nanorods could target actively and image subcutaneous gastric cancer vessels via photoacoustic imaging at 4 h post-injection, could enhance immunotherapy efficacy by up-regulating cytokines such as IL-1, IL-12, IL-2, IL-4, IL-17, and IFN-γ, and kill gastric cancer tissues by photothermal therapy via direct injection into tumor site under near-infrared (NIR) laser irradiation.  High-performance human CIK cells labeled with Au nanorods are a good novel theranostic platform to exhibit great potential in applications such as tumor-targeted photoacoustic imaging, enhanced immunotherapy, and photothermal therapy in the near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRFBHW9ajsjmFf1XRtfYM0dfW6udTcc2ebyZachlmsfnLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252FnvFKnsQ%253D%253D&md5=d1c93a038e4b3647e09e613feaef29ad</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1186%2Fs11671-016-1468-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs11671-016-1468-8%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DXia%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DQian%26aufirst%3DQ.%26aulast%3DZhi%26aufirst%3DX.%26aulast%3DYue%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DR.%26aulast%3DCheng%26aufirst%3DS.%26aulast%3DFang%26aufirst%3DS.%26aulast%3DJin%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DCui%26aufirst%3DD.%26atitle%3DHuman%2520CIK%2520Cells%2520Loaded%2520with%2520Au%2520Nanorods%2520as%2520a%2520Theranostic%2520Platform%2520for%2520Targeted%2520Photoacoustic%2520Imaging%2520and%2520Enhanced%2520Immunotherapy%2520and%2520Photothermal%2520Therapy%26jtitle%3DNanoscale%2520Res.%2520Lett.%26date%3D2016%26volume%3D11%26spage%3D285%26doi%3D10.1186%2Fs11671-016-1468-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez de la Fuente, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, D.</span></span> <span> </span><span class="NLM_article-title">Cytokine Induced Killer Cells-Assisted Delivery of Chlorin E6Mediated Self-Assembled Gold Nanoclusters to Tumors for Imaging and Immuno-Photodynamic Therapy</span>. <i>Biomaterials</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>170</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">11</span>, <span class="refDoi"> DOI: 10.1016/j.biomaterials.2018.03.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.biomaterials.2018.03.048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=29635107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntFyls7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2018&pages=1-11&author=F.+Xiaauthor=W.+Houauthor=Y.+Liuauthor=W.+Wangauthor=Y.+Hanauthor=M.+Yangauthor=X.+Zhiauthor=C.+Liauthor=D.+Qiauthor=T.+Liauthor=J.+Martinez+de+la+Fuenteauthor=C.+Zhangauthor=J.+Songauthor=D.+Cui&title=Cytokine+Induced+Killer+Cells-Assisted+Delivery+of+Chlorin+E6Mediated+Self-Assembled+Gold+Nanoclusters+to+Tumors+for+Imaging+and+Immuno-Photodynamic+Therapy&doi=10.1016%2Fj.biomaterials.2018.03.048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Cytokine induced killer cells-assisted delivery of chlorin e6 mediated self-assembled gold nanoclusters to tumors for imaging and immuno-photodynamic therapy</span></div><div class="casAuthors">Xia, Fangfang; Hou, Wenxiu; Liu, Yanlei; Wang, Wentao; Han, Yu; Yang, Meng; Zhi, Xiao; Li, Chenlu; Qi, Daizong; Li, Tianliang; Martinez de la Fuente, Jesus; Zhang, Chunlei; Song, Jie; Cui, Daxiang</div><div class="citationInfo"><span class="NLM_cas:title">Biomaterials</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-11</span>CODEN:
                <span class="NLM_cas:coden">BIMADU</span>;
        ISSN:<span class="NLM_cas:issn">0142-9612</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The cytotoxicity and unique tumor-tropic properties of cytokine-induced killer (CIK) cells render them promising in the field of cancer immunotherapy and delivery systems.  Here, we report a novel and facile approach to assemble gold nanoclusters (GNCs) into stable and monodispersed nanoparticles (NPs) using Chlorin e6 (Ce6) mols.  Notably, the fluorescence intensity of the GNCs-Ce6 NPs was about 4.5 folds stronger than the GNCs counterparts.  The as-prepd. GNCs-Ce6 NPs were conjugated with CD3 antibody (Ab) and further employed to label CIK cells to create a CIK cell-based drug delivery system (Ce6-GNCs-Ab-CIK).  The Ce6-GNCs-Ab-CIK exhibited high tumor-targeting efficiency and excellent therapeutic efficacy toward MGC-803 tumor-bearing mice.  Benefiting from the synergistic therapeutic effect between GNCs-Ce6-Ab NPs and CIK cells, the GNCs-Ce6-Ab-CIK strategy may present an ideal cancer theranostic platform for tumor targeted imaging and combination therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbkTGhHmQye7Vg90H21EOLACvtfcHk0ljTtdbMuO3_iA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntFyls7g%253D&md5=2858a16fd527f92d1a294eebc0037639</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2Fj.biomaterials.2018.03.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biomaterials.2018.03.048%26sid%3Dliteratum%253Aachs%26aulast%3DXia%26aufirst%3DF.%26aulast%3DHou%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DZhi%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DQi%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DMartinez%2Bde%2Bla%2BFuente%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DCui%26aufirst%3DD.%26atitle%3DCytokine%2520Induced%2520Killer%2520Cells-Assisted%2520Delivery%2520of%2520Chlorin%2520E6Mediated%2520Self-Assembled%2520Gold%2520Nanoclusters%2520to%2520Tumors%2520for%2520Imaging%2520and%2520Immuno-Photodynamic%2520Therapy%26jtitle%3DBiomaterials%26date%3D2018%26volume%3D170%26spage%3D1%26epage%3D11%26doi%3D10.1016%2Fj.biomaterials.2018.03.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rotte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhandaru, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McElwee, K. J.</span></span> <span> </span><span class="NLM_article-title">Immunotherapy of Melanoma: Present Options and Future Promises</span>. <i>Cancer Metastasis Rev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">128</span>, <span class="refDoi"> DOI: 10.1007/s10555-014-9542-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1007%2Fs10555-014-9542-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=25589384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVOmtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2015&pages=115-128&author=A.+Rotteauthor=M.+Bhandaruauthor=Y.+Zhouauthor=K.+J.+McElwee&title=Immunotherapy+of+Melanoma%3A+Present+Options+and+Future+Promises&doi=10.1007%2Fs10555-014-9542-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Immunotherapy of melanoma: Present options and future promises</span></div><div class="casAuthors">Rotte, Anand; Bhandaru, Madhuri; Zhou, Youwen; McElwee, Kevin J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer and Metastasis Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">115-128</span>CODEN:
                <span class="NLM_cas:coden">CMRED4</span>;
        ISSN:<span class="NLM_cas:issn">0167-7659</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Metastatic melanoma is notorious for its immune evasion and resistance to conventional chemotherapy.  The recent success of ipilimumab, a human monoclonal antibody against cytotoxic T-lymphocyte-assocd. antigen 4 (CTLA-4), in increasing the median survival time and stabilizing the disease progression renewed, hopes in treatment for melanoma.  Currently, ipilimumab and high-dose interleukin-2 (IL-2; Aldesleukin) are approved as monotherapies for the treatment of patients with unresectable advanced melanoma, and pegylated interferon-α2b (p-IFN-α2b) is approved as an adjuvant for the treatment of patients with surgically resected high-risk melanoma.  The present review describes the currently approved immune-modulators and the promising immune-based interventions that are currently in clin. trials.  We present the four commonly used strategies to boost immune responses against the tumors; monoclonal antibodies, cytokines, cancer vaccines, and adoptive T cell transfer.  The corresponding lists of ongoing clin. trials include details of the trial phase, target patients, intervention details, status of the study, and expected date of completion.  Further, our review discusses the challenges faced by immunotherapy and the various strategies adopted to overcome them.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptvc-D5REioLVg90H21EOLACvtfcHk0ljTtdbMuO3_iA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVOmtbg%253D&md5=285f6156c8539af05e79d5699c74b930</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1007%2Fs10555-014-9542-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10555-014-9542-0%26sid%3Dliteratum%253Aachs%26aulast%3DRotte%26aufirst%3DA.%26aulast%3DBhandaru%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DMcElwee%26aufirst%3DK.%2BJ.%26atitle%3DImmunotherapy%2520of%2520Melanoma%253A%2520Present%2520Options%2520and%2520Future%2520Promises%26jtitle%3DCancer%2520Metastasis%2520Rev.%26date%3D2015%26volume%3D34%26spage%3D115%26epage%3D128%26doi%3D10.1007%2Fs10555-014-9542-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span> <span> </span><span class="NLM_article-title">Photothermal Therapy with Immune-Adjuvant Nanoparticles Together with Checkpoint Blockade for Effective Cancer Immunotherapy</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">13193</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">13</span>, <span class="refDoi"> DOI: 10.1038/ncomms13193</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1038%2Fncomms13193" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=1-13&issue=13193&author=Q.+Chenauthor=L.+Xuauthor=C.+Liangauthor=C.+Wangauthor=R.+Pengauthor=Z.+Liu&title=Photothermal+Therapy+with+Immune-Adjuvant+Nanoparticles+Together+with+Checkpoint+Blockade+for+Effective+Cancer+Immunotherapy&doi=10.1038%2Fncomms13193"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1038%2Fncomms13193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms13193%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DPeng%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DZ.%26atitle%3DPhotothermal%2520Therapy%2520with%2520Immune-Adjuvant%2520Nanoparticles%2520Together%2520with%2520Checkpoint%2520Blockade%2520for%2520Effective%2520Cancer%2520Immunotherapy%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26issue%3D13193%26spage%3D1%26epage%3D13%26doi%3D10.1038%2Fncomms13193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Velpurisiva, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jadia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rai, P.</span></span> <span> </span><span class="NLM_article-title">Nanoparticle Design Strategies for Effective Cancer Immunotherapy</span>. <i>J. Biomed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">64</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.7150/jbm.18877</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.7150%2Fjbm.18877" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2017&pages=1-26&issue=64&author=P.+Velpurisivaauthor=A.+Gadauthor=B.+Pielauthor=R.+Jadiaauthor=P.+Rai&title=Nanoparticle+Design+Strategies+for+Effective+Cancer+Immunotherapy&doi=10.7150%2Fjbm.18877"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.7150%2Fjbm.18877&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fjbm.18877%26sid%3Dliteratum%253Aachs%26aulast%3DVelpurisiva%26aufirst%3DP.%26aulast%3DGad%26aufirst%3DA.%26aulast%3DPiel%26aufirst%3DB.%26aulast%3DJadia%26aufirst%3DR.%26aulast%3DRai%26aufirst%3DP.%26atitle%3DNanoparticle%2520Design%2520Strategies%2520for%2520Effective%2520Cancer%2520Immunotherapy%26jtitle%3DJ.%2520Biomed.%26date%3D2017%26volume%3D2%26issue%3D64%26spage%3D1%26epage%3D26%26doi%3D10.7150%2Fjbm.18877" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meir, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shamalov, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motiei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yaari, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popovtzer, R.</span></span> <span> </span><span class="NLM_article-title">Fast Image-Guided Stratification Using Anti-Programmed Death Ligand-1 Gold Nanoparticles for Cancer Immunotherapy</span>. <i>ACS Nano</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">11127</span>– <span class="NLM_lpage">11134</span>, <span class="refDoi"> DOI: 10.1021/acsnano.7b05299</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsnano.7b05299" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Grur%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=11127-11134&author=R.+Meirauthor=K.+Shamalovauthor=T.+Sadanauthor=M.+Motieiauthor=G.+Yaariauthor=C.+J.+Cohenauthor=R.+Popovtzer&title=Fast+Image-Guided+Stratification+Using+Anti-Programmed+Death+Ligand-1+Gold+Nanoparticles+for+Cancer+Immunotherapy&doi=10.1021%2Facsnano.7b05299"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Fast Image-Guided Stratification Using Anti-Programmed Death Ligand 1 Gold Nanoparticles for Cancer Immunotherapy</span></div><div class="casAuthors">Meir, Rinat; Shamalov, Katerina; Sadan, Tamar; Motiei, Menachem; Yaari, Gur; Cohen, Cyrille J.; Popovtzer, Rachela</div><div class="citationInfo"><span class="NLM_cas:title">ACS Nano</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">11127-11134</span>CODEN:
                <span class="NLM_cas:coden">ANCAC3</span>;
        ISSN:<span class="NLM_cas:issn">1936-0851</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cancer immunotherapy has made enormous progress in offering safer and more effective treatments for the disease.  Specifically, programmed death ligand 1 antibody (αPDL1), designed to perform immune checkpoint blockade (ICB), is now considered a pillar in cancer immunotherapy.  However, due to the complexity and heterogeneity of tumors, as well as the diversity in patient response, ICB therapy only has a 30% success rate, at most; moreover, the efficacy of ICB can be evaluated only two months after start of treatment.  Therefore, early identification of potential responders and nonresponders to therapy, using noninvasive means, is crucial for improving treatment decisions.  Here, we report a straightforward approach for fast, image-guided prediction of therapeutic response to ICB.  In a colon cancer mouse model, we demonstrate that the combination of computed tomog. imaging and gold nanoparticles conjugated to αPDL1 allowed prediction of therapeutic response, as early as 48 h after treatment.  This was achieved by noninvasive measurement of nanoparticle accumulation levels within the tumors.  Moreover, we show that the nanoparticles efficiently prevented tumor growth with only a fifth of the std. dosage of clin. care.  This technol. may be developed into a powerful tool for early and noninvasive patient stratification as responders or nonresponders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdM2b1IJd6P7Vg90H21EOLACvtfcHk0lhWE_CPRv5CAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Grur%252FJ&md5=6dfea4e2cc9c9011eca18510172c9bcc</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1021%2Facsnano.7b05299&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsnano.7b05299%26sid%3Dliteratum%253Aachs%26aulast%3DMeir%26aufirst%3DR.%26aulast%3DShamalov%26aufirst%3DK.%26aulast%3DSadan%26aufirst%3DT.%26aulast%3DMotiei%26aufirst%3DM.%26aulast%3DYaari%26aufirst%3DG.%26aulast%3DCohen%26aufirst%3DC.%2BJ.%26aulast%3DPopovtzer%26aufirst%3DR.%26atitle%3DFast%2520Image-Guided%2520Stratification%2520Using%2520Anti-Programmed%2520Death%2520Ligand-1%2520Gold%2520Nanoparticles%2520for%2520Cancer%2520Immunotherapy%26jtitle%3DACS%2520Nano%26date%3D2017%26volume%3D11%26spage%3D11127%26epage%3D11134%26doi%3D10.1021%2Facsnano.7b05299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cano-Mejia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burga, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollard, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandler, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, C. R. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, R.</span></span> <span> </span><span class="NLM_article-title">Prussian Blue Nanoparticle-Based Photothermal Therapy Combined with Checkpoint Inhibition for Photothermal Immunotherapy of Neuroblastoma</span>. <i>Nanomedicine</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">771</span>– <span class="NLM_lpage">781</span>, <span class="refDoi"> DOI: 10.1016/j.nano.2016.10.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.nano.2016.10.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=27826115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjs1Onu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=771-781&author=J.+Cano-Mejiaauthor=R.+A.+Burgaauthor=E.+E.+Sweeneyauthor=J.+P.+Fisherauthor=C.+M.+Bollardauthor=A.+D.+Sandlerauthor=C.+R.+Y.+Cruzauthor=R.+Fernandes&title=Prussian+Blue+Nanoparticle-Based+Photothermal+Therapy+Combined+with+Checkpoint+Inhibition+for+Photothermal+Immunotherapy+of+Neuroblastoma&doi=10.1016%2Fj.nano.2016.10.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Prussian blue nanoparticle-based photothermal therapy combined with checkpoint inhibition for photothermal immunotherapy of neuroblastoma</span></div><div class="casAuthors">Cano-Mejia, Juliana; Burga, Rachel A.; Sweeney, Elizabeth E.; Fisher, John P.; Bollard, Catherine M.; Sandler, Anthony D.; Cruz, Conrad Russell Y.; Fernandes, Rohan</div><div class="citationInfo"><span class="NLM_cas:title">Nanomedicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">771-781</span>CODEN:
                <span class="NLM_cas:coden">NANOBF</span>;
        ISSN:<span class="NLM_cas:issn">1549-9634</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">We describe "photothermal immunotherapy," which combines Prussian blue nanoparticle (PBNP)-based photothermal therapy (PTT) with anti-CTLA-4 checkpoint inhibition for treating neuroblastoma, a common, hard-to-treat pediatric cancer.  PBNPs exhibit pH-dependent stability, which makes them suitable for intratumorally-administered PTT.  PBNP-based PTT is able to lower tumor burden and prime an immune response, specifically an increased infiltration of lymphocytes and T cells to the tumor area, which is complemented by the antitumor effects of anti-CTLA-4 immunotherapy, providing a more durable treatment against neuroblastoma in an animal model.  We observe 55.5% survival in photothermal immunotherapy-treated mice at 100 days compared to 12.5%, 0%, 0%, and 0% survival in mice receiving: anti-CTLA-4 alone, PBNPs alone, PTT alone, and no treatment, resp.  Addnl., long-term surviving, photothermal immunotherapy-treated mice exhibit protection against neuroblastoma rechallenge, suggesting the development of immunity against these tumors.  Our findings suggest the potential of photothermal immunotherapy in improving treatments for neuroblastoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonO8vFz11ZQ7Vg90H21EOLACvtfcHk0lhWE_CPRv5CAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjs1Onu74%253D&md5=80a981875ccf60f26dbd94524642f6a6</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2Fj.nano.2016.10.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nano.2016.10.015%26sid%3Dliteratum%253Aachs%26aulast%3DCano-Mejia%26aufirst%3DJ.%26aulast%3DBurga%26aufirst%3DR.%2BA.%26aulast%3DSweeney%26aufirst%3DE.%2BE.%26aulast%3DFisher%26aufirst%3DJ.%2BP.%26aulast%3DBollard%26aufirst%3DC.%2BM.%26aulast%3DSandler%26aufirst%3DA.%2BD.%26aulast%3DCruz%26aufirst%3DC.%2BR.%2BY.%26aulast%3DFernandes%26aufirst%3DR.%26atitle%3DPrussian%2520Blue%2520Nanoparticle-Based%2520Photothermal%2520Therapy%2520Combined%2520with%2520Checkpoint%2520Inhibition%2520for%2520Photothermal%2520Immunotherapy%2520of%2520Neuroblastoma%26jtitle%3DNanomedicine%26date%3D2017%26volume%3D13%26spage%3D771%26epage%3D781%26doi%3D10.1016%2Fj.nano.2016.10.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heo, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, D. K.</span></span> <span> </span><span class="NLM_article-title">New Opportunities for Nanoparticles in Cancer Immunotherapy</span>. <i>Biomater. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1186/s40824-018-0133-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1186%2Fs40824-018-0133-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=29308274" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1MXivVCrtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2018&pages=1-10&issue=24&author=W.+Parkauthor=Y.-J.+Heoauthor=D.+K.+Han&title=New+Opportunities+for+Nanoparticles+in+Cancer+Immunotherapy&doi=10.1186%2Fs40824-018-0133-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced osteogenic commitment of murine mesenchymal stem cells on graphene oxide substrate</span></div><div class="casAuthors">Kim, Jiyong; Kim, Hwan D.; Park, Jungha; Lee, Eun-seo; Kim, Eugene; Lee, Seunghun S.; Yang, Jin-Kyung; Lee, Yoon-Sik; Hwang, Nathaniel S.</div><div class="citationInfo"><span class="NLM_cas:title">Biomaterials Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1/1-1/9</span>CODEN:
                <span class="NLM_cas:coden">BRIEFJ</span>;
        ISSN:<span class="NLM_cas:issn">2055-7124</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Tissue engineering is an interdisciplinary field that attempts to restore or regenerate tissues and organs through biomimetic fabrication of scaffolds with specific functionality.  In recent years, graphene oxide (GO) is considered as promising biomaterial due to its nontoxicity, high dispersity, and hydrophilic interaction, and these characteristics are key to stimulating the interactions between substrates and cells.  In this study, GO substrates were fabricated via chem. immobilizing GO at 1.0 mg/mL on glass slides.  Furthermore, we examd. the osteogenic responses of murine mesenchymal-like stem cells, C3H10T1/2 cells, on GO substrates.  C3H10T1/2 cells on GO substrates resulted in increased cell surface area, enhanced cellular adhesions, and instigated osteogenic differentiation.  Furthermore, priming of C3H10T1/2 cells with chondrocyte-conditioned medium (CM) could further induce a synergistic effect of osteogenesis on GO substrates.  All of these data suggest that GO substrate along with CM is suitable for upregulating osteogenic responses of mesenchymal stem cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyRcm4CmNstbVg90H21EOLACvtfcHk0lhWE_CPRv5CAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXivVCrtbs%253D&md5=0365d2deebd72344e59c7e0cf77f03e5</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1186%2Fs40824-018-0133-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40824-018-0133-y%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DW.%26aulast%3DHeo%26aufirst%3DY.-J.%26aulast%3DHan%26aufirst%3DD.%2BK.%26atitle%3DNew%2520Opportunities%2520for%2520Nanoparticles%2520in%2520Cancer%2520Immunotherapy%26jtitle%3DBiomater.%2520Res.%26date%3D2018%26volume%3D22%26issue%3D24%26spage%3D1%26epage%3D10%26doi%3D10.1186%2Fs40824-018-0133-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hagan, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medik, Y. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A. Z.</span></span> <span> </span><span class="NLM_article-title">Nanotechnology Approaches to Improving Cancer Immunotherapy</span>. <i>Adv. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">35</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1016/bs.acr.2018.05.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fbs.acr.2018.05.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=29941106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252Fhs1Ghuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2018&pages=35-56&author=C.+T.+Haganauthor=Y.+B.+Medikauthor=A.+Z.+Wang&title=Nanotechnology+Approaches+to+Improving+Cancer+Immunotherapy&doi=10.1016%2Fbs.acr.2018.05.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Nanotechnology Approaches to Improving Cancer Immunotherapy</span></div><div class="casAuthors">Hagan C Tilden 4th; Medik Yusra B; Wang Andrew Z</div><div class="citationInfo"><span class="NLM_cas:title">Advances in cancer research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">35-56</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cancer immunotherapy is a powerful, growing treatment approach to cancer that can be combined with chemotherapy, radiotherapy, and oncosurgery.  Modulating the immune system to enhance anticancer response by several strategies has yielded improved cancer survival.  Despite this progress, the success rate for immunotherapy has been below expectations due to unpredictable efficacy and off-target side effects from systemic dosing.  Nanotechnology offers numerous different materials and targeting properties to overcome many of these challenges in immunotherapy.  In this chapter, we review current immunotherapy and its challenges as well as the latest nanotechnology applications in cancer immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRh-u_uJ3fLMAMthz5_Rx5rfW6udTcc2eYADxFaw-WWT7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252Fhs1Ghuw%253D%253D&md5=f7cb5bd4a4c456c8b69a719b22168c07</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1016%2Fbs.acr.2018.05.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.acr.2018.05.003%26sid%3Dliteratum%253Aachs%26aulast%3DHagan%26aufirst%3DC.%2BT.%26aulast%3DMedik%26aufirst%3DY.%2BB.%26aulast%3DWang%26aufirst%3DA.%2BZ.%26atitle%3DNanotechnology%2520Approaches%2520to%2520Improving%2520Cancer%2520Immunotherapy%26jtitle%3DAdv.%2520Cancer%2520Res.%26date%3D2018%26volume%3D139%26spage%3D35%26epage%3D56%26doi%3D10.1016%2Fbs.acr.2018.05.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ansari, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raza, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, R.</span></span> <span> </span><span class="NLM_article-title">Zinc Gluconate-Loaded Chitosan Nanoparticles Reduce Severity of Collagen-Induced Arthritis in Wistar Rats</span>. <i>ACS Biomater. Sci. Eng.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">3380</span>– <span class="NLM_lpage">3397</span>, <span class="refDoi"> DOI: 10.1021/acsbiomaterials.9b00427</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsbiomaterials.9b00427" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVehurrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2019&pages=3380-3397&issue=7&author=M.+M.+Ansariauthor=A.+Ahmadauthor=R.+K.+Mishraauthor=S.+S.+Razaauthor=R.+Khan&title=Zinc+Gluconate-Loaded+Chitosan+Nanoparticles+Reduce+Severity+of+Collagen-Induced+Arthritis+in+Wistar+Rats&doi=10.1021%2Facsbiomaterials.9b00427"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Zinc gluconate-loaded chitosan nanoparticles reduce severity of collagen-induced arthritis in Wistar Rats</span></div><div class="casAuthors">Ansari, Md. Meraj; Ahmad, Anas; Mishra, Rakesh Kumar; Raza, Syed Shadab; Khan, Rehan</div><div class="citationInfo"><span class="NLM_cas:title">ACS Biomaterials Science & Engineering</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3380-3397</span>CODEN:
                <span class="NLM_cas:coden">ABSEBA</span>;
        ISSN:<span class="NLM_cas:issn">2373-9878</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Rheumatoid arthritis (RA) is the most prevalent autoimmune disease affecting about 1% world population.  Zinc (Zn) is necessary for the maintenance of bone homeostasis and the level of Zn was reported to be decreased in RA patients and collagen-induced arthritic rats.  Effective delivery of Zn has been reported using zinc gluconate but oral absorption of Zn from zinc gluconate (ZG) is very low in humans.  Zn supplementation reduces disease severity in patients suffering from chronic, refractory RA and exerts mild and transient side effects.  The aim of this study was to synthesize and characterize zinc gluconate-loaded chitosan nanoparticles (ZG-Chit NPs) and to evaluate and compare therapeutic efficacy of ZG-Chit NPs and zinc gluconate against collagen-induced RA in Wistar rats.  The nanoparticles were formulated by ionic gelation method and the hydrodynamic diam. was 106.5 ± 79.55 nm as measured using DLS.  The particle size, shape, and surface morphol. was further confirmed by transmission electron microscopy, SEM, and at. force microscopy.  These nanoparticles showed good cytocompatibility against foreskin fibroblasts (BJ) and L929 cells.  Arthritic rats were treated with ZG (20 mg/kg body wt., i.p.) and equiv. doses of ZG-Chit NPs.  The treatment of both ZG and ZG-Chit NPs reduced the severity of arthritis as evidenced by reduced joint swelling, erythema, and edema but ZG-Chit NPs exhibited superior efficacy.  Furthermore, it was found that ZG and ZG-Chit NPs attenuate biomarkers of inflammation (C-reactive protein, myeloperoxidase, nitric oxide, TNF-α, and IL-1β) and oxidative stress (articular elastase, lipid peroxidn., catalase, glutathione, and superoxide dismutase).  The results of the histopathol. further confirmed that ZG-Chit NPs markedly suppressed infiltration of inflammatory cells as compared to ZG at the ankle joint tissue.  Immunohistochem. anal. also revealed that treatment with ZG-Chit NPs resulted in reduced pro-inflammatory marker (TNF-α, IL-6, and iNOS) expression and enhanced SOD1 expression.  Overall, this study suggests that ZG and ZG-Chit NPs suppressed the severity of arthritis plausibly mediated by attenuation of inflammation and oxidative stress and more importantly ZG-Chit NPs exhibited superior efficacy as compared to ZG.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpzCEMCGdsvLVg90H21EOLACvtfcHk0ljMXjCOvDJMOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVehurrL&md5=d694d19695f50d23b1ff3b1d70cbb1f6</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1021%2Facsbiomaterials.9b00427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsbiomaterials.9b00427%26sid%3Dliteratum%253Aachs%26aulast%3DAnsari%26aufirst%3DM.%2BM.%26aulast%3DAhmad%26aufirst%3DA.%26aulast%3DMishra%26aufirst%3DR.%2BK.%26aulast%3DRaza%26aufirst%3DS.%2BS.%26aulast%3DKhan%26aufirst%3DR.%26atitle%3DZinc%2520Gluconate-Loaded%2520Chitosan%2520Nanoparticles%2520Reduce%2520Severity%2520of%2520Collagen-Induced%2520Arthritis%2520in%2520Wistar%2520Rats%26jtitle%3DACS%2520Biomater.%2520Sci.%2520Eng.%26date%3D2019%26volume%3D5%26issue%3D7%26spage%3D3380%26epage%3D3397%26doi%3D10.1021%2Facsbiomaterials.9b00427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fauzia, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raza, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, R.</span></span> <span> </span><span class="NLM_article-title">Engineering. Gelatin-Coated Polycaprolactone Nanoparticle-Mediated Naringenin Delivery Rescues Human Mesenchymal Stem Cells from Oxygen Glucose Deprivation-Induced Inflammatory Stress</span>. <i>ACS Biomater. Sci. Eng.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">683</span>– <span class="NLM_lpage">695</span>, <span class="refDoi"> DOI: 10.1021/acsbiomaterials.8b01081</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsbiomaterials.8b01081" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVCisb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2019&pages=683-695&author=A.+Ahmadauthor=E.+Fauziaauthor=M.+Kumarauthor=R.+K.+Mishraauthor=A.+Kumarauthor=M.+A.+Khanauthor=S.+S.+Razaauthor=R.+Khan&title=Engineering.+Gelatin-Coated+Polycaprolactone+Nanoparticle-Mediated+Naringenin+Delivery+Rescues+Human+Mesenchymal+Stem+Cells+from+Oxygen+Glucose+Deprivation-Induced+Inflammatory+Stress&doi=10.1021%2Facsbiomaterials.8b01081"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Gelatin-Coated Polycaprolactone Nanoparticle-Mediated Naringenin Delivery Rescue Human Mesenchymal Stem Cells from Oxygen Glucose Deprivation-Induced Inflammatory Stress</span></div><div class="casAuthors">Ahmad, Anas; Fauzia, Eram; Kumar, Manish; Mishra, Rakesh Kumar; Kumar, Ajay; Khan, Mohsin Ali; Raza, Syed Shadab; Khan, Rehan</div><div class="citationInfo"><span class="NLM_cas:title">ACS Biomaterials Science & Engineering</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">683-695</span>CODEN:
                <span class="NLM_cas:coden">ABSEBA</span>;
        ISSN:<span class="NLM_cas:issn">2373-9878</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Ischemic stroke involves pro-inflammatory species, which implicates inflammation in the disease mechanism.  Recent studies indicate that the prevalence of therapeutic choice such as stem cell transplantation has seen an upsurge in ischemic stroke.  However, after transplantation the fate of transplanted cells is largely unknown.  Human mesenchymal stem cells (MSCs), due to their robust survival rate upon transplantation in brain tissue, are being widely employed to treat ischemic stroke.  In the present study, we have evaluated naringenin-loaded gelatin-coated polycaprolactone nanoparticles (nar-gel-c-PCL NPs) to rescue MSCs against oxygen glucose deprived insult.  Naringenin, due to its strong anti-inflammatory effects, remains a therapeutic choice in neurol. disorders.  Though, the low soly. and inefficient delivery remain challenges in using naringenin as a therapeutic drug.  The present study showed that inflammation occurred in MSCs during their treatment with oxygen glucose deprivation (OGD) and was well overturned by treatment with nar-gel-c-PCL NPs.  In brief, the results indicated that nar-gel-c-PCL NPs were able to protect the loss of cell membrane integrity and restored neuronal morphol.  Then nar-gel-c-PCL NPs successfully protected the human MSCs against OGD-induced inflammation as evident by reduced level of pro-inflammatory cytokine (TNF-α, IFN-γ, and IL-1β) and other inflammatory biomarkers (COX2, iNOS, and MPO activity).  Therefore, the modulation of inflammation by treatment with nar-gel-c-PCL NPs in MSCs could provide a novel strategy to improve MSC-based therapy, and thus, our nanoformulation may find a wide therapeutic application in ischemic stroke and other neuro-inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquDn8OxnaxjrVg90H21EOLACvtfcHk0ljMXjCOvDJMOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVCisb7O&md5=5e3c2fbfbe53dbf9a763fe65bf2f1a5e</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1021%2Facsbiomaterials.8b01081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsbiomaterials.8b01081%26sid%3Dliteratum%253Aachs%26aulast%3DAhmad%26aufirst%3DA.%26aulast%3DFauzia%26aufirst%3DE.%26aulast%3DKumar%26aufirst%3DM.%26aulast%3DMishra%26aufirst%3DR.%2BK.%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DKhan%26aufirst%3DM.%2BA.%26aulast%3DRaza%26aufirst%3DS.%2BS.%26aulast%3DKhan%26aufirst%3DR.%26atitle%3DEngineering.%2520Gelatin-Coated%2520Polycaprolactone%2520Nanoparticle-Mediated%2520Naringenin%2520Delivery%2520Rescues%2520Human%2520Mesenchymal%2520Stem%2520Cells%2520from%2520Oxygen%2520Glucose%2520Deprivation-Induced%2520Inflammatory%2520Stress%26jtitle%3DACS%2520Biomater.%2520Sci.%2520Eng.%26date%3D2019%26volume%3D5%26spage%3D683%26epage%3D695%26doi%3D10.1021%2Facsbiomaterials.8b01081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez de la Fuente, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, D.</span></span> <span> </span><span class="NLM_article-title">Martinez de la Fuentea, Human Induced Pluripotent Stem Cells for Tumor Targeted Delivery of Gold Nanorods and Enhanced Photothermal Therapy</span>. <i>ACS Nano</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2375</span>– <span class="NLM_lpage">2385</span>, <span class="refDoi"> DOI: 10.1021/acsnano.5b07172</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsnano.5b07172" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvFCnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=2375-2385&author=Y.+Liuauthor=M.+Yangauthor=J.+Zhangauthor=X.+Zhiauthor=C.+Liauthor=C.+Zhangauthor=F.+Panauthor=K.+Wangauthor=Y.+Yangauthor=J.+Martinez+de+la+Fuenteauthor=D.+Cui&title=Martinez+de+la+Fuentea%2C+Human+Induced+Pluripotent+Stem+Cells+for+Tumor+Targeted+Delivery+of+Gold+Nanorods+and+Enhanced+Photothermal+Therapy&doi=10.1021%2Facsnano.5b07172"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Human Induced Pluripotent Stem Cells for Tumor Targeted Delivery of Gold Nanorods and Enhanced Photothermal Therapy</span></div><div class="casAuthors">Liu, Yanlei; Yang, Meng; Zhang, Jingpu; Zhi, Xiao; Li, Chao; Zhang, Chunlei; Pan, Fei; Wang, Kan; Yang, Yuming; Martinez de la Fuentea, Jesus; Cui, Daxiang</div><div class="citationInfo"><span class="NLM_cas:title">ACS Nano</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">2375-2385</span>CODEN:
                <span class="NLM_cas:coden">ANCAC3</span>;
        ISSN:<span class="NLM_cas:issn">1936-0851</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">How to improve effective accumulation and intratumoral distribution of plasmonic gold nanoparticles has become a great challenge for photothermal therapy of tumors.  Herein, we reported a nanoplatform with photothermal therapeutic effects by fabricating Au <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="8ae4ebe4e5f8e5eef9cad9e3c5b8">[email protected]</a>@CXCR4 nanoparticles and loading the prepd. nanoparticles into the human induced pluripotent stem cells(AuNRs-iPS).  In virtue of the prominent optical properties of Au <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="80eee1eeeff2efe4f3c0d3e9cfb2">[email protected]</a>@CXCR4 and remarkable tumor target migration ability of iPS cells, the Au nanorods delivery mediated by iPS cells via the nanoplatform AuNRs-iPS was found to have a prolonged retention time and spatially even distribution in MGC803 tumor-bearing nude mice obsd. by photoacoustic tomog. and two-photon luminescence.  On the basis of these improvements, the nanoplatform displayed a robust migration capacity to target the tumor site and to improve photothermal therapeutic efficacy on inhibiting the growth of tumors in xenograft mice under a low laser power d.  The combination of gold nanorods with human iPS cells as a theranostic platform paves an alternative road for cancer theranostics and holds great promise for clin. translation in the near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnNNHynfNaZLVg90H21EOLACvtfcHk0ljU1fbJ1W948A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvFCnsA%253D%253D&md5=703a918880b938efe6f91658b3a7f8a6</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1021%2Facsnano.5b07172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsnano.5b07172%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhi%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DPan%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DMartinez%2Bde%2Bla%2BFuente%26aufirst%3DJ.%26aulast%3DCui%26aufirst%3DD.%26atitle%3DMartinez%2520de%2520la%2520Fuentea%252C%2520Human%2520Induced%2520Pluripotent%2520Stem%2520Cells%2520for%2520Tumor%2520Targeted%2520Delivery%2520of%2520Gold%2520Nanorods%2520and%2520Enhanced%2520Photothermal%2520Therapy%26jtitle%3DACS%2520Nano%26date%3D2016%26volume%3D10%26spage%3D2375%26epage%3D2385%26doi%3D10.1021%2Facsnano.5b07172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gasch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ffrench, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Leary, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallagher, M. F.</span></span> <span> </span><span class="NLM_article-title">Catching Moving Targets: Cancer Stem Cell Hierarchies, Therapy-Resistance & Considerations for Clinical Intervention</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">43</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1186/s12943-017-0601-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1186%2Fs12943-017-0601-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=28093071" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=1-15&issue=43&author=C.+Gaschauthor=B.+Ffrenchauthor=J.+J.+O%E2%80%99Learyauthor=M.+F.+Gallagher&title=Catching+Moving+Targets%3A+Cancer+Stem+Cell+Hierarchies%2C+Therapy-Resistance+%26+Considerations+for+Clinical+Intervention&doi=10.1186%2Fs12943-017-0601-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1186%2Fs12943-017-0601-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-017-0601-3%26sid%3Dliteratum%253Aachs%26aulast%3DGasch%26aufirst%3DC.%26aulast%3DFfrench%26aufirst%3DB.%26aulast%3DO%25E2%2580%2599Leary%26aufirst%3DJ.%2BJ.%26aulast%3DGallagher%26aufirst%3DM.%2BF.%26atitle%3DCatching%2520Moving%2520Targets%253A%2520Cancer%2520Stem%2520Cell%2520Hierarchies%252C%2520Therapy-Resistance%2520%2526%2520Considerations%2520for%2520Clinical%2520Intervention%26jtitle%3DMol.%2520Cancer%26date%3D2017%26volume%3D16%26issue%3D43%26spage%3D1%26epage%3D15%26doi%3D10.1186%2Fs12943-017-0601-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suryaprakash, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lao, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leong, K. W.</span></span> <span> </span><span class="NLM_article-title">Graphene Oxide Cellular Patches for Mesenchymal Stem Cell-Based Cancer Therapy</span>. <i>Carbon</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">863</span>– <span class="NLM_lpage">868</span>, <span class="refDoi"> DOI: 10.1016/j.carbon.2017.12.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.carbon.2017.12.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvF2ks7nM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2018&pages=863-868&author=S.+Suryaprakashauthor=M.+Liauthor=Y.-H.+Laoauthor=H.-X.+Wangauthor=K.+W.+Leong&title=Graphene+Oxide+Cellular+Patches+for+Mesenchymal+Stem+Cell-Based+Cancer+Therapy&doi=10.1016%2Fj.carbon.2017.12.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Graphene oxide cellular patches for mesenchymal stem cell-based cancer therapy</span></div><div class="casAuthors">Suryaprakash, Smruthi; Li, Mingqiang; Lao, Yeh-Hsing; Wang, Hong-Xia; Leong, Kam W.</div><div class="citationInfo"><span class="NLM_cas:title">Carbon</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">863-868</span>CODEN:
                <span class="NLM_cas:coden">CRBNAH</span>;
        ISSN:<span class="NLM_cas:issn">0008-6223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Graphene oxide (GO) is a versatile platform for drug delivery, but poor accumulation at the tumor site limits the translation of this technol.  Mesenchymal stem cells (MSC) on the other hand is tumor trophic but is limited to delivering only protein-based drugs.  Our soln. is to combine the individual attributes of GO and MSC by loading GO on the surface of MSC to create a unique drug delivery platform wherein, GO can be used to load a range of therapeutics and MSC can carry the drug effectively to the site of the tumor.  Here, we demonstrated that GO can be loaded with two types of chemo drugs, doxorubicin and mitoxantrone, with similar efficiency (>30%).  The drug-GO complex was loaded on MSC without affecting the MSC viability significantly.  On exposure to GO-mitoxantrone, 87% of MSC survived while only 28% of the cancer cells (LN18) survived, demonstrating the selective killing of the cancer cells but not MSC.  Furthermore, drug-GO loading did not affect the tumor trophic property of MSC, and coculture of the drug-GO loaded MSC with LN18 showed a dose-dependent killing of LN18.  Together, these results show the feasibility of using drug-GO loaded MSC as an effective carrier for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQKyWZ4T-BxbVg90H21EOLACvtfcHk0ljU1fbJ1W948A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvF2ks7nM&md5=3e5ac45c92070d6efb53c30a92e8497d</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1016%2Fj.carbon.2017.12.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.carbon.2017.12.031%26sid%3Dliteratum%253Aachs%26aulast%3DSuryaprakash%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DLao%26aufirst%3DY.-H.%26aulast%3DWang%26aufirst%3DH.-X.%26aulast%3DLeong%26aufirst%3DK.%2BW.%26atitle%3DGraphene%2520Oxide%2520Cellular%2520Patches%2520for%2520Mesenchymal%2520Stem%2520Cell-Based%2520Cancer%2520Therapy%26jtitle%3DCarbon%26date%3D2018%26volume%3D129%26spage%3D863%26epage%3D868%26doi%3D10.1016%2Fj.carbon.2017.12.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwacka, R.</span></span> <span> </span><span class="NLM_article-title">The Future of Mesenchymal Stem Cell-Based Therapeutic Approaches for Cancer–From Cells to Ghosts</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>414</i></span>,  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">249</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2017.11.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.canlet.2017.11.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=29175461" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFWhurzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=414&publication_year=2018&pages=239-249&author=A.+Mohrauthor=R.+Zwacka&title=The+Future+of+Mesenchymal+Stem+Cell-Based+Therapeutic+Approaches+for+Cancer%E2%80%93From+Cells+to+Ghosts&doi=10.1016%2Fj.canlet.2017.11.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">The future of mesenchymal stem cell-based therapeutic approaches for cancer - From cells to ghosts</span></div><div class="casAuthors">Mohr, Andrea; Zwacka, Ralf</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">414</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">239-249</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Mesenchymal stem cells (MSCs) are multipotent stromal cells which can differentiate into a variety of cell types including osteoblasts, adipocytes and chondrocytes.  They are normally resident in adipose tissue, bone marrow and the umbilical cord, but can also be found in other tissues and are known to be recruited to sites of wound healing as well as growing tumors.  The therapeutic potential of MSCs has been explored in a no. of phase I/II and III clin. trials, of which several were targeted against graft-vs.-host disease and to support engraftment of haematopoietic stem cells (HSCs), but currently only very few in the oncol. field.  There are now three clin. trials either ongoing or recruiting patients that use MSCs to treat tumor disease.  In these, MSCs target gastrointestinal, lung and ovarian cancer, resp.  The first study uses MSCs loaded with a HSV-TK expression construct under the control of the CCL5 promoter, and has recently reported successful completion of Phase I/II.  While no adverse side effects were seen during this study, no outcomes with respect to therapeutic benefits have been published.  The other clin. trials targeting lung and ovarian cancer will be using MSCs expressing cytokines as therapeutic payload.  Despite these encouraging early steps towards their clin. use, many questions are still unanswered regarding the biol. of MSCs in normal and pathophysiol. settings.  In this review, in addn. to summarising the current state of MSC-based therapeutic approaches for cancer, we will describe the remaining questions, obstacles and risks, as well as novel developments such as MSC-derived nanoghosts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrALBOMlqeCX7Vg90H21EOLACvtfcHk0ljU1fbJ1W948A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFWhurzJ&md5=d246250bcbcf66ffe7e0af0084d0ac2f</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2017.11.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2017.11.025%26sid%3Dliteratum%253Aachs%26aulast%3DMohr%26aufirst%3DA.%26aulast%3DZwacka%26aufirst%3DR.%26atitle%3DThe%2520Future%2520of%2520Mesenchymal%2520Stem%2520Cell-Based%2520Therapeutic%2520Approaches%2520for%2520Cancer%25E2%2580%2593From%2520Cells%2520to%2520Ghosts%26jtitle%3DCancer%2520Lett.%26date%3D2018%26volume%3D414%26spage%3D239%26epage%3D249%26doi%3D10.1016%2Fj.canlet.2017.11.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sehl, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wicha, M. S.</span></span> <span> </span><span class="NLM_article-title">Modeling of Interactions Between Cancer Stem Cells and Their Microenvironment: Predicting Clinical Response</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>1711</i></span>,  <span class="NLM_fpage">333</span>– <span class="NLM_lpage">349</span>, <span class="refDoi"> DOI: 10.1007/978-1-4939-7493-1_16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1007%2F978-1-4939-7493-1_16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=29344897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFKrsL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1711&publication_year=2018&pages=333-349&author=M.+E.+Sehlauthor=M.+S.+Wicha&title=Modeling+of+Interactions+Between+Cancer+Stem+Cells+and+Their+Microenvironment%3A+Predicting+Clinical+Response&doi=10.1007%2F978-1-4939-7493-1_16"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Modeling of interactions between cancer stem cells and their microenvironment: predicting clinical response</span></div><div class="casAuthors">Sehl, Mary E.; Wicha, Max S.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">1711</span>
        (<span class="NLM_cas:issue">Cancer Systems Biology</span>),
    <span class="NLM_cas:pages">333-349</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1940-6029</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Math. models of cancer stem cells are useful in translational cancer research for facilitating the understanding of tumor growth dynamics and for predicting treatment response and resistance to combined targeted therapies.  In this chapter, we describe appealing aspects of different methods used in math. oncol. and discuss compelling questions in oncol. that can be addressed with these modeling techniques.  We describe a simplified version of a model of the breast cancer stem cell niche, illustrate the visualization of the model, and apply stochastic simulation to generate full distributions and av. trajectories of cell type populations over time.  We further discuss the advent of single-cell data in studying cancer stem cell heterogeneity and how these data can be integrated with modeling to advance understanding of the dynamics of invasive and proliferative populations during cancer progression and response to therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGAJtUHRE5yLVg90H21EOLACvtfcHk0lgHRlkPn069fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFKrsL3L&md5=6ae71c9ee33c9cb398fbde019e5ad05f</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-7493-1_16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4939-7493-1_16%26sid%3Dliteratum%253Aachs%26aulast%3DSehl%26aufirst%3DM.%2BE.%26aulast%3DWicha%26aufirst%3DM.%2BS.%26atitle%3DModeling%2520of%2520Interactions%2520Between%2520Cancer%2520Stem%2520Cells%2520and%2520Their%2520Microenvironment%253A%2520Predicting%2520Clinical%2520Response%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2018%26volume%3D1711%26spage%3D333%26epage%3D349%26doi%3D10.1007%2F978-1-4939-7493-1_16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, M.</span></span> <span> </span><span class="NLM_article-title">Exosome-Based Cancer Therapy: Implication for Targeting Cancer Stem Cells</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">533</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">11</span>, <span class="refDoi"> DOI: 10.3389/fphar.2016.00533</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.3389%2Ffphar.2016.00533" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=1-11&issue=533&author=J.+Wangauthor=Y.+Zhengauthor=M.+Zhao&title=Exosome-Based+Cancer+Therapy%3A+Implication+for+Targeting+Cancer+Stem+Cells&doi=10.3389%2Ffphar.2016.00533"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2016.00533&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2016.00533%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DM.%26atitle%3DExosome-Based%2520Cancer%2520Therapy%253A%2520Implication%2520for%2520Targeting%2520Cancer%2520Stem%2520Cells%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D7%26issue%3D533%26spage%3D1%26epage%3D11%26doi%3D10.3389%2Ffphar.2016.00533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Nanomaterials in Targeting Cancer Stem Cells for Cancer Therapy</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.3389/fphar.2017.00001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.3389%2Ffphar.2017.00001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=28149278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtl2mtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1-15&author=W.+Qinauthor=G.+Huangauthor=Z.+Chenauthor=Y.+Zhang&title=Nanomaterials+in+Targeting+Cancer+Stem+Cells+for+Cancer+Therapy&doi=10.3389%2Ffphar.2017.00001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Nanomaterials in targeting cancer stem cells for cancer therapy</span></div><div class="casAuthors">Qin, Weiwei; Huang, Guan; Chen, Zuanguang; Zhang, Yuanqing</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-15</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Cancer stem cells (CSCs) have been identified in almost all cancers and give rise to metastases and can also act as a reservoir of cancer cells that may cause a relapse after surgery, radiation, or chemotherapy.  Thus they are obvious targets in therapeutic approaches and also a great challenge in cancer treatment.  The threat presented by CSCs lies in their unlimited proliferative ability and multidrug resistance.  These findings have necessitated an effective novel strategy to target CSCs for cancer treatment.  Nanomaterials are on the route to providing novel methods in cancer therapies.  Although, there have been a large no. of excellent work in the field of targeted cancer therapy, it remains an open question how nanomaterials can meet future demands for targeting and eradicating of CSCs.  In this review, we summarized recent and highlighted future prospects for targeting CSCs for cancer therapies by using a variety of nanomaterials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogBDr6a6L-CbVg90H21EOLACvtfcHk0lgHRlkPn069fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtl2mtb0%253D&md5=18c8fcfe71cacd450e98eb61967ade02</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00001%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DNanomaterials%2520in%2520Targeting%2520Cancer%2520Stem%2520Cells%2520for%2520Cancer%2520Therapy%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D1%26epage%3D15%26doi%3D10.3389%2Ffphar.2017.00001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kong, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mäkilä, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salonen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hai, M.</span></span> <span> </span><span class="NLM_article-title">Gold Nanorods, DNA Origami, and Porous Silicon Nanoparticle-Functionalized Biocompatible Double Emulsion for Versatile Targeted Therapeutics and Antibody Combination Therapy</span>. <i>Adv. Mater.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">10195</span>– <span class="NLM_lpage">10203</span>, <span class="refDoi"> DOI: 10.1002/adma.201602763</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1002%2Fadma.201602763" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=27689681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1SlsrrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2016&pages=10195-10203&author=F.+Kongauthor=H.+Zhangauthor=X.+Quauthor=X.+Zhangauthor=D.+Chenauthor=R.+Dingauthor=E.+M%C3%A4kil%C3%A4author=J.+Salonenauthor=H.+A.+Santosauthor=M.+Hai&title=Gold+Nanorods%2C+DNA+Origami%2C+and+Porous+Silicon+Nanoparticle-Functionalized+Biocompatible+Double+Emulsion+for+Versatile+Targeted+Therapeutics+and+Antibody+Combination+Therapy&doi=10.1002%2Fadma.201602763"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Gold Nanorods, DNA Origami, and Porous Silicon Nanoparticle-functionalized Biocompatible Double Emulsion for Versatile Targeted Therapeutics and Antibody Combination Therapy</span></div><div class="casAuthors">Kong, Feng; Zhang, Hongbo; Qu, Xiangmeng; Zhang, Xu; Chen, Dong; Ding, Ruihua; Maekilae, Ermei; Salonen, Jarno; Santos, Helder A.; Hai, Mingtan</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Materials (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">10195-10203</span>CODEN:
                <span class="NLM_cas:coden">ADVMEW</span>;
        ISSN:<span class="NLM_cas:issn">0935-9648</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Gold nanorods, DNA origami, and porous silicon nanoparticle-functionalized biocompatible double emulsion are developed for versatile mol. targeted therapeutics and antibody combination therapy.  This advanced photothermal responsive all-in-one biocompatible platform can be easily formed with great therapeutics loading capacity for different cancer treatments with synergism and multidrug resistance inhibition, which has great potential in advancing biomedical applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkywVMIALbz7Vg90H21EOLACvtfcHk0lgYbO1lOzhwAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1SlsrrF&md5=8e70e2a810acd265d95e829904a00e23</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1002%2Fadma.201602763&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fadma.201602763%26sid%3Dliteratum%253Aachs%26aulast%3DKong%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DQu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DDing%26aufirst%3DR.%26aulast%3DM%25C3%25A4kil%25C3%25A4%26aufirst%3DE.%26aulast%3DSalonen%26aufirst%3DJ.%26aulast%3DSantos%26aufirst%3DH.%2BA.%26aulast%3DHai%26aufirst%3DM.%26atitle%3DGold%2520Nanorods%252C%2520DNA%2520Origami%252C%2520and%2520Porous%2520Silicon%2520Nanoparticle-Functionalized%2520Biocompatible%2520Double%2520Emulsion%2520for%2520Versatile%2520Targeted%2520Therapeutics%2520and%2520Antibody%2520Combination%2520Therapy%26jtitle%3DAdv.%2520Mater.%26date%3D2016%26volume%3D28%26spage%3D10195%26epage%3D10203%26doi%3D10.1002%2Fadma.201602763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palazzolo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadla, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo Spena, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo Re, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adeel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caligiuri, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romano, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corona, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canzonieri, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toffoli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzolio, F.</span></span> <span> </span><span class="NLM_article-title">A Proof-of-Concept Multi-Stage Biomimetic Liposomal DNA Origami Nanosystem for the Remote Loading of Doxorubicin</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">517</span>– <span class="NLM_lpage">521</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00557</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00557" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1Cisro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=517-521&issue=4&author=S.+Palazzoloauthor=M.+Hadlaauthor=C.+Russo+Spenaauthor=S.+Baydaauthor=V.+Kumarauthor=F.+Lo+Reauthor=M.+Adeelauthor=I.+Caligiuriauthor=F.+Romanoauthor=G.+Coronaauthor=V.+Canzonieriauthor=G.+Toffoliauthor=F.+Rizzolio&title=A+Proof-of-Concept+Multi-Stage+Biomimetic+Liposomal+DNA+Origami+Nanosystem+for+the+Remote+Loading+of+Doxorubicin&doi=10.1021%2Facsmedchemlett.8b00557"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Proof-of-Concept Multistage Biomimetic Liposomal DNA Origami Nanosystem for the Remote Loading of Doxorubicin</span></div><div class="casAuthors">Palazzolo, Stefano; Hadla, Mohamad; Spena, Concetta Russo; Bayda, Samer; Kumar, Vinit; Lo Re, Francesco; Adeel, Muhammad; Caligiuri, Isabella; Romano, Flavio; Corona, Giuseppe; Canzonieri, Vincenzo; Toffoli, Giuseppe; Rizzolio, Flavio</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">517-521</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">One of the most promising applications of DNA origami is its use as an excellent evolution of nanostructured intelligent systems for drug delivery, but short in vivo lifetime and immune-activation are still major challenges to overcome.  On the contrary, stealth liposomes have long-circulation time and are well tolerated by the immune system.  To overcome DNA origami limitations, we have designed and synthesized a compact short tube DNA origami (STDO) of approx. 30 nm in length and 10 nm in width.  These STDO are highly stable ≥48 h in physiol. conditions without any postsynthetic modifications.  The compact size of STDO precisely fits inside a stealthy liposome of about 150 nm and could efficiently remotely load doxorubicin in liposomes (LSTDO) without a pH driven gradient.  We demonstrated that this innovative drug delivery system (DDS) has an optimal tumoral release and high biocompatible profiles opening up new horizons to encapsulate many other hydrophobic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQgk2vYEQxY7Vg90H21EOLACvtfcHk0lgYbO1lOzhwAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1Cisro%253D&md5=5444e0fa2b8fd5b6b3279be9d01f7e06</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00557&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00557%26sid%3Dliteratum%253Aachs%26aulast%3DPalazzolo%26aufirst%3DS.%26aulast%3DHadla%26aufirst%3DM.%26aulast%3DRusso%2BSpena%26aufirst%3DC.%26aulast%3DBayda%26aufirst%3DS.%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DLo%2BRe%26aufirst%3DF.%26aulast%3DAdeel%26aufirst%3DM.%26aulast%3DCaligiuri%26aufirst%3DI.%26aulast%3DRomano%26aufirst%3DF.%26aulast%3DCorona%26aufirst%3DG.%26aulast%3DCanzonieri%26aufirst%3DV.%26aulast%3DToffoli%26aufirst%3DG.%26aulast%3DRizzolio%26aufirst%3DF.%26atitle%3DA%2520Proof-of-Concept%2520Multi-Stage%2520Biomimetic%2520Liposomal%2520DNA%2520Origami%2520Nanosystem%2520for%2520the%2520Remote%2520Loading%2520of%2520Doxorubicin%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26issue%3D4%26spage%3D517%26epage%3D521%26doi%3D10.1021%2Facsmedchemlett.8b00557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gurunathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.-H.</span></span> <span> </span><span class="NLM_article-title">Biocompatible Gold Nanoparticles Ameliorate Retinoic Acid-Induced Cell Death and Induce Differentiation in F9 Teratocarcinoma Stem Cells</span>. <i>Nanomaterials</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">396</span>, <span class="refDoi"> DOI: 10.3390/nano8060396</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.3390%2Fnano8060396" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlOmt7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=396&author=S.+Gurunathanauthor=J.-H.+Kim&title=Biocompatible+Gold+Nanoparticles+Ameliorate+Retinoic+Acid-Induced+Cell+Death+and+Induce+Differentiation+in+F9+Teratocarcinoma+Stem+Cells&doi=10.3390%2Fnano8060396"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Biocompatible gold nanoparticles ameliorate retinoic acid-induced cell death and induce differentiation in F9 teratocarcinoma stem cells</span></div><div class="casAuthors">Gurunathan, Sangiliyandi; Kim, Jin-Hoi</div><div class="citationInfo"><span class="NLM_cas:title">Nanomaterials</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">396/1-396/21</span>CODEN:
                <span class="NLM_cas:coden">NANOKO</span>;
        ISSN:<span class="NLM_cas:issn">2079-4991</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The unique properties of gold nanoparticles (AuNPs) have attracted much interest for a range of applications, including biomedical applications in the cosmetic industry.  The current study assessed the anti-oxidative effect of AuNPs against retinoic acid (RA)-induced loss of cell viability; cell proliferation; expression of oxidative and anti-oxidative stress markers, pro- and anti-apoptotic genes, and differentiation markers; and mitochondrial dysfunction in F9 teratocarcinoma stem cells.  AuNPs were prepd. by redn. of gold salts using luteolin as a reducing and stabilizing agent.  The prepd. AuNPs were spherical in shape with an av. diam. of 18 nm.  F9 cells exposed to various concns. of these AuNPs were not harmed, whereas cells exposed to RA exhibited a dose-dependent change in cell viability and cell proliferation.  The RA-mediated toxicity was assocd. with increased leakage of lactate dehydrogenase, reactive oxygen species, increased levels of malondialdehyde and nitric oxide, loss of mitochondrial membrane potential, and a reduced level of ATP.  Finally, RA increased the level of pro-apoptotic gene expression and decreased the expression of anti-apoptotic genes.  Interestingly, the toxic effect of RA appeared to be decreased in cells treated with RA in the presence of AuNPs, which was coincident with the increased levels of anti-oxidant markers including thioredoxin, glutathione peroxidases, glutathione, glutathione disulfide, catalase, and superoxide dismutase.  Concomitantly, AuNPs ameliorated the apoptotic response by decreasing the mRNA expression of p53, p21, Bax, Bak, caspase-3, caspase-9, and increasing the expressions of Bcl-2 and Bcl-Xl.  Interestingly, AuNPs not only ameliorated oxidative stress but also induced differentiation in F9 cells by increasing the expression of differentiation markers including retinoic acid binding protein, laminin 1, collagen type IV, and Gata 6 and decreasing the expressions of markers of stem cell pluripotency including Nanog, Rex1, octamer-binding transcription factor 4, and Sox-2.  These consistent cellular and biochem. data suggest that AuNPs could ameliorate RA-induced cell death and facilitate F9 cell differentiation.  AuNPs could be suitable therapeutic agents for the treatment of oxidative stress-related diseases such as atherosclerosis, cancer, diabetes, rheumatoid arthritis, and neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozX-U_84A5qLVg90H21EOLACvtfcHk0lgYbO1lOzhwAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlOmt7fP&md5=ad42f557c452dfbc6d9e3bd15bc5ec98</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.3390%2Fnano8060396&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fnano8060396%26sid%3Dliteratum%253Aachs%26aulast%3DGurunathan%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DJ.-H.%26atitle%3DBiocompatible%2520Gold%2520Nanoparticles%2520Ameliorate%2520Retinoic%2520Acid-Induced%2520Cell%2520Death%2520and%2520Induce%2520Differentiation%2520in%2520F9%2520Teratocarcinoma%2520Stem%2520Cells%26jtitle%3DNanomaterials%26date%3D2018%26volume%3D8%26spage%3D396%26doi%3D10.3390%2Fnano8060396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mooney, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batalla-Covello, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdul Majid, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aboody, K. S.</span></span> <span> </span><span class="NLM_article-title">Concise Review: Neural Stem Cell-Mediated Targeted Cancer Therapies</span>. <i>Stem Cells Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">740</span>– <span class="NLM_lpage">747</span>, <span class="refDoi"> DOI: 10.1002/sctm.18-0003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1002%2Fsctm.18-0003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=30133188" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A280%3ADC%252BB3c3gs1Cjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2018&pages=740-747&author=R.+Mooneyauthor=M.+Hammadauthor=J.+Batalla-Covelloauthor=A.+Abdul+Majidauthor=K.+S.+Aboody&title=Concise+Review%3A+Neural+Stem+Cell-Mediated+Targeted+Cancer+Therapies&doi=10.1002%2Fsctm.18-0003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Concise Review: Neural Stem Cell-Mediated Targeted Cancer Therapies</span></div><div class="casAuthors">Mooney Rachael; Hammad Mohamed; Batalla-Covello Jennifer; Abdul Majid Asma; Aboody Karen S; Mooney Rachael; Batalla-Covello Jennifer</div><div class="citationInfo"><span class="NLM_cas:title">Stem cells translational medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">740-747</span>
        ISSN:<span class="NLM_cas:issn">2157-6564</span>.
    </div><div class="casAbstract">Cancer is one of the leading causes of morbidity and mortality worldwide, with 1,688,780 new cancer cases and 600,920 cancer deaths projected to occur in 2017 in the U.S. alone.  Conventional cancer treatments including surgical, chemo-, and radiation therapies can be effective, but are often limited by tumor invasion, off-target toxicities, and acquired resistance.  To improve clinical outcomes and decrease toxic side effects, more targeted, tumor-specific therapies are being developed.  Delivering anticancer payloads using tumor-tropic cells can greatly increase therapeutic distribution to tumor sites, while sparing non-tumor tissues therefore minimizing toxic side effects.  Neural stem cells (NSCs) are tumor-tropic cells that can pass through normal organs quickly, localize to invasive and metastatic tumor foci throughout the body, and cross the blood-brain barrier to reach tumors in the brain.  This review focuses on the potential use of NSCs as vehicles to deliver various anticancer payloads selectively to tumor sites.  The use of NSCs in cancer treatment has been studied most extensively in the brain, but the findings are applicable to other metastatic solid tumors, which will be described in this review.  Strategies include NSC-mediated enzyme/prodrug gene therapy, oncolytic virotherapy, and delivery of antibodies, nanoparticles, and extracellular vesicles containing oligonucleotides.  Preclinical discovery and translational studies, as well as early clinical trials, will be discussed.  Stem Cells Translational Medicine 2018;7:740-747.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQr9VjUb_7DjbmQt-ICR3qNfW6udTcc2ebmQdH7gzHYCbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c3gs1Cjsw%253D%253D&md5=3471fefe5a2d5f2b391637ca41238e81</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1002%2Fsctm.18-0003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fsctm.18-0003%26sid%3Dliteratum%253Aachs%26aulast%3DMooney%26aufirst%3DR.%26aulast%3DHammad%26aufirst%3DM.%26aulast%3DBatalla-Covello%26aufirst%3DJ.%26aulast%3DAbdul%2BMajid%26aufirst%3DA.%26aulast%3DAboody%26aufirst%3DK.%2BS.%26atitle%3DConcise%2520Review%253A%2520Neural%2520Stem%2520Cell-Mediated%2520Targeted%2520Cancer%2520Therapies%26jtitle%3DStem%2520Cells%2520Transl.%2520Med.%26date%3D2018%26volume%3D7%26spage%3D740%26epage%3D747%26doi%3D10.1002%2Fsctm.18-0003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Bertoni, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozielski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lal, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaughan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mihelson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberhart, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laterra, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, J.</span></span> <span> </span><span class="NLM_article-title">Bioreducible Polymeric Nanoparticles Containing Multiplexed Cancer Stem Cell-Regulating MiRNAs Inhibit Glioblastoma Growth and Prolong Survival</span>. <i>Nano Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4086</span>– <span class="NLM_lpage">4094</span>, <span class="refDoi"> DOI: 10.1021/acs.nanolett.8b00390</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.nanolett.8b00390" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFyqt7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=4086-4094&author=H.+Lopez-Bertoniauthor=K.+Kozielskiauthor=Y.+Ruiauthor=B.+Lalauthor=H.+Vaughanauthor=D.+Wilsonauthor=N.+Mihelsonauthor=C.+Eberhartauthor=J.+Laterraauthor=J.+Green&title=Bioreducible+Polymeric+Nanoparticles+Containing+Multiplexed+Cancer+Stem+Cell-Regulating+MiRNAs+Inhibit+Glioblastoma+Growth+and+Prolong+Survival&doi=10.1021%2Facs.nanolett.8b00390"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Bioreducible Polymeric Nanoparticles Containing Multiplexed Cancer Stem Cell Regulating miRNAs Inhibit Glioblastoma Growth and Prolong Survival</span></div><div class="casAuthors">Lopez-Bertoni, Hernando; Kozielski, Kristen L.; Rui, Yuan; Lal, Bachchu; Vaughan, Hannah; Wilson, David R.; Mihelson, Nicole; Eberhart, Charles G.; Laterra, John; Green, Jordan J.</div><div class="citationInfo"><span class="NLM_cas:title">Nano Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">4086-4094</span>CODEN:
                <span class="NLM_cas:coden">NALEFD</span>;
        ISSN:<span class="NLM_cas:issn">1530-6984</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Despite our growing mol.-level understanding of glioblastoma (GBM), treatment modalities remain limited.  Recent developments in the mechanisms of cell fate regulation and nanomedicine provide new avenues by which to treat and manage brain tumors via the delivery of mol. therapeutics.  Here, we have developed bioreducible poly(β-amino ester) nanoparticles that demonstrate high intracellular delivery efficacy, low cytotoxicity, escape from endosomes, and promotion of cytosol-targeted environmentally triggered cargo release for miRNA delivery to tumor-propagating human cancer stem cells.  In this report, we combined this nanobiotechnol. with newly discovered cancer stem cell inhibiting miRNAs to develop self-assembled miRNA-contg. polymeric nanoparticles (nano-miRs) to treat gliomas.  We show that these nano-miRs effectively intracellularly deliver single and combination miRNA mimics that inhibit the stem cell phenotype of human GBM cells in vitro.  Following direct intratumoral infusion, these nano-miRs were found to distribute through the tumors, inhibit the growth of established orthotopic human GBM xenografts, and cooperatively enhance the response to std.-of-care γ radiation.  Co-delivery of two miRNAs, miR-148a and miR-296-5p, within the bioreducible nano-miR particles enabled long-term survival from GBM in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzu2F4Tq9m87Vg90H21EOLACvtfcHk0ljp3gssHBDHog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFyqt7rN&md5=980ccb688441948880685d5c69fc898a</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1021%2Facs.nanolett.8b00390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.nanolett.8b00390%26sid%3Dliteratum%253Aachs%26aulast%3DLopez-Bertoni%26aufirst%3DH.%26aulast%3DKozielski%26aufirst%3DK.%26aulast%3DRui%26aufirst%3DY.%26aulast%3DLal%26aufirst%3DB.%26aulast%3DVaughan%26aufirst%3DH.%26aulast%3DWilson%26aufirst%3DD.%26aulast%3DMihelson%26aufirst%3DN.%26aulast%3DEberhart%26aufirst%3DC.%26aulast%3DLaterra%26aufirst%3DJ.%26aulast%3DGreen%26aufirst%3DJ.%26atitle%3DBioreducible%2520Polymeric%2520Nanoparticles%2520Containing%2520Multiplexed%2520Cancer%2520Stem%2520Cell-Regulating%2520MiRNAs%2520Inhibit%2520Glioblastoma%2520Growth%2520and%2520Prolong%2520Survival%26jtitle%3DNano%2520Lett.%26date%3D2018%26volume%3D18%26spage%3D4086%26epage%3D4094%26doi%3D10.1021%2Facs.nanolett.8b00390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hua, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Matos, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metselaar, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storm, G.</span></span> <span> </span><span class="NLM_article-title">Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">790</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">14</span>, <span class="refDoi"> DOI: 10.3389/fphar.2018.00790</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.3389%2Ffphar.2018.00790" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=29387012" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1-14&issue=790&author=S.+Huaauthor=M.+B.+de+Matosauthor=J.+M.+Metselaarauthor=G.+Storm&title=Current+Trends+and+Challenges+in+the+Clinical+Translation+of+Nanoparticulate+Nanomedicines%3A+Pathways+for+Translational+Development+and+Commercialization&doi=10.3389%2Ffphar.2018.00790"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2018.00790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2018.00790%26sid%3Dliteratum%253Aachs%26aulast%3DHua%26aufirst%3DS.%26aulast%3Dde%2BMatos%26aufirst%3DM.%2BB.%26aulast%3DMetselaar%26aufirst%3DJ.%2BM.%26aulast%3DStorm%26aufirst%3DG.%26atitle%3DCurrent%2520Trends%2520and%2520Challenges%2520in%2520the%2520Clinical%2520Translation%2520of%2520Nanoparticulate%2520Nanomedicines%253A%2520Pathways%2520for%2520Translational%2520Development%2520and%2520Commercialization%26jtitle%3DFront.%2520Pharmacol.%26date%3D2018%26volume%3D9%26issue%3D790%26spage%3D1%26epage%3D14%26doi%3D10.3389%2Ffphar.2018.00790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Youn, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bae, Y. H.</span></span> <span> </span><span class="NLM_article-title">Perspectives on the Past, Present, and Future of Cancer Nanomedicine</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">11</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2018.05.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.addr.2018.05.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=29778902" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVantbjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2018&pages=3-11&author=Y.+S.+Younauthor=Y.+H.+Bae&title=Perspectives+on+the+Past%2C+Present%2C+and+Future+of+Cancer+Nanomedicine&doi=10.1016%2Fj.addr.2018.05.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Perspectives on the past, present, and future of cancer nanomedicine</span></div><div class="casAuthors">Youn, Yu Seok; Bae, You Han</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3-11</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The justification of cancer nanomedicine relies on enhanced permeation (EP) and retention (R) effect and the capability of intracellular targeting due primarily to size after internalization (endocytosis) into the individual target cells.  The EPR effect implies improved efficacy.  Affinity targeting for solid tumors only occur after delivery to individual cells, which help internalization and/or retention.  The design principles have been supported by animal results in numerous publications, but hardly translated.  The natures of EP and R, such as frequency of large openings in tumor vasculature and their dynamics, are not understood, in particular, in clin. settings.  Although various attempts to address the issues related to EP and delivery, by modifying design factors and manipulating tumor microenvironment, are being reported, they are still verified in artificial rodent tumors which do not mimic the nature of human tumor physiol./pathol. in terms of transport and delivery.  The clin. trials of exptl. nanomedicine have experienced unexpected adverse effects with modest improvement in efficacy when compared to current frontline therapy.  Future nanomedicine may require new design principles without consideration of EP and affinity targeting.  A possible direction is to set new approaches to intentionally minimize adverse effects, rather than aiming at better efficacy, which can widen the therapeutic window of an anticancer drug of interest.  Broadening indications and administration routes of developed therapeutic nanotechnol. would benefit patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3h7U16UUscbVg90H21EOLACvtfcHk0liiHpd53ckDGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVantbjN&md5=19e61fff4b7e3f4b6ef55bb97cdbfcae</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2018.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2018.05.008%26sid%3Dliteratum%253Aachs%26aulast%3DYoun%26aufirst%3DY.%2BS.%26aulast%3DBae%26aufirst%3DY.%2BH.%26atitle%3DPerspectives%2520on%2520the%2520Past%252C%2520Present%252C%2520and%2520Future%2520of%2520Cancer%2520Nanomedicine%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2018%26volume%3D130%26spage%3D3%26epage%3D11%26doi%3D10.1016%2Fj.addr.2018.05.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herrera, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colby, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz-Opazo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grinstaff, M. W.</span></span> <span> </span><span class="NLM_article-title">Nucleic Acid Nanomedicines in Phase II/III Clinical Trials: Translation of Nucleic Acid Therapies for Reprogramming Cells</span>. <i>Nanomedicine</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">2083</span>– <span class="NLM_lpage">2098</span>, <span class="refDoi"> DOI: 10.2217/nnm-2018-0122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.2217%2Fnnm-2018-0122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=30204054" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVaqt7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=2083-2098&author=V.+L.+Herreraauthor=A.+H.+Colbyauthor=N.+Ruiz-Opazoauthor=D.+G.+Colemanauthor=M.+W.+Grinstaff&title=Nucleic+Acid+Nanomedicines+in+Phase+II%2FIII+Clinical+Trials%3A+Translation+of+Nucleic+Acid+Therapies+for+Reprogramming+Cells&doi=10.2217%2Fnnm-2018-0122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Nucleic acid nanomedicines in Phase II/III clinical trials: translation of nucleic acid therapies for reprogramming cells</span></div><div class="casAuthors">Herrera, Victoria L. M.; Colby, Aaron H.; Ruiz-Opazo, Nelson; Coleman, David G.; Grinstaff, Mark W.</div><div class="citationInfo"><span class="NLM_cas:title">Nanomedicine (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2083-2098</span>CODEN:
                <span class="NLM_cas:coden">NLUKAC</span>;
        ISSN:<span class="NLM_cas:issn">1748-6963</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">This review presents an integrated anal. of the current-state-of-the-art in nucleic acid nanotherapies and highlights the importance of nanotechnol. in the delivery of nucleic acid therapies.  While there is no one dominant nanodesign, the diversity of nanodesigns and delivery of different siRNAs, miRNA and DNA to inhibit more than 20 targets in seven disease states in Phase II/III clin. trials reflects the potential of nucleic acid therapies to treat intractable diseases and non-druggable targets.  We provide benchmarks to aid in comparing the design, proof-of-concept studies and clin. trials.  From this, we demonstrate the importance of generating a strategic framework for integrating clin. 'wish lists' for a means to treat intractable diseases with engineering 'design checklists' for nucleic acid nanotherapies.  Lay abstr. : The application of nanotechnol. to medicine - nanomedicine - offers an unprecedented opportunity to improve patient outcomes.  This integrated review of emerging clin. successes and failures in Phase II/III clin. trials provides insight into how best to design new technologies for the delivery of nucleic acid therapies.  An integrated anal. of the current-state-of-the-art in nucleic acid nanotherapies is presented with an emphasis on medical perspectives in nanomedicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocwN-TsJHvXbVg90H21EOLACvtfcHk0liiHpd53ckDGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVaqt7nE&md5=c3ae325b9d6bbd7a86f96a4d075418e3</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.2217%2Fnnm-2018-0122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fnnm-2018-0122%26sid%3Dliteratum%253Aachs%26aulast%3DHerrera%26aufirst%3DV.%2BL.%26aulast%3DColby%26aufirst%3DA.%2BH.%26aulast%3DRuiz-Opazo%26aufirst%3DN.%26aulast%3DColeman%26aufirst%3DD.%2BG.%26aulast%3DGrinstaff%26aufirst%3DM.%2BW.%26atitle%3DNucleic%2520Acid%2520Nanomedicines%2520in%2520Phase%2520II%252FIII%2520Clinical%2520Trials%253A%2520Translation%2520of%2520Nucleic%2520Acid%2520Therapies%2520for%2520Reprogramming%2520Cells%26jtitle%3DNanomedicine%26date%3D2018%26volume%3D13%26spage%3D2083%26epage%3D2098%26doi%3D10.2217%2Fnnm-2018-0122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caster, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span> <span> </span><span class="NLM_article-title">Investigational Nanomedicines in 2016: A Review of Nanotherapeutics Currently Undergoing Clinical Trials</span>. <i>Nanomedicine</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">e1416</span>– <span class="NLM_lpage">e1434</span>, <span class="refDoi"> DOI: 10.1002/wnan.1416</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1002%2Fwnan.1416" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=e1416-e1434&author=J.+M.+Casterauthor=A.+N.+Patelauthor=T.+Zhangauthor=A.+Wang&title=Investigational+Nanomedicines+in+2016%3A+A+Review+of+Nanotherapeutics+Currently+Undergoing+Clinical+Trials&doi=10.1002%2Fwnan.1416"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1002%2Fwnan.1416&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fwnan.1416%26sid%3Dliteratum%253Aachs%26aulast%3DCaster%26aufirst%3DJ.%2BM.%26aulast%3DPatel%26aufirst%3DA.%2BN.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DA.%26atitle%3DInvestigational%2520Nanomedicines%2520in%25202016%253A%2520A%2520Review%2520of%2520Nanotherapeutics%2520Currently%2520Undergoing%2520Clinical%2520Trials%26jtitle%3DNanomedicine%26date%3D2017%26volume%3D9%26spage%3De1416%26epage%3De1434%26doi%3D10.1002%2Fwnan.1416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papoian, T.</span></span> <span> </span><span class="NLM_article-title">Safety of Antisense Oligonucleotide and SiRNA-Based Therapeutics</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">823</span>– <span class="NLM_lpage">833</span>, 144. <span class="refDoi"> DOI: 10.1016/j.drudis.2017.01.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.drudis.2017.01.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=28159625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2sXit1eqs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=823-833&author=X.+Chiauthor=P.+Gattiauthor=T.+Papoian&title=Safety+of+Antisense+Oligonucleotide+and+SiRNA-Based+Therapeutics&doi=10.1016%2Fj.drudis.2017.01.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Safety of antisense oligonucleotide and siRNA-based therapeutics</span></div><div class="casAuthors">Chi, Xuan; Gatti, Philip; Papoian, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">823-833</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Oligonucleotide-based therapy is an active area of drug development designed to treat a variety of gene-specific diseases.  Two of the more promising platforms are the antisense oligonucleotides (ASOs) and short interfering RNAs (siRNAs), both of which are often directed against similar targets.  In light of recent reports on clin. trials of severe thrombocytopenia with two different ASO drugs and increased peripheral neuropathy with an siRNA drug, we compared and contrasted the specific safety characteristics of these two classes of oligonucleotide therapeutic.  The objectives were to assess factors that could contribute to the specific toxicities obsd. with these two classes of promising drugs, and get a better understanding of the potential mechanism(s) responsible for these rare, but serious, adverse events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2Ej7iOK40PbVg90H21EOLACvtfcHk0libQPo9f0egxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXit1eqs70%253D&md5=40ef4591957b37ab501c95f53b6aa07b</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2017.01.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2017.01.013%26sid%3Dliteratum%253Aachs%26aulast%3DChi%26aufirst%3DX.%26aulast%3DGatti%26aufirst%3DP.%26aulast%3DPapoian%26aufirst%3DT.%26atitle%3DSafety%2520of%2520Antisense%2520Oligonucleotide%2520and%2520SiRNA-Based%2520Therapeutics%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2017%26volume%3D22%26spage%3D823%26epage%3D833%26doi%3D10.1016%2Fj.drudis.2017.01.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ventola, C. L.</span></span> <span> </span><span class="NLM_article-title">Progress in Nanomedicine: Approved and Investigational Nanodrugs</span>. <i>Pharm. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">742</span>– <span class="NLM_lpage">755</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2017&pages=742-755&author=C.+L.+Ventola&title=Progress+in+Nanomedicine%3A+Approved+and+Investigational+Nanodrugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVentola%26aufirst%3DC.%2BL.%26atitle%3DProgress%2520in%2520Nanomedicine%253A%2520Approved%2520and%2520Investigational%2520Nanodrugs%26jtitle%3DPharm.%2520Ther.%26date%3D2017%26volume%3D42%26spage%3D742%26epage%3D755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Erdoǧar, N.</span>; <span class="NLM_string-name">Bilensoy, E.</span></span> <span> </span><span class="NLM_article-title">Cyclodextrin-Based Nanosystems in Targeted Cancer Therapy</span>. In  <i>Cyclodextrin Applications in Medicine, Food, Environment and Liquid Crystals</i>; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">Gewerbestrasse 11, 6330 Cham, Switzerland</span>, <span class="NLM_year">2018</span>; pp  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">80</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1007%2F978-3-319-76162-6_3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&pages=59-80&author=N.+Erdo%C7%A7ar&author=E.+Bilensoy&title=Cyclodextrin+Applications+in+Medicine%2C+Food%2C+Environment+and+Liquid+Crystals"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1007%2F978-3-319-76162-6_3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-3-319-76162-6_3%26sid%3Dliteratum%253Aachs%26aulast%3DErdo%25C7%25A7ar%26aufirst%3DN.%26atitle%3DCyclodextrin-Based%2520Nanosystems%2520in%2520Targeted%2520Cancer%2520Therapy%26btitle%3DCyclodextrin%2520Applications%2520in%2520Medicine%252C%2520Food%252C%2520Environment%2520and%2520Liquid%2520Crystals%26pub%3DSpringer%26date%3D2018%26spage%3D59%26epage%3D80" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bor, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mat Azmi, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yaghmur, A.</span></span> <span> </span><span class="NLM_article-title">Nanomedicines for Cancer Therapy: Current Status, Challenges and Future Prospects</span>. <i>Ther. Delivery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.4155/tde-2018-0062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.4155%2Ftde-2018-0062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=30678550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisFWgsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=113-132&author=G.+Borauthor=I.+D.+Mat+Azmiauthor=A.+Yaghmur&title=Nanomedicines+for+Cancer+Therapy%3A+Current+Status%2C+Challenges+and+Future+Prospects&doi=10.4155%2Ftde-2018-0062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Nanomedicines for cancer therapy: current status, challenges and future prospects</span></div><div class="casAuthors">Bor, Gizem; Mat Azmi, Intan Diana; Yaghmur, Anan</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Delivery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">113-132</span>CODEN:
                <span class="NLM_cas:coden">TDHEA7</span>;
        ISSN:<span class="NLM_cas:issn">2041-5990</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The emergence of nanomedicine as an innovative and promising alternative technol. shows many advantages over conventional cancer therapies and provides new opportunities for early detection, improved treatment, and diagnosis of cancer.  Despite the cancer nanomedicines capability of delivering chemotherapeutic agents while providing lower systemic toxicity, it is paramount to consider the cancer complexity and dynamics for bridging the translational bench-to-bedside gap.  It is important to conduct appropriate investigations for exploiting the tumor microenvironment, and achieving a more comprehensive understanding of the fundamental biol. processes in cancer and their roles in modulating nanoparticle-protein interactions, blood circulation, and tumor penetration.  This review provides an overview of the current cancer nanomedicines, the major challenges, and the future opportunities in this research area.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7xUAn3El1QbVg90H21EOLACvtfcHk0libQPo9f0egxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisFWgsbY%253D&md5=8b826e36413b87761c551032560dd9e5</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.4155%2Ftde-2018-0062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ftde-2018-0062%26sid%3Dliteratum%253Aachs%26aulast%3DBor%26aufirst%3DG.%26aulast%3DMat%2BAzmi%26aufirst%3DI.%2BD.%26aulast%3DYaghmur%26aufirst%3DA.%26atitle%3DNanomedicines%2520for%2520Cancer%2520Therapy%253A%2520Current%2520Status%252C%2520Challenges%2520and%2520Future%2520Prospects%26jtitle%3DTher.%2520Delivery%26date%3D2019%26volume%3D10%26spage%3D113%26epage%3D132%26doi%3D10.4155%2Ftde-2018-0062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeGiovanni, P.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rai, P.</span></span> <span> </span><span class="NLM_article-title">Cancer Nanomedicine: A Review of Recent Success in Drug Delivery</span>. <i>Clin. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">44</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1186/s40169-017-0175-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1186%2Fs40169-017-0175-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=28044245" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2017&pages=1-21&issue=44&author=S.+Tranauthor=P.-J.+DeGiovanniauthor=B.+Pielauthor=P.+Rai&title=Cancer+Nanomedicine%3A+A+Review+of+Recent+Success+in+Drug+Delivery&doi=10.1186%2Fs40169-017-0175-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1186%2Fs40169-017-0175-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40169-017-0175-0%26sid%3Dliteratum%253Aachs%26aulast%3DTran%26aufirst%3DS.%26aulast%3DDeGiovanni%26aufirst%3DP.-J.%26aulast%3DPiel%26aufirst%3DB.%26aulast%3DRai%26aufirst%3DP.%26atitle%3DCancer%2520Nanomedicine%253A%2520A%2520Review%2520of%2520Recent%2520Success%2520in%2520Drug%2520Delivery%26jtitle%3DClin.%2520Transl.%2520Med.%26date%3D2017%26volume%3D6%26issue%3D44%26spage%3D1%26epage%3D21%26doi%3D10.1186%2Fs40169-017-0175-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pooja, D.</span>; <span class="NLM_string-name">Kadari, A.</span>; <span class="NLM_string-name">Kulhari, H.</span>; <span class="NLM_string-name">Sistla, R.</span></span> <span> </span><span class="NLM_article-title">Lipid-Based Nanomedicines: Current Clinical Status and Future Perspectives</span>.  <i>Lipid Nanocarriers for Drug Targeting</i>; <span class="NLM_publisher-name">Elsevier</span>: <span class="NLM_year">2018</span>; pp  <span class="NLM_fpage">509</span>– <span class="NLM_lpage">528</span>, <span class="refDoi"> DOI: 10.1016/B978-0-12-813687-4.00013-X</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2FB978-0-12-813687-4.00013-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&pages=509-528&author=D.+Pooja&author=A.+Kadari&author=H.+Kulhari&author=R.+Sistla&title=Lipid+Nanocarriers+for+Drug+Targeting"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-813687-4.00013-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-0-12-813687-4.00013-X%26sid%3Dliteratum%253Aachs%26aulast%3DPooja%26aufirst%3DD.%26atitle%3DLipid-Based%2520Nanomedicines%253A%2520Current%2520Clinical%2520Status%2520and%2520Future%2520Perspectives%26btitle%3DLipid%2520Nanocarriers%2520for%2520Drug%2520Targeting%26pub%3DElsevier%26date%3D2018%26spage%3D509%26epage%3D528%26doi%3D10.1016%2FB978-0-12-813687-4.00013-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Asadian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhaenens, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onyshchenko, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Waele, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Declercq, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cools, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devreese, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deforce, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morent, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Geyter, N.</span></span> <span> </span><span class="NLM_article-title">Plasma Functionalization of Polycaprolactone Nanofibers Changes Protein Interactions with Cells, Resulting in Increased Cell Viability</span>. <i>ACS Appl. Mater. Interfaces</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">41962</span>– <span class="NLM_lpage">41977</span>, <span class="refDoi"> DOI: 10.1021/acsami.8b14995</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsami.8b14995" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1artb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=41962-41977&author=M.+Asadianauthor=M.+Dhaenensauthor=I.+Onyshchenkoauthor=S.+De+Waeleauthor=H.+Declercqauthor=P.+Coolsauthor=B.+Devreeseauthor=D.+Deforceauthor=R.+Morentauthor=N.+De+Geyter&title=Plasma+Functionalization+of+Polycaprolactone+Nanofibers+Changes+Protein+Interactions+with+Cells%2C+Resulting+in+Increased+Cell+Viability&doi=10.1021%2Facsami.8b14995"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Plasma Functionalization of Polycaprolactone Nanofibers Changes Protein Interactions with Cells, Resulting in Increased Cell Viability</span></div><div class="casAuthors">Asadian, Mahtab; Dhaenens, Maarten; Onyshchenko, Iuliia; De Waele, Stijn; Declercq, Heidi; Cools, Pieter; Devreese, Bart; Deforce, Dieter; Morent, Rino; De Geyter, Nathalie</div><div class="citationInfo"><span class="NLM_cas:title">ACS Applied Materials & Interfaces</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">41962-41977</span>CODEN:
                <span class="NLM_cas:coden">AAMICK</span>;
        ISSN:<span class="NLM_cas:issn">1944-8244</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The surface properties of electrospun scaffolds can greatly influence protein adsorption and, thus, strongly dictate cell-material interactions.  In this study, we aim to investigate possible correlations between the surface properties of argon, nitrogen, and ammonia and helium plasma-functionalized polycaprolactone (PCL) nanofibers (NFs) and their cellular interactions by examg. the protein corona patterns of the plasma-treated NFs as well as the cell membrane proteins involved in cell proliferation.  As a result of the performed plasma treatments, PCL NFs morphol. was preserved, while wettability was improved profoundly after all treatments because of the incorporation of polar surface groups.  Depending on the discharge gas, different types of groups are incorporated, which influenced the resultant cell-material interactions.  Argon plasma-functionalized PCL NFs, only enriched by oxygen-contg. functional groups, were found to show the best cell-material interactions, followed by N2 and He/NH3 plasma-treated samples.  Sodium dodecyl sulfate polyacrylamide gel electrophoresis and liq. chromatog.-mass spectrometry clearly indicated an increased protein retention compared with non-treated PCL NFs.  The nine proteins retained best on plasma-treated NF are important mediators of extracellular matrix interaction, illustrating the importance thereof for cell proliferation and the viability of cells.  Finally, 92 proteins that can be used to differentiate how the different plasma treatments are clustered and subjected to a gene ontol. study, illustrating the importance of keratinization and extracellular matrix organization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3KeF8cqssqbVg90H21EOLACvtfcHk0lhUoByu2kCilg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1artb7O&md5=3e44be3a8b70048554bbc659cfad37e6</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1021%2Facsami.8b14995&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsami.8b14995%26sid%3Dliteratum%253Aachs%26aulast%3DAsadian%26aufirst%3DM.%26aulast%3DDhaenens%26aufirst%3DM.%26aulast%3DOnyshchenko%26aufirst%3DI.%26aulast%3DDe%2BWaele%26aufirst%3DS.%26aulast%3DDeclercq%26aufirst%3DH.%26aulast%3DCools%26aufirst%3DP.%26aulast%3DDevreese%26aufirst%3DB.%26aulast%3DDeforce%26aufirst%3DD.%26aulast%3DMorent%26aufirst%3DR.%26aulast%3DDe%2BGeyter%26aufirst%3DN.%26atitle%3DPlasma%2520Functionalization%2520of%2520Polycaprolactone%2520Nanofibers%2520Changes%2520Protein%2520Interactions%2520with%2520Cells%252C%2520Resulting%2520in%2520Increased%2520Cell%2520Viability%26jtitle%3DACS%2520Appl.%2520Mater.%2520Interfaces%26date%3D2018%26volume%3D10%26spage%3D41962%26epage%3D41977%26doi%3D10.1021%2Facsami.8b14995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corbo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molinaro, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parodi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toledano
Furman, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvatore, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tasciotti, E.</span></span> <span> </span><span class="NLM_article-title">The impact of Nanoparticle Protein Corona on Cytotoxicity, Immunotoxicity and Target Drug Delivery</span>. <i>Nanomedicine</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">81</span>– <span class="NLM_lpage">100</span>, <span class="refDoi"> DOI: 10.2217/nnm.15.188</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.2217%2Fnnm.15.188" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=26653875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVejtb7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=81-100&author=C.+Corboauthor=R.+Molinaroauthor=A.+Parodiauthor=N.+E.+Toledano%0AFurmanauthor=F.+Salvatoreauthor=E.+Tasciotti&title=The+impact+of+Nanoparticle+Protein+Corona+on+Cytotoxicity%2C+Immunotoxicity+and+Target+Drug+Delivery&doi=10.2217%2Fnnm.15.188"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">The impact of nanoparticle protein corona on cytotoxicity, immunotoxicity and target drug delivery</span></div><div class="casAuthors">Corbo, Claudia; Molinaro, Roberto; Parodi, Alessandro; Toledano Furman, Naama E.; Salvatore, Francesco; Tasciotti, Ennio</div><div class="citationInfo"><span class="NLM_cas:title">Nanomedicine (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">81-100</span>CODEN:
                <span class="NLM_cas:coden">NLUKAC</span>;
        ISSN:<span class="NLM_cas:issn">1743-5889</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">In a perfect sequence of events, nanoparticles (NPs) are injected into the bloodstream where they circulate until they reach the target tissue.  The ligand on the NP surface recognizes its specific receptor expressed on the target tissue and the drug is released in a controlled manner.  However, once injected in a physiol. environment, NPs interact with biol. components and are surrounded by a protein corona (PC).  This can trigger an immune response and affect NP toxicity and targeting capabilities.  In this review, we provide a survey of recent findings on the NP-PC interactions and discuss how the PC can be used to modulate both cytotoxicity and the immune response as well as to improve the efficacy of targeted delivery of nanocarriers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIXwVKlfiRp7Vg90H21EOLACvtfcHk0lhUoByu2kCilg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVejtb7K&md5=541d052dabe708f6970385fdbdf8238b</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.2217%2Fnnm.15.188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fnnm.15.188%26sid%3Dliteratum%253Aachs%26aulast%3DCorbo%26aufirst%3DC.%26aulast%3DMolinaro%26aufirst%3DR.%26aulast%3DParodi%26aufirst%3DA.%26aulast%3DToledano%2BFurman%26aufirst%3DN.%2BE.%26aulast%3DSalvatore%26aufirst%3DF.%26aulast%3DTasciotti%26aufirst%3DE.%26atitle%3DThe%2520impact%2520of%2520Nanoparticle%2520Protein%2520Corona%2520on%2520Cytotoxicity%252C%2520Immunotoxicity%2520and%2520Target%2520Drug%2520Delivery%26jtitle%3DNanomedicine%26date%3D2016%26volume%3D11%26spage%3D81%26epage%3D100%26doi%3D10.2217%2Fnnm.15.188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span> <span> </span><span class="NLM_article-title">Ligand Size and Conformation Affects the Behavior of Nanoparticles Coated with In-Vitro and In-Vivo Protein Corona</span>. <i>ACS Appl. Mater. Interfaces</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">9094</span>– <span class="NLM_lpage">9103</span>, <span class="refDoi"> DOI: 10.1021/acsami.7b16096</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsami.7b16096" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtlOnsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=9094-9103&author=H.+Zhangauthor=T.+Wuauthor=W.+Yuauthor=S.+Ruanauthor=Q.+Heauthor=H.+Gao&title=Ligand+Size+and+Conformation+Affects+the+Behavior+of+Nanoparticles+Coated+with+In-Vitro+and+In-Vivo+Protein+Corona&doi=10.1021%2Facsami.7b16096"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand size and conformation affect the behavior of nanoparticles coated with in vitro and in vivo protein corona</span></div><div class="casAuthors">Zhang, Huajin; Wu, Tianmu; Yu, Wenqi; Ruan, Shaobo; He, Qin; Gao, Huile</div><div class="citationInfo"><span class="NLM_cas:title">ACS Applied Materials & Interfaces</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">9094-9103</span>CODEN:
                <span class="NLM_cas:coden">AAMICK</span>;
        ISSN:<span class="NLM_cas:issn">1944-8244</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Protein corona is immediately established on the surface of nanoparticles upon their introduction into biol. milieu.  Several studies have shown that the targeting efficiency of ligand-modified nanoparticles is attenuated or abolished owing to the protein adsorption.  Here, transferrin receptor-targeting ligands, including LT7 (CHAIYPRH), DT7 (hrpyiahc, all D-form amino acids), and transferrin, were used to identify the influence of the ligand size and conformation on protein corona formation.  The results showed that the targeting capacity of ligand-modified nanoparticles was lost after incubation with plasma in vitro, whereas it was partially retained after in vivo corona formation.  Results from sodium dodecyl sulfate polyacrylamide gel electrophoresis and liq. chromatog.-mass spectrometry revealed the difference in the compn. of in vitro and in vivo corona, wherein the ligand size and conformation played a crit. role.  Differences were obsd. in cellular internalization and exocytosis profiles on the basis of the ligand and corona source.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhsaHUdzBEOLVg90H21EOLACvtfcHk0lhUoByu2kCilg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtlOnsrs%253D&md5=81c7e3a9515800776053a9bdfccabc58</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1021%2Facsami.7b16096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsami.7b16096%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DRuan%26aufirst%3DS.%26aulast%3DHe%26aufirst%3DQ.%26aulast%3DGao%26aufirst%3DH.%26atitle%3DLigand%2520Size%2520and%2520Conformation%2520Affects%2520the%2520Behavior%2520of%2520Nanoparticles%2520Coated%2520with%2520In-Vitro%2520and%2520In-Vivo%2520Protein%2520Corona%26jtitle%3DACS%2520Appl.%2520Mater.%2520Interfaces%26date%3D2018%26volume%3D10%26spage%3D9094%26epage%3D9103%26doi%3D10.1021%2Facsami.7b16096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span> <span> </span><span class="NLM_article-title">Electrical-Charge-Mediated Cancer Cell Targeting via Protein Corona-Decorated Superparamagnetic Nanoparticles an a Simulated Physiological Environment</span>. <i>ACS Appl. Mater. Interfaces</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">41986</span>– <span class="NLM_lpage">41998</span>, <span class="refDoi"> DOI: 10.1021/acsami.8b15098</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsami.8b15098" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitF2qtrfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=41986-41998&author=J.+Zhaoauthor=S.+Wuauthor=J.+Qinauthor=D.+Shiauthor=Y.+Wang&title=Electrical-Charge-Mediated+Cancer+Cell+Targeting+via+Protein+Corona-Decorated+Superparamagnetic+Nanoparticles+an+a+Simulated+Physiological+Environment&doi=10.1021%2Facsami.8b15098"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Electrical-Charge-Mediated Cancer Cell Targeting via Protein Corona-Decorated Superparamagnetic Nanoparticles in a Simulated Physiological Environment</span></div><div class="casAuthors">Zhao, Jian; Wu, Shengming; Qin, Jingwen; Shi, Donglu; Wang, Yilong</div><div class="citationInfo"><span class="NLM_cas:title">ACS Applied Materials & Interfaces</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">41986-41998</span>CODEN:
                <span class="NLM_cas:coden">AAMICK</span>;
        ISSN:<span class="NLM_cas:issn">1944-8244</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A crit. issue in nanomedicine is on the understanding of nano-bio interface behaviors, particularly when the nanoparticles are inevitably decorated by protein coronas in the physiol. fluids.  In this study, the effects of particle surface corona on cancer cell targeting were investigated in simulated physiol. fluids.  Cell targeting was achieved by two strategies: (1) using conventional epithelial cell adhesion mol. antibody-functionalized Fe3O4 nanoparticles and (2) rendering the same but naked magnetic nanoparticles elec. pos. charged, enabling them to electrostatically bind onto the neg. charged cancer cells.  The cell-particle electrostatic binding was found to be much stronger with faster reaction kinetics than the immunol. interactions even at 4 nC.  Both types of nanoparticles were decorated with various protein coronas by administration in a simulated physiol. system.  Well-decorated by protein coronas, the elec. charged particles retained strong electrostatic interactions with cancer cells, even upon reversal of the particle zeta potential from pos. to neg.  This behavior was explained by a nonuniform corona modulation of the particle surface charge distributions, exposing locally pos. charged regions, capable of strong electrostatic cell binding and magnetic capturing in a physiol. environment.  This fundamental discovery paves new way for sensitive detection of circulating tumor cells in whole blood in clin. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiwq7S_-e1iLVg90H21EOLACvtfcHk0liaPzd677rwrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitF2qtrfL&md5=e5f09271a3ebfe9f97955f869e669267</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1021%2Facsami.8b15098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsami.8b15098%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DQin%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DY.%26atitle%3DElectrical-Charge-Mediated%2520Cancer%2520Cell%2520Targeting%2520via%2520Protein%2520Corona-Decorated%2520Superparamagnetic%2520Nanoparticles%2520an%2520a%2520Simulated%2520Physiological%2520Environment%26jtitle%3DACS%2520Appl.%2520Mater.%2520Interfaces%26date%3D2018%26volume%3D10%26spage%3D41986%26epage%3D41998%26doi%3D10.1021%2Facsami.8b15098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Westmeier, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauber, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Docter, D.</span></span> <span> </span><span class="NLM_article-title">The Concept of Bio-Corona in Modulating the Toxicity of Engineered Nanomaterials (ENM)</span>. <i>Toxicol. Appl. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>299</i></span>,  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">57</span>, <span class="refDoi"> DOI: 10.1016/j.taap.2015.11.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.taap.2015.11.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=26592323" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFeqsr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=299&publication_year=2016&pages=53-57&author=D.+Westmeierauthor=R.+H.+Stauberauthor=D.+Docter&title=The+Concept+of+Bio-Corona+in+Modulating+the+Toxicity+of+Engineered+Nanomaterials+%28ENM%29&doi=10.1016%2Fj.taap.2015.11.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">The concept of bio-corona in modulating the toxicity of engineered nanomaterials (ENM)</span></div><div class="casAuthors">Westmeier, Dana; Stauber, Roland H.; Docter, Dominic</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">299</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">53-57</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Besides the wide use of engineered nanomaterials (ENM) in tech. products, their application spectrum in biotechnol. and biomedicine is steadily increasing.  In complex physiol. environments the physico-chem. properties and the behavior of nanoparticles (NPs) are challenging to characterize.  Biomols. rapidly adsorb to the nanomaterial, leading to the formation of the protein/biomol. corona, which critically affects the nanomaterials' (patho)biol. and tech. identities.  This formation can trigger an immune response and affect nanoparticles' toxicity and targeting capabilities.  In this review, we provide a survey of recent findings on the (protein)corona-nanoparticle interaction and discuss how the corona modulates both cytotoxicity and the immune response as well as to improve the efficacy of targeted delivery of nanocarriers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosmfxIZQo8abVg90H21EOLACvtfcHk0liaPzd677rwrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFeqsr7I&md5=a315836d5baee92935e5314dfe89f179</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1016%2Fj.taap.2015.11.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.taap.2015.11.008%26sid%3Dliteratum%253Aachs%26aulast%3DWestmeier%26aufirst%3DD.%26aulast%3DStauber%26aufirst%3DR.%2BH.%26aulast%3DDocter%26aufirst%3DD.%26atitle%3DThe%2520Concept%2520of%2520Bio-Corona%2520in%2520Modulating%2520the%2520Toxicity%2520of%2520Engineered%2520Nanomaterials%2520%2528ENM%2529%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D2016%26volume%3D299%26spage%3D53%26epage%3D57%26doi%3D10.1016%2Fj.taap.2015.11.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salvati, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitek, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monopoli, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prapainop, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bombelli, F. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hristov, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Åberg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, K. A.</span></span> <span> </span><span class="NLM_article-title">Transferrin-Functionalized Nanoparticles Lose Their Targeting Capabilities When a Biomolecule Corona Adsorbs on the Surface</span>. <i>Nat. Nanotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">137</span>– <span class="NLM_lpage">143</span>, <span class="refDoi"> DOI: 10.1038/nnano.2012.237</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1038%2Fnnano.2012.237" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=23334168" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFSjtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=137-143&author=A.+Salvatiauthor=A.+S.+Pitekauthor=M.+P.+Monopoliauthor=K.+Prapainopauthor=F.+B.+Bombelliauthor=D.+R.+Hristovauthor=P.+M.+Kellyauthor=C.+%C3%85bergauthor=E.+Mahonauthor=K.+A.+Dawson&title=Transferrin-Functionalized+Nanoparticles+Lose+Their+Targeting+Capabilities+When+a+Biomolecule+Corona+Adsorbs+on+the+Surface&doi=10.1038%2Fnnano.2012.237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface</span></div><div class="casAuthors">Salvati, Anna; Pitek, Andrzej S.; Monopoli, Marco P.; Prapainop, Kanlaya; Bombelli, Francesca Baldelli; Hristov, Delyan R.; Kelly, Philip M.; Aberg, Christoffer; Mahon, Eugene; Dawson, Kenneth A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Nanotechnology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">137-143</span>CODEN:
                <span class="NLM_cas:coden">NNAABX</span>;
        ISSN:<span class="NLM_cas:issn">1748-3387</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Nanoparticles have been proposed as carriers for drugs, genes and therapies to treat various diseases.  Many strategies have been developed to target nanomaterials to specific or over-expressed receptors in diseased cells, and these typically involve functionalizing the surface of nanoparticles with proteins, antibodies or other biomols.  Here, we show that the targeting ability of such functionalized nanoparticles may disappear when they are placed in a biol. environment.  Using transferrin-conjugated nanoparticles, we found that proteins in the media can shield transferrin from binding to both its targeted receptors on cells and sol. transferrin receptors.  Although nanoparticles continue to enter cells, the targeting specificity of transferrin is lost.  Our results suggest that when nanoparticles are placed in a complex biol. environment, interaction with other proteins in the medium and the formation of a protein corona can 'screen' the targeting mols. on the surface of nanoparticles and cause loss of specificity in targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEAjBW1PnMK7Vg90H21EOLACvtfcHk0liaPzd677rwrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFSjtLg%253D&md5=cf3fbdf4d460fc8f016bbc2337719d96</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1038%2Fnnano.2012.237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnnano.2012.237%26sid%3Dliteratum%253Aachs%26aulast%3DSalvati%26aufirst%3DA.%26aulast%3DPitek%26aufirst%3DA.%2BS.%26aulast%3DMonopoli%26aufirst%3DM.%2BP.%26aulast%3DPrapainop%26aufirst%3DK.%26aulast%3DBombelli%26aufirst%3DF.%2BB.%26aulast%3DHristov%26aufirst%3DD.%2BR.%26aulast%3DKelly%26aufirst%3DP.%2BM.%26aulast%3D%25C3%2585berg%26aufirst%3DC.%26aulast%3DMahon%26aufirst%3DE.%26aulast%3DDawson%26aufirst%3DK.%2BA.%26atitle%3DTransferrin-Functionalized%2520Nanoparticles%2520Lose%2520Their%2520Targeting%2520Capabilities%2520When%2520a%2520Biomolecule%2520Corona%2520Adsorbs%2520on%2520the%2520Surface%26jtitle%3DNat.%2520Nanotechnol.%26date%3D2013%26volume%3D8%26spage%3D137%26epage%3D143%26doi%3D10.1038%2Fnnano.2012.237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dai, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ang, C.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kempe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamphuis, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodds, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caruso, F.</span></span> <span> </span><span class="NLM_article-title">Monoclonal Antibody-Functionalized Multilayered Particles: Targeting Cancer Cells in the Presence of Protein Coronas</span>. <i>ACS Nano</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">2876</span>– <span class="NLM_lpage">2885</span>, <span class="refDoi"> DOI: 10.1021/nn506929e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/nn506929e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtlChsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=2876-2885&author=Q.+Daiauthor=Y.+Yanauthor=C.-S.+Angauthor=K.+Kempeauthor=M.+M.+Kamphuisauthor=S.+J.+Doddsauthor=F.+Caruso&title=Monoclonal+Antibody-Functionalized+Multilayered+Particles%3A+Targeting+Cancer+Cells+in+the+Presence+of+Protein+Coronas&doi=10.1021%2Fnn506929e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Monoclonal Antibody-Functionalized Multilayered Particles: Targeting Cancer Cells in the Presence of Protein Coronas</span></div><div class="casAuthors">Dai, Qiong; Yan, Yan; Ang, Ching-Seng; Kempe, Kristian; Kamphuis, Marloes M. J.; Dodds, Sarah J.; Caruso, Frank</div><div class="citationInfo"><span class="NLM_cas:title">ACS Nano</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">2876-2885</span>CODEN:
                <span class="NLM_cas:coden">ANCAC3</span>;
        ISSN:<span class="NLM_cas:issn">1936-0851</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Engineered particles adsorb biomols. (e.g., proteins) when introduced in a biol. medium to form a layer called a "corona".  Coronas, in particular the protein corona, play an important role in detg. the surface properties of particles and their targeting abilities.  This study examines the influence of protein coronas on the targeting ability of layer-by-layer (LbL)-assembled polymer capsules and core-shell particles functionalized with monoclonal antibodies.  Upon exposure of humanized A33 monoclonal antibody (huA33 mAb)-functionalized poly(methacrylic acid) (PMA) capsules or huA33 mAb-PMA particles to human serum, a total of 83 or 65 proteins were identified in the protein coronas, resp.  Human serum of varying concns. altered the compn. of the protein corona.  The antibody-driven specific cell membrane binding was qual. and quant. assessed by flow cytometry and fluorescence microscopy in both the absence and presence of a protein corona.  The findings show that although different protein coronas formed in human serum (at different concns.), the targeting ability of both the huA33 mAb-functionalized PMA capsules and particles toward human colon cancer cells was retained, demonstrating no significant difference compared with capsules and particles in the absence of protein coronas: ∼70% and ∼90% A33-expressing cells were targeted by the huA33 mAb-PMA capsules and particles, resp., in a mixed cell population.  This result demonstrates that the formation of protein coronas did not significantly influence the targeting ability of antibody-functionalized LbL-polymer carriers, indicating that the surface functionality of engineered particles in the presence of protein coronas can be preserved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGru61EZOY1VE7Vg90H21EOLACvtfcHk0liYLWOnmztVcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtlChsLg%253D&md5=f1a4822e298052519b11980e337dff9b</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1021%2Fnn506929e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fnn506929e%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DQ.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DAng%26aufirst%3DC.-S.%26aulast%3DKempe%26aufirst%3DK.%26aulast%3DKamphuis%26aufirst%3DM.%2BM.%26aulast%3DDodds%26aufirst%3DS.%2BJ.%26aulast%3DCaruso%26aufirst%3DF.%26atitle%3DMonoclonal%2520Antibody-Functionalized%2520Multilayered%2520Particles%253A%2520Targeting%2520Cancer%2520Cells%2520in%2520the%2520Presence%2520of%2520Protein%2520Coronas%26jtitle%3DACS%2520Nano%26date%3D2015%26volume%3D9%26spage%3D2876%26epage%3D2885%26doi%3D10.1021%2Fnn506929e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Safavi-Sohi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maghari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raoufi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jalali, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hajipour, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghassempour, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahmoudi, M.</span></span> <span> </span><span class="NLM_article-title">Bypassing Protein Corona Issue on Active Targeting: Zwitterionic Coatings Dictate Specific Interactions of Targeting Moieties and Cell Receptors</span>. <i>ACS Appl. Mater. Interfaces</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">22808</span>– <span class="NLM_lpage">22818</span>, <span class="refDoi"> DOI: 10.1021/acsami.6b05099</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsami.6b05099" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlehsrnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=22808-22818&author=R.+Safavi-Sohiauthor=S.+Maghariauthor=M.+Raoufiauthor=S.+A.+Jalaliauthor=M.+J.+Hajipourauthor=A.+Ghassempourauthor=M.+Mahmoudi&title=Bypassing+Protein+Corona+Issue+on+Active+Targeting%3A+Zwitterionic+Coatings+Dictate+Specific+Interactions+of+Targeting+Moieties+and+Cell+Receptors&doi=10.1021%2Facsami.6b05099"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Bypassing Protein Corona Issue on Active Targeting: Zwitterionic Coatings Dictate Specific Interactions of Targeting Moieties and Cell Receptors</span></div><div class="casAuthors">Safavi-Sohi, Reihaneh; Maghari, Shokoofeh; Raoufi, Mohammad; Jalali, Seyed Amir; Hajipour, Mohammad J.; Ghassempour, Alireza; Mahmoudi, Morteza</div><div class="citationInfo"><span class="NLM_cas:title">ACS Applied Materials & Interfaces</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">22808-22818</span>CODEN:
                <span class="NLM_cas:coden">AAMICK</span>;
        ISSN:<span class="NLM_cas:issn">1944-8244</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Surface functionalization strategies for targeting nanoparticles (NP) to specific organs, cells, or organelles, is the foundation for new applications of nanomedicine to drug delivery and biomedical imaging.  Interaction of NPs with biol. media leads to the formation of a biomol. layer at the surface of NPs so called as "protein corona".  This corona layer can shield active mols. at the surface of NPs and cause mistargeting or unintended scavenging by the liver, kidney or spleen.  To overcome this corona issue, we have designed biotin-cysteine conjugated silica NPs (biotin was employed as a targeting mol. and cysteine was used as a zwitterionic ligand) to inhibit corona-induced mistargeting and thus significantly enhance the active targeting capability of NPs in complex biol. media.  To probe the targeting yield of our engineered NPs, we employed both modified silicon wafer substrates with streptavidin (i.e., biotin receptor) to simulate a target and a cell-based model platform using tumor cell lines that overexpress biotin receptors.  In both cases, after incubation with human plasma (thus forming a protein corona), cellular uptake/substrate attachment of the targeted NPs with zwitterionic coatings were significantly higher than the same NPs without zwitterionic coating.  Our results demonstrated that NPs with a zwitterionic surface can considerably facilitate targeting yield of NPs and provide a promising new type of nanocarriers in biol. applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4WQu-uOT6HrVg90H21EOLACvtfcHk0liYLWOnmztVcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlehsrnJ&md5=115c6eea9dfadcff81979cbf7e972809</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1021%2Facsami.6b05099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsami.6b05099%26sid%3Dliteratum%253Aachs%26aulast%3DSafavi-Sohi%26aufirst%3DR.%26aulast%3DMaghari%26aufirst%3DS.%26aulast%3DRaoufi%26aufirst%3DM.%26aulast%3DJalali%26aufirst%3DS.%2BA.%26aulast%3DHajipour%26aufirst%3DM.%2BJ.%26aulast%3DGhassempour%26aufirst%3DA.%26aulast%3DMahmoudi%26aufirst%3DM.%26atitle%3DBypassing%2520Protein%2520Corona%2520Issue%2520on%2520Active%2520Targeting%253A%2520Zwitterionic%2520Coatings%2520Dictate%2520Specific%2520Interactions%2520of%2520Targeting%2520Moieties%2520and%2520Cell%2520Receptors%26jtitle%3DACS%2520Appl.%2520Mater.%2520Interfaces%26date%3D2016%26volume%3D8%26spage%3D22808%26epage%3D22818%26doi%3D10.1021%2Facsami.6b05099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neagu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piperigkou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karamanou, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engin, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Docea, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Constantin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negrei, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikitovic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsatsakis, A.</span></span> <span> </span><span class="NLM_article-title">Protein Bio-Corona: Critical Issue in Immune Nanotoxicology</span>. <i>Arch. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">1031</span>– <span class="NLM_lpage">1048</span>, <span class="refDoi"> DOI: 10.1007/s00204-016-1797-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1007%2Fs00204-016-1797-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=27438349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Sgsr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2017&pages=1031-1048&author=M.+Neaguauthor=Z.+Piperigkouauthor=K.+Karamanouauthor=A.+B.+Enginauthor=A.+O.+Doceaauthor=C.+Constantinauthor=C.+Negreiauthor=D.+Nikitovicauthor=A.+Tsatsakis&title=Protein+Bio-Corona%3A+Critical+Issue+in+Immune+Nanotoxicology&doi=10.1007%2Fs00204-016-1797-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Protein bio-corona: critical issue in immune nanotoxicology</span></div><div class="casAuthors">Neagu, Monica; Piperigkou, Zoi; Karamanou, Konstantina; Engin, Ayse Basak; Docea, Anca Oana; Constantin, Carolina; Negrei, Carolina; Nikitovic, Dragana; Tsatsakis, Aristidis</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Toxicology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1031-1048</span>CODEN:
                <span class="NLM_cas:coden">ARTODN</span>;
        ISSN:<span class="NLM_cas:issn">0340-5761</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  With the expansion of the nanomedicine field, the knowledge focusing on the behavior of nanoparticles in the biol. milieu has rapidly escalated.  Upon introduction to a complex biol. system, nanomaterials dynamically interact with all the encountered biomols. and form the protein "bio-corona.".  The decoration with these surface biomols. endows nanoparticles with new properties.  The present review will address updates of the protein bio-corona characteristics as influenced by nanoparticle's physicochem. properties and by the particularities of the encountered biol. milieu.  Undeniably, bio-corona generation influences the efficacy of the nanodrug and guides the actions of innate and adaptive immunity.  Exploiting the dynamic process of protein bio-corona development in combination with the new engineered horizons of drugs linked to nanoparticles could lead to innovative functional nanotherapies.  Therefore, bio-medical nanotechnologies should focus on the interactions of nanoparticles with the immune system for both safety and efficacy reasons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2WVdIGRRKQrVg90H21EOLACvtfcHk0liYLWOnmztVcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Sgsr%252FM&md5=d9c11c551cbe5e4a5c8f428175ea680f</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1007%2Fs00204-016-1797-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00204-016-1797-5%26sid%3Dliteratum%253Aachs%26aulast%3DNeagu%26aufirst%3DM.%26aulast%3DPiperigkou%26aufirst%3DZ.%26aulast%3DKaramanou%26aufirst%3DK.%26aulast%3DEngin%26aufirst%3DA.%2BB.%26aulast%3DDocea%26aufirst%3DA.%2BO.%26aulast%3DConstantin%26aufirst%3DC.%26aulast%3DNegrei%26aufirst%3DC.%26aulast%3DNikitovic%26aufirst%3DD.%26aulast%3DTsatsakis%26aufirst%3DA.%26atitle%3DProtein%2520Bio-Corona%253A%2520Critical%2520Issue%2520in%2520Immune%2520Nanotoxicology%26jtitle%3DArch.%2520Toxicol.%26date%3D2017%26volume%3D91%26spage%3D1031%26epage%3D1048%26doi%3D10.1007%2Fs00204-016-1797-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tonigold, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estupiñán, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokkinopoulou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinholz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kintzel, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaltbeitzel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domogalla, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbrink, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieberwirth, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crespy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landfester, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mailander, V.</span></span> <span> </span><span class="NLM_article-title">Pre-Adsorption of Antibodies Enables Targeting of Nanocarriers Despite a Biomolecular Corona</span>. <i>Nat. Nanotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">862</span>– <span class="NLM_lpage">869</span>, <span class="refDoi"> DOI: 10.1038/s41565-018-0171-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1038%2Fs41565-018-0171-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=29915272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFGksLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=862-869&author=M.+Tonigoldauthor=J.+Simonauthor=D.+Estupi%C3%B1%C3%A1nauthor=M.+Kokkinopoulouauthor=J.+Reinholzauthor=U.+Kintzelauthor=A.+Kaltbeitzelauthor=P.+Renzauthor=M.+P.+Domogallaauthor=K.+Steinbrinkauthor=I.+Lieberwirthauthor=D.+Crespyauthor=K.+Landfesterauthor=V.+Mailander&title=Pre-Adsorption+of+Antibodies+Enables+Targeting+of+Nanocarriers+Despite+a+Biomolecular+Corona&doi=10.1038%2Fs41565-018-0171-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Pre-adsorption of antibodies enables targeting of nanocarriers despite a biomolecular corona</span></div><div class="casAuthors">Tonigold, Manuel; Simon, Johanna; Estupinan, Diego; Kokkinopoulou, Maria; Reinholz, Jonas; Kintzel, Ulrike; Kaltbeitzel, Anke; Renz, Patricia; Domogalla, Matthias P.; Steinbrink, Kerstin; Lieberwirth, Ingo; Crespy, Daniel; Landfester, Katharina; Mailaender, Volker</div><div class="citationInfo"><span class="NLM_cas:title">Nature Nanotechnology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">862-869</span>CODEN:
                <span class="NLM_cas:coden">NNAABX</span>;
        ISSN:<span class="NLM_cas:issn">1748-3387</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">To promote drug delivery to exact sites and cell types, the surface of nanocarriers is functionalized with targeting antibodies or ligands, typically coupled by covalent chem.  Once the nanocarrier is exposed to biol. fluid such as plasma, however, its surface is inevitably covered with various biomols. forming the protein corona, which masks the targeting ability of the nanoparticle.  Here, we show that we can use a pre-adsorption process to attach targeting antibodies to the surface of the nanocarrier.  Pre-adsorbed antibodies remain functional and are not completely exchanged or covered by the biomol. corona, whereas coupled antibodies are more affected by this shielding.  We conclude that pre-adsorption is potentially a versatile, efficient and rapid method of attaching targeting moieties to the surface of nanocarriers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7KwxlOIkCW7Vg90H21EOLACvtfcHk0liDuzNmh8Iaow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFGksLjP&md5=3cadadfffbc7c3caefecbec690ebcf9f</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1038%2Fs41565-018-0171-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41565-018-0171-6%26sid%3Dliteratum%253Aachs%26aulast%3DTonigold%26aufirst%3DM.%26aulast%3DSimon%26aufirst%3DJ.%26aulast%3DEstupi%25C3%25B1%25C3%25A1n%26aufirst%3DD.%26aulast%3DKokkinopoulou%26aufirst%3DM.%26aulast%3DReinholz%26aufirst%3DJ.%26aulast%3DKintzel%26aufirst%3DU.%26aulast%3DKaltbeitzel%26aufirst%3DA.%26aulast%3DRenz%26aufirst%3DP.%26aulast%3DDomogalla%26aufirst%3DM.%2BP.%26aulast%3DSteinbrink%26aufirst%3DK.%26aulast%3DLieberwirth%26aufirst%3DI.%26aulast%3DCrespy%26aufirst%3DD.%26aulast%3DLandfester%26aufirst%3DK.%26aulast%3DMailander%26aufirst%3DV.%26atitle%3DPre-Adsorption%2520of%2520Antibodies%2520Enables%2520Targeting%2520of%2520Nanocarriers%2520Despite%2520a%2520Biomolecular%2520Corona%26jtitle%3DNat.%2520Nanotechnol.%26date%3D2018%26volume%3D13%26spage%3D862%26epage%3D869%26doi%3D10.1038%2Fs41565-018-0171-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahmoudi, M.</span></span> <span> </span><span class="NLM_article-title">Antibody Orientation Determines Corona Mistargeting Capability</span>. <i>Nat. Nanotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">775</span>– <span class="NLM_lpage">776</span>, <span class="refDoi"> DOI: 10.1038/s41565-018-0147-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1038%2Fs41565-018-0147-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=29915270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFGksLjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=775-776&author=M.+Mahmoudi&title=Antibody+Orientation+Determines+Corona+Mistargeting+Capability&doi=10.1038%2Fs41565-018-0147-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody orientation determines corona mistargeting capability</span></div><div class="casAuthors">Mahmoudi, Morteza</div><div class="citationInfo"><span class="NLM_cas:title">Nature Nanotechnology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">775-776</span>CODEN:
                <span class="NLM_cas:coden">NNAABX</span>;
        ISSN:<span class="NLM_cas:issn">1748-3387</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Antibody pre-adsorption can reduce the adverse effects of the biomol. corona.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBQG8-zd4iUrVg90H21EOLACvtfcHk0ljzFtL5A0KGqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFGksLjL&md5=03b8fe46098e8edf59cc5ffed88a0799</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1038%2Fs41565-018-0147-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41565-018-0147-6%26sid%3Dliteratum%253Aachs%26aulast%3DMahmoudi%26aufirst%3DM.%26atitle%3DAntibody%2520Orientation%2520Determines%2520Corona%2520Mistargeting%2520Capability%26jtitle%3DNat.%2520Nanotechnol.%26date%3D2018%26volume%3D13%26spage%3D775%26epage%3D776%26doi%3D10.1038%2Fs41565-018-0147-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, H.</span></span> <span> </span><span class="NLM_article-title">The potential of Protein–Nanomaterial Interaction for Advanced Drug Delivery</span>. <i>J. Controlled Release</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>225</i></span>,  <span class="NLM_fpage">121</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1016/j.jconrel.2016.01.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.jconrel.2016.01.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=26812004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhslyhu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=225&publication_year=2016&pages=121-132&author=Q.+Pengauthor=H.+Mu&title=The+potential+of+Protein%E2%80%93Nanomaterial+Interaction+for+Advanced+Drug+Delivery&doi=10.1016%2Fj.jconrel.2016.01.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">The potential of protein-nanomaterial interaction for advanced drug delivery</span></div><div class="casAuthors">Peng, Qiang; Mu, Huiling</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">225</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">121-132</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Nanomaterials, like nanoparticles, micelles, nano-sheets, nanotubes and quantum dots, have great potentials in biomedical fields.  However, their delivery is highly limited by the formation of protein corona upon interaction with endogenous proteins.  This new identity, instead of nanomaterial itself, would be the real substance the organs and cells firstly encounter.  Consequently, the behavior of nanomaterials in vivo is uncontrollable and some undesired effects may occur, like rapid clearance from blood stream; risk of capillary blockage; loss of targeting capacity; and potential toxicity.  Therefore, protein-nanomaterial interaction is a great challenge for nanomaterial systems and should be inhibited.  However, this interaction can also be used to functionalize nanomaterials by forming a selected protein corona.  Unlike other decoration using exogenous mols., nanomaterials functionalized by selected protein corona using endogenous proteins would have greater promise for clin. use.  In this review, we aim to provide a comprehensive understanding of protein-nanomaterial interaction.  Importantly, a discussion about how to use such interaction is launched and some possible applications of such interaction for advanced drug delivery are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqZitagPA6rrVg90H21EOLACvtfcHk0ljzFtL5A0KGqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhslyhu7Y%253D&md5=51f036bc4814aa2a71b2f9ebc9ebd97d</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2016.01.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2016.01.041%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DQ.%26aulast%3DMu%26aufirst%3DH.%26atitle%3DThe%2520potential%2520of%2520Protein%25E2%2580%2593Nanomaterial%2520Interaction%2520for%2520Advanced%2520Drug%2520Delivery%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2016%26volume%3D225%26spage%3D121%26epage%3D132%26doi%3D10.1016%2Fj.jconrel.2016.01.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miclaus, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murugadoss, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takamiya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scavenius, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kjaer-Sorensen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enghild, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strähle, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oxvig, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherland, D. S.</span></span> <span> </span><span class="NLM_article-title">Female Versus Male Biological Identities of Nanoparticles Determine the Interaction with Immune Cells in Fish</span>. <i>Environ. Sci.: Nano</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">895</span>– <span class="NLM_lpage">906</span>, <span class="refDoi"> DOI: 10.1039/C7EN00071E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1039%2FC7EN00071E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjs1GktLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2017&pages=895-906&author=Y.+Hayashiauthor=T.+Miclausauthor=S.+Murugadossauthor=M.+Takamiyaauthor=C.+Scaveniusauthor=K.+Kjaer-Sorensenauthor=J.+J.+Enghildauthor=U.+Str%C3%A4hleauthor=C.+Oxvigauthor=C.+Weissauthor=D.+S.+Sutherland&title=Female+Versus+Male+Biological+Identities+of+Nanoparticles+Determine+the+Interaction+with+Immune+Cells+in+Fish&doi=10.1039%2FC7EN00071E"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Female versus male biological identities of nanoparticles determine the interaction with immune cells in fish</span></div><div class="casAuthors">Hayashi, Yuya; Miclaus, Teodora; Murugadoss, Sivakumar; Takamiya, Masanari; Scavenius, Carsten; Kjaer-Sorensen, Kasper; Enghild, Jan J.; Strahle, Uwe; Oxvig, Claus; Weiss, Carsten; Sutherland, Duncan S.</div><div class="citationInfo"><span class="NLM_cas:title">Environmental Science: Nano</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">895-906</span>CODEN:
                <span class="NLM_cas:coden">ESNNA4</span>;
        ISSN:<span class="NLM_cas:issn">2051-8161</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Biomol. decoration of nanoparticles provides a corona that modulates how the nanoparticles interact with biol. milieus.  The corona compn. has proved to reflect the differences in the repertoire of proteins to which the nanoparticles are exposed, and as a result the same nanoparticles can acquire a differential biol. identity.  Here we examd. whether a unique biol. identity acquired from sex-specific protein repertoires could alter the degree of nanoparticle uptake by cognate immune cells.  We chose zebrafish as a model species of which blood plasma is sexually contrasted by the unique presence/absence of the egg yolk precursor protein vitellogenin.  Sex-specific protein coronas were thus formed around 70 nm SiO2 nanoparticles using female/male blood plasma from zebrafish or fetal bovine serum as a non-native ref.  In contrast to protein coronas formed of male blood plasma, a "female" biol. identity of the nanoparticles was represented by prevailing contribution of vitellogenins to the corona proteome.  We then exposed zebrafish blood cells to the three types of pre-formed nanoparticle-protein complexes and compared nanoparticle uptake using flow cytometry.  Lymphoid and myeloid populations of the blood cells preferentially accumulated the nanoparticles with a female biol. identity, irresp. of the sex of the fish from which the cells were obtained.  The concept of repertoire differences in the corona proteome therefore deserves further attention, as various factors such as sex-specific biol. conditions exemplified in this study could alter the nanoparticle-cell interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8X4Lcw_LbY7Vg90H21EOLACvtfcHk0ljzFtL5A0KGqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjs1GktLs%253D&md5=f825c6816fa7cfa3a38ba891d54dd6db</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1039%2FC7EN00071E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7EN00071E%26sid%3Dliteratum%253Aachs%26aulast%3DHayashi%26aufirst%3DY.%26aulast%3DMiclaus%26aufirst%3DT.%26aulast%3DMurugadoss%26aufirst%3DS.%26aulast%3DTakamiya%26aufirst%3DM.%26aulast%3DScavenius%26aufirst%3DC.%26aulast%3DKjaer-Sorensen%26aufirst%3DK.%26aulast%3DEnghild%26aufirst%3DJ.%2BJ.%26aulast%3DStr%25C3%25A4hle%26aufirst%3DU.%26aulast%3DOxvig%26aufirst%3DC.%26aulast%3DWeiss%26aufirst%3DC.%26aulast%3DSutherland%26aufirst%3DD.%2BS.%26atitle%3DFemale%2520Versus%2520Male%2520Biological%2520Identities%2520of%2520Nanoparticles%2520Determine%2520the%2520Interaction%2520with%2520Immune%2520Cells%2520in%2520Fish%26jtitle%3DEnviron.%2520Sci.%253A%2520Nano%26date%3D2017%26volume%3D4%26spage%3D895%26epage%3D906%26doi%3D10.1039%2FC7EN00071E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Serpooshan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheibani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pushparaj, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wojcik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoso, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safavi-Sohi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haghjoo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nejadnik, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aghaverdi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vali, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinsella, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Presley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P. C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahmoudi, M.</span></span> <span> </span><span class="NLM_article-title">Effect of Cell Sex on Uptake of Nanoparticles: The Overlooked Factor at the Nanobio Interface</span>. <i>ACS Nano</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2253</span>– <span class="NLM_lpage">2266</span>, <span class="refDoi"> DOI: 10.1021/acsnano.7b06212</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsnano.7b06212" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktlKhsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2018&pages=2253-2266&author=V.+Serpooshanauthor=S.+Sheibaniauthor=P.+Pushparajauthor=M.+Wojcikauthor=A.+Y.+Jangauthor=M.+R.+Santosoauthor=J.+H.+Jangauthor=H.+Huangauthor=R.+Safavi-Sohiauthor=N.+Haghjooauthor=H.+Nejadnikauthor=H.+Aghaverdiauthor=H.+Valiauthor=J.+M.+Kinsellaauthor=J.+Presleyauthor=K.+Xuauthor=P.+C.-M.+Yangauthor=M.+Mahmoudi&title=Effect+of+Cell+Sex+on+Uptake+of+Nanoparticles%3A+The+Overlooked+Factor+at+the+Nanobio+Interface&doi=10.1021%2Facsnano.7b06212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of Cell Sex on Uptake of Nanoparticles: The Overlooked Factor at the Nanobio Interface</span></div><div class="casAuthors">Serpooshan, Vahid; Sheibani, Sara; Pushparaj, Pooja; Wojcik, Michal; Jang, Albert Y.; Santoso, Michelle R.; Jang, Joyce H.; Huang, Haina; Safavi-Sohi, Reihaneh; Haghjoo, Niloofar; Nejadnik, Hossein; Aghaverdi, Haniyeh; Vali, Hojatollah; Kinsella, Joseph Matthew; Presley, John; Xu, Ke; Yang, Phillip Chung-Ming; Mahmoudi, Morteza</div><div class="citationInfo"><span class="NLM_cas:title">ACS Nano</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">2253-2266</span>CODEN:
                <span class="NLM_cas:coden">ANCAC3</span>;
        ISSN:<span class="NLM_cas:issn">1936-0851</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cellular uptake of nanoparticles (NPs) depends on the nature of the nanobio system including the solid nanocomponents (e.g., physicochem. properties of NPs), nanobio interfaces (e.g., protein corona compn.), and the cellular characteristics (e.g., cell type).  In this study, we document the role of sex in cellular uptake of NPs as an "overlooked" factor in nanobio interface investigations.  We demonstrate that cell sex leads to differences in NP uptake between male and female human amniotic stem cells (hAMSCs), with greater uptake by female cells. hAMSCs are one of the earliest sources of somatic stem cells.  The expts. were replicated with primary fibroblasts isolated from the salivary gland of adult male and female donors of similar ages, and again the extent of NP uptake was altered by cell sex.  However, in contrast to hAMSCs, uptake was greater in male cells.  We also found out that female vs. male amniotic stem cells exhibited different responses to reprogramming into induced pluripotent stem cells (iPSCs) by the Yamanaka factors.  Thus, future studies should consider the effect of sex on the nanobio interactions to optimize clin. translation of NPs and iPSC biol. and to help researchers to better design and produce safe and efficient therapeutic sex-specific NPs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcunRw1WljebVg90H21EOLACvtfcHk0lhcNmNJ58V5-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktlKhsro%253D&md5=6a2dc803b0c39122e1786b052d918ccd</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1021%2Facsnano.7b06212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsnano.7b06212%26sid%3Dliteratum%253Aachs%26aulast%3DSerpooshan%26aufirst%3DV.%26aulast%3DSheibani%26aufirst%3DS.%26aulast%3DPushparaj%26aufirst%3DP.%26aulast%3DWojcik%26aufirst%3DM.%26aulast%3DJang%26aufirst%3DA.%2BY.%26aulast%3DSantoso%26aufirst%3DM.%2BR.%26aulast%3DJang%26aufirst%3DJ.%2BH.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DSafavi-Sohi%26aufirst%3DR.%26aulast%3DHaghjoo%26aufirst%3DN.%26aulast%3DNejadnik%26aufirst%3DH.%26aulast%3DAghaverdi%26aufirst%3DH.%26aulast%3DVali%26aufirst%3DH.%26aulast%3DKinsella%26aufirst%3DJ.%2BM.%26aulast%3DPresley%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DP.%2BC.-M.%26aulast%3DMahmoudi%26aufirst%3DM.%26atitle%3DEffect%2520of%2520Cell%2520Sex%2520on%2520Uptake%2520of%2520Nanoparticles%253A%2520The%2520Overlooked%2520Factor%2520at%2520the%2520Nanobio%2520Interface%26jtitle%3DACS%2520Nano%26date%3D2018%26volume%3D12%26spage%3D2253%26epage%3D2266%26doi%3D10.1021%2Facsnano.7b06212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, S.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.-D.</span></span> <span> </span><span class="NLM_article-title">Sex Differences in the Toxicity of Polyethylene Glycol-Coated Gold Nanoparticles in Mice</span>. <i>Int. J. Nanomed.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">2409</span>– <span class="NLM_lpage">2419</span>, <span class="refDoi"> DOI: 10.2147/IJN.S46376</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.2147%2FIJN.S46376" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=23861586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A280%3ADC%252BC3sfhtleruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=2409-2419&author=J.+Chenauthor=H.+Wangauthor=W.+Longauthor=X.+Shenauthor=D.+Wuauthor=S.-S.+Songauthor=Y.-M.+Sunauthor=P.-X.+Liuauthor=S.+Fanauthor=F.+Fanauthor=X.-D.+Zhang&title=Sex+Differences+in+the+Toxicity+of+Polyethylene+Glycol-Coated+Gold+Nanoparticles+in+Mice&doi=10.2147%2FIJN.S46376"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Sex differences in the toxicity of polyethylene glycol-coated gold nanoparticles in mice</span></div><div class="casAuthors">Chen Jie; Wang Hao; Long Wei; Shen Xiu; Wu Di; Song Sha-Sha; Sun Yuan-Ming; Liu Pei-Xun; Fan Saijun; Fan Feiyue; Zhang Xiao-Dong</div><div class="citationInfo"><span class="NLM_cas:title">International journal of nanomedicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2409-19</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Gold nanoparticles have received wide interest in disease diagnosis and therapy, but one of the important issues is their toxicological effects in vivo.  Sex differences in the toxicity of gold nanoparticles are not clear.  In this work, body weight, organ weight, hematology, and biochemistry were used to evaluate sex differences in immune response and liver and kidney damage.  Pathology was used to observe the general toxicity of reproductive organs.  The immune response was influenced significantly in female mice, with obvious changes in spleen and thymus index.  Hematology results showed that male mice treated with 22.5 nm gold nanoparticles received more significant infection and inflammation than female mice.  Meanwhile, the biochemistry results showed that 4.4 and 22.5 nm gold nanoparticles caused more significant liver damage in male mice than female mice, while 22.5, 29.3, and 36.1 nm gold nanoparticles caused more significant kidney damage in female mice than male mice.  No significant toxicological response was found in the reproductive system for female or male mice.  It was found that gold nanoparticles caused more serious liver toxicity and infection in male mice than female mice.  These findings indicated that sex differences may be one of the important elements for in vivo toxicity of gold nanoparticles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRcle_nAtSdN4JKJbLTgsvCfW6udTcc2eb30LEQiR1mm7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sfhtleruw%253D%253D&md5=1f4e7421673de77b2c3bf596762a9c2a</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.2147%2FIJN.S46376&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIJN.S46376%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLong%26aufirst%3DW.%26aulast%3DShen%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DSong%26aufirst%3DS.-S.%26aulast%3DSun%26aufirst%3DY.-M.%26aulast%3DLiu%26aufirst%3DP.-X.%26aulast%3DFan%26aufirst%3DS.%26aulast%3DFan%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DX.-D.%26atitle%3DSex%2520Differences%2520in%2520the%2520Toxicity%2520of%2520Polyethylene%2520Glycol-Coated%2520Gold%2520Nanoparticles%2520in%2520Mice%26jtitle%3DInt.%2520J.%2520Nanomed.%26date%3D2013%26volume%3D8%26spage%3D2409%26epage%3D2419%26doi%3D10.2147%2FIJN.S46376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mahmoudi, M.</span></span> <span> </span><span class="NLM_article-title">Debugging Nano–Bio Interfaces: Systematic Strategies to Accelerate Clinical Translation of Nanotechnologies</span>. <i>Trends Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">755</span>– <span class="NLM_lpage">769</span>, <span class="refDoi"> DOI: 10.1016/j.tibtech.2018.02.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.tibtech.2018.02.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=29559165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXks1yrt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=755-769&author=M.+Mahmoudi&title=Debugging+Nano%E2%80%93Bio+Interfaces%3A+Systematic+Strategies+to+Accelerate+Clinical+Translation+of+Nanotechnologies&doi=10.1016%2Fj.tibtech.2018.02.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Debugging Nano-Bio Interfaces: Systematic Strategies to Accelerate Clinical Translation of Nanotechnologies</span></div><div class="casAuthors">Mahmoudi, Morteza</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biotechnology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">755-769</span>CODEN:
                <span class="NLM_cas:coden">TRBIDM</span>;
        ISSN:<span class="NLM_cas:issn">0167-7799</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Despite considerable efforts in the field of nanomedicine that have been made by researchers, funding agencies, entrepreneurs, and the media, fewer nanoparticle (NP) technologies than expected have made it to clin. trials.  The wide gap between the efforts and effective clin. translation is, at least in part, due to multiple overlooked factors in both in vitro and in vivo environments, a poor understanding of the nano-bio interface, and misinterpretation of the data collected in vitro, all of which reduce the accuracy of predictions regarding the NPs' fate and safety in humans.  To minimize this bench-to-clinic gap, which may accelerate successful clin. translation of NPs, this opinion paper aims to introduce strategies for systematic debugging of nano-bio interfaces in the current literature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9y9myq9nI3rVg90H21EOLACvtfcHk0lhcNmNJ58V5-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXks1yrt7Y%253D&md5=abc95b1de26771b846ebef773399965f</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1016%2Fj.tibtech.2018.02.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tibtech.2018.02.014%26sid%3Dliteratum%253Aachs%26aulast%3DMahmoudi%26aufirst%3DM.%26atitle%3DDebugging%2520Nano%25E2%2580%2593Bio%2520Interfaces%253A%2520Systematic%2520Strategies%2520to%2520Accelerate%2520Clinical%2520Translation%2520of%2520Nanotechnologies%26jtitle%3DTrends%2520Biotechnol.%26date%3D2018%26volume%3D36%26spage%3D755%26epage%3D769%26doi%3D10.1016%2Fj.tibtech.2018.02.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fragiadakis, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjornson-Hooper, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madhireddy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sachs, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitzer, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendall, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolan, G. P.</span></span> <span> </span><span class="NLM_article-title">Variation of Immune Cell Responses in Humans Reveals Sex-Specific Coordinated Signaling Across Cell Types</span>. <i>Bio Rxiv</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>567784</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">11</span>, <span class="refDoi"> DOI: 10.1101/567784</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1101%2F567784" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=567784&publication_year=2019&pages=1-11&author=G.+K.+Fragiadakisauthor=Z.+B.+Bjornson-Hooperauthor=D.+Madhireddyauthor=K.+Sachsauthor=M.+H.+Spitzerauthor=S.+C.+Bendallauthor=G.+P.+Nolan&title=Variation+of+Immune+Cell+Responses+in+Humans+Reveals+Sex-Specific+Coordinated+Signaling+Across+Cell+Types&doi=10.1101%2F567784"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1101%2F567784&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252F567784%26sid%3Dliteratum%253Aachs%26aulast%3DFragiadakis%26aufirst%3DG.%2BK.%26aulast%3DBjornson-Hooper%26aufirst%3DZ.%2BB.%26aulast%3DMadhireddy%26aufirst%3DD.%26aulast%3DSachs%26aufirst%3DK.%26aulast%3DSpitzer%26aufirst%3DM.%2BH.%26aulast%3DBendall%26aufirst%3DS.%2BC.%26aulast%3DNolan%26aufirst%3DG.%2BP.%26atitle%3DVariation%2520of%2520Immune%2520Cell%2520Responses%2520in%2520Humans%2520Reveals%2520Sex-Specific%2520Coordinated%2520Signaling%2520Across%2520Cell%2520Types%26jtitle%3DBio%2520Rxiv%26date%3D2019%26volume%3D567784%26spage%3D1%26epage%3D11%26doi%3D10.1101%2F567784" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joossens, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macko, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palosaari, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerloff, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ojea-Jiménez, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrent, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gineste, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Römer, I.</span></span> <span> </span><span class="NLM_article-title">A High Throughput Imaging Database of Toxicological Effects of Nanomaterials Tested on HepaRG Cells</span>. <i>Sci. Data</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">46</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1038/s41597-019-0053-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1038%2Fs41597-019-0053-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=30647409" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2019&pages=1-10&issue=46&author=E.+Joossensauthor=P.+Mackoauthor=T.+Palosaariauthor=K.+Gerloffauthor=I.+Ojea-Jim%C3%A9nezauthor=D.+Gillilandauthor=J.+Novakauthor=S.+F.+Torrentauthor=J.-M.+Ginesteauthor=I.+R%C3%B6mer&title=A+High+Throughput+Imaging+Database+of+Toxicological+Effects+of+Nanomaterials+Tested+on+HepaRG+Cells&doi=10.1038%2Fs41597-019-0053-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1038%2Fs41597-019-0053-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41597-019-0053-2%26sid%3Dliteratum%253Aachs%26aulast%3DJoossens%26aufirst%3DE.%26aulast%3DMacko%26aufirst%3DP.%26aulast%3DPalosaari%26aufirst%3DT.%26aulast%3DGerloff%26aufirst%3DK.%26aulast%3DOjea-Jim%25C3%25A9nez%26aufirst%3DI.%26aulast%3DGilliland%26aufirst%3DD.%26aulast%3DNovak%26aufirst%3DJ.%26aulast%3DTorrent%26aufirst%3DS.%2BF.%26aulast%3DGineste%26aufirst%3DJ.-M.%26aulast%3DR%25C3%25B6mer%26aufirst%3DI.%26atitle%3DA%2520High%2520Throughput%2520Imaging%2520Database%2520of%2520Toxicological%2520Effects%2520of%2520Nanomaterials%2520Tested%2520on%2520HepaRG%2520Cells%26jtitle%3DSci.%2520Data%26date%3D2019%26volume%3D6%26issue%3D46%26spage%3D1%26epage%3D10%26doi%3D10.1038%2Fs41597-019-0053-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kermanizadeh, A.</span>; <span class="NLM_string-name">Brown, D. M.</span>; <span class="NLM_string-name">Møller, P.</span></span> <span> </span><span class="NLM_article-title">Toxicological Hazard Analysis of Nanomaterials with Potential for Utilization in Consumer Goods</span>. In  <i>Nanomaterials for Food Applications</i>; <span class="NLM_publisher-name">Elsevier</span>: <span class="NLM_publisher-loc">Valencia, Spain</span>, <span class="NLM_year">2019</span>; pp  <span class="NLM_fpage">355</span>– <span class="NLM_lpage">380</span>, <span class="refDoi"> DOI: 10.1016/B978-0-12-814130-4.00012-9</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2FB978-0-12-814130-4.00012-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&pages=355-380&author=A.+Kermanizadeh&author=D.+M.+Brown&author=P.+M%C3%B8ller&title=Nanomaterials+for+Food+Applications"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-814130-4.00012-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-0-12-814130-4.00012-9%26sid%3Dliteratum%253Aachs%26aulast%3DKermanizadeh%26aufirst%3DA.%26atitle%3DToxicological%2520Hazard%2520Analysis%2520of%2520Nanomaterials%2520with%2520Potential%2520for%2520Utilization%2520in%2520Consumer%2520Goods%26btitle%3DNanomaterials%2520for%2520Food%2520Applications%26pub%3DElsevier%26date%3D2019%26spage%3D355%26epage%3D380%26doi%3D10.1016%2FB978-0-12-814130-4.00012-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blázquez, M.</span>; <span class="NLM_string-name">Fernández-Cruz, M.</span>; <span class="NLM_string-name">Gajewicz, A.</span>; <span class="NLM_string-name">Puzyn, T.</span>; <span class="NLM_string-name">Benfenati, E.</span></span> <span> </span><span class="NLM_article-title">In On the Uses of Predictive Toxicology to Approve the Use of Engineered Nanomaterials as Biocidal Active Substances Under the Biocidal Products Regulation</span>. In  <i>IOP Conference Series: Materials Science and Engineering, 2019</i>; <span class="NLM_publisher-name">IOP Publishing</span>, <span class="NLM_year">2019</span>;  <span class="NLM_volume">012007</span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1088/1757-899X/499/1/012007</span> .</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&pages=1-8&author=M.+Bl%C3%A1zquez&author=M.+Fern%C3%A1ndez-Cruz&author=A.+Gajewicz&author=T.+Puzyn&author=E.+Benfenati&title=In+On+the+Uses+of+Predictive+Toxicology+to+Approve+the+Use+of+Engineered+Nanomaterials+as+Biocidal+Active+Substances+Under+the+Biocidal+Products+Regulation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DBl%25C3%25A1zquez%26aufirst%3DM.%26atitle%3DIn%2520On%2520the%2520Uses%2520of%2520Predictive%2520Toxicology%2520to%2520Approve%2520the%2520Use%2520of%2520Engineered%2520Nanomaterials%2520as%2520Biocidal%2520Active%2520Substances%2520Under%2520the%2520Biocidal%2520Products%2520Regulation%26jtitle%3DIOP%2520Conference%2520Series%253A%2520Materials%2520Science%2520and%2520Engineering%252C%25202019%26pub%3DIOP%2520Publishing%26date%3D2019%26volume%3D012007%26spage%3D1%26epage%3D8%26doi%3D10.1088%2F1757-899X%2F499%2F1%2F012007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span> <span> </span><span class="NLM_article-title">A Safe-By-Design Strategy Towards Safer Nanomaterials in Nanomedicines</span>. <i>Adv. Mater.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_fpage">1805391</span>, <span class="refDoi"> DOI: 10.1002/adma.201805391</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1002%2Fadma.201805391" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1Cgtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&pages=1805391&author=L.+Yanauthor=F.+Zhaoauthor=J.+Wangauthor=Y.+Zuauthor=Z.+Guauthor=Y.+Zhao&title=A+Safe-By-Design+Strategy+Towards+Safer+Nanomaterials+in+Nanomedicines&doi=10.1002%2Fadma.201805391"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">A safe-by-design strategy towards safer nanomaterials in nanomedicines</span></div><div class="casAuthors">Yan, Liang; Zhao, Feng; Wang, Jing; Zu, Yan; Gu, Zhanjun; Zhao, Yuliang</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Materials (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">1805391</span>CODEN:
                <span class="NLM_cas:coden">ADVMEW</span>;
        ISSN:<span class="NLM_cas:issn">0935-9648</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The marriage of nanotechnol. and medicine offers new opportunities to fight against human diseases.  Benefiting from their unique optical, thermal, magnetic, or redox properties, a wide range of nanomaterials have shown potential in applications such as diagnosis, drug delivery, or tissue repair and regeneration.  Despite the considerable success achieved over the past decades, the newly emerging nanomedicines still suffer from an incomplete understanding of their safety risks, and of the relationships between their physicochem. characteristics and safety profiles.  Herein, the most important categories of nanomaterials with clin. potential and their toxicol. mechanisms are summarized, and then, based on this available information, an overview of the principles in developing safe-by-design nanomaterials for medical applications and of the recent progress in this field is provided.  These principles may serve as a starting point to guide the development of more effective safe-by-design strategies and to help identify the major knowledge and skill gaps.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1tB-7kw0vmbVg90H21EOLACvtfcHk0lh5l8p7ywD3-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1Cgtb4%253D&md5=a69bffdab372e5db5436e681260d0fbb</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1002%2Fadma.201805391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fadma.201805391%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZu%26aufirst%3DY.%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DZhao%26aufirst%3DY.%26atitle%3DA%2520Safe-By-Design%2520Strategy%2520Towards%2520Safer%2520Nanomaterials%2520in%2520Nanomedicines%26jtitle%3DAdv.%2520Mater.%26date%3D2019%26spage%3D1805391%26doi%3D10.1002%2Fadma.201805391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hodson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastlake, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbers, R.</span></span> <span> </span><span class="NLM_article-title">An Evaluation of Engineered Nanomaterial Safety Data Sheets for Safety and Health Information Post Implementation of the Revised Hazard Communication Standard</span>. <i>J. Chem. Health Saf.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">12</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1016/j.jchas.2018.10.002</span> </span><div class="citationLinks">[<a href="/doi/10.1016/j.jchas.2018.10.002" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=12-18&author=L.+Hodsonauthor=A.+Eastlakeauthor=R.+Herbers&title=An+Evaluation+of+Engineered+Nanomaterial+Safety+Data+Sheets+for+Safety+and+Health+Information+Post+Implementation+of+the+Revised+Hazard+Communication+Standard&doi=10.1016%2Fj.jchas.2018.10.002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1016%2Fj.jchas.2018.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jchas.2018.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DHodson%26aufirst%3DL.%26aulast%3DEastlake%26aufirst%3DA.%26aulast%3DHerbers%26aufirst%3DR.%26atitle%3DAn%2520Evaluation%2520of%2520Engineered%2520Nanomaterial%2520Safety%2520Data%2520Sheets%2520for%2520Safety%2520and%2520Health%2520Information%2520Post%2520Implementation%2520of%2520the%2520Revised%2520Hazard%2520Communication%2520Standard%26jtitle%3DJ.%2520Chem.%2520Health%2520Saf.%26date%3D2019%26volume%3D26%26spage%3D12%26epage%3D18%26doi%3D10.1016%2Fj.jchas.2018.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benchimol, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourne, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moghimi, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simberg, D.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic Analysis Reveals Limitations and Opportunities for Nanomedicine Targeting of Endothelial and Extravascular Compartments of Tumours</span>. <i>J. Drug Targeting</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">690</span>– <span class="NLM_lpage">698</span>, <span class="refDoi"> DOI: 10.1080/1061186X.2019.1566339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1080%2F1061186X.2019.1566339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=30614276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlGis7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=690-698&author=M.+J.+Benchimolauthor=D.+Bourneauthor=S.+M.+Moghimiauthor=D.+Simberg&title=Pharmacokinetic+Analysis+Reveals+Limitations+and+Opportunities+for+Nanomedicine+Targeting+of+Endothelial+and+Extravascular+Compartments+of+Tumours&doi=10.1080%2F1061186X.2019.1566339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic analysis reveals limitations and opportunities for nanomedicine targeting of endothelial and extravascular compartments of tumours</span></div><div class="casAuthors">Benchimol, Michael J.; Bourne, David; Moghimi, Seyed Moein; Simberg, Dmitri</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Drug Targeting</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">690-698</span>CODEN:
                <span class="NLM_cas:coden">JDTAEH</span>;
        ISSN:<span class="NLM_cas:issn">1026-7158</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Targeting of nanoparticles to tumors can potentially improve the specificity of imaging and treatments.  We have developed a multicompartmental pharmacokinetic model in order to analyze some of the factors that control efficiency of targeting to intravascular (endothelium) and extravascular (tumor cells and stroma) compartments.  We make the assumption that transport across tumor endothelium is an important step for subsequent nanoparticle accumulation in the tumor (area-under-the-curve, AUC) regardless of entry route (interendothelial and transendothelial routes) and study this through a multicompartmental simulation.  Our model reveals that increasing endothelial targeting efficiency has a much stronger effect on the AUC than increasing extravascular targeting efficiency.  Furthermore, our anal. reveals that both extravasation and intratumoral diffusion rates need to be increased in order to significantly increase the AUC of extravascular-targeted nanoparticles.  Increasing the nanoparticle circulation half-life increases the AUC independently of extravasation and intratumoral diffusion.  Targeting the extravascular compartment leads to a buildup in the first layer surrounding blood vessels at the expense of deeper layers (binding site barrier).  This model explains some of the limitations of tumor targeting and provides important guidelines for the design of targeted nanomedicines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_DGPfsbvZNrVg90H21EOLACvtfcHk0lhlUxUl_pIIRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlGis7c%253D&md5=f4154e7feef28c8aaf6debb1f0e55d34</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1080%2F1061186X.2019.1566339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F1061186X.2019.1566339%26sid%3Dliteratum%253Aachs%26aulast%3DBenchimol%26aufirst%3DM.%2BJ.%26aulast%3DBourne%26aufirst%3DD.%26aulast%3DMoghimi%26aufirst%3DS.%2BM.%26aulast%3DSimberg%26aufirst%3DD.%26atitle%3DPharmacokinetic%2520Analysis%2520Reveals%2520Limitations%2520and%2520Opportunities%2520for%2520Nanomedicine%2520Targeting%2520of%2520Endothelial%2520and%2520Extravascular%2520Compartments%2520of%2520Tumours%26jtitle%3DJ.%2520Drug%2520Targeting%26date%3D2019%26volume%3D27%26spage%3D690%26epage%3D698%26doi%3D10.1080%2F1061186X.2019.1566339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosenblum, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karp, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peer, D.</span></span> <span> </span><span class="NLM_article-title">Progress and Challenges Towards Targeted Delivery of Cancer Therapeutics</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1410</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-03705-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1038%2Fs41467-018-03705-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=29317637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVOitLjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1-12&issue=1410&author=D.+Rosenblumauthor=N.+Joshiauthor=W.+Taoauthor=J.+M.+Karpauthor=D.+Peer&title=Progress+and+Challenges+Towards+Targeted+Delivery+of+Cancer+Therapeutics&doi=10.1038%2Fs41467-018-03705-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes</span></div><div class="casAuthors">Veiga, Nuphar; Goldsmith, Meir; Granot, Yasmin; Rosenblum, Daniel; Dammes, Niels; Kedmi, Ranit; Ramishetti, Srinivas; Peer, Dan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-9</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Therapeutic alteration of gene expression in vivo can be achieved by delivering nucleic acids (e.g., mRNA, siRNA) using nanoparticles.  Recent progress in modified mRNA (mmRNA) synthesis facilitated the development of lipid nanoparticles (LNPs) loaded with mmRNA as a promising tool for in vivo protein expression.  Although progress have been made with mmRNA-LNPs based protein expression in hepatocytes, cell specificity is still a major challenge.  Moreover, selective protein expression is essential for an improved therapeutic effect, due to the heterogeneous nature of diseases.  Here, we present a precision protein expression strategy in Ly6c+ inflammatory leukocytes in inflammatory bowel disease (IBD) induced mice.  We demonstrate a therapeutic effect in an IBD model by targeted expression of the interleukin 10 in Ly6c+ inflammatory leukocytes.  A selective mmRNA expression strategy has tremendous therapeutic potential in IBD and can ultimately become a novel therapeutic modality in many other diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEExH7iEJNeLVg90H21EOLACvtfcHk0lhlUxUl_pIIRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVOitLjM&md5=007a9ad4f420a1e35857b73a9064133d</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-03705-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-03705-y%26sid%3Dliteratum%253Aachs%26aulast%3DRosenblum%26aufirst%3DD.%26aulast%3DJoshi%26aufirst%3DN.%26aulast%3DTao%26aufirst%3DW.%26aulast%3DKarp%26aufirst%3DJ.%2BM.%26aulast%3DPeer%26aufirst%3DD.%26atitle%3DProgress%2520and%2520Challenges%2520Towards%2520Targeted%2520Delivery%2520of%2520Cancer%2520Therapeutics%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26issue%3D1410%26spage%3D1%26epage%3D12%26doi%3D10.1038%2Fs41467-018-03705-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantoff, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wooster, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farokhzad, O. C.</span></span> <span> </span><span class="NLM_article-title">Cancer Nanomedicine: Progress, Challenges and Opportunities</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">20</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.1038/nrc.2016.108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1038%2Fnrc.2016.108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=27834398" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVGisr%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=20-37&author=J.+Shiauthor=P.+W.+Kantoffauthor=R.+Woosterauthor=O.+C.+Farokhzad&title=Cancer+Nanomedicine%3A+Progress%2C+Challenges+and+Opportunities&doi=10.1038%2Fnrc.2016.108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer nanomedicine: progress, challenges and opportunities</span></div><div class="casAuthors">Shi, Jinjun; Kantoff, Philip W.; Wooster, Richard; Farokhzad, Omid C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">20-37</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The intrinsic limits of conventional cancer therapies prompted the development and application of various nanotechnologies for more effective and safer cancer treatment, herein referred to as cancer nanomedicine.  Considerable technol. success has been achieved in this field, but the main obstacles to nanomedicine becoming a new paradigm in cancer therapy stem from the complexities and heterogeneity of tumor biol., an incomplete understanding of nano-bio interactions and the challenges regarding chem., manufg. and controls required for clin. translation and commercialization.  This Review highlights the progress, challenges and opportunities in cancer nanomedicine and discusses novel engineering approaches that capitalize on our growing understanding of tumor biol. and nano-bio interactions to develop more effective nanotherapeutics for cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvEyH3WmeaOLVg90H21EOLACvtfcHk0lhlUxUl_pIIRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVGisr%252FK&md5=58ce4c202687ce16c66de979c5b185e4</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1038%2Fnrc.2016.108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc.2016.108%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DKantoff%26aufirst%3DP.%2BW.%26aulast%3DWooster%26aufirst%3DR.%26aulast%3DFarokhzad%26aufirst%3DO.%2BC.%26atitle%3DCancer%2520Nanomedicine%253A%2520Progress%252C%2520Challenges%2520and%2520Opportunities%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2017%26volume%3D17%26spage%3D20%26epage%3D37%26doi%3D10.1038%2Fnrc.2016.108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raucher, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dragojevic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, J.</span></span> <span> </span><span class="NLM_article-title">Macromolecular Drug Carriers for Targeted Glioblastoma Therapy: Preclinical Studies, Challenges and Future Perspectives</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">624</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.3389/fonc.2018.00624</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.3389%2Ffonc.2018.00624" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=29404275" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=1-15&issue=624&author=D.+Raucherauthor=S.+Dragojevicauthor=J.+Ryu&title=Macromolecular+Drug+Carriers+for+Targeted+Glioblastoma+Therapy%3A+Preclinical+Studies%2C+Challenges+and+Future+Perspectives&doi=10.3389%2Ffonc.2018.00624"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2018.00624&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2018.00624%26sid%3Dliteratum%253Aachs%26aulast%3DRaucher%26aufirst%3DD.%26aulast%3DDragojevic%26aufirst%3DS.%26aulast%3DRyu%26aufirst%3DJ.%26atitle%3DMacromolecular%2520Drug%2520Carriers%2520for%2520Targeted%2520Glioblastoma%2520Therapy%253A%2520Preclinical%2520Studies%252C%2520Challenges%2520and%2520Future%2520Perspectives%26jtitle%3DFront.%2520Oncol.%26date%3D2018%26volume%3D8%26issue%3D624%26spage%3D1%26epage%3D15%26doi%3D10.3389%2Ffonc.2018.00624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haque, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jasinski, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binzel, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, P.</span></span> <span> </span><span class="NLM_article-title">Favorable Biodistribution, Specific Targeting and Conditional Endosomal Escape of RNA Nanoparticles in Cancer Therapy</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>414</i></span>,  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2017.09.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.canlet.2017.09.043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=28987384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1aisrbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=414&publication_year=2018&pages=57-70&author=C.+Xuauthor=F.+Haqueauthor=D.+L.+Jasinskiauthor=D.+W.+Binzelauthor=D.+Shuauthor=P.+Guo&title=Favorable+Biodistribution%2C+Specific+Targeting+and+Conditional+Endosomal+Escape+of+RNA+Nanoparticles+in+Cancer+Therapy&doi=10.1016%2Fj.canlet.2017.09.043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Favorable biodistribution, specific targeting and conditional endosomal escape of RNA nanoparticles in cancer therapy</span></div><div class="casAuthors">Xu, Congcong; Haque, Farzin; Jasinski, Daniel L.; Binzel, Daniel W.; Shu, Dan; Guo, Peixuan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">414</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">57-70</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The past decades have witnessed the successful transition of several nanotechnol. platforms into the clin. trials.  However, specific delivery of therapeutics to tumors is hindered by several barriers including cancer recognition and tissue penetration, particle heterogeneity and aggregation, and unfavorable pharmacokinetic profiles such as fast clearance and organ accumulation.  With the advent of RNA nanotechnol., a series of RNA nanoparticles have been successfully constructed to overcome many of the aforementioned challenges for in vivo cancer targeting with favorable biodistribution profiles.  Compared to other nanodelivery platforms, the physiochem. properties of RNA nanoparticles can be tuned with relative ease for investigating the in vivo behavior of nanoparticles upon systemic injection.  The size, shape, and surface chem., esp. hydrophobic modifications, exert significant impacts on the in vivo fate of RNA nanoparticles.  Rationally designed RNA nanoparticles with defined stoichiometry and high homogeneity have been demonstrated to specifically target tumor cells while avoiding accumulation in healthy vital organs after systemic injection.  RNA nanoparticles were proven to deliver therapeutics such as siRNA and anti-miRNA to block tumor growth in several animal models.  Although the release of anti-miRNA from the RNA nanoparticles has achieved high efficiency of tumor regression in multiple animal models, the efficiency of endosomal escape for siRNA delivery needs further improvement.  This review focuses on the advances and perspectives of this promising RNA nanotechnol. platform for cancer targeting and therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYAA8rGnWqIbVg90H21EOLACvtfcHk0lgKEWbsOEM9sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1aisrbL&md5=241ceed5006262c0ada21e1e3a62673d</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2017.09.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2017.09.043%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DC.%26aulast%3DHaque%26aufirst%3DF.%26aulast%3DJasinski%26aufirst%3DD.%2BL.%26aulast%3DBinzel%26aufirst%3DD.%2BW.%26aulast%3DShu%26aufirst%3DD.%26aulast%3DGuo%26aufirst%3DP.%26atitle%3DFavorable%2520Biodistribution%252C%2520Specific%2520Targeting%2520and%2520Conditional%2520Endosomal%2520Escape%2520of%2520RNA%2520Nanoparticles%2520in%2520Cancer%2520Therapy%26jtitle%3DCancer%2520Lett.%26date%3D2018%26volume%3D414%26spage%3D57%26epage%3D70%26doi%3D10.1016%2Fj.canlet.2017.09.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maniam, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mai, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zulkefeli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dufes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, D. M.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J. Y.</span></span> <span> </span><span class="NLM_article-title">Challenges and Opportunities of Nanotechnology as Delivery Platform for Tocotrienols in Cancer Therapy</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1358</span>, <span class="refDoi"> DOI: 10.3389/fphar.2018.01358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.3389%2Ffphar.2018.01358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=30534071" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVGmtb7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1358&author=G.+Maniamauthor=C.+W.+Maiauthor=M.+Zulkefeliauthor=C.+Dufesauthor=D.+M.-Y.+Tanauthor=J.+Y.+Fu&title=Challenges+and+Opportunities+of+Nanotechnology+as+Delivery+Platform+for+Tocotrienols+in+Cancer+Therapy&doi=10.3389%2Ffphar.2018.01358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Challenges and opportunities of nanotechnology as delivery platform for tocotrienols in cancer therapy</span></div><div class="casAuthors">Maniam, Geetha; Mai, Chun-Wai; Zulkefeli, Mohd; Dufes, Christine; Tan, Doryn Meam-Yee; Fu, Ju-Yen</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1358</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Plant-derived phytonutrients have emerged as health enhancers.  Tocotrienols from the vitamin E family gained high attention in recent years due to their multi-targeted biol. properties, including lipid-lowering, neuroprotection, anti-inflammatory, antioxidant, and anticancer effects.  Despite well-defined mechanism of action as an anti-cancer agent, their clin. use is hampered by poor pharmacokinetic profile and low oral bioavailability.  Delivery systems based on nanotechnol. were proven to be advantageous in elevating the delivery of tocotrienols to tumor sites for enhanced efficacy.  To date, preclin. development of nanocarriers for tocotrienols include niosomes, lipid nanoemulsions, nanostructured lipid carriers (NLCs) and polymeric nanoparticles.  Active targeting was explored via the use of transferrin as targeting ligand in niosomes.  In vitro, nanocarriers were shown to enhance the anti-proliferative efficacy and cellular uptake of tocotrienols in cancer cells.  In vivo, improved bioavailability of tocotrienols were reported with NLCs while marked tumor regression was obsd. with transferrin-targeted niosomes.  In this review, the advantages and limitations of each nanocarriers were critically analyzed.  Furthermore, a no. of key challenges were identified including scale-up prodn., biol. barriers, and toxicity profiles.  To overcome these challenges, three research opportunities were highlighted based on rapid advancements in the field of nanomedicine.  This review aims to provide a wholesome perspective for tocotrienol nanoformulations in cancer therapy directed toward effective clin. translation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqk68OnOyFcvLVg90H21EOLACvtfcHk0lgKEWbsOEM9sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVGmtb7J&md5=84afd2f1436b5db303325067c972b31f</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2018.01358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2018.01358%26sid%3Dliteratum%253Aachs%26aulast%3DManiam%26aufirst%3DG.%26aulast%3DMai%26aufirst%3DC.%2BW.%26aulast%3DZulkefeli%26aufirst%3DM.%26aulast%3DDufes%26aufirst%3DC.%26aulast%3DTan%26aufirst%3DD.%2BM.-Y.%26aulast%3DFu%26aufirst%3DJ.%2BY.%26atitle%3DChallenges%2520and%2520Opportunities%2520of%2520Nanotechnology%2520as%2520Delivery%2520Platform%2520for%2520Tocotrienols%2520in%2520Cancer%2520Therapy%26jtitle%3DFront.%2520Pharmacol.%26date%3D2018%26volume%3D9%26spage%3D1358%26doi%3D10.3389%2Ffphar.2018.01358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Belfiore, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurecht, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storm, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vine, K. L.</span></span> <span> </span><span class="NLM_article-title">Towards Clinical Translation of Ligand-Functionalized Liposomes in Targeted Cancer Therapy: Challenges and Opportunities</span>. <i>J. Controlled Release</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">13</span>, <span class="refDoi"> DOI: 10.1016/j.jconrel.2018.02.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1016%2Fj.jconrel.2018.02.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=29501721" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltVKlu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2018&pages=1-13&author=L.+Belfioreauthor=D.+N.+Saundersauthor=M.+Ransonauthor=K.+J.+Thurechtauthor=G.+Stormauthor=K.+L.+Vine&title=Towards+Clinical+Translation+of+Ligand-Functionalized+Liposomes+in+Targeted+Cancer+Therapy%3A+Challenges+and+Opportunities&doi=10.1016%2Fj.jconrel.2018.02.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and opportunities</span></div><div class="casAuthors">Belfiore, Lisa; Saunders, Darren N.; Ranson, Marie; Thurecht, Kristofer J.; Storm, Gert; Vine, Kara L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Controlled Release</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-13</span>CODEN:
                <span class="NLM_cas:coden">JCREEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-3659</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The development of therapeutic resistance to targeted anticancer therapies remains a significant clin. problem, with intratumoral heterogeneity playing a key role.  In this context, improving the therapeutic outcome through simultaneous targeting of multiple tumor cell subtypes within a heterogeneous tumor is a promising approach.  Liposomes have emerged as useful drug carriers that can reduce systemic toxicity and increase drug delivery to the tumor site.  While clin. used liposomal drug formulations show marked therapeutic advantages over free drug formulations, ligand-functionalized liposomes that can target multiple tumor cell subtypes may further improve the therapeutic efficacy by facilitating drug delivery to a broader population of tumor cells making up the heterogeneous tumor tissue.  Ligand-directed liposomes enable the so-called active targeting of cell receptors via surface-attached ligands that direct drug uptake into tumor cells or tumor-assocd. stromal cells, and so can increase the selectivity of drug delivery.  Despite promising preclin. results demonstrating improved targeting and anti-tumor effects of ligand-directed liposomes, there has been limited translation of this approach to the clinic.  Key challenges for translation include the lack of established methods to scale up prodn. and comprehensively characterize ligand-functionalized liposome formulations, as well as the inadequate recapitulation of in vivo tumors in the preclin. models currently used to evaluate their performance.  Herein, we discuss the utility of recent ligand-directed liposome approaches, with a focus on dual-ligand liposomes, for the treatment of solid tumors and examine the drawbacks limiting their progression to clin. adoption.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2lasK_w_g3LVg90H21EOLACvtfcHk0lgKEWbsOEM9sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltVKlu7c%253D&md5=feca6592e27d7bc3f5a4f3081d82f045</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1016%2Fj.jconrel.2018.02.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jconrel.2018.02.040%26sid%3Dliteratum%253Aachs%26aulast%3DBelfiore%26aufirst%3DL.%26aulast%3DSaunders%26aufirst%3DD.%2BN.%26aulast%3DRanson%26aufirst%3DM.%26aulast%3DThurecht%26aufirst%3DK.%2BJ.%26aulast%3DStorm%26aufirst%3DG.%26aulast%3DVine%26aufirst%3DK.%2BL.%26atitle%3DTowards%2520Clinical%2520Translation%2520of%2520Ligand-Functionalized%2520Liposomes%2520in%2520Targeted%2520Cancer%2520Therapy%253A%2520Challenges%2520and%2520Opportunities%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2018%26volume%3D277%26spage%3D1%26epage%3D13%26doi%3D10.1016%2Fj.jconrel.2018.02.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Akhter, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizwanullah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahsan, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mujtaba, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amin, S.</span></span> <span> </span><span class="NLM_article-title">Nanocarriers in Advanced Drug Targeting: Setting Novel Paradigm in Cancer Therapeutics</span>. <i>Artif. Cells, Nanomed., Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">873</span>– <span class="NLM_lpage">884</span>, <span class="refDoi"> DOI: 10.1080/21691401.2017.1366333</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=10.1080%2F21691401.2017.1366333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=28830262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVans7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=873-884&author=M.+H.+Akhterauthor=M.+Rizwanullahauthor=J.+Ahmadauthor=M.+J.+Ahsanauthor=M.+A.+Mujtabaauthor=S.+Amin&title=Nanocarriers+in+Advanced+Drug+Targeting%3A+Setting+Novel+Paradigm+in+Cancer+Therapeutics&doi=10.1080%2F21691401.2017.1366333"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Nanocarriers in advanced drug targeting: setting novel paradigm in cancer therapeutics</span></div><div class="casAuthors">Akhter, Md. Habban; Rizwanullah, Md.; Ahmad, Javed; Ahsan, Mohamed Jawed; Mujtaba, Md. Ali; Amin, Saima</div><div class="citationInfo"><span class="NLM_cas:title">Artificial Cells, Nanomedicine, and Biotechnology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">873-884</span>CODEN:
                <span class="NLM_cas:coden">ACNBCI</span>;
        ISSN:<span class="NLM_cas:issn">2169-141X</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Cancer has been growing nowadays consequently high no. of death ascertained worldwide.  The medical intervention involves chemotherapy, radiation therapy and surgical removal.  This conventional technique lacking targeting potential and harm the normal cells.  In drug treatment regimen, the combination therapy is preferred than single drug treatment module due to higher internalization of chemotherapeutics in the cancer cells both by enhance permeation retention effect and by direct cell apoptosis.  The cancer therapeutics involves different methodologies of delivering active moiety to the target site.  The active and passive transport mode of chemotherapeutic targeting utilizes advance nanocarriers.  The nanotechnol. strategic treatment applying advance nanocarrier greatly helps in mitigating the cancer prevalence.  The nanocarrier-incorporating nanodrug directed for specific area appealed scientist across the globe and issues to be addressed in this regard.  Therefore, various techniques and approaches invented to meet the objectives.  With the advances in nanomedicine and drug delivery, this review briefly focused on various modes of nanodrug delivery including nanoparticles, liposomes, dendrimer, quantum dots, carbon nanotubes, metallic nanoparticles, nanolipid carrier (NLC), gold nanoshell, nanosize cantilevers and nanowire that looks promising and generates a novel horizon in cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOyP9-YsodZLVg90H21EOLACvtfcHk0lhXk1HPON5vmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVans7zK&md5=8064ddb463a4b39e309cfe7e167abc81</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1080%2F21691401.2017.1366333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F21691401.2017.1366333%26sid%3Dliteratum%253Aachs%26aulast%3DAkhter%26aufirst%3DM.%2BH.%26aulast%3DRizwanullah%26aufirst%3DM.%26aulast%3DAhmad%26aufirst%3DJ.%26aulast%3DAhsan%26aufirst%3DM.%2BJ.%26aulast%3DMujtaba%26aufirst%3DM.%2BA.%26aulast%3DAmin%26aufirst%3DS.%26atitle%3DNanocarriers%2520in%2520Advanced%2520Drug%2520Targeting%253A%2520Setting%2520Novel%2520Paradigm%2520in%2520Cancer%2520Therapeutics%26jtitle%3DArtif.%2520Cells%252C%2520Nanomed.%252C%2520Biotechnol.%26date%3D2018%26volume%3D46%26spage%3D873%26epage%3D884%26doi%3D10.1080%2F21691401.2017.1366333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b00511&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b00511%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-23" class="show-recommended-placeholder"></div>




        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b00511" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67992c12683f3de3","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
